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Plenary Lectures
Monday 23 June 2014
PL-01. The Arvid Carlsson Lecture: The ups and
downs of amphetamines: A diversity of
actions on cellular signaling pathways
PL-01-001 The ups and downs of amphetamines: A diversity of
actions on cellular signaling pathways
S. G. Amara. National Institute of Mental Health, Bethesda, MD, USA
Neurotransmitter transporters present at the plasma membrane contribute
to the clearance and recycling of neurotransmitters and have a profound
impact on the extent of receptor activation during neuronal signaling.
These carriers also are the primary targets for psychostimulant drugs of
abuse, antidepressant medications, and drugs such as methylphenidate
and amphetamines, which are used to treat attention deficit disorders.
This lecture will highlight several of the major signaling pathways that
regulate dopamine transporter function and will also consider recent
work showing that amphetamine-like drugs can directly activate intra-
cellular signaling pathways in dopamine neurons to trigger changes in
membrane protein trafficking and other cellular activities. Although sev-
eral steps in the process remain undefined, the intracellular actions of
amphetamine modulate both dopaminergic and glutamatergic signaling
and contribute to the acute behavioral effects of the drug. These actions
of amphetamine within dopamine neurons have implications for mechan-
isms of neuroplasticity and neurotoxicity associated with psychostimulant
use and suggest novel drug targets for modulating the actions of
amphetamines.
Policy of full disclosure: None.
PL-02. Nobel Lecture – Structural insights into
G protein coupled receptor signaling
PL-02-001 Nobel Lecture – Structural insights into G protein
coupled receptor signaling
B. Kobilka. Department of Molecular and Cellular Physiology, Stanford
University, USA
G protein coupled receptors (GPCRs) conduct the majority of transmem-
brane responses to hormones and neurotransmitters, and mediate the
senses of sight, smell and taste. The β2 adrenergic receptor (β2AR) and
the M2 muscarinic receptors are prototypical Family A GPCRs that med-
iates physiologic responses to autonomic nervous system activity. We
have obtained three-dimensional structures of the β2AR and the M2 mus-
carinic receptor in inactive and active conformations, as well as a structure
of the β2AR in complex with the G protein Gs. We have also used fluor-
escence, EPR and NMR spectroscopy to study the dynamic properties of
the β2AR, and to map ligand-specific conformational changes. I will dis-
cuss what we these studies have taught us about allosteric regulation of
GPCR structure by G proteins and ligands.
Policy of full disclosure: There is no financial conflict of interest.
Tuesday 24 June 2014
PL-03. The endocannabinoid system – a fifty
years trip
PL-03-001 The endocannabinoid system – a fifty years trip
R. Mechoulam. Institute for Drug Research, Hebrew University, Jerusalem,
Israel
The endocannabinoid system was discovered and we learned about its in-
volvement in biological processes only over the last two decades –many
years after the better knownadrenergic, serotonergic or cholinergic systems.
However it has already been suggested that ”modulating endocannabinoid
system activity may have therapeutic potential in almost all diseases affect-
ing humans, including . . .neurodegenerative, inflammatory,. . . . pain, . . .
psychiatric disorders, amongst many others “ – as stated in a recent review.
I shall discuss the development of the endocannabinoid system – from the
isolation and structure elucidation of delta-9-tetrahydrocannabinol in
1964, through the identification of the CB1 and CB2 receptors and the
specific agonists anandamide and 2-AG, to the involvement of endocanna-
binoids and structurally related endogenous molecules in a long list of bio-
logical processes. Recent progress in several areas will be discussed:
A. Endocannabinoids as endogenous neuroprotective agents, particularly
in traumatic injury; B. The CB2 cannabinoid receptors as part of a general
protective system; C. Acyl fatty acids as novel endocannabinoid-like com-
pounds; D. Cannabidiol as a novel therapeutic entity.
Policy of full disclosure: 1. I have no significant financial interest or
other affiliation with a funding organization or with a commercial sup-
porter of the session and/or provider of commercial services. 2. I had a
grant from NIH (ended 30 Nov 2013).
PL-04. Brain science using iPS cell technology
non-human primates
PL-04-001 Brain science using iPS cell technology non-human
primates
H. Okano. Keio University, Tokyo, Japan
What makes the investigation of human psychiatric/psychiatric disorders
so difficult? This could be attributed to the following reasons 1) Diseases
model mice do not always recapitulate the pathophysiology of human dis-
eases, 2) It is extremely difficult to investigate what is taking place in vivo
at the onset of the disease due to the low accessibility to the pathological
foci in the brain, and 3) The responsible neuronal circuits for the pheno-
type are not identified. In order to overcome these difficulties, we took ad-
vantage of iPS cell technologies and transgenic non-human primates for
modeling human psychiatric/psychiatric disorders. So far, we have estab-
lished iPS cells from the patients of more than 25 human psychiatric/psy-
chiatric disorders and characterized their pathophysiology. For example,
in collaboration with the group of RIKEN BSI and University of Tokyo,
we established iPS cells from the schizophrenia patients containing
22q11 deletions (Bundo et al., Neuron, 2014). Interestingly, we found
that the copy number of a retrotransposon, long interspersed nuclear
element-1 (L1), was increased in neurons induced from iPS cells from
schizophrenia patients containing 22q11 deletions, indicating that hyper-
active retrotransposition of L1 in neurons triggered by genetic risk factors
may contribute to the susceptibility and pathophysiology of schizo-
phrenia. Furthermore, for faithfully modeling the human human psychi-
atric/psychiatric disorders in vivo, we developed transgenic non-human
primates (common marmosets) with germline transmission (Sasaki
et al., Nature, 2009). In the present talk, we also wish to mention our re-
cent data of generation of common marmoset transgenic models of neuro-
degenrerative diseases, including Parkinson disease, Alzheimer disease
and ALS. I will also mention about our recent trials on the development
of knock-in and knock-out technologies of common marmoset using gen-
ome editing technologies for the generation of transgenic marmoset model
of autism and psychiatric disorders.
Policy of full disclosure: H. Okano is the scientific consultant of San
Bio, Inc; Eisai Co Ltd; and Daiichi Sankyo Co Ltd.
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Wednesday 25 June 2014
PL-05. Preventive strategies in emerging mental
disorders in young people: Clinical staging
and translational research
PL-05-001 Preventive strategies in emerging mental disorders in
young people: Clinical staging and translational
research
P. McGorry. Orygen Youth Health Research Centre, University of Melbourne,
Melbourne, Australia
A key goal in psychiatry is to build new diagnostic, therapeutic and
translational tools and capacity to reduce the impact of emerging mental
disorders in young people on survival, distress, quality of life and pro-
ductivity. Young people bear the major burden of onset for mental dis-
orders with 75% of such illnesses appearing before age 25 years. This can
only be done within a novel non-stigmatising interface between young
people and clinical care in mental health such as that recently created by
headspace in Australia and increasingly in some other developed nations.
We must also develop new terminology enabling early clinical phenotypes
of mental disorders to be defined in a normalizing and health-promoting
way that will promote trust and confidence. A transdiagnostic strategy is
critical, transcending existing subthreshold risk syndromes, with new
“pluripotential” criteria capturing clinical high risk for multiple syn-
dromes. This strategy seeks to solve problems with specificity, power and
reduce false positives. Secondly, we must focus on novel therapeutics.
This starts with the development and evaluation of novel forms of psycho-
social intervention for early stage illness. A complementary strategy needs
to focus upon candidate biomarkers as therapeutic probes within a reverse
translation strategy moving towards biosignatures or profiles of emerging
disorder. Relationships between response and baseline levels of and
changes in biomarkers may create a pathway to personalised / stratified
medicine. Finally translation of existing expertise and systematic reform
of clinical practice and cultures of care is something that is achievable
with the present state of knowledge yet is poorly implemented. McGorry
PD, van Os J. 2013. Redeeming diagnosis in psychiatry: timing versus spe-
cificity. Lancet 381:343–345. McGorry PD. 2013. Early clinical phenotypes,
clinical staging and strategic biomarker research: Building blocks for perso-
nalized psychiatry. Biological Psychiatry 74:394–395 McGorry PD, Bates T,
Birchwood M. 2012. Designing youth mental health services for the 21st
century: Examples from Australia, Ireland and the UK. British Journal of
Psychiatry Suppl. 54:s30–s35.
Policy of full disclosure: None.
PL-06. Optical deconstruction of fully-assembled
biological systems
PL-06-001 Optical deconstruction of fully-assembled biological
systems
K. Deisseroth. Stanford University, Stanford, USA
This talk will report on recent results in development of both optogenetics
(a technology for precisely controlling millisecond-scale activity patterns
in specific cell types using microbial opsin genes and fiberoptic-based
neural interfaces (1, 2) and CLARITY (a technology to optically resolve
high-resolution structural and molecular detail within intact tissues with-
out disassembly). In the optogenetics domain, strategies will be discussed
for targeting microbial opsins and light to meet the challenging con-
straints of the freely-behaving mammal, newly engineered microbe al
opsin genes spanning a range of optical, kinetic, and ion permeability
properties, high-speed behavioral and neural activity-readout tools com-
patible with real-time optogenetic control, and application of these
tools to develop circuit-based insight into anxiety, depression, and moti-
vated behaviors (3, 4). Distinct from optogenetics, new advances in the
CLARITY technology (5) will be covered that accelerate (by orders of mag-
nitude) the extraction of information from intact biological tissue that has
been transformed into a hybrid form in which components are removed
and replaced with exogenous elements, resulting in a transparent tissue-
hydrogel that both preserves, and makes accessible, struc-tural and mol-
ecular information for visualization and analysis (both for whole mouse
brains and banked human brain tissue). Together these complementary
approaches help to unlock rich sources of information for probing disease
mechanisms as well as the native structure and complexity of the nervous
system (6).
References
1. Deisseroth K (2010) Optogenetics: controlling the brain with light.
Scientific American 303(5): 48–55.
2. Deisseroth K (2011) Optogenetics. Nature Methods 8: 26–9.
3. Kim SY, Adhikari A, Lee SY, Marshel JH, Kim CK, Mallory CS, Lo M,
Pak S, Mattis J, Lim BK, Malenka RC, Warden MR, Neve R, Tye KM &
Deisseroth K (2013). Assembling behavioral states: divergent neural
pathways recruit separable anxiety features. Nature 496: 219–23.
4. Warden M, Selimbeyoglu A, Mirzabekov J, Lo M, Thompson K,
Kim S, Adhikari A, Tye K, Frank L & Deisseroth K (2012). A pre-
frontal cortex-brainstem projection controlling response to behavioral
challenge. Nature 492: 428–32.
5. Chung K, Wallace J, Kim S, Kalyanasundaram S, Andalman A,
Davidson T, Mirzabekov J, Zalocusky K, Mattis J, Denisin A, Pak S,
Bernstein H, Ramakrishnan C, Grosenick L, Gradinaru V &
Deisseroth K (2013). Structural and molecular interrogation of intact
biological systems. Nature 497: 332–7.
6. Deisseroth K (2014). Circuit dynamics of adaptive and maladaptive
behaviour. Nature 505: 309–17.
Policy of full disclosure: no disclosures.
Thursday 26 June 2014
PL-07. CINP/CCNP Lecture: Interactions between
neurotransmitters –The key to remission
for depression
PL-07-001 CINP/CCNP Lecture: Interactions between
neurotransmitters – The key to remission for depression
P. Blier. University of Ottawa, Ottawa, Canada
Current antidepressants target neuronal elements controlling the release
of serotonin (5-HT) and/or norepinephrine (NE). The interference with
such targets triggers negative feedback mechanisms preventing an im-
mediate and sustained increase in the synaptic availability of these neuro-
transmitters. After prolonged administration, these mechanisms exerted
by cell body and/or terminal autoreceptors become less effective thereby
producing a sustained elevation of transmission in the targeted systems.
One way to understand the low remission rates with antidepressants is
that an increase in one transmission system can dampen the activity of
other neurotransmitters. For instance, selective 5-HT reuptake inhibitors,
while enhancing 5-HT transmission, dampen NE and dopamine neuronal
activity. Another way to understand low remission rates in major de-
pression is to realize that its pathophysiology may differ widely: it is poss-
ible to have two patients meeting diagnostic criteria and yet not have a
single sign or symptom in common. The treatment of depression therefore
often requires more than one mechanism. Consequently, the therapeutic
principles for depression do not differ from those of other medical
diseases, such as hypertension whereby more than one mechanism is
used even from treatment initiation. In fact, some of the first antidepres-
sants, such as clomipramine and MAO inhibitors, target more than one
mechanism. Now that we have wide choices of antidepressants that
have fewer side effects, it is possible to go back to the multiple target ap-
proach. A better understanding of the reciprocal interactions between
monoaminergic transmitter systems allows clinicians to follow a neurobio-
logical algorithm. This consists in combining various strategies acting on
different neuronal elements and avoiding pharmacologically redundant
strategies. Double-blind controlled studies have indeed shown that combi-
nations of antidepressants with a variety of other medications, for exam-
ple low doses of atypical antipsychotics, can lead to remission in
treatment-resistant patients, and in some cases to a more rapid onset of
action.
Policy of full disclosure: Dr Blier received grants and/or honoraria for
giving lectures and/or participating in advisory boards for Astra Zeneca,
Bristol Myers Squibb, Eli Lilly, Forest, Janssen, Lundbeck, Merck, Pfizer,
Pierre Fabre Medicaments, Servier, Sunovion, Takeda, and Valeant.
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Symposia
Monday 23 June 2014
S-01. Remodeling the neurocircuitry of
depression: Ketamine and glutamate
S-01-001 Current treatments of depression: Impact of monoamine
and glutamate
P. Blier1, K. El Iskandarani1, C.A. Oosterhof1, M. El Mansari1. 1University
of Ottawa, Ottawa, Canada
Objective: Ketamine is a non-competitive NMDA antagonist that acts pri-
marily by blocking the NMDA receptor at the PCP site. The antidepres-
sant qualities of ketamine were demonstrated in the clinic and in
several behavioral models of depression in rodents. We hypothesized
that the rapid antidepressant effects of ketamine are due to, at least in
part, its effects on the monoaminergic systems.
Methods: Experiments were carried out on male Sprague Dawley rats.
Rats were anesthetized with chloral hydrate (400mg/kg; ip) and mounted
on a stereotaxic frame. Recordings were carried out in the locus coeruleus
(LC) and the ventral tegmental area (VTA), 30 minutes following intra-
peritoneal ketamine administration (10mg/kg) for acute experiments.
The responsiveness of CA3 pyramidal neurons to iontophoretically ap-
plied AMPA and NMDA was assessed prior to, and up to 30 minutes fol-
lowing administration of ketamine.
Results: Following acute ketamine administration, an immediate and
significant increase in the firing rate of NE neurons was observed (29%).
Additionally, there was an enhancement in the number neurons exhibit-
ing bursting activity (control: 17%±1.7, ketamine: 30%±3.8, p<0.01). A
doubling in the number of spontaneously firing DA neurons was also
observed (control: 1.2±0.08 neurons/track, ketamine: 2.6±0.4 neurons/
track, p<0.01). The effect of ketamine on these electrophysiological para-
meters was prevented by pre-administration of the AMPA receptor antag-
onist NBQX 10 minutes prior to ketamine administration. A significant
increase (60%) in the responsiveness to iontophoretically applied AMPA
was observed 30 minutes following ketamine administration at a dose
of 10mg/kg.
Conclusion: The present results show that acute ketamine adminis-
tration produces an increase in NE and DA activity. These enhancements
were blocked by NBQX, indicating that these effects are mediated, at least
in part, via AMPA receptors. Furthermore, ketamine administration
caused an increase in the responsiveness of pyramidal neurons to ionto-
phoretically applied AMPA, suggesting an increased responsiveness of
these receptors.
Policy of full disclosure: Dr Blier received grants and/or honoraria for
giving lectures and/or participating in advisory boards for Astra Zeneca,
Bristol Myers Squibb, Eli Lilly, Forest, Janssen, Lundbeck, Merck, Pfizer,
Pierre Fabre Medicaments, Servier, Sunovion, Takeda, and Valeant.
S-01-002 Results of brain imaging of Ketamine using fMRI
and PET
R. Lanzenberger. Medical University of Vienna, Psychiatry, Vienna, Austria
Policy of full disclosure: R. Lanzenberger received travel grants and con-
ference speaker honoraria from AstraZeneca, Roche and Lundbeck A/S.
S-01-003 Prefrontal-amygdala attenuation of dopamine neuron
activity in animal models of depression: Reversal by
Ketamine
A. Grace1, P. Belujon1, C.-H. Chang1. 1University of Pittsburgh, Pittsburgh,
USA
Objective: Imaging studies reveal that depression correlates with hyper-
activity in Area 32 (infralimbic) PFC and hyper-responsivity in the amyg-
dala. We used the chronic mild stress (CMS) and learned helplessness
(LH) models of depression to examine this circuitry, how it impacts dopa-
mine neuron responsivity, and the therapeutic actions of ketamine.
Methods: Rats were exposed to either the CMS model or LH models of
depression/anhedonia. Dopamine neuron activity was sampled in the
ventral tegmentum, and rats were tested for escape behavior and forced
swim. Ketamine was administered in a subgroup of rats prior to record-
ing/assessing escape behavior.
Results: Rats exposed to CMS showed decreased dopamine neuron
activity and increased immobility in forced swim. Dopamine activity
was restored by inactivating the infralimbic PFC, the basolateral amyg-
dala, or blocking amygdala drive of the ventral pallidum. Only LH rats
that exhibited helpless behavior showed a deficit in the number of dopa-
mine neurons firing spontaneously, and a switch from hippocampal-
accumbens plasticity from LTP to LTD. Escape behavior, dopamine
neuron firing, and hippocampal-accumbens plasticity was restored to
baseline following ketamine.
Conclusion: The number of dopamine neurons firing is a measure of
the level of responsivity of the dopamine system, with fewer neurons ac-
tive greatly diminishing the ability of rewarding stimuli to activate the
dopamine system. This would be expected to lead to anhedonia; a
major feature of depression. Dopamine neuron activity is regulated by
two systems: a facilitatory system originating in the ventral hippocampus
that, via the accumbens, activates dopamine neurons. This contrasts with
an inhibitory circuit driven by the ilPFC-amygdala-ventral pallidal path-
way. These data suggest that in models of depression, there is an imbal-
ance between the hippocampal dopamine excitatory circuit and the
ilPFC-amygdala dopamine inhibitory circuit, in which the excitatory sys-
tem is taken off-line. This balance is restored by acute administration of
ketamine.
Policy of full disclosure: Johnson & Johnson, Lundbeck, Pfizer, GSK,
Puretech Ventures, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly,
Roche, Asubio, Abbott.
S-01-004 Too little or too much? The place of glutamate in
depression
M. Popoli. University of Milan, Milan, Italy
The glutamate system is recognized as a primary mediator of psychiatric
pathology and a target for rapid-acting antidepressants. Brain imaging
studies of depressed patients provided evidence of decreased volume of
cortical/limbic regions, suggestive of neuronal atrophy related to length
of illness and time of treatment. At the same time, rodent studies provided
evidence of dendritic remodeling and loss of synapses in depression/stress
models, suggesting neurocircuitry remodeling as a main factor in volu-
metric changes. Destabilization (enhancement) of glutamate release and
transmission, in turn induced by acute stress and glucocorticoids, is a
major factor for structural/functional changes in cortical and limbic
areas (1,2). Conversely, antidepressants dampen the stress-induced en-
hancement of glutamate release in prefrontal and frontal cortex (PFC/
FC), an action that may contribute to stabilize neurotransmission during
therapy (3). Further support for the glutamate hypothesis comes from stu-
dies showing rapid and sustained antidepressant action of NMDA recep-
tor antagonists, particularly ketamine, whose rapid action has been linked
to a burst of glutamate release and transmission (4). However, the nature
and direction of changes in the glutamate system, in pathophysiology and
during treatment, is not clear. While acute stress in adulthood induces en-
hancement of glutamate release/transmission, through distinct structural
and functional changes at different synapses of PFC, the behavioral conse-
quences of prenatal stress in adulthood have been shown to be associated
with reduced glutamate release in hippocampus (5). This talk will propose
a speculative model on changes associated with stress and stress-related
neuropsychiatric disorders, based on current available evidence.
References
1. Popoli M, Yan Z, McEwen BS, Sanacora G (2012) Nat. Rev. Neurosci.
13: 22.
2. Treccani G et al. (2014) Mol Psychiatry in press.
3. Musazzi L et al. (2010) PLoS ONE 18: 1413.
4. Duman RS, Aghajanian GK (2012) Science 338: 68.
5. Marrocco J et al. J Neurosci 32: 17143–17154.
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S-02. Neuron-glia interaction in schizophrenia:
Focus on D-serine
S-02-001 Neuron-glia regulation of D-serine signaling: Implication
in schizophrenia
T. Nishikawa. Tokyo Medical and Dental University, Tokyo, Japan
Objective: D-Serine, a putative endogenous coagonist for the NMDA type
glutamate receptor (NMDAR), and its metabolism and extracellular sig-
naling systems in the brain could dysfunction in schizophrenia and
could be the targets for the development of a novel pharmacotherapy
for this intractable disorder, because (1) NMDAR antagonists cause
schizophrenia-like symptoms and (2) D-serine has been reported to im-
prove these symptoms in schizophrenic patients as well as their animal
models. We therefore have investigated the molecular and cellular
mechanisms underlying these D-serine regulation systems by in vivo
and in vitro experiments and human sample analyses.
Methods: A molecular cloning, gene expression analysis, quantitation
of various amino acids by high-performance liquid chromatography, in
vivo microdialysis, and single nucleotide polymorphism genotyping tech-
nique were applied to the present animal and human studies that have
been approved by the ethics committees of the Tokyo Medical and
Dental University and National Center of Neurology and Psychiatry.
Results: In the rodent brains, the selective manipulations of the neurons
and glia resulted in the changes in the tissue and extracellular contents of
D-serine, suggesting the involvement of neuron-glia interaction in the
regulation of D-serine signaling. In vivo microdialysis experiments have
demonstrated that AMPA type glutamate receptors, GABAA receptors,
neutral amino acid transporters, Asc-1 and ASCT2, and neuronal serine
racemase participate in the control of extracellular D-serine contents
in the medial frontal cortex or hippocampus. Moreover, we have isolated
a gene, D-serine-modulator-1, that encodes the protein influencing
the intra- and extracellular D-serine contents when expressed in the
Xenopus oocytes.
Conclusion: The present findings suggest that neuron-glia communi-
cation could integrate the D-serine signaling by linking to
glutamate-GABA interaction and D-serine metabolism-related molecules.
These systems and molecules are under investigations of their genetic as-
sociation with schizophrenia and of their expressions in the postmortem
brains.
Policy of full disclosure: None.
S-02-002 D-Serine localization: Fact or artifact
J. Coyle1, D. Balu2, M. Puhl2, M. Benneyworth2, S. Takagi2. 1Harvard
University, Boston, USA; 2McLean Hospital, Belmont, USA
Recent results from genome wide association studies and from copy num-
ber variants associated with schizophrenia (SCZ) have implicated genes
encoding proteins involved in glutamatergic neurotransmission. This
includes serine racemase (SR), the enzyme responsible for the synthesis
of D-serine, the co-agonist at NMDA receptors (R), which is concentrated
in the cortico-limbic regions. Mice with null mutations of SR exhibit many
of the pathologic stigmata of SCZ including impaired working memory,
increased ventricular volume, decreased cortical volume, reduced
BDNF, phospho-TrkB, phospho-mTOR, dendritic complexity and den-
dritic spines on pyramidal neurons. To understand better the localization
of SR and D-serine, we used a combination of quantitative genetic and
immunologic methods. SR expression was blocked in a cell specific fash-
ion using mice expressing Cre in astrocytes with a GFAP promoter and in
forebrain glutamatergic neurons with CAMKIIα promoter. Cortical
D-serine levels were unaffected in the astrocyte SR knock-out (KO) and
were reduced by only 30% in the glutamatergic SRKO. Less than 15%
of SR was expressed in astrocytes and ∼65% in glutamatergic neurons.
Using the SR-/- mouse as a control for immuno-specificity, we found
that neither SR nor D-serine was expressed in the astrocytes in the adult
brain, but virtually all SR and D-serine was localized to neurons in neocor-
tex. Notably, only a subset of D-serine positive neurons contained SR in
the neocortex and hippocampus. Over half of the D-serine positive neu-
rons were GABAergic interneurons with the majority of these expressing
somatostatin and/or parvalbumin. These findings are consistent with
D-serine serving as the co-transmitter with glutamate in cortico-limbic
glutamatergic neurons and raise questions about the role of D-serine loca-
lized to GABAergic interneurons.
Policy of full disclosure: JT Coyle, MD has consulted with AbbVie and
EnVivo within the last 2 years and holds a patent on the clinical use of
D-serine that is owned by Massachusetts General Hospital. D. Balu,
M. Puhl, M. Benneyworth and S. Tagaki report no conflicts of interest.
This research was supported by grants from the N.I.H.
S-02-003 Role of glia-neuron crosstalk and the neuronal Asc-1
transporter in D-serine dynamics: Implications for
schizophrenia
H. Wolosker. The Rappaport Family Institute, Haifa, Israel
Objective: D-Serine is a physiologic regulator of NMDA receptors
(NMDARs) that mediates several NMDAR-mediated processes, ranging
from normal neurotransmission to neurodegeneration. Until recently,
D-serine was thought to be exclusively released by exocytosis from astro-
cytes, a type of glia cells that ensheath synapses. However, recent data
demonstrate that neurons are the main site of D-serine production and
storage in the brain. D-Serine is synthesized from L-serine by the enzyme
serine racemase (SR), which is predominantly expressed in neurons. Yet,
little is known about the regulation of D-serine synthesis and release
from nerve cells. We now sought to investigate the role of glia-neuron
crosstalk and plasma membrane transporters in regulating D-serine
dynamics.
Results: We demonstrate that neurons are indeed the major D-serine
producing cells in the CNS, but D-serine synthesis depends on glial
metabolism as well. Glia-selective knockout of 3-phosphoglycerate de-
hydrogenase, a key enzyme in L-serine synthesis, markedly decreases
the levels of D-serine in neurons. By exporting L-serine to neurons, astro-
cytes are essential for the neuronal synthesis of D-serine in a process we
call “serine shuttle”. Using pharmacological approaches and mice lacking
the neuronal Asc-1 transporter, we demonstrate that this transporter med-
iates neuronal D-serine release and regulates synaptic NMDAR potentials
and plasticity. Long term potentiation at hippocampal CA1 and isolated
NMDAR synaptic potentials were mostly dependent on endogenous
D-serine release, thought glycine also contributed to optimal NMDAR
activity.
Conclusion: Our results highlight the role of glia-neuron metabolic
crosstalk for optimal synthesis of D-serine. The data also suggest a
novel role of Asc-1 transporter in regulating NMDARs by mediating non-
vesicular release of D-serine. Drugs that enhance D-serine release via
Asc-1 might be useful to counteract the NMDAR hypofunction thought
to play a role in schizophrenia.
Policy of full disclosure: None.
S-02-004 DISC1-serine racemase interaction in astrocytes: At the
intersection of two major pathways of schizophrenia
M. Pletnikov. Johns Hopkins University, Baltimore, USA
Objective: Genetic polymorphisms of Disrupted-In-Schizophrenia-1
(DISC1) and D-serine/NMDA receptor hypofunction have both been asso-
ciated with schizophrenia. Recent reports have identified expression of
DISC1 in astrocytes that are the main source of D-serine in the brain.
Thus, we studied a pathogenic role of DISC1 in D-serine metabolism in
astrocytes.
Methods: We evaluated interplay between DISC1 and serine racemase
(SR), the enzyme that coverts L-serine to D-serine. The effects of mutant
DISC1 on D-serine production were also assessed in primary astrocytes
and brain tissue derived from transgenic mice that selectively express
mutant DISC1 in astrocytes. Glutamate uptake and expression of the
major astrocytic markers were measured in the same samples as well. In
a series of behavioral tests, we analyzed schizophrenia-related behavioral
alterations and ameliorative effects of D-serine treatments in GFAP-
mutant DISC1 mice.
Results: We found that DISC1 binds to and stabilizes SR. Pathogenic
disruption of this interaction by mutant DISC1 leads to accelerated ubiqui-
tination of SR and decreased D-serine production. We also observed
decreased expression of GlyT1 and increased expression of ASCT2 in mu-
tant astrocytes and transgenic mice with astrocytic expression of mutant
DISC1. On the contrary, mutant DISC1 does not change levels of
ALDH1L1, connexins, GLT-1 or binding partners of DISC1 and SR, LIS1
or PICK1. Consistently with our biochemical findings, transgenic mice
display greater responses to an NMDA antagonist, MK-801, in open
field and pre-pulse inhibition of the acoustic startle tests and are more sen-
sitive to the ameliorative effects of D-serine.
Conclusion: Our results indicate that DISC1 plays an important role in
regulation of D-serine production in astrocytes and for the first time links
DISC1 and NMDA pathophysiological mechanisms of schizophrenia.
Policy of full disclosure: None.
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S-03. Developing novel drug classes for
bipolar disorder
S-03-001 Development of mood stabilizers based on mitochondrial
dysfunction hypothesis of bipolar disorder
T. Kato. RIKEN Brain Science Institute, Wako, Japan
Objective: Except for lithium, currently available drugs for bipolar dis-
order are antiepileptics or antipsychotics. There have been no novel
drugs developed specifically for bipolar disorder. This is partly because
lack of animal models to test prophylactic efficacy of mood stabilizers.
Animal models based on genetics should be developed to promote drug
discovery. There are two strategies for development of novel mood stabi-
lizers; one is to mimic lithium’s effect, and the other is to identify new
drug targets based on genetic animal models.
Methods: Mitochondrial diseases, especially chronic progressive exter-
nal ophthalmoplegia (CPEO), frequent accompany bipolar disorder and
recurrent depression. Mitochondrial dysfunction is suggested in bipolar
disorder. Thus, we developed a transgenic mouse carrying a dominant
negative mutant of Polg (mitochondrial DNA polymerase), a causative
gene for CPEO, in a forebrain specific manner. The mice showed periodic
alteration of wheel running activity, which was suppressed by lithium
treatment. To search for a new drug target, we searched for the common
gene expression changes in the transgenic mice and postmortem brains of
patients with bipolar disorder.
Results: We identified that Ppif encoding cyclophilin D was commonly
altered both in the transgenic mice and postmortem brains. Cyclophilin D
is a component of mitochondrial permeability transition pore, which acts
as a mitochondrial calcium efflux channel. NIM811, an inhibitor of cyclo-
philin D, enhanced the calcium uptake in mitochondria isolated from
mouse brains. NIM811 was effective for the behavioral phenotype of the
transgenic mice.
Conclusion: Based on a genetic animal model of bipolar disorder, we
identified a candidate target molecule of mood stabilizers. This proof of
concept study would facilitate further screening of compounds acting
on mitochondria as candidates of new mood stabilizers.
Policy of full disclosure: Dr. Kato received a research grant from
Takeda Pharmaceutical Company Limited and honorarium for lectures,
manuscripts, or consultancy from Kyowa Hakko Kirin Co., Ltd., Eli
Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., GlaxoSmithKline
K.K., Taisho Toyama Pharmaceutical Co., Ltd., Dainippon Sumitomo
Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc.,
Mochida Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Janssen
Pharmaceutical K.K. and Astellas Pharma Inc.
S-03-002 Roles of genetics-based animal models in drug
development in bipolar disorder
T. Petryshen. Massachusetts General Hospital, Harvard Medical School,
Boston, USA
Objective: The development of new treatments for bipolar disorder has
been hindered by sparse knowledge of the neural mechanisms underlying
this disorder and the use of animal models with questionable validity.
Human genome-wide association studies (GWAS) have consistently iden-
tified the ankyrin 3 gene (ANK3) among the strongest genetic risk factors
for bipolar disorder. We are conducting a series studies using mouse gen-
etic models to investigate the disease mechanism of ankyrin 3 and evalu-
ate new pharmacological agents as potential therapeutics.
Methods: Using transgenic, RNA interference, and genome editing
methods, we are examining the behavioral, neurobiological, and molecu-
lar effects of modulating ankyrin 3 expression in mouse brain. Treatment
of ankyrin 3 mouse models with mood stabilizers highlights effects that
are relevant to the clinical disorder and implicates potential new drug tar-
gets. Therapeutic potential of novel agents, such as inhibitors of glycogen
synthase kinase 3 beta (GSK3B), is evaluated in behavioral studies of
ankryin 3 mouse models.
Results: Ankryin 3 reduction in mouse brain robustly increases impul-
sivity, exploration, and motivation for reward, heightens stress response,
and alters synaptic function. Transcriptional and proteomic changes in
Ank3+/- mouse brain implicate specific pathways containing potential
new treatment targets. The behavioral and synaptic changes are reversed
by chronic lithium treatment, supporting the clinical relevance of ankryin
3 mouse models for evaluating the therapeutic potential of novel agents.
Conclusion: Behavioral, neurobiological, and molecular alterations in
mice with reduced ankyrin 3 expression that are reversed by mood stabi-
lizers suggest potential new drug targets for bipolar disorder and support
the use of mouse genetic models for examining novel agents. These stu-
dies support the investigation of genetic risk factors using mouse models
to elucidate the neural mechanisms underlying bipolar disorder as a criti-
cal step in the development of new treatments.
Policy of full disclosure: Research supported by the NIMH, Stanley
Medical Research Institute, and Avis and Clifford Barrus Medical
Foundation.
S-03-003 Targeting synaptic and neural plasticity to develop novel,
improved, therapeutics for severe mood disorders
H. Manji. Johnson & Johnson, Titusville, USA
Objective: In recent years, significant advances have been made in our
understanding of serious neuropsychiatric illnesses, including severe
mood disorders. Typically, these common disorders start early in life,
making them chronic diseases of the young. Here, we review the under-
lying mechanisms of serious neuropsychiatric disorders and discuss the
clear need to develop improved treatments for these devastating illnesses.
Methods: Public and private resources devoted to research in this
area are diminishing. In the face of these challenges, a host of cutting-
edge approaches-from genomics to data mining, proteomics to bio-
markers, pathway modeling to protein engineering, neuroimaging to
optogenetics-is revolutionizing how we study these illnesses and develop
novel treatments for them. Mood disorders are multifactorial, resulting
from both genetic vulnerability and environmental stressors. They are
characterized by dysfunction in diverse biological systems, including
the intricate network of limbic, striatal, and fronto-cortical circuits that
mediate mood state, cognition, self-awareness, and insight.
Results: Recent progress has been made in understanding the under-
lying molecular and cellular basis of mood disorders. In particular,
there is a growing appreciation that impaired signaling pathways may
be involved in these disorders, and that targeting neural plasticity and re-
silience pathways may lead to novel therapeutics. Furthermore, recent evi-
dence suggests that mood stabilizers significantly affect the signaling
pathways that regulate neural and synaptic plasticity. Abnormalities in
cellular plasticity cascades likely also underlie impaired structural plas-
ticity. Many of these pathways are critical to both synaptic plasticity
and long-term cellular resilience. In turn, these changes in structural plas-
ticity appear to regulate resilience as well as long-term course of illness.
Based on these findings, a number of targeted strategies are being inves-
tigated that hold promise for developing improved therapeutics to treat
severe mood disorders.
Conclusion: Ongoing research may help to reconceptualize diagnostic
classifications and, ultimately, help design treatment approaches tailored
to illness stage and patient subpopulations.
Policy of full disclosure: Dr. Manji is an employee of Janssen
Pharmaceuticals/Johnson & Johnson.
S-03-004 Ebselen as a novel IMPase inhibitor as a lithium mimetic
G. Churchill1, N. Singh2, S. Vasudevan2, J. Thomas2, A. Halliday2,
I. Antoniadou2, T. Sharp2, A. Sharpley3, P. Cowen3. 1University of
Oxford, Oxford, United Kingdom; 2University of Oxford, Department of
Pharmacology, Oxford, United Kingdom; 3University of Oxford, Department
of Psychiatry, Oxford, United Kingdom
Objective: To identify a drug-like inhibitor of the enzyme inositol mono-
phosphatase for treating bipolar disorder with the efficacy of lithium with
less toxicity and fewer side effects.
Methods: Known experimental and approved drugs (National
Institutes of Health Clinical Collection) were screened for their ability to
inhibit bacterially expressed human and mouse forms of the enzyme in-
ositol monophosphatase type 1, the possible therapeutic target of lithium
underlying the inositol depletion hypothesis. Screening hits were vali-
dated by determining the mechanism of inhibition of the enzyme, intact
cell assays monitoring the metabolism of tritiated inositol, and brains
from mice injected intraperitoneally with ebselen in ex vivo assays of
enzyme activity and inositol levels. A validated inhibitor was then
tested in mouse behavioural tests of mania (exploratory behaviour and
amphetamine-induced mania) and depression (forced-swim test).
Results: Ebselen inhibits inositol monophosphatase, both in vitro with
isolated enzyme and ex vivo in homogenized brains of mice after intra-
peritoneal injection. Inhibition is dependent on a covalent selinium-sulfur
bond between ebselen and a cysteine near the enzyme’s active site.
Ebselen increased inositol 1-phosphate in cell cultures stimulated with
acetylcholine and decreased inositol in the brains of mice after intraperito-
neal injection. Ebselen was lithium-like in several mouse behavioural tests
as it increased exploratory behaviour and decreased hyperlocomotion
induced by amphetamine, which were reversed by intracerebraventricular
injection of inositol.
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Conclusion: Ebselen may be a lithium mimetic with less toxicity and
fewer side effects compared to lithium itself that is blood-brain
barrier permeant and acts through inhibition of inositol monophospha-
tase, supporting Berridge’s inositol depletion hypothesis. As ebselen has
a known safety profile (it reached Phase 3 trials for stroke but was not
marketed), it can be rapidly progressed into man. Indeed, we are currently
conducting a proof-of-concept study for lithium-like effects in healthy
volunteers.
Policy of full disclosure: Certain authors hold a patent on the use of
ebselen for treating bipolar disorder.
S-04. Paediatric disorders characterised by
aggression and/or social impairment: From
preclinical research to clinical subtyping
S-04-001 Gene-by-environment interaction and epigenetic
mechanisms in aggression: Lessons from animal models
K.-P. Lesch. School of Mental Health and Neuroscience (MHENS), Department
of Neuroscience, Maastricht, Netherlands
Objective: Although converging evidence links exposure to stressful life
events with increased risk for disorders of emotion regulation, including
aggression and antisocial behavior, there is extraordinary interindividual
variability in vulnerability to adversity. The environmentally moderated
penetrance of genetic variation is thought to play a major role in determin-
ing who will either develop dysfunctional and maladaptive behavior or
remain resilient.
Methods: Research on genetic factors in emotion regulation and
related disorders has, nevertheless, been complicated by a discrepancy
between high heritability estimates and a scarcity of replicable gene-
trait/disorder associations. One explanation for this incongruity is that
at least some specific gene effects are conditional on environmental
cues, i.e. gene-by-environment interaction (GxE) is present. For example,
a number of studies reported an association of variation in human sero-
tonin (5-HT) system-regulating genes with emotional and cognitive traits
as well as increased risk for disorders of emotion regulation in interaction
with psychosocial adversity.
Results: The results from investigations in non-human primate and
mouse support the occurrence of GxE by showing that variation of
5-HT gene function is associated with a vulnerability to adversity across
the lifespan leading to unfavourable outcomes resembling various
emotional disorders. The neural and molecular mechanisms by which en-
vironmental adversity in early life increases disease risk in adulthood are
not known but may include epigenetic programming of gene expression
during development. Epigenetic mechanisms, such as DNA methylation,
histone modification and chromatin remodeling, are dynamic and revers-
ible. Animal models amenable to genetic manipulation are useful in the
identification of molecular mechanisms underlying epigenetic program-
ming by adverse environments and individual differences in resilience
to stress.
Conclusion: Therefore, deeper insight into the role of epigenetic regu-
lation in the process of neurodevelopmental programmes is likely to result
in prevention or early diagnosis and will contribute to the design of inno-
vative treatments targeting the epigenetic machinery that foster resilience.
Policy of full disclosure: None.
S-04-002 Screening for novel aggression therapeutics in zebrafish
W. Norton. University of Leicester, United Kingdom
Aggression is common side effect of psychiatric disorders including
attention-deficit/hyperactivity disorder (ADHD) and conduct disorder.
However, our knowledge about the aetiology of aggression is limited
and current treatment strategies are insufficient. The zebrafish is an
ideal model organism to address this issue. Zebrafish display aggression
from around one month of age and agonistic behaviour can be reliably
measured by recording the interaction of a fish with its own mirror
image. Furthermore, aggression is controlled by similar genes and neuro-
transmitters in zebrafish and other vertebrates allowing the translation of
data to other species. Finally, drugs can be administered by immersion
(dissolving the drug in the tank water) thus speeding up their application.
Work in our laboratory has already established protocols to measure
aggression and used them to characterise fish lacking the function of a sin-
gle gene in the brain. As part of an EU-wide project called Aggressotype
we are now undertaking a screen to identify novel drugs that can modu-
late aggression levels. We will start by investigating the ability of existing
aggression therapeutics (methylphenidate, risperidone, valproate and
lithium) to reduce aggression levels in fish. We will then choose novel
drugs with similar chemical properties and examine their behavioural
function. Our screen will investigate a minimum of one hundred novel
drugs in the first year, and will test further compounds time permitting.
Promising drugs will be validated in aggressive mouse strains in order
to demonstrate a conserved behavioural function across species. This ap-
proach represents an excellent opportunity to identify novel aggression
therapeutics, with the global aim of improving treatments options for
patients suffering from psychiatric disorders.
Policy of full disclosure: No financial conflicts of interest.
S-04-003 Genetics of adult ADHD and antisocial personality
disorder
A. Reif. University of Wuerzburg, Wuerzburg, Germany
Objective: Attention deficit/hyperactivity disorder (ADHD) is amongst
the most common childhood neuropsychiatric disorders, often is
co-morbid with conduct disorder (CD) and syndromal aggression.
Regarding its etiology, ADHD is highly genetic and also CD has genetic
components. Despite being the candidate phenotype in several GWAS
and CNV studies, still only few risk genes have emerged for both
ADHD, CD, as well as symptomatic aggression. In 30–60% of cases, child-
hood ADHD persist into adult ADHD and also CD can develop into anti-
social personality disorder (APD). Especially childhood ADHD with
co-morbid CD can take the trajectory towards adult ADHD with
co-morbid APD. Only few studies however have addressed the genetic
basis of adult ADHD and APD.
Methods: Review of the literature, case-control studies, genome-wide
association studies.
Results: Still, no targeted GWAS have been published for adult ADHD
apart from a small pooled GWAS, although these are expected for spring
2014. Nevertheless, some candidate gene studies were published on
reasonably large samples and provided evidence for at least a few risk
genes. These mainly overlap with childhood ADHD risk genes (such as
DAT), however, there are also some risk genes that seem to be exclusive
for adult ADHD, e.g. NOS1. The latter genes therefore do not seem to in-
crease the risk for ADHD as such but rather its persistence into adulthood.
Studies on APD ofter suffer from small sample sizes, while studies on
symptomatic aggression or criminality have the drawback of phenotype
heterogeneity. Amongst the best replicated candidate genes in these
phenotypes is MAOA, acting in a gene x environment manner.
Conclusion: Despite being strongly genetic, present data still falls short
to explain the molecular architecture of adult ADHD and ASD. Larger
and well-controlled studies therefore are urgently needed that take into
account the developmental trajectory of these phenotypes, previous life
events, and psychophysiological endophenotypes.
Policy of full disclosure: None.
S-04-004 Overlap and differences between ADHD and conduct
disorder: Imaging genetics approaches
B. Franke. Radboud University Medical Centre, Department of Human Genetics
& Psychiatry, Nijmegen, Netherlands
Objective: ADHD and conduct disorder (CD) are highly common neuro-
developmental disorders and often co-occur. Both disorders have a strong
societal impact – through health care costs, but, especially in the case of
conduct disorder, also as a direct result of social maladjustment and
crime. Pathological aggression is regularly observed in both disorders.
This trait can be subdivided into two main subtypes, reactive impulsive
and low-emotional instrumental aggression, which facilitates research
into the underlying mechanisms.
Methods: As part of the EU project ‘Aggressotype’ we are investigating
the neural correlates of aggression in ADHD and CD. People with ADHD
often show impulsive aggression while those with CD more often display
instrumental aggression. Since both disorders show a strong influence of
genetic factors, our main question is how aggression risk genes influence
the brain in its structure, connectivity and function using imaging genetics
approaches.
Results: ADHD and CD are characterized by altered brain
structure, connectivity and function in cortical and subcortical structures.
Implicated in aggression traits in these disorders are mainly structures
in the limbic system (amygdala, hippocampus, ventral striatum) and sub-
regions of prefrontal cortex. Especially the amygdala and striatum and
their connections with prefrontal cortex are the subject of our research
investigating overlap and differences between ADHD and CD and be-
tween impulsive and instrumental aggression. We show that genetic vari-
ation in NOS1, a gene for ADHD and other impulse control disorders,
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indeed alters the activity of the ventral striatum during reward antici-
pation, while variants in the archetypical ADHD gene DAT1 do not
show this effect. Results of our consortium also implicate MAOA in
altered connectivity between amygdala and prefrontal cortex.
Conclusion: Genes with a role in ADHD indeed influence neural
substrates of aggression. The results for NOS1 and MAOA both fit with
a role of these genes in impulsive aggression.
Policy of full disclosure: None.
S-05. Alcohol dependence: Neuroimaging and
pharmacology
S-05-001 Mapping of functional brain activity in alcohol drinking
rats using manganese-enhanced magnetic resonance
imaging
P. Hyytiä1, M. Dudek2, U. Abo-Ramadan3. 1Helsinki, Finland; 2Institute of
Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland;
3Department of Neurology, University Central Hospital, Helsinki, Finland
Objective: Development of compulsive drug seeking is hypothesized
to involve neural adaptations in brain circuits mediating motivation and
reward. Although these circuits have been identified by previous work,
alterations in global functional brain activity in these circuits by long-
term use of abused drugs remain to be described. Therefore, in these
experiments, we used manganese-enhanced magnetic resonance imaging
(MEMRI) for measuring functional activity changes induced by voluntary
alcohol drinking in alcohol-preferring AA (Alko Alcohol) rats, one of the
best characterized animal models of high alcohol consumption.
Methods: The usefulness of MEMRI for functional brain imaging is
based on the ability of manganese ions to enter excitable cells via voltage-
gated calcium channels and to accumulate into neurons in proportion to
neural activity. The accumulation of manganese in active brain regions
can be seen as enhanced signal intensity in T1-weighted scans. Because
high acute systemic manganese doses are toxic, we used 7-day subcuta-
neous osmotic minipumps for manganese chloride administration. The
pumps were implanted following 6 weeks of voluntary alcohol drinking,
and the rats were then scanned at the end of the 7-day manganese chloride
infusion using a 4.7 T Bruker scanner.
Results: Compared to water-drinking controls, voluntary alcohol drink-
ing produced a widespread region-specific increase in MEMRI signal both
in cortical and subcortical brain regions. Increased signal was observed
also at the end of the alcohol-free period in animals with a previous his-
tory of long-term alcohol drinking. Many specific brain regions showing
altered activity were largely overlapping with the reward circuitry estab-
lished previously by other methods, including regions of the mesolimbic
and nigrostriatal dopamine pathways.
Conclusion: Collectively, our data suggest that MEMRI is a sensitive
method for detecting alterations in neuronal activity caused by long-term
voluntary alcohol consumption. Future experiments are designed to
examine the effect of potential medications on alcohol-induced brain
activation.
Policy of full disclosure: None.
S-05-002 Increased brain activity during protracted abstinence as a
predictor for relapse behaviour in alcohol dependent rats
W. Sommer1, W. Weber-Fahr1, K. Mann1, D. Hermann1, P. Hyytiä2,
S. Canals3, M. Brown4, M. Meinhardt1. 1Central Institute of Mental Health,
University of Heidelberg, Mannheim, Germany; 2Institute of Biomedicine,
University of Helsinki, Helsinki, Finland; 3Instituto de Neurociencias, CSIC,
Alicante, Spain; 4University of Alberta, Edmonton, Canada
Objective: Bringing novel medications from preclinical to clinical devel-
opment is challenging, especially when efficacy predictors are based on
subjective assessments. Neuroimaging methods such as magnet resonance
imaging (MRI) may allow for objective human-animal comparisons by
identifying brain imaging signatures that are comparable between
patients with alcohol use disorders (AUD) and animal models. Such sig-
natures may represent “AUD-networks” that should be positively modu-
lated (i.e. towards normal states) by effective pharmacological treatments.
Methods: Here, we used resting state functional MRI (rsfMRI) and
manganese enhanced MRI (MEMRI) for global mapping of brain activity
in an established rat model of abstinence from alcohol dependence.
Results: The combined analysis of rsfMRI and MEMRI data identified
abstinence related changes in cortical and subcortical brain regions
known to be involved in the addiction circuitry, but also regions currently
not in the focus of alcohol research. These results from neuroimaging cor-
roborate recent molecular findings from this model.
Conclusion: We expect that by integrating data from animal neuroima-
ging with respective human findings, it will be possible to increase the
translational value of all MRI modalities and the power of our strategy
to identify relevant neuronal networks in AUD and potential therapeutic
targets.
Policy of full disclosure: None.
S-05-003 Alcohol use disorder: Structural and functional brain
changes in abstinence and effects of naltrexone
A. J. Greenshaw. Department of Psychiatry, University of Alberta, Edmonton,
Canada
We are examining brain functional connectivity as part of the ERA-NET
NEURON and CIHR project TRANSALC. Using a 4.7 T MRI scanner to
measure resting state fMRI in patients with alcohol use disorder, patients
(5–10 days abstinent) and healthy controls were scanned and re-scanned
after three weeks. Patients underwent treatment during the three week
period with care as usual (participation in a residential addiction treat-
ment program involving groups and behaviour therapy) or naltrexone
plus care as usual. Seed region correlation analysis was used to investigate
functional brain networks. Using first scan data, with an anterior cingulate
cortex (ACC) seed there were larger correlations (i.e. greater involvement
in networks including ACC as a major component) in perigenual ACC for
controls compared to patients. With the seed in left anterior insula, first
session, there were greater correlations in subgenual ACC and ventral me-
dial prefrontal cortex for controls vs. patients and greater correlations for
patients vs. controls in right ventrolateral prefrontal cortex. In the first
scan, with the seed in right anterior insula, there were greater correlations
in subgenual ACC and ventral medial prefrontal cortex for controls vs.
patients and greater correlations for patients vs. controls in right anterior
insula. With data from the second scan, these differences were not present.
Our interpretation is that newly-abstinent patients had lesser resting state
activity compared to controls in the conflict and performance monitoring
network involving ACC. Newly-abstinent patients had larger resting state
activity in reward and value judgement networks involving right anterior
insula and right ventrolateral prefrontal cortex. Patients’ functional con-
nectivity patterns normalized during the three week treatment period be-
coming more similar to those of controls. The results from our studies will
be discussed in the context of current and emerging concepts of maladap-
tive and adaptive brain changes in relation to alcohol and drug abuse.
Policy of full disclosure: None.
S-05-004 NK1 and dopamine D3 antagonists as new approaches to
alcohol dependence
D. Nutt. Imperial College, London, United Kingdom
The massive prevalence of alcohol dependence and the relatively
limited efficacy of interventions means that there is a great unmet need.
One area particularly poorly served is that of relapse prevention treat-
ments. To begin to remedy this area we have developed an MRC funded
collaborative experimental medicine research ‘platform’ between Imperial
College, Cambridge and Manchester (ICCAM) (with GSK and Imanova as
partners). This uses psychological and MRI measures to assess the brain
processes underpinning relapse – reward, impulsivity and emotional
salience – and their associated brain systems in alcohol, cocaine and
opioid addiction. Moreover we studied the modulation of these effects
by an opioid receptor antagonist (naltrexone), a dopamine D3 antagonist
(GSK598809) and an NK1 antagonist (vofipitant or apipretant) with a
view to detecting potential effects that might be predictive of relapse pre-
vention. My talk will present the first data with from these studies in the
group of abstinent alcoholics and the implications for using these drugs in
relapse prevention.
Policy of full disclosure: I have no interests to declare other than have
been a consultant for GSK.
S-06. Emerging neuromechanisms for the
treatment of depression: Insights from
animal and human studies
S-06-001 Role of mTOR signaling and synaptogenesis in the
response to rapid acting antidepressants
R. Duman. Yale University, School of Medicine, New Haven, USA
Objective: Currently available medications for depression have significant
limitations, including a slow onset of action, low rates of response, and
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treatment resistance, emphasizing a major unmet need for more effica-
cious and faster-acting antidepressants. Recent studies have reported
that ketamine produces rapid (∼2 hr) antidepressant effects in patients
who have failed to respond to conventional antidepressants. The dis-
covery that NMDA receptor blockade produces such profound antide-
pressant effects represents one of the most important discoveries in the
field of depression in over 60 years. Preclinical studies have begun to un-
ravel the cellular mechanisms underlying the rapid actions of ketamine, as
well as other rapid acting agents.
Methods: The effects of ketamine and other rapid acting agents on
mTORC1 signaling, the number and function of spine synapse in PFC
neurons, and behavior in models of depression and antidepressant
response were determined.
Results: These studies demonstrate that ketamine rapidly increases the
number and function of synapses in the medial prefrontal cortex (PFC) via
a burst of glutamate and activation of mTORC1 signaling. Studies of such
additional putative rapid agents will be discussed, including selective
NR2B and mGlu2/3 receptor antagonists that also increase glutamate
transmission and stimulate mTORC1 signaling. In addition, scopolamine,
a muscarinic receptor antagonist scopolamine that produces rapid antide-
pressant effects in humans, also increases glutamate, mTORC1 and synap-
togenesis in PFC. Finally, drugs that enhance synapse formation, such as
GSK-3b inhibitors, and could thereby enhance or sustain the effects of
ketamine will be discussed.
Conclusion: The discovery that different rapid acting agents, but not
typical, antidepressants increase glutamate, mTORC1 and synaptogenesis
represents a fundamental shift in our understanding of the treatment and
pathophysiology of depression, and is informing and guiding current
drug discovery and development.
Policy of full disclosure: Dr. Duman is a consultant and/or receives re-
search funds from Taisho, Sunovion, Lundbeck, Forest, Johnson &
Johnson, Naurex, and Lilly.
S-06-002 Resilence and susceptibility to stress: Predictors of
response to antidepressants and ketamine
A. Markou1, A. Der-Avakian1. 1University of California San Diego, La Jolla,
USA
Objective: Anhedonia, or diminished interest or pleasure in rewarding
activities, is a core symptom of depression and reflects deficits in brain re-
ward circuitries. Social stress induces anhedonia in a subset of individuals
and increases the risk for depression, although the factors predicting this
susceptibility are poorly understood. The objectives of the present studies
were to characterize resilience and susceptibility to anhedonia in response
to chronic severe stress exposure, and investigate the effects of antidepres-
sants on the anhedonic response in susceptible rats.
Methods: Rats trained in the intracranial self-stimulation (ICSS) pro-
cedure were exposed to chronic social defeat and subordination. We
also evaluated the effects of chronic treatment with fluoxetine or desipra-
mine, or acute treatment with ketamine in susceptible rats.
Results: Exposure to chronic social defeat and subordination induced
profound and enduring deficits in brain reward function, reflecting a per-
sistent anhedonic response (i.e, ICSS threshold elevations), in a subset of
‘susceptible’ rats, while the remaining ‘resilient’ rats showed no long-term
deficits in brain reward function. Social defeat, regardless of susceptibility
or resilience, persistently decreased and increased brain-derived neuro-
trophic factor (BDNF) and phosphorylated AKT protein levels, respect-
ively, in the ventral tegmental area (VTA), whereas only susceptibility
was associated with increased phosphorylated mammalian target of rapa-
mycin (mTOR) in the VTA. Chronic administration of fluoxetine or desi-
pramine reversed brain reward deficits in susceptible rats with lower,
but not higher, stress-induced threshold elevations. Acute ketamine
administration reversed anhedonia only in a very small percentage of sus-
ceptible rats exhibiting mild anhedonia.
Conclusion: The differential persistent anhedonic response to psycho-
social stress may be mediated by VTA signaling molecules independent
of BDNF, and indicate that greater stress-induced anhedonia is associated
with resistance to antidepressant treatment. Consideration of these beha-
vioral and neurobiological factors associated with resistance to stress and
antidepressant action may promote the discovery of novel targets to treat
stress-related mood disorders.
Policy of full disclosure: Research contract support from
Bristol-Myers-Squibb, Forest Laboratories and Astra-Zeneca, and consult-
ing fee from AbbVie, Germany during the last 3 year.
S-06-003 Neuropeptide receptors as targets for drug discovery for
the treatment of depression
S. Chaki. Taisho Pharmaceutical Co. Ltd., Discovery Pharmacology, Saitama,
Japan
Objective: Stress has been well recognized as the primary cause of de-
pression and anxiety disorders, and neuropeptides have been suggested
to play a pivotal role in stress responses. The expression and secretion
of neuropeptides changes upon stress exposure so as to regulate
hypothalamus-pituitary-adrenal (HPA) axis activity and monoaminergic
neuronal activity. Therefore, the dysregulation of neuropeptide systems
may cause stress-related disorders, and neuropeptide receptors provide
an opportunity to develop novel treatments for depression and anxiety
disorders, in spite of recent failures of drug discovery targeting neuro-
peptide receptors.
Methods: We investigated antidepressant/anxiolytic potential of
antagonists for neuropeptide receptors, which are involved in the regu-
lation of HPA axis activity (vasopressin V1b receptor) and reward activity
(melanin-concentrating hormone MCH1 receptor and melanocortin MC4
receptor) in various animal models of depression and anxiety.
Results: V1b receptor antagonists having different scaffolds exhibited
antidepressant effects in animal models of depression such as a forced
swimming test and an olfactory bulbectomy model. In addition, a V1b re-
ceptor antagonist showed an antidepressant effect in a repeated corticos-
terone treatment model, which severely impaired HPA axis, consistent
with a mechanism of V1b receptor antagonism. At doses exerting antide-
pressant effects, a V1b receptor antagonist attenuated plasma ACTH elev-
ation induced by stimulation of the anterior pituitary V1b receptor,
supporting that V1b receptor antagonists may exert the effects through
blockade of HPA axis hyperactivity. Moreover, both MCH1 receptor
antagonists and MC4 receptor antagonists exerted antidepressant effects
in animal models of depression. Of note, these neuropeptide receptor
antagonists also showed anxiolytic effects in a variety of animal models
with more prominent effects in models which contains highly stressful
situation.
Conclusion: Therefore, neuropeptide receptor antagonists may have
potential for the treatment of depression and anxiety. Issues of drug dis-
covery approaches aiming at neuropeptide receptors will also be
discussed.
Policy of full disclosure: None.
S-06-004 Rewiring faulty circuits: The promise of deep brain
stimulation for severe major depression
T. Schlaepfer. University of Bonn, Department of Psychiatry, Bonn, Germany
Policy of full disclosure: None.
S-07. Allosteric modulators of metabotropic
glutamate receptors (mGlu) as novel tools
for the treatment of CNS disorders
S-07-001 Therapeutic implications of diverse modes of efficacy and
stimulus bias of allosteric modulators of mGlu receptors
P. J. Conn. Vanderbilt University Medical Center, Drug Discovery, Nashville,
USA
Objective: Allosteric modulators of GPCRs provide a novel approach to
modulation of specific GPCR subtypes. Negative allosteric modulators
(NAMs) inhibit whereas positive allosteric modulators (PAMs) potentiate
responses to endogenous agonists. Allosteric modulators offer high selec-
tivity for targeted receptors and provide an exciting new approach to de-
velopment of novel therapeutic agents.
Methods: We use a multidisciplinary approach to optimize highly
selective allosteric modulators for multiple subtypes of metabotropic glu-
tamate (mGlu) receptors and muscarinic acetylcholine receptors
(mAChRs) for treatment of CNS disorders. We evaluate these compounds
using molecular, cellular, and in vivo approaches.
Results: The diversity of allosteric modulators now available is allow-
ing us to develop fundamental new insights into the multiple mechanisms
by which these compounds regulate GPCR function and are providing
new insights into the functional impact of different modes of efficacy of
allosteric modulators. Closely related allosteric modulators can display
striking differences in their effects on GPCR signaling and subtle chemical
changes to convert a PAM to a NAM. In addition, some scaffolds display
allosteric agonist activity whereas others are pure PAMs. In addition, we
have observed multiple examples in which allosteric modulators confer
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“stimulus bias” and selectively regulate agonist effects on some but not all
signaling pathways coupled to a given GPCR. Finally, we have identified
allosteric modulators that differentially regulate activity of GPCR homo-
mers and heterodimers. Closely related allosteric modulators can have
fundamentally different effects in vivo, depending on subtle differences
in their effects on GPCR signaling.
Conclusion: Allosteric modulators of GPCRs provide a promising new
approach to targeting this important class of neurotransmitter receptors.
Subtle differences in modes of efficacy of different allosteric modulators
can have a major impact on efficacy and adverse effect liability of closely
related compounds.
Policy of full disclosure: Dr. Conn receives research funding from
Astrazeneca and Bristol Myers Squibb and is an inventor on multiple
patents protecting allosteric modulators of mGlu receptors and muscarinic
acetylcholine receptors.
S-07-002 Design, synthesis and evaluation of Novel Group II
Metabotropic Glutamate Receptor Allosteric Modulators
in rodent models of CNS disorders
N. D. P. Cosford1, R. Dhanya1, S. Sidique1, R. Dahl1, M. S. D’Souza2,
S. Semenova2, A. Der-Avakian2, P. J. Conn3, D. J. Sheffler1, A. Markou2.
1Sanford Burnham Medical Research Institute, La Jolla, CA, USA; 2University
of California, Department of Psychiatry, San Diego, La Jolla, CA, USA;
3Vanderbilt University Medical Centre, Nashville, TN, USA
The Group II metabotropic glutamate (mGlu) receptors include the mGlu2
and mGlu3 receptor subtypes and couple via Gi/o proteins to negatively
regulate the activity of adenylyl cyclase. Localization studies suggest
that mGlu2 receptors act as presynaptic autoreceptors to modulate release
of glutamate, whereas mGlu3 receptors exhibit a broad distribution in the
brain and have been shown to be present on astrocytes [1]. Recent findings
suggest that neuroadaptations in glutamatergic transmission produced by
repeated exposure to drugs of abuse such as cocaine or nicotine are likely
to contribute to the maintenance of addictive behaviors including drug
use, craving, and relapse to drug taking in humans. Repeated cocaine ex-
posure alters the function of mGlu2 and mGlu3 receptors while nicotine
increases glutamatergic neurotransmission by activating excitatory nic-
otinic acetylcholine (nACh) receptors located on glutamatergic terminals.
Brain regions implicated in different aspects of drug abuse and drug de-
pendence display high levels of mGlu2 and mGlu3 receptor binding,
suggesting a role for mGlu2/3 receptors in the development of drug de-
pendence and as potential targets for therapeutic agents. We recently
reported data on selective mGlu2 receptor positive allosteric modulators
(PAMs) in models of drug dependence [2–4]. We now report the design
and synthesis of novel, systemically active PAMS that selectively modu-
late both mGlu2 and mGlu3 receptors. Structure-activity relationship
(SAR) data on this series will be described in addition to results from
behavioral models of self-administration in rats.
Policy of full disclosure: None.
S-07-003 The antipsychotic activity of allosteric vs./orthosteric
agonists of mGlu4 receptors
A. Pilc1, J. Wieronska1, F. Acher2, D. Doller3. 1Institute of Pharmacology,
Polish Academy of Sciences, Krakow, Poland; 2UMR 8601 CNRS and
Université Paris Descartes, Paris, France; 3Lundbeck Research USA, Paramus,
USA
Objective: Clinical and basic studies suggest that a dysregulation of the
glutamatergic system plays an important role in some of the pathologic
changes associated with schizophrenia. Modulation of the central gluta-
matergic system via metabotropic glutamate (mGlu) receptors might
lead to novel pharmacological treatments. The objective of this work
was to explore, compare and contrast the pharmacological effects of cen-
tral activation of the mGlu4 receptor through orthosteric and allosteric
ligands.
Methods: Two groups of compounds that selectively activate the
mGlu4 receptor, the orthosteric agonists LSP1-2111 and LSP4-2022, as
well as the positive allosteric modulators (PAM) Lu AF21934 and Lu
AF32615, were characterized in terms of their in vivo properties in pre-
clinical models thought to represent different aspects of psychosis, includ-
ing positive, negative and cognitive disturbances. The role of 5-HT1A
receptors in the observed phenotype was also investigated with the use
of a selective agonist or an antagonist at this receptor.
Results: Compounds activating mGlu4 receptors through an orthosteric
or allosteric mechanism were efficacious in a number of preclinical rodent
models reflecting behaviors linked to positive, negative and cognitive
schizophrenia-like symptoms. These include dose-dependent inhibition
of both MK-801 and amphetamine-induced hyperactivity; antagonism of
2,5-dimethoxy-4-iodoamphetamine (DOI)-induced head twitches in
mice; MK-801-induced disruption in the social interaction test and efficacy
in the delayed spatial alternation test. The action of the ligands (as shown
for LSP1-2111 and Lu AF21934) was 5-HT1A receptor dependent.
Conclusion: The efficacy shown by compounds activating the mGlu4
receptor as assessed by mechanistic and behavioral models provides evi-
dence for a potential role played by this receptor in the pathophysiology
of schizophrenia. Regulation of synaptic glutamate concentrations using
compounds which activate the functional response of the mGlu4 receptor,
and the concomitant regulation of glutamate release by serotonine, may
be a promising mechanism for the discovery of novel antipsychotic drugs.
Policy of full disclosure: None.
S-07-004 Metabotropic glutamate and GABA receptors in fragile X
syndrome
D. R. Hampson. University Toronto, Leslie Dan Faculty of Pharmacy, Toronto,
ON, Canada
Fragile X syndrome is a genetic disorder caused by a CGG repeat expan-
sion in the fragile X Fmr1 gene. This syndrome is the most common single
gene cause of mental retardation. FXS is a “syndromic” form of autism
spectrum disorders (ASDs); about 35% of persons with FXS meet the
full criteria for autism while, over 90% have at least some autistic symp-
toms. Because non-syndromic ASDs have many causes, most of which
are unknown, the study of idiopathic autism has been hindered due to
a lack of good animal models. In contrast, there are several excellent an-
imal models of FXS. Animal models of FXS, particularly the Fmr1 KO
mouse, are widely studied not only to provide insight into FXS, but
also as a window into the non-syndromic forms of ASDs. In FXS there
is a perturbation of the delicate balance between neuronal excitation
and inhibition. Drugs acting at metabotropic glutamate receptors
(mGluRs) and GABAB receptors are currently in clinical trials for both
FXS and ASD. The results of clinical trials assessing the effects of negative
allosteric modulators of mGluR5 receptors, and agonists of the GABAB re-
ceptor, will be discussed along with the preclinical findings that led to the
initiation of the trials.
Policy of full disclosure: This work was supported by the Fragile X
Research Foundation of Canada, Lundbeck Research Inc., and the
Canadian Institutes of Health Research. The author has no financial confl-
ict of interest.
S-08. Obsessive-compulsive and related
disorders: A translational approach
S-08-001 Coherence between orbitofrontal cortex and nucleus
accumbens reflects OCD-like persistent avoidance
A. Grace1, T. Banasikowski1, C. McCracken1, T. Sesia2, G. Quirk2,
J. Rodriguez-Romaguera2. 1University of Pittsburgh, Pittsburgh, USA;
2University of Puerto Rico, San Juan, Puerto Rico
Objective: OCD is characterized by compulsive actions that may result
from a failure to use learned information to extinquish events that are
no longer salient, leading to inappropriate persistent avoidance. We
propose that this is due to deficits in the ability to devalue an avoidance-
triggering stimulus; consistent with overactivity in the orbitofrontal cortex
(OFC). This circuitry was examined by correlating local field potential
(LFP) coherence with OCD-like behavior.
Methods: Food-deprived rats trained to lever press for food were re-
peatedly exposed to a tone (CS) paired with a footshock; shock could be
avoided by stepping onto a nearby Plexiglas platform. Groups were
trained to low (60%), normal (90%) or overtrained (90% plus 7 additional
sessions) avoidance criteria. A Plexiglas barrier was subsequently inserted
into the chamber to prevent access to the platform and the CS was #deva-
lued# with repeated tone alone (without shock) presentation. This ap-
proach is believed to model the #extinction with response prevention
(Ext-RP) behavioral therapy used in OCD. After three Ext-RP sessions
the barrier was removed and animals were tested to see if the #devalued#
CS could still elicit avoidance.
Results: Overtrained, but not low or normal criteria rats, failed to deva-
lue the CS during Ext-RP training and continued to avoid excessively dur-
ing its presentation across test sessions. This finding suggests that
OCD-like behavior results from a failure to devalue avoidance-triggering
stimuli. LFP analyses suggest that such habitual avoidance behavior cor-
relates with an increase in OFC-NAc and decrease in OFC-BLA and
ilPFC-BLA coherence.
Conclusion: Therefore, deficits leading to excessive avoidance may be
mediated by a failure to normalize OFC-NAc network activity following
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devaluation of an evoking stimulus. This would result in an impairment
of the prefrontal cortex to down-modulate amygdala-driven anxiety states
in conditions in which the stimulus is no longer behaviorally salient.
Policy of full disclosure: Johnson & Johnson, Lundbeck, Pfizer, GSK,
Puretech Ventures, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly,
Roche, Asubio, Abbott.
S-08-002 The streptococcal model of obsessive-compulsive and
related disorders
D. Joel1, D. Lotan1, L. Brimberg1, M. Cunningham2. 1University of Tel-Aviv,
School of Psychological Sciences, Tel Aviv, Israel; 2University of Oklahoma,
Health Sciences Center, Microbiology and Immunology, Health Sciences
Center, Oklahoma City, USA
Objective: Group A ß-hemolytic streptococcal (GAS) infection is asso-
ciated with a spectrum of neuropsychiatric disorders, including
Sydenham’s chorea, pediatric autoimmune neuropsychiatric disorders
associated with streptococcus (PANDAS), obsessive-compulsive disorder,
and Tourette’s syndrome. The leading hypothesis regarding this associ-
ation proposes that a GAS infection induces the production of auto-
antibodies, which cross-react with neuronal determinants in the brain
through the process of molecular mimicry.
Methods:We have established a novel rat model of GAS-related neuro-
psychiatric disorders, which mimics behavioral, pharmacological, immu-
nological and neural characteristics of GAS-related neuropsychiatric
disorders (Brimberg et al., 2012, Neuropsychopharmacology, 37, 2076–
2087).
Results: Using this model we found that exposure of male Lewis rats to
GAS antigen leads to induction of antibodies, which react with D1 and D2
dopamine receptors and 5-HT2a and 5-HT2c serotonin receptors, in vitro,
and deposit in the striatum, prefrontal cortex and thalamus in vivo.
Calcium calmodulin dependent protein kinase II was activated by
serum IgG in a human neuronal cell line and dopamine and glutamate
levels were altered in the medial frontal cortex and basal ganglia of
GAS-exposed rats, supporting functional effects of the autoantibodies.
Behaviorally, GAS-exposed rats show increased compulsive-like behavior
and motor disturbances, which are attenuated by a selective serotonin
reuptake inhibitor and a D2 blocker, respectively, further supporting the
link between GAS-exposure, dysfunction of the serotonergic and dopami-
nergic systems and behavioral abnormalities. Finally, infusion of IgG from
GAS-exposed rats to naïve rats led to behavioral and motor alterations
partially mimicking those seen in GAS-exposed rats, and to IgG deposits
in the striatum of infused rats, which colocalized with dopamine receptors
and with the serotonin transporter.
Conclusion: Our results demonstrate the potential pathogenic role of
anti-neuronal autoantibodies produced following exposure to GAS in
the induction of behavioral and motor alterations, and support a causal
role for autoantibodies in GAS-related neuropsychiatric disorders.
Policy of full disclosure: None.
S-08-003 Current perspectives on compulsivity
T. Robbins. University of Cambridge, Department of Psychology, Cambridge,
United Kingdom
Compulsivity is a burgeoning dimensional construct in neuropsychiatry
that can be defined as the maladaptive tendency to repeat behaviour with-
out apparent purpose, often with adverse consequences. It is relevant not
only to disorders which explicitly describe compulsive behaviour as a key
symptom, such as the prototypical obsessive-compulsive disorder (OCD),
and also drug addiction and gambling, but also eating disorders, and el-
ements of autism and schizophrenia. Like impulsivity, compulsivity may
have several forms and could be understood for example at the levels of
sterotyped motor behaviour at one extreme (e.g. tics) and perseverative
and inflexible, rigid thinking at the other. Compulsive behaviours can the-
oretically be understood as resulting from excessively engaged attentional
processing, from aberrant stimulus-response habits, excessively retarded
extinction, and perseverative responding in reversal learning tasks or
from combinations of these factors. Consequently, such experimental
paradigms may be implemented to delineate underpinning psychological
processes that contribute to compulsive behaviour, and their precise
neural substrates in experimental animals as well as in humans. This
talk will illustrate several examples of this translational strategy with re-
spect to OCD and addiction. For example, the balance of competing
neural systems mediating action-outcome learning and stimulus-response
habit learning appears to be shifted towards the latter in obsessive-
compulsive disorder, based on performance of a human associative learn-
ing paradigm inspired by neuropsychological experiments on associative
learning in rodents. A further approach to establishing a
neurobehavioural understanding of compulsivity using such methods as
resting state functional connectivity, is to compare directly neural net-
works affected in such disorders in order to establish whether their appar-
ently different compulsive behaviours are mediated by shared
neuroanatomical circuitry, thus further validating a common construct
of compulsivity.
Policy of full disclosure: None.
S-08-004 Clinical advances in obsessive-compulsive and related
disorders
D. Stein. University of Cape Town, Cape Town, South Africa
Objective: To review recent clinical research on obsessive-compulsive and
related disorders (OCRDs), and to assess advantages and disadvantages
of including this new category in the diagnostic classification system.
Methods: As part of the DSM-5 and ICD-11 process, reviews of
obsessive-compulsive and related disorders, including relevant psycho-
biology, were undertaken. Key findings from these reviews, as well as
from DSM-5 field surveys, are summarized here.
Results: There is growing evidence that the psychobiology of obsessive-
compulsive disorder (OCD) differs from that of anxiety disorders. There
are important overlaps in symptom evaluation and treatment approach
across OCDRs characterized by preoccupations and repetitive behaviors
(e.g. OCD, body dysmorphic disorder, hoarding disorder), and across
OCDRs characterized by body-focused repetitive behaviors (e.g. trichotil-
lomania, excoriation disorder).
Conclusion: The new category of obsessive-compulsive and related dis-
orders may encourage appropriate recognition and treatment of these
under-diagnosed disorders. However, it is important for clinicians to be
aware of key differences across these conditions. Additional work to con-
solidate a translational neuroscience approach to these conditions is
needed.
Policy of full disclosure: In the past 3 years, Dr. Stein has received re-
search grants and/or consultancy honoraria from Biocodex, Lundbeck,
Novartis, Servier, and Sun.
S-09. Neuroimaging vulnerability to
neuropsychiatric disorders
S-09-001 Using neuroimaging to identify neural markers of
familial vulnerability to depression
P. Cowen. University of Oxford, Department of Psychiatry, Warneford
Hospital, Headington, Oxford, United Kingdom
Objective: To identify neuroimaging biomarkers of vulnerability to de-
pression in young people at increased familial risk.
Methods: Functional neuroimaging using fMRI with BOLD and struc-
tural MR in euthymic young people with a biological parent with recur-
rent major depression.
Results: Young people at increased familial risk of depression may have
smaller hippocampal volumes though the expression of this abnormality
may depend on a combination of childhood maltreatment and genetic
risk. Young people at risk of depression exhibit impaired neural responses
to rewarding and aversive stimuli. There is also behavioural evidence for a
conservative approach to risk-taking even when the odds of a good out-
come are favourable.
Conclusion: Young people without significant depressive symptoms
but at increased familial risk of illness demonstrate a range of abnormal
neuroimaging biomarkers. The relation of these abnormalities to the risk
of experiencing subsequent depression is unclear and follow-up studies
are needed. It is possible that impaired reward mechanisms could be
linked to sub-optimal decision-making, thereby increasing psychosocial
adversity and the risk of depression.
Policy of full disclosure: The studies of the author were supported by
the UK Medical Research Council PJC has been a member of advisory
boards for Lundbeck and Servier.
S-09-002 Neuroimaging the vulnerability to depression: The
glutamate system
G. Hasler. University of Bern, Psychiatric University Hospital, Bern,
Switzerland
Objective: To review the current evidence for a glutamatergic
vulnerability to depression based on molecular neuroimaging studies in
humans.
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Methods: Magnetic resonance spectroscopy, positron emission
tomography.
Results: Glutamate is the major excitatory neurotransmitter in the brain,
playing an important role in neuronal plasticity, learning, and memory.
Reduced prefrontal and subcortical glutamate/glutamine, as determined
by magnetic resonance spectroscopy, has been found to be a specific
marker of unipolar depression. In bipolar disorder, glutamate/glutamine
has been shown to be consistently increased in all mood states (1).
Moreover, there is increasing evidence demonstrating abnormalities in
glutamate receptors in depressed individuals. The metabotopic glutamate
receptor 5 (mGluR5) has been found to be decreased in depression in both
a positron emission tomography study and in a postmortem study on
mGluR5 protein expression (2). In some depressed patients, increased
levels of N-Methyl-D-Aspartate (NMDA) receptor antibodies (epitope:
Nr1a/NR2b) have been detected.
Conclusion: Taken together, neuroimaging and possibly neuroimmune
measures of the glutamate system may provide promising mood disorder
subtype-specific biomarkers for the vulnerability to clinical depression.
Policy of full disclosure: None.
S-09-003 What underlies the onset of psychosis? Multi-modal
and longitudinal imaging data from people at risk
of psychosis
O. D. Howes. Imperial College –Hammersmith, Cyclotron Building,
Hammersmith Hospital, London, United Kingdom
Objective: It is not known when dopaminergic overactivity first occurs in
the development of psychotic disorders such as schizophrenia or the re-
lationship between dopaminergic dysfunction and the neural substrates
of cognitive impairment.
Methods: The following age-matched groups have received longitudi-
nal [18F]-DOPA PET imaging: A) individuals with at risk mental states
(ARMS, n=54) who show prodromal signs of developing psychosis; B)
individuals with persistent sub-clinical symptoms who have not devel-
oped psychosis (psychosis continuum, n=14); C) healthy controls
(n=36). The ARMS subjects received follow-up to determine who devel-
oped psychosis and repeat PET scans to determine change in
[18F]-DOPA influx constants (Ki) values. The neural substrates of cogni-
tive impairments seen in the ARMS were investigated using functional
magnetic resonance imaging whilst subjects performed tasks involving
working memory and executive function.
Results: There was a significant group effect on Ki values at baseline
for the whole striatum (F=3.7, df=2,42, p=0.035), and the AST striatal
subdivision (F=6.5, df=2,42, p=0.004); and this was replicated in a second
independent cohort (p=0.001). The elevation in the ARMS group was seen
in the nine ARMS subjects who developed psychosis but was not evident
in those who have not developed psychosis to date, or in the psychosis
continuum group. Furthermore there was a longitudinal increase in
Ki value as subjects developed psychosis (t =3.01, df=7, p=0.020).
ARMS subjects showed greater activation during the cognitive task, and
this was directly correlated with striatal dopamine function (r=0.732,
p<0.001).
Conclusion: These findings indicate that i) elevated dopamine synthesis
capacity predates the onset of psychosis in people with prodromal symp-
toms, ii) is related to the neural substrates of neurocognitive dysfunction;
iii) increases further over time with the development of psychosis; and iv)
is specific to the risk of a psychotic disorder.
Policy of full disclosure: Funded by MRC UK.
S-09-004 PET studies of dopamine responses in subjects at risk
for substance use disorders
M. Leyton. McGill University, Montreal, Canada
Objective: Only some people who try drugs of abuse develop a substance
use disorder. Here, we tested whether people at elevated risk for addic-
tions have disturbed drug-induced activations of the dopamine reward
system.
Methods: Striatal dopamine release was measured in two studies using
positron emission tomography (PET) with [11C]raclopride. In Study 1,
d-amphetamine (0.3 mg/kg, p.o.), given in the absence of drug-related
cues, was administered to three groups: (1) high-risk young adults with
a multigenerational family history (FH) of substance use disorders (FH+,
n=16), (2) stimulant drug-naïve healthy controls with no known risk
factors for addiction (Ctls_naive, n=17), and (3) subjects matched to the
high-risk group on personal drug use but without a FH of substance
use problems (Ctls_exposed, n=15). In Study 2, an alcohol beverage
was ingested with cues present (sight, smell, taste & touch, 0.75 g
ethanol/kg, p.o.) by two groups (n=13/group) differentiated by reward-
sensitivity related personality traits and the Subjective High Assessment
Scale index of risk for alcohol use disorders.
Results: Study 1: When given encapsulated d-amphetamine, the
high-risk FH+ subjects exhibited significantly smaller [11C]raclopride
responses, as compared to both control groups. Past drug use correlated
negatively with the [11C]raclopride response, but including it as a covari-
ate increased the group differences. Study 2: High-risk subjects exhibited
significantly larger [11C]raclopride responses than low-risk subjects after
drinking alcohol.
Conclusion: These studies provide the first evidence that young
adults at high-risk for substance use disorders have disturbed dopamine
responses to drug challenges, the exact direction of which may depend
upon conditions of the study, such as the presence vs. absence of
drug-related cues. Since the participants were non-dependent, the pertur-
bation expresses itself well before extensive drug exposure, potentially
reflecting a trait marker for addictions.
Policy of full disclosure: None.
S-10. Coming of age for phosphodiesterase
inhibitors as central nervous system
therapeutics
S-10-001 Role of PDE-mediated signaling and its crosstalk in
brain function
A. Nishi1, M. Kuroiwa1, T. Shuto1, S. Gretchen2. 1Kurume University School
of Medicine, Department of Pharmacology, Fukuoka, Japan; 2Intra-Cellular
Therapies, New York, USA
Objective: Dopamine neurotransmission is mainly mediated through
cAMP/PKA signaling. Phosphodiesterases (PDEs) that inactivate cAMP
and/or cGMP are involved in dopamine neurotransmission. PDE inhibi-
tors have therapeutic potential in treating neuropsychiatric disorders,
but development of therapeutic drugs has not successful because of the
complexity of CNS PDE systems. Multiple PDEs with different substrate
specificity and subcellular localization control cAMP and cGMP signaling
in a neuron-type specific manner. We have screened the effect of various
PDE inhibitors on cAMP/PKA signaling in brain slices, and found that
inhibitors of PDE2A, PDE4 and PDE10A are useful to dissect the role of
each PDE.
Methods:We used in vitro biochemical techniques to dissect the role of
PDEs in dopamine neurotransmission. The ability of selective PDE inhibi-
tors to regulate phosphorylation of presynaptic (e.g., tyrosine hydroxy-
lase) and postsynaptic (e.g., DARPP-32 and GluA1) PKA substrates was
monitored in mouse brain slices from striatum, prefrontal cortex and hip-
pocampal dentate gyrus.
Results: In the striatum, the PDE10A inhibitor, papaverine, and the
PDE2 inhibitor, BAY 60-7550, activated cAMP/PKA signaling in both
striatonigral and striatopallidal neurons, and potentiated dopamine D1 re-
ceptor signaling. The PDE4 inhibitor, rolipram, mainly acted at dopami-
nergic terminals and increased dopamine turnover. Nitric oxide/cGMP
signaling counteracted cAMP/PKA signaling via activation of PDE2A,
demonstrating a mechanism for interaction of cAMP and cGMP signaling.
In the prefrontal cortex, PDE4 and PDE2A, but not PDE10A, activated
cAMP/PKA signaling, and the inhibition of PDE4 or PDE2A potentiated
dopamine D1 receptor signaling. Furthermore, actions of PDE4 and
PDE2A inhibitors were synergistic. In the hippocampal dentate gyrus,
PDE4, PDE2A and PDE10A are involved in the regulation of cAMP/
PKA signaling. The roles of these PDEs in antidepressant effects are
under investigation.
Conclusion: These data suggest that PDE inhibitors, acting at multiple
PDEs, have the potential to regulate cAMP/PKA signaling efficiently in a
neuron-type specific manner, and may be a useful therapeutic approach to
neuropsychiatric disorders.
Policy of full disclosure: None.
S-10-002 Role of cyclic nucleotides in cognitive function in
the brain
L. Wennogle. Intra-Cellular Therapies, Drug Discovery, New York, USA
Objective: The objective of this work is to test the effectiveness of phos-
phodiesterase inhibitors for disorders of the central nervous system in-
volving cognitive dysfunction, and in particular cognitive impairments
associated with schizophrenia (CIAS).
Methods: Potent and selective phosphodiesterase 1 (PDE1) inhibitors
have been evaluated in various models of cognition.
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Results: We have developed potent, selective and safe small molecules
with good oral bio-availability. The lead compound for CIAS, ITI-214, is
active in animal models of cognition including the rat novel object recog-
nition with a broad time course of effectiveness.
Conclusion: In view of the well-established hypo-functionality of the
dopamine D1 receptor in pre-frontal areas of the brain associated with
cognitive function in schizophrenia and the close association of PDE1
with the signaling of the D1 receptor, we have been evaluating PDE1 inhi-
bitors, together with our collaborators at Takeda Pharmaceuticals, for cog-
nitive impairment associated with schizophrenia (CIAS). The background
to this work as well as the status of development will be reviewed.
We have potent, selective and safe small molecules with good oral
bio-availability. The lead compound for CIAS, ITI-214, is active in animal
models of cognition including the rat novel object recognition with a
broad time course of effectiveness.
Policy of full disclosure: Lawrence Wennogle is a full-time employee of
Intra-Cellular Therapies, Inc.
S-10-003 PDE4 and PDE5 inhibitors in cognition enhancement:
From animals to humans and back again
J. Prickaerts. Maastricht University, Maastricht, Netherlands
Objective: Phosphodiesterases (PDEs) are enzymes that differ in their
substrate, i.e. cyclic adenosine monophosphate (cAMP) and/or cyclic
guanosine monophosphate (cGMP), being hydrolyzed. Since these cyclic
nucleotides have been suggested to play specific roles in processes of
cognition, selective PDE inhibitors preventing the breakdown of cAMP
and/or cGMP could improve cognition. Our objective is to elucidate the
putative procognitive effects of PDE inhibitors in a translational approach.
Methods: Rodents and monkeys were treated with different inhibitors
of PDE2, PDE4, or PDE5 and tested in cognitive tasks. In a translational
approach we also investigated the effect of PDE5 inhibition on cognition
in humans.
Results: Animal studies with different timing of treatment with specific
PDE inhibitors indicated that distinct underlying signaling pathways for
early and late consolidation processes exist corresponding to specific time-
windows for memory consolidation. We also explored other cognitive
domains including acquisition processes/short-term memory and infor-
mation processing. It was found that elevation of central cGMP levels as
well as cAMP levels after treatment with a specific PDE inhibitor
improves acquisition processes/short-term memory. Further, the effects
of specific PDE inhibitors on information processing by using a sensory
gating paradigm indicate that elevation of cGMP as well as cAMP with
a specific PDE inhibitor improves sensory gating, whereas elevation of
cGMP alone has no effect. We also investigated the effect of PDE5 inhi-
bition on cognition in humans. In contrast to animal studies, PDE5 inhi-
bition had no effect on memory processes in humans. Yet sensory
gating was also not affected underlying the translational value of this
measure.
Conclusion: Obviously, the transition of a drug from preclinical to clini-
cal creates translational hurdles. This has to be taken into consideration
and minimized in order to be able to select a specific PDE inhibitor (e.g.
PDE2, PDE4 or PDE5) as a promising drug to enhance cognitive function
in humans.
Policy of full disclosure: None.
S-10-004 Differential effects of PDE2, 4, 9 and 10 inhibition on
biochemical and behavioral markers of striatal function
C. Schmidt. Pfizer, Groton, USA
Objective: The complexity of cyclic nucleotide phosphodiesterases in the
striatum underscores the importance of second messenger signaling in
this nucleus. This presentation will focus on the use of selective inhibitors
of four enzyme families: two dual substrate enzymes, PDE2A and
PDE10A, the cGMP-specific PDE9A and the cAMP selective PDE4 family.
Results: PDE10A is the most highly expressed PDE in the striatum and
its inhibition elevates activity in both the cAMP and cGMP signaling cas-
cades to amplify striatal output. Behaviorally, PDE10A inhibition mimics
the effects of D2 receptor blockade. The cGMP pool regulated by PDE10A
is generated by the soluble guanylyl cyclase (sGC)/nNOS/NO system and
play a role in regulating the response of striatal neurons to cortical input.
In contrast to PDE10A inhibition, PDE2A inhibition results in only modest
changes in cGMP and cAMP signaling and behavior under basal condi-
tions. However, during D1 receptor stimulation, cGMP derived from the
sGC/NO/nNOS pathway activates PDE2A to regulate striatal cAMP sig-
naling. Although PDE9A has one of the lowest expression levels of any
striatal PDE, inhibition of this enzyme elevates levels of cGMP throughout
the brain. Significantly, PDE9 appears to regulate a pool of cGMP inde-
pendent of NO/nNOS and therefore distinct from that regulated by
PDE10A and from that involved in the regulation of PDE2A activity.
The activity of PDE4 inhibitors in models linked to striatal function
such as CAR and catalepsy has been well-described. Despite this beha-
vioral similarity to PDE10A inhibition, the neurochemical effects of
PDE4 inhibition are modest by comparison. Yet, while the administration
of rolipram does not affect basal cAMP or pCREB levels or other elements
of cAMP cascade, pharmacological manipulations decreasing cAMP sig-
naling are reversed by PDE4 inhibition.
Conclusion: These studies, using selective PDE inhibitors, reveal the
presence of functionally overlapping but biochemically distinct pools of
both cAMP and cGMP in the striatum.
Policy of full disclosure: In am a full time employee of Pfizer, Inc.
JS-01. Japanese Session: Current research topics
in schizophrenia and future perspectives
JS-01-001 Cognitive impairment and response to antipsychotic
drug treatment as intermediate phenotypes in
schizophrenia: Integrating animal model, genetic and
clinical trial approaches
H. Meltzer1, Y. Oyamada1, L. Rajagopal1, J. Li1. 1Psychiatry and Behavioural
Science, Northwestern Feinberg School, Chicago, USA
Objective: Cognitive impairment in schizophrenia (CIS) and persistent
psychotic symptoms in patients not responsive to antipsychotic drugs
(APDs) other than clozapine are endophenotypes and treatment targets.
Deficiencies in glutamate, GABA, dopamine (DA), and acetylcholine
(Ach) neurotransmission in cortex and hippocampus are hypothesized
causes of CIS.To clarify which neurotransmitters enable atypical APDs
to be more effective means of preventing or treating cognitive impairment
due to subchronic PCP treatment and to identify a genetic biomarker and
treatment target for treatment resistant schizophrenia (TRS).
Methods: Rodents treated sub-chronically with the N-methyl-D-
aspartate (NMDAR) antagonist phencyclidine (PCP) were administered
serotonin (5-HT)1A, 5-HT2A, 5-HT2C and 5-HT7 receptor agentss, or
D1, D2, and GABA A receptor agents, to determine which prevent or
restore cognitive function in subchronic PCP- treated rodents. A GWAS
study of TRS and NonTRS patients was used to identify a potential bio-
marker for TRS
Results: 5-HT1A partial agonism, 5-HT2A, 5-HT7 antagonism, GABA
A agonism, and weak D2 antagonism will be shown to impact PCP
induced cognitive impairment in rodent. The SNP rs2237457, located in
7p12.2, had the lowest p value to discriminate RS and NRS, and is
70 kb upstream from dopa decarboxylase (DDC), the rate limiting enzyme
for trace amine synthesis. Animal model studies have shown that the trace
amine associated receptor 1 (TAAR1) is a target for developing novel anti-
psychotic drugs (Revel et al. 2013 Mol Psychiatry 18:543–565). An agonist
for TAAR1 is also effective in the subchronic PCP model of CIS noted
above.
Conclusion: These results suggest animal models and genetic studies
based upon endophenotypes can be of great value in developing novel
treatments for specific dimension of the schizophrenia syndrome.
Prevention of development of CIS by early treatment with tolerable neuro-
protective agents may be the best way to minimize cognitive impairment
of schizophrenia.
Policy of full disclosure: Financial disclosure for Dr. Meltzer-
Ownership/Investment Interests-Suregene, ACADIA, GlaxoSmithKline
Industry activities (such as speaking, advising, consulting, providing
educational programs)- Janssen Pharmaceuticals, Lundbeck Inc.,
Sunovion Pharmaceuticals Inc, Dainippon Sumitomo Pharma Co., Ltd,
TEVA, BiolineRx, BI (Boehringer Ingelheim Pharma GmbH & Co. KG,
Envivo, Companion Diagnostics, ACADIA Grant Support (in last
3 years)-Bioline Rx,Cephalon, Eli Lilly,Janssen,Pfizer, Sunovion
Novartis, Dainippon Sumitomo, Envivo NeuroTherapeutics Pharma,
Inc, Otsuka, Takeda Alkermes, Naurex, Inc, Reviva Pharmaceuticals,
Inc, Astellas Research Institute of America.
JS-01-002 Identification of chromosomal segments and individual
genes critical for schizophrenia in mouse models of
22q11.2 copy number variants
N. Hiroi. Albert Einstein College of Medicine, USA
Objective: Hemizygosity of 22q11.2 is associated with extraordinarily
high rates of schizophrenia and autism spectrum disorders (ASDs). The
critical barrier to understanding precise genotype-phenotype relationship
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is that this chromosomal deletion is minimally 1.5Mb in size and includes
at least 30 genes. We and others previously demonstrated, using genetic
mouse models, that a 200 kb region is responsible for many behavioral
phenotypes of 22q11.2 hemizygosity. We have further evaluated the role
of Tbx1, one of the genes encoded in the 200 kb region, in behavioral
and neuronal phenotypes.
Methods: Male, congenic Tbx1 heterozygous (HT) mice and their wild-
type (WT) littermates, at 2 months of age, were evaluated for behavioral
phenotypes in a battery of behavioral tests. Moreover, because Tbx1 pro-
tein is enriched in postnatal neural progenitor cells (pNPCs), we examined
the role of this gene in proliferation of pNPCs using Tbx1 HT mice and
Tbx1 siRNA in culture of pNPCs derived from postnatal day 0 (P0)
C57BL/6J pups.
Results: Tbx1 HT mice exhibited deficits in prepulse inhibition, social
interaction and communication, behavioral alternation, working memory
and anxiety-related behavior. Tbx1 HT mice had less pNPCs in the hippo-
campal dentate gyrus, compared to WT mice. Tbx1 siRNA suppressed the
proliferation of pNPCs in vitro.
Conclusion: Tbx1 deficiency contributes to 22q11.2-assoicated beha-
vioral phenotypes and defective proliferation of pNPCs in mice. Given
that some of the behavioral phenotypes of Tbx1 HT mice mimic sympto-
matic elements of 22q11.2-associated neuropsychiatric disorders, Tbx1
deficiency and defective proliferation of pNPCs could be exploited as
potential therapeutic targets of schizophrenia and ASDs.
Policy of full disclosure: Dainippon Sumitomo Pharma Co., Ltd.
JS-01-003 Intermediate phenotype studies in schizophrenia
R. Hashimoto1, K. Ohi1, H. Yamamori1, Y. Yasuda1, M. Fujimoto1,
S. Umeda-Yano1, M. Takeda1. 1Osaka University, Osaka, Japan
Objective: The effects of schizophrenia susceptibility genes would be
more penetrant at the level of biologically based intermediate phenotypes
than at the level of a complex and phenotypically heterogeneous
psychiatric syndrome. Intermediate phenotype concept is that the associ-
ation between intermediate phenotypes (neurocognition, neuroimaging,
neurophysiology, etc.) and genetic variations such as SNP (single nucleo-
tide polymorphism) shows stronger evidence for association between
the disease itself and genetic variants. Intermediate phenotypes should
be heritable, have good psychometric properties, be related to the disorder
and its symptoms in the general population, be stable over time, show
increased expression in unaffected relatives of probands, cosegregate
with the disorder in families, and have common genetic influences with
the disorder.
Methods: We developed human brain phenotype consortium in Japan,
which is a database of intermediate phenotypes with research resource
(DNA, blood RNA, serum and lymphoblastoid cell line) in patients
with schizophrenia, mood disorder, autism spectrum disorders and
healthy controls: total of more than 2000. Using data in human brain
phenotype consortium, we present several new data of intermediate
phenotype analysis.
Results: Using data in human brain phenotype consortium, we present
several intermediate phenotype analysis of genes identified by recent case
control GWAS (genome wide association study) as well as GWAS of inter-
mediate phenotypes.
Conclusion: Although these studies should be replicated with a larger
sample size, our results show that intermeadiate phenotype analysis (in
conjunction with GWAS) could be a gene discovery tool. We should
note, however, that we cannot rule out an interaction of our gene variants
with the affect of antipsychotic drugs on intermeadiate phenotypes.
Policy of full disclosure: There is no financial conflict of interest.
This work was supported by research grants from KAKENHI,
22390225-Grant-in-Aid for Scientific Research (B), 23659565-Grant-in-Aid
for Challenging Exploratory Research and Grant-in-Aid for Scientific
Research on Innovative Areas (Comprehensive Brain Science Network)
from the Japanese Ministry of Education, Culture, Sports, Science and
Technology (MEXT), and the Japan Foundation for Neuroscience and
Mental Health. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Dr. Hashimoto reports having received support from Dainippon
Sumitomo Pharma Co., Ltd. and Novartis Pharma K.K for a project unre-
lated to this research and speaker’s fees from Eli Lilly Japan K.K.,
GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co., Inc. , Janssen
Pharmaceutical K.K., Nippon Zoki Pharmaceutical Co., Ltd., Novartis
Pharma K.K., and Otsuka Pharmaceutical Co., Ltd.
JS-01-004 The research and development of aripiprazole
T. Kikuchi. Otsuka Pharmaceutical Company, Japan
Otsuka Pharmaceutical firstly initiated research on dopamine autorecep-
tor agonists in the late 1970s. This research evolved into developing
novel compounds that exhibit agonistic activity at presynaptic dopamine
autoreceptors and antagonistic activity at postsynaptic dopamine D2
receptors. The result of this research was aripiprazole, a novel antipsycho-
tic with dopamine D2 receptor partial agonistic activity. Today’s presen-
tation will review the history of the research and development of
aripiprazole and present the pharmacological data of aripiprazole.
Policy of full disclosure: None.
Tuesday 24 June 2014
S-11. The potential of high-risk studies to inform
early intervention in bipolar disorder
S-11-001 Use of genetic and clinical variables for clinical
intervention in subjects at risk for bipolar disorder
J. Nurnberger. Indiana University, Indianapolis, USA
Objective: Childhood precursors of adult bipolar disorder (BP) are still a
matter of controversy. Our objective was to identify early clinical predic-
tors of psychiatric disorders in offspring from families of probands with
DSM-IV Bipolar Disorder compared to offspring of controls.
Methods: Participants were offspring ages 12–21 in families with a BP
proband (n=141, designated as cases) as well as similarly aged offspring
of control parents (n=91). The outcome measure was lifetime DSM IV di-
agnosis of major affective disorder (BPI, SABP, BPII, or Major Depression)
determined by a best estimate diagnostic process that included infor-
mation from the K-SADS-BP and also medical records. We have now
added genetic data from 33 SNPs identified by the PGC Bipolar
Working Group (2011) as reflecting BP vulnerability.
Results: At an average age of 17, cases showed 23.4% lifetime preva-
lence of major affective disorder compared to 4.4% in controls (p=0.002,
adjusting for age, gender, ethnicity, and correlation between siblings).
Prevalence of bipolar disorder in cases was 8.5% vs. 0% in controls
(adjusted p=0.007). In cases but not controls, a childhood diagnosis of
an anxiety disorder (Relative Risk (RR)=2.6 (1.1 # 6.3), p=0.039) or an
externalizing disorder (RR=3.6 (1.4 # 9.0), p=0.007) was predictive of
later onset of major affective disorder. These results were published
(Nurnberger et al., 2011). We have found that a risk allele score derived
from the 33 SNPs separates affected BP cases (N=243) from controls
(N=403) (p<0.0001); the same SNP panel separates high risk subjects
from controls as well.
Conclusion: An expanded sample with follow-up now includes 241
cases and 158 controls (unpublished data). We have confirmed the predic-
tive value of early anxiety diagnoses and early externalizing disorder
diagnoses in this larger sample (p<0.0005 for each). We are also analyzing
risk score data in this larger sample.
Policy of full disclosure: None.
S-11-002 The clinical trajectory into bipolar disorder: Targeting
early intervention in high-risk youth
A. Duffy. University of Calgary, Calgary, Canada
Bipolar disorder is largely a familial illness with an estimated heritability
of 85 % and typically onsets starting in adolescence. However it takes
many years before the disorder is accurately identified. As a result there
is substantial morbidity and premature mortality associated with the ill-
ness. Therefore, longitudinal investigation of the offspring of a parent
with confirmed well-characterized bipolar disorder is an important re-
search strategy to describe the early natural history of the developing ill-
ness and to identify targets for early intervention and prevention. In this
talk we will review the latest findings regarding the early clinical stages of
evolving bipolar disorder based on high-risk research and highlight criti-
cal junctures in the early illness trajectory important for intervention. In
addition, new findings highlighting promising underlying neurobiologi-
cal correlates of illness risk and progression will be presented.
Policy of full disclosure: None.
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S-11-003 What interventions can be used in high risk offspring?
An evidence map of currently available therapies, and
their potential for preventing disease onset or progression
J. Scott. Newcastle University, Newcastle-upon-Tyne, United Kingdom
Objective: The goal of this study is to produce an evidence map of the
emerging literature on prevention and treatment interventions for the
early stages of Bipolar Disorder (BD) and to use this strategy to highlight
the strength of and gaps in the available evidence-base.
Methods: Given that there are few randomized controlled trials (RCTs)
targeting interventions at individuals at risk of or with early onset BD, it
was not realistic to apply the gold standard approaches to data synthesis
such as a systematic review. Therefore we used a process termed ‘evidence
mapping’ which is emerging as a means of systematically identifying the
‘extent, distribution and methodological quality’ of evidence in a clinical
or research field.
Results: The search strategies identified only 203 potentially relevant
records, whilst another 32 were obtained from hand searches, known
experts, conference proceedings and grey literature. Of the 92 publications
screened, 30 were included in the final map: 15 papers for the narrative
review and 15 studies for the review of outcomes.
Conclusion: The evidence map demonstrates that therapies for the early
stages of BD are emerging and that the models being developed draw on a
range of clinical and research fields, especially adaptations of adult BD
therapies, and from those employed in first episode psychosis. The time
lag in the translation of research models for early intervention and clinical
staging from psychosis and depression to BD is frustrating, but we antici-
pate a significant expansion in the BD literature in the next decade. The
additional prize in BD is that, even if a young person has previously ex-
perienced depression or sub-threshold manic symptoms, it is conceivable
that we could use psychological interventions to prevent a first episode of
mania- offering opportunities to understand the interplay between
psychological and biological mechanisms, and risk and protective factors.
Policy of full disclosure: None.
S-11-004 Using brain imaging and genetics to identify those at high
risk for bipolar disorder
P. Mitchell1, G. Roberts1, A. Frankland1, M. Breakspear2, P. Schofield3,
J. Fullerton1. 1University of New South Wales, Randwick, Australia; 2QIMR,
Brisbane, Australia; 3NeuRA, Randwick, Australia
Objective: It is becoming increasingly apparent that young people at high
genetic risk of bipolar disorder evidence changes in brain function
(Whalley et al., 2011; Roberts et al., 2013) and structure (Sprooten et al.,
2011). Furthermore, there is some suggestion that such changes may pre-
dict those who later develop major depressive disorder (Whalley et al.,
2013). In this paper we report on our functional studies, elaborating
upon our 2013 finding of reduced inferior frontal gyrus (IFG) activation
in a facial-emotion go/no-go task using fMRI.
Methods: Two studies were undertaken: i) using dynamic causal mod-
elling (DCM) to model effective dysconnectivity in the fMRI data pre-
viously reported (Roberts et al., 2013) in at-risk and control subjects;
and ii) resting state functional connectivity of the IFG using 3 complemen-
tary approaches in at-risk, bipolar disorder and control subjects.
Results: First, the DCM study demonstrated significant dysregulation
in the relative salience of emotion over inhibitory control in the at-risk
subjects. Second, the functional connectivity study found that the left
IFG was functionally dysconnected in the BD group from a network of
regions including bilateral insulae, dorsal anterior cingulate cortex, su-
perior temporal gyri and the putamen. Compared to healthy controls, un-
affected at-risk participants showed a functional dysconnection
intermediate in strength to the BD group. The dysconnected constellation
of regions overlapped with fronto-limbic regions that predicted group
membership with significant accuracy.
Conclusion: Functional dysconnectivity of the IFG from regions
involved in emotional regulation may represent a trait abnormality for
BD which may potentially distinguish such subjects from normal controls.
Future studies will explore the capacity of functional and structural ima-
ging to predict future onset of bipolar disorder and MDD.
Policy of full disclosure: None.
S-12. Targeting the endocannabinoid system to
treat psychiatric disorders: Clinical and
pre-clinical evidence
S-12-001 CB1 receptor imaging provides a model for
evidence-based treatment development in post-traumatic
stress disorder
A. Neumeister. New York University School of Psychiatry and Radiology,
New York, USA
Objective: Central clinical features of PTSD are the persistence of a heigh-
tened salience of traumatic memories (i.e., experience of alarm and dis-
tress) and a failure of the extinction process to diminish the impact of
traumatic memories. Cannabinoid type 1 (CB1) receptor-mediated eCB
signaling plays a key role in normal fear extinction and impaired CB1 re-
ceptor function leads to chronic anxiety-like and depression-like symp-
toms in animals.
Methods: Untreated individuals with PTSD with non-combat trauma
histories, and TC and HC participated in a magnetic resonance (MR) ima-
ging scan and a resting PET scan with the CB1 receptor antagonist radio-
tracer [11C]OMAR, which measures volume of distribution (VT) linearly
related to CB1 receptor availability. Peripheral levels of anandamide,
2-arachidonoylglycerol (2-AG), oleoylethanolamide (OEA), palmitoy-
lethanolamide (PEA), and cortisol were also assessed.
Results: In the PTSD group, relative to the HC and TC groups,
we found elevated brain-wide [11C]OMAR VT values (F(2,53)=7.96,
p=0.001; 19.5% and 14.5% higher, respectively). Anandamide concentra-
tions were reduced in the PTSD relative to the TC (53.1% lower) and
HC (58.2% lower) groups. Cortisol levels were lower in the PTSD and
TC groups relative to the HC group.
Conclusion: These data suggest a deficit of eCB signaling in PTSD
and suggest pathways for novel, mechanism based discoveries of the
next generation of PTSD treatments.
Policy of full disclosure: None.
S-12-002 A homeostatic role for the endocannabinoid system in
schizophrenia
F.M. Leweke1, C. Rohleder2, F. Enning2, F. Pahlisch2, C. Schaefer2,
J. K. Mueller2, M. Hellmich3, D. Koethe4, J. M. Bumb2. 1Ruprecht-Karls
University, Psychiatry and Psychotherapy, Mannheim, Germany; 2Central
Institute of Mental Health, Heidelberg University, Psychiatry and
Psychotherapy, Mannheim, Germany; 3University of Cologne, Institute of
Medical Statistics, Informatics and Epidemiology, Cologne, Germany;
4Heidelberg University, General Psychiatry, Heidelberg, Germany
Objective: The endocannabinoid system represents a major homeostatic
system of the central nervous system. It has been shown to play an adapt-
ive role in schizophrenia. We therefore aimed to further elucidate the
therapeutic potential of this system in acute psychosis.
Methods: We performed a randomized, double-blind, placebo-
controlled, cross-over clinical trial in acute, antipsychotic-naive, first-break
paranoid schizophrenia patients, fulfilling diagnostic criteria of DSM-IV.
29 patients were treated after written informed consent with either canna-
bidiol (600mg per day) or placebo for 14 days and than switched to the
corresponding cross-over condition. Drop-out patients were replaced to
gain a total of 18 patients treated per protocol.
Results: Cannabidiol significantly improved psychotic symptoms in
the cannabidiol-placebo condition during the first 14 days of treatment
when compared to baseline. A MMRM analysis of all randomized patients
(n=29) yielded an mean improvement of 2.4 points (standard error 3.0) on
PANSS total in favor of cannabidiol (vs. placebo), albeit not statistically
significant. Only one patient on sequence cannabidiol-placebo terminated
treatment early (last seen at visit 3) whereas 10 patients terminated early
on sequence placebo- cannabidiol. The most frequent reason given was
worsening of symptoms (5/11 patients). In addition, cannabidiol was de-
tectable in serum of almost all patients in the cannabidiol-placebo group.
Side-effects of cannabidiol were on the level of placebo.
Conclusion: Although limited by design issues (cross-over), duration
of treatment (14 days), carry-over effects (serum levels of cannabidiol),
and relevant placebo-response rates, this is the second study to provide
evidence for antipsychotic properties of cannabidiol accompanied by a
superior side-effect profile. Future placebo-controlled parallel-group trials
studying the antipsychotic properties of cannabidiol in acute schizo-
phrenia are necessary to provide further evidence for its efficacy in the
treatment of this devastating disease.
Policy of full disclosure: None.
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S-12-003 Cannabinoid receptors in the human CNS: Changes in
psychotic disorders
B. Dean. Molecular Psychiatry Lab., FINMH, Howard Florey Laboratories,
Melbourne, Australia
Objective: It is still debated whether cannabis use constitutes an environ-
mental factor that increases the risk of developing schizophrenia and
worsens the severity of symptoms or is used by people with the disorder
as a self-medication1. This presentation will review a growing body of
research seeking to determine if the cannabis 1 receptor (CB1), the pre-
dominant cannabis receptor in the human CNS2, is affected by the patho-
physiology of schizophrenia and whether this information may be
informative as to whether cannabis use may constitute self-medication.
Methods: The notions presented will be from review of studies in the
literature that have involved both the use of neuroimaging techniques
and post-mortem tissue3. This approach was taken to look for any form
of consensus across these two approaches to studying the human CNS.
Results:Neuroimaging ligands are being developed that allow the visu-
alisation of CB1 receptors in the human CNS. Using one such ligand,
[11C] OMAR, it has been reported that CB1 receptor trend to being higher
in many CNS regions in people with schizophrenia with that increase
reaching significance (23%) within the pons. Two CNS regionally focussed
studies using postmortem CNS have reported higher CB1 receptors in
people with schizophrenia whilst one study has reported the receptor
levels to be no different and one study has reported lower levels of the re-
ceptor in people with the disorder.
Conclusion: These results will be reviewed and discussed more in-
tensely in this presentation where it will be argued that further study of
the CB 1 receptor in the CNS of subjects with schizophrenia is necessary
but that current data would favour higher levels of CB1 receptors in peo-
ple with schizophrenia.
References
1. Arnold JC et al. (2012) Curr Pharm Des 18: 5113–5130.
2. Fratta W et al. (2013) Curr Opin Neurobiol 23: 487–492.
3. Dean B (2013) Curr Top Med Chem 12: 2375–2392.
Policy of full disclosure: None.
S-12-004 What do CB1 knockout mice tell us about the
endocannabinoid system
E. Scarr. University of Melbourne, Melbourne, Australia
Objective: Cannabis or rather its major psychoactive ingredient,
(#6aR,10aR)-delta-9-tetrahydro-cannabinol (THC), can cause psychosis,
anxiety and short term memory deficits. The effects of cannabinoids are
predominantly mediated by CB1 receptors in the brain, which constitute
a part of the endocannabinoid system. Although CB1 receptors have
been shown to dampen synaptic input (1) and a number of neurotransmit-
ter systems have been shown to interact with the endocannabinoid system
(2), we still don#t understand the mechanisms behind the unwanted psy-
choactive effects. In order to better understand the consequences of alter-
ing transmission via the CB1 receptor, we examined tissue from cb1
knockout mice.
Methods:mRNA from cb1 knockout and wildtype mice was hybridised
to an Affymetrix# GeneChip® (Mouse Exon 1.0 ST Array) overnight.
Following post-hybridization washes, the chips were scanned and the
fluorescent signals used to generate subsequent cell intensity (CEL) and
chip (CHP) files for analysis. Data from the CEL files were imported
into JMP Genomics 6.1, using the relevant Affymetrix library files, and
summarised at the gene level. The data was analysed to determine vari-
ance between the two genotypes.
Results: The expression profiles of over 11,000 genes were altered by
knocking out the cb1 receptor, with over 90 canonical pathways dis-
rupted. Exploration of the gene expression changes revealed that a signifi-
cant proportion of the molecules interacted with other neurotransmitter
systems.
Conclusion: The effect of knocking out one G-protein coupled receptor
was far-reaching. The pathways and interactomes that are affected pro-
vide possible mechanisms by which the endocannabinoid system
influences disparate aspects of brain chemistry.
References
1. Freund TF, Katona I, Piomelli D (2003) “Role of endogenous cannabi-
noids in synaptic signaling”. Physiol. Rev 83(3): 1017–66.
2. Mechoulam R, Parker LA (2013) The endocannabinoid system and the
brain. Annu Rev Psychol 64: 21–47
Policy of full disclosure: None.
S-13. The epigenetic embedding of early life
stress in humans and animal models
S-13-001 Epigenetic signature of life adversities in utero and
long-term consequence for mental illness
M.A. Riva. University of Milan, Milan, Italy
Objective: Perinatal life is a period of high plasticity and vulnerability
to adverse life conditions, which may reshape the normal developmental
trajectory of several structures, leading to enhanced risk for psychiatric
disorders. Epigenetic modifications have been proposed to translate en-
vironmental cues into persistent cellular memories that are responsible
for behavioral and functional alterations.
Methods: We used the rat prenatal stress (PNS) model and character-
ized persistent behavioral and neuroplastic alterations produced by the
early life manipulation. We next analyzed genome-wide promoter methy-
lation profiles of the hippocampus and prefrontal cortex from adult PNS
rats. Methylation profiles were created using the method MeDIP with
microarray hybridization.
Results: PNS rats show a region- and time-specific reduction in the
expression of the neurotrophin BDNF, a marker of neuronal plasticity
that has an important role in mood and cognitive function. Using the
epigenome-wide analysis an overlap of 893 differentially methylated
genes was observed between the hippocampus and prefrontal cortex of
adult male and female rats that were exposed to PNS. Interestingly, the
list includes several genes previously associated with schizophrenia and
other psychiatric conditions, such as calcium and potassium voltage oper-
ated channels as well as GABA and glutamate receptor subunits.
Cross-species analyses of human and non-human samples exposed to
early life adversities allowed us to restrict the list of genes that may
hold psychopathologic implications.
Conclusion: These results highlight the importance for the identifica-
tion of methylation signatures through which stress exposure early in
life could engrave on the outcome of the adult phenotype, and may
allow the identification of novel genes and pathways that are affected as
a consequence of early life adversities.
Policy of full disclosure: M.A. Riva has received honoraria or research
support from Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Eli
Lilly, Servier and Sunovion.
S-13-002 Early life stress and genome wide adaptation
M. Szyf1, R. Masart1, S. Suomi2, N. Provencal1, C. Yi1. 1McGill University,
Department of Pharmacology and Therapeutics, Montreal, Canada;
2NIH/NICHD, Laboratory of Comparative Et., Bethesda, MD , USA
Objective: Early life social adversity is known to have long-lasting impact
on the phenotype of the offspring. What are the mechanisms that mediate
between exposure to adversity during early life and long-term changes in
the phenotype?
Methods:Models of non-primate maternal deprivation were previously
examined (Suomi et al.,). We tested whether maternal deprivation will af-
fect the methylome in T cells which provide a noninvasive tissue source.
Results: Early life maternal separation in monkeys is associated with a
DNA methylation signature that is seen at 14 days. A large fraction of
these differentially methylated regions remains to adulthood and there
is gender specificity in the stability of the differentially methylated signa-
tures associate with early life maternal deprivation.
Conclusion: These data support the hypothesis that system wide
DNA methylation changes early in life in response to social stress occur
in both humans and animals in a genome wide and system wide manner.
These are proposed to be ‘adaptive genomic’ mechanisms that prepares
life-long genome programming to the anticipated life-long environment
based on stress signals received during gestation and early life. We will
discuss the hypothesis that stress hormones might be mediating the
genome wide and system wide response of the methylome to stress.
Glucocorticoids might act as ‘integrators’ that translate the social stress
signals during gestation to genome wide methylation changes across mul-
tiple systems.
Policy of full disclosure: None.
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S-13-003 Activation of the glucocorticoid receptor: A possible
mediator of genome-wide changes in DNA-methylation
following early trauma
E. Binder. Max Planck Institute for Psychiatry, Munich, Germany
Objective: A number of studies point to the fact that the biological embed-
ding of the longterm effects of early trauma can be mediated by epigenetic
effects. This talk will highlight several lines of evidence suggesting that
glucocorticoid-receptor (GR) activation induced changes in
DNA-methylation may be one of the mechanisms contributing to these
longterm effects.
Methods: Genome-wide DNA methylation has been investigated in
a human hippocampal neuron progenitor cell line treated with the GR
agonist dexamethasone during as well as after hippocampal differen-
tiation. In a sample of 394 African American individuals, expression
(eQTL) and methylation quantitative trait loci (mQTL) moderated by ex-
posure to early trauma were investigated using peripheral blood cells.
Results: In the neuronal progenitor cell line, we observed
differentiation-depedent differences in the longterm effects of
GR-administration. Over 450 CpG showed significant changes in
methylation with administration of dexamethasone during prolifration
and early differentiation that remained stable after 20 days of washout.
These CpG were not affected by treatment after differentiation of
the cells and 43% were located in the opean sea and not within CpG
islands. In analyses investigating the effects of early trauma exposure on
eQTLs and mQTLs, we identified 598 cis eQTLs showing significant
SNP×early trauma interaction on gene expression. Of these eSNPs, over
20% were also associated with mQTLs in the same cis window, suggesting
that the early trauma× SNP interaction on gene expression could be
mediated by changes in DNA methylation. The SNPs sequences were
enriched for brain-relevant enhancer regions as well as for GR response
elements. In addition, the differentially methylated CpGs within the
mQTLs showed significant overlap, with the CpGs differentially methyl-
ated following GR agonist treatment in the neuronal cell lines.
Conclusion: Our data suggest that a combined approach using in vitro
and in vivo data can help to elucidate the role glucocorticoids and DNA
methylation changes in the longterm effects of early trauma.
Policy of full disclosure: None.
S-13-004 Prenatal exposure to a natural disaster and life long
health risks
S. King. Department of Psychiatry, McGill University, Douglas Mental Health
University Institute, Verdun, Quebec, Canada
Objective: Prenatal maternal stress (PNMS) is challenging to study in
humans using experimental methods. The goal of our PNMS research pro-
gram is to increase understanding of the effects of PNMS on the unborn
child as well as the biopsychosocial mechanisms of these effects. In par-
ticular, we wish to disentangle the effects of objective levels of maternal
hardship from subjective levels of maternal distress, and to determine
moderating effects of child sex and timing of stress in pregnancy.
Natural disasters offer the possibility of quasi-random assignment of
stress exposure from an independent stressor.
Methods:We have three studies of pregnant women exposed to natural
disasters. In each, we assessed objective exposure and subjective distress
shortly following the disaster. We began Project Ice Storm in Quebec
in 1998; The Iowa Flood Study in 2008 (adding pre-disaster data from
an on-going study of pregnant women); and The QF2011 Queensland
Flood Study in Australia in 2011 (including pre-trauma data on pregnant
women, a pre-existing RCT of two prenatal care programs, plus placenta,
umbilical cords and cord blood samples). We evaluated pregnancy out-
comes, and the cognitive, behavioural, motor and physical development
of the children.
Results: We demonstrate strong and long-lasting effects of prenatal
stress on children’s cognitive outcomes (IQ, language, memory); behav-
iour (anxiety, depression, aggression, autistic-like traits); motor develop-
ment (coordination, visual-motor integration); and physical
development (brain, sexual dimorphisms, body composition, immune
function, insulin secretion, obesity).
Conclusion: Using a natural disaster as a platform for studying prenatal
maternal stress is a powerful approach for capturing the unique effects of
objective and subjective aspects of prenatal stress, as well as precise timing
of in utero effects.
Policy of full disclosure: None.
S-14. Prefrontal norepinephrine in arousal and
executive function
S-14-001 Functional network effects of selective LC-NE stimulation
G. Aston-Jones. Medical University of South Carolina, Department of
Neurosciences, Charleston, SC, USA
Objective: The nucleus locus coeruleus (LC) projects widely throughout
the CNS and is the primary source of norepinephrine (NE) to cortex. It
has been functionally implicated in a range of activities including arousal,
mood and executive functions. Electrical or pharmacological manipula-
tions have been used previously to investigate modulation of LC.
However, the development of novel tools now allows unprecedented spe-
cificity and precision for testing causal roles of LC-NE neuron functions.
We have optimised and validated several methods for targeting LC-NE
neurons for modulation with both optogenetics and synthetic receptors.
Methods: Using electrophysiologically guided injections and cell-type
specific viral vectors in vivo, along with optogenetics or synthetic recep-
tors (DREADDs, Designer Receptors Exclusively Activated by Designer
Drugs), we can selectively manipulate LC-NE activity in anesthetized or
behaving rats. Use of a synthetic DBH promotor has allowed us to achieve
robust expression specifically restricted to noradrenergic LC neurons.
Both optogenetic and DREADD tools can be employed across a range
of dosing patterns to modify local LC-NE activity, which produce global
cortical and behavioral responses.
Results: Our results show that selective activation of LC-NE neurons
has a number of functional effects, including cortical EEG activation,
modulation of cortical responses to sensory events, acceleration of emerg-
ence from anesthesia. These findings are consistent with previous work
indicating a role for LC-NE neurons in cortical modulation that regulates
executive functions including attention, decision processes and behavioral
flexibility.
Conclusion: These new tools that afford selective manipulation of
LC-NE neurons open new avenues for therapeutic development to treat
a host of mental disorders association with LC-NE dysfunction.
Supported by USPHS grants R01MH092868 and R21MH099534, the
Parkinson’s Disease Foundation, and the Neuroscience Institute of MUSC.
Policy of full disclosure: None.
S-14-002 Monoaminergic regulation of impulsivity and
gambling-related decision-making
C. Winstanley. University of British Columbia, Department of Psychology,
Vancouver, BC, Canada
Objective: Impulse control deficits have been associated with problem
gambling behaviour. Drugs which act on monoaminergic systems signifi-
cantly alter multiple forms of impulsivity. Determining whether such
compounds likewise influence gambling-related decision-making could
inform our understanding of the degree to which these cognitive pro-
cesses overlap, and also speak to whether treatments that influence differ-
ent forms of impulse control would be appropriate for individual with a
gambling disorder.
Methods: Rats were trained on distinct operant behavioural paradigms
designed to measure different aspects of gambling-related decision-
making. Once stable behaviour has been established, the effects of dopa-
minergic, serotonergic and noradrenergic manipulations were deter-
mined, and the results compared to a measurement of impulsive action
in the form of premature responses.
Results: While both dopaminergic and serotonergic compounds can
influence choice under uncertainty across multiple paradigms, the effects
of both acute and chronic administration of D2- family agonists differs
drastically across the tasks, with greater effects observed in tasks in
which gains rather than losses are emphasised. Noradrenergic com-
pounds in isolation had little effect on tests of gambling behaviour, de-
spite robust changes in impulsivity. Amphetamine, which potentiates
the actions of dopamine, serotonin and noradrenaline, increases pre-
mature responding and also impairs decision-making on a rat gambling
task. Whereas the effects of this psychostimulant on impulsivity can be
blocked by dopamine antagonists, the effects on choice could not.
Conclusion: Although broadly speaking the same neurotransmitter
systems are implicated in both impulsivity and gambling-related decision-
making, different forms of choice under uncertainty vary in the degree to
which they can be influenced by dopaminergic compounds. Although
analysis is preliminary, noradrenergic compounds do not appear to
have such a great effect on models of gambling as compared to tests of
impulse control.
Policy of full disclosure: I do not have any financial conflicts of interest.
16 Symposia, Tuesday 24 June 2014
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
S-14-003 The dual role of norepinephrine in modulating cognitive
flexibility in prefrontal cortex: Acute facilitation and
chronic stress-induced attenuation
D. Morilak1, J. Jett1, M. Girotti1, J. Donegan1. 1University Texas Health
Science Center, San Antonio, USA
Objective: To address the role of the modulatory neurotransmitter, nore-
pinephrine, in facilitating cognitive flexibility in the prefrontal cortex as
an adaptive component of acute stress responsivity, and in the beneficial
effects of chronic reuptake blockade, but also to address the potential
mechanisms by which repeated elicitation of this facilitatory modulation
during chronic stress can be detrimental.
Methods: Cognitive flexibility, including cognitive set-shifting and
reversal learning, were measured using the rat attentional set-shifting
test. Chronic unpredictable stress was applied for 2 weeks, producing
a deficit in these measures. Receptor-specific antagonists were applied
directly into prefrontal cortex by local microinjection. NE and glutamate
release were measured by microdialysis. Prefrontal function was assessed
by fos response to activation of GLU afferents in mediodorsal thalamus.
Chronic drug treatment was administered by osmotic minipump.
Results: Acute activation of NE in prefrontal cortex facilitates cognitive
flexibility through actions at alpha1 receptors. After chronic stress, cogni-
tive flexibility is compromised, but still facilitated acutely by NE in PFC
via alpha1 receptors. Glutamate function in PFC is similarly com-
promised. Tonic NE elevation by chronic reuptake blockade is beneficial.
However, blocking adrenergic receptors in PFC during chronic stress pro-
tects cognitive flexibility and glutamate function, implying that repeated
acute facilitation during chronic stress contributes to a cumulative func-
tional deficit.
Conclusion: The adaptive and acutely facilitatory effects of NE are
maintained after chronic stress, contributing to the cumulative compro-
mise of cognitive flexibility and prefrontal function over time. But
tonic elevations of NE by chronic reuptake blockade are beneficial in
restoring function compromised by chronic stress, suggesting that acute,
stress-induced activation of NE function must act convergently with
other factors that are also activated by stress, perhaps including gluta-
mate, glucocorticoids or cytokines, to contribute to the deficit. The signal-
ing mechanisms underlying these convergent effects may suggest novel
therapeutic targets.
Policy of full disclosure: This work was supported by grants from the
National Institutes of Health (MH053851 and MH072672). Dr. Morilak
has received research funding from H. Lundbeck A/S in the past year,
for work unrelated to the research presented in this symposium.
S-14-004 Noradrenergic modulation of cognitive control and
attention in rodents and humans; translational
implications
T. Robbins. University of Cambridge, Department of Psychology, Cambridge,
United Kingdom
The notion that the locus coerueleo-cortical noradrenergic projection
has a prominent role in cognitive control in humans and experimental
animals has been discussed in various forms by several authors.
Cognitive control is a broad term that covers several aspects of executive
function including attention and inhibitory response control, there being
good evidence of noradrenergic involvement in both of these interacting
processes. The stop-signal reaction time (SSRT) task is a useful paradigm
for measuring motor inhibitory functions and has been associated
with a specified neural network in the human brain including the inferior
frontal cortex, striatum, subthalamic nucleus and supplementary motor
area, among other regions. Based primarily on the effects of the selective
noradrenergic reuptake inhibitor atomoxetine in human volunteers and
rodents, there is excellent evidence that noradrenaline released in the
prefrontal cortex (PFC) may contribute importantly to improve SSRT per-
formance (by speeding the SSRT), and that this involvement is significant
for neuropsychiatric syndromes such as attention deficit hyperactivity dis-
order (ADHD) where there is excessive impulsive behaviour. Relevant
evidence is based on paradigms of pharmacological functional magnetic
resonance imaging in human volunteers, intra-cerebral microinfusions in
rats, and genomics. Thus for example, the improvement in SSRT perform-
ance produced by atomoxetine is correlated with a BOLD response in
the right inferior frontal region, an area that is also correlated with
(i) the capacity to perform the task (ii) the presence of ADHD symptoms
and (iii) the modulatory effect of a single nucleotide polymorphism affect-
ing the noradrenaline transporter. Moreover, when infused into possibly
homologous regions of the rat prefrontal cortex, similar improvements
in SSRT performance are found that appear to depend on cortical noradre-
naline. The translational significance of these parallel effects in humans
and rodents are discussed in terms of the treatment of ADHD, stimulant
addiction and Parkinson’s disease.
Policy of full disclosure: Research funded by the Wellcome Trust,
MRC and EU (IMAGEN project). TWR discloses consultancy with
Cambridge Cognition, E. Lilly, Shire Pharmaceuticals, Teva, Lundbeck.
He has held research grants from Lilly and Lundbeck. He is an editor of
Psychopharmacology (Springer Verlag).
S-15. BACE1 in Alzheimer’s disease pathogenesis
and drug development
S-15-001 GSK3 signaling regulates BACE1 expression and APP
processing and its pharmaceutical potential for
Alzheimer’s disease
W. Song1, P. Ly1, Y. Wu1. 1University of British Columbia, Vancouver, Canada
Objective: Alzheimer’s disease (AD) is the most common neurodegenera-
tive disorder leading to dementia. Deposition of neuritic plaques is one of
the characteristic pathologies observed in AD. Abeta, the central compo-
nent of neuritic plaques, is produced from sequential cleavages of the
amyloid beta precursor protein (APP) by the beta- and gamma-secretases.
Beta-site APP cleaving enzyme 1 (BACE1) is the beta-secretase in vivo
essential for Abeta generation. Inhibition of Abeta generation by targeting
BACE1 will have therapeutic implications for AD. Previous studies indi-
cated that glycogen synthase kinase 3 (GSK3) plays an intimate role in
APP processing to promote Abeta production. However, the mechanistic
action of GSK3 in APP processing has not been thoroughly examined. This
study aimed to examine the role of GSK3 signaling in Alzheimer patho-
genesis and its pharmaceutical potentials.
Methods: To address this issue, we applied GSK3alpha and beta iso-
form specific knockdown and highly potent GSK3 inhibitors. APP proces-
sing and Abeta production was examined by Western blot analysis and
ELISA. Luciferase assay was used to study BACE1 promoter activity.
The effect of GSK3 on AD phenotypes was examined using transgenic
AD model mice in vivo.
Results: We found that specific inhibition of GSK3beta, but not
GSK3alpha reduced BACE1-mediated cleavage of APP and Abeta pro-
duction by decreasing BACE1 gene transcription and expression.
Furthermore, the regulation of BACE1 transcription by GSK3beta is de-
pendent on NFkB signaling. We also demonstrate that specific inhibition
of GSK3 signaling markedly reduced Abeta deposition and neuritic
plaque formation, and rescued memory deficits in the double transgenic
AD model mice.
Conclusion: Our results demonstrate that GSK3beta regulates BACE1
expression and AD pathogenesis and inhibition of GSK3 signaling can re-
duce Abeta neuropathology and alleviate memory deficits in AD model
mice. Our study suggests that interventions specifically targeting the
GSK3beta isoform may be a safe and effective approach for treating AD.
Policy of full disclosure: None.
S-15-002 Alteration of BACE1 processing of APP in Alzheimer’s
disease
K. Stefansson. deCODE Genetics, Reykjavik, Iceland
Policy of full disclosure: None.
S-15-003 Inhibition of BACE1 for benefiting AD patients
R. Yan. Case Western Reserve University, Cleveland, USA
BACE1, a type I transmembrane aspartyl protease, cleaves amyloid pre-
cursor protein (APP) at the ß-secretase site. Following this cleavage,
ß-secretase processes the membrane-bound APP C-terminal fragment to
release amyloid peptides (Aß). Since Aß aggregation is the major compo-
nent in amyloid plaques and excessive production of Aß is linked to both
familial and sporadic Alzheimer’s disease (AD) pathogenesis, inhibition of
BACE1 is widely pursued as an important target for AD therapy. A large
volume of experimental results has shown that chemical inhibition of
BACE1 in both mouse models and humans produces substantial inhi-
bition of Aß generation and amyloid deposition. Because of its important
applications in human AD treatment, it is imperative to understand the
potential side effects associated with mechanistic inhibition of BACE1.
To address this practical question, we have used BACE1-knockout mice
to explore the physiological functions of BACE1. We demonstrate that
BACE1 can also process other membrane-bound substrates such as
neuregulin-1 and Jagged-1 in addition to APP. The abolished cleavage
of these two important substrates leads to hypomyelination of both central
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and peripheral nerves as well as altered neurogenesis. Collectively, we
conclude that BACE1 is an important molecule that plays multiples
roles in various neurological processes and that inhibition of BACE1 in
the adult requires cautious monition of other neurological functions.
Policy of full disclosure: I have no conflict of interest to declare. For the
funding, my research is funded by three NIH grants: R01AG025493,
NS074256, and R01AG046929.
S-15-004 MCI and dementia in China
J. Jia. Capital Medical University, Beijing, China
Objective: Estimate the prevalence of MCI and dementia including
Alzheimer’s disease (AD), and vascular dementia (VaD) among elderly
Chinese individuals.
Methods: A total of 10,276 community residents (6096 urban, 4180
rural) aged 65 years were evaluated and diagnosed with normal cog-
nition, MCI, or dementia. MCI was further categorized by imaging into
MCI caused by prodromal Alzheimer’s disease (MCI-A), MCI resulting
from cerebrovascular disease (MCI-CVD), MCI with vascular risk factors
(MCI-VRF), and MCI caused by other diseases (MCI-O). Dementia, AD,
and VaD were diagnosed. The data were analyzed between rural and
urban areas.
Results: The prevalences of overall MCI, MCI-A, MCI-CVD, MCI-VRF,
and MCI-O were 20.8% (95%CI=20.0#21.6%), 6.1% (95%CI=5.7#6.6%),
3.8% (95%CI=3.4#4.2%), 4.9% (95%CI=4.5#5.4%), and 5.9% (95%CI=
5.5#6.4%) respectively. The rural population had a higher prevalence of
overall MCI (23.4% vs. 16.8%, P<0.001). The prevalence of dementia,
AD, and VaD among individuals aged 65 and older were 5.14% (95%CI
=4.71#5.57%), 3.21% (95%CI=2.87#3.55%), 1.50% (95%CI=1.26#1.74%), re-
spectively. The prevalence of dementia was significantly higher in rural
than in urban areas (6.05% vs. 4.40%, P<0.001). The same regional differ-
ence was also seen for AD (4.25% vs. 2.44%, P<0.001) but not for VaD
(1.28% vs. 1.61%, P=0.166). The difference in AD disappeared when the
sample was stratified by educational level.
Conclusion: The prevalence of MCI in elderly Chinese is higher in rural
than in urban. Vascular-related MCI (MCI-CVD and MCI-VRF) was most
common. A notably higher prevalence of dementia and AD was found in
rural than in urban areas.
Policy of full disclosure: None.
S-16. New basic and clinical developments for
treatment resistant depression
S-16-001 Drug development in treatment-resistant depression:
Current progress, major hurdles and future strategies
C. Zarate. NIMH, CRC, Bethesda, USA
Objective: Current treatments for patients are generally unsuccessful
for a number of patients with severe and recurrent mood disorders. A bet-
ter understanding of the neurobiology of mood disorders, informed by
preclinical research and bi-directionally translated to clinical research, is
critical for the future development of new and effective treatments.
Recently, diverse new targets/compounds have been specifically tested
in preclinical models and in proof-of-concept studies, with potential rel-
evance as treatments for mood disorders.
Methods: This talk will review clinical translational studies conducted
at the National Institute of Mental Health (NIMH) on the following can-
didate targets with the goal of developing novel therapeutics for TRD.
These targets include: (1) the glutamatergic system (NMDA receptor com-
plex), (2) the cholinergic system (muscarinic receptor), (3) the opioid
neuropeptide system (delta opioid), and (4) the cAMP cascade (PDE4).
Results: Our studies targeting the glutamatergic and cholinergic
systems found that the NMDA antagonists ketamine, MK-0657 (oral
NR2B antagonist), and AZD6765 (low trapping non-selective NMDA an-
tagonist) and the cholinergic antagonist scopolamine were found to have
rapid antidepressant effects in TRD. AZD2327, a delta opioid agonist,
showed anxiolytic effects in patients with anxious depression. Finally,
by using 11C-(R)-rolipram, an inhibitor of phosphodiesterase 4, we
found that the cAMP cascade is downregulated in unmedicated patients
with major depressive disorder, and antidepressant treatment normalizes
the cascade.
Conclusion: These targets may be of substantial interest in defining
future directions in drug development, as well as in developing the next
generation of therapeutic agents for the treatment of mood disorders.
Overall, further study of these and similar drugs may lead to a better
understanding of relevant and clinically useful drug targets in the treat-
ment of these devastating illnesses.
Policy of full disclosure: Dr Zarate is listed as a coinventor on a patent
application for the use of ketamine and its metabolites in major de-
pression. Dr Zarate has assigned his rights in the patent to the US govern-
ment but will share a percentage of any royalties that may be received by
the government.
S-16-002 TRD: Results of a European multi-centre study
S. Kasper. Medical University of Vienna, Department of Psychiatry and
Psychotherapy, Vienna, Austria
Objective: It has been estimated that 30 to 45% of adequately treated
major depressive disorder (MDD) episodes in a psychiatric setting fail
to achieve an adequate response.
Methods: The Group for the Study of Resistant Depression (GSRD)
(Souery et al., 2007; Journal of Clinical Psychiatry 68: 1062–1070), a colla-
borative project between 8 centers in Europe in Belgium, France, Greece,
Italy, Israel, and Austria developed a staging model that distinguishes be-
tween ‘non-responders’ (patients who fail to respond to one form of treat-
ment, administered for 6–8 weeks), a condition which is now termed
‘insufficient response’ by the European Medicines Agency (EMA), ‘treat-
ment resistant depression’ (TRD, patients that fail to respond to two or
more adequate antidepressant trials of different classes of antidepres-
sants), and ‘chronic resistant depression’ (CRD, patients being treated
with several antidepressants for more than 12 months).
Results: The clinical findings of the GSRD provide a set of 11 variables
associated with treatment response, among them comorbid anxiety disor-
ders as well as melancholic features (Souery et al., 2007; Journal of Clinical
Psychiatry 68: 1062–1070). The GSRD performed the until now largest
candidate gene studies to investigate associations with treatment response
phenotypes (Serretti et al., 2011; Journal of Affective Disorders 128: 56–63).
Although there is a plethora of hints in textbooks that switching the mech-
anism of action should be obtained when a patient does not respond to
one medication, the results of the GSRD challenge this notion by describ-
ing that staying on the same antidepressant mechanism of action for a
longer time is more beneficial than switching (Souery et al., 2011; World
Journal of Biological Psychiatry 12: 364–375).
Conclusion: The results of the GSRD European multicentre project has
recently been summarized by Schosser et al. (European
Neuropsychopharmacology, 2012; 22: 259–266) and will be presented in
the symposium.
Policy of full disclosure: Prof. Kasper has received grant/research
support from Bristol Myers-Squibb, Eli Lilly, GlaxoSmithKline,
Lundbeck, Organon, Sepracor and Servier; he has served as a consultant
or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly,
GlaxoSmithKline, Janssen, Lundbeck, Merck Sharp and Dome (MSD),
Novartis, Organon, Pfizer, Schwabe, Sepracor, and Servier; and he has
served on speakers’ bureaus for Angelini, AstraZeneca, Bristol
Myers-Squibb, Eli Lilly, Janssen, Lundbeck, Neuraxpharm, Pfizer, Pierre
Fabre, Schwabe, Sepracor, and Servier.
S-16-003 Potential of mGlu2/3 receptor antagonists for
treatment-resistant depression: An alternative to ketamine
S. Chaki. Taisho Pharmaceutical Co. Ltd, Discovery Pharmacology, Saitama,
Japan
Objective: Ketamine, a non-competitive NMDA receptor antagonist, has
been demonstrated to exert rapid and sustained antidepressant effects
for patients with depression including treatment-resistant depression
(TRD). However, a number of adverse effects including psychotomimetic
symptoms and neurotoxicity preclude routine use of ketamine, and alter-
natives to ketamine are needed. Metabotropic glutamate (mGlu) 2/3 recep-
tors are distributed in brain regions related to emotion and affect where
they have important roles in regulating glutamatergic tone, suggesting
that mGlu2/3 receptors may be implicated in pathophysiology of de-
pression. Therefore, we investigated antidepressant potential of mGlu2/3
receptor antagonists, and compared their effects with those of ketamine.
Methods: The effects of mGlu2/3 receptor antagonists such as MGS0039
and LY341495 were examined in animal models of depression. Moreover,
the neuronal mechanisms through which mGlu2/3 receptor antagonists
exert antidepressant effects were examined, and compared with those of
ketamine.
Results: mGlu2/3 receptor antagonists exerted antidepressant effects in
some animal models of depression, which sustained for at least 24 hrs.
Antidepressant effects of mGlu2/3 receptor antagonists were attenuated
by NBQX (an AMPA receptor antagonist), K252a (a TrkB inhibitor) and
rapamycine (an mTOR inhibitor), indicating that mGlu2/3 receptor
antagonists exerts antidepressant effects through stimulation of AMPA
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receptor-BDNF-mTOR signaling, and shared similar neuronal mechan-
isms with ketamine. In addition, mGlu2/3 receptor antagonists increased
serotonergic and dopaminergic transmission in the medial prefrontal cor-
tex and nucleus accumbens shell, respectively, through AMPA receptor
stimulation, which may also be involved in the antidepressant effects of
the compounds. Moreover, mGlu2/3 receptor antagonists, like ketamine,
exhibited antidepressant effects in animal models, which are refractory
to currently used antidepressants. In contrast, mGlu2/3 receptor antago-
nists, unlike ketamine, did not increase locomotor activity at doses
which show antidepressant effects.
Conclusion: These results suggest that mGlu2/3 receptor antagonists
may be an alternative approach to treating patients with TRD.
Policy of full disclosure: None.
S-16-004 Neurochemical and behavioral effects of vagal nerve
stimulation
A. Frazer1, A. Shah1, F. Carreno1. 1UTHSCSA, San Antonio, USA
Objective: Therapies for treatment resistant depression include vagal
nerve stimulation (VNS), already approved in several countries, and
ketamine which blocks glutamatergic N-methyl-D-aspartate (NMDA)
receptors and produces rapid effects. The objective of our study was to
compare effects produced by VNS and ketamine with those caused by
traditional antidepressants such as desipramine (DMI) or sertraline on
neurochemical and behavioral parameters.
Results: Traditional antidepressants phosphorylated two sites on Trkb,
the receptor for the neurotrophin BDNF. Both VNS and ketamine phos-
phorylated these sites also as well as an additional site on TrkB that is
linked to activation of PI3 K. To examine the role of TrkB phosphorylation
in behavioral effects of the antidepressants, use was made of K252a, which
prevents the autophosphorylation of TrkB. Chronic intraventricular
administration of K252a blocked the phosphorylation of TrkB caused by
either VNS or DMI. Its administration also prevented the anxiolytic-like
effect of chronic VNS shown using the novelty-suppressed feeding test
(NSFT). By contrast, chronic administration of K252a did not prevent
either the anxiolytic-like effect of DMI in the NSFT or its antidepressant-
like effect in the forced swim test (FST). A single injection of ketamine had
antidepressant-like effects in the FST measured either 30min or 7 days
later. Ketamine caused phosphorylation of TrkB, but this effect was rela-
tively transient, seen 30min after its administration but not after 7 days.
K252a, administered directly into the ventral hippocampus (vHipp),
was able to prevent the transient increase in TrkB phosphorylation caused
by ketamine as well as its positive effects in the FST 7 days later.
Conclusion: Thus, ketamine’s prolonged behavioral effect is prevented
by blocking its ability to cause an early and transient increase in TrkB
phosphorylation in the vHipp. Behavioral effects of VNS and ketamine
may be dependent upon activation of TrkB whereas this may not be so
for traditional antidepressants.
Policy of full disclosure: Previously, Dr. Frazer has received financial
support both as a consultant and in the form of a grant from
Cyberonics, Inc., the manufacturer of the VNS stimulation device.
S-17. Novel glutamatergic treatment approaches
for schizophrenia: Pharmacology, imaging
and clinical trials
S-17-001 Challenges for novel treatment approaches in
schizophrenia
G. Gründer. RWTH Aachen University, Aachen, Germany
Objective: Drug development for CNS disorders has been in a crisis for
more than two decades. New treatments with truly novel mechanisms
of action are lacking, and several large pharmaceutical companies stopped
their programmes for CNS disorders. A huge number of experimental
drugs failed in late stage development. Glutamatergic compounds re-
present one of the most promising approaches to address the unmet
needs of schizophrenia treatment.
Results: Reasons for the lack in innovation might be 1) the search for
drugs that are directed against all different psychopathological dimen-
sions (positive, negative, affective, cognitive) of schizophrenia, 2) the
lack of biomarkers for subtyping of schizophrenia, 3) study designs that
neglect the biological heterogeneity of this group of disorders, and 4)
the lack of outcome parameters that are related to long-term outcome.
Conclusion: Here we propose that the goal of drug research should be
to develop different compounds for the different dimensions of schizo-
phrenic psychopathology to allow for a “rational polypharmacy”.
This is directly linked to the establishment of new outcome measures
that reflect long-term functional outcome. However, this will only be poss-
ible with new study designs that account for patient heterogeneity and the
chronic nature of the diseases.
Policy of full disclosure: Gerhard Gründer has been on advisory
boards, acted as consultant, has been on the speaker’s bureau and
received grant support from the following companies: Cheplapharm, Eli
Lilly, Gedeon Richter, Lundbeck, Roche, Servier, Takeda.
S-17-002 The pharmacological basis for novel glutamatergic
treatments
D. C. Javitt. Columbia University, New York, USA
Objective: Disturbances in N-methyl-D-aspartate receptor (NMDAR)
function contribute to schizophrenia (Sz) and are indexed by objective
neurophysiological disturbances. Agents such as glycine and D-serine
bind to an allosteric regulatory site of the NMDA receptor complex and
may be therapeutically beneficial in Sz.
Methods: Two recent studies were conducted with 60 mg/kg/d (∼4 g/d)
D-serine. Study 1 investigated D-serine effects (4–6wks) on neurophysio-
logical biomarkers including MMN and visual P1 in 35 stabilized, chronic
Sz subjects, along with PANSS symptoms and MCCB neurocognitive
function. Study 2 investigated D-serine effects (16-wk) on prodromal
symptoms in 44 individuals at clinical high risk (CHR) for Sz based on
SIPS/SOPS criteria.
Results: Study#1: D-serine patients showed a significant (8.5±13.2%) de-
cline in PANSS symtpoms vs. placebo, along with a small but significant
improvement in MCCB composite score. Significant improvements were
also observed for MMN (p=0.044) and visual P1 (p=0.043, d=0.67).
Study#2: a highly significant (p=0.03; d=0.68) 35.7±17.8% reduction
was observed in effect was observed on SOPS negative symptoms.
Furthermore, >20% improvement was observed in 9/10 subjects who com-
pleted all 16 weeks of treatment vs. only 5/11 placebo patients (p=0.023).
A 30.9±14.9% reduction was observed on total symptoms that ap-
proached significance (p=0.07, d=0.67).
Conclusion: These are the first double-blind studies of D-serine at a
dose of 60mg/kg. Although magnitude of symptoms improvement was
small in chronic patients, objective effects were observed on brain function
including improvements in both auditory and visual neurophysiological
measures. Moreover, in prodromal patients, robust improvements in
symptoms were observed, suggesting that NMDAR-based interventions
may be most effective when applied early in the course of Sz.
Policy of full disclosure: Supported by NIMH grant U01 MH074356.
The author holds intellectual property rights for treatment of schizo-
phrenia with D-serine.
S-17-003 Characterization of novel glutamatergic treatments
with PET imaging
D. F. Wong. Johns Hopkins Medical Institute, Baltimore, USA
Despite the hypotheses of NMDA receptor hypofunction and low cortical
glutamate in the pathophysiology and treatment of schizophrenia (SZ);
there has been only recent progress in imaging biomarkers and treatment
trials. This presentation will describe recent events in imaging and poten-
tial treatment of two specific glutamatergic targets, mGluR5 and GlyT1.
There has been a confluence of PET imaging potential biomarkers and
clinical trials involving mGluR5 drugs primarily Negative Allosteric
Modulators (NAM) that inhibits the efficacy and/or affinity of the ortho-
static magnet and may have clinical applications in addiction and de-
pression and fragile X. There is also a parallel development in Positive
Allosteric Modulators (PAMs) which may have applications in SZ. In par-
allel a number of PET radioligands labeled [11C] and [18F] have been de-
veloped and applied to human imaging. [11C]ABP688 and more recently
[18F]FPEB have shown considerable utility in imaging studies of various
neuropsychiatric disorders. Occupancy studies using NAMs in current
clinical trials will be demonstrated. The second focus of imaging and
therapeutic interest is the glycine transporter (GlyT1) with inhibitors
that are currently in clinical trials for SZ. This is an attractive target be-
cause it is an alternative way of increasing glutamate in cortex which
may be much more effective than the direct administration of glutamater-
gic drugs. We will document the development of human GlyT1 PET radi-
oligands developed for non-human primate and human studies and show
how one in particular was used for occupancy studies in pre-clinical and
Phase I. These studies will demonstrate that there is a good correlation be-
tween pre-clinical animal models and early SZ efficacy studies with a mid-
range of occupancy of one particular GlyT1 compound using a specific
human PET radioligand, in healthy humans. Thus, the development of
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PET radioligands for neuropsychiatric and occupancy studies for target
engagement, together with the growing number of mGluR5 and GlyT1
inhibitors, opens new opportunities for SZ treatment.
Policy of full disclosure: Dean F. Wong, M.D., Ph.D. Disclosure of the
existence of any significant financial interest or other affiliation with a
funding organization or with a commercial supporter of the session
and/or provider of commercial services. Below is the declaration of re-
lationship to the funding agencies: Roche Investigator Research funding
through JHU contracts Novartis Investigator Fenoban drug received for
research studies Merck Investigator Radiopharmaceutical precursor
received for research studies NIH Investigator Research grants.
S-17-004 Clinical results with novel glutamatergic treatments
D. Umbricht. F. Hoffmann La Roche Ltd., Basel, Switzerland
Despite progress in our understanding of the genetics and the neurobiol-
ogy of schizophrenia, an array of psychosocial interventions and effective
antipsychotic pharmacotherapy, the long-term disability of patients
with schizophrenia remains high. Over the last two decades the search
for alternative therapeutic approaches beyond D2 antagonists has
focused on the glutamate system. Several lines of evidence implicate
N-methyl-D-aspartate (NMDA) receptor hypofunction as a factor under-
lying many symptoms of schizophrenia, in particular negative symptoms.
In recent years various pharmacological approaches to normalizing
NMDA receptor function have been tested including glycine reuptake
inhibitors (GRI) and N-acetyl cysteine (NAC). GRIs are assumed to in-
crease NMDA function by increasing intrasynaptic concentrations of
glycine – a mandatory coagonist at the NMDA receptor. Two GRIs –
bitopertin and ORG25935 – have recently been tested in proof-of-concept
studies in which patients with predominant negative symptoms of schizo-
phrenia received adjunctive treatment with the respective GRI for 8 and
12 weeks, respectively. While 8 week treatment with bitopertin led to a
significant amelioration of negative symptoms, ORG25935 treatment
was not associated with a significant improvement over placebo.
However, closer inspection of the results indicate that the magnitude of
observed effects were comparable to the effects of bitopertin lending sup-
port for glycine reuptake inhibition as a viable treatment of negative
symptoms. In addition, two proof-of-concept studies evaluated adjunctive
treatment with NAC in patients with schizophrenia. NAC is assumed to
increase deficient glutathione levels which can induce NMDA hypofunc-
tion in preclinical models. In both studies treatment with NAC was asso-
ciated with significant improvement, in particular of negative symptoms.
Thus, the available evidence supports the hypothesis that normalizing
NMDA hypofunction leads to an amelioration of negative symptoms in
schizophrenia. In the presentation the results of these studies will be
reviewed in detail. Challenges and promises of these therapeutic
approaches will be discussed.
Policy of full disclosure: I am an employee of F.Hoffmann-La Roche,
Ltd.
S-18. Breakthroughs in psychopharmacology for
prevention and treatment of PTSD
S-18-001 Three decades of research in circuits and receptor
systems in PTSD
E. Vermetten. University Medical Center Utrecht, Utrecht, Netherlands
Objective: Three decades of PTSD research have placed it well on the
map. PTSD is a young disorder that started being properly understood
only from 1980 with incorporation in DSMIII in which it was acknowl-
edged that exposure to traumatic events can lead to long term
psychopathology.
Methods: The biological framework is based on the concepts of stress
sensitization, fear conditioning as well as failure of inhibition. After the
decade of the hippocampus we have seen a shift to the decade of the
amygdala in the new milennium. Given the specific role of the prefrontal
cortex in (neuro) psychological functions in patients with PTSD (i.e. atten-
tion and cognitive interference), the interest in the role of the prefrontal
cortex has increased significantly.
Results: Evidence for neurobiological dysfunction in PTSD, such as
dysregulation of both main arms of the stress response system, the HPA
axis and the LC-norepinephrine system, as well as dysfunctional
responses of other neurotransmitter systems, including serotonergic,
GABA, and glutamate, suggest an opportunity for pharmacotherapeutic
interventions; however, data obtained from RCTs thus far suggest limited
efficacy.
Conclusion: There are no specific drugs for PTSD, except for the treat-
ment of irritability and depressive features with SSRI. Atypical neuro-
leptics have been more recently been introduced as well as mood
stabilizers. Other options are specific serotonergic agents such as 5-HT
1A antagonists, NA-blockers, CRF antagonists, GC-receptor antagonists,
prazosin and α1-adrenergic blocker with nightmares, use of β-blockers
early after trauma exposure are investigated. The last few years two
windows of opportunity to reduce fear memories can be defined as
‘golden hours’ in treatment of PTSD symptoms: event-based golden
hours and exposure-based golden hours. New treatment options such as
D-cycloserine and cortisol seem to offer opportunities to influence mem-
ory consolidation of traumatic experiences in timed relation to exposure.
Policy of full disclosure: None.
S-18-002 New insights into secondary prevention in PTSD
J. Zohar. Sheba Medical Center, Tel Aviv, Israel
Objective: Current psychopharmacological interventions in PTSD are
administrated to the patients once PTSD diagnosis is well established
(i.e. at least several months after the exposer to the traumatic event).
The well-established medical concept of “Golden Hours” is increasingly
became a focus in PTSD research since the time the symptoms have
unset (the exposure to trauma) could be clearly detected. Data from an-
imal study suggests that hypo-reactive hypothalamic–pituitary–adrenal
(HPA) axis may be associated with increased venerability to PTSD. The
objective of the present study was to examine early intervention with a
single shot of hydrocortisone in the “Golden Hours” in humans.
Methods: 25 patients with acute stress symptoms were administered
a single intravenous bolus of high-dose hydrocortisone (100–140mg) or
placebo within 6 hours of a traumatic event in a prospective, randomized,
double-blind, placebo-controlled pilot study. They have followed up at
2 weeks, one month, and 3 months.
Results: The hydrocortisone and placebo groups did not differ signifi-
cantly on any of the demographic measures such as age, gender, marital
status, education or on any clinical characteristics. Early single high doze
hydrocortisone intervention attenuated the core symptoms of both the
acute stress and of subsequent PTSD in patients, as measured by clinicians
administrated PTSD scale (CAPS). (Using the CAPS total scores, partici-
pants treated with hydrocortisone exhibited significantly lower total
CAPS score than those treated with placebo at the 2-week and 3-month
follow-up assessments).
Conclusion: The results of these studies highlight the potential thera-
peutic value of an initial bolus of endogenous corticosteroids in the nor-
mative response to stress as a key to a return to homeostasis. The data
provides initial evidence that a single dose of hydrocortisone adminis-
tered in the acute aftermath of trauma promotes recovery. The current
finding suggests that a further evaluation of a single high dose hydro-
cortisone treatment as a potential option for secondary intervention of
stress related clinical disorders is warranted.
Policy of full disclosure: Joseph Zohar has received grant/research sup-
port from Lundbeck, Servier and Pfizer, has served as a consultant or on
advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca
and Roche, and has served on speakers’ bureaus for Lundbeck, Roch,
and Abbott.
S-18-003 Update on the use of alpha-1 adrenoreceptor antagonists
for PTSD
M. Raskind. University of Washington, VA Puget Sound Health Care Sys.,
Seattle, USA
Objective: Increased CNS noradrenergic activity contributes to the patho-
physiology of PTSD, possibly by increased postsynaptic adrenoreceptor
(AR) responsiveness to norepinephrine. Prazosin, a CNS active alpha-1
AR antagonist, has been demonstrated effective for treatment refractory
trauma nightmares and sleep disruption in several placebo controlled
trials. Here we evaluated prazosin in active duty US combat soldiers
with PTSD and frequent trauma nightmares. The authors conducted a
15-week randomized controlled trial of the alpha-1 adrenoreceptor antag-
onist prazosin for combat trauma nightmares, sleep quality, global func-
tion, and overall symptoms in active-duty soldiers with posttraumatic
stress disorder (PTSD) returned from combat deployments to Iraq and
Afghanistan.
Methods: Sixty-seven soldiers were randomly assigned to prazosin or
placebo for 15 weeks. Drug was titrated based on nightmare response
over 6 weeks to a possible maximum dose of 5mg midmorning and
20mg at bedtime for men and 2mg midmorning and 10mg at bedtime
for women. Mean achieved bedtime doses were 15.6 mg of prazosin
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(SD=6.0) and 18.8 mg of placebo (SD=3.3) for men and 7.0 mg of prazosin
(SD=3.5) and 10.0 mg of placebo (SD=0.0) for women. Mean achieved
midmorning doses were 4.0 mg of prazosin (SD=1.4) and 4.8 mg of
placebo (SD=0.8) for men and 1.7 mg of prazosin (SD=0.5) and 2.0 mg
of placebo (SD=0.0) mg for women. Primary outcome measures were
the nightmare item of the CAPS, the Pittsburgh Sleep Quality Index,
and the CGIC. Maintenance psychotropic medications and supportive
psychotherapy were held constant.
Results: Prazosin was effective for trauma nightmares, sleep quality,
global function, total CAPS score and hyperarousal cluster. Prazosin
was well tolerated.
Conclusion: Prazosin is effective for combat-related PTSD with trauma
nightmares in active-duty soldiers, and benefits are clinically meaningful.
Policy of full disclosure: None.
S-18-004 Does the endocannabinoid system provide a new
avenue for treatment development in PTSD?
A. Neumeister. New York University, School of Psychiatry and Radiology,
New York, USA
Objective: To date, drug development in posttraumatic stress disorder
(PTSD) has been opportunistic, building almost exclusively on empirical
observations with drugs approved for other indications. there have been
increasing efforts to unravel the neurobiological mechanisms that underlie
the symptom development in PTSD in order to provide an evidence-based
approach in generating the next generation of PTSD treatments and poss-
ible PTSD prevention.
Methods: Patients with PTSD and controls with (TC) and without (HC)
trauma histories participated in a single magnetic resonance imaging scan
and a positron emission tomography (PET) study under resting conditions
with the novel, CB1 receptor-specific radiotracer [11C]OMAR. Peripheral
levels of anandamide and cortisol levels were collected on the day of the
imaging studies in all participants.
Results: In PTSD, we found brain-wide upregulation of CB1 receptors
in a stress circuit that is routinely involved in PTSD. These alterations
were associated with increased stress sensitivity and increased anxiety.
Peripheral reductions in anandamide levels suggest a lower endocannabi-
noid tone in PTSD.
Conclusion: Despite their potential therapeutic value, direct-acting CB
receptor compounds have very limited medical applications, mainly be-
cause of their undesirable psychotropic side effects and liability to cause
addiction. In contrast, blocking eCB deactivation or eCB uptake may
lead to a more circumscribed and beneficial spectrum of biological
responses than those produced by direct CB1 receptor activation.
Policy of full disclosure: None.
S-19. The psychopharmacology of aggression:
From biomarkers to therapeutics
S-19-001 Genetic determinants in aggression
K.-P. Lesch. School of Mental Health and Neuroscience (MHENS), Department
of Neuroscience, Maastricht, Netherlands
Objective: The expression of aggressiveness, which constitutes
many facets of behavior, is influenced by a complex interaction of biologic,
psychologic, and social variables. Even though individual differences in
impulsivity and the behavioral consequences, including externalized or
inwardly directed aggression are substantially heritable, they ultimately
result from an interplay between genetic variation and environmental fac-
tors. The molecular mechanisms by which e.g. early-life adversity
increases impulsive/aggressive behavior in adolescence and adulthood
is likely to include epigenetic programming of risk gene expression in con-
junction with modulation of neural plasticity.
Methods: While formation and integration of multiple neural networks
is dependent on the actions of neurotransmitters, such as serotonin
(5-HT), converging lines of evidence indicate that (epi)genetically deter-
mined variability in 5-HT system-regulating gene expression influences
impulsivity and inappropriately violent behavior. Based on the remark-
able progress in technologies that allow the alteration or elimination of in-
dividual genes to create transgenic animal models, gene modification
strategies further increase our knowledge about which genes are involved
in behavioral traits.
Results: This overview focuses on mouse models which have been
modified by deletion of genes coding for key players of 5-HT neurotrans-
mission. In particular, phenotypic changes in mice bearing inactivation
mutations of 5-HT1A and 5-HT1B receptors, 5-HT neuron-specific tran-
scription factor Pet1, tryptophan hydroxylase-2, 5-HT transporter, and
monoamine oxidase A, and genes related to 5-HT signaling will be dis-
cussed and major findings highlighted.
Conclusion: Although special emphasis is given to the molecular psy-
chobiology of 5-HT in aggression-related behavior in rodents, nonhuman
primates, and humans, relevant conceptual and methodological issues in
the search for candidate genes for impulsivity and aggression and for the
development of mouse models of aggressive and antisocial behavior in
humans are also considered.
Policy of full disclosure: None.
S-19-002 Biomarkers in aggressive behavior
S. Comai1, A. Bertazzo2, J. Vachon3, G. Côté3, G. Gobbi4. 1Department of
Psychiatry, McGill University, Montreal, Canada; 2University of Padua,
Padua, Italy; 3Institut Philippe-Pinel, Montreal, Canada; 4McGill University,
Montreal, Canada
Objective: Aggressive behavior is a major concern in social and criminal
justice settings and also in mental health. To date it is known that impair-
ments in the serotonin (5-HT) system, but also imbalances in the levels of
trace elements are implicated in the neurobiology of aggression. However,
it is still unknown at which level the 5-HT metabolic pathway is impaired
in aggression as well as how trace elements are linked to aggression and
mental disease.
Methods: Between January 2007 and March 2012, we collected a unique
databank of 360 male prisoners from a federal penitentiary in Montreal in
which we evaluated Axe I and Axe II disorders (SCID I and II), levels of
impulsivity and aggression toward others and themselves, attention-
deficit/hyperactivity disorder (ADHD) indices, and some biological corre-
lates of aggressive behavior such the serum concentration of tryptophan
(Trp), 5-hydroxytryptophan (5-HTP), 5-HT, kynurenine (Kyn), zinc, cop-
per and cadmium
Results: Our preliminary results showed that aggressive prisoners had
significant higher prevalence of mood disorders, drug abuse/dependence,
and borderline, conduct and antisocial behaviors. In addition, they exhib-
ited higher levels of impulsivity and CAARS indices, lower serum levels
of Trp and Kyn but higher serum levels of 5-HT. A logistic regression
analysis using psychiatric/psychological and biological variables indicated
that antisocial behavior and the ratio 5-HT/Trp were predictors of prison-
ers with aggressive behavior. Moreover, we found that zinc was linked to
personality disorders and addictions, but not directly to aggression.
Conclusion: This study suggests that not only impulsivity but also
adult ADHD indices are related to aggressive behavior. Noteworthy, it
shows that peripheral markers related to the 5-HT pathway are signifi-
cantly altered in aggressive behavior and discriminate aggressive vs. non-
aggressive prisoners.
Policy of full disclosure: None.
S-19-003 Mood stabilizers in aggression: Basic and clinical research
G. Gobbi. McGill University, Montreal, Canada
Objective: In the last ten years a major change has occurred in the treat-
ment of aggression. The introduction of novel atypical antipsychotics/
mood stabilizers into the market and the prevalent use of anticonvulsants
and lithium in clinical psychiatry have completely changed the thera-
peutic approach used to treat aggressive patients. The purpose of this
study has been to examine the recent advancements in the treatment of
aggression by integrating pharmacological findings on mood stabilizers
from clinical research with neurobiological knowledge gained from
basic science research. This translational approach is necessary, as the
results of clinical trials alone are limited in utility by the complexity of ag-
gressive behavior.
Methods: Relevant clinical studies were identified by searching
PubMed using the names of the putative drugs (belonging to the family
of atypical antipsychotics and anticonvulsants as well as lithium) along
with the keywords “aggression,” “hostility,” and “agitation”. Studies
were selected if they reported on the effects of the target drugs on mea-
sures of aggression, hostility, or agitation. Dementia-associated aggression
was excluded, as its etiology has a distinct neurobiological basis. Basic re-
search studies focusing on the pharmacological targets of mood stabili-
zers, mainly serotonin, dopamine, norepinephrine, GABA, glutamate
and ion channels, and their role in the etiopathogenesis of aggressive
behavior were also collected using PubMed.
Results: The neurobiology of aggressive behavior is complex and multi-
factorial including different neurotransmitters and a large spectrum of
membrane receptors, ion channels, intracellular elements and epigenetic/
genetic mechanisms. Consequently, the association of atypical antipsycho-
tics with antiepileptics and/or lithium which allows targeting several dif-
ferent cellular and intracellular pharmacological sites might represent the
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actual most valid therapeutic strategy for the treatment of aggressive
patients.
Conclusion: Additional randomized, double-blind clinical trials
are needed to confirm the clinical efficacy of the combination of mood
stabilizers in the treatment of aggression.
Policy of full disclosure: Dr Gobbi has been a speaker for Eli Lilly and
Merck, and has received grant/honoraria from GlaxoSmithKline, Merck,
and AstraZeneca in the past.
S-19-004 Atypical antipsychotics for the management of agitation
and aggression: An update
L. Citrome. New York Medical College, Clinical Professor of Psychiatry &
Behavioral Sciences, Suffern, USA
Objective: To review the current evidence supporting the use of atypical
antipsychotics for the management of agitation and aggression.
Methods: Literature review, with emphasis on randomized controlled
trials.
Results: The etiology of aggressive behavior is multifactorial and can
be driven by psychosis, impulsivity, psychopathy, intoxication, cognitive
impairment, or a combination of all of these. Recognition of the different
factors behind the aggression can inform medication selection and the
relative need for specific environmental and behavioral interventions in
hospitals and forensic psychiatric settings. Atypical antipsychotics have
supplanted the use of older agents and have substantial advantages in
terms of avoiding dystonic reactions and akathisia. Effect sizes for the re-
lief of agitation are comparable with that of intramuscular haloperidol.
Using the a priori definitions of response at 2 hours after first adminis-
tration, NNT for response vs. placebo (or placebo equivalent) in treating
agitation for the pooled data at the recommended dose of ziprasidone
10–20mg was 3 (95% CI=2 to 4), for olanzapine 10mg was 3 (95%
CI=2 to 3), and for aripiprazole 9.75 mg was 5 (95% CI=4 to 8).
Similarly, the NNT for response vs. placebo for haloperidol 6.5–7.5 mg
was 4 (95% CI=3 to 5). In contrast to agitation associated with schizo-
phrenia or bipolar mania, no agents have yet been approved by regulatory
authorities for the treatment of persistent aggressive behavior. However,
some atypical antipsychotics, such as clozapine and olanzapine, appear
to have specific anti-hostility effects over time, as evidenced in specifically
designed randomized controlled trials and in post hoc analyses of large
effectiveness studies such as CATIE and EUFEST.
Conclusion: Several atypical antipsychotics have regulatory approval
for the treatment of agitation. Although not approved for persistent ag-
gressive behavior, clozapine and olanzapine demonstrate specific anti-
hostility effects.
Policy of full disclosure: In the past 12 months, L. Citrome, was a con-
sultant for, has received honoraria from, or has engaged in collaborative
research supported by the following: Alexza, Alkermes, AstraZeneca,
Bristol-Myers Squibb, Eli Lilly, Envivo, Forest, Genentech, Janssen,
Lundbeck, Merck, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt
Benckiser, Reviva, Shire, Sunovion, and Takeda.
S-20. Remodeling synaptic connections in the
pathophysiology and treatment of
depression
S-20-001 Synaptic plasticity of reward circuitry in stress-related
disorders and antidepressant responses
S. Russo. Mount Sinai School of Medicine, New York, USA
Objective: Chronic social defeat stress induces changes in nucleus accum-
bens (NAc) excitatory synaptic plasticity that contributes to the expression
of depression- and anxiety-like behavior.
Methods: Using a series of retrograde expressing Cre viruses and con-
ditional channel rhodopsin, we have defined differential roles of pre-
frontal cortical versus thalamic glutamatergic inputs to the NAc in
controlling stress-induced depression-like behavior.
Results: Stimulation of thalamo-striatal glutamate inputs promotes
depression-like behavior while stimulation of cortico-striatal inputs has
limited effects. Silencing the thalamo-accumbal circuits using genetically
encoded pre-synaptic voltage gated Ca+ channel toxins prevents stress-
induced depression-like behavior while silencing the cortico-accumbal
inputs promotes depression-like behavior.
Conclusion: Our data identifies specific roles for glutamatergic inputs
to the NAc, suggesting that there is a very complex relationship between
the input and the resulting behavioral and cellular response to stress.
Policy of full disclosure: None.
S-20-002 Cell genesis and dendritic plasticity: A neuroplastic pas
de deux in the onset and remission from depression
N. Sousa. University of Minho, Braga, Portugal
The ability to set an appropriate response to stimuli through dynamic
rearrangements of synapto-dendritic networks, as well as by regulating
the generation of new neuronal and glial cells, renders the brain highly
mutable. These phenomena, collectively known as neuroplasticity, are
critical to promote the neuronal adaptations; its failure is now increasingly
considered to be a major component in many neuropsychiatric conditions.
Among these, depressive spectrum disorders are a paradigmatic example
of the importance of neuroplastic alterations in the adult brain. In this talk
a comprehensive picture of the effects of stress, a major trigger factor in
depression, in the (de)regulation of neuroplasticity will be provided; the
latter is, in turn, related to the emergence of physiological and behavioral
alterations comprised in the symptomatic profile of depressive disorders.
While these molecular and physiological mechanisms regulating neuro-
plastic processes are relevant for the onset of depressive symptoms,
they also proved to be implicated in the action of antidepressants. So
far, and although there is still much to be elucidated, it is becoming
increasingly evident that the triad stress-neuroplasticity-depression consti-
tutes ground for new findings and discoveries.
Policy of full disclosure: The author has no conflict of interest.
S-20-003 TRKing the neurobiological mechanisms of conventional
and rapid-acting antidepressants
T. Rantamäki. University of Helsinki, Neuroscience Center, Helsinki, Finland
Previous studies show that conventional monoaminergic antidepressant
drugs slowly reactivate developmental-like of plasticity in the adult
brain. Long-term molecular and functional alterations in interneuron
maturation and subsequent changes in excitation-inhibition balance are
thought to critically underlie this antidepressant-induced plasticity.
Most importantly, when combined with appropriate rehabilitation, this
induced plasticity allows rewiring of neuronal networks with functional
and behavioral consequences. Remarkably, some medications that primar-
ily target brain excitation-inhibition mechanisms have been shown to pro-
duce rapid amelioration of depressive symptoms. Interestingly, activation
of BDNF (brain-derived neurotrophic factor) receptor TrkB is associated
with the neuroplastic and therapeutic actions of both conventional –
gradually acting – antidepressants (e.g. fluoxetine) as well as rapid-acting
antidepressants (ketamine, isoflurane). Understanding the short- and
long-term neurobiological effects of diverse antidepressant treatments
on TrkB signaling, synaptic plasticity and neuronal network function is
important for future attempts to develop novel rapid-acting and more ef-
fective antidepressant therapies with sustained clinical benefits.
Policy of full disclosure: T.R. has received research support from Orion
Pharma, Hermo Pharma and Ono Pharmaceuticals.
S-20-004 Synaptic homeostasis in the etiology and treatment of
depression
R. Duman. Yale University, School of Medicine, New Haven, USA
Objective: Basic research studies have demonstrated that stress causes
neuronal atrophy, characterized by decreased dendrite branching and
reduced numbers of spine synapses in brain regions implicated in
depression, notably the prefrontal cortex (PFC) and hippocampus. These
effects of stress could contribute to the reduced volume of PFC and hippo-
campus that has been observed in depressed patients. Recent studies have
examined the molecular mechanisms underlying these effects, as well as
the ability of rapid acting antidepressants (i.e., ketamine) to increase syn-
aptic connections and block the effects of stress.
Methods: The mTORC1 signaling pathway controls translation of syn-
aptic prorteins and plays a role in synaptogenesis. We have examined tthe
effects of chronic stress and ketamine on mTORC1 signaling, the number
and function of spine synapse in PFC neurons, and behavior in models of
depression.
Results: We have found that ketamine causes a rapid induction
of synaptogenesis and spine formation in the PFC via stimulation of
mTORC1 signaling and increased synthesis of synaptic proteins. This
effect is driven by stimulation of glutamate-AMPA receptors and activity
dependent release of BDNF. These effects rapidly reverse the atrophy of
PFC neurons caused by chronic stress and underlie the rapid antidepres-
sant behavioral responses to ketamine. We have also found that the
neuronal atrophy caused by stress occurs, in part via inhibition of
mTORC1 and synaptogenesis, and is mediated by increased expression
of REDD1, an inhibitor of mTORC1 signaling.
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Conclusion: The results demonstrate that neuronal atrophy is caused
by inhibition of synaptic protein synthesis. Conversely the rapid acting
antidepressant ketamine stimulates activity dependent induction of pro-
tein synthesis, increases synapse formation, and rapidly reverses the defic-
its caused by chronic stress. This remodeling of synaptic connections
restores homeostatic balance of depression related circuits that are essen-
tial for control of mood and emotion, and thereby underlies the rapid anti-
depressant responses to ketamine.
Policy of full disclosure: Dr. Duman is a consultant and/or receives
research funds from Taisho, Sunovion, Lundbeck, Forest, Johnson &
Johnson, Naurex, and Lilly.
KS-01. Korean Session: Neural basis of poor
social functions in schizophrenia
KS-01-001 Mismatch negativity, theory of mind, neurocognition,
and functional outcomes in patients with schizophrenia
S.-H. Lee. Inje University Ilsan Paik Hospital, Republic of Korea
Objective: Mismatch negativity (MMN) is known to be associated with
neurocognition, social cognition, and functional outcomes. The present
study explored the relationships of MMN with neurocognition, theory
of mind, and functional outcomes in patients with schizophrenia, the
first-degree relatives of patients with schizophrenia, and healthy controls.
Methods: Twenty-five patients with schizophrenia, 21 first-degree rela-
tives of patients with schizophrenia, and 29 healthy controls were
recruited. We examined symptom severity, neurocognition, theory of
mind, functional outcomes, and the MMN.
Results: Mismatch negativity amplitudes decreased in order of patients
with schizophrenia, then first-degree relatives, then healthy controls.
Mismatch negativity amplitude was significantly correlated with mea-
sures of neurocognition, theory of mind, and functional outcome measure-
ments in patients with schizophrenia. However, the most powerful
correlations were those between MMN in the frontal region and measures
of functional outcomes. The power and frequency of the correlations were
weaker in first-degree relatives and healthy controls than in patients with
schizophrenia.
Conclusion: Hierarchical regression analysis revealed that functional
outcomes (relative to measures of neurocognition and theory of mind)
constituted the most powerful predictor of mismatch negativity. Our
results suggested that mismatch negativity reflects functional outcomes
more efficiently than do measures of neurocognition and theory of
mind in patients with schizophrenia.
Policy of full disclosure: None.
KS-01-002 Neural basis of deficits in emotional experience and
expression in schizophrenia
J. S. Lee. Bundang Jesaeng Hospital, Republic of Korea
Objective: Previous researches have revealed deficits in emotional experi-
ence and expression in schizophrenia. Neuroimaging studies in patients
with schizophrenia indicate regional brain activation abnormalities are re-
lated to the deficits in emotional experience and expression.
Methods: Data from our laboratory and other research groups using
neuroimaging will be presented.
Results: For emotional experience, neuroimaging studies about current
pleasant feelings in schizophrenia demonstrated deficient activation in
limbic/paralimbic regions (e.g., nucleus accumbens, amygdala and hippo-
campus), while studies about non-current feelings showed additional
deficits in the default-mode network (e.g., medial prefrontal cortex, precu-
neus and posterior cingulate cortex). For emotional expression, previous
neuroimaging studies using indirect approaches like emotional appraisal
or experience found that more severe blunted affect was correlated with
higher amygdala and parahippocampal activities, whereas a recent
study using a direct approach like facial expression showed that func-
tional disturbance of the mirror neuron system was related to the severity
of blunted affect.
Conclusion: An underrecruitment of limbic/paralimbic regions, ac-
companied by limited activations in the default-mode network or mirror-
neuron system may play an important role in deficits in emotional experi-
ence and expression in patients with schizophrenia.
Policy of full disclosure: None.
KS-01-003 Cortical thinning and disrupted structural connectivity
in medial prefrontal region associated with theory of
mind and social functioning in first-episode psychosis
T. Y. Lee1, J. S. Kwon1, W. H. Jung2, J. W. Hur1, J.-Y. Yun1, S. N. Kim1,
J. H. Jang1, D.-H. Kang1. 1Seoul National University, Seoul, Republic of
Korea; 2University of Pennsylvania, Philadelphia, USA
Objective: Decreased performance in theory of mind, the ability to
attribute mental states to oneself and others, is considered as the core con-
tributor of the poor psychosocial functioning in patients with schizo-
phrenia. Recent evidence suggests that the medial prefrontal cortex
(mPFC) has a special role in social cognition. However, relationship be-
tween theory of mind, social functioning, and the cortical thickness and
structural connectivity in the mPFC has not been fully understood.
Methods: This study included 34 first-episode psychosis (FEP) patients
and 34 age and gender-matched healthy controls (HCs). False-belief, story
task and social functioning scale were employed to assess theory of mind
performance and social functioning, respectively. For investigate the white
matter (WM) connectivity, the seed regions of interest was given in the
medial orbitofrontal cortex (mOFC) and rostral anterior cingulate cortex
(rACC) of mPFC. Differences in cotical thickness and WM connectivity be-
tween the two groups were assessed. Further correlational analyses were
examined between measures of false-belief, story task and social function-
ing scale and cortical thickness and WM connectivity in regions showing
significant differences.
Results: Patients with FEP showed lower scores of false-belief, story
task and social functioning scale than HCs. The bilateral mOFC and left
rACC thickness, left mOFC and bilateral rACC WM track numbers, and
bilateral rACC WM track volume were decreased in patients with FEP
compared with HCs. The scores of story task were positively correlated
with the left rACC thickness and right rACC WM track numbers, respect-
ively. There were positive correlations between scores of the all domains
of social functioning scale and left rACC thickness, WM track volume,
right rACC WM track number, respectively.
Conclusion: Our results suggest that decreased theory of mind per-
formance and social functioning in FEP may reflect dysfunction of
mPFC, which likely stems from both cortical thinning and disrupted
WM connectivity.
Policy of full disclosure: None.
KS-01-004 Neurocognitive components of social impairments
in schizophrenia
S. Park1, K. Thakkar2. 1Vanderbilt University, Nashville, USA; 2USA
Objective: In the past two decades, cognitive impairments such as work-
ing memory deficits have become central to our understanding of the nat-
ure of this disorder but surprisingly little is known about the origins and
consequences of these problems.
Methods: In a series of experiments, we examined generation, inspec-
tion and manipulation of mental representations (imagery) to identify
the loci of difficulties that may contribute to working memory deficits.
In another series of studies, we investigated one’s ability to simulate
and model other people’s behavior to understand the role of mental re-
presentation and perspective taking in social understanding.
Results: The results from these studies indicate that in contrast to stable
deficits in cognition overall, there exist surprising pockets of enhanced
abilities in schizophrenia. Individuals with schizophrenia appear to
show superior mental imagery generation, inspection and manipulation
abilities in spite of their permanent working memory deficits. Moreover,
their enhanced imagery ability extends to perspective taking and is related
to a porous sense of the body boundary and self. Individuals with schizo-
phrenia can put themselves in other people’s shoes with ease and speed.
Further investigation revealed that about half of outpatients with schizo-
phrenia have experienced out-of-body phenomenon and that these distur-
bances of self may be associated with reduced social interactions and
increased social isolation.
Conclusion: Taken together, these results depict a complex and richly
contoured internal landscape of schizophrenia. Severe cognitive deficits
coupled with superior abilities may lead to misperception, misinterpret-
ation and miscalculation of the internal and external worlds and contrib-
ute to a subjective experience of unreality. This brings us back to the core
nature of schizophrenia as the disorder of self, and highlights the import-
ance of integrating the methods of cognitive neuroscience with the subjec-
tive phenomenology of the psychosis experience.
Policy of full disclosure: None.
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Wednesday 25 June 2014
S-21. Personalized medicine in mood and anxiety
disorders
S-21-001 Neurobiological consequences of child abuse
C. Nemeroff. University of Miami, Miami, USA
Genetic, brain imaging and neurotransmitter studies have revealed
the long-term consequences of child abuse and neglect. These changes
increase vulnerability to mood and anxiety disorders in adulthood.
Exposure to trauma during childhood increases the risk of certain psychi-
atric disorders beyond the risk associated with adult violence exposure.
We have demonstrated a number of long term neurobiological conse-
quences of child abuse and neglect including structural and functional
brain imaging changes, neuroendocrine and immune alterations. In par-
ticular, alterations in the hypothalamic-pituitary-adrenal (HPA) axis, a
major mediator of the stress response, contribute to the long standing
effects of early life trauma. However, not all exposed individuals demon-
strate altered HPA axis physiology, suggesting that genetic variations
influence the psychiatric consequences of trauma exposure. Variants in
the gene encoding the CRF R1 receptor, FKBP5, PAC1 and others interact
with adverse early environmental factors to predict risk for stress-related
psychiatric disorders. These studies suggest molecular targets for new
drug development, biological risk factors, and predictors of treatment re-
sponse. In addition, the effect of abuse may extend beyond the immediate
victim into subsequent generations as a consequence of epigenetic effects
transmitted directly to offspring and/or behavioral changes in affected
individuals. Recognition of the biological consequences and transgenera-
tional impact of trauma has critical importance for both treatment research
and public health policy.
Policy of full disclosure: Charles B. Nemeroff, M.D., Ph.D. Declaration
of Financial/Propriety Interest 2011–2014 Monday, February 03, 2014
Research/Grants: National Institutes of Health (NIH) Consulting: Xhale,
Takeda, SK Pharma, Shire, Roche, Lilly, Allergan, Mitsubishi Tanabe
Pharma Development America, Taisho Pharmaceutical Inc., Lundbeck
Stockholder: CeNeRx BioPharma, PharmaNeuroBoost, Revaax Pharma,
Xhale, Celgene, Seattle Genetics, Abbvie Scientific Advisory Boards:
American Foundation for Suicide Prevention (AFSP), CeNeRx
BioPharma (2012), National Alliance for Research on Schizophrenia and
Depression (NARSAD), Xhale, PharmaNeuroBoost (2012), Anxiety
Disorders Association of America (ADAA), Skyland Trail Board of
Directors: AFSP, NovaDel (2011), Skyland Trail, Gratitude America,
ADAA Income sources or equity of $10,000 or more:
PharmaNeuroBoost, CeNeRx BioPharma, NovaDel Pharma, Reevax
Pharma, American Psychiatric Publishing, Xhale Patents: Method and
devices for transdermal delivery of lithium (US 6,375,990B1) Method of
assessing antidepressant drug therapy via transport inhibition of mono-
amine neurotransmitters by ex vivo assay (US 7,148,027B2) Speakers
Bureau: None Honoraria: Various Royalties: Various Expert Witness:
Various.
S-21-002 Advances in genomics and epigenetic biomarkers for
vulnerability and treatment response in mood and anxiety
disorders
E. Binder. Max Planck Institute for Psychiatry, Munich, Germany
Objective: Our current efforts in identifying reliable markers to stratify
patients with mood and anxiety disorders into biologically relevant cat-
egories have so far not been highly successful. Here we will highlight
approaches that combine genetic and environmental risk factors and epi-
genetic measures to identify subsets of patients that are likely biologically
more homogeneous and may profit from similar treatment strategies.
Methods: DNA methylation, gene expression and genotyping, com-
bined with endocrine and neuroimaging measures as well as information
on antidepressant treatment response from different studies will be
presented.
Results: Interaction of a specific functional polymorphism in the FKBP5
gene together with exposure to early trauma leads to epigenetic changes
that further derepress the transcription of that gene. This interaction of
two risk factors is on the one hand associated with a number of distinct
psychiatric diagnoses, including depression, PTSD and psychosis. On
the other hand, patients with this specific epigenetic profile represent a
subgroup of patients with unique endocrine, gene expression and neuroi-
maging biomarkers. Preliminary evidence suggest that depressed patients
with the FKBP5 risk allele and exposure to early trauma may preferen-
tially respond to cognitive behavioral therapy (CBT). We will also present
data from genome-wide genetic and epigenetic studies investigating
pattern associated with differential antidepressive response to CBT vs.
medication.
Conclusion: This series of studies highlights that identifying
subgroups of patients using epigenetic measures and integrating genetic
and environmental factors could be useful for more targeted treatment
approaches that make use of pathophysiologic findings that can transcend
current diagnostic categories.
Policy of full disclosure: None.
S-21-003 The role of inflammation in the pathophysiology of
depression: Treatment implications
C. Pariante. King´s College London, London, United Kingdom
Objective: To review the evidence linking increased inflammation with
(lack of) treatment response in major depression.
Methods: An overview of the most recent studies in this field, from us
and others, with an emphasis on studies using inflammatory biomarkers
as predictors of response to conventional antidepressants (SSRIs, tricyc-
lics) as well as anti-inflammatory strategies (COX-inhibitors, cytokines
blockers, omega-3 PUFAs).
Results: Consistent evidence across clinical trials and naturalistic
studies confirms that increased inflammation is associated with a lack of
response to conventional antidepressants. Suggestive evidence indicates
that increased inflammation is associated with a better response to anti-
inflammatories strategies.
Conclusion: Anti-inflammatory strategies are a promising therapeutic
strategy in patients who have high inflammatory biomarkers and fail to
respond to conventional antidepressants.
Policy of full disclosure: Professor Pariante has received research fund-
ing from companies interested in the use of anti-inflammatories in psychi-
atric disorders, such as Janssen; this amounts to approximately 5% of all of
his research funding, which comes predominantly from governmental
agencies and charities.
S-21-004 The contribution of HPA axis alterations in defining
subtypes in depression: Genetic, endocrine and treatment
studies
A. F. Schatzberg. Stanford University, Stanford, USA
Objective: To assess the role of HPA axis activity and genetic variation in
the development of psychosis and cognitive impairment in the context of
major depression.
Methods: Approximately 135 subjects (1/3rd each major depression
severe without psychotic features –NPMD, major depression with psy-
chotic features – PMD, and healthy controls) were assessed for neuropsy-
chological impairment, cortisol activity from 6pm to 9am. In
approximately 80%, blood samples were collected for allelic variation
for genes that encode for components of the HPA axis. Patients were al-
lowed to be on stable medication for at least one week prior to study
but were excluded if they were on substances with clear HPA effects –
e.g., estrogen.
Results: PMD patients demonstrated significantly elevated cortisol
activity from 6pm-1am (the nadir) than did the other two groups. They
also demonstrated poorer performance on a number of measures of atten-
tion, response inhibition, and working and verbal memory than did
healthy controls, often performing significantly worse than NPMD
patients. Mean cortisol levels from 6pm-1am were significantly and nega-
tively correlated with most neuropsychological measures, particularly
strongest with verbal memory as measured with the CVLT. The contri-
bution of variation for SNP’s of genes that encode for specific components
of the HPA axis (CRH, CRH-R1, CRH-R2, NR3C1 (GR), MR, and FBP-5)
to mean cortisol from 6pm–1am was assessed using linear regression with
each gene explored separately with its alleles after controlling for the ef-
fects of age, measures of psychosis/depression, and medication status.
Only GR contributed significantly to cortisol levels. Using similar analyses
performed to predict depression severity and psychosis severity, GR pre-
dicted psychosis and CRH-R1 predicted psychosis significantly. Data on
genetic prediction of cognitive measures indicate GR also predicts per-
formance on some measures, even after controlling for cortisol.
Conclusion: Elevated cortisol is associated with psychosis and cogni-
tive impairment in depression. GR variation predicts cortisol levels, psy-
chosis and cognitive performance.
Policy of full disclosure: Disclosure of Financial Interest – 1 Year Alan
F. Schatzberg, MD 2013-Present Consultant Bay City Capital CeNeRx
Cervel Eli Lilly Genentech Gilead Lunbeck/Takeda McKinsey Merck
MSI Naurex Neuronetics PharmaNeuroBoost Xhale Equity Amnestix
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S-22. Is schizophrenia a progressive disease?
S-22-001 Early course of cognitive impairment in schizophrenia:
Effects and influences
E. Joyce. University College London, London, United Kingdom
Objective: To understand the course of neurocognitive impairment in
schizophrenia and how this relates to clinical outcome and brain structure
and function.
Methods: Patients with schizophrenia or schizoaffective disorder were
recruited at first-onset of psychosis, aged 16–55 years. They were assessed
at presentation and twice more over the first 4 years of illness on tests of
cognitive function including IQ, memory and executive function. A subset
underwent structural MRI twice over the same period. Healthy controls
were assessed at similar time points. A subset also underwent magnetoen-
cephalography (MEG) while performing a change detection task.
Results: In two separate cohorts, cognitive function showed no evi-
dence of deterioration over the first 4 years of illness. There was improve-
ment in several domains but, when compared to changes in controls, were
attributable to practice effects. A subgroup showed evidence of having
undergone cognitive decline by the time of psychosis onset. Cognition
at onset predicted functional outcome 3–4 years later. MRI measures of
cortical thickness and area at psychosis onset showed reduced fronto-
temporal area compared to controls and the degree of area reduction
was related to current and premorbid IQ. A mean of 2 years later there
was a reduction in the thickness of frontal and parietal cortex. Although
there was no concomitant deterioration in cognitive function over this per-
iod, IQ and working memory at psychosis onset predicted the degree of
thinning of frontal and parietal cortex in patients two years later. MEG
analysis was consistent with functional disconnection in the frontoparietal
network.
Conclusion: Cognitive impairment is generalised and present at the
time of psychosis onset. Despite progressive changes in cortical pathology
following the first episode, cognitive impairment does not progress
further. This suggests that cognitive impairment may be longstanding in
some and, in others, deteriorate around the time of psychosis onset.
Generalised cognitive impairment is related to structural and functional
abnormalities of frontal-temporal-parietal association cortex supporting
the dysconnectivity hypothesis of schizophrenia.
Policy of full disclosure: None.
S-22-002 Schizophrenia is not progressive: The clinical evidence
R. Murray. Institute of Psychiatry, King´s College London, London, United
Kingdom
Objective: Although schizophrenia is frequently said to be progressive,
there is little evidence that this is so. Indeed, 40 years ago Manfred
Bleuler indicated that there was little deterioration after 5 years.
Subsequently, many follow-up studies have come to a similar conclusions.
Methods: In the epidemiologically-based AEESOP study we followed
up 480 patients with their first episode of psychosis for 10 years.
Results: Over 40% had not had significant psychotic symptoms in the
two years before the re-assessment. A small proportion (13%) met criteria
for treatment-resistance; however, 80% of these had always responded
badly.
Conclusion: This suggests that the majority of patients have an illness
which responds to dopamine blockers but a minority may have a different
disorder which does not and in whom the pathogenesis may be non-
dopaminergic; there are some suggestions that glutamatergic abnormali-
ties may be more important in this sub-group.
Policy of full disclosure: None.
S-22-003 Explaining progressive brain changes in schizophrenia.
The role of drugs, stress and inflammation
C. Pantelis. University of Melbourne, Melbourne Neuropsychiatry Centre,
Melbourne, Australia
Objective: Recent studies demonstrate that brain changes in schizo-
phrenia are progressive particularly at earliest illness stages. While such
changes would be consistent with the clinical picture of psychosis, the
functional relevance of such changes and the mechanisms underlying
them has been unclear. In particular, it has been proposed that neurocog-
nitive function does not show evidence of deterioration. It is suggested
that the observed progressive changes may be due to imaging method-
ology, diagnostic heterogeneity, or secondary to antipsychotic drug treat-
ment, the impact of illicit drugs (e.g. cannabis), or the influence of stress
and HPA-axis function. Our recent studies have examined these factors
in detail.
Methods: We have undertaken a series of longitudinal imaging studies
across the stages of illness from pre-psychosis onset and examined these
potential confounds. In particular, recent studies have detailed the effects
of antipsychotic medication, differences across psychotic diagnoses and
examined the extent of brain structural changes caused by cannabis. We
have also examined the impact of neuroinflammation in a PK-11195
PET study assessing activated microglia at the earliest stages of psychosis.
Results: I will present the findings from our series of studies investigat-
ing progressive brain changes in psychosis from before illness onset and
examine confounds that may explain these changes (esp. cannabis, stress
and medication). I will present preliminary data on neuroinflammation as
a possible mechanism for progressive brain change.
Conclusion: Progressive brain changes begin from before illness onset
and are most apparent over the first few years of illness. Factors such as
drug use, the impact of stress and medication need to be taken into ac-
count in understanding these changes. Neuroinflammation may underpin
the changes observed and help to reconcile the heterogeneity of findings
(Cropley et al., Int Clin Psychopharmacol, 2013).
Policy of full disclosure: The studies were funded by National
Health and Medical Research Council (NHMRC) of Australia and
Australian Research Council (ARC). Additional support was provided
by University of Melbourne, Melbourne Health, Jack Brockhoff
Foundation, Ian Potter Foundation, AE Rowden White Foundation,
Ramaciotti Foundation, Pratt Foundation, Woods Family Trust,
Rebecca L Cooper Medical Research Foundation, Australian Computing
& Communications Institute, Wellcome Trust, NARSAD, Stanley
Foundation. Prof Christos Pantelis was supported by a NHMRC Senior
Principal Research Fellowship (ID: 628386), NHMRC Program Grant
(ID: 566529) and NARSAD Distinguished Investigator Grant.
S-22-004 Expecting recovery not progression in schizophrenia
R. Zipursky. St. Joseph’s Healthcare, Hamilton, Canada
Objective: For more than a century, progressive decline has been con-
sidered to be an intrinsic feature of schizophrenia. The development of
early intervention programs has provided new opportunities to investi-
gate clinical outcomes from schizophrenia as well as the course of brain
structure and function over time.
Methods: Longitudinal studies are reviewed to determine whether
clinical outcomes worsen over time. Magnetic resonance imaging (MRI)
and cognitive testing have been carried out in many samples of indivi-
duals who have been studied longitudinally following a first episode of
non-affective psychosis. A systematic review was undertaken to investi-
gate the risk of recurrence when medications are discontinued following
a remission from a first episode of non-affective psychosis in order to de-
termine the extent to which recurrences can be explained by medication
discontinuation.
Results: Longitudinal MRI studies have found evidence of progressive
decrements in brain tissue volumes over time. However, the change
detected over time may be best explained by factors other than schizo-
phrenia per se such as exposure to antipsychotic medication. Cognitive
deficits are also apparent at the first episode of psychosis but do not on
average worsen over time. The majority of individuals are able to achieve
a remission of psychotic symptoms and to sustain remission over the
longer term. Individuals who have achieved a clinical remission and
then discontinue antipsychotic medication have a weighted mean 1-year
recurrence rate of 77%; by the 2-year point, the cumulative risk of recur-
rence approaches 95%.
Conclusion: Longitudinal outcome studies do not support the view that
schizophrenia is associated with progressive functional or cognitive de-
cline. It is essential that researchers, clinicians, patients and family mem-
bers have a shared understanding that progressive deterioration is not an
inherent feature of schizophrenia. Helping individuals to achieve the full-
est degree of recovery should be the objective of current treatments and
services.
Policy of full disclosure: Dr. Zipursky has received grant support from
Roche and served as a consultant to Amgen, Sunovion, Otsuka, Lundbeck
and Roche.
25S-22. Is schizophrenia a progressive disease?
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
S-23. Psychiatric disorders, 24-hour circadian
rhythms: Clock genes and new treatment
implications
S-23-001 Clock genes in control and major depressive disorder
brain tissue: Possible mode of action of the rapid-acting
antidepressant low-dose Ketamine
W. Bunney. University of California, Irvine, USA
Objective: This presentation will focus on clock genes and their role in
controlling consistently reported abnormal circadian rhythms (sleep, tem-
perature, hormonal secretion, and mood) in major depressive disorder
patients (MDD). A further objective involves the evaluation of the hypoth-
esis that the rapid antidepressant effects of low-dose Ketamine may in-
volve the alterations of clock genes.
Methods: Study 1: Analyzed highest quality brain tissue, all with
rapid death, accurate time of death high pH and RIN values, next-of-kin
interviews and short PMI. Microarray results (12,000 transcripts) were
screened for genes having a significant sinusoidal 24-hour cycle. We eval-
uated the statistical significance of the findings by permutation, randomly
reassigning time-of death data across subjects 1,000 times and determined
peak times of gene expression. Study 2: Test the effects of Ketamine on
clock genes in neuronal cell culture. A reporter constituted by the
mPer1 gene promoter fused with the luciferase gene was expressed in
neuronal cells. E-boxes which drive CLOCK/BMAL1 transcription of
PER and CRY genes were mutated to determine a site of action.
Results: Study 1: Our findings provide the first direct evidence of clock
gene sinusoidal rhythms which vary in synchrony over 24 hrs across
6 regions of normal human brain. These rhythms are disrupted in
MDD. Study 2: This is the first study to provide evidence that Ketamine
inhibits the function of the core clock gene complex, CLOCK/BMAL1,
and that e-box elements are critical for Ketamine’s actions.
Conclusion: Study 1: Clock genes in control subjects show significant
circadian patterns based on time of death over 24 hours, while MDD
patients show a marked disruption. Study 2: Ketamine’s inhibition of
CLOCK/BMAL1 could potentially provide a mechanism by which ‘reset-
ting’ clock gene machinery could normalize dysregulated rhythms and
treat mood disorders.
Policy of full disclosure: None.
S-23-002 Clock gene expression in schizophrenia; and effect of
chronic stress on molecular rhythmicity
G. Lundkvist1, A.-S. Johansson1, B. Owe-Larsson2, M. Bartlang3, S. Reber4,
C. Förster5. 1Karolinska Institutet, Department of Neuroscience, Stockholm,
Sweden; 2Huddinge Hospital, Stockholm, Sweden; 3University of Wuerzburg,
Wuerzburg, Germany; 4University of Ulm, Ulm, Germany; 5Wuerzburg,
Germany
Objective: 1) To analyze clock gene expression in cells obtained from
patients diagnosed with schizophrenia. 2) To investigate the role of the cir-
cadian clock on the body response to stress.
Methods: 1) We sampled mononuclear cells from whole blood obtained
from psychotic patients, and cultured fibroblasts from skin biopsies
obtained from patients with chronic schizophrenia. The fibroblasts cul-
tures were serum-schocked and sampled every 4 hr during 3 days in
order to analyze rhythmic patterns in clock gene expression. Clock
gene and protein expression was analyzed with qRT-PCR and Western
blot. 2) We exposed PERIOD2::LUCIFERASE mice to repetitive psyscho-
social stress in the morning (inactive phase) or in the evening (active
phase) and analyzed the PER2::LUC molecular rhythm in the suprachias-
matic nucleus and adrenal glands.
Results: 1) Cells from psychotic patients expressed lower levels of Cry1,
Per2 and Clock. Serum-schocked fibroblasts from schizophrenic patients
showed less rhythmicity in clock gene expression. In particular, Cry1 rhyt-
micity could only be detected in 20% of the cells from schizophrenic
patients, whereas cells from healthy controls expressed Cry1 rhythmicity
in 100% of the cases. 2) Psychosocial stress in the evening, but not in the
morning, altered the PER2::LUC rhythm in the SCN. Psychosocial stress in
the morning phase advanced the adrenal PER2::LUC rhythm.
Conclusion: Expression patterns of some clock genes, in particular
Cry1, are altered in cells from schizophrenic patients. Psychosocial even-
ing stress affects the central molecular clock, whereas morning stress
appears to have more impact on peripheral clocks.
Policy of full disclosure: None.
S-23-003 Effects of clock gene variants and chronotherapeutics on
hopelessness and suicidality in drug-resistant bipolar
depression
F. Benedetti. Instituto Scientifico, University Ospedale San Raffaele,
Department of Clinical Neurosciences, Milan, Italy
Previous researches by our group showed that clock genes can bias non-
clock brain functions in patients with Bipolar Disorder, such as neural
responses to positive and negative moral stimuli. Some components of
the molecular machinery of the clock also participate in signal transduc-
tion pathways regulating core neuronal and glial metabolic functions,
and we showed that their genetic variants bias integrity and function of
grey and white matter in the brain. Focusing on genetic mutations of
CLOCK, we showed that they bias core psychopatological symptoms
such as instability of circadian rhythms, insomnia, recurrence of illness.
Now we studied the core negative cognitive biases associated with bipolar
depression and found that CLOCK mutants have a worse tendency
toward the generalization across time of negative distortions, with
worse hopelessness, higher ratings on the suicide item of the Hamilton
rating scale, and a dimished resilience as shown by a stroger relationship
between early life stress and current suicidality. The effects of external
stimuli on circadian rhythms, with clock resetting or perturbing action,
may become more apparent when the circadian timing system is compro-
mised. Perturbations of sleep-wake and dark-light exposure cause mini-
mal effects in healthy people, but can produce major clinical effects in
patients with mood disorders. Chronotherapeutic antidepressant inter-
ventions that directly target the clock, such as the combined adminis-
tration of sleep deprivation and light therapy, cause an immediate
decrease of depression and suicidality thus being able to provide an im-
mediate therapeutic effects for the patients. Alltogether, these findings
sustain a central role for the biological clock as a target for the treatment
of mood disorders, and of factors affecting the molecular machinery of the
clock as core biological components in the gene-environment interaction
which shapes the depressive psychopatology.
Policy of full disclosure: None.
S-23-004 Circadian transcriptional network in mammals
J. Takahashi. Howard Hughes Medical Institute, University of Texas,
Southwestern Medical Center, Dallas, USA
Objective: The circadian clock mechanism in animals involves an autore-
gulatory transcriptional feedback loop in which CLOCK and BMAL1
activate the transcription of the Period and Cryptochrome genes. The
PERIOD and CRYPTOCHROME proteins then feedback and repress
their own transcription by interaction with CLOCK and BMAL1.
Methods: We have studied the biochemistry of the CLOCK:BMAL1
transcriptional activator complex as well as the genomic targets of
CLOCK and BMAL1 using ChIP-seq methods.
Results:We describe the dynamics of the core circadian clock transcrip-
tional system. CLOCK and BMAL1 interact with the regulatory regions of
thousands of genes. The gene network and dynamics of the system will be
discussed.
Conclusion: A mechanistic description of the core circadian clock
mechanism should promote our understanding of how the circadian
clock system influences complex behavior and behavioral disorders such
as mood disorders.
References
1. Lowrey P.L. and Takahashi J.S. (2011) Genetics of circadian rhythms
in mammalian model organisms. Advances in Genetics 74: 175–230.
PMCID: 3709251.
2. Takahashi JS, Hong H-K, Ko CH and McDearmon EL (2008) The gen-
etics of mammalian circadian order and disorder: Implications
for physiology and disease. Nature Reviews Genetics 9: 764–775.
PMCID: 3758473.
3. Bass J and Takahashi JS (2010) Circadian integration of metabolism
and energetics. Science 330: 1349–1354. PMCID: 3756146.
4. Huang N, Chelliah Y, Shan Y, Taylor CA, Yoo S-H, Partch C, Green
CB, Zhang H and Takahashi JS (2012) Crystal structure of the hetero-
dimeric CLOCK:BMAL1 transcriptional activator complex. Science
337: 189–194. DOI: 10.1126/science.1222804. PMCID: 3694778.
5. Koike N, Yoo SH, Huang HC, Kumar V, Lee C, Kim TK and
Takahashi JS (2012) Transcriptional architecture and chromatin land-
scape of the core circadian clock in mammals. Science 338: 349–354.
DOI: 10.1126/science.1226339. PMCID: 3694775.
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S-24. Gut microbiota and brain function:
Relevance to psychiatric disorders
S-24-001 The gut microbiota and neuroendocrine function
M. Lyte. Texas Technical University, Health Science Center, Abilene, USA
Objective: To identify common, evolutionary-based, mechanism(s) by
which the microbiota and brain interface in the determination of behavior
as part of the microbiota-gut-brain axis.
Methods: 1. In vitro: Examination of the capacity of microbes to re-
spond to and produce neurochemicals that are more commonly associated
with mammalian neurophysiology. 2. In vivo: (a) Ability of neurochem-
icals released during stress to influence growth of gut microbiota. (b)
Ability of gut microbiota to directly alter behavior.
Results: The ability of microorganisms, whether present as commensals
within the microbiota or introduced as part of a therapeutic regimen, to
influence behavior has been demonstrated by numerous laboratories
over the last few years. Our understanding of the mechanisms that are
responsible for microbiota-gut-brain interactions is, however, lacking.
The complexity of the microbiota is, of course, a contributing factor.
Nonetheless, while microbiologists approaching the issue of microbiota-
gut-brain interactions in the determination of behavior well recognize
such complexity, what is often overlooked is the equal complexity of
the host neurophysiological system, especially within the gut which is dif-
ferentially innervated by the enteric nervous system. As such, both in vitro
and in vivo work has demonstrated that a common mechanism by which
the microbiota may influence behavior is through the production and rec-
ognition of neurochemicals which are shared by both host and microbiota.
The study of host neuroendocrine-microbiota interactions has been
termed microbial endocrinology.
Conclusion: The examination of the microbiota from the vantage point
of host-microbiota neuroendocrine interactions can not only identify new
microbial endocrinology-based mechanisms by which the microbiota can
influence host behavior, but also lead to the design of interventions in
which the composition of the microbiota may be modulated in order to
achieve a specific microbial endocrinology-based profile beneficial to
overall host behavior.
Policy of full disclosure: None.
S-24-002 Gut-brain axis: How the microbiome influences anxiety
and depression
J. Foster1, K.-A. Neufeld1. 1McMaster University, Hamilton, Canada
Objective: The human gut contains an enormous number of microorgan-
isms referred to as commensal bacteria, or gut microbiota. Research in
the gut-brain field has demonstrated that microbiota are important to
the development of brain systems that are important to stress reactivity
and behaviour.
Methods: In the past 5 years, our lab and other groups have studied
the gut-brain axis in germ-free mice, raised in a sterile microisolator and
lacking all gut microbiota. Our first experiments followed on the obser-
vation that germ-free mice showed enhanced stress-reactivity (Sudo
et al., 2004) and we sought to determine if this resulted in changes in
stress-related behaviours.
Results: Surprisingly, our results revealed that germ-free mice showed
reduced anxiety-like behaviour in the elevated plus maze, a well estab-
lished behavioural test that examines approach and avoidance behaviour
in mice, in comparison to specific pathogen free (SPF) mice. These
findings suggest that gut-brain interactions are important to development
of stress systems. The low anxiety-like behavioural phenotype observed in
germ-free mice was accompanied by long-term changes in plasticity-
related genes in the hippocampus and amygdala (Neufeld et al., 2011a).
In addition, the low anxiety-like behavioural phenotype in germ-free
mice persisted after colonization with normal intestinal microbiota dem-
onstrating that gut-brain interactions influence CNS wiring early in life
(Neufeld et al., 2011b). Our recent results show that the developmental
trajectory of CNS stress circuits is altered in GF mice. Interestingly, both
microbiota and sex influenced the changes observed.
Conclusion: Research in the last decade has established the link
between gut microbiota and brain function. We have learned that gut
microbiota are numerous and are important to healthy brain function.
Our findings demonstrate that gut microbiota are important during
early development and can influence the wiring of stress circuitry in the
brain.
Policy of full disclosure: None.
S-24-003 Probiotics as regulators of brain and behavior
J. Cryan1, T. Dinan1. 1University College Cork, Cork, Ireland
Objective: There is a growing appreciation of the relationship between
gut microbiota, and the host in maintaining homeostasis in health
and predisposing to disease. Bacterial colonisation of the gut plays a
major role in postnatal development and maturation of key systems that
have the capacity to influence central nervous system (CNS) programming
and signaling, including the immune and endocrine systems. Individu-
ally, these systems have been implicated in the neuropathology of many
CNS disorders and collectively they form an important bidirectional path-
way of communication between the microbiota and the brain in health
and disease. Over the past 5 years substantial advances have been made
in linking alterations in microbiota to brain development and even behav-
iour and the concept of a microbiota-gut brain axis has emerged. Animal
models have been essential in moving forward this frontier research area.
Methods: In order to assess such a role we use studies involving, germ
free mice and early-life microbiota manipulations and finally probiotic ad-
ministration in adulthood. We assess neurochemical, molecular and beha-
vioural effects following these manipulations.
Results: Our data show that the gut microbiota is essential for normal
stress, antidepressant and anxiety responses. Moreover, microbiota is es-
sential for both social cognition and visceral pain. Finally, there are critical
time-windows early in life when the effects of microbiota on brain and be-
haviour appear to be more potent. Our data also demonstrates that these
effects may be mediated via the vagus nerve, spinal cord, or neuroendo-
crine systems.
Conclusion: Such data offer the enticing proposition that specific
modulation of the enteric microbiota by dietary means may be a useful
“psychobiotic”-based strategy for both stress-related and neurodevelop-
mental disorders ranging from depression to autism.
Policy of full disclosure: The authors are supported in part by Science
Foundation Ireland in the form of a centre grant (Alimentary
Pharmabiotic Centre Grant Number SFI/12/RC/2273); by the Health
Research Board of Ireland (Grant Numbers HRA_POR/2011/23 and
HRA_POR/2012/32) and received funding from the European
Community’s Seventh Framework Programme Grant MyNewGut under
Grant Agreement No. FP7/2007–2013. The Centre has conducted studies
in collaboration with several companies including GSK, Pfizer, Cremo,
Suntory, Wyeth and Mead Johnson. The authors have spoken at meetings
sponsored by food and pharmaceutical companies.
S-24-004 Imaging the brain-gut-microbiome axis in humans
E. Mayer1, K. Tillisch1, J. Labus1. 1UCLA, Los Angeles, USA
Objective: Previous studies in rodents have shown changes in brain
neurochemistry and behavior in rodents in response to changes in the
gut microbiota. The current study aimed to test the hypothesis that pertur-
bation of the normal human gut microbiome by regular ingestion of pro-
biotics will result in measurable changes in the brain as indexed by resting
state and evoked brain responses.
Methods: Healthy women with no gastrointestinal or psychiatric
symptoms were randomly assigned to groups given the test product
(fermented milk product with probiotics [FMPP] (n=12), a control con-
dition (nonfermented milk product) (n=11), or no intervention (n=13)
twice daily for 4 weeks. The FMPP was a consortium of probiotics con-
taining Bifidobacterium animalis subsp Lactis, Streptococcus thermo-
philes, Lactobacillus bulgaricus, and Lactococcus lactis subsp Lactis.
Participants completed questionnaires to assess subjective symptoms
and underwent functional magnetic resonance imaging (fMRI) before
and after the intervention to measure brain response to an emotional rec-
ognition attention task and resting brain activity. Multivariate and region
of interest analyses were performed.
Results: No effect of the FMPP on subjective or behavioral measures
were observed. FMPP intake was associated with reduced task-related re-
sponse of a distributed functional network (49% cross-block covariance;
P=0.004) containing affective, viscerosensory, and somatosensory cortices.
Alterations in intrinsic activity of the resting brain indicated that ingestion
of FMPP was associated with changes in midbrain connectivity, which
could explain the observed differences in activity during the task.
Conclusion: Four-week intake of an FMPP by healthy women affected
the responsiveness of brain regions that control emotion recognition and
sensation. This pilot study provides the first demonstration in humans
for a gut microbiome brain communication.
Policy of full disclosure: None.
27S-24. Gut microbiota and brain function: Relevance to psychiatric disorders
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
S-25. The expanding roles of microglia in chronic
pain: Implications for therapy
S-25-001 Gene regulation in microglia in neuropathic pain
K. Inoue. Kyushu University, Fukuoka, Japan
Objective: Neuropathic pain is a debilitating chronic pain that occurs
after peripheral nerve injury (PNI). We reported that activated microglia
overexpressed P2X4 receptors after PNI evoking the pain (Nature, 2003
& 2005). However, the mechanism of microglia is poorly understood.
We wanted to know this by gene regulation.
Methods: Methods are as usual.
Results: The expression the transcription factor interferon-regulatory
factor 8 (IRF8) was markedly upregulated only in microglia after PNI.
IRF8 overexpression in cultured microglia promoted the transcription of
genes of molecules related the pain. IRF8 deficiency prevented the expres-
sions of these genes in the spinal cord and the pain following PNI.
Conclusion: IRF8 may activate a program of gene expression that trans-
forms microglia into a reactive phenotype.
Policy of full disclosure: None.
S-25-002 Microglia-neuron signalling mediates chronic
pain-induced alterations in reward pathways
C. Cahill1, A. Taylor1, A. Castonguay2, N. Murphy3, A. Ghogha3,
Y. De Koninck2, C. Evans3. 1University California Irvine, Irvine, USA;
2Laval University, Quebec City, Canada; 3University California, Los Angeles,
USA
Objective: It is known that neuronal-glia interactions, particularly pro-
ducts released from activated astrocytes and microglia are proposed to
underlie synaptic plasticity pertinent to the development and persistence
of NP pain. In the present study we sought to determine whether micro-
glial activation in brain structures responsible for reward may contribute
to neuropathic pain as pain and reward are processed within overlapping
brain structures and are interacting processes.
Methods:Male C57Bl/6J mice were subjected to peripheral nerve injury
or sham surgery. At 14 days post surgery, when pain hypersensitivities
are clearly established, animals were subjected to either: (1) in vivo micro-
dialysis for determination of opioid-evoked release of dopamine in the
nucleus accumbens, (2) fresh tissue extracted from specific brain structures
to measure levels of BDNF and the K/Cl co-transporter KCC2, (3) cardiac
perfusion of formaldehyde for immuohistochemical labeling of glia,
BDNF and KCC2, and (4) MQAE fluorescent lifetime measurements of
Cl- in live tissue slices from the ventral tegmental area.
Results: In the present study, we identify microglial activation in
the mesolimbic reward circuitry following peripheral nerve injury. This
microglial activation causes release of BDNF within the ventral tegmental
area, which in turn disruptions chloride (Cl-) transport in GABAergic
neurons. The result is an exaggerated inhibitory tone on dopaminergic
neurons projecting to the nucleus accumbens. Morphine-evoked release
of dopamine is significantly blunted in neuropathic pain animals and
this is recovered by treatment with a microglial inhibitor.
Conclusion: In conclusion, we present a novel mechanism that is re-
sponsible for dysfunction of mesolimbic dopaminergic transmission in
chronic neuropathic pain that may account for the co-morbidities of
mood disorders in chronic pain. Moreover, the blunted analgesic effect
of opioids in chronic pain maybe due to alterations in neural systems re-
sponsible for reward as their analgesic effects are strongly linked to their
rewarding capacity.
Policy of full disclosure: None.
S-25-003 The P2X4+ state of microglia is critical for
neuropathic pain
M. Salter. SickKids Hospital, Toronto, Canada
Neuron-microglial interactions are increasingly recognized as being
key for physiological and pathological processes in the central nervous
system. Microglia have been found to play a causal role in neuropathic
pain behaviours resulting from peripheral nerve injury, and a core
neuron-microglia-neuron signaling pathway has been elucidated. Within
the dorsal horn, microglia suppress neuronal inhibition by a cascade in-
volving activation of microglial P2X4 receptors causing the release of
brain derived neurotrophic factor (BDNF). BDNF acts on trkB receptors
which leads to a rise in intracellular chloride concentration in dorsal
horn nociceptive output neurons, transforming the response properties
of these neurons. In addition to suppressing inhibition, peripheral nerve
injury causes activity-dependent facilitation at dorsal horn glutamatergic
synapses which enhances nociceptive transmission. This enhancement is
mediated by intracellular signaling networks involving serine/threonine
and tyrosine kinases within nociceptive transmission neurons. Key for
this enhancement is facilitation of NMDA receptor function by Src family
tyrosine kinases. Recently we have discovered that microglia-to-neuron
signaling is not only critical for pain hypersensitivity after peripheral
nerve injury but also for the paradoxical hyperalgesic effect of morphine
and other opioids. We anticipate that by targeting microglia-neuron sig-
naling pathways new therapeutic strategies for chronic pain as well as
its comorbid sequelae may be developed.
Policy of full disclosure: None.
S-25-004 Microglia-mediated disruption of neuronal
Cl-homeostasis mediates morphine hyperalgesia
Y. De Koninck. Université Laval, Québec, Canada
Objective: Morphine, and other opiates, are indispensable in the treat-
ment of moderate to severe postoperative and chronic pain, but use of
these drugs is plagued by the development of a particularly debilitating
side effect: the development of paradoxical hyperalgesia. Knowing that
morphine treatment causes microglial activation, we sought to determine
whether morphine-induced hyperalgesia would involve similar mechan-
isms as those we previously found to underlie neuropathic pain.
Methods: Rats and mice were treated repeatedly with morphine to
5–7 days and nociceptive withdrawal threshold were measured every
morning before morphine injection to test for a change in baseline re-
sponse. A multidisciplinary approach was used involving immunocyto-
chemistry, immunoblotting, patch clamp electrophysiology, cellular
imaging, pharmacological interventions and conditional gene deletion to
identifying the underlying mechanisms at the level of the spinal dorsal
horn, namely those that were previously implicated in neuropathic pain:
microglial activation, P2X4 receptors, Brain-Derived Neurotrophic Factor
(BDNF), TrkB receptors and the K-Cl-cotransporter KCC2.
Results:We found that hyperalgesia-inducing treatment with morphine
caused a downregulation of KCC2, impairing Cl– homeostasis in spinal
lamina l neurons. Restoring Eanion reversed the morphine-induced
hyperalgesia without affecting tolerance. The hyperalgesia was also
reversed by ablating spinal microglia. Morphine hyperalgesia, but not
tolerance, required μ opioid receptor-dependent expression of P2X4
receptors (P2X4Rs) in microglia and μ-independent gating of the release
of brain-derived neurotrophic factor (BDNF) by P2X4Rs. Blocking
BDNF-TrkB signalling preserved Cl– homeostasis and reversed the hyper-
algesia. Gene-targeted mice in which BDNF was deleted from microglia
did not develop hyperalgesia to morphine. Yet, neither morphine antino-
ciception nor tolerance was affected in these animals.
Conclusion: Our findings dissociate morphine-induced hyperalgesia
from tolerance and unveil the microglia-to-neuron P2X4-BDNF-KCC2
pathway as a therapeutic target to prevent hyperalgesia without affecting
morphine analgesia.
Policy of full disclosure: None.
S-26. Depression in pregnancy and postpartum:
A treatment dilemma?
S-26-001 Antidepressant treatment in a model of post-partum
depression age- and gender-dependently alter offspring’s
CNS development
M.-C. Pardon1, A.-A. Hidayah1, A. Trist1. 1University of Nottingham,
Nottingham, United Kingdom
Objective: Gestational chronic mild stress in mice induces hormonal and
behavioural changes reminiscent of post-partum depression and produces
developmental effects in offspring which appear in an age and sex depen-
dent manner, with females being more vulnerable. We investigated
whether antidepressant exposure (via breast milk) reversed the develop-
mental effects of gestational chronic mice stress, or whether it induced ad-
verse behavioural consequences in offspring.
Methods: Chronic mild stress was applied to pregnant B6D2F1 dams
after until delivery. Antidepressants (fluoxetine, 10mg/kg/day and clomi-
pramine, 20mg/kg/day) were administered through drinking water from
post-partum day (PD) 1 until weaning (PD22). Offspring belonged to one
of four groups: Control group (no prenatal stress), S group (prenatally
stressed and not treated), CL group (prenatally stressed and treated
postpartum with clomipramine) or FL group (prenatally stressed and
treated postpartum with fluoxetine). On PD7, each litter was subjected
to the pup retrieval test during which ultrasonic vocalisations were
recorded. Cognitive function, locomotor and anxiety-related behaviour
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were then assessed in juvenile (PD23 to PD28) or adults (PD52 to PD58)
offspring.
Results: During the pup retrieval test, S offspring emitted more
chevron calls in the absence of the dams, and this was reversed by both
antidepressants. Dams treated with fluoxetine were more likely to retrieve
the pups back to the nest, but there was no effect of either treatment on
the number or type of calls. The behaviour of juvenile offspring and of
adult female was not affected by maternal exposure to antidepressants.
Adult male from the CL group, however, exhibited reduced anxiety-like
behaviour in the open-field, increased object recognition memory and de-
crease contextual fear memory. Adult male from the FL group were
hyperactive in the open-field and exhibited reduced anxiety-like
behaviour.
Conclusion: Thus, antidepressants administered during breastfeeding
can alter maternal behaviour as well as offspring central nervous system
function in an age and gender dependent manner.
Policy of full disclosure: None.
S-26-002 Maternal antidepressant exposure and CNS development
in the rat offspring
J. Kelly1, S. O’Brien2. 1NUI Galway, Galway, Ireland; 2University of Limerick,
Limerick, Ireland
Objective: Assessing the risks of antidepressant exposure clinically
during pregnancy and lactation is extremely challenging due to logistical
and ethical reasons. Laboratory animals provide an alternative; however,
studies evaluating antidepressant exposure have often employed doses
and routes of exposure which are not clinically relevant, examined terato-
genic effects without exploring behavioural consequences and confined
endpoint evaluation to the early life period. Thus the objective of this
study was to examine whether prenatal and/or postnatal exposure to
the SSRI fluoxetine affected anxiety-related behaviour in the resulting off-
spring, from early life extending to adulthood.
Methods: Female Sprague-Dawley rats received daily injections of
fluoxetine (5 mg/kg by oral gavage) from gestational day (GD) 7 until lit-
tering and throughout the neonatal period, i.e. from postnatal day (PND)
1 to 21. Other groups received fluoxetine either only during the prenatal
or postnatal period, whilst control animals received distilled water
alone. The elevated plus maze and open field test were examined in sep-
arate groups of rats either at 1, 2, 3 or 4 months of age. All results were
analysed using TwoWay ANOVA, followed by post-hoc Student
Newman Keuls tests, where appropriate, p<0.05 denoting statistical
significance.
Results: Fluoxetine treatment was well tolerated, with no significant ef-
fects on maternal weight gain, nor any effect on the weight of the offspring
in the neonatal period. A significant reduction in % open arm time in the
elevated plus maze for male groups that had received prenatal fluoxetine
(p<0.05 vs. controls) was observed at 2 months of age, with no significant
drug-induced changes in open field behaviour.
Conclusion: It can be concluded that prenatal (but not postnatal) fluox-
etine exposure results in selective anxiogenic effects that are transient and
confined to male offspring, and indicates the value of using a clinically rel-
evant exposure regime that enables a better extrapolation to the human
situation.
Policy of full disclosure: None.
S-26-003 What are the molecular and psychological mechanisms
underlying the impact of maternal depression and
antidepressant use on the offspring?
C. Pariante. King´s College London, London, United Kingdom
Objective: To review our research on the effects of depression in preg-
nancy on offspring neurobiology and psychopathology.
Methods: We will present data from our current study on women who
are depressed in pregnancy, and their offspring who have been
followed-up until 1 year of age (Psychiatric and Motherhood – PRAM
study), as well as from our ongoing longitudinal cohort of young
adults born from mothers who were depressed in pregnancy in 1986
(South London Child Development Study).
Results: Women who are depressed in pregnancy have high levels
of cortisol and of pro-inflammatory cytokines, and their offspring
have increased stress responses and more immature behaviour. In the
longitudinal study, offspring of women who were depressed in pregnancy
appear more at risk of developing depression in adulthood, and to be ex-
posed to life stressors; moreover, they have disrupted inflammation even
in the absence of depression. Across the two studies, maternal childhood
trauma is a very strong risk factor for mothers developing depression
specifically in pregnancy.
Conclusion: Depression in pregnancy has specific biological and clini-
cal effects that could participate to the transmission of psychopathology
from one generation to the next.
Policy of full disclosure: None.
S-26-004 Impact of in utero exposure to antidepressants on
the foetus
M. Reis. National Board of Forensic Medicine, Linköping, Sweden
An update of the Swedish Medical Birth Register (1996–2011) will be pre-
sented. During these years 1,552,382 women gave birth in Sweden and
antidepressant use in early pregnancy was reported by 23,342 women
(23,658 infants). The register contains information on nearly all births in
the country and is based on standardized medical records: information
from the first antenatal visit (gestation weeks 10–12); information from
further antenatal care; data from the delivery; and finally data from the
paediatric examination of the newborn. Further, neonatal as well as ma-
ternal diagnosis from women who got prescriptions for an antidepres-
sants during the 2nd or 3rd trimester (7,940 women; 8,053 infants) will
be presented. Few drug categories have been studied as extensively as
antidepressants and notably SSRI. Some of the studies which seem to
demonstrate teratogenic effects are retrospective case-control studies
which may introduce methodological errors. In prospective studies little
evidence of teratogenicity is found but the use of clomipramine or parox-
etine may have a specific effect on cardiovascular defects, notably cardiac
septum defects. Relatively little is known about other antidepressants than
tricyclic or SSRI drugs but no major risk appears to exist. Use of antide-
pressants during the 2nd or 3rd trimester is associated with a number
of pregnancy and neonatal complications which usually are of temporary
nature but will increase the need for neonatal intensive care. Data in the
literature indicate that these effects may only partly be due to the drugs
but partly is a result of underlying disease, a confounding by indication.
There is a tendency that TCA causes stronger effects than SSRI at least for
preterm birth, low birth weight and neonatal diagnoses which supports a
drug effect but there may exist differences in underlying pathology.
Policy of full disclosure: None.
S-27. A new nomenclature proposal for
psychotropic drugs
S-27-001 Introduction and antidepressants
J. Zohar. Sheba Medical Center, Tel Aviv, Israel
Objective: Current psychopharmacological nomenclature remains wed-
ded to earlier period of scientific understanding, failing to reflect contem-
porary developments and knowledge, does not help clinicians to select the
best medication for a given patient, and tending to confuse patients as
they are being given a drug with a different name compared to their iden-
tified diagnosis (e.g. “Antipsychotic” for depression). A five-axis pharma-
cology based nomenclature template as a potential system which refresh
current nomenclature by using contemporary scientific concepts of
Neurospsychopharma- cology will be presented.
Methods: Four major colleges of Neuropsychopharmacology (ECNP,
ACNP, Asian CNP, and CINP) proposed a new template comprising a
multi-axial pharmacologically-driven nomenclature. The template com-
prises of five axes: 1) class and Relevant mechanism; 2) sub-class; 3)
neurobiological activity; 4) Efficacy (including major side effects); and 5)
Indications (FDA or EMA approved, or as stated). Several surveys in
four different continents were conducted in order to examine satisfaction
with the current psychopharmalogical nomenclature, as well as test the
five-axis template.
Results: A significant proportion of the participants in the surveys were
in favour of the proposed system, a similar number wanting to consider
the idea further, and only a small proportion were against it.
Conclusion: The results of the surveys suggest that clinicians found
the available nomenclature system dissatisfactory and at times even con-
fusing for them and the patients. The proposed 5 axis template seeks to
up-end current usage by placing pharmacology rather than indication
as the primary axes. Based on the results the authors envision that the
primary usage would relate to Axis 1—the class—Axis 4 – Efficacy, Axis
5 – Indications. The other Axis 2—sub-class and 3 – neurobiological ac-
tivity – being optional and largely depending upon the extent to which
the clinician seeks to dig into the scientific base.
Policy of full disclosure: Joseph Zohar has received grant/research
support from Lundbeck, Servier and Pfizer, has served as a consultant
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or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion,
AstraZeneca and Roche, and has served on speakers’ bureaus for
Lundbeck, Roch, and Abbott.
S-27-002 Anxiolytics and hypnotics
D. Nutt. Imperial College, London, United Kingdom
My talk will focus in the new approach to nomenclature for anxiolytics
that is being developed by the ECNP ACNP CINP AsCNP groups – I
shall show how a focus on pharmacology can help understand the actions
and adverse effects of these medicines.
Policy of full disclosure: None.
S-27-003 Antipsychotics
S. Stahl. NEI, Carlsbad, CA, USA
Objective: To illustrate the confusion in classifying antipsychotics and
to propose nomenclature based upon pharmacologic action rather than
simply reduction of psychosis
Methods: Literature review and consensus panel
Results: Antipsychotics are not merely effective in psychosis, but many
are effective in mania, in bipolar depression, in unipolar depression and
as adjuncts to antidepressants in treatment resistant depression. This
has created confusion in classifying these agents, compounded by notions
of whether the antipsychotic is first generation or ‘conventional, versus
second generation and ‘atypical.’
Conclusion: A nomenclature based upon principle and secondary phar-
macologic actions is proposed and will be presented and discussed.
Policy of full disclosure: None.
S-27-004 A view on the new nomenclature from the perspective
of the drugs developed in Japan
S. Yamawaki1, H. Hashimoto2, K. Ikeda3, T. Kato4, S. Kanba5, N. Ozaki6,
I. Kusumi7. 1Hiroshima University, Hiroshima, Japan; 2Osaka University,
Osaka, Japan; 3Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan;
4RIKEN Brain Research Institute, Wako, Japan; 5Kyushu University, Fukuoka,
Japan; 6Nagoya University, Nagoya, Japan; 7Hokkaido University, Sapporo,
Japan
There is a growing consensus in Asia as well as in Western world that the
current nomenclature for psychiatric drugs is outdated and new no-
menclature based on scientific evidence by the up-to-date
Neuropsychopharmacology is anticipated. Recently some members of
Japanese Society of Neuropsychopharmacology (JSNP), with the cooper-
ation of 3 Japanese pharmaceutical companies, reviewed the new
Nomenclature proposal introduced by ECNP. As well as presenting over-
all comments on the format, we have created our experimental proposals
of the 3 representative drugs developed in Japan (Aripiprazol, Lurasidone
and Donepezil) on the assumption that the new Nomenclature will be pre-
sented in a 2-step approach, a simplified version for clinical practice and a
more detailed one for reference. General comments on the format are: 1)
5-Axes format provides appropriate elements required for the
Nomenclature, 2) The information described in Axes 4 (Efficacy and
Side effects) and 5 (Indications) should be reviewed periodically to keep
accuracy. Especially, the information in Axis 5 increases over time and
it is necessary to consider frequency of updating the contents in both
Axes, 3) Axis 3 (Neurobiological description) contains several items but
it is difficult to classify data and information into these items, and 4) for
Axis 4, criterion for listing information should be developed. It may be
practically feasible to include adverse events with more than 5% incidence
rate. In addition there was a comment that original 5-axes format is too
much for clinical doctors for daily practice, but in the latest version, it is
improved properly by dividing the format into 2 pages # ‘front page’
for the bedside clinicians with Axes 1, 4 and 5 and the committee note
and the ‘back page’ providing details including Axes 2 and 3. In this sym-
posium, our proposals on the 3 drugs developed in Japan will be
presented.
Policy of full disclosure: None.
S-28. Serotonin, stress and depression: Genetic
and epigenetic factors
S-28-001 Genetic mechanisms for longterm alterations in serotonin
in depression
P. Albert. University of Ottawa, Ottawa, Canada
Objective: This symposium focuses on new findings that strengthen
the long-held link between serotonin, early life stress and depression.
Evidence will be presented to demonstrate that genetic and stress-induced
epigenetic alterations in the expression of the serotonin regulatory sero-
tonin (1A) receptor gene (HTR1A) that are associated with depression
leads to altered serotonin activity, ultimately underlying depression and
response to antidepressant treatments.
Methods: Evidence from functional studies of the regulation of sero-
tonin genes focusing on the 5-HT1A receptor gene, from cellular to animal
models to clinical imaging studies will be presented.
Results: Dr. Albert has studied the underlying transcription mechan-
isms that regulate serotonin gene expression, focusing on regulation of
the 5-HT1A receptor gene, a critical regulator and transducer of serotonin
action. He has identified the rs6295 HTR1A genetic polymorphism that
associated with depression and suicide that is located in the promoter
of this gene and that alters the activity of specific transcription factors
resulting in altered levels of the receptor and reduced serotonin content.
Using genetic knockout models, he has shown that the transcription fac-
tors that he has identified modify the expression of 5-HT1A receptor
and may account for brain region specific alterations in 5-HT1A receptor
expression that predispose to depression.
Conclusion: The evidence presented will identify specific gene regulat-
ory mechanisms that lead to dys-regulation of the 5-HT1A receptor and
ultimately to increase in susceptibility to depression. Targeting these regu-
latory mechanisms may provide novel and multimodal new treatments
for depression.
Policy of full disclosure: None.
S-28-002 Brain serotonin 1A receptor binding in major
depressive disorder
R. V. Parsey1, G. Sullivan2, J. Kaufman2, C. Delorenzo2, N. Hesselgrave2,
R. T. Ogden3, M. Oquendo3, J. J. Mann3, J. Miller2. 1SUNY Stony Brook,
Columbia University, Stony Brook, NY, USA; 2Columbia University,
New York, USA; 3New York, USA
Objective: The serotonin 1A (5-HT1A) receptor has been implicated in the
pathophysiology of MDD. We previously reported higher 5-HT1A recep-
tor binding in two cohorts of subjects with MDD during a major depress-
ive episode (MDE) using PET imaging with [11C]WAY-100635. This is a
state phenomenon, not trait, as we have demonstrated that the effect per-
sists in subjects who are remitted and off of medication. We have also
shown that 5-HT1A binding is also associated with treatment outcome
after non-standardized antidepressant treatment. Most recently, we exam-
ined whether pre-treatment 5-HT1A binding is associated with treatment
outcome following standardized escitalopram treatment in MDD. We also
compared 5-HT1A binding between all MDD subjects in this cohort and a
sample of healthy controls.
Methods: 24 MDD subjects in a current MDE underwent PET scanning
with [11C]WAY-100635, acquiring a metabolite-corrected arterial input
function and free-fraction measurement to estimate 5-HT1A binding
(BPF=Bmax/KD, where Bmax=available receptors and KD=dissociation
constant). MDD subjects then received eight weeks of treatment with esci-
talopram. Remission was defined as a post-treatment 24-item HDRS <10.
Results: 46% of subjects achieved remission following eight weeks
of escitalopram. Remitters to escitalopram had 33% higher baseline
5-HT1A binding in the raphe nuclei than non-remitters (p=0.047,
p=0.033 with covariates). Across 12 cortical and subcortical regions,
5-HT1A binding did not differ between remitters and non-remitters
(p=0.86). 5-HT1A binding was higher in MDD than historical controls
across all regions (p=0.0003), a triplication of our finding. Remitters did
not differ from non-remitters in several relevant clinical measures.
Conclusion: Elevated 5-HT1A binding in raphe nuclei is associated
with subsequent remission with the SSRI escitalopram; this is consistent
with data from a separate cohort receiving naturalistic antidepressant
treatment. We confirmed our previous findings of higher 5-HT1A binding
in current MDD compared to controls.
Policy of full disclosure: None.
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S-28-003 Stress and depression: A vicious cycle?
C. Belzung. INSERMUMR930, Tours, France
Objective: Major depression has been much related to chronic stress, par-
ticularly in subjects having a low diathesis for depression. In fact, chronic
stress induces chronic exposure to glucocorticoids, which elicits a decrease
of glucocorticoid receptors in granule cells located in the dentate gyrus of
the hippocampus and, later on, to a loss of hippocampal granule cells that
can be counteracted by the generation of new granule cells via increased
adult hippocampal neurogenesis. Interestingly, all available antidepres-
sant drugs stimulate cell proliferation in the hippocampus and accelerate
the maturation of these cells. However, the mechanisms underlying this
action are still poorly understood. The objective of this study is to inves-
tigate the mechanisms underlying the antidepressant-like action of selec-
tive serotonin reuptake inhibitors (SSRIs).
Methods:We combined unpredictable chronic mild stress as a model of
depression in mice with chronic SSRIs, focal irradiations of the hippocam-
pus, genetic strategies, immunohistochemistry and hormonal dosages.
Results: We show that newborn neurons of the hippocampus are
necessary and sufficient to elicit therapeutic effects in an animal model
of depression. This then enables the recruitment of projection areas of
the hippocampus, particularly of the anteromedial nucleus of the bed nu-
cleus of stria terminalis, the inhibition of the paraventricular nucleus of the
hypothalamus, and thus remission. Resistance to SSRIs is associated with
poor aptitude of SSRIS to stimulate neurogenesis.
Conclusion: Drugs of the future could treat depression by targeting
directly adult hippocampal neurogenesis or the stress axis.
Policy of full disclosure: None.
S-28-004 The role of SLC6A4 DNA methylation in stress-related
changes in hippocampal volume: A study in depressed
patients and healthy controls
L. Booij1, M. Szyf2, A. Carballedo3, E.-M. Frey4, D. Morris3, V. Ly2,
C. Fahey3, J. Meaney3, M. Gill3, T. Frodl3. 1Université de Montréal, CHU
Sainte-Justine, Montreal, Canada; 2McGill University, Montreal, Canada;
3University of Dublin, Trinity College, Dublin, Ireland; 4University of
Regensburg, Regensburg, Germany
Objective: Serotonin (5-HT) plays an important role in the etiology of
depression. Serotonin is also crucial for brain development. For instance,
animal studies showed that early 5-HT disruptions affect brain develop-
ment and emotion regulation in later life. We found that childhood
trauma in humans interacting with the short allele of the 5-HTTLPR poly-
morphism was associated with smaller hippocampal volumes in de-
pression (Frodl et al., 2010). However, specific mechanisms of this
interaction are not known. A plausible mechanism is that environmental
stressors reprogram the 5-HT system through epigenetic processes by
altering 5-HT system gene expression. This in turn may affect brain devel-
opment, including the hippocampus, a region with dense 5-HT innerva-
tions and important in stress-regulation. Here, we test whether greater
DNA methylation in specific CpG sites at the SLC6A4 promoter in periph-
eral cells is associated with childhood trauma, depression and smaller
hippocampal volume. We were particularly interested in those CpGs
that had previously been associated with in vivo measures of brain
5-HT synthesis (Wang et al., 2012).
Methods: Thirty-three adults with major depressive disorder and 36
healthy matched controls were included. Symptoms, childhood trauma
and high-resolution structural MRI for hippocampal volume were
assessed (Frodl et al., 2010). SLC6A4 methylation was assessed using
pyrosequencing.
Results: Regression analyses showed that childhood trauma, female
gender and smaller hippocampal volume were independently associated
with greater SLC6A4 methylation. Greater SLC6A4 methylation in the de-
pressed group was observed only in SSRI-treated patients. Interestingly,
associations were primarily observed in CpGs previously being associated
with brain 5-HT synthesis (Wang et al., 2012).
Conclusion: SLC6A4 methylation might be a mechanism for physio-
logical gene-environment interaction in the development of stress-related
brain alterations. The results provide some indications that site-specific
SLC6A4 methylation may be a biomarker for 5-HT-associated stress-
related psychopathology.
Policy of full disclosure: None.
S-29. Clinically useful biomarkers in psychiatry:
The promise and problem
S-29-001 Progress toward clinically useful biomarkers in psychiatry
B. Dean. Molecular Psychiatry Lab, FINMH, Howard Florey Laboratories,
Melbourne, Australia
Objective: In psychiatric disorders, the development of neuroimaging and
other tools to measure CNS function and the notion that the biology of
psychiatric disorders affects whole of body has fuelled efforts to discover
biomarkers that would have diagnostic utility or aid in treatment decision
making. Focussing on molecular approaches to biomarker discovery, cost
considerations strongly suggest that for any biomarker to have wide-
spread utility it would need to use an easily accessible peripheral tissue
with a low risk of collection side-effects. Following this logic, this presen-
tation will focus on the approaches, progress and problems in identifying
molecular biomarkers for psychiatric disorders. The focus will be on
non-DNA sequence biomarkers because levels of such biomarkers are
more likely to reflect interactions between genes and environment that
are now predicted to play a pivotal role in the genesis of a psychiatric
disorder1.
Methods: Data from the presenter and the literature will be presented to
highlight possible approaches to biomarker discovery and the problems
and pitfalls from discovery to validation and the use across multi-centres.
Results: Available data would suggest that some progress is being
made toward biomarkers that can aid in diagnoses and response to treat-
ment. However, interpreting available data is being hampered because of
a lack of standardisation across groups undertaking biomarker discovery
programs.
Conclusion: This presentation will suggest that there is growing evi-
dence to support the discovery of clinically useful biomarkers. That
such tools will likely be based on changes in panels of analytes, rather
than on a single analyte, but that progress needs to be made in standardis-
ing sample collecting to allow the potential utility of biomarker system as
a widely use clinical aids to be assessed.
Reference
1. Uher R (2014) Gene-environment interactions in common mental
disorders: an update and strategy for a genome-wide search. Soc.
Psychiatry Psychiatr Epidemiol 49: 3–14.
Policy of full disclosure: None.
S-29-002 Biomarkers for psychosis onset: Promising candidates
from the genome
C. Bousman. University of Melbourne, Parkville, Australia
Objective: Identification of individuals at high risk for psychotic disorder
has proven challenging. The development and validation of standardised
clinical criteria to detect individuals at high risk of psychosis has
improved our ability to identify individuals at the greatest risk for tran-
sition from an at-risk state to frank-level psychotic symptoms. However,
the majority of individuals meeting high risk criteria do not develop psy-
chosis and as such biomarkers could further refine our ability to detect
those most at risk for psychosis transition/onset. The focus of this presen-
tation will be on recent biomarker discovery efforts within this high-risk
group with particular emphasis on genotypic makers for psychosis tran-
sition/onset.
Methods: Data from prospective cohort studies that have examined the
effects of genotypic variation on transition to psychosis will be presented,
with particular focus on the presenter’s recent research in the area.
Results: To date, studies have identified variation in neuregulin 1
(NRG1), D-amino acid oxidase activator (DAOA), and catechol-o-
methyltransferase (COMT) as potential biomarkers for psychosis
transition. However, only genetic variation in NRG1 has support from
more than one study.
Conclusion: Current tools used for early identification of individuals at
risk for transition, although standardized, are dependent on subjective
measures (e.g. clinical rating scales) that relative to genotyping are more
susceptible to measurement errors and consequently reduced prediction
accuracy. Current findings support the addition of measures that are
not dependent on state-related changes. However, the temptation to in-
clude genetic variation in psychosis risk prediction must be cautioned
until replication has been undertaken in much larger samples, and the
true effect size of associations can be more accurately determined.
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Additional investigation may then determine which genetic markers, in
what contexts, and at what costs will provide the most clinically useful
genetically informed risk prediction among at-risk populations.
Policy of full disclosure: None.
S-29-003 Measuring oxidative damage to cortical white matter
in blood samples from patients with mood disorders:
Evolution of biomarkers in psychiatry
T. Young1, A. Andreazza1. 1University of Toronto, Toronto, Canada
Objective: Bipolar disorder (BD) continues to be a leading cause of dis-
ability but the etiology is only partly understood. Among the pathophy-
siological mechanisms which are important in BD, oxidative stress is
increasingly well supported. Lipids are particularly abundant in brain, es-
pecially white matter, and are targets for oxidative damage. In the present
study, we examined the relation between white matter and oxidative
stress.
Methods: Several complimentary approaches were used. We examined
post mortem brain from subjects with BD, blood samples from subjects
with BD including adults and those from an older age group and from
patients with brain imaging data examining white matter tracts. The
work was done in collaboration with investigators at University of
Toronto and University of Pittsburgh and with tissue from the Harvard
Brain Bank.
Results: Increased lipid peroxidation was found in the myelin fraction
from frontal cortex but not hippocampus of patients with BD. Increased
markers of lipid damage were found in both adults and older patients
with BD. There was a relationship between serum lipid peroxidation
and white matter integrity.
Conclusion: Oxidative stress may be critically important in BD, be
measurable in blood and may be related to white matter tracts. Lipid per-
oxidation is a potentially relevant target for therapeutic intervention
which deserves more intensive study.
Policy of full disclosure: None.
S-29-004 Biomarkers for psychiatric disorders: Expectations and
problems from a clinical point of view
H.-J. Moeller. Ludwig-Maximilians-University, Munich, Germany
There was and is still great hope for biomarkes in psychiatry, both for di-
agnosis and treatment. Intensive efforts have been made in the recent dec-
ades, but so far nothing evolved for clinical use, inspite of all the technical
progress in terms of genetics, brain imaging and other methods. The in-
vention of diagnostic biomarkers so far is not fulfilled, although for the
diagnoses of Alzheimer dementia it seems more and more realistic. But
even in this field DSM-5 did not include biomarkers, not to speak about
other diagnostic entities like schizophrenia and depression. When it
comes to the term personalized medicine most people think about bio-
markers driven clinical decision making and indeed, there was great
hope that among others based on pharmacogenetic findings we would
be able to fulfill the dream of personalized medicine. Many polymorph-
isms were described as relevant for treatment outcome, both related
to efficacy or tolerability. But the results were often quite unstable and in-
consistent and the explained variance by each of this genetic alterations
extremely low. There is still hope, that a combination of such polymorph-
isms might be helpful in predicting the outcome of drug treatment and
improve in clinical decision making. But so far, given the low size of
explained variance even for such a combination, it is more realistic to
think that this will be not in the sense of individualized/personalized
medicine, but in the sense of stratified medicine. Probably beside genetics
also other parameters like brain imaging results might be helpful in im-
proving the clinical decision making in this sense.
Policy of full disclosure: Conflict of Interest – Financial Disclosure
Statement Prof. Dr. Moeller has received grants or is a consultant for
and on the speakership bureaus of AstraZeneca, Bristol-Myers Squibb,
Eisai, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck,
Novartis, Organon, Pfizer, Sanofi-Aventis, Schering-Plough, Schwabe,
Sepracor, Servier and Wyeth.
S-30. Brain-Derived Neurotrophic Factor (BDNF)
and synaptic plasticity as a drug target for
cognitive dysfunction in CNS disorders
S-30-001 Molecular and cellular mechanisms of synaptic plasticity:
Role of BDNF
L. Minichiello. University of Oxford, Department of Pharmacology, Oxford,
United Kingdom
Objective: A recent main aspect of our research is to understand the con-
tribution of different subsets of inhibitory neurons to animal behavior
and neurological conditions. Huntington#s disease (HD) is a progressive
neurodegenerative disorder characterized by progressive motor impair-
ment and cognitive dysfunction. This is due to the fact that the disease
firstly causes degeneration of cells in the basal ganglia, which controls
movement, emotion, and cognitive ability. In particular, the subpopula-
tion expressing enkephalin and the D2 dopamine receptor, originating
the indirect pathway, are the first to be affected. Brain derived neuro-
trophic factor (BDNF) is believed to play a pivotal role in HD pathogen-
esis by decreased cortical Bdnf expression levels, and/or impaired
anterograde BDNF transport induced by mutant Huntingtin. This leads
to preferential striatal neuron vulnerability and cell death. However, the
murine genetic models used to reach the above conclusions were not
ideal because the induced alterations of BDNF levels were not confined
to the striatum, but also affected cortical physiology.
Methods: To accurately define the protective role of BDNF in striatopal-
lidal neurons we recently performed a selective deletion of the high
affinity BDNF receptor, TrkB, from the striatopallidal, enkephalin-positive
(ENK+), MSNs defining the indirect pathway, using a Penk-Cre BAC
transgene (generating TrkbPenk-KO mice).
Results: Unexpectedly, loss of TrkB signalling in ENK+ MSNs did
not lead to neuronal loss, but to age-dependent spontaneous, as well
as drug-induced, hyperlocomotion, associated with increased D2R-
dependent MAPK/PKC phosphorylation and reduced striatopallidal acti-
vation. However, no procedural learning defects were found.
Conclusion: We therefore have demonstrated that BDNF-TrkB signal-
ing in striatal ENK+ MSNs contributes to the inhibitory control of loco-
motor behavior exerted by the indirect pathway, but is dispensable for
their maintenance. This is unexpected, and challenges the widely held
view that BDNF-TrkB signaling supports the long-term survival of ENK
+ MSNs (Besusso et al., Nat Commun 4, 2013).
Policy of full disclosure: None.
S-30-002 BDNF, adult neurogenesis and pattern separation in
the hippocampus
T. Bussey. Cambridge University, Cambridge, United Kingdom
Objective: Brain-derived neurotrophic factor (BDNF) has been shown to be
one of the essential proteins for memory formation in a variety of brain
structures. In this presentation I will present some results to illustrate the
role of BDNF and hippocampal adult neurogenesis in ‘pattern separation’,
the process of creating less overlapping, less confusable memories.
Methods: This work combines different behavioural and molecular
strategies to assess specific features of memory process and pattern
separation.
Results: Our findings show that BDNF and adult neurogenesis in the
dentate gyrus are required for consolidation of overlapping memories.
Conclusion: BDNF participates in different aspects of memory and
therefore may be an interesting target to treat maladaptive memory
disorders.
Policy of full disclosure: None.
S-30-003 Effect of BDNF polymorphism on markeres of synaptic
activity and cognition in healthy subjects
P. Nathan. UCB Pharma and University of Cambridge, Brain Mapping Unit,
Cambridge, United Kingdom
Objective: Increasing evidence suggests that synaptic dysfunction is a
core pathophysiological hallmark of neurodegenerative disorders. Brain-
derived neurotropic factor (BDNF) is key synaptogenic molecule and
targeting synaptic repair through modulation of BDNF signalling has
been suggested as a potential drug discovery strategy. The development
of such synaptogenic therapies depend on the availability of BDNF sensi-
tive markers of synaptic function that could be utilized as biomarkers for
examining target engagement or drug efficacy in humans. We utilized the
BDNF Val66Met genetic polymorphism in order to examine the effect of
the polymorphism and genetic load on markers of synaptic activity.
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Methods: 60 healthy subjects (20 val/val; 20 val/met and 20 met/met)
were recruited for the study. Synaptic activity and cognition were quan-
tified using Imaging (electrophysiology, fMRI), brain stimulation (TMS)
and behavioural (CANTAB tasks) methods.
Results: A number of BDNF sensitive markers of synaptic activity
were identified. Compared to val homozygotes, met carries (val/met
and met/met) showed evidence of inefficient synaptic activity as demon-
strated by impaired EEG activity (i.e. decreased delta/theta power and
phase synchrony) during cognitive processing in an error related nega-
tivity task of executive function (all p<0.05), increased frontal, central,
temporal and parieto-occipital relative slow wave EEG power in the
theta frequency (all p<0.05), and increased hippocampal (p<0.05) and in-
ferior frontal (p=0.004) and parietal (p=0.009) cortical activation during
retrieval of an episodic memory task. There was no evidence for a met
load effect on any of the markers examined.
Conclusion: Using BDNF val66met polymorphism, we have identified
several electrophysiological and functional imaging biomarkers that could
sensitively measure synaptic changes in the human brain, using relatively
small number of subjects. These endpoints may potentially be used in
early Phase 1 or 2 clinical trials in pre-clinical AD to monitor drug effects
on synaptic activity or cognitive function.
Policy of full disclosure: This study was funded by GSK. PJN is a
former employee of GSK.
S-30-004 BDNF and markers of disease progression in Alzheimer’s
disease: Findings from the Australian Imaging
Biomarkers & Lifestyle Flagship Study of Ageing
P. Maruff. Cogstate Ltd, Melbourne, Australia
Objective: Abnormal levels of beta-amyloid (Ab) has consistently been
shown to be associated with unremitting memory decline in healthy
individuals. However, other genetic factors may moderate the rate of
this decline. We investigate the role of apolipoprotein E (APOE) and
brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in
the extent to which they moderate A#-related memory decline in the
preclinical stages of Alzheimer’s disease.
Methods: Healthy adults (HA; n=333) who had undergone PET neuro-
imaging for Ab were recruited from the Australian Imaging, Biomarkers
and Lifestyle (AIBL) Study. Comprehensive neuropsychological assess-
ments were conducted at baseline, and at 18-, 36- and 54-month follow-
ups. ApoeE4 and BDNF val66met genotyping was also conducted at
baseline.
Results: Relative to Ab-E4 non-carriers, AB+E4 carriers showed signifi-
cantly greater rates of decline over 54-months across all memory and other
cognitive domains (d=0.40–1.22). Relative to Ab-E4 non-carriers, Ab+E4
non-carriers showed significantly greater decline only on verbal episodic
memory. No differences in group mean slopes were observed between
AB- E4 non-carriers and Ab- E4 carriers within any cognitive domain.
Amongst all Ab+ HAs, relative to E4 non-carrier-BDNFVal homozygotes,
E4 carriers who were also BDNFMet carriers showed a significantly
greater rate of decline on verbal and visual episodic memory, and lan-
guage over 54-months (d=0.90–1.02).
Conclusion: APOE and BDNFVal66Met were found to moderate
clinical manifestation of preclinical AD in different ways.b Possession of
the APOE E4 allele increased the severity of A#-related memory decline,
while BDNFVal homozygosity increased the ability of the central nervous
system to tolerate Ab-related memory decline. These results suggest
that while abnormal Ab is central to early AD, the clinical manifestation
of cognitive change is complex and moderated by APOE and
BDNFVal66Met polymorphisms.
Policy of full disclosure: None.
Thursday 26 June 2014
S-31. Polypharmacy in psychotic and affective
disorders: Co-medication with antipsychotic
and antidepressant drugs
S-31-001 Treatment of negative vs. other symptoms in
schizophrenia
H.-J. Moeller. Ludwig-Maximilians-University, Munich, Germany
Although there is a phenomenological overlap between the depressive
and the negative symptoms and to a certain degree also with cognitive
symptoms of schizophrenia, most psychiatrists feel able to distinguish
between the two syndromes under clinical conditions. Also cross-sectional
and longitudinal clinical studies using standardised rating procedures
demonstrate the differentiation between the negative syndrome, the de-
pressive syndrome and cognitive disturbances. All these three dimensions
are more or less distinct from the positive syndrome, although there are
often associations between positive symptoms and e.g. negative symp-
toms (secondary negative symptoms) These and other aspects of the
rich clinical phenomenology of schizophrenia, i lead often clinicians to
use co-medications or even polypharmacy. These clinical strategies are
often not sufficiently evidence based, however, some have at least a cer-
tain empirical support. Antidepressants are applied both in the treat-ment
of depressive symptoms as well as also negative symptoms in schizo-
phrenia. Mirtazapine has beside the SSRIs a special place in these indica-
tions and might also have in addition a positive effect on cognitive
functioning due to its presynaptic alpha 2-receptor antagonistic effect.
The new glutamatergic compound Bitopertin, a glycine reuptake inhibitor
under clinical development, demonstrated efficacy on negative symptoms,
not on positive symptoms in a phase II study, and if further developed,
would be a candidate for co-medication strategies. Some data for
Modafenil support the co-medicati on use in schizophrenia under differ-
ent aspects. However, the acetyltylcholinesterase-inhibitors, the typical
antidementia medications, did not demonstrate consistent efficacy on cog-
nitive disturbances in schizophrenia.
Policy of full disclosure: Conflict of Interest – Financial Disclosure
Statement Prof. Dr. Moeller has received grants or is a consultant
for and on the speakership bureaus of AstraZeneca, Bristol-Myers
Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck,
Merck, Novartis, Organon, Pfizer, Sanofi-Aventis, Schering-Plough,
Schwabe, Sepracor, Servier and Wyeth.
S-31-002 Concomitant antidepressant and antipsychotic medication
in schizophrenia and depression. Mechanisms of action.
T. Svensson. Physiology and Pharmacology, Karolinska Institutet, Stockholm,
Sweden
Objective: Clozapine and add-on antidepressant drugs (AD) to other
antipsychotic drugs (APD), may improve positive, negative and cognitive
symptoms and also reduce suicidality in schizophrenia. Moreover,
co-medication with low doses of atypical APD may augment and
hasten the onset of clinical response to AD in treatment-resistant major
depression (TRD). We have here analyzed in rats the underlying neuro-
biological mechanisms for these clinical results, focusing on monoaminer-
gic and glutamatergic systems in the medial prefrontal cortex (mPFC).
Methods: We used electrophysiological intracellular recording in pyr-
amidal cells in a prefrontal cortical slice preparation to assess NMDA-R
function, microdialysis in freely moving animals to assess regional mono-
amine efflux in brain, and behavioral methodologies, i.e. the conditioned
avoidance response (CAR) test to assess antipsychotic activity, the 8-arm
radial maze to study working memory (WM) and a catalepsy test for
extrapyramidal side effects (EPS).
Results: Contrasting typical D2 antagonists, both clozapine and a
combination of other APD and AD or the selective alpha2-R antagonist
idazoxan effectively suppressed CAR at reduced D2 occupancy levels,
caused no significant catalepsy, selectively enhanced mPFC DA outflow
and, via D1-R activation, facilitated prefrontal NMDA-R mediated trans-
mission., Clozapine also reversed the WM impairment induced by the
selective NMDA-R antagonist MK-801. Add-on low nanomolar concentra-
tions of APD to SSRIs also facilitated AMPA- induced responses in pyr-
amidal cells of the mPFC, an effect not attainable by each drug alone
and blocked by a selective D1-R antagonist. Analogous effects on both
AMPA-and NMDA responses in the mPFC were produced by a systemic
antidepressant dose of ketamine 24 h after administration.
Conclusion: We propose that facilitation of prefrontal monoaminergic
and NMDA-R mediated glutamatergic transmission may be critically
involved in the beneficial effects of combined treatment with AD and
APD in schizophrenia, and that activation of AMPA-R may be critical
for the APD augmentation of AD in TRD.
Policy of full disclosure: Grants/research support: The Swedish
Research Council, The Karolinska Institutet, Stockholm (Sweden), The
Brain Foundation (Sweden), AstraZeneca, Organon, Schering-Plough,
Merck Sharp and Dome, Lundbeck, Otsuka, Astellas Consultant/advisory
board: AstraZeneca, Janssen, Lundbeck, Otsuka, Merck Sharp and Dome,
Organon, Pfizer, Carnegie Health Care Funds (Sweden).
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S-31-003 The role of atypical antipsychotics as add-on medication
in major depression
S. Kasper. Medical University of Vienna, Department of Psychiatry and
Psychotherapy, Vienna, Austria
Objective: There is a wide-spread use of atypical antipsychotics (AAPs)
and low-potency typical neuroleptics as add-on for the treatment of de-
pression in clinical practice, even in a time when controlled studies had
not been conducted and health regulatory authorities had not provided
treatment indication either.
Methods:We set out to investigate the use of AAPs in a European sam-
ple of depressed inpatients and the possible changes in their prescription
over the time period from 2000 to 2007. On two reference days in the years
2000 (32 psychiatric institutions, N=1.078) and 2007 (54 psychiatric insti-
tutions, N=1.826), the following data were recorded for all depressed
inpatients (ICD-10: F32.00, F32.01, F32.1, F32.10, F32.11, F32.2, F33.0,
F33.00, F33.01, F33.1, F33.10, F33.11 and F33.2) monitored as part of the
AMSP (Arzneimittelsicherheit in der Psychiatrie), a drug surveillance pro-
gram of participating hospitals in Germany, Switzerland and Austria: age,
sex, ICD-10 diagnosis and all medication applied on that day. Depressed
inpatients with psychotic symptoms were excluded.
Results: We found a significant increase in the number of AAP-treated
inpatients from 37.9% in 2000 to 45.8% in 2007. The number of inpatients
who received an AAP rose significantly between 2000 and 2007, from
12.8% to 28.3%. In contrast, the percentage of inpatients receiving typical
neuroleptics showed a significant decrease from 30.2% to 24.1% over the
same time-period. Examining only the subgroup of severely depressed
inpatients we found an increase in the number of AP-treated inpatients,
but this was not statistically significant. Our study reveals a significant in-
crease in the usage of AAPs.
Conclusion: The study is insofar of importance since it emphasizes the
fact that although controlled studies were scarce and health regulatory
authorities did not provide treatment indication, this therapy principle
was used among clinicians.
Policy of full disclosure: Prof. Kasper has received grant/research
support from Bristol Myers-Squibb, Eli Lilly, GlaxoSmithKline,
Lundbeck, Organon, Sepracor and Servier; he has served as a consultant
or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly,
GlaxoSmithKline, Janssen, Lundbeck, Merck Sharp and Dome (MSD),
Novartis, Organon, Pfizer, Schwabe, Sepracor, and Servier; and he has
served on speakers’ bureaus for Angelini, AstraZeneca, Bristol
Myers-Squibb, Eli Lilly, Janssen, Lundbeck, Neuraxpharm, Pfizer, Pierre
Fabre, Schwabe, Sepracor, and Servier.
S-31-004 Cognitive dysfunction in depression: Implications
for treatment
B. J. Sahakian. University of Cambridge, School of Clinical Medicine,
Cambridge, United Kingdom
Objective: Depression is a common, debilitating and life threatening dis-
order, projected to become the second leading cause of disability by 2020
by the World Health Organization. It robs individuals and societies of
mental capital and wellbeing, and is extremely expensive to governments
due to absenteeism and presenteeism at work. In this talk, we will con-
sider ‘hot’ and ‘cold’ cognitive processes and how these are impaired
in depression. Implications for treatment of cognitive dysfunction in de-
pression will be discussed.
Methods: Cognitive dysfunction is a core feature of depression and
cognitive symptoms are included in the diagnostic criteria of the DSM
5. The criteria for depression include a reduced ability to concentrate
and indecisiveness. Objective measurement of cognitive impairments in
depression using CANTAB (www.camcog.com; www.cantab.com) and
other cognitive tests will be discussed.
Results: Cognitive domains that are altered in patients with depression
include executive control, decision making, memory, affective processing
and feedback sensitivity.
Conclusion: Depressive disorders account for a substantial proportion
of disease burden across the globe and have a devastating impact on qual-
ity of life, wellbeing and occupational functioning. Given the cost of de-
pression in terms of distress to the individual and their family as well
as cost financially to society and governments, new developments for
treatments which preserve or enhance cognition, functionality and return
to work should be a priority so that all members of society can flourish.
Policy of full disclosure: Barbara Sahakian consults for Cambridge
Cognition, Lundbeck, Servier, Roche and holds a grant from Janssen/J &
J. She also receives funding from the Wellcome Trust and is a member
of the MRC/Wellcome Trust Behavioural and Clinical Neuroscience
Institute.
S-32. New insights into the role of NMDA
receptors in cognition and psychosis
S-32-001 NMDA-GluN2B receptors govern corticostriatal learning
A. Holmes. NIAAA, Rockville, USA
Objective: Corticostriatal systems are known to mediate choice learning
and flexibility, but the molecular mechanisms of these processes are not
well understood. I will present data on integrated mouse behavioral,
immunocytochemical, in vivo electrophysiological, genetic and pharma-
cological approaches to study discrimination and reversal learning. The
objective of the presentation is to provide a point of comparison and con-
vergence with the other presentations in this session that together aim to
provide both preclinical and clinical researchers with a state of the art up-
date on current understanding of how NMDA receptor mediate cognition
and the mechanisms by which NMDA receptor dysfunction produces
cognitive dysfunction in psychotic illness.
Methods: This presentation will present convergent data from pharma-
cology, in vivo electrophysiology and optogenetics that reveal a critical
role for NMDA receptor subunits, notably GluN2B, in controlling
prefrontal-striatal circuits mediating learning and cognitive flexibility.
Results: The dorsal striatum (DS) is increasingly activated with learn-
ing, whereas reversal of learned choice engaged prefrontal regions. In
vivo, DS neurons show altered activity associated with learning and
relearning. Corticostriatal or striatal deletion of Grin2b (encoding the
NMDA-type glutamate receptor subunit GluN2B) or DS-restricted
GluN2B antagonism impairs choice learning, whereas cortical Grin2b de-
letion or OFC GluN2B antagonism impairs early relearning.
Conclusion: These convergent data demonstrate how corticostriatal
GluN2B circuits govern the ability to learn and relearn in a choice task.
Policy of full disclosure: None.
S-32-002 NMDA receptor-associated proteins, cognition, and
neuropsychiatric disorders: Translation between mouse
and human
T. Bussey. Cambridge University, Cambridge, United Kingdom
Objective: The NMDA receptor complex, comprising glutamate receptor
subunits and scaffold and signalling proteins, is organised into a signal
transduction complex thought to be essential for synaptic plasticity and
behaviour. Furthermore many of these molecules have been implicated
in neuropsychiatric disease. The specific functional role of the vast ma-
jority of proteins within the NMDA receptor complex is, however, less
well understood.
Methods: The experiments I will discuss evaluated the cognitive
profiles, on a battery of touchscreen tests, of mice with mutations in
genes coding for various NMDA receptor-associated scaffolding proteins
in the same gene family – Dlg1 (SAP-97, hDlg), Dlg2 (PSD-93, Chapsyn-
110), Dlg3 (SAP-102) and Dlg4 (PSD-95, SAP-90). In addition I will discuss
the cognitive profiles, on comparable touchscreen tasks, of human indivi-
duals with mutations in dlg2.
Results: The mice show dissociable phenotypes on tests of cognition in-
cluding learning and memory, behavioural inhibition, and attention.
Human subjects were impaired in the same cognitive domains as the cor-
responding mutant mice.
Conclusion: Our results provide evidence that even closely related pro-
teins within the NMDA receptor complex have different roles in cognition.
The findings have implications for understanding cognitive dysfunction in
brain disorders, particularly psychiatric conditions such as schizophrenia,
where aberrant plasticity associated with the NMDA receptor is thought
to underlie the disease.
Policy of full disclosure: None.
S-32-003 NMDA receptors and behavioural flexibility: For when
things aren’t the way they used 2B
S. Floresco. UBC, Vancouver, Canada
Objective: NMDA glutamate receptors are critical for formation of new
memories, such as aversive Pavlovian associations and discrimination
learning. However, these receptors also play a key role in regulating cer-
tain higher-order executive functions governed by the prefrontal cortex.
The ability to adjust ongoing behaviour in the face of changing environ-
mental contingencies is one collection of functions mediated by the frontal
lobes regions that are perturbed in a variety of psychiatric disorders. How
different subtypes of NMDA receptors may make selective contributions
to these processes related to behavioural flexibility remains to be clarified.
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Methods: Recent psychopharmacological studies in rodents have
pointed to GluN2B subunit-containing NMDA receptors in facilitating
modifications of existing associations or rules in a manner distinct from
other NMDA receptors, which appear to play a more generalized role
in learning. These findings will be reviewed, focusing on the contribution
of GluN2B NMDA receptors to processes such as extinction, reversal and
strategy shifts and probabilistic learning.
Results: As opposed to the effects of non-specific NMDA receptor
antagonism, selective blockade of GluN2B-NMDA receptors with the
Ro25-6981 does not affect the initial learning of conditioned fear response.
However, GluN2B blockade markedly impairs within-session extinction
and extinction recall of conditioned fear a context-dependent manner.
Similarly, GluN2B antagonism does not affect the initial learning of
visuospatial discriminations, but induces marked perseverative deficits
during reversal or strategy shifts. Interestingly, GluN2B blockade actually
facilitated performance of a probabilistic reversal task, with these effects
resembling those induced by inactivation of the medial prefrontal cortex.
Conclusion: Collectively, these studies suggest that activity at GluN2B
receptors make a fundamental contribution to multiple forms of beha-
vioral flexibility, potentially via actions within the frontal lobes.
Development of compounds that may selectively enhance activity at
these receptors may lead to novel treatments for impairments in these
executive functions associated with numerous psychiatric disorders.
Policy of full disclosure: None.
S-32-004 The human ketamine model: Translational insights
into psychosis
P. R. Corlett. Yale University, Department of Psychiatry, Connecticut Mental
Health Center, New Haven, USA
Delusions are odd and persistent beliefs. They characterize serious mental
illnesses like schizophrenia. Cognitive neuroscience approaches to delu-
sions conceive of them forming via aberrant learning mechanisms. The
NMDA glutamate receptor antagonist drug ketamine has been used to
test these hypotheses. Ketamine induces a state redolent of the early
phases of psychosis, transiently, reversibly and safely, in healthy volun-
teers. It does so by engaging inappropriate prediction error signals, mis-
matches between expectation and experience, that drive attention and
learning toward irrelevant stimuli, thoughts and percepts. Such signals
render the world strange, unpredictable and pregnant with new meaning.
Across subjects, aberrant prediction error signals measured with func-
tional magnetic resonance imaging correlate with ketamine induced psy-
chotic symptoms; a relationship that has also been observed in patients
with endogenous psychotic illnesses. Learning theories of delusions ex-
plain odd belief formation. However, delusions can be fixed, tenacious
in the face of contradictory evidence. How can a promiscuous learning
mechanism explain delusion fixity? I will suggest that this process
involves memory reactivation and reconsolidation such that, even when
delusions do not come true they are maintained or even strengthened.
Appetitive and aversive memories that are reactivated whilst subjects
are on ketamine are strengthened. The magnitude of strengthening corre-
lates with ketamine induced psychosis and aberrant prediction error
signaling. Such a mechanism can explain the peculiar elasticity of delu-
sions – they expand and envelop contradictory information rather than
yielding. By taking inspiration from preclinical behavioral neuroscience
and psychopharmacology, we approach an explanation of delusions in
terms of cognitive processes and neural mechanisms.
Policy of full disclosure: I have no financial conflicts of interest.
S-33. Converting biological findings into routine
clinical tests – Psychiatry’s next big
challenge
S-33-001 Converting biological psychiatry into clinical tests –why
it has been so hard and what to do about it
A. Mechelli. Department of Psychosis Studies, Institute of Psychiatry, King’s
College London, London, United Kingdom
Despite the publication of thousands of scientific articles on the biological
correlates of psychiatric disorders, the findings have not resulted in any
significant changes in everyday clinical practice. In my presentation,
I will provide a brief overview of the current state-of-the-art regarding
the development of diagnostic and prognostic biological markers in psy-
chiatry. As part of this overview I will discuss the main theoretical and
practical challenges that need to be overcome in order to be able to trans-
late current research evidence into clinical practice. I will then discuss the
use of machine learning methods as a possible way of overcoming some of
these challenges. Machine learning methods allow inferences at single-
subject level and, therefore, have the potential of informing the diagnostic
and prognostic assessment of individual patients. I will show a number of
recent applications of machine learning methods in biological psychiatry,
and will illustrate how this approach could be used to develop stratified
interventions in everyday clinical practice.
Policy of full disclosure: None.
S-33-002 Clinical significance: What does it mean when developing
biomarker and clinical tests for treatment response in
depression and schizophrenia
R. Uher. Dalhousie University, Halifax, Canada
Objective: Clinical and biomarker tests have been suggested to improve
personalized indications of treatment for depression and schizophrenia.
To be useful in clinical settings, such tests have to fulfill criteria for clinical
significance in addition to statistical significance. However, no benchmark
is available for what is a clinical significant prediction.
Methods: We reviewed information on what effect size of prediction is
clinically significant and we performed simulations, based on large data-
sets, to translate benchmark into a metric of percentage of variance
explained, that is broadly applicable to most biomarker and clinical tests.
Results: For tests predicting treatment outcome in major depressive dis-
order, a clinical significant prediction should explain at least 6.3% of vari-
ance in outcomes (e.g. HAMD or MADRS). For tests predicting treatment
outcome in schizophrenia, definite clinical significance requires explaining
15% of variance in outcomes.
Conclusion: We provide benchmarks for clinical significance of a range
of biomarker and clinical tests. On-line calculators facilitate evaluation of
tests for clinical significance.
Policy of full disclosure: None.
S-33-003 From pharmacogenetics to clinical tests: The role of
electronic health records
R. Perlis. Harvard University, Boston, USA
Objective: Common genetic variation, in aggregate, has been associated
with antidepressant treatment response. Characterizing individual var-
iants which are clinically actionable remains a challenge.
Methods: This presentation will review emerging evidence of associ-
ation between common or rare genetic variation and antidepressant re-
sponse. It will emphasize barriers to clinical application, including
modest effect sizes and absence of evidence of specificity, and suggest
ways in which these barriers may be addressed.
Results: Large-scale application of electronic health records provides a
means to identify relevant variants, integrate them with other clinical pre-
dictors, and assess their utility. Examples of these applications, including
recent examinations of rare variants and development of clinical risk stra-
tification tools, will be discussed.
Conclusion: The identification and application of individual variants
associated with antidepressant treatment response will require consider-
ation of novel study designs and approaches; electronic health records
represent one such strategy.
Policy of full disclosure: Dr. Perlis serves on scientific advisory boards
or provides consultation to Genomind, Perfect Health, Proteus
Biomedical, Psybrain, and RID Ventures.
S-33-004 Pharmacogenomic tests for psychotropic medications –A
journey from bench to bedside
T. Altar. AssureRx Health, Inc., Mason, OH, USA
Objective: Assurex Health has developed a combinatorial pharmacoge-
nomic test for 36 antidepressant and antipsychotic medications,
GeneSight® Psychotropic. The test measures individual genotypes for
the cytochrome P450 enzymes 1A2, 2D6, 2C9, 2C19, 2B6 and 3A4 and
the serotonin receptor HTR2A and transporter protein SLC6A4 (Altar
et al., Int. Rev. Psychiatry, 2013, 25: 509) to recommend medication selec-
tion and dosing.
Methods: DNA was collected for 96 subjects in a 1 year retrospective
healthcare utilization study, and 258 subjects in three 8 week, prospective
antidepressant studies. In the later studies, the GeneSight report was
either provided to clinicians of guided patients to use at their discretion,
or not given to clinicians of patients who were treated as usual (TAU).
Results: The test identified 29 of the TAU subjects who, at baseline,
were prescribed one or more “red bin” medications, to “Use with
increased caution and more frequent monitoring”. They showed only a
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13.4% symptom improvement, less than the 32% improvement of 59
TAU subjects on yellow status drugs (“Use with caution”), and 28.6%
improvement of 31 on green (“Use as recommended”) status drugs
(p=0.023). Four kinds of greater annual health care utilizations or burdens
were predicted retrospectively for patients on red bin medications. When
provided to the 128 GeneSight-guided subjects, the test increased the
odds of clinical response by 2.3-fold compared to the 126 TAU subjects
(p=0.004), demonstrating a 1.71-fold relative benefit (p<0.0003).
Compared with TAU subjects, guided subjects originally prescribed
green, yellow, or red bin medications showed 6.5%, 13.8% and 23.3%
greater HAMD score decreases at eight weeks.
Conclusion: The GeneSight Psychotropic test predicted the lesser im-
provement and greater healthcare burdens of depressed patients pre-
scribed genetically inappropriate medications and, when used by
clinicians, influences medication selection and dose adjustment, and dou-
bles antidepressant responders.
Policy of full disclosure: Genetic testing and funding for data collection
and analysis personnel were provided by AssureRx Health, Inc. Dr. Altar
is employed by AssureRx Health, Inc.
S-34. Boosting and blunting neurocognitive
function in the laboratory and in life
S-35. Adult ADHD and obesity: Neurotransmitter
imaging and pharmacotherapies targeting
impulsivity
S-35-001 Preclinical models of impulsivity: Pharmacological
and dietary manipulations
C. Winstanley. University of British Columbia, Department of Psychology,
Vancouver, BC, Canada
Objective: High impulsivity has been associated with obesity, and may
lead to an inability to control further food consumption despite negative
consequences. However, impulsivity has thus far only been considered as
a vulnerability factor for over-eating; whether consumption of palatable
dietary constituents influences impulsivity itself is unclear. Given that
highly palatable food stimulates activity in some of the same neurotrans-
mitter systems as we know to be involved in the regulation of impulse
control, we therefore hypothesized that appetitive foods could precipitate
impulsivity directly.
Methods: We examined the effects of a high-fat or high-sugar diet on
performance in the 5-Choice Serial Reaction Time task (5CSRT), a rodent
analogue of the continuous performance test used clinically to assess im-
pulse control and attention. Molecular mechanisms underlying beha-
vioural effects were subsequently assessed. All rats were fed
calorie-equivalent amounts of their respective diets.
Results: Rats on the high-fat diet showed a selective and sustained en-
hancement of impulsive responding, with no change in other behavioural
measures. In contrast, the high-sugar diet had no effect on task perform-
ance. Molecular analyses revealed that animals on the high-fat diet had
reduced levels of D1 receptor protein and DARPP in the striatum, and
reduced D2 receptor protein, CREB and pCREB in the nucleus accumbens,
compared to controls.
Conclusion: Prolonged consumption of high-fat, but not high-sugar,
food increases motor impulsivity in rats which is associated with marked
reductions in dopaminergic markers in the dorsal and ventral striatum
similar to those seen in chemical addictions. These data suggest that
chronic consumption of foods rich in fat lead to molecular and beha-
vioural alterations in mesolimbic impulse control circuits, which may, in
turn, contribute to compulsive over-eating in obesity.
Policy of full disclosure: I do not have any financial conflicts of interest.
S-35-002 Imaging of the dopaminergic system in ADHD,
binge eating and obesity
G.-J. Wang1, N. Volkow2. 1Brookhaven National Laboratory, Upton, NY, USA;
2NIDA, NIH, Rockville, MD, USA
Objective: Recent literatures suggest a possible comorbidity between
Attention-Deficit/Hyperactivity Disorder (ADHD) and obesity. ADHD is
characterized by a persistent and pervasive pattern of inattention and/or
impulsivity, which might foster binge eating and obesity. The neurobio-
logy mechanism underlying abnormal eating behaviors in subjects with
ADHD is unknown.
Methods: We used positron emission tomography (PET) to assess the
involvement of brain dopamine (DA) in adults with ADHD and with
obesity.
Results: DA modulates circuits in pathological eating behaviors. Food
cues increase striatal DA, indicating the involvement of DA in the motiva-
tional properties of food. Food cues also increase metabolism in the orbi-
tofrontal cortex indicating its association with the motivation for food
consumption. Striatal DA D2/D3 receptor availability (D2R) is reduced
in obese subjects, which predisposes obese subjects to seek food to tem-
porarily compensate for under-stimulated reward circuits. Decreased
D2R in the obese subjects is also associated with decreased metabolism
in prefrontal regions involved in inhibitory control that may underlie
their inability to control food intake. Using food cues and methylpheni-
date, a drug that blocks the DA reuptake transporter, we found obese
binge eaters increased DA in the caudate and putamen but not in obese
non-binge eaters. DA increases in the caudate were correlated with the
binge eating scores. The greater DA increases occur when exposed to a
salient stimulus, i.e. food cues that presumably increases DA cell firing
in the binge eaters. In the studies of ADHD, the ADHD subjects had
reduced D2R in the nucleus accumbens and midbrain regions. The D2R
measures in the nucleus accumbens were correlated with their dimension
of attention and motivation.
Conclusion: The results from these studies suggest that the lower D2R
in striatum in ADHD subjects would have greater risk for compulsive/
binge eating to compensate their DA deficits.
Policy of full disclosure: None.
S-35-003 Imaging of the noradrenergic system in adults with
obesity and ADHD
S. Hesse. University of Leipzig, Department of Nuclear Medicine, Leipzig,
Germany
Objective: Although obesity (OB) has been attributed to failure in impulse
control and alterations of brain norepinephrine (NE) system, the role of
impulsivity and NE levels has not yet been investigated in vivo in OB.
In this study, we tested whether in-vivo NE transporter (NET) availability
as measured with PET using the highly selective radiotracer [11C] methyl-
reboxetine (MRB) is associated with trait impulsivity in heavily OB indi-
viduals compared with normal-weighted, healthy controls (HC).
Methods: Ten OB (Body-Mass-Index 42.4±3.3 kg/m2, age 34.4±9 years,
4 females) without co-morbidities and ten HC (BMI 23.9±2.5 kg/m2, age
33.3±10 years, 4 females) underwent dynamic MRB-PET and MRI.
Assessment included behavioral inhibition scale (BIS)/activation Scale
(BAS) and Barrett impulsiveness scale (BIS-11).
Results: MRB binding potential BP did not differ between OB and HC;
by applying discriminant analysis, groups were correctly identified based
on regional NET availability. BP correlated significantly with the BIS-11
(mainly attentional scores) in distinct brain areas in OB but not in HC in-
cluding the prefrontal cortex (PFC) and limbic system (i.e., the hippocam-
pus), and with BIS in the thalamus (r=0.81, p<0.001). BAS Reward and
BP correlated in the PFC, head of the caudate and hippocampus in OB
(r=0.66; p=0.04, r=0.61; p=0.06 and r=0.83; p<0.001) in an opposite man-
ner when compared with BP versus BIS-11.
Conclusion: These correlations suggest NET changes and thus an
altered NE tone are related to cognitive control and behavioral perform-
ance as an adaptive mechanism that fails in OB. They link attention/arou-
sal to NE and as a possible explanation an altered neuronal
responsiveness in reward anticipation as it was found in adult ADHD.
Findings integrate in particular the hippocampus and help to frame
joint future research on adult ADHD and OB by generating new testable
hypotheses.
Policy of full disclosure: None.
S-35-004 Pharmacological treatment of ADHD in adults:
Implications for binge eating and obesity
U. Muller. University of Cambridge, Cambridge, United Kingdom
Objective: To compare current and emerging pharmacological treatments
for ADHD in adults with ADHD and eating disorders.
Methods: This is a review of published clinical trials, reviews,
meta-analyses and guidelines.
Results: Stimulants like methylphenidate and D-amphetamine as well
as the noradrenaline reuptake inhibitor atomoxetine are recommended
as first-line pharmacological treatment for adults with ADHD by
evidence-based guidelines. Non-stimulant drugs modulating noradrena-
line, acetylcholine, histamine, adenosine, glutamate, GABA and multiple
transmitters have been investigated in animal models of ADHD and
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clinical trials in adults with ADHD – but none of the newer medications is
established or has been approved for the treatment of ADHD. The most
recent review of approved medications for obesity is positive about
longer-term effects of lorcaserin, orlistat and phentermine/topiramate.
A review of clinical trials in binge eating disorder found some evidence
for positive effects of topiramate on binge eating frequency and weight re-
duction; but psychological treatments are generally recommended.
Conclusion: Animal studies and clinical PET studies have demon-
strated overlapping noradrenergic and dopaminergic mechanisms in
ADHD, binge eating and obesity. So far, no controlled trials have investi-
gated the use of approved ADHD or obesity medications in adults with
ADHD and comorbid eating disorder. Single case studies and case series
found positive effects of stimulants on ADHD symptoms and binge eating
in comorbid patients. Noradrenergic modulation of impulsive behaviour
and dopaminergic modulation of reward mechanisms are promising
approaches for the treatment of patients with ADHD and comorbid
binge eating disorder and obesity. More clinical research is needed.
Policy of full disclosure: Honoraria for consultancy, speaking at and
organising conferences and travel expenses for attending and presenting
at conferences from Eli Lilly, Heptares, Janssen-Cilag, Lundbeck, Shire
and UCB Pharma.
S-36. Synaptic plasticity and neurodegeneration
S-36-001 Synaptic plasticity and AD: Roles of GSK-3beta and
the JAK/STAT pathway
G. Collingridge. University of Bristol, Bristol, United Kingdom
Objective: To identify the signalling cascades that are involved in
N-methyl-D-aspartate (NMDA) receptor-mediated long-term depression
(LTD) in the hippocampus. To establish how dysregulation of components
of these pathways leads to synaptic injury and cognitive deficits in neuro-
degenerative diseases, such as Alzheimer’s disease.
Methods: Experiments were performed on acute and organotypic hip-
pocampal slices prepared from juvenile rats. Proteins were targeted phar-
macologically and using RNAi.
Results: We have identified the following pathways in NMDAR-LTD.
GluA2/NSF/hippocalcin Akt1/GSK-3beta/tau PI3 K JAK2/STAT3 GIT1/
Arf-1/PICK1/Arp2/3
Conclusion: We propose that synaptic injury, an early event in AD, is
caused, at least in part, by dysregulation of NMDA receptor-dependent
LTD. This process is normally involved in physiological synaptic pruning
but in response to a variety of genetic or environmental influences can
prune synapses in an aberrant manner. A fuller understanding of this
mechanism should lead to better therapeutic strategies.
Policy of full disclosure: None.
S-36-002 Molecular mechanisms underlying the maintenance
of LTP and memory
Y. T. Wang. University of British Columbia, Vancouver, Canada
Objective: Hippocampal long-term potentiation, one of the most well
characterized forms of synaptic plasticity, can be temporally and mechan-
istically classified into early phase, decaying LTP (E-LTP) and late phase,
non-decaying LTP (L-LTP). While the non-decaying nature of L-LTP is
thought to be dependent on protein synthesis and contributes to memory
maintenance, little is known about the mechanisms and roles of the decay-
ing E-LTP. Our objective is to test our working hypothesis that the decay-
ing of E-LTP is mediated by an active process involving homeostatic
endocytosis of postsynaptic a-amino-3-hydroxy-5-methyl-isoxazole-4-
propionic acid glutamate receptors (AMPARs) at the potentiated synapses
during E-LTP and that during the L-LTP, there is a transcription and
translation of a PKMz-like molecule that tonically inhibits this homeostatic
AMPAR endocytosis, thereby preventing LTP from decaying.
Methods: The hypothesis was tested using a combination of electrophy-
siological investigation of hippocampal CA1 E-LTP and L-LTP using
extracellular recordings of field potentials and behavioral assessments of
memory performance using passive avoidance tasks in freely moving
rats and transgenic mice carrying APP23/PS45 double mutations.
Results: In support of our hypothesis, we demonstrate that inhibiting
endocytosis of postsynaptic AMPARs prevents the decay of E-LTP,
thereby converting it into L-LTP. Conversely, releasing AMPAR endocyto-
sis by inhibiting a PKMz-like molecule with ZIP peptide causes L-LTP to
decay, thereby converting it into E-LTP. Similarly, inhibition of AMPAR
endocytosis is able to prolong memory retention in normal animals, and
reduce memory loss in Alzheimer’s transgenic mice.
Conclusion: These results strongly suggest that the decay of E-LTP is
mediated by an active process involving facilitated AMPAR endocytosis,
and inhibiting this process can prolong the longevity of LTP as well as
memory under both physiological and pathological conditions.
Policy of full disclosure: None.
S-36-003 Caspases in synaptic plasticity, neurodegeneration and
cognitive function
M. Sheng. Genentech, San Francisco, USA
NMDA receptor-dependent synaptic modifications such as long-term
potentiation (LTP) and long-term depression (LTD) are essential for
brain development and function. LTD and synapse elimination are natural
processes that sculpt the developing brain, akin to programmed cell death
(also termed apoptosis). NMDA receptor-dependent LTD and synapse
elimination share common molecular mechanisms with apoptosis.
Stimulation of the mitochondrial (or intrinsic) pathway of apoptosis,
which culminates in caspase-3 activation, is required for LTD and
AMPA receptor internalization in hippocampal neurons. This pathway
is activated transiently, moderately and locally in the vicinity of synapses
to effect synapse depression without killing the cell. Local activation of the
mitochondrial apoptosis pathway in dendrites of neurons by an opto-
genetic approach is sufficient to cause local loss of dendritic spines and re-
traction of dendrite branches, without neuronal death. Thus apoptotic
mechanisms can sculpt the morphology of neurons in localized fashion.
The ubiquitin proteasome system is important for spatially limiting the ac-
tivation of the apoptotic mechanisms and preventing cell death. Similar
‘synaptic apoptosis’ mechanisms are co-opted by amyloid-beta to impair
synaptic plasticity, which could contribute to the synapse dysfunction
and loss of Alzheimer’s disease. Mice lacking caspase-3 have normal
LTP but show deficits in LTD and homeostatic synaptic plasticity (synap-
tic downscaling during heightened activity). Behaviorally, caspase-3
knockout mice show hyperactivity as well as defects in attention, habitu-
ation to novel stimuli and cognitive flexibility, which are characteristic of
human ADHD.
Policy of full disclosure: Morgan Sheng is a full time employee of
Genentech Inc, a member of the Roche Group.
S-36-004 Inflammation and hypoxia trigger synaptic depression
via microglia CR3 receptors
B. MacVicar1, J. Zhang1, A. Malik1, H. B. Choi1, R.W. Y. Ko1,
L. Dissing-Olesen1. 1University of British Columbia, Vancouver, Canada
Complement receptor 3 (CR3) activation in microglia is involved in
neuroinflammation-related brain disorders and pruning of neuronal
synapses. Hypoxia, often observed together with neuroinflammation in
brain trauma, stroke, and neurodegenerative diseases, is thought to
exacerbate inflammatory responses and synergistically enhance brain
damage. Here we show that when hypoxia and an inflammatory stimulus
(lipopolysaccharide, LPS) are combined, they act synergistically to
trigger long-term synaptic depression (LTD) that requires microglial
CR3, activation of nicotinamide adenine dinucleotide phosphate oxidase
(NADPH oxidase) and GluA2-mediated Α-amino-3-hydroxy-5-methyl
-4-isoxazolepropionic acid receptor (AMPAR) internalization. Microglial
CR3 triggered LTD is novel in that it is independent of N-methyl-D-
aspartate receptors (NMDARs), metabotropic glutamate receptors
(mGluRs) or patterned synaptic activity. This type of LTD may contribute
to memory impairments and synaptic disruptions in neuroinflammation-
related brain disorders. This work was supported by operating
grants from the Canadian Institutes of Health Research (CIHR Funding
reference numbers 8545 and 115121 (B.A.M.), a Canada Research Chair
in Neuroscience (B.A.M.), a Natural Sciences and Engineering Research
Council of Canada Studentship Award (A.M.), a CIHR studentship
award (R.W.Y.K.) and a Heart and Stroke Studentship Award (L.D.O.).
Policy of full disclosure: None.
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Educational Workshops
Monday 23 June 2014
EW-02. The use of psychotropic drugs during
pregnancy and breast feeding
EW-02-001 The use of psychotropic drugs during pregnancy
and breast feeding
M.-J. Poulin. Institut Universitaire en Sante Mentale de Quebec, Quebec,
Canada
Policy of full disclosure: None.
EW-03. Managing treatment resistance in
psychiatry
EW-03-001 Managing treatment resistance in psychiatry
R. Murray. Institute of Psychiatry, King´s College London, London, United
Kingdom
Policy of full disclosure: None.
EW-03-002 Treatment resistant depression
C. Nemeroff. University of Miami, Miami, USA
It is now well-established that a minority of patients with major
depression attain remission after treatment with antidepressant
monotherapy. This presentation will focus on the factors associated with
treatment-resistance including a history of child abuse and neglect, promi-
nent anxiety and certain comorbid medical and psychiatric conditions.
The importance of accurate diagnosis will be highlighted including family
history and evaluation for medical disorders associated with poor treat-
ment response such as hypothyroidism and hypogonadism. Once a
patient has failed an adequate trial of an antidepressant, a decision to
either: 1) increase the dose of the current antidepressant, 2) engage in com-
bination therapy of the current agent and another antidepressant or
evidence-based psychotherapy (e.g. CBT), 3) utilize an augmentation
strategy by adding an agent (e.g. lithium or T3) that is not an effective
antidepressant, but when added to an antidepressant converts non-
remitters to remitters, 4) switch to an entirely different antidepressant
class, e.g. SSRISNRI or SSRIMAOI or 5) use a somatic non-
pharmacological approach such as rTMS, VNS, or ECT. The evidence
for these approaches will be summarized. Finally, the status of experimen-
tal treatments including ketamine and DBS will be discussed.
Policy of full disclosure: Research/Grants: National Institutes of Health
(NIH) Consulting: Xhale, Takeda, SK Pharma, Shire, Roche, Lilly,
Allergan, Mitsubishi Tanabe Pharma Development America, Taisho
Pharmaceutical Inc., Lundbeck Stockholder: CeNeRx BioPharma,
PharmaNeuroBoost, Revaax Pharma, Xhale, Celgene, Seattle Genetics,
Abbvie Scientific Advisory Boards: American Foundation for Suicide
Prevention (AFSP), CeNeRx BioPharma (2012), National Alliance for
Research on Schizophrenia and Depression (NARSAD), Xhale,
PharmaNeuroBoost (2012), Anxiety Disorders Association of America
(ADAA), Skyland Trail Board of Directors: AFSP, NovaDel (2011),
Skyland Trail, Gratitude America, ADAA Income sources or equity of
$10,000 or more: PharmaNeuroBoost, CeNeRx BioPharma, NovaDel
Pharma, Reevax Pharma, American Psychiatric Publishing, Xhale
Patents: Method and devices for transdermal delivery of lithium (US
6,375,990B1) Method of assessing antidepressant drug therapy via trans-
port inhibition of monoamine neurotransmitters by ex vivo assay (US
7,148,027B2) Speakers Bureau: None Honoraria Various Royalties
Various Expert Witness Various.
Tuesday 24 June 2014
EW-05. Understanding modern genetics
EW-05-001 Genetic prediction of antipsychotic response
and side effects
J. Kennedy1, A. Tiwari1, D. Taylor1, C. Zai1, J. Pouget1, N. Chowdhury1,
J. Lieberman2, H. Meltzer3, D. Mueller1. 1University of Toronto, Toronto,
Canada; 2Columbia University, Department of Psychiatry, New York, USA;
3Northwestern University, Department of Psychiatry, Chicago, USA
Objective: In terms of antipsychotic response we have begun to examine
the glutamate system gene variants for their potential role in predicting
changes in negative and/or positive symptoms. For antpsychotic-induced
weight gain (AIWG), we have examined genetic markers from the bio-
logical systems involved in appetite and satiety in the hypothalamus.
Previously, the MC4R gene has shown consistent association with the
same genotype across four independent AIWG samples, with an overall
p=5×10E-12 (Malhotra et al., 2012). Continued development of predictive
genetic models is an important area currently under investigation.
Methods: Our sample of schizophrenia patients was prospectively
treated with clozapine. Response (n=252) and weight gain (n=100)were
measured at 6 weeks and 3 months, and genetic variants were typed
using standard PCR methods.
Results: A combination of markers in the glycine transporter
gene (GLYT) predicted improvement in response to clozapine (corrected
p=0.017). Weight gain was associated with the MC4R gene and replica-
tions have been found in two additional clinical samples. The NPY gene
also exhibits significant association with AIWG (corrected p<0.03). An
algorithm to combine these and other markers together for AIWG has
shown very promising results in our sample with over 60% of the variance
accounted for (p<0.0001).
Conclusion: Overall there is increasing support indicating that testing
of the GLYT gene, along with previously reported dopamine system
genes (DRD2), may be useful to help predict which patients will be
good versus poor responders. Also, an algorithmic genetic model incor-
porating genes expressed in the hypothalamus shows strong potential
to help clinicians avoid antipsychotic induced weight gain in a given indi-
vidual patient.
Policy of full disclosure: Dr Kennedy has received honoraria from
Novartis, Roche, and Eli Lilly. He is an unpaid member of the
AssureRx Health Inc scientific advisory board.
EW-05-002 Pharmacogenetics: Using genetic information to
enhance treatment
A. Malhotra. The Zucker Hillside Hospital, Glen Oaks, USA
Objective: To review key issues in the design and interpretation of phar-
macogenetic studies of psychotropic drug response. To discuss the poten-
tial clinical implications of pharmacogenetic studies of psychotropic drug
response.
Methods: Pharmacogenetics offers the prospect of the identification of
readily accessible biological predictors of psychotropic drug response,
may provide information about the molecular substrates of drug efficacy,
and guide new drug development strategies for the treatment of psychi-
atric disorders. In this presentation, we will review basic methodological
concerns encountered in pharmacogenetic studies. These include design
issues, power considerations, appropriate outcome measures, and issues
pertaining to candidate gene and GWAS studies. These issues will be dis-
cussed in the context of pharmacogenetic studies of antipsychotic drug re-
sponse – including data implicating the dopamine D2 receptor gene in
antipsychotic drug efficacy, as well as results suggesting that genetic fac-
tors may be highly predictive of key adverse events associated with treat-
ment. The implication of these developments for the state of the art
treatment of psychiatric disorders will be discussed.
Policy of full disclosure: None.
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EW-07. Treatment of ADHD across the lifespan
EW-07-001 Treatment of ADHD across the lifespan: The
psychotherapeutic perspective
S. Groß-Lesch. Germany
Objective: Attention-deficit/hyperactivity disorder (ADHD) is a common
neurodevelopmental disorder with profound cognitive, behavioural and
psychosocial impairments in multiple domains of personal and pro-
fessional life frequently persisting across the lifespan. Given a prevalence
of 4.4% (NCS-R; Kessler et al., 2005), the persistence of ADHD is associated
with a psychiatric comorbidity rate of more than 60% in adults (Jacob et al.,
2013). Due to the high prevalence and societal impact of ADHDand the lim-
ited effectiveness of existing pharmacologic treatment strategies there is a
considerable need for psychotherapeutic treatment options.
Methods: Taking into account the disorder’s variable and changing
phenotype and also different expectations regarding age-related behav-
iour the main focus here will be on non-medical options which are propa-
gated in various national and international guidelines. Since for
pre-schoolers and school children stimulant medication may – dependent
on the severity of symptoms and impairments – not be the first-line treat-
ment, the initial step is to provide information about diagnosis and treat-
ment options to parents or caregivers. Emphasis will be on parental
training programs, most often offered as group training. Providing infor-
mation to teachers should support behavioral interventions at school.
With moderate to severe levels of impairment, and for older children in-
dividual psychological interventions rather than group training, focus
should be put on acquiring social skills with peers, problem solving,
self control, listening skills and dealing with and expressing feelings.
Results: For adolescents and adults there are CBT programmes with
different therapeutic aims, e.g. comorbidity, disorganisation, or problems
with keeping a daily routine. A recent German study used a different
therapeutic approach, taking into account some shared symptoms be-
tween ADHD and borderline personality disorder. Mindfulness offers a
opportunity to improve self-awarness, a typical problem related to the
core symptom of inattention, and therefore is the critical step into emotion
regulation and improving impulsivity.
Policy of full disclosure: I declare that I received speaker’s fees from
Medice Company.
EW-07-002 Treatment of ADHD across the lifespan
U. Muller. University of Cambridge, Cambridge, United Kingdom
Policy of full disclosure: None.
EW-08. Translating schizophrenia to animal
models: What works and what doesn’t
Shared presentation of Prof. Weiner, Dr. Howland,
Prof. Grace and Dr. Floresco
EW-08-001 Translating schizophrenia to animal models: What
works and what doesn’t
I. Weiner1, S. Floresco2, A. Grace3, J. Howland4. 1School of Psychological
Sciences, Tel Aviv University, Tel Aviv, Israel; 2UBC, Vancouver, Canada;
3University of Pittsburgh, Pittsburgh, USA; 4University of Saskatchewan,
Health Sciences Building, Saskatoon, SK, Canada
Schizophrenia is a complex disorder with prominent symptoms that are
uniquely human and apoorly understood etiology.As a result, the develop-
ment of animal models of the disorder has proven difficult. Recently, well-
validated and standardized testing procedures for animalmodels of schizo-
phrenia have been established by initiatives such as the Measurement and
Treatment Research to Improve Cognition in Schizophrenia (MATRICS).
These procedures are useful in furthering hypotheses related to the etiology,
symptoms, and pathophysiology of the disorder, as well as novel treatment
strategies. This educational session will enable a discussion of these testing
procedures. The panelists will give brief presentations regarding rodent
models that involve manipulations either during adulthood (acute
NMDA receptor antagonism, pharmacological reductions in prefrontal
GABA transmission) or early development (maternal immune activation,
methylazoxymethanol acetate treatment during gestation). Presentations
will include a particular focus on rodent behavioural tests that translate to
the MATRICS battery, electrophysiological recordings, brain imaging
approaches, and drug development. The remainder of the session will be
dedicated to an open discussion among the panelists and audience regard-
ing the strengths and weaknesses of the various approaches.
Policy of full disclosure: None.
Wednesday 25 June 2014
EW-10. Optimising clinical trial designs
EW-10-001 Increasing signal detection in clinical trials: Lessons
learned
G. Sachs. Bracket Global, Wayne, USA
Policy of full disclosure: None.
EW-10-002 From biological psychiatry to stratified medicine
clinical trials – lessons for psychiatry from the rest
of medicine
S. Kapur. Institute of Psychiatry, KCL, London, United Kingdom
Policy of full disclosure: None.
Thursday 26 June 2014
EW-11. The ABCs and CpGs of epigenetics
EW-11-001 The ABCs and CpGs of epigenetics
G. Turecki1, P. Albert2. 1McGill University, Douglas Research Institute,
Montreal, Canada; 2University of Ottawa, Ottawa, Canada
This educational workshop will review the rapidly changing landscape of
epigenetics and its application to mental health. We will cover basic con-
cepts and review some of the major findings, both in animal models of
mental disorders and in humans.
Policy of full disclosure: None.
EW-11-002 The ABCs and CpGs of epigenetics
P. Albert. University of Ottawa, Ottawa, Canada
Objective: In this session I will provide an introduction to epigenetic
mechanisms of relevance to mental health.
Methods: Basic concepts of DNA and chromatin structure, nucleosome
structure, histone structure and regulation and mechanisms by which
these are modified to alter gene expression will be presented.
Results: Epigenetic mechanisms including Chromatin modification
(histone acetylation, phosphorylation, methylation); DNA methylation;
and non-coding RNA’s will be presented. The effect of environment, sig-
naling and genome on epigenetic modifications and resulting vulner-
ability to mental illness will be discussed.
Conclusion: The participants will obtain a comprehensive yet compre-
hensible overview of which and how epigenetic mechanisms can translate
enviromental stress into lifelong predisposition.
Policy of full disclosure: None.
EW-12. The impact of neuroimaging on
understanding psychiatric disorder
EW-12-001 Bright future of PET and fMRI?
R. Lanzenberger. Medical University of Vienna, Psychiatry, Vienna, Austria
Policy of full disclosure: R. Lanzenberger received travel grants and con-
ference speaker honoraria from AstraZeneca, Roche and Lundbeck A/S.
EW-12-002 The impact of neuroimaging on understanding
psychiatric disorders
D. Nutt. Imperial College, London, United Kingdom
My talk will explore the nature of anxiety disorders and their treatments
from the perspectives of neuro-imaging both PET and fMRI. The role of
GABA 5HT and noradrenaline neurotransmitters will be discussed par-
ticularly in relation to how current treatments such as benzodiazepines
and antidepressants might work.
Policy of full disclosure: None.
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Scientific Workshops
Monday 23 June 2014
SW-01. The pitfalls, problems using gene
knockout animals in
neuropsychopharmacology
SW-01-001 Should we do away with the knockout mouse?
C. McOmish. Florey Institute of Neuroscience and Mental Health, Melbourne,
Australia
Our understanding of psychiatric disorders is accelerating rapidly, reveal-
ing extraordinary levels of complexity, heterogeneity and pleiotropy, re-
quiring systematic analysis to experimentally explore the mediators and
modulators of each condition. Commonly, we turn to animal models; a
reductionist approach by which we may begin to dissect the neurochem-
ical and structural components involved, while still working at a systems
level, with the intention of using this knowledge to develop novel and ef-
fective neuropsychopharmacological treatments. However, to date, these
approaches have failed to deliver effective treatments and we must thus
critically assess the strategies that have been employed. In this workshop
we will explore the progress that has been made in establishing valid an-
imal models of psychiatric disorders, and the use of these models for the
development of novel therapeutics, while beginning to unravel the com-
plex factors that may be contributing to the limitations of current metho-
dological approaches. Emerging approaches for optimizing the validity of
animal models and developing effective interventions will be discussed.
We will address the key aspects of construct, face, and predictive validity
in animal models, incorporating genetic and environmental factors. We
will also cover novel transgenic technology and how this may contribute
towards improving translational outcomes of preclinical studies.
Policy of full disclosure: no conflicts of interest.
SW-04. GPCRs and psychotherapeutic drug
development
SW-04-001 GPCRs and psychotherapeutic drug development
H. Manji. Johnson & Johnson, Titusville, USA
Policy of full disclosure: None.
SW-04-002 GPCRs and psychotherapeutic drug development
G. Gründer. RWTH Aachen University, Aachen, Germany
Policy of full disclosure: None.
Wednesday 25 June 2014
SW-09. Pathways to drug discovery in CNS
SW-09-001 Novel therapeutic approaches constituting multi target
neurorstorative drugs, with cell cycle activity and
mitochnondria biogenesis for neurodegenerative
disorders
M. Youdim. Technion-Faculty of Medicine, Haifa, Israel
Alzheinmer’s disease (AD), Parkinson’s disease (PD), Huntington disease
(HD), amyotrophic lateral sclerosis (ALS) and multiple Sclerosis (MS) are
initiated by cascade of neurotoxic events, that includes oxidative stress,
brain iron dysregulation, glutamate excitotoxicity, nitric oxide, inflamma-
tory process, neurotxic processes. These also include misfolding and ag-
gregation of Aβ∼amyloid peptide and α-synuclein resulting from the
demise of ubiquitin-proteasome system (UPS) as demonstrated neuro-
chemically and transcriptomics and proteomic profiling. AD and PD sub-
jects are benefiting from symptomatic effects of cholinesterase inhibitors,
memantine, monoamine oxidase B inhibitors, L-dopa, dopamine receptor
agonists, COMT inhibitors and amantadine. These drug were developed
to act on a single molecular target. For HD and ALS there are no effective
drugs. The present drugs have limited symptomatic activities and current
pharmacological approaches have sever limitation in their ability to mod-
ify the course of the diseases (neuroprotection), offering incomplete and
transient benefit to patients. However, the new therapeutic strategies for
neurodegenerative and neuropsychiatric diseases are those in which
drug candidates are designed expressly to act on multiple neural and bio-
chemical targets involved in the disease process and to possesses neuro-
potective and neurorestorative activities. Thus we have hypothesized
and developed a series of innovative novel multi target neurorestorative
drugs from our successful neuroprotective disease modifying anti
Parkinson drug, rasagiline (Azilect). These drugs possess anti Parkinson,
anti Azlheimer and anti depressant activities in animal models employed
by the pharma to develop mono target drugs.
Policy of full disclosure: None.
SW-09-002 Pathways to drug discovery in CNS
P. H. Andersen. Hongaard Consulting, Farum, Denmark
Understanding of the biology of most CNS diseases has historically in the
best case been limited. Consequently, Drug Discovery in the CNS have
until recently been guided primarily by a retro pharmacological approach,
i.e. trying to either mimic or prevent the effect of various psycho-active
drugs. This has led to several generations of me-too drugs with only
minor improvements in both the efficacy and side-effect profile.
However, in the past decade or so we have seen a number of identified
genes conferring increased risk of acquiring a given CNS disease, how-
ever, the increased risk mediated by these genes are typically low and can-
not alone explain the family linked frequency of these diseases. Thus, a
strong influence of social, environmental or other “external” factors can
via Epigenetic mechanisms be expected to explain the real life penetrance
of these genes. The changes seen in CNS Drug Discovery over the past 30
years will be discussed and potential areas for identification of novel tar-
gets for treating CNS diseases will be presented.
Policy of full disclosure: None.
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Clinical Perspectives and Personal Perspective
Monday 23 June 2014
CP-01. Biological tests to aid decision making in
clinical psychiatry – how long will the
clinician have to wait?
CP-01-001 Developing biological tests for clinical psychiatry:
How long will the clinician have to wait?
S. Kapur. Institute of Psychiatry, KCL, London, United Kingdom
Patients with mental disorders show many biological abnormalities; how-
ever, few of these have converted into tests with clinical utility. Why is this
the case? The talk will suggest that the lack of a biological ‘gold standard’
definition of psychiatric illnesses; a profusion of statistically significant,
but minimally differentiating, biological findings; ‘approximate replica-
tions’ of these findings; and a focus on comparing prototypical patients
to healthy controls has limited clinical applicability. Overcoming these
hurdles will require a new approach. Rather than seek biomedical tests
that can ‘diagnose’ DSM-defined disorders, the field should focus on iden-
tifying biologically homogenous subtypes within the current psychiatric
classifications (thereby side-stepping the issue of a gold standard).
Rather than chasing p-values versus normal controls, we must focus on
clinically meaningful effect sizes within a diagnosis and in particular iden-
tify biomarkers that lead to ‘discordant predictions’. And validating
these new biomarker-defined subtypes will require longitudinal studies,
standardised measures at a scale not previously attempted by biological
psychiatry. To achieve this scale will need to consortia that share individ-
ual patient-data across studies – thereby overcoming the problem of sign-
ificance chasing and approximate replications. Such biological psychiatry
derived clinical tests, and the subtypes they define, will exist, at least for
the foreseeable future, side-by-side of the DSM-like diagnosis. However,
they will provide a natural basis for new therapeutics and if this venture
is successful, it will give rise to a ‘stratified psychiatry’ that will improve
clinical outcomes across conventional diagnostic boundaries. The talk
will make the case for these assertions by reviewing data from within psy-
chiatry and from the rest of medicine – and will point out the early signs of
success.
Policy of full disclosure: None.
Wednesday 25 June 2014
CP-02. Strategies to manage treatment resistant
depression
CP-02-001 Strategies to manage treatment resistant depression
S. Kasper. Medical University of Vienna, Department of Psychiatry and
Psychotherapy, Vienna, Austria
The term treatment resistant depression (TRD) was introduced in 1974
and since then it has been a topic of different publications and research
strategies. Unfortunately, different definitions of TRD are used. Based
on the literature available it is evident that the following four categories
need to be distinguished: insufficient response, treatment resistant, treat-
ment refractory and chronic depression. These definitions have practical
as well research implications and different results can be expected when
these patients are summarized as a group. For pharmacotherapy of
TRD it is evident that switching the mechanism of action of antidepressant
medication does not benefit the patient and it is apparent that
augmentation with another agent, for instance atypical antipsychotics,
the combination with another antidepressant or the addition of lithium
or T3 might provide a better option. Unfortunately genetic characteriza-
tion is not there as yet to be of practical value to predict treatment re-
sponse but a more refined methodology like the new generation exome
and full genome-sequencing and genome-wide pathway analysis pro-
mises to be helpful for prediction and prevention of depression and to
identify molecular targets for new generations of psychotropic
medication.
Policy of full disclosure: Prof. Kasper has received grant/research
support from Bristol Myers-Squibb, Eli Lilly, GlaxoSmithKline,
Lundbeck, Organon, Sepracor and Servier; he has served as a consultant
or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly,
GlaxoSmithKline, Janssen, Lundbeck, Merck Sharp and Dome (MSD),
Novartis, Organon, Pfizer, Schwabe, Sepracor, and Servier; and he has
served on speakers’ bureaus for Angelini, AstraZeneca, Bristol
Myers-Squibb, Eli Lilly, Janssen, Lundbeck, Neuraxpharm, Pfizer, Pierre
Fabre, Schwabe, Sepracor, and Servier.
Tuesday 24 June 2014
PP-01. DSM5 will be the death of
psychopharmacology
PP-01-001 DSM and psychopharmcology – the New Normal
I. Everall. Department of Psychiatry, University of Melbourne, Parkville,
Australia
The DSM is a classification system for mental health problems that exists
alongside the international classification of diseases that is used globally
for all physical and mental illnesses. Originally the DSM was utilized
for research purposes. Within the United States it has also become the
staple for making clinical diagnoses, however globally just over 20% of
psychiatrists rely on the DSM for clinical practice. In the research sphere
the use of the DSM has remained dominant globally in terms of deciding
whether potential research study subjects exhibit the necessary signs
and symptoms to achieve the threshold for a categorical mental health
disorder diagnosis. Consequently, changes in disorder classification,
as occurs in evolving versions of the DSM, can have major impacts
on research efforts that can significantly affect study outcomes.
Psychopharmacology is one research discipline that is heavily reliant on
DSM criteria for the design of testing the efficacy on new molecules in
treating disorders such as major depressive disorder (MDD). Over recent
years it has been noted that the observed efficacy of antidepressant such
as selective serotonin reuptake inhibitors (SSRI) has diminished in psycho-
pharmacological study to just above the effect of placebo. This lack of
efficacy could be real and should lead to a questioning of the validity
of the serotonin hypothesis of MDD or it could reflect broadening of the
diagnostic criteria for MDD resulting inappropriate subjects being admit-
ted to therapeutic trials. In this presentation I will present some of the
difficulties that the DSM poses to fields such as psychopharmacology,
the challenge of an increasingly medicalized society and potential ways
forward.
Policy of full disclosure: None.
PP-01-002 DSM5 will be the death of psychopharmacology
G. Burrows. University of Melbourne, Richmond, Australia
Policy of full disclosure: None.
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Rafaelsen Poster Session
Monday 23 June 2014 – Wednesday 25 June 2014
RA-01. Rafaelsen Award Posters
RA-01-001 Reduction of hippocampal leptin levels may be
involved in anxiety-like behavior observed in balb-c
mice fed with carbohydrate-enriched diet
D. Aguiar1, A. L. Oliveira1, C. Santos1, A. Ferreira2. 1UFMG-ICB, Belo
Horizonte, Brazil; 2UFMG-Nursing School, Belo Horizonte, Brazil
Objective: The obesity is a chronic disease which is frequently associated
with other diseases such as, diabetes type II and metabolic syndrome.
Moreover, obesity and stress related psychiatric disorders are comorbid-
ity. Epidemiologic data have been shown that obesity constitutes a
risk factor for the development of mood disorders, such as anxiety.
However, the understanding of the relationship between diet, stressful
events and the development of psychiatric disorders is poorly understood.
Thus, the aim of this study is verify if animals underwent to a diet normo-
caloric/high carbohydrate, which does not modify the weight of the ani-
mals, but promotes the expansion of abdominal fat are more susceptible
to stressful events.
Methods: Balb-c mice with five weeks of age were fed over 12 weeks
with standard (C-39.5% carbohydrate, 8% fiber) or high-carbohydrate
diet (HC-58% carbohydrate). After this period, the behavioral effects
induced by acute stress restriction were observed in animals exposed to
the elevated plus maze (EPM) 24 hours after stress. After this, animals
were sacrificed immediately after EPM, their hippocampus was dissected
and the leptin levels were measured
Results: Animals fed with HC diet displayed reduced the percentage of
entries into the open arms of the EPM 24 h after the restraint stress (control
stress=69.7±5.5; HC stress=36.8±6.1, p<0.05 two-way ANOVA). The
number of enclosed arms entries in the E.P.M. was significantly higher
in diet stress animals as compared to control stress animals (control stress
=6.8±1.8; HC stress=12.±1.2, p<0.05 two-way ANOVA). However, this is
not due impairment in locomotor activity since no effect was observed in
the open field test. These behavioral effects were followed by a reduction
of leptin levels in HPC (control stress=1309±70.21; HC stress=759.3±46.6,
p<0.05 two-way ANOVA).
Conclusion: The animals fed with HC diet displayed anxiogenic-like
behavior in the E.P.M 24hours after stress. These data suggest that ex-
posure to an imbalance diet facilitates susceptibility to stressful events.
Moreover, the mechanisms responsible for these effects may be related
with impairment in hippocampal leptin signaling
Policy of full disclosure: Finnancial Suport: CAPES, CNPq (475899/
2010-5).
RA-01-002 Increased MIF and IL-1ß mRNA blood levels and
childhood trauma events as accurate predictors of
treatment response in depressed patients
A. Cattaneo1, L. Bocchio Chiavetto2, R. Uher3, M. A. Riva4, C. Pariante1.
1King´s College London, London, United Kingdom; 2IRCCS San Giovanni di
Dio, Brescia, Italy; 3King´s College London, SGDP, London, United Kingdom;
4University of Milan, Milan, Italy
Objective: A third of patients do not respond to any currently available
antidepressants and there is a need to establish predictive biomarkers of
treatment response useful for therapy personalization.
Methods: To identify predictive biomarkers of treatment response to be
easily replicated in different laboratories we measured by Real Time PCR
the absolute blood mRNA expression of MIF and IL-1β, two proinflamma-
tory genes that we previously found associated with treatment response.
Results: The absolute number of molecules for MIF and IL-1β were
higher in non responders (83.1±4.8×106 for IL-1β and 102.5±4.2×106
for MIF) as compared with responders (50.4±2.1×106 for IL-1β, and
55.4±1.9×106 for MIF). By using a Linear Discriminant Analysis we com-
bined MIF and IL-1β values with treatment response and we defined a
rule able to discriminate responders vs. non-responders. We also calcu-
lated MIF and IL-1β cut-off values and the relative probability of being
a responder or a non-responder. We then validated these findings in an
independent sample of depressed patients and we found that our
predictive model had 14% of false positives and 16% of false negatives.
The patients which erroneously have been identified as non responders
because of high baseline levels of cytokines showed a reduction in the
cytokines levels -to levels similar to responders- already at week 4; more-
over, the patients which were erroneously classified as responders be-
cause of normal baseline cytokine levels reported severe childhood
trauma events.
Conclusion: Our data suggest that both high cytokines levels and a his-
tory of childhood trauma may provide a clinically-suitable approach to
identify patients who are non-responders to classic antidepressants and
maybe benefit from immune-targeted therapy.
Policy of full disclosure: None.
RA-01-003 Genetic predictor of antidepressant response for major
depressive disorder accounting for clinical subgroups:
A genome-wide association study
W. Nakano1, D. Mehta2, M. Ising3, H. Pfister3, D. Czamara3,
T. Carrillo-Roa3, F. Holsboer3, S. Lucae3, A. Erhardt-Lehmann3,
E. Binder3. 1UOEH, Kitakyushu, Japan; 2Max Planck Institute of Psychiatry,
Munich, Germany; 3Munich, Germany
Objective: To date, a number of genome-wide association studies, includ-
ing a meta-analysis have tried to detect genetic associations with antide-
pressant response for major depressive disorder (MDD) but with
limited success. We performed a genome-wide association analysis and
tested the hypothesis that accounting for clinical subgroups of depression
(anxious depression group: ANX versus non-anxious depression
group: NON-ANX) will provide increased sensitivity and higher power
to detect subgroup-specific genetic variants associated with antidepres-
sant treatment response.
Methods: A total of 626 inpatients (n=366 ANX, n=260 NON-ANX)
with MDD were treated with antidepressants from the Munich
Antidepressant Response Signature (MARS) project. The association be-
tween genotypes and percentage improvement in Hamilton Depression
Rating Scale (HAM-D) scores was tested using PLINK.
Results: No single-nucleotide polymorphism (SNP) reached genome-
wide significance in the whole sample but upon stratification into sub-
groups we identified 2 SNPs (rs4278478 and rs10831500) within the
mastermind-like 2 (MAML2) gene on chromosome 11 significantly asso-
ciated with percent improvement HAM-D score at the genome-wide
significance level (p=3.04×10–8 and p=3.57×10–8) in NON-ANX. The
direction of the effects for these SNPs was in the opposite direction in
non-anxious depression group versus anxious depression group. In
NON-ANX, each SNP explained >11% variance of percentage improve-
ment in HAM-D scores.
Conclusion: In the current study, we reported SNPs within the MAML2
gene significantly associated with response to antidepressant treatment in
MDD at the genome-wide level but this association was observed only
after stratification into subgroups and not when assessing the whole sam-
ple. A replication in an independent sample is currently underway. This
study highlights that it is essential to identify and interrogate specific clini-
cal subgroups of depression, to allow identification of robust and reliable
genetic predictors of antidepressant treatment. We are confirming our
findings in independent samples.
Policy of full disclosure: None.
RA-01-004 Cognitive function, serum IL-10 level, and IL-10 -592 A/
C polymorphism in first-episode drug naive patients
with schizophrenia versus healthy controls
M. Xiu1, D. Chen1, X. Zhang1. 1Beijing Hui-Long-Guan Hospital, Beijing,
China
Objective:Numerous studies have shown that activation of the peripheral
innate immune system induces production of cytokines within the brain
that can have deleterious effects on cognition. Recent study has shown
that IL-10, a potential anti-inflammatory cytokine, can exert neuroprotec-
tion and may play a role in pathogenic processes leading to cognitive dys-
function. Cognitive impairment is a core feature in the pathology of
schizophrenia, and recent studies showed altered IL-10 in schizophrenia.
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However, no study has explored the role of IL-10 in cognitive deficits of
schizophrenia.
Methods: In the present study, we recruited 241 first episode and
drug-naïve patients with schizophrenia and 240 healthy controls and com-
pared them on the Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS), serum IL-10 levels and the IL-10
-592A/C polymorphism. We assessed patient psychopathology using the
Positive and Negative Syndrome Scale.
Results: Our result showed a significant difference in the allelic fre-
quency (p<0.05) and a trend toward to significant difference in the
genotypic frequency (p<0.1) between patients and healthy controls.
Further analysis showed significant differences in the genotype and allele
distributions between patients and controls only in males. The A variant
was associated with worse attention performance among schizophrenia
patients but not among normal controls. Serum IL-10 levels were signifi-
cantly decreased in patients compared with that in normal controls.
Moreover, IL-10 levels among the schizophrenia A allele carriers were
correlated with the degree of cognitive impairments, especially attention
performance.
Conclusion: Our results suggest that the IL-10 -592A/C polymorphism
may play a role in susceptibility to male schizophrenia. Further, we dem-
onstrated an association between the IL-10-592A/C polymorphism and
poor attention in schizophrenia. The association between lower IL-10
levels and cognitive impairment in schizophrenia is dependent on the
IL-10-592A/C polymorphism.
Policy of full disclosure: None.
RA-01-005 Genetic variations across remote regulatory regions of
14 obsessive-compulsive disorder candidate genes in
antidepressant response
G. Zai1, C. Zai1, V. Goncalves1, K. Wigg2, J. Kennedy1, M. Richter3.
1CAMH, University of Toronto, Toronto, Canada; 2Toronto Western Hospital,
UHN, Toronto, Canada; 3Sunnybrook Health Sciences, Centre, Toronto, Canada
Objective: Obsessive-compulsive disorder (OCD) is a chronic and debili-
tating disorder with a strong genetic etiology. Genetic associations be-
tween OCD and several candidate genes including the glutamate
transporter (SLC1A1), monoamine oxidase (MAOA), glutamate NMDA
receptor 2B (GRIN2B), serotonin 2A receptor (5HTR2A), serotonin trans-
porter (SLC6A4), brain-derived neurotrophic factor (BDNF), and
catecholamine-O-methyl transferase (COMT) genes have previously
been reported. Pharmacogenetics represents a valuable alternative strat-
egy to define subtypes of OCD and to define clinically useful inter-
individual genetic variation in drug response. We investigated 14 genes
including those mentioned above as well as top hit genes from a recent
OCD genome-wide association study: Disks Large (drosophila)
homolog-associated protein 1 (DLGAP1), BTB (POZ) domain containing
3 (BTBD3), serotonin 1B receptor (5HT1B), SLIT and NTRK-like family
(SLITRK5), Fas apoptotic inhibitory molecule 2 (FAIM2), glutamate recep-
tor, ionotropic, kainite 2 (GRIK2), and fucosyl-transferase 2 (FUT2).
Methods: examined a total of 32 single nucleotide polymorphisms
across these candidate genes and their regulatory regions using a custom-
made 32-SNP OpenArray chip and genotyping was performed using the
QuantStudioTM 12 K Flex Real-Time PCR System in 222 OCD patients
with retrospective response data on multiple serotonin reuptake inhibitor
(SRI) trials. Individuals were grouped into those who improved following
an adequate trial of one or more SRI(s) as compared with those who
reported “minimal”, “no change”, or “worsening”. Genotypes and re-
sponse data were examined on a combined SSRI/SRI basis.
Results: Interesting associations (P<0.05) were detected for DLGAP1,
SLITRK5, BTBD3, 5HT1B, and SLC1A1 in SSRI/SRI response. These
results suggest that genetic variants may play a role in SRI response to
OCD.
Conclusion: Combination of these variants may be clinically useful in
predicting treatment resistance versus response in OCD.
Policy of full disclosure: –Gwyneth Zai=no financial disclosure –
Clement Zai=Eli Lilly (fellowship research salary support) and Gerson
Lehrman Group (consultant fees) –Vanessa Goncalves=no financial
disclosure –Karen Wigg=no financial disclosure – James Kennedy=
AssureRx (scientific advisory board member), Eli Lilly (speaker honor-
arium and expenses), Novartis (speaker honorarium), and Roche (consult-
ant honorarium and expenses) –Margaret Richter=Lundbeck (speaker
honorarium and speaker fees) and Roche (research support/grant).
RA-01-006 Toxoplasma gondii seropositivity is positively
associated with anxiety and burnout-syndrome
C. Bay-Richter1, H. Buttenschøn1, L. Foldager1, H. Kolstad2, L. Kærlev3,
J. Thomsen4, N.P. Ole Mors2, G. Wegener1. 1TNU, Aarhus University,
Risskov, Denmark; 2Aarhus University, Aarhus, Denmark; 3Odense
University Hospital, Odense, Denmark; 4Bispebjerg Hospital, Copenhagen,
Denmark
Objective: Toxoplasma gondii (TOX) is a common parasite affecting
approximately one-third of the human population, primarily targeting
neurons. An increasing number of studies are now providing evidence
that the disease is associated with behavioural changes and psychiatric
disease. It has for example been demonstrated that TOX seropositivity
was higher in schizophrenia, depression, anxiety, and bipolar patients
compared to healthy controls. The objective of this study is to examine
TOX seropositivity in a large human population in relation to psychiatric
symptoms.
Methods: A population of 548 participants was initially included and
the participants went through a semi-structured diagnostic interview
(SCAN interview) followed by blood sampling. From this population, a
control group (n=158) with no diagnosis of psychiatric disorders was
extracted as well as a group consisting of subjects showing symptoms
of anxiety (SCAN interview, n=106) and burnout syndrome
(Copenhagen Burnout Inventory, n=51). Blood serum was examined for
IgG antibodies to TOX using ELISA assays.
Results: Data were analysed using logistic regression models with
gender, age and BMI as confounding factor and show that seropositivity
of TOX is positively associated with anxiety (adjusted odds ratio [OR]=
2.05; 95% CI, 1.14-3.70; p=0.016). In addition, we find an association be-
tween seropositivity and burnout syndrome (OR=3.43; 95% CI, 1.67–
7.05; p<0.001).
Conclusion: These data supports the notion that TOX is associated with
psychiatric disorders. Our results are consistent with previous reports on
an association between TOX and anxiety. Furthermore, we show a posi-
tive association between TOX seropositivity and the stress related syn-
drome, burnout syndrome.
Policy of full disclosure: None.
RA-01-007 Antidepressant-like activity of
1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin
-4-YL)-cyclohexanol, a beta-substituted
phenylethylamine in animal models of behavioral
despair
A. Dhir1, S. K. Kulkarni2. 1Gujarat Forensic Sciences University, Institute
of Research and Development, Gandhinagar, India; 2University Institute of
Pharmaceutical Sciences, Panjab University, Chandigarh, India
Objective: The β-phenylethylamines are known to act as ligands for the
trace amine receptors, a novel family of G-protein-coupled receptors
that is known to play an important role in the pathophysiology of
major depression. The present study is an attempt to evaluate one of
such molecules, 1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-
cyclohexanol, in animal models of depression.
Methods: Various behavioral paradigms of despair such as forced swim
and tail-suspension tests were used to assess the antidepressant-like ac-
tivity. Further, an alteration in the levels of various neurotransmitters
(norepinephrine, serotonin, and dopamine) in the mouse brain was
evaluated.
Results: The molecule (4–16mg/kg., i.p.) dose-dependently inhibited
the immobility period in mouse forced swim test and tail-suspension
tests, the effect comparable to venlafaxine. Additionally, the molecule at
8mg/kg., i.p. reversed reserpine-induced behavioral despair in mouse
forced swim test. When administered simultaneously, it enhanced the
antidepressant activity of sub-effective doses of imipramine or fluoxetine
in the mouse forced swim test. The molecule at 8 mg/kg., i.p. enhanced
the levels of norepinephrine without affecting serotonin in the mouse
brain. However, at higher dose (16mg/kg., i.p.), it increased the levels
of norepinephrine, serotonin, and dopamine. The molecule enhanced
the locomotor activity in mice only at higher doses. The molecule, unlike
venlafaxine, which potentiated barbiturate-induced hypnosis, was
devoid of any sedative activity. Finally, there is an involvement of
L-arginine-nitric oxide-cyclic guanosine monophosphate signaling path-
way in its antidepressant action.
Conclusion: In conclusion, 1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-
isoquinolin-4-yl)-cyclohexanol, possess antidepressant-like activity in an-
imal models of depression by modulating the neurotransmitter levels in
the brain. Such an activity might be due to the modulating action of
this novel molecule on trace amine receptors.
Policy of full disclosure: None.
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RA-01-008 Review of trait impulsivity in suicide: A
pharmacological target
S. Sahoo1, C. Schuetz2. 1Essendon, Australia; 2University of British Columbia,
Vancouver, Canada
Objective: This paper aimed to review trait impulsivity in suicidal
attempts, which can serve as unique pharmacological target.
Methods: Using keywords “impulsivity and suicide” to search on
Medline, EMBASE, Psychinfo & including those studies that had reported
trait impulsivity scores using validated and reliable assessment measures,
we searched all English language studies from 1990 to December 2012
with 33 studies meeting inclusion criteria, which were then reviewed by
the two reviewers independently. We generated standardized mean dif-
ferences (SMDs) for impulsivity using RevManager 5.1 from Cochrane
analysis.
Results: The Barratt Impulsivity Scale (BIS) 11 was the instrument com-
monly used in attempted suicides. 33 studies met criteria for inclusion in
suicide, yielding a SMD of 0.71 on all assessment measures combined.
Conclusion: Impulsivity is significantly higher in patients attempting
suicide than normal controls, which indicates that trait impulsivity can
drive suicidal attempts, and can serve as an unique pharmacological tar-
get for intervention.
Policy of full disclosure: None.
RA-01-009 Parahippocampal and insular gray matter volume
correlates with empathic concern
C. Kraus1, G. S. Kranz2, D. Pfabigan3, A. Hoffmann4, A. Hahn2,
S. Eva-Maria3, M. Küblböck4, S. Kasper2, C. Windischberger4,
C. Lamm3, R. Lanzenberger2. 1Medical University of Vienna, Vienna,
Austria; 2Medical University of Vienna, Department of Psychiatry, and
Psychotherapy, Vienna, Austria; 3Faculty of Psychology, University of Vienna,
Vienna, Austria; 4Medical University of Vienna, Center for Medical Physics
and Biomedical Engineering, Vienna, Austria
Objective: While functional magnetic resonance imaging (MRI) studies
have identified brain regions, which are tightly linked to empathy, evi-
dence of structural variance due to the ability to empathize is scarce.
Therefore, we aimed to investigate cortical gray matter associated with
the ability to empathize.
Methods: Gray matter volume (GMV) was measured with structural
MRI at 3 T and voxel-based morphometry (VBM) in 25 sex and age-
matched healthy young volunteers (13 female, age: 25.4±5.2years).
High-resolution anatomical images were acquired using a MPRAGE se-
quence (240×256×160 voxels, 1mm3 isotropic; TR=2.3 s, TE=4.2 ms).
Data were preprocessed with an optimized VBM protocol applying
Diffeomorphic Anatomical Registration Through Exponentiated Lie
Algebra (DARTEL) as implemented in SPM8. Empathic concern was
quantified with a German version of the interpersonal reactivity index
(IRI). A voxel-wise multiple linear regression analysis was performed in
SPM8 between GMV maps and empathy scores with total brain GMV
as covariate in a-priori selected brain regions (insula, amygdalae, hippo-
campus, parahippocampus, anterior cingulate). All analyses were per-
formed in standardized Montreal Neurological Institute (MNI)-space at
statistical threshold of p<0.001 uncorrected, the family-wise-error (FWE)
rate at p<0.05 was applied to correct for multiple comparisons where
appropriate.
Results: Significant positive correlations of regional GMV with empa-
thy scores were observed in the left anterior parahippocampal gyrus
(p=0.024, FWE-corrected, x,y,z=−27, −9, −30, r =0.615) and in the right
anterior insula (p<0.001, x, y, z=24, 22, −9, r=0.618).
Conclusion: We have detected significant gray matter increases accord-
ing to empathic ability. Both, the parahippocampal gyrus and the anterior
insula are involved in emotional processing, which is a prerequisite for
empathy. Furthermore, this study confirms previous work showing the
central role of the anterior insula in empathizing.
Policy of full disclosure: Without any relevance to this work,
S. Kasper declares that he has received grant/research support from Eli
Lilly, Lundbeck A/S, Bristol-Myers Squibb, Servier, Sepracor,
GlaxoSmithKline, Organon, and has served as a consultant or on advisory
boards for AstraZeneca, Austrian Sick Found, Bristol-Myers Squibb,
GlaxoSmithKline, Eli Lily, Lundbeck A/S, Pfizer, Organon, Sepracor,
Janssen, and Novartis, and has served on speakers’ bureaus for
AstraZeneca, Eli Lilly, Lundbeck A/S, Servier, Sepracor and
Janssen. R. Lanzenberger has received travel grants and conference
speaker honoraria from AstraZeneca, Lundbeck A/S and Roche Austria
GmbH. C. Kraus received travel grants and conference speaker honoraria
from Roche. G.S. Kranz received travel grants from Roche and AOP
Orphan.
RA-01-010 In vivo phenotyping of a mouse model of the human
22q11.2 deletion syndrome
F. Gastambide1, K. Phillips1, K. Fejgin2, S. Nilsson3, A. McCarthy1,
K. Wafford1, T. Bussey3, J. Nielsen2, M. Didriksen2, G. Gilmour1,
M. Tricklebank1. 1Eli Lilly & Company, Windlesham, United Kingdom; 2H.
Lundbeck A/S, Copenhagen, Denmark; 3University of Cambridge, Cambridge,
United Kingdom
Objective: Recent findings have provided strong evidence that specific
copy number variants (CNVs) pose a considerably increased risk of
neuropsychiatric disorders. Up to 30% of adolescents and adults with
the 22q11.2 deletion syndrome develop schizophrenia-like psychosis
and related cognitive problems. Therefore, this rare and highly penetrant
CNV represents an important model for understanding the pathophysiol-
ogy of schizophrenia. Several mouse models for the human 22q11.2 de-
letion have been engineered, however, their phenotype remains to be
fully characterized.
Methods: The present study was designed to further investigate
phenotypic manifestations in a novel mouse model for the human
22q11.2 deletion syndrome (Df(h22q11)/+) recently generated within the
NEWMEDS consortium. A broad range of neurophysiological and beha-
vioural functions was assessed at baseline as well as under acute psycho-
logical stressor or pharmacological challenge. These include sleep
architecture, locomotor activity, prepulse inhibition, reaction time, impul-
sive responding, sustained attention, spatial learning and memory, and
spatial working memory.
Results: Df(h22q11)/+ mice showed no or minor changes in baseline
and/or stress-induced sleep architecture, locomotor activity, operant
reaction time, sustained attention, impulsive responding, spatial learning
and memory and spatial working memory. However, they had a
robust deficit in prepulse inhibition and an increased sensitivity to
psychostimulant-induced hyperactivity.
Conclusion: These results suggest that the deletion in mice of an ortho-
logous region of the human 22q11.2 locus recapitulates some of the
phenotypic manifestations observed in the 22q11.2 deletion syndrome
and schizophrenia. Detailed electrophysiological and molecular character-
ization of the mechanisms underlying these alterations is currently
ongoing.
Policy of full disclosure: NEWMEDS – The research leading to these
results has received support from the Innovative Medicine Initiative
Joint Undertaking under grant agreement n° 115008 of which resources
are composed of EFPIA in-kind contribution and financial contribution
from the European Union’s Seventh Framework Programme (FP7/
2007-2013).
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P-01. Addictive disorders A
P-01-001 Problems with the prescription of benzodiazepines in
Japan. Evaluation of suicide attempts by overdosing
A. Akahane1, K. Matsumura1, E. Ikebuchi1. 1Teikyo University, School of
Medicine, Tokyo, Japan
Objective: In Japan, larger doses of benzodiazepines are known to be
prescribed than in Western countries. This raises doubts about whether
Japanese physicians have sufficient knowledge and understanding
about the risk of benzodiazepines. Recently, suicide attempts by overdos-
ing on psychotropic drugs prescribed by physicians are increasing, and
benzodiazepines are used in many of such suicide attempts. We investi-
gated the contents of prescriptions by previous physicians for patients
who attempted suicide by overdosing on psychotropic drugs and were
admitted to our emergency medical center to clarify the actual situation
concerning the prescription of benzodiazepines and evaluate the relation-
ship between benzodiazepines and repeated suicide attempts by drug
overdosing.
Methods: The 116 patients were investigated. On the basis of the clini-
cal data obtained on admission from the previous physicians, the doses of
benzodiazepines were calculated. The doses are expressed as diazepam
equivalents. The doses of benzodiazepines were compared between
patients with and without a history of suicide attempts.
Results: Benzodiazepines were prescribed to all 116 patients, their
diazepam-equivalent dose was 27.78±21.92 mg. The dose of benzodiaze-
pines was compared between the patients with and without a history of
suicide attempts by overdosing on psychotropic drugs, but no significant
difference was observed. However, in those who attempted or repeatedly
attempted suicide using psychotropic drugs, the dose of benzodiazepines
markedly exceeded 15mg/day, which is the maximum dose of diazepam,
and it was 31.88±24.81 mg, more than twice the maximum dose, in the 47
patients who had repeatedly attempted suicide.
Conclusion: Benzodiazepines are known to infrequently cause impul-
sive actions, i.e., violence, self-injury behavior, and suicide attempts,
due to their pharmacological effect of disinhibition. The results of this
study did not rule out the possibility that the prescription of large doses
of benzodiazepines is a factor affecting suicide attempts by overdosing.
Therefore, the appropriate use of benzodiazepines may contribute to the
prevention of repeated suicide attempts by overdosing.
Policy of full disclosure: None.
P-01-002 Pathway-specific modulation of nucleus accumbens in
reward and aversive learning behaviors and drug
addiction via selective transmitter receptors
T. Hikida1, S. Yawata2, T. Yamaguchi2, T. Danjo2, T. Sasaoka3, Y. Wang4,
S. Nakanishi2. 1Kyoto University, Graduate School of Medicine, Kyoto, Japan;
2Osaka Bioscience Institute, Suita, Japan; 3Kitasato University, Sagamihara,
Japan; 4University of Illinois, Urbana, USA
Objective: The basal ganglia-thalamocortical circuitry plays a central role
in reward and aversive learning and drug addiction. Inputs of the nucleus
accumbens in this circuitry are transmitted through two parallel striatoni-
gral direct and striatopallidal indirect pathways and controlled by dopa-
mine transmitter. We explored how dopaminergic modulation of
nucleus accumbens in the basal ganglia circuitry regulates the associative
learning behavior and drug addiction.
Methods: We developed an asymmetric reversible neurotransmission-
blocking technique in which transmission of each pathway was unilater-
ally blocked by transmission-blocking tetanus toxin and the transmission
on the intact side was pharmacologically manipulated by local infusion of
a receptor-specific agonist or antagonist. Reward learning and addictive
behaviors was measured by chocolate-associated and cocaine-induced
conditioned place preference. Aversive learning was tested by performing
one-trial inhibitory avoidance task.
Results: The activation of D1 receptors and the inactivation of D2 recep-
tors postsynaptically control reward learning/cocaine addiction and aver-
sive learning in a direct pathway-specific and indirect pathway-specific
manner, respectively. Furthermore, this study demonstrated that aversive
learning is elicited by elaborate actions of NMDA receptors, adenosine
A2a receptors, and endocannabinoid CB1 receptors, which serve as key
neurotransmitter receptors in inducing long-term potentiation in the in-
direct pathway.
Conclusion: Reward and aversive learning and cocaine addiction is
regulated by pathway-specific neural plasticity via selective transmitter
receptors in the nucleus accumbens circuit.
Policy of full disclosure: None.
P-01-003 Associations of an orexin (hypocretin) receptor 2 gene
polymorphism with nicotine dependence found in
genome-wide and following association studies
D. Nishizawa1, S. Kasai1, J. Hasegawa1, N. Sato2, F. Tanioka3,
M. Nagashima4, H. Ujike5, R. Hashimoto6, M. Tanaka7, H. Sugimura3,
K. Ikeda1. 1Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan;
2Hamamatsu, Japan; 3Iwata, Japan; 4Sakura, Japan; 5Okayama, Japan; 6Osaka,
Japan; 7Tokyo, Japan
Objective:Many genetic and environmental factors can be involved in the
etiology of nicotine dependence. To date, several candidate genetic varia-
tions have been identified to be associated with smoking behaviors and
vulnerability to nicotine dependence by candidate gene or genome-wide
association studies (GWAS), which is mostly conducted for subjects
with European ancestry. However, genetic factors have not been report-
edly investigated for Japanese population utilizing whole-genome geno-
typing arrays. To elucidate genetic factors involved in nicotine
dependence in Japanese, the present study comprehensively explored gen-
etic contributors to nicotine dependence by using whole-genome genotyp-
ing arrays with more than 200,000 markers in Japanese subjects.
Methods: Subjects for GWAS and replication study were 300 and 700
patients, respectively. A two-stage GWAS was conducted using 150 sam-
ples for each stage using the Fagerström Test for Nicotine Dependence
(FTND), the Tobacco Dependence Screener (TDS), and the numbers of
cigarettes smoked per day (CPD), as indices of nicotine dependence. For
additional association analyses, patients undergoing major abdominal
surgery, patients with methamphetamine dependence/psychosis, healthy
subjects with schizotypal personality trait data, and subjects of autopsy
specimens with various diseases, were recruited.
Results: After association study between over 200,000 marker single
nucleotide polymorphisms (SNPs) and FTND, TDS, and CPD, the nonsy-
nonymous rs2653349 SNP (1237G>A; Val308Ile) located on the gene
encoding orexin (hypocretin) receptor 2, was selected as the most promis-
ing SNP associated with FTND, and the association was replicated for re-
maining 700 samples. This SNP was also associated with postoperative
pain, initiation of methamphetamine use, schizotypal personality traits,
and susceptibility to goiter.
Conclusion: The nonsynonymous rs2653349 SNP located on the orexin
(hypocretin) receptor 2 gene was suggested to be a genetic factor for nic-
otine dependence and possibly pain, schizotypal personality traits, and
goiter in Japanese population.
Policy of full disclosure: This work was supported by grants from
the MEXT KAKENHI (Grant Number 20602020, 20390162, 23390377,
22240072, 25242062, and S-001), the Ministry of Health, Labour and
Welfare (MHLW) of Japan (no. H21-3jigan-ippan-011 and
H22-Iyaku-015, H23-016, H23-119, H24-Nanchi-Ippan-005 and
H25-Iyaku-020), Grants-in-Aid for the U.S.-Japan Cooperative Medical
Science Program, National Cancer Center Research and Development
Fund, Smoking Research Foundation, Astellas Foundation for Research
on Metabolic Disorders, and a Grant-in-Aid for Scientific Research on
Innovative Areas (Comprehensive Brain Science Network) from the
Ministry of Education, Science, Sports and Culture of Japan. This work
was partly supported by the Smoking Research Foundation. The funders
including the Smoking Research Foundation had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript. Dr. Ikeda reports having received support from Eisai for a
project unrelated to this research and speaker#s fees from Taisho
Pharmaceutical Co., Ltd. and Japan Tobacco Inc. The authors report no
other biomedical financial interest or potential conflicts of interest.
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P-01-004 Study of anxiety and depression in alcoholic patients
during therapy
A. Bandati1, A. Milshtein1. 1Chisinau, Republic of Moldova
Objective: Anxiety is among the most frequent affective disorder in al-
cohol dependence – from 11 up to 100%. In the remission period alcoholic
anxiety becomes protracted, pharmacoresistence over and often contribute
to relapse. The link between alcohol and depressive disorder indicates that
the alcohol is used as a ‘modifier’ of mood, to alleviate the condition of
stress, anxiety and depression. Thus, alcohol, used to improve mood
affects subsequent (probable) formation of alcoholic illness.
Methods: 45 patients were examined in order to study the dynamics
of anxiety and depressive disorders in alcoholic patients admitted to
the Republican Narcological Dispensary. It was included in the
study 5 patients female and 40 male patients. The median age was
38.8±9.8 years. All patients were evaluated using the Hospital Anxiety
and Depression Scale. This technique allows the dynamic monitoring
of alcoholic anxiety and depression during treatment. Amitriptyline at
a daily dose of 150mg 3 weeks was used to treat clinically expressed de-
pression accompanied by anxiety disorders. In the forefront of depressive
disorders with subclinical anxiety patients appointed Venlafaxine dose
75–150mg, depending on severity of depression.
Results: High level of depression (18 +/- 4 points) and anxiety (13 +/-
3 points) were founded in all 45 examined patients. There was only a
slight improvement in the level of anxiety (1 +/- 2 points) and depression
(2 +/- 2 points) in 8 patients during the treatment. The remaining
33 patients has showed clinically meaningful improvement: the level of
anxiety has decreased on average by 6 +/- 4 points, while the depression
decreased by 5 +/- 3 points.
Conclusion: The data indicate a high level of both depression and
anxiety in patients that allows to treat alcoholic affective disorders. Thus
reducing the clinical manifestations of alcoholic anxiety may prevent de-
velopment of relapse.
Policy of full disclosure: None.
P-01-005 Win-related cues drive risky decision-making on a
rodent gambling task
M. Barrus1, C. Winstanley1. 1University of British Columbia, Vancouver,
Canada
Objective: Animal models of gambling behavior allow insight into the
neurobiology of gambling that is otherwise lacking because of technical,
practical and ethical limitations of human research. Our laboratory has
developed a model of gambling behavior for use with rodents called
the rodent Gambling Task (rGT).
Methods: The rGT allows animals to choose between four options that
are associated with varying levels of risk and reward; the optimal strategy
on the task is to choose the option with a relatively small reward but also
infrequent punishment, allowing the animal to collect the maximum
amount of reward over the course of the 30 minute session. A new version
of the rGT incorporates flashing lights and tones to signal wins. These win
cues are not proportional to the win size; as in a human gambling para-
digm, the win-related cues are exponentially larger for large wins, making
these options more attractive despite the fact that they are ultimately dis-
advantageous. Current work is aimed at delineating the specific contribu-
tions of catecholamines to this behavior, with a focus on dopaminergic
D2-like receptors.
Results: Animals quickly learn the task, and their behavior has been
well characterized; most animals adopt an optimal strategy and perform
well on the task, while some behave in a riskier manner, preferring a high-
risk, high-reward strategy, much like a high-stakes human gambler. It
appears that the addition of cues drives a detrimental, risk-seeking pattern
of behavior, as rats trained on this task show a higher preference for the
risky options than rats trained on the uncued version of the task.
Conclusion: The use of the rGT provides greater insight into the neuro-
biology of gambling, especially risky decision-making in the face of uncer-
tain or probabilistic outcomes, and use of the cued version enables
exploration of the neuropsychopharmacology of the influence of cues on
the decision-making process.
Policy of full disclosure: None.
P-01-006 Efficacy of energotropic modulators of cellular
metabolism in therapy of withdrawal syndrome in
associated forms of alcoholism
N. Bokhan1, I. E. Ankudinova2, N. V. Aslanbekova3. 1Mental Health
Research Institute, Tomsk, Russia; 2Novosibirsk, Russia; 3Pavlodar, Kazakhstan
Objective: For overcoming polypharmacy during treatment of alcoholism
(A) in patients with remote consequences of comorbid brain injury and
associated dismetabolic effects, search for new energotropic modulators
of cellular metabolism is relevant. Composite medication “Reamberin”
for intravenous injections is a metabolic corrector with antioxidant activity
and represents by itself a balanced poly-ionic solution with addition of
succinic acid.
Methods: In parallel groups, simple comparative study of efficacy of
7-day application of medication “Reamberin” in therapy of alcohol with-
drawal syndrome (AWS) in 32 alcoholic patients with comorbid brain in-
jury (group 1; F10.2; S06.00; mean age 41,2+/-6,3 years) as compared with
group (2) of 46 patients without the above medication. All patients gave
informed consent. Scales were used: CIWA-Ar, HDRS, and HARS in 3
points. The sign of endogenous intoxication (EI) was increase of content
of molecules with low mean molecular weight (MMW) and oligopetides
in serum of blood.
Results: In patients of groups 1 and 2 in AWS, EI with reliable increase
of toxic fraction (TF), recorded during wavelength A254 and nuclear frac-
tion of MMW230 has been revealed. Increase of nuclear fraction of
MMW230 is likely associated with accumulation in blood of nucleic acid
residues as a result of reinforcement of apoptosis of cells and heightened
protein breakdown. At the end of the therapy in group 1, reliable decrease
of content of TF has been recorded, concerning nuclear fraction, trend to
decrease was observed. In group 2, reliable dynamics in alteration of spec-
trum of MMW have not been revealed. In group 1, accelerated reduction
of somatovegetative manifestations of AWS with normalization of its af-
fective components has been shown.
Conclusion: Use of medication “Reamberin” in therapy of AWS posi-
tively influences decrease of level of endogenous intoxication, improves
dynamics of basic somatovegetative and psychopathological disorders,
reduces polypharmacy, normalizes the metabolic background for stabili-
zation of remission.
Policy of full disclosure: None.
P-01-007 The prevalence and patterns of continuous use of
benzodiazepines following a psychiatric admission as a
risk factor for benzodiazepine use disorder. Preliminary
report
S. Castel1, P. Sabioni1, B. Sproule1. 1University of Toronto, Toronto, Canada
Objective: Benzodiazepines (BDZ) are addictive drugs widely prescribed
in psychiatric units as PRN (pro re nata) – “as needed” basis. More than
50% of the psychiatric inpatients have a history of substance use disorders
(SUD) therefore they are more vulnerable to the harms associated with the
exposure to addictive drugs. Objective: To determine the prevalence and
patterns of the use of BDZ following the prescription during a psychiatric
admission after one and three months from discharge.
Methods: Twenty-three adult inpatients non-regular users of BDZs ad-
mitted to the psychiatric unit at Sunnybrook Health Sciences Centre were
recruited. We collected demographic and clinical data; and data about
prescription and administration of PRN BDZ, including dosage, route, fre-
quency, indication, reasons for administration and prescription at dis-
charge. Patients were contacted by phone at one (n=19) and three
months (n=11) after discharge and were asked about the use of BDZ
since the discharge.
Results: The mean age of the participants was 40.4 years old. Most of
them were female (65.2%), single (65.2%), unemployed (56.2%) and had
a history of SUD (52.1%). Sixteen patients (60%) had at least one benzodia-
zepine prescribed and fourteen (48%) received at least one administration
of benzodiazepine. Lorazepam was the most frequently prescribed
(87.5%) and administered (87.3%). At one month follow-up, five patients
(26%) were using benzodiazepines and at three months follow-up, two
patients (18%) were still using the medication.
Conclusion: Considering that (1) the indications for long term use of
benzodiazepines are quite scarce; (2) these patients were not chronic
users at admission; and (3) chronic use of BDZs is associated with addic-
tion and its complications; the proportion of patients still using BDZ one
and three months after discharge is of concern.
Policy of full disclosure: Pamela Sabioni is supported by the Conselho
Nacional de Desenvolvimento Cientifico e Tecnologico – Brazil.
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P-01-008 The effects of behavioral drug and risk counseling on
methadone patients in Taiwan
C.-H. Chan1, C.-C. Hung2, S.-H. Li2, T. S.-H. Lee3, M. Chawarski4,
D. Metzger5. 1Taichung General Hospital, Taichung, Taiwan; 2Taichung
Veterans General Hospital, Taichung, Taiwan; 3National Taiwan Normal
University, Taipei, Taiwan; 4Yale School of Medicine, New Haven, USA;
5University of Pennsylvania, Philadelphia, USA
Objective: Few methadone maintenance treatment (MMT) programs in
Taiwan offer drug counseling to injecting drug users (IDUs). Behavior
and drug risk behavior reduction counseling (BDRC) provides a cognition
behavior therapy (CBT)-based approach to patents in MMT. We conduc-
ted a study to evaluate the BDRC add-on treatment in MMT patients in
Taiwan.
Methods: Patients were invited to attend the research program
while they first time visit methadone clinic. They signed consent forms
and voluntarily randomly assigned to either 12 sessions BDRC or treat-
ment as usual (TAU) programs. BDRC was performed weekly in the
first month, and every two weeks in the following two months, and
once a month in the following period. Two training nurses provided the
counseling. Both the two groups were assessed by individual interviewing
with Addiction Severity Index, Risk Assessment Battery and Quality of
life every three months. Urine morphine tests were done with counseling
in BDRC and with outpatient visits in TAU.
Results: From May 2012 to Aug 2013, there are 51 patients recruited
(BDRC n=27 and TAU n=24). Patients received average 6.3 sections of
counseling in the first three months. From preliminary analysis, there
are better treatment retention rates (BDRC 77.78% vs. TAU 66.67%) and
attendance rates of methadone treatment (BDRC 90.45% vs. 79.15%) in
BDRC groups after three months follow up. Both of the groups had
improved quality of life and lower drug-related risk behaviors after re-
ceiving methadone treatment. The positive morphine urine test rate was
obvious reduced in BDRC group (BDRC 28.60% vs. TAU 72.10%).
Conclusion: BDRC might reduce heroin use behaviors of patients in the
initial months of methadone treatment program and improve their reten-
tion rates. The effects need further confirmation with long-term follow up.
Policy of full disclosure: None.
P-01-009 Neurocognitive and individual drug use characteristics
for predicting in-treatment performance and relapse in
methamphetamine users
C.-K. Chen1, Y.-C. Chen1, L.-J. Wang1. 1Chang Gung Memorial Hospital,
Keelung, Taiwan
Objective: This study aims to examine the utility of neurocognitive and
individual drug use characteristics for predicting in-treatment perform-
ance and relapse in methamphetamine (METH) users.
Methods: METH abusers among individuals who were preparing to
participate in a 12-week weekly out-patient treatment program using a
psychosocial and behavioral model received neurocognitive measure-
ments including Conners’ Continuous Performance Tests, Wisconsin
Card Sorting Test, Iowa Gambling Task, and The Barratt impulsiveness
scale. After baseline assessments, the subjects started a12-week weekly
out-patient treatment program. The in-treatment performance variables
used in analyses include abstinence and completion.
Results: Thirty-four METH users were categorized into METH users
without psychosis (N=16) and METH users with past experience of
brief psychosis or perceptual disturbance (N=18). METH users with
past experience of psychosis had poorer performances in perseverative
responses, perseverative errors than those without psychosis experience.
Younger age of first METH use was associated with more omission
error, more perseverative errors, and high novelty-seeking. Higher
doses of METH use were associated with poor self-control. High CPT
confidence index and not-married status were significantly associated
with earlier relapse of METH use.
Conclusion: High impulsivity was significantly associated with earlier
onset of METH use, larger dose of METH use and earlier relapse of METH
use during socio-behavioral treatment. METH users with past experience
of psychosis or perceptual disturbance after use of METH have poorer
executive function than those without psychosis experience.
Policy of full disclosure: None.
P-01-010 Dopamine D4 receptors in the anterior cingulate cortex
appear to modulate reward expectancy on a rodent slot
machine task
P. Cocker1, J. Hosking1, C. Winstanley1. 1University of British Columbia,
Vancouver, Canada
Objective: Pathological gambling is a growing public health concern,
yet treatment options remain limited and of questionable efficacy. Slot
machines represent a particularly potent form of gambling, purportedly
due to the reinforcing effects of ‘near-misses’ (unsuccessful outcomes
that are proximal to a win). We have previously demonstrated that D4
receptors may underlie susceptibility to the reinforcing effects of putative
winning signals within non-winning trials. D4 receptors are predomi-
nantly located within frontal-cortical regions, and thus present an in-
triguing target for modulating higher-order cognitive processes. One
area that has a relatively high proportion of D4 receptors is the anterior
cingulate cortex (ACC); human imaging studies have shown robust acti-
vation of the ACC during slot machine play and evidence suggests a
role for the ACC in biasing choice towards a prepotent but sub-optimal
response. Taken together, this suggests that ACC activation may underlie
the ability of ‘near-misses’ to evoke reward expectancy in human
gamblers.
Methods: We have developed a rodent slot machine task wherein ani-
mals respond to three flashing lights that could be set to on or off. A win
was signaled if all three lights were set to on, whereas any other light pat-
tern indicated a loss. Rats then chose between responding on the collect
lever, which delivered 10 sugar pellets on win trials but a 10-second
time penalty on loss trials, or to start a new trial instead
Results: Inactivations of the ACC increase animals’ erroneous expecta-
tions of reward on non-winning trials. Additionally we have preliminary
evidence to suggest this effect may be driven by D4 receptors as local infu-
sions of a D4 agonist into the ACC produced similar impairments in
performance.
Conclusion: This data suggests that the D4 receptors within the ACC
may be critically involved in generating reward expectancy in response
to winning signals within non-winning outcomes on slot machines.
Policy of full disclosure: None.
P-01-011 Motor activity, anxiety, and learning in adolescent and
adult rats undergoing tobacco smoke withdrawal
J. B. de La Peña1, R. Tampus1, N. R. Jeong1, J. H. Kim1, I. J. de La Peña1,
G. Y. Yu2. 1Uimyung Research Institute, Seoul, Republic of Korea;
2Department of Chemistry, Sahmyook University, Seoul, Republic of Korea
Objective: Tobacco addiction is one of the most prevalent addictions
worldwide. It is a chronic, relapsing, and in most cases lifelong problem.
Individuals addicted to tobacco (cigarette) smoking experience with-
drawal symptoms upon smoking cessation. In the present study we
seek to evaluate the motor activity, anxiety, and learning of adolescent
and adult animals undergoing tobacco smoke withdrawal.
Methods: Adolescent (4–6 weeks) and adult (8 weeks onward), male,
Sprauge-Dawley rats were exposed to tobacco smoke through a standard
smoking machine (whole body exposure machine) for 7 or 14 days. After
tobacco smoke exposure, changes in motor activity (open-field test), anxi-
ety (elevated plus-maze test), and learning (passive-avoidance test) were
evaluated. Nicotine withdrawal-related behaviors were also assessed
(e.g. rearing, burrowing, grooming, scratching, etc.). These behavioral eva-
luations were conducted during the first, third, and seventh day after last
tobacco smoke exposure.
Results: The results showed that adolescent and adult rats repeatedly
exposed to tobacco smoke significantly exhibited nicotine withdrawal-
related behaviors, as compared to the control (no exposure) group.
Furthermore, these rats displayed increased locomotor activity in the
open-field test and anxiety-like behavior in the elevated-plus maze test.
However, no alterations in learning and memory were observed in the
passive-avoidance test.
Conclusion: These results suggest that individuals undergoing tobacco/
nicotine withdrawal may be hyperactive and anxious.
Policy of full disclosure: None.
P-01-012 The addictive potential of nicotine in tobacco
smoke-naïve or pre-exposed adolescent and adult rats
J. B. de La Peña1, H.M. Ahsan1, H. S. Lee1, H. Shim1, H. J. Kim1,
J. H. Cheong1. 1Uimyung Research Institute, Seoul, Republic of Korea
Objective: Chronic tobacco (cigarette) smoking starts young. Most adult
smokers started when they were teenagers. The main psychoactive and
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addictive component in tobacco is nicotine. Here, we investigated the
addictive potential of nicotine in tobacco smoke-naive or pre-exposed
adolescent and adult rats.
Methods: The rewarding and reinforcing effects of nicotine were eval-
uated in tobacco smoke-naive or pre-exposed adolescent (4–6 weeks)
and adult (8–10 weeks), male, Sprauge-Dawley rats. Two of the most
widely used and accepted animal models of addiction were employed;
the conditioned place preference (CPP) and self-administration (SA) tests.
Results: Consistent with previous reports, tobacco smoke-naïve ado-
lescent rats demonstrated enhanced nicotine CPP (0.2 mg/kg) and SA
(0.03 mg/kg/infusion) as compared to the naïve adult group. Rats pre-
exposed to tobacco smoke exhibited greater CPP for the initially unre-
warding high dose (0.06 mg/kg) of nicotine, especially appreciable in ado-
lescent rats. However, in the SA test, smoke pre-exposed adolescent and
adult rats demonstrated reduced/diminished nicotine (0.03 mg/kg) SA.
Conclusion: These results suggest that (1) adolescents are more vulner-
able to the addictive effects of nicotine or tobacco smoke, and (2) repeated
tobacco smoke exposure affects subsequent response to nicotine.
Policy of full disclosure: None.
P-01-013 Acute cocaine administration decreases advantageous
decision-making but does not affect impulsive action
as measured by a rodent gambling task
J.-M. Ferland1, M. Tremblay2, W. K. Adams2, C. A. Winstanley2.
1University of British Columbia, Vancouver, Canada; 2University of British
Columbia, Department of Psychology, Vancouver, Canada
Objective: Drug addiction is a behavioural disorder that poses a world-
wide health concern. Higher levels of impulsivity and maladaptive
decision-making are common traits found amongst substance abusers
and may play an integral role in commencement of drug use. Studies
using the Iowa Gambling Task (IGT), a validated measure of decision-
making, have found that substance-dependent individuals tend to choose
the least advantageous option (associated with less reward over the
course of the task) and are less likely to change their strategy following
losses compared to controls. However, the majority of studies in humans
and in related animal models have explored the effects of chronic cocaine
exposure. We therefore examined the effects of acute cocaine adminis-
tration on decision-making behaviour, in efforts to gain insight into beha-
vioural changes that follow initial drug use.
Methods:We trained 16 male Long-Evans rats on the Rodent Gambling
Task, a rodent analogue of the IGT designed to assay decision-making
and impulsive action. Following training, the animals were administered
saline, 5, 10, or 20mg/kg of cocaine via i.p. injection prior to engaging in
the task.
Results: We found that, compared to saline, the medium dose of co-
caine decreased choice of the most advantageous option and increased
choice of the least advantageous option. Similarly administration of the
high dose of cocaine decreased choice of the advantageous option but
also increased the number of omissions, a common effect of high doses
of psychostimulants in operant tasks. Interestingly, impulsive action as
measured by premature responses, or the inability to withhold respond-
ing in the task, was not affected by acute cocaine treatment.
Conclusion: These data indicate that singular administration of cocaine
may be enough to initiate changes in decision-making behaviour, provid-
ing a foundation to understand how these behaviours involved in addic-
tion begin and change following chronic cocaine exposure.
Policy of full disclosure: None.
P-01-014 Changes in [3 h]mpep binding to brain mglu5 receptors in
rats trained to self-administer cocaine and assigned to live
in different living conditions during abstinence
M. Frankowska1, L. Pomierny-Chamiolo2, J. Miszkiel1, B. Pomierny2,
L. Szumiec1, M. Filip2. 1Institute of Pharmacology PAS, Krakow, Poland;
2Faculty of Pharmacy, JU CM, Krakow, Poland
Objective: Several evidence suggests that the glutaminergic transmission
and mGlu5 receptors (mGluR5) play critical role in cocaine seeking and
relapse behaviors. As found in animals models, self-administration of co-
caine is reduced by mGluR5 antagonists while neither conditioned or
passive cocaine injections altered density of mGluR5 in rat brain regions.
Methods: The aim of study was to further uncover the role of mGluR5
in craving-related brain neuroadaptations in the cocaine addicted rats.
With using the titrated receptor antagonist [3H]MPEP, binding assays
were performed to evaluate mGluR5 densities in the neural circuitry of
rats trained to self-administer cocaine (0.5 mg/kg/inf., FR5) that were sub-
sequently assigned to live in either isolation conditions (HC), exposed to
experimental cage (EC), or to enriched environment (EE) during an absti-
nence, and a #yoked# procedure was used.
Results: EC resulted in a significant decrease (29%) in density of
mGluR5 in the prefrontal cortex (PFC) and an increase (26%) in the
nucleus accumbens (NAc) in rats previously self-administered cocaine.
A trend to decrease in mGluR5 density was detected in PFC (20%) in co-
caine #yoked# rats. Abstinence in EE in rats self-administered cocaine
evoked a significant decreased in the PFC (11%) and increase in the
NAc (20%) with no changes in cocaine #yoked# animals. In the brains
of rats withdrawn in HC we observed a significant reduction in density
of mGluR5 in the hippocampus of rats actively (24%) and passively
(19%) administered cocaine. Moreover, cocaine self-administration and
subsequent HC isolation produced decreases in mGluR5 density level in
the PFC (25%).
Conclusion: To conclude, differences in density of mGluR5 in several
brain structures depend on living condition during abstinence from co-
caine. mGluR5 may be a target to reduce drug craving, and presumably
incentive motivation. Supported by the grant no. 2011/03/D/NZ7/06295
by the NCN (Poland) and by the statutory activity of Institute of
Pharmacology PAS.
Policy of full disclosure: None.
P-01-015 Gaining insights from patients seeking treatment in drug
de addiction centre: A retrospective study of 2 years
R. Gupta1, M. Ghosh2, V. Kumar2, S. Rathee2. 1Department of Psychiatry,
Pt. Bhagwat Dayal Sharma Post, Rohtak, India; 2University of Health
Sciences, Rohtak, India
Objective: To study the socio-demographic and clinical profile of sub-
stance users attending the out-patient services of a de-addiction centre
attached to a tertiary level health set-up in north India on a yearly basis
for 2 consecutive years and thereby to understand the pattern as well as
trend of substance use in this part of the country.
Methods: This is a retrospective record analysis and the data pertains to
the period from 1st Jan 2012 to 31st December 2013.These years have been
chosen because these were the first 2 calendar years when full records
were maintained according to the semi-structured standardized proforma
as recommended by National Drug Dependence Treatment Centre. The
data was analysed using the SPSS.
Results: A total of 1598 patients (703 in 2012 and 895 in 2013) utilised
the services of the centre in the given period. The mean age was 36.18±
11.8 years (2012) and 36.24±11.3 years (2013). Majority were self-
employed males (98.7% in 2012 and 98.3% in 2013) and were married.
The most common substance used was alcohol showing an increasing
trend (59.7% to 63%) along with tobacco (41.4% to 45.4%), cannabis
(13.8% to 17.1%), sedative-hypnotics (1.7% to 4.8%), multiple substances
use (5.8% to 6.5%) and injection drug use (2.3% to 4.1%). There was
also a rise in adolescent substance users (3.6% to 4.8%).
Conclusion: Our observations point towards the rising trend of sub-
stance use disorder both in terms of prevalence and early age of onset.
This may be attributed to major socio- economic changes and towards
the ineffective regulatory control mechanisms. It is recommended that
analysis of case records in different types of set ups should be carried
out to understand the changing trend of the substance use problems
and gain insights to plan better and effective services.
Policy of full disclosure: None.
P-01-016 DRD4 and SLC6a4 are not associated with sustained
binge drinking in young adults
M. Sloan1, G. Contreras2, M.-P. Sylvestre2, E. Dugas2, R. Wellman3, J. O´
Loughlin2, N. Low4. 1McGill University, Department of Psychiatry,
Montreal, Canada; 2Université de Montréal, Montreal, Canada; 3University of
Massachusetts, Worcester, MA, USA; 4McGill University, Montreal, Canada
Objective: Binge drinking often persists from adolescence into adulthood
and is associated with numerous poor health outcomes. Twin studies have
shown that alcohol use disorder is highly heritable, although the genes
that contribute to binge drinking are not fully known. Several but not
all studies implicate DRD4 (dopamine receptor 4) and SLC6A4 (a sero-
tonin transporter gene). Our objective was to examine whether these
genes were associated with sustained binge drinking in a cohort of
young adults.
Methods: Data were drawn from the Nicotine Dependence in Teens
Study, a longitudinal study of a school-based cohort in Montreal. The ana-
lytic sample comprised 458 Caucasians who had given blood or saliva
samples for genotyping and had completed self-report questionnaires at
age 20 and 24 years that collected data on the frequency of binge drinking.
Participants who reported binge drinking at both ages were categorized as
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“sustainers” while those who reported binge drinking at age 20 but not at
age 24 were considered “stoppers”. Ordinal logistic regression was used
to study the associations between frequency of sustained binge drinking
(less than monthly, monthly, and weekly) and 4 and 7 tag SNPs in
DRD4 and SLC64A, respectively.
Results: One single nucleotide polymorphisms (SNP) in DRD4,
rs3758653, was associated with frequency of sustained binge drinking
(OR (95% CI)=0.65 (0.45–0.94)), but the association was no longer statisti-
cally significant after adjusting for multiple comparisons. None of the
SNPs in SLC6A4 were associated with frequency of sustained binge
drinking.
Conclusion: Our study differed from previous studies by examining
sustained binge drinking, which may be a more useful indicator of sever-
ity of alcohol misuse than binge drinking at a single time-point. However,
neither DRD4 nor SLC6A4 was associated with this outcome after correct-
ing for multiple testing. The use of genetic risk scores which examine
cumulative risk of multiple genetic variants rather than single candidate
genes may be more successful at predicting frequency of sustained
binge drinking.
Policy of full disclosure: None.
P-01-017 The genetics of binge drinking: A systematic review
M. Sloan1, J. Ejdelman2, N. Low1. 1McGill University, Department of
Psychiatry, Montreal, Canada; 2McGill University, Montreal, Canada
Objective: Binge drinking continues to be a problem in American youth
with a prevalence that is highest amongst adult males age 21–25 years
old. Binge drinking is associated with a number of negative outcomes in-
cluding cardiac disease, pancreatic cancer, and mortality. Although al-
cohol dependence has been shown to be highly heritable, studies
examining the genetic determinants of binge drinking have yet to be
reviewed systematically. Our objective was to perform as systematic re-
view to determine which genes have been linked to binge drinking.
Methods: An extensive keyword literature search was developed for
each database with the help of a librarian. MEDLINE, Embase, and
PsycINFO were searched from their inception until September 2013.
This search yielded 525 citations. Abstracts were assessed independently
and in duplicate. Genome-wide association studies, candidate gene stu-
dies, and linkage studies conducted in humans were included in the
review.
Results: Genetic studies have found that polymorphisms in ALDH1B,
ALDH2, DRD4, SLC6A4, CRHR1, and PER1 are associated with increased
binge drinking. These studies were generally limited by small sample
sizes and other methodological weaknesses.
Conclusion: Polymorphisms in genes associated with alcohol metab-
olism, novelty seeking, mood regulation, stress response, and circadian
rhythm regulation are associated with binge drinking. A consensus re-
garding the definition of binge drinking would improve the quality and
comparability across studies. Future studies should look for additional
genetic determinants and seek to further elucidate the molecular and
psychological mechanisms by which known polymorphisms confer
increased risk.
Policy of full disclosure: None.
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P-02-001 Effectiveness of long-term benzodiazepine use in the
treatment of anxiety disorders; a systematic review
M. Shinfuku1, T. Kikuchi2, T. Suzuki3, A. Endo3, M. Mimura3, H. Uchida3.
1Tokyo Medical Center, Tokyo, Meguro-Ku, Japan; 2Department of
Neuropsychiatry, Keio University, School of Medicine, Tokyo, Japan; 3Tokyo,
Japan
Objective: Although current experts consensus and clinical guidelines do
not endorse long-term use of benzodiazepines in the treatment of anxiety
disorders for fear of adverse consequences, many patients are routinely re-
ceiving those medications in the real world. The objective of this study
was to synthesize the evidence of effectiveness on long-term use of benzo-
diazepines in anxiety disorders.
Methods: A literature search was performed to identify randomized
controlled trials (RCT) that examined effectiveness of benzodiazepines
in patients with anxiety disorders for 13 or more weeks, using PubMed.
The search terms included “benzodiazepine” and “long-term”, “mainten-
ance”, or “prevention”. Cross-referencing was also performed.
Results: The literature search identified six studies. Two of them were
ordinary RCTs lasting 16 and 24 weeks, while the other four were follow-
up studies subsequent to RCTs lasting 6, 8, 8, and 36 months, respectively.
Comparators to benzodiazepines were placebo for 1 trial, paroxetine for 1
trial, buspirone for 1 trial, and imipramine and placebo for 2 trials, and 1
trial was a head-to-head comparison of katazolam and diazepam. In all
studies, benzodiazepines were found to be effective, which was main-
tained during the follow-up periods without any significant increase in
the dosage. In each study, adverse events were not generally so problem-
atic but inadequately recorded, and attrition rates in patients receiving
benzodiazepines (4–59%) were in general lower than those on placebo
(74–92%), paroxetine (11%), buspirone (28%), and imipramine (65–74%).
Conclusion: The literature search clearly underscores the inadequacy of
data, which warrants further investigations on this controversial but com-
mon and highly relevant clinical practice. As evidence to date is rather
scarce, careful and thorough risk assessment with benzodiazepine usage
is critically needed in light of a number of well-known side effects.
Policy of full disclosure: None.
P-02-003 Measurement of anxiety in young obese adult
P. Ashok1, J. Kharche1, A. R. Joshi1. 1Bharati Vidyapeeth Medical College,
Pune, India
Objective: Anxiety is easily assessed by Zung Self Rating Anxiety Scale
questionnaires as they are easy to understand by the participants. This
study was planned to assess anxiety using in young obese adults. Zung
Self Rating Anxiety Scale (SAS) of I year MBBS students & to correlate
Body Mass Index (BMI) with anxiety levels
Methods: 138 medical students were involved in the study (56 males
and 82 females). Without knowing the interpretation of the scoring sys-
tem, subjects were asked to fill the anxiety inventories in speculated
time using Zung Self Rating Anxiety Scale (SAS), a 20-item self-report as-
sessment device which included measures of state and trait anxiety.
Results: There was no statistical significance in the anxiety score of
overweight and normal weight group even though the mean levels
were higher in overweight group.
Conclusion: This study demonstrated no statistically significant differ-
ence in anxiety scores of overweight & normal weight young adults. Also
there is no statistically significant association between anxiety & BMI. This
type of study will help in detection of high anxiety students at an early
stage which will be helpful in implementation of preventive measures at
an early age. This will prevent harmful effects of stress on body functions
Policy of full disclosure: None.
P-02-004 Ssri and antipsychotic usage in rehabilitation setting
M.A. Çinar. TAF Rehabilitation Center, Ankara, Turkey
Objective: Rehabilitation setting includes patients with comorbid psychi-
atric disorders. Varieties of psychiatric symptoms are substantial during
the rehabilitation course. We aimed to examine the usage of SSRI and anti-
psychotic drug usage at liaison psychiatry department referrals in one
year.
Methods: Referrals to Consultation Liaison Department between
November 2011 and November 2012 were examined retrospectively.
Age, sex, marital status, referring clinic, major complaint, primary and
comorbid psychiatric diagnoses and given treatment data were collected
from the patient records.
Results: A total of 544 patients were admitted to the Consultation
Liaison Psychiatry Department. Seventy point eight percent (n=385) of
them were male, and 29.2% of them (n=159) were female. Patients were
42.5±20.9 years old (mean±SD). Anxiety (47.6%, n=246) was the most
often complaint among the patients. The three most common psychiatric
diagnoses were anxiety disorder (46.4%, n=246), depression (20.6%,
n=109), and post-traumatic stress disorder (12.1%, n=64). SSRI and anti-
psychotic drugs were prescribed for 59.6% (n=324), and 15.2% (n=83)
patients respectively.
Conclusion: High prevalence of comorbid psychiatric disorders among
rehabilitation setting inpatients leading extensive usage of psychopharma-
cologic treatment agents such as SSRI, and antipsychotic drugs. Potential
positive or negative effects of the psychopharmacologic treatments on re-
habilitation course need to be addressed.
Policy of full disclosure: None.
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P-02-005 Role of astrocytic network on hippocampal-dependent
functions
B. Guiard1, G. Quesseveur2, P. Ezan3, C. Giaume3, A. Gardier2. 1UMR
CNRS 5169, Toulouse, France; 2EA 3544, Lab. Neuropharmacologie,
Châtenay-Malabry, France; 3College de France, Paris, France
Objective: Astrocytes, classically considered as supportive cells for
neurons without a direct role in brain information processing, are emerg-
ing as relevant elements in brain physiology through their ability to regu-
late neuronal activity, synaptic transmission and plasticity. Recent
evidence demonstrates that astrocytes may regulate high brain functions
including emotional states. One of the main characteristics of astrocytes
is their high network connectivity underlied by connexin 30 and 43 pro-
teins. The aim of this study was to investigate the link between stress
and hippocampal connexins expression.
Methods: Mice were administered with corticosterone given either
alone for 8 weeks or in combination with the antidepressant fluoxetine
or an overexpression of BDNF in the hippocampus using a lentiviral ap-
proach. Consequences of these treatments on anxiety along with the hip-
pocampal expression of connexins were determined.
Results: CORT-administered mice displayed an anxious like-phenotype
compared to controls as reflected in the elevated plus maze by an attenu-
ated time spent in the open arms (3.7±1.6 vs. 11.6±5.3; p<0.05) and in the
novelty suppressed feeding paradigm (NSF) by an increased latency to
feed (305.8±50.8 vs. 41.7±9.8; p<0.001). These behavioral anomalies
were accompanied by an attenuation of the unphosphorylated Cx43/
Total Cx43 ratio (0.403±0.06 vs. 0.505±0.02; p<0.05). Fluoxetine but not
hippocampal BDNF overexpression, produced anxiolytic-like activity in
the NSF (102.8±18.8; p<0.01). However, both fluoxetine and BDNF over-
expression restored a normal ratio of unphosphorylated Cx43/Total Cx43
compared to CORT-mice administered with the vehicle alone (0.523±0.02,
p<0.05; 0.550±0.03, p<0.01; respectively).
Conclusion: These data raise the possibility that modifications of astro-
cytic network by acting directly on Cx43 may reverberate on hippocampal
dependent-functions. Experiments are in progress in order to determine
whether adult hippocampal neurogenesis is affected by pharmacological
or genetic manipulation of Cx43.
Policy of full disclosure: None.
P-02-006 Evidence for association between Brain-Derived
Neurotrophic Factor (BDNF) gene and panic disorder:
Novel haplotype analysis study
Y.-K. Kim1, S.-W. Han2, E. J. Han1. 1Korea University, Ansan City, Republic
of Korea; 2Soonchunhwang University, Seoul, Republic of Korea
Objective: Panic disorder(PD) is a common psychiatric disorders with a
complex etiology and several studies have suggested a genetic component
to PD. Brain-derived neurotrophic factor (BDNF) is the most abundant of
the neurotrophins in the brain, and is recognized as playing an important
role in the survival, differentiation and growth of neurons. Several lines
of research have suggested possible associations between the BDNF
gene and PD. In this study, we investigated the BDNF 196G/A (rs6265),
11757G/C (rs16917204), and 270C/T (rs56164415) SNPs for association
with PD. We also identified the genetic sequence associations with PD
via haplotype analysis.
Methods: The participants in this study were 136 PD patients and 263
healthy controls. Male and female subjects were analyzed separately. The
genotype and allele frequencies of the PD patients and controls were ana-
lyzed using #2 statistics. Frequencies and haplotype reconstructions were
calculated using the SNP analyzer 2.0.
Results: We found no significant statistical differences in the genotype
distributions or allele frequencies of the three tested polymorphisms be-
tween the PD and control groups. In addition, no differences were
found between PD patients and controls in either the male or female sub-
groups. However, we found that, the frequency of the GC haplotype was
significantly higher in PD patients than in the controls.
Conclusion: Our result is the first study to identify associations be-
tween two BDNF SNPs and PD in the Korean population by investigating
the related haplotypes. Further studies are needed to replicate the associa-
tions that we observed.
Policy of full disclosure: None.
P-02-007 Non-verbal memory abnormality of checking symptoms
with obsessive-compulsive disorder
M.-S. Koo1, H. S. Lee2, H. S. Suh3. 1Kwandong University, Gwangmyung,
Republic of Korea; 2Yonsei University, Seoul, Republic of Korea; 3Cha
University, Seoul, Republic of Korea
Objective: The purpose of this study is to examine the role of memory
dysfunction in obsessive-compulsive disorder (OCD). Especially we tested
the memory function of checking type of obsessive-compulsive disorder
compare to that of cleaning type and that of normal controls.
Methods: Subjects were 16 patients aged 18–45 years who met the diag-
nostic criteria of obsessive compulsive disorder and 8 normal controls.
Informed consent was done. 16 OCD patients was divided into two
groups, 8 #checking# type and 8 #cleaning# type patients by evaluation
of Yale-Brown Obsessive compulsive scale and Maudsley Obsessive
compulsive inventory. All patients were tested memory functions by
Rey-Osterrich comlex figure test (RCFT) for non-verbal memory function,
Hopkins verbal learning test (HVLT) for verbal memory function,
Wisconsin card sorting test (WCST) and evaluated depression and anxiety
by Beck Depression Inventory (BDI) and Taylor Anxiety scale.
Results: The Reyimmediate and Reydelayed memory test scores were
significantly lower (P<0.05) in checking types than in cleaning types
and normal controls(student t-test). There were no significant differences
of Reycopy test scores, and verbal memory test(HVLT) scores, BDI and
Taylor Anxiety scale scores in checking, cleaning type groups and normal
controls.
Conclusion: The non-verbal memory function of checking type OCD
patients were significantly decreased than other OCD patients and normal
controls. This non-verbal memory dysfunction is not related to depression
and anxiety. This results suggest that checking symptoms development of
OCD is related to non-verbal memory dysfunctions.
Policy of full disclosure: None.
P-02-008 Clinical characteristics of obsessive compulsive disorder
with schizophrenia
M.-S. Koo1, C. H. Kim2. 1Kwandong University, Gwangmyung, Republic of
Korea; 2Yonsei University, Seoul, Republic of Korea
Objective: We investigated the prevalence of obsessive compulsive dis-
order (OCD) among patients with schizophrenia. We also investigated
the differences in the psychotic symptoms and suicidality between
patients with schizophrenia who did or did not have OC symptoms.
Methods: Seventy-one subjects with the DSM-IV diagnosis of schizo-
phrenia were evaluated by the Structured Clinical Interview for DSM-IV
Axis I disorders, the Yale-Brown Obsessive-compulsive Scale and the
Positive and Negative Syndrome Scale.
Results: The OCD patients with schizophrenia were 20 (28.2%) among
71 subjects. The 20 subjects with OCD had significantly more severe nega-
tive and total psychotic symptoms evaluated with PANSS than subjects
without OCD. The schizophrenia with OCD had significant higher recent
suicidal attempt rate than the subjects without OCD.
Conclusion: The results of this study suggest the possibility that OCD
symptoms in schizophrenia may be related to negative symptoms and
the OC symptoms may be related to the impulsivity expressed as suicidal
attempts.
Policy of full disclosure: None.
P-03. Bipolar disorders A
P-03-001 Retrospective prediction of behavioral state by
hippocampal transcriptome of the mice showing
infradian rhythm
H. Hagihara1, T. Horikawa2, H. Nakamura1, H. Shoji1, Y. Kamitani2,
T. Miyakawa1. 1Fujita Health University, Toyoake, Japan; 2ATR Computation
Neuroscience Laboratories, Kyoto, Japan
Objective: Our mood changes over time, regardless of the amplitude and
the period; however, biological mechanism underlying such mood
changes remain unknown. We previously reported that αCaMKII hetero-
zygous knockout mice show periodic mood-change-like behavior. In the
mutants, locomotor activity level in their home cage gradually and greatly
changes over time with an approximate cycle length of 10–20 days, sug-
gesting that they may serve as an animal model showing mood cyclicity.
Methods: In the present study, to elucidate molecular basis of the per-
iodic mood-change-like behavior, we conducted a genome-wide gene ex-
pression analysis of the dentate gyrus (DG) in the hippocampus of 37
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mutant mice after longitudinal monitoring of their locomotor activity over
70 days.
Results: We revealed that locomotor activity of a mouse can be accu-
rately estimated by the gene expression levels. The retrospective predic-
tion was successful for the past 4 days, suggesting that gene expression
patterns in the DG may contain information about locomotor activity of
the past several days. The periodic change in locomotor activity was con-
comitant with changes in expression level of circadian clock genes and of
genes related to maturational status of certain types of cells in the DG.
Conclusion: These results demonstrate that the gene expression pat-
terns in the DG can be predictors of behavioral state of a mouse, and
that the expression of circadian clock genes and the reversible maturation
of cells in the DG might be involved in an infradian rhythm in the mutant
mice.
Policy of full disclosure: None.
P-03-002 Efficacy of olanzapine monotherapy in the treatment of
bipolar mania with mixed features as defined by DSM-5
H. Katagiri1, M. Tohen2, R. S. McIntyre3, S. Fujikoshi1, S. Kanba4. 1Eli Lilly
Japan K.K., Kobe, Japan; 2University of New Mexico, Health Sciences Center,
Department of Psychiatry, Health Sciences Center, Albuquerque, NM, USA;
3University of Toronto, Mood Disorders Psychopharmacology, University
Health Network, Toronto, ON, Canada; 4Kyushu University, Department of
Neuropsychiatry, Fukuoka, Japan
Objective: The objective of this analysis was to compare the efficacy of
olanzapine monotherapy in bipolar I patients having manic episodes
with or without mixed features, as newly defined in DSM-5.
Methods: Pooled data from 3 double-blind placebo-controlled olanza-
pine studies in patients with bipolar I disorder with manic episode were
analyzed (Total 447 patients; 228 olanzapine monotherapy, 219 placebo).
Patients were categorized for mixed features by the number of concurrent
depressive symptoms at baseline (0, 1, 2 [category A] and53[category B])
as determined by HAMD item score 51. Depressive symptoms corre-
sponded to the 6 HAMD items used in the DSM-5 definition of a manic
episode with mixed features: Depressed mood, work and activities, retar-
dation, somatic symptoms general, feelings of guilt, suicide. Efficacy was
evaluated by changes in YMRS total score from baseline to 3 weeks.
Results: Of the 447 patients, 322 patients (72.0%) were categorized in
mixed feature category A and 125 patients (28.0%) in mixed feature cate-
gory B. The mean baseline YMRS total scores were 28.1 in category A and
27.8 in category B. Least-squares mean change of YMRS total scores after
3 weeks (LOCF) in categories A and B (olanzapine vs. placebo [LS Mean
difference]) were −11.78 vs. −6.86 [−4.93] and −13.21 vs. −4.72 [−8.48],
respectively. Patients in the olanzapine-group experienced a statistically
significantly greater mean decrease in YMRS total score compared with
those in the placebo group for both categories (p<0.001). An interaction
between mixed features and treatment was seen in the YMRS change at
the significance level of 0.3 (p=0.175).
Conclusion: Olanzapine monotherapy was efficacious in the treatment
of bipolar I mania, in both mixed feature categories A & B. Greater efficacy
was seen in the mixed feature category B (patients with 53 depressive
symptoms at baseline).
Policy of full disclosure: The studies were funded by Eli Lilly and
Company and/or Eli Lilly Japan. Dr. Katagiri and Mr. Fujikoshi are
employees of Eli Lilly Japan. Dr. Tohen was an employee of Eli Lilly
and Company (1997–2008). He has served as consultant for Eli Lilly and
Company and has received honoraria from Eli Lilly and Company. His
spouse is a former employee of Eli Lilly (1998–2013). Dr. McIntyre has
received speaker/consultant fees from Eli Lilly. He sits on the advisory
board and receives research funding from Eli Lilly. Dr. Kanba has received
grant/research support from Eli Lilly Japan. He was a consultant for Eli
Lilly Japan and has also received honoraria from Eli Lilly Japan.
P-03-003 One-year rehospitalization rates in patients with
first-episode bipolar mania on lithium and valproate with
adjunctive atypical antipsychotics
W.-M. Bahk1, Y. S. Woo2, J.-H. Jeong3, K. H. Lee4, D.-I. Jon5, B.-H. Yoon6,
M.-D. Kim7, Y. J. Kwon8. 1Yeouido St. Mary’s Hospital, Seoul, Republic of
Korea; 2Seoul, Republic of Korea; 3Suwon, Republic of Korea; 4Gyeongju,
Republic of Korea; 5Anyang, Republic of Korea; 6Naju, Republic of Korea;
7Jeju, Republic of Korea; 8Chunan, Republic of Korea
Objective:We compared the 1-year rehospitalization rates of first-episode
bipolar manic patients who were discharged while being treated with lith-
ium or valproate in combination with an atypical antipsychotic.
Methods: We investigated the rehospitalization status of first-episode
bipolar manic patients who were discharged between January 1, 2003,
and December 31, 2010, while they were taking lithium or valproate in
combination with aripiprazole, olanzapine, quetiapine, or risperidone.
Rehospitalization rates during a 1-year period after discharge were com-
pared between the group receiving lithium plus an atypical antipsychotic
and the group receiving valproate plus an atypical antipsychotic using the
Kaplan#Meier method. A Cox regression model was used to analyze cov-
ariates hypothesized to affect time to rehospitalization.
Results: The rehospitalization rate was 17.3% during the 1-year follow-
up period. We found significant differences in the rehospitalization rates
of patients in the lithium (23.1%) and the valproate (13.3%) groups
using the Kaplan#Meier formula. According to Cox proportional hazards
regression analysis, higher Clinical Global Impression-Bipolar Version
Severity (CGI-BP-S) score at discharge (p=0.005) and lithium treatment
(p=0.055) contributed to the risk of rehospitalization.
Conclusion: Treatment with valproate and an atypical antipsychotic
can be more effective than treatment with lithium and an atypical antipsy-
chotic in preventing rehospitalization during the 1 year after hospitaliza-
tion due to a first manic episode in patients with bipolar I disorder.
Higher CGI-BP-S scores at discharge also negatively affected rehospitali-
zation rates.
Policy of full disclosure: None.
P-03-004 The current state of maintenance treatments for bipolar
patients: A focus on the transition from acute treatments
W.-M. Bahk1, H. R. Song2, Y. S. Woo2, H.-B. Lee2, S.-Y. Lee3, M.-D. Kim4,
K. H. Lee5, I. Sohn6, S. Chung7, Y. Jae8, B.-H. Yoon9. 1Yeouido St. Mary’s
Hospital, Seoul, Republic of Korea; 2Seoul, Republic of Korea; 3Iksan, Republic
of Korea; 4Jeju, Republic of Korea; 5Gyeongju, Republic of Korea; 6Uiwang,
Republic of Korea; 7Jeonju, Republic of Korea; 8Busan, Republic of Korea;
9Naju, Republic of Korea
Objective: We examined prescription patterns in maintenance treatment
for recovered bipolar patients and compared these with acute treatments.
Methods: This study entailed a nationwide review of medical records
of 14 Korean hospitals. From among adult patients with a diagnosis of
bipolar disorder, including types I, II, NOS, who had been treated for
acute episodes, the patients who met the criteria of clinical recovery
(Clinical Global Impression Bipolar Version [CGI-BP] score #2 for
6 months) were selected. We reviewed the demographic data, present con-
dition, and differences between prescription patterns at remission and
after a maintenance period of at least 6 months.
Results: A total of 340 patients were selected. During the maintenance
period, more than half of patients (192, 56.5%) took a MS+AP combi-
nation. Among MSs, valproate (149, 43.8%) was most prescribed, and lith-
ium (98, 28.8%) was second, but as patients moved into maintenance
treatment, lithium use decreased, and the use of lamotrigine (86, 25.3%)
increased. Preferred APs were quetiapine (125, 36.8%), aripiprazole (67,
19.7%), risperidone (48, 14.1%), and olanzapine (39, 11.5%). The use of
olanzapine in maintenance was greatly decreased compared with that
during acute treatment (67, 19.7%). Most patients did not take an AD,
but the proportion using an AD was increased during maintenance
(18.0 to 30.3%), and bupropion (28, 8.2%) was the preferred AD. Doses
were decreased in all drugs, but lamotrigine was maintained at a dose
of 133.2±68.5 mg/day.
Conclusion: This study shows that the most common prescription com-
bination for bipolar maintenance treatment was MS+AP, but the type of
MS and AP changed. Olanzapine and lithium were decreased, whereas
lamotrigine was increased. Finally, the doses of MSs and APs were gener-
ally decreased during the maintenance periods, with the exception of
lamotrigine.
Policy of full disclosure: None.
P-03-005 Changes of cortical excitability as markers of
antidepressant response in bipolar depression
F. Benedetti1, P. Canali1, G. Papa Sferrazza1, E. Smeraldi2, C. Colombo2.
1Instituto Scientifico, Univ. Ospedale San Raffaele, Dept of Clinical
Neurosciences, Milan, Italy; 2Milan, Italy
Objective: It is still unclear which biological changes are needed to re-
cover from a major depressive episode. Current perspectives focus on cor-
tical synaptic neuroplasticity. Measures of cortical responses evoked by
transcranial magnetic stimulation (TMS) have been correlated with synap-
tic strenght in rodents, and change with sleep homeostasic pressure in
humans. Using repeated total sleep deprivation (SD) as a model antide-
pressant treatment, we aimed at correlating recovery from depression
with these measures of synaptic potentiation.
Methods: We recorded electroencephalographic responses to TMS in
the prefrontal cortex of 21 bipolar depressed inpatients (BPD) treated
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with repeated SD combined with light therapy. We performed 7 TMS/
EEG sessions during one week, in the morning and in the evening, before
and after the first SD, after the first sleep recovery night, and at the end of
treatment. We calculated three measures of cortical excitability (slope of
the first evoked component, local and global mean field power.
Results: Twelve patients responded to treatment. Cortical excitability
progressively increased during the antidepressant treatment and as a
function of time awake. Higher values differentiated responders from
non responders both at baseline, during, and after treatment on all
measures.
Conclusion: Changes in measures of cortical excitability, which reflect
the build-up of synaptic strength during wake, parallel and predict anti-
depressant response to combined SD and light therapy. Data suggest
that promoting cortical plasticity in bipolar depression could be a major
effect of successful antidepressant treatments, and that patients not
responding could suffer a persistent impairment in their neuroplasticity
mechanisms.
Policy of full disclosure: None.
P-03-006 Is the association between mood disorders and alcohol
use disorders modified by social support? Results from a
large nationally, representative study (CCHS 1.2)
V. Bhat1, N. Low1. 1Montreal, Canada
Objective: There is a strong association between alcohol use disorders and
mood disorders (i.e., mania and depression), and the co-occurrence of
these disorders is associated with worse outcomes for both disorders.
This study aims to examine the twelve month prevalence of mood disor-
ders, co-occurrence with alcohol use disorders, and the role of social sup-
ports in the association between alcohol use disorders and mood
disorders
Methods: The 2002 Canadian Community Health Survey, Mental
Health and Well-Being Cycle 1.2 (CCHS 1.2) used the World Mental
Health Composite International Diagnostic Interview (WMH#CIDI), and
included mood and alcohol use disorders. Social support was measured
using the Medical Outcomes Social Support Survey which assesses tan-
gible, affective, emotional/informational and social interaction dimensions
of support. Chi-square and ANOVA tests were conducted to compare the
social support variables between the mood disorders. Logistic regression
models were conducted adjusting for the 4 different types of social sup-
ports to examine their role as potential moderators of the association be-
tween mood and alcohol use disorders.
Results: Subjects with mania have an earlier age of onset and
co-occurrence with alcohol use disorders. Mood disorders are strongly
associated with alcohol dependence, but not alcohol abuse. Only positive
social interaction support was statistically different among the mood dis-
orders, and it diminished the association between mood disorders and
co-occurrence with alcohol dependence.
Conclusion: Availability of positive social interactions could be a target
of intervention which diminishes the association between mood disorders
and alcohol dependence, and has the potential to reduce negative out-
comes of both disorders.
Policy of full disclosure: None.
P-03-007 Cognitive styles in bipolar disorder and unipolar
depression
V. Bhat1, J. Cohen1, A. Iskric1, G. Kraus1, N. Low1. 1Montreal, Canada
Objective: Specific cognitive styles could trigger a mood episode, or result
in worsening of existing mood symptoms, in the presence of stressful
events. Bipolar disorder is related to high levels of Behavioral
Activation System (BAS) sensitivity in situations with the potential for
high-reward and immediate gratification. However, both unipolar and bi-
polar depression are characterized by high levels of Behavioral Inhibition
System (BIS) sensitivity in response to potentially threatening events. To
date, this is the first study to compare the cognitive styles between
patients with bipolar disorder and unipolar depression.
Methods: 22 subjects with unipolar depression and 34 subjects with
bipolar disorder were recruited from a tertiary-care level specialty out-
patient mood disorders clinic. Two self-report questionnaires the
CSQ-SF, and the BIS/BAS Scales were employed. Diagnostic interviews
were administered to yield mood diagnoses, comorbid psychiatric diag-
noses and sociodemographic characteristics. Association between mood
diagnosis and specific cognitive styles was studied with multiple re-
gression models.
Results: Compared to bipolar subjects, unipolar subjects (1) tended to
respond and react with more negative affect and ‘inhibited’ behavior in
anticipation of potentially threatening events, in addition to (2) exhibiting
lower levels of self-worth. In contrast, bipolar subjects (3) showed more
‘fun-seeking’ behaviors compared to unipolar subjects, implying that
they have a stronger tendency to pursue pleasurable things (p<0.05).
Conclusion: Mood disorder subjects exhibit specific differences on cog-
nitive styles, specifically in the way they interpret and approach negative
and/or threatening events. Cognitive style abnormalities indicate specific
targets of therapy and their assessment may be helpful in individualizing
treatment.
Policy of full disclosure: None.
P-03-008 Efficacy and safety of treatment with lurasidone
adjunctive with lithium or valproate in bipolar I
depression: Results of two 6-week studies
J. Calabrese1, T. Suppes2, K. Sarma3, R. Silva3, J. Cucchiaro3, A. Pikalov3,
A. Loebel3. 1USA; 2Palo Alto, USA; 3Fort Lee, USA
Objective: To evaluate the efficacy and safety of lurasidone adjunctive
with lithium (Li) or valproate (VPA) in bipolar I depression.
Methods: Data were pooled from 2 studies in which patients
meeting DSM-IV-TR criteria for bipolar I depression received 6 weeks
of double-blind treatment with lurasidone 20–120mg/day (N=355) or
placebo (N=327), adjunctive with Li or VPA. The primary and key sec-
ondary efficacy measure were, respectively, the Montgomery Asberg
Depression Rating Scale (MADRS) and the Clinical Global Impression
Bipolar Severity of Illness (CGI-BP-S), analyzed by MMRM. Secondary
efficacy outcomes included the Quick Inventory of Depressive
Symptomology – Self Report (QIDS-SR16), Hamilton Anxiety Rating
Scale (HAM-A), and Quality of Life, Enjoyment and Satisfaction
Questionnaire (Q-LES-Q).
Results: At week 6 endpoint, treatment with lurasidone (vs. placebo)
was associated with improvement vs. placebo in the mean MADRS
(−14.4 vs. −11.9; p=0.003), CGI-BP-S (−1.7 vs. −1.3; p=0.001),
QIDS-SR16 (−7.4 vs. −5.7; p40.001), HAM-A score (−7.0 vs. −5.0;
p40.001 [LOCF]), and Q-LES-Q (+18.5 vs. +13.2; P<0.001). Responder
rates (MADRS reduction550%) were significantly higher with lurasidone
vs. placebo (48% vs. 37%; p=0.002; LOCF-endpoint). Minimal
LOCF-endpoint changes were observed for adjunctive lurasidone vs. pla-
cebo in mean weight (+0.1 vs. +0.2 kg), median total cholesterol (−4.0 vs.
−1.0 mg/dL), LDL (−3.0 vs. −1.0 mg/dL), triglycerides (+4.0 vs. −2.0 mg/
dL), and glucose (0.0 vs. 0.0 mg/dL). Discontinuation rates due to adverse
events were similar for lurasidone vs. placebo (5.8% vs. 4.8%); adverse
events (55% incidence) were nausea (13.9% vs. 10.2%), Parkinsonism
(12.8% vs. 8.1%), somnolence (11.4% vs. 5.1%), and akathisia (10.8% vs.
4.8%).
Conclusion: Results of this pooled analysis demonstrated that adjunc-
tive therapy with lurasidone and Li or VPA was effective in treatment
of patients with bipolar depression, with a low rate of discontinuation
due to adverse events and minimal effect on weight or metabolic
parameters.
Policy of full disclosure: Dr. Calabrese has provided consultant
services and/or received grant support and/or received payment for
lectures from AstraZeneca, Benecke, Biomedical Development Corp.,
Cephalon, Convergent Health Solutions, Cortex Congress, Elan, Eisai,
Forest Labs, GSK, Health & Wellness, Hoffman LaRoche, Lundbeck,
Medwiz Healthcare, Merck, Otsuka, Pfizer, Promedica Scientia, Spirant
Communications Private Limitrex, Sunovion, Takeda, and Teva.
Dr. Suppes has received funding, medications for clinical grants, consult-
ing fees and/or travel expenses from: Sunovion, Elan Pharma
International, H. Lundbeck A/S, NIMH, VA Cooperative Studies
Program, and Jones and Bartlett (formerly Compact Clinicals). Drs.
Sarma, Silva, Kroger, Cucchiaro, Pikalov, and Loebel are full-time
employees of Sunovion Pharmaceuticals Inc.
P-03-009 Insulin resistance: An occult, modifiable risk factor for
refractory bipolar disorder?
C. Calkin1, M. Ruzickova1, C. Slaney1, J. Garnham1, R. Uher1,
C. O’Donovan1, M. Alda1. 1Dalhousie University, Halifax, Canada
Objective: Rates of type II diabetes (T2D) are increased among patients
with bipolar disorder (BD). Insulin resistance (IR) typically precedes
T2D, but no previous study has explored the relationship between
laboratory-established IR and outcomes in BD. Studying IR is relevant
as it may be an occult, modifiable risk factor for treatment refractory
BD, yet there are no recommendations for testing for IR. This study exam-
ines the relationships between IR, T2D, and clinical course and treatment
response in BD. We hypothesize that patients with IR or T2D have a more
severe and treatment-refractory form of BD.
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Methods: We measured fasting plasma glucose and fasting serum
insulin in 121 adult patients with BD. We established the diagnosis of
T2D and determined IR according to the Homeostatic Model
Assessment-IR equation. The National Institute of Mental Health-Life
Chart Method was used to record clinical course of BD. The
Retrospective Criteria of Long-Term Treatment Response in BD scale
was used to establish response to prophylactic lithium treatment.
Results: Of 121 patients with BD, 21.5% had T2D and an additional
32.2% had IR. Bipolar patients with T2D or IR had three times higher
odds of a chronic course of BD compared to glucose tolerant bipolar
patients (50% vs. 27%; OR=3.07, p=0.007). Bipolar patients with T2D or
IR were more likely to be refractory to lithium treatment compared to
glucose tolerant bipolar patients (37% versus 3.2%, OR=8.40, p<0.0001).
All associations remained significant after controlling for antipsychotic
exposure in sensitivity analyses.
Conclusion: Insulin resistance and T2D are associated with chronic
course and poor response to prophylactic lithium treatment. Notably,
patients with IR had comparably poor outcomes to those with T2D.
Further studies are needed to explain the mechanism of this relationship
and establish whether management of IR and T2D may improve the
course of bipolar disorder and treatment response.
Policy of full disclosure: This study was funded by grants to Dr. Calkin
from the Brain and Behaviour Research Foundation (formerly the
National Alliance for Research on Schizophrenia and Depression, grant
number 1003065-NARSAD-CALKIN) and the Capital Health Research
Fund (grant number CDHA/RS-2002-061) and to Dr. Alda from the
Canadian Institute of Health Research (CIHR grant number 64410).
None of the authors have competing interests to declare.
Glucose metabolism and response to lithium:
P-03-010 Differential changes in metabolic profile of bipolar
patients following switching to aripiprazole
J. S. Chang1, T. H. Ha1, H. Y. Jung1, K. Ha1. 1Seoul National University,
Seongnam, Republic of Korea
Objective: High rate of metabolic derangement necessitate various
attempts to enhance the safety of the maintenance treatment of bipolar
disorders. This study aimed to investigate the changes in metabolic
profile in bipolar patients with antipsychotic-induced weight gain follow-
ing switching to aripiprazole.
Methods: Patients with DSM-IV bipolar I or II disorder who experi-
enced antipsychotic-induced weight gain were recruited. A total of 31
patients with 7% or more increase in weight due to prior antipsychotic
use were randomly assigned to continuation (n=15) or switching to aripi-
prazole (n=16) for 26 weeks.
Results: In terms of the change from baseline, significant differences in
both body weight and body mass index between the two groups were
detected at week 12 onward. A significant decrease in fasting glucose
was observed in the aripiprazole group at week 18 onward. While no
significant change in HDL cholesterol was found, a significant improve-
ment of LDL cholesterol was detected at week 12. In addition, a reduction
in triglyceride level was observed in the aripiprazole group at week 8
onward.
Conclusion: Switching aripiprazole from other antipsychotics may re-
verse weight gain associated with antipsychotic treatment in bipolar
patients. Long-term aripiprazole use did not appear to worsen abnormali-
ties in glucose metabolism in patients previously treated with
antipsychotics.
Policy of full disclosure: This study was supported by Grant A101915
from the Korea Healthcare Technology R&D Project, Ministry of Health &
Welfare, Republic of Korea and a research grant from Korea Otsuka
Pharmaceutical. The authors report no additional financial or other re-
lationship relevant to this study.
P-03-011 Mental disorders in offspring of parents with bipolar
disorders in Korea
Y.-S. Cho1, S.-H. Shim2, Y.-J. Kwon, H.-Y. Lee3. 1Soonchunhyang University,
Cheonan, Republic of Korea; 2Department of Psychiatry, College of Medicine,
Soonchunhyang University, Cheonan, Republic of Korea; 3Republic of Korea
Objective: There is limited information on the specificity of associations
between parental bipolar disorder and the risk of psychopathology in
their offspring. The chief aim of this study was to investigate the associ-
ation between bipolar disorders in the parents and mental disorders in
the offspring in Korea.
Methods: The sample consisted of 100 child and adolescent offspring
(aged 6.0–18.9 years; mean±S.D.=13.6±3.9 years) from 65 nuclear families
with at least one parent with BPD. Parents with BPD were recruited
through inpatient/outpatient clinics at department of Psychiatry,
Soonchunhyang University Hospital between January, 2012, and
December, 2013. Probands, offspring were interviewed by psychologists,
and the offsprings were diagnostically evaluated using the K-SADS-PL.
Results: 59 of the 100 participants met the DSM-IV criteria for at least
one psychiatric disorder, most commonly a mood disorder. Of these 59
children, 22 were diagnosed with BPD. 16 children received a diagnosis
of any depressive disorder. The remaining 21 received other Axis 1 diag-
noses, as follows: Four were diagnosed with ADHD, mostly combined
type; four with any anxiety disorder and two with DBD alone; one with
Tic disorder; one with an autistic disorder; and one with schizophrenia
plus anxiety disorder. 41 of the children and adolescents did not receive
any psychiatric diagnosis. Comorbidity with ADHD was present in 12
of the 38 children with mood disorders, including those with BPD; In
all 12 of these subjects, ADHD onset occurred at least one year before
the onset of mood disorders. The mean age at onset of mood symptoms
among the subjects with bipolar and major depressive disorder was
11.8±2.3 years.
Conclusion: Offspring of parents with BPD are at high risk for psychi-
atric disorders and specifically for early onset BP spectrum disorders.
These findings further support the familiality and validity of BPD in
youth and indicate the need for early identification and treatment.
Policy of full disclosure: None.
P-03-012 Effects of cytokines on brain serotonin transporter
in bipolar I disorder
Y.-H. Chou. Taipei Veterans General Hospital, Taipei, Taiwan
Objective: A growing body of studies has demonstrated the reciprocal
relationships between serotonin metabolism and immune-inflammatory
pathways in depression but lack of data in bipolar disorder (BD). The
aim of this study was to investigate the interaction of cytokines and
brain serotonin transporter (SERT) in BD.
Methods: Twenty-eight patients with euthymic BD and 28 age- and sex-
matched healthy controls (HCs) were recruited. Single photon emission
computed tomography with the radiotracer 123I-ADAM was used for
the SERT image. Specific uptake ratio, which represents the SERT avail-
ability, was the primary measured outcome. Regions of interest included
the midbrain, thalamus, putamien and caudate. Seven cytokines included
the pro-inflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha),
interferon-gamma (IFN-gamma), interleukin-1-alpha (IL-1-alpha),
IL-1-beta, IL-4, IL-6 and the anti-inflammatory cytokine, IL-10 were mea-
sured using an enzyme linked immune-sorbent assay.
Results: The SERT availability in the midbrain and caudate was signifi-
cant lower in BD than HCs. IL-1-beta was significant higher, whereas
IL-10 was significant lower in BD than those in HCs. Pearson’s correlation
showed that IL-1-alpha was significantly correlated with the SERT avail-
ability in the midbrain and caudate, TNF-alpha was significantly corre-
lated with the SERT availability in the thalamus in HCs. However,
these correlations cannot be found in BD. A stepwise regression model
that considered these cytokines showed similar results.
Conclusion: This study firstly demonstrates the effects of cytokines on
the SERT availability in different brain regions. Apparently, IL-1-alpha
plays an important role in regulating the SERT availability in HCs but
this relationship was disrupted in BD.
Policy of full disclosure: None.
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P-03-013 Clinical assessment of lurasidone benefit and risk in the
treatment of bipolar I depression using number needed to
treat, number needed to harm, and likelihood to be
helped or harmed
L. Citrome1, T. Ketter2, J. Cucchiaro3, A. Loebel3. 1New York Medical
College, Clinical Professor of Psychiatry & Behavioral Sciences, Suffern, USA;
2Stanford University, School of Medicine, Stanford, USA; 3Sunovion
Pharmaceuticals Inc., Fort Lee, USA
Objective: To assess the clinical utility of lurasidone for bipolar de-
pression, using number needed to treat (NNT, for benefits), number
needed to harm (NNH, for harms), and likelihood of being helped or
harmed (LHH, ratio of NNH to NNT, for trade-offs between benefits vs.
harms).
Methods: Data are from two 6-week placebo-controlled registration stu-
dies, one using lurasidone monotherapy at 20–60 or 80–120mg/d, and the
other using 20–120mg/d adjunctive to lithium or valproate.
Results: NNT vs. placebo for response (>=50% reduction on the
Montgomery Asberg Depression Rating Scale (MADRS) total score) was
5 for lurasidone monotherapy (both dose ranges) and 7 for adjunctive
therapy. NNT vs. placebo for remission (MADRS total score <=12) for
lurasidone monotherapy was 6 for 20–60mg/d and 7 for 80–120mg/d
and 7 for adjunctive lurasidone. NNH vs. placebo for discontinuation
due to an adverse event (AE) for lurasidone monotherapy was 642 for
20–60mg/d and -181 for 80–120mg/d, and for adjunctive lurasidone
was −54. Lurasidone was not associated with any clinically meaningful
weight/metabolic changes vs. placebo. The three most frequently occur-
ring AEs with the largest difference in incidence for lurasidone vs.
placebo were nausea, akathisia, and somnolence, with NNH values for
lurasidone vs. placebo ranging from 11 (nausea with lurasidone mono-
therapy 80–120 mg/d) to 130 (somnolence with lurasidone monotherapy
20–60mg/d). LHH was consistently >1 (indicating benefit being more
likely than harm) when contrasting response or remission versus AEs or
weight gain.
Conclusion: Lurasidone, compared to other treatments approved for bi-
polar depression, yielded comparable benefits (all had single-digit NNT
vs. placebo for response or remission), and less risk of harm (double-digit
or greater NNHs with lurasidone compared to single-digit NNHs for sed-
ation with quetiapine and for weight gain with olanzapine-fluoxetine
combination).
Policy of full disclosure: This study was supported by Sunovion
Pharmaceuticals Inc., Marlborough, MA and Fort Lee, NJ. In the past 36
months L. Citrome has engaged in collaborative research with, or received
consulting or speaking fees, from: Alexza, Alkermes, AstraZeneca,
Avanir, Bristol-Myers Squibb, Eli Lilly, Envivo, Forest, Genentech,
Janssen, Lundbeck, Merck, Mylan, Novartis, Noven, Otsuka, Pfizer,
Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, and Valeant. In
the past 36 months T. Ketter has engaged in collaborative research
with, or received consulting or speaking fees, from Abbott, Allergan,
AstraZeneca, Avanir, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest,
GlaxoSmithKline, Janssen, Otsuka, Pfizer, Sunovion, and Teva;
T. Ketter’s spouse is an employee of and holds stock in Janssen
Pharmaceuticals. J. Cucchiaro and A. Loebel are full-time employees of
Sunovion Pharmaceuticals.
P-03-014 Categorical improvements in severity of mania and
schizophrenia symptoms: Pooled analyses of cariprazine
phase II/III trials
S. Durgam1, I. Laszlovszky2, K. Nagy2, K. Lu3, S. Volk4, R. Litman5. 1Forest
Research Institute, Jersey City, USA; 2Budapest, Hungary; 3Jersey City, USA;
4Long Beach, USA; 5Rockville, USA
Objective: Cariprazine, a dopamine D3 and D2 receptor partial agonist
with preferential binding to D3 receptors, has demonstrated efficacy in
the treatment of both schizophrenia and bipolar I disorder in Phase
II/III clinical trials. In this analysis, the effect of cariprazine on overall dis-
ease severity in both patient populations was evaluated by measuring
clinically relevant shifts in CGI-S scores.
Methods: Data from 6 phase II/III, double-blind, placebo-controlled
trials in patients with schizophrenia or bipolar mania (6-week schizo-
phrenia trials: NCT00694707, NCT01104766, NCT01104779; 3-week bi-
polar mania trials: NCT00488618, NCT01058096, NCT01058668) were
analyzed; data were pooled separately for each disease and cariprazine
dose groups were combined (schizophrenia, 1.5–9mg/day; bipolar
mania, 3–12mg/day). The secondary efficacy parameter in all studies
was change from baseline in CGI-S. This analysis evaluated the pro-
portion of patients who improved from more severe CGI-S categories at
baseline to less severe categories at endpoint.
Results: In schizophrenia studies, a significantly greater proportion of
severely ill patients at baseline (CGI-S56, n=161) improved to mildly
ill or better (CGI-S43) in the cariprazine group vs. placebo (42% vs.
18%; odds ratio [OR]=3.43; P=0.004). In patients who were markedly ill
or worse at baseline (CGI-S55, n=1033), 7% of cariprazine vs. 3% of pla-
cebo patients improved to borderline ill/normal (CGI-S42) at Week
6 (OR=2.33; P=0.022). In bipolar mania studies, a greater percentage
of cariprazine vs. placebo patients shifted from markedly ill or worse
(n=1033) to borderline ill/normal (32% vs. 18%; OR=2.10; P<0.001). In
severely or extremely ill patients (n=97), 55% and 36% of cariprazine
and placebo patients, respectively, improved to mildly ill or better (OR
=2.12; P=0.09).
Conclusion: Cariprazine treatment compared with placebo resulted in a
significantly greater proportion of patients achieving clinically relevant
improvements in global disease severity as measured by CGI-S category
shifts in both patients with schizophrenia and patients with bipolar
mania.
Policy of full disclosure: Supported by funding from Forest
Laboratories, Inc. and Gedeon Richter Plc. Suresh Durgam is an employee
of Forest Research Institute.
P-03-015 Naturalistic study of efficacy of acute treatment with
lithium and valproate in the treatment of manic inpatients
E. Nieto1, L. Plans1, M. Gallardo1, A. Gomez1. 1Althaia Xarxa Assistencial,
Manresa, Spain
Objective: The aim of this study was to evaluate the efficacy of acute treat-
ment with lithium compared with valproate in manic inpatients.
Methods: This study included all patients with DSM-IV- diagnosed bi-
polar I disorder, current episode pure mania (N=234), who were admitted
to our Psychiatric inpatient Unit during the years 2009–2013 period.
Patients treated with lithium and valproate concomitantly (N=21) and
patients no treated with lithium or valproate (N=36) were excluded.
Patients were separated into 2 groups according to the medications
used: A- Lithium group: All treated with lithium and oral antipsychotics
(N=85) B- Valproate group: All treated with valproate and oral antipsy-
chotic (N=92). Outcome was measured using the scores in YMRS and
CGI-S scales and the length of stay (LOS).
Results: Baseline characteristics of patients were similar between
groups except that lithium -treated patients were significantly (P<0.001)
younger (mean of 37,8 years vs. 45), had significantly (P<0.05) more psy-
chotic symptom (86% vs. 36%), had significantly (P<0.02) more percent-
age of smokers (67% vs. 51%) and had significantly (P<0,003) higher
baseline score in CGI-s scale (Mean 0f 5,83 vs. 5.58). In the two groups,
all patients were also treated with oral antipsychotics (mainly with olan-
zapine or risperidone). No significant differences in the initial score in
YMRS and in the mean change in YMRS were found (YMRS of 29,8,
−25,3 in lithium group vs. 29,7 and −23,9 in valproate group). Mean
change in CGI from baseline to the day of discharge were significantly
(P<0.05) higher in lithium group (−2,84 vs. −2,6). The LOS was lower
in lithium group (Mean of 26,9 days vs. mean of 29,8) but the differences
were not significant (P<0.19).
Conclusion: Although it is used in more severe cases, treatment of
manic inpatients with lithium associated with antipsychotics is more effec-
tive than treatment with valproate associated with antipsychotics.
Policy of full disclosure: None.
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P-03-016 Naturalistic study of efficacy of acute treatment with
paliperidone palmitate as add-on therapy in the treatment
of manic inpatients
E. Nieto1, J. Carreras1, M. Rius1, M. Puig1. 1Althaia Xarxa Assistencial,
Manresa, Spain
Objective: The aim of this study was to evaluate the efficacy of two del-
toid injections of Paliperidone Palmitate (PP) (the first injection of 150mg
and, one week after, the second injection of 100mg) as add-on treatment
of manic inpatients.
Methods: This study included all patients with DSM-IV- diagnosed bi-
polar I disorder, current episode pure mania (N=55), who were admitted
to our Psychiatric inpatient Unit during the year 2013. Patients were sepa-
rated into 2 groups according to the medications used: A- PP Group:
Mood stabilizer and oral antipsychotic more two deltoid injections of
PP (N=12) B-Standard treatment (ST Group) : mood stabilizer and oral
antipsychotic (N=43). Outcome was measured using the scores in
YMRS and CGI-S scales and the length of stay (LOS).
Results: Baseline characteristics of patients were similar between
groups except that PP-treated patients were significantly (P<0.03)
younger (mean of 32,17 years vs. 42,79). In the group treated with PP,
all patients were also treated with oral antipsychotics (50% with paliper-
idone). No significant differences in the initial score in scales between
both groups were found (YMRS of 30,8 and CGI of 5,67 in PP group vs.
YMRS of 28,9 and CGI of 5,7 in ST group). Mean change in YMRS and
CGI from baseline to the day of discharge were similar in both groups
(−24,75 and −2,83 in PP group vs. −23 and −2,7 in ST Group). The
LOS was significantly lower (P<0.05) in PP group (Mean of 21,33 days
vs. mean of 27,35 days in ST group).
Conclusion: Add-on treatment with two deltoid injections of paliperi-
done palmitate (150mg and 100mg one week after) in manic inpatients
significantly reduces the length of stay. Multicenter studies with larger
samples are needed to verify our data.
Policy of full disclosure: None.
CGI,YMRS scores and LOS in PP and ST groups:
P-03-017 Inflammation associated with elevation of triglyceride in
subsequent remission of bipolar mania
S. Tsai1, K.-H. Chung1, S.-H. Huang1, P.-H. Chen1. 1Taipei Medical
University, Taipei, Taiwan
Objective: Racial difference in lipid metabolism is known. Low density
lipid levels have been reported in bipolar mania of Western population.
The alteration of circulating lipids throughout the bipolar manic episode
remains unclear in Asian patients.
Methods: The physically healthy patients with bipolar I, manic under
45 years of age along with their age-and gender- matched normal subjects
were enrolled. We measured the fasting blood levels of glucose, choles-
terol, triglyceride (TG), low density lipid (LDL), high density lipid
(HDL), and inflammatory parameters including soluble tumor necrosis
factor receptor (sTNF-R1) and soluble interleukin-2 receptor (sIL-2R) in
acute mania, subsequently partial and full remission.
Results: Twelve female and 21 male patients with mean 31.6 years old
and 33 matched normal subjects were recruited .The mean level of LDL in
acute mania (85.6±37.1 mg/dl) of bipolar patients was significantly lower
than that (105.2±23.2 mg/dl) of normal controls. The levels of TG in partial
(126.6±82.0 mg/dl) and full (121.6±88.2 mg/dl) remission were signifi-
cantly higher than that of normal controls (74.0±42.8 mg/dl). The elevated
TG in full remission had positive relationship with levels of sTNF-R1 and
sIL-2R.
Conclusion: Metabolism of lipid may vary across manic episode in bi-
polar disorder and differ from that in Western patients. Activation of
inflammatory response system may be associated with higher TG in
euthymic bipolar patients.
Policy of full disclosure: None.
P-04. Depression A
P-04-001 COMT gene polymorphism, plasma MHPG, and response
to duloxetine in Japanese MDD patients
K. Atake1, R. Yoshimura1, A. Katsuki2, H. Hori2, A. Sugita2, J. Nakamura2.
1UOEH, Japan, Kitkyushu, Japan; 2Kitkyushu, Japan
Objective: We recently reported that responders to duloxetine increased
plasma 3-methoxy-4- hydroxyphenylglycol (MHPG) in patients with
MDD (Atake et al., in press). The result suggests that duloxetine improves
depressive symptoms via enhancing noradrenergic neurons. In a multi-
center European study, an association was found between the COMT
gene Val158Met (G324A) functional polymorphism and major depressive
disorder (MDD). Therefore it is speculated that the amount of noradrena-
lin in the patients with Val/Val in less than those with Met-carriers. From
these findings into account, we hypothesized that the MDD patients with
Val/Val response better to duloxetine than those with Met-carriers. To
examine the hypothesis we investigated effects of duloxetine on plasma
concentration of catecholamine metabolites for each type of the COMT
gene polymorphism and response to duloxetine.
Methods: Sixty-four patients were enrolled in the study. Major depress-
ive episode was diagnosed by using the Structured Clinical Interview for
DSM-IV according to the DSM-IV-TR criteria. The severity of depression
was evaluated using the 17-item Hamilton Rating Scale for Depression
(HAMD-17). All patients were administered duloxetine for 8 weeks.
lasma MHPG was analyzed by HPLC-ECD. The genotyping of the
COMT gene polymorphism (rs4680) was conducted in the direct sequence
in the related region.
Results: 45 of 64 patients have completed the study. The distribution of
Val/Val, Val/Met, Met/Met were 19, 25, and 1, respectively. This was fit
with the Hardy-Weinberg Equilibrium. Treatment with duloxetine for
8 weeks significantly increased plasma MHPG levels (p=0.049) in Val/
Val group but did not change in Met-carrier group, however, the
COMT gene polymorphism (rs4680) and duloxetine response was not
associated.
Conclusion: The relationship among the COMT gene Val158Met,
plasma MHPG levels, and duloxetine response in patients with MDD
was complicated. In short, the response to duloxetine and plasma
MHPG might not be determined by only COMT activity.
Policy of full disclosure: None.
P-04-002 A novel anesthetical method of ECT using remifentanil,
rocuronium and sugammadex, in a patient with
depression and Brugada syndrome
Y. Fujita1, Y. Demoto2, K. Nakatsu1, T. Miyazaki1, K. Tahara1, A. Hiraoka1,
T. Sato1, G. Sato1. 1Kusatsu Hospital, Hiroshima, Japan; 2Hiroshima, Japan
Objective: Brugada syndrome (BS) is one of the most common causes of
sudden death in young people and many anesthetic and psychotrophic
drugs need to be avoided. Electroconvulsive therapy (ECT) induces sign-
ificant autonomic change, which could occur malignant arrhythmias.
Although propofol and suxamethonium were usually used with anesthe-
sia of ECT, these drugs are discouraged to avoid the vagotonic effects that
can precipitate ventricular fibrillation during anesthesia in patients with
BS.
Methods: We report the successful anesthetic management of a patient
with BS who underwent ECT to treat treatment-resistant depression.
Results: A patient was 49 years-old Japanese man. He received intra-
venous low dose of thiamylal sodium (effect-site concentration (Ce) was
10#g/ml) and high dose of remifentanil (Ce: 20 ng/ml). Thereafter, The
combination of rocuronium (0.8 mg/kg) and sugammadex (4mg/kg)
were used to induce and antagonize neuromuscular block. Total 10 ses-
sions of ECT were safely and effectively underwent through this anesthe-
tical method. Therefore, the depressive symptoms were improved and 17
items of Hamilton Depression Rating Score (HAM-D17) was decreased
from 27 to 8.
Conclusion: The ECT anesthetical method of adjuvant use of high-dose
remifentanil and the combination of rocuronium and sugammadex
may be useful in patients with BS, which could avoid vagotonic effects
and malignant arrhythmias.
Policy of full disclosure: None.
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P-04-003 Early treatment improvement in predicting later remission
in Asian patients with major depressive disorder treated
with mirtazapine
K. Funaki1, S. Nakajima2, T. Suzuki3, R. Kitahata3, M. Nagaoka3,
M. Mimura3, H. Uchida3. 1Sakuragaoka Memorial Hospital, Tokyo, Japan;
2Toronto, Canada; 3Tokyo, Japan
Objective: The objective of this analysis was to examine the usefulness
of an early treatment improvement (at weeks one and two) in predicting
later remission in Asian patients with major depressive disorder (MDD).
Methods: Data of 261 patients with MDD from a six-week double-blind
placebo-controlled randomized trial of mirtazapine in subjects with major
depression were used for this post-hoc analysis. We compared trajectories
of individual depressive symptoms over six weeks between remitters
and non-remitters. Early improvement and remission were defined with
a #20% and a #50% decrease in the Hamilton Rating Scale for
Depression (HAM-D) total scores, respectively, and reliability parameters
were obtained for an early improvement to predict later remission.
Moreover, which symptom improvement in the HAM-D at week 2 pre-
dicted remission was identified, using binary logistic regression analysis.
Results: Early improvement was a highly sensitive predictor of re-
mission; an improvement at week one was associated with sensitivity
of 0.742–0.897, specificity of 0.441–0.639, a positive predictable value of
0.548–0.648 and a negative predictable value of 0.652–0.857 in predicting
remission status at week six. The corresponding figures, defined by
an early improvement at week two, were 0.968–1.000, 0.364–0.471,
0.588–0.617 and 0.923–1.000, respectively.
Conclusion: While the data pertain to nonpsychotic MDD Asian
patients who received mirtazapine, early improvements in depressive
symptoms may serve as a predictor of subsequent remission.
Policy of full disclosure: None.
P-04-004 Effect of mirtazapine for benzodiazepines use compared
with selective serotonin reuptake inhibitors in patients
with major depressive disorder: A multicenter,
open-label, randomized, controlled trial
T. Hashimoto1, A. Shiina2, T. Hasegawa2, H. Kimura3, T. Niitsu1,
M. Tachibana4, K. Muneoka5, S. Matsuki1, M. Nakazato1, T. Shiraishi1,
M. Iyo1. 1Chiba University, Chiba, Japan; 2Chiba University, Kokoronokenko
Clinic Tsudanuma, Chiba, Japan; 3Chiba University, Kokoronokaze Clinic,
Chiba, Japan; 4Fujita Hospital, Chiba, Japan; 5Kimura Hospital, Chiba, Japan
Objective:We investigated the effect of mirtazapine for continuous use of
benzodiazepines, compared with selective serotonin reuptake inhibitors
(SSRIs), in treatment with major depressive disorder (MDD). In addition,
we identified serum brain-derived neurotrophic factor (BDNF), as biomar-
ker for the treatment response and differential diagnosis for bipolar
disorder.
Methods:We examined an open-label, randomized, and controlled trial
in out-patients with both MDD and current depressive episode from
10 sites in Japan. Subjects were randomly assigned to a 24-week adminis-
tration of mirtazapine or SSRIs (sertraline or paroxetine). A total of
76 patients with MDD were enrolled up to the date of 30th Aug 2013.
We defined the way of using benzodiazepines was on patient’s own
judgment, after our drug administration instruction during follow-up.
We performed at baseline and 1, 2, 6, 12, and 24 weeks to evaluate
clinical assessments, and measured serum BDNF at baseline and 6, 12,
24 weeks. The primary outcome was the rates of patients who used
benzodiazepines.
Results: 17 (68%) of 25 people in the mirtazapine group, 20 (65%) of 31
in the sertraline group, 10 (67%) of 15 in the paroxetine group had never
received any psychiatric care and any psychotropic medications before
this study enrollment. The rates of continuous using of benzodiazepines
in the mirtazapine group were significantly lower than other two groups
at 6, 12, 24 weeks (#2 test, p<0001).
Conclusion: Pharmacological treatment with mirtazapine for major
depression could reduce continuous use of benzodiazepines compared
with SSRI.
Policy of full disclosure: None.
P-04-005 Differentiated uses of antidepressant agents
Y. Hayashi. University of Kochi, Koshi, Japan
This study attempts to map different uses of new antidepressant agents
such as Selective serotonin reuptake inhibitors (SSRIs) and serotonin-
norepinephrine reuptake inhibitor (SNRIs). Based on cases where anti-
depressants worked effectively and that were published in casebooks in
Japan, the following distinguishing characteristics may be suggested:
Fluvoxamine (an SSRI) may be indicated for masked depression with
mainly physical complications and for treatment-resistant (refractory)
depression with mainly anxiety and physical symptoms, and paroxetine
(an SSRI) may be indicated for anxiety, irritation, palpitation, loss of mo-
tivation, sense of guilt caused by cerebrovascular disorders, and pain, all
of which may be comorbid. In addition, milnacipran (an SNRI) works for
inhibition (loss of motivation) and depressed mood (sadness and despair).
Furthermore, by adding other SSRIs, such as sertraline and mirtazapine,
this study attempts to map differentiated uses of new antidepressant
agents.
Policy of full disclosure: None.
P-04-006 Risk for bipolar disorder and physical comorbidity in
patients initially hospitalized with severe depression:
Results of a retrospective chart review
J.-I. Iga1, K. Nakamura1, N. Matsumoto1, T. Ohmori1. 1University of
Tokushima, Tokushima, Japan
Objective: Many cases of bipolar disorder (BD) present with depressive
episodes at onset. ICD-10 severe depressive episode (severe depression)
may be a risk factor for diagnostic conversion into BD and psychotic de-
pression (PD) has been consistently associated with BD. The aim of the
present study was to check the stability of the diagnosis of severe de-
pression within an inpatient setting, as well as to assess the differences be-
tween PD and non-psychotic severe depression (non-PD).
Methods: Patients who were hospitalized for severe depression both
with and without psychotic symptoms (N=89; mean age=55.6 years,
SD=13.9) from 2001 to 2010 were retrospectively assessed. Clinical vari-
ables were determined by using clinical records.
Results: By 75 months of follow-up, 11 patients (12.4% of the sample)
had developed one or more distinct period(s) of mania or hypomania
and their diagnosis was changed to BD. Of these 11 converters, 9
(81.8%) had developed BD within one year after admission. Only the pres-
ence of sub-threshold hypomanic symptoms during hospitalization was
significantly related to developing BD. 37.1% (33/89) of the patients
with severe depression were PD. Number of depressive episodes and his-
tory of physical diseases were significantly increased in non-PD compared
to PD, while electroconvulsive therapy (ECT) during hospitalization was
significantly increased in PD compared to non-PD.
Conclusion: Patients with severe depression were at a higher risk for
developing BD, especially within one year after admission. Sub-threshold
hypomanic symptoms during severe depressive episode may represent a
prodrome of formal BD, which suggests a close follow-up and cautious
use of antidepressants. In severe depression, non-PD may often occur sec-
ondary to physical diseases and experience more reccurrences than PD,
which, on the other hand, may be a more ‘primary’ disorder and often
need ECT for the treatment.
Policy of full disclosure: None.
P-04-007 Ketamine and non-ketamine NMDA receptor antagonists
for unipolar and bipolar depression: A meta-analysis
T. Kishimoto1, J. Chawla2, J. Kane2, C. Correll2. 1Keio University, Shinjuku,
Japan; 2The Zucker Hillside Hospital, Glen Oaks, USA
Objective: Recent studies demonstrated antidepressant efficacy of keta-
mine and non-ketamine N-methyl-D-aspartate receptor (NMDAR) antago-
nists, but the effect size trajectory and possible class effects are unclear.
Methods: We conducted a systematic review and meta-analysis of
NMDAR-antagonists for depression searching PubMed, PsycINFO, ISI
Web of Science, and clinicaltrials.gov from database inception until
November 2013 for parallel group or cross-over randomized trials com-
paring single intravenous infusion ketamine or NMDAR-antagonist ver-
sus placebo for major depressive disorder (MDD) and/or bipolar
depression (BD). Primary outcome was symptom improvement measured
by Hamilton Depression Rating Scale (HAM-D) or Montgomery-Asberg
Depression Rating Scale. Secondary outcomes included response, re-
mission, all cause discontinuation, and side effects, such as mania, psy-
chotic symptoms, dissociation and others.
Results: Nine trials (ketamine=6 studies, non-ketamine NMDAR-
antagonists=3 studies) with 331 participants (MDD=297, BD=34) were
meta-analyzed. Regarding symptom improvement, ketamine (n=163)
showed significant superiority over placebo 40 minutes after the infusion
of ketamine until day 4, peaking at day 2 (Hedge’s g on day 2: 1.015, 95%
CI: 0.610-1.419, p<0.001), loosing superiority by day 5–8. Conversely, non-
ketamine NMDA antagonists (n=168) showed superiority over placebo
only on days 5–8 (Hedge’s g: 0.422, 95%CI: 0.109-0.735, p=0.008).
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Response and remission were significant for ketamine from 40 minutes to
day 7 and 80 minutes to day 3–5; while for non-ketamine NMDAR-
antagonists only response was significant and only at day 3–5.
Although some adverse effects were more common with
NMDAR-antagonists than placebo, these were transient and clinically
insignificant.
Conclusion: Single infusion of ketamine, but less so of other, non-
ketamine NMDA antagonists, has ultra-rapid efficacy for MDD and BD,
but the effect does not last longer than a week. Development of rapidly
acting NMDAR-antagonists that can be given orally and repeatedly with-
out inducing brain toxicity is of key importance.
Policy of full disclosure: Dr. Kishimoto has received consultant fees
from Dainippon Sumitomo, Novartis, Otsuka and speaker’s honoraria
from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Mochida,
Novartis, Otsuka Pfizer and Shionogi. He has received grant support
from the Byoutaitaisyakenkyukai Fellowship (Fellowship of Astellas
Foundation of Research on Metabolic Disorders), Eli Lilly Fellowship
for Clinical Psychopharmacology, Research Group for Schizophrenia
Japan, Dainippon-Sumitomo, Mochida and Otsuka. Dr. Chawla has
nothing to disclose. Dr. Kane has been a consultant to Alkermes,
Amgen, Astra-Zeneca, Janssen, Pfizer, Eli Lilly, Bristol-Myers
Squibb, Dainippon Sumitomo/Sepracor/Sunovion, Johnson & Johnson,
Otsuka, Pierre Fabre. Vanda, Proteus, Takeda, Targacept, IntraCellular
Therapies, Merck, Lundbeck, Novartis, Roche, Rules Based Medicine,
Sunovion and has received honoraria for lectures from Otsuka, Eli Lilly,
Esai, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck and Janssen.
He is a shareholder of MedAvante. He has received grant support from
The National Institute of Mental Health. Dr. Correll has been a consultant
and/or advisor to or has received honoraria from: Actelion, Alexza;
American Academy of Child and Adolescent Psychiatry, Bristol-Myers
Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group,
IntraCellular Therapies, Lundbeck, Medavante, Medscape, Merck,
National Institute of Mental Health, Janssen/J&J, Otsuka, Pfizer,
ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received
grant support from BMS, Feinstein Institute for Medical Research,
Janssen/J&J, National Institute of Mental Health.
P-04-008 Gray matter volume in the thalamus is correlated
with rumination in patients with treatment-resistant
depression: A structural magnetic resonance
imaging study
A. Machino1, Y. Kunisato2, T. Matsumoto1, S. Yoshimura3, G. Okada1,
Y. Okamoto1, S. Yamawaki1, K. Ueda4. 1Hiroshima University, Hiroshima,
Japan; 2Sensyu University, Kawasaki, Japan; 3Otemon Gakuin University,
Ibaraki, Japan; 4The University of Tokyo, Tokyo, Japan
Objective: Magnetic resonance imaging (MRI) studies have previously
identified brain regions with gray matter (GM) abnormalities in patients
with treatment-resistant depression (TRD). However, it remains to be
assessed whether there are brain regions where GM volume is related to
rumination, a risk factor for TRD, in such patients.
Methods: We performed structural MRI scans and voxel-based
morphometry (VBM) to identify GM volume related to rumination in 29
TRD patients. Response Style Questionnaire was used to assess the
degrees of rumination in TRD patients.
Results: Whole brain analysis revealed that rumination correlated to
GM volume in the right thalamus in TRD patients. Limitations: Healthy
control was not included in this study.
Conclusion: We identified, for the first time, brain regions where GM
volume correlated to rumination in TRD patients. These results improve
our understanding for the anatomical characteristics of TRD.
Policy of full disclosure: None.
P-04-009 Depression-like behaviors were induced by
overexpression of Shati/Nat8 l, an N-acetyltransferase,
in the striatum of mice
Y. Miyamoto1, N. Iegaki1, K. Sumi1, Y. Ishikawa1, T. Furuta1,
Y. Furukawa-Hibi2, S.-I. Muramatsu3, T. Nabeshima4, K. Uno1,
A. Nitta1. 1University of Toyama, Toyama, Japan; 2Nagoya University,
Nagoya, Japan; 3Jichi Medical University, Shimotsuke, Japan; 4Meijo
University, Nagoya, Japan
Objective: We previously identified an N-acetyltransferase Shati/Nat8 l
from the brain of psychosis animal model. Shati/Nat8 l synthesizes
N-acetylaspartate (NAA) from aspartate and acetyl-CoA, and then its
NAA is converted into N-acetylaspartylglutamate (NAAG) by condensing
with glutamate. Several postmortem brain studies are suggested that
NAA and NAAG in human brain related to psychiatric disorders
including major depressive disorder. In the present study, to clarify the
functional roles of Shati/Nat8 l, we carried out various behavioral and bio-
chemical analyses in Shati/Nat8 l gene-manipulated mice.
Methods: C57BL/6J mice were bilaterally injected adeno-associated
virus (AAV)-Shati/Nat8 l or AAV-Mock vector in the dorsal striatum.
Results: In general Shati/Nat8 l transgenic mice, the expression levels of
Shati/Nat8 l mRNAwere significantly increased in the striatum, but not in
the prefrontal cortex and hippocampus. Shati/Nat8 l transgenic mice
exhibited decreased approach time to the stranger mouse in the three
chamber social interaction test. Alternatively, the expression levels of
Shati/Nat8 l mRNA in AAV-Shati/Nat8 l mice were assessed at about
seven times in the dorsal striatum compared with that in AAV-Mock
mice. As the same to Shati/Nat8 l transgenic mice, AAV-Shati/Nat8 l
mice exhibited decreased sociability in the three chamber social interac-
tion test. In addition, AAV-Shati/Nat8 l mice revealed increased immo-
bility time in both the tail suspension and forced swimming tests. These
three behavioral impairments in AAV-Shati/Nat8 l mice were recovered
by treatment with a selective serotonin reuptake inhibitor fluvoxamine
(10mg/kg, i.p.), which has no effect in AAV-Mock mice. Furthermore,
in vivo brain microdialysis, the basal levels of extracellular serotonin in
the dorsal striatum of AAV-Shati/Nat8 l mice were significantly lower
than that of AAV-Mock mice.
Conclusion: These findings suggest that overexpression of Shati/Nat8 l
in the striatum induces depression-like behaviors including diminished
sociability and motivation via malfunction of the serotonergic neuronal
system.
Policy of full disclosure: None.
P-04-010 The mRNA expressions of the nicotinic acetylcholine
receptor genes in rat brains after a 21-day sertraline
treatment
S. Ochi1, M. Abe1, T. Kitano1, Y. Otsuka1, Y. Mori1, T. Ishimaru1,
Y. Yoshino1, S.-I. Ueno1. 1Ehime University, Toon, Ehime, Japan
Objective: Most antidepressants, including serotonin selective reuptake
inhibitors (SSRIs), work as modulators of monoamines. Nicotinic acetyl-
choline receptor (nAChR) modulation is also reported to be involved in
the effects of antidepressants. For example, cytisine, an a4b2 nAChR par-
tial agonist, and varenicline, an a7 nAChR agonist, are reported to have a
potential antidepressive effects. However, it has not been sufficiently
examined whether antidepressants work via nAChRs. In the present
study, we investigated the effects of sertraline, an SSRI, on nAChRs in
rat brains.
Methods: Eight male Wistar rats (5 weeks old) were treated for 21 days
with sertraline (15 mg/kg/day), using osmotic pumps. Controls (n=8, 5
weeks old) were not given sertraline, but otherwise were treated the
same as the sertraline group After 21 days, rats were sacrificed by decapi-
tation and the brain tissues of nine regions (olfactory bulb, frontal cortex,
temporal cortex, striatum, thalamus, hippocampus, midbrain, pons, and
cerebellum) were dissected. RNA was extracted from each brain tissue
and reversely transcribed. The mRNA expressions of the nAchR genes
were examined by real-time quantitative PCR with TaqMan primer-probe
sets: a3 (Chrna3), a4 (Chrna4), a7 (Chrna7), and b2 (Chrnb2) with
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) as an endogenous
control.
Results: The mRNA expression of Chrna3 in the midbrain and that of
Chrnb2 in the frontal cortex, the thalamus, and the cerebellum were sign-
ificantly increased in the sertraline group. The expression of Chrna4 and
Chrna7 were not different between groups.
Conclusion: In conclusion, sertraline may modulate some nicotinic acet-
ylcholinergic systems directly or indirectly. Further studies should be con-
ducted to clarify that mechanism.
Policy of full disclosure: None.
P-04-011 Chronic mild stress and antidepressant treatment alter
5-ht1a receptor DNA methylation of a conserved sp4 site
P. Albert1, B. Le Francois1, J. Soo1, A. Millar1, A.M. Leguisquet2,
S. Leman2, F. Minier2, C. Belzung2. 1University of Ottawa, Ottawa,
Canada; 2Inserm U 930, Université François Rabelais, Tours, France
Objective: The serotonin 1A receptor (5-HT1A), a critical regulator of the
brain serotonergic tone, is implicated in major depressive disorder (MDD)
and has been found to be dys-regulated in depressive individuals.
However, the extent to which stress and antidepressant treatment can af-
fect 5-HT1A methylation remains unclear. In the present study, we
addressed the effects of unpredictable chronic mild stress (UCMS), a
mouse model of adult depression responsive to chronic antidepressants,
on 5-HT1A promoter methylation.
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Methods: BALB/c mice were subjected to the UCMS paradigm for
2 weeks, followed by treatment or not with 10mg/kg imipramine for
7 weeks. Genomic DNA was isolated from prefrontal cortex (PFC) or
raphe-midbrain, digested and analyzed for methylation of the 5-HT1A
promoter using bisulfite modification procedure.
Results: In PFC and midbrain tissue, UCMS increased DNA methyla-
tion of a conserved promoter CpG site, Site 1 located within an Sp1-like
element. Chronic imipramine treatment reversed UCMS-induced increase
in methylation of Site 1 in the PFC but not significantly in raphe of
stressed animals. We show that site 1 is repressed by Sp4, the predomi-
nant neuronal Sp1-like factor, and that Sp4-induced repression is attenu-
ated by DNA methylation of Site 1, providing evidence of a novel
Sp4-dependent mechanism to link DNA methylation to enhanced gene
expression.
Conclusion: These results indicate that adult life stress may induce
5-HT1A receptor expression by antagonizing Sp4 repression at the con-
served promoter site. Chronic imipramine treatment is only partially
able to reverse the stress-induced molecular changes in 5-HT1A methyla-
tion, suggesting that the efficient reversal of the behavioural impairment
recruits alternative pathways, which fail to normalize the behavioral
vulnerability.
Policy of full disclosure: None.
P-04-012 Vortioxetine: Exploratory analysis of the relation between
target engagement and integrated clinical database
analysis of MADRS single items
J. Areberg1, A. Mahableshwarkar2, C. Sánchez3. 1H. Lundbeck A/S, Valby,
Denmark; 2Takeda Development Center, Deerfield, USA; 3H. Lundbeck A/S,
Lundbeck Research USA, Paramus, USA
Objective: Vortioxetine is a multimodal antidepressant with 5-HT3,
5-HT7 and 5-HT1D receptor antagonism, 5-HT1B receptor partial agon-
ism, 5-HT1A receptor agonism and inhibition of the 5-HT transporter
(SERT). Lack of clinically validated binding ligands for targets (except
SERT) led us to develop preclinical assays relating # dose with target en-
gagement # clinically and pre-clinically determined target occupancies
with antidepressant response measured by analysis of single
Montgomery-Asberg Depression Rating Scale (MADRS) items.
Methods: Occupancies for all targets were measured in rat brain by ex
vivo autoradiography. SERT binding in the human brain was measured
using the PET-ligands [11C]-MADAM and [11C]-DASB (1). Clinical
efficacy data for single MADRS items for multiple doses of vortioxetine
5, 10 and 20mg were obtained from an integrated clinical database of
9 short-term major depression studies.
Results: The human PET studies demonstrated increased SERT occu-
pancy with increasing dose. At the clinically efficacious dose of 5 mg,
SERT inhibition was about 50%, indicating involvement of 5-HT receptors,
since SSRI efficacy requires approximately 80% SERT inhibition (2). For
5mg, preclinical data predicted that SERT and 5-HT3 receptors were pri-
marily occupied, while at 20mg all targets were predicted to be occupied
at functionally relevant levels. Data from the integrated clinical database
illustrated a clear dose-response relationship for 9 of the 10 MADRS items.
Conclusion: The present study suggests not only a quantitative but
also a qualitative increase in target engagement over the clinical dose
range, i.e., mainly 5-HT3 receptors and SERT are occupied at 5 mg, with
functionally relevant occupancy at all targets at 20mg vortioxetine.
We hypothesize that the relation between clinical efficacy and dose can
be ascribed to this gradually increasing target engagement. 1. Areberg
et al. Basic Clin Pharmacol Toxicol 2012; 110:401–404 2. Meyer.
J Psychiatry Neurosci 2007; 32:86–102
Policy of full disclosure: All authors are employed by Lundbeck or
Takeda, the sponsors of the studies included.
P-04-013 Clinical experience treating depressive disorders among
cancer patients using Fluoxetine 20mg
A. Bandati1, A. Milshtein1. 1Chisinau, Republic of Moldova
Objective: Cancer patients may request the assistance of the psychiatrists
and psychotherapists, but they do it very seldom, because that is their suf-
fering at the forefront and to have an “on mood”. A study was designed to
assess the effectiveness of 20mg fluoxetine monotherapy and in combi-
nation with psychotherapy.
Methods: 27 patients with cancer of the urinary system in the conserva-
tive rehabilitation outpatient clinic of Oncology Institute, Moldova were
treated. Of 27 cancer patients, 10 patients were randomized to a
fluoxetine-monotherapy treatment group (FT), 10 patients to a fluoxetine
prescibing combined with psychotherapeutic intervention treatment
group (FPT) and 7 patients to a psychotherapeutic treatment group
(PT). The Montgomery and Asberg Depression Scale (MADRS), the
Hamilton Anxiety Scale (HAS), the Hamilton Depression Scale (HDS),
the Hospital Anxiety and Depression Scale (HADS), were used to assess
the efficacy of fluoxetine.
Results: The response rate, defined by a HADS score lower than 8 after
4 weeks of treatment, was not significantly higher in the FT group (10%)
compared to the PT group (8%), but lower than in the FPT group (13%).
Compared to the PT group, patients in the FT and FTP groups showed
a significantly greater decrease in HADS mean score after 4 weeks. No dif-
ference between the three groups was found in observer-reported assess-
ments (MADRS, HAS and HDS). Although the frequencies of side-effects
of prescribed Fluoxetine 20 mg were not significantly different.
Conclusion: Use monotherapy Fluoxetine20 mg justified out the most
acute affective reactions as a maintenance therapy. The most effective
use of combination therapy (Fluoxetine+psychotherapy session).
Obtained results provoking another aspect, namely, with each of the
patients was conducted long solo work more professionals (psychiatrist,
psychotherapist, nurses).
Policy of full disclosure: None.
P-04-014 Deficient suppression of the default mode network
during working memory engagement in remitted major
depression
L. Bartova1, B. Meyer2, K. Diers3, U. Rabl2, A. Popovic2, K. Kalcher4,
R. Boubela4, S. Kasper2, N. Praschak-Rieder2, E. Moser4, L. Pezawas2.
1Medical University of Vienna, Vienna, Austria; 2Medical University of
Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria;
3Dresden University of Technology, Department of Psychology, Dresden,
Germany; 4Medical University of Vienna, MR Centre of Excellence, Vienna,
Austria
Objective: Proper working memory (WM) processing requires activation
of the WM network (WMN) going along with suppression of the default
mode network (DMN) activation that occurs physiologically during rest.
While lacking suppression of the DMN has been recently observed in
symptomatic Major Depressive Disorder (MDD), studies dedicated to re-
mitted MDD (rMDD), a condition associated with increased relapse rates
specifically in adolescent-onset, are sparse and largely inconclusive.
Methods: We conducted a cross-sectional functional magnetic reson-
ance imaging (fMRI) study in a large sample of long-term remitted, drug-
free MDD patients with adolescent- (n=42) and adult (n=36) onset as well
as healthy subjects (n=42) without any previous psychiatric life-time diag-
nosis. The classical digit variant of the n-back task was employed in order
to investigate the WM function and its neurobiological correlates on a re-
gional and a brain systems level.
Results: Relative to healthy subjects, significantly reduced suppression
of the DMN with punctum maximum in the anterior cingulate cortex
(ACC) was found in rMDD patients (pcorrected<0.01). Insufficient
DMN suppression in rMDD patients was further reflected on a brain sys-
tems level by a significantly increased coupling between the ACC and the
dorsolateral prefrontal cortex (pcorrected<0.01). Importantly, these re-
gional as well as brain systems measures revealed significant differences
between adolescent-onset rMDD patients and healthy subjects.
Adult-onset rMDD patients exhibited less pronounced and non-
significant effects, which were, however, located between the remaining
subgroups.
Conclusion: Incomplete DMN suppression seems to be present in MDD
patients even after full recovery and discontinuation of antidepressant
maintenance treatment. Furthermore, the present study is in line with
clinical evidence that clearly links adolescent-onset with a more severe
disease course, and encourages the investigation of DMN suppression
as a putative predictor of relapse, which may further support implications
for antidepressant maintenance therapy.
Policy of full disclosure: None.
P-04-015 Does coping moderate the association between mood
disorders and alcohol dependence? Results from the
CCHS study
V. Bhat1, N. Low1. 1Montreal, Canada
Objective: Individuals with mood disorders and alcohol use disorders
have a high prevalence of maladaptive coping behaviours compared to
individuals without these disorders. This study aims to compare coping
behaviours between individuals with mania and depression, and examine
their role in modifying the association between mood disorders and al-
cohol dependence and abuse disorders.
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Methods: This study is based on the 2002 Canadian Community Health
Survey, Mental Health and Well-Being Cycle 1.2 (CCHS 1.2). The CCHS
used the World Mental Health Composite International Diagnostic
Interview (WMH-CIDI), and included mood and alcohol use disorders.
The coping behaviours were based on validated questionnaires and
grouped into three factors. Chi-square and ANOVA tests were used to
compare coping behaviours between depression and mania. Logistic
regression models were used with alcohol use disorders as outcomes,
and mood disorders as main effects. The model was then adjusted for
the coping behaviours to examine their role as moderators of the associ-
ation. Statistical significance was at p<0.05 or Odds ratios with 95% CIs.
Results: Mood disorders were strongly associated with alcohol depen-
dence, but not alcohol abuse. The coping behaviours of ‘eating often’,
‘blaming self often’, ‘rarely talking to others’, and ‘smoking often’ were
significantly more common in individuals with mania as compared to
depression, and these variables significantly increase the association
between mania and co-occurrence with alcohol dependence.
Conclusion: Coping may be a target of behavioural intervention in
subjects with mania, and promotion of positive coping behaviours may
diminish negative outcomes of both mania and alcohol dependence.
Policy of full disclosure: None.
P-04-016 Attachment styles in bipolar disorder and unipolar
depression
V. Bhat1, Y. Q. Huang1, E. Yung1, G. Kraus1, A. Iskric1, N. Low1. 1Montreal,
Canada
Objective: Maladaptive attachment styles have been previously asso-
ciated with several well-established depression vulnerability factors. The
attachment patterns can be categorized into four types: secure, anxious,
preoccupied and dismissive. This study aimed to compare attachment
styles between mood disorders by examining differences between patients
with unipolar depression versus bipolar disorder on measures of attach-
ment style.
Methods: Data on attachment patterns were collected by administrating
two self-report questionnaires (RQ-CV and ECRQ-R) to individuals diag-
nosed with unipolar depression and bipolar disorder from the Mood
Disorders Program of the McGill University Health Centre. Structured di-
agnostic interviews were conducted by a trained interviewer to obtain
participants’ psychiatric status and their sociodemographic information.
Responses to the close-relationship questionnaires were examined using
linear regression models.
Results: The study included 101 subjects 39 of whom had unipolar de-
pression, 62 had bipolar disorder and there were no demographic differ-
ences between the two groups. In comparison to patients with bipolar
disorder, individuals with unipolar depression reported an attachment
pattern associated with significantly higher level of fear in relationships
(p=0.03) and avoidance in adult romantic relationships (p=0.01).
Conclusion: The study included 101 subjects 39 of whom had unipolar
depression, 62 had bipolar disorder and there were no demographic dif-
ferences between the two groups. In comparison to patients with bipolar
disorder, individuals with unipolar depression reported an attachment
pattern associated with significantly higher level of fear in relationships
(p=0.03) and avoidance in adult romantic relationships (p=0.01).
Policy of full disclosure: None.
P-04-017 Role of central and peripheral monoamine metabolism in
obesity induced neuropsychiatric behavioural changes
M. Bishnoi1, D. P. Singh1, K. K. Kondepudi1, K. Chopra2. 1Sas Nagar, India;
2Chandigarh, India
Objective: Obesity and increased visceral fat mass is major risk factor for
neuropsychiatric illnesses like depression, anxiety and cognitive losses.
The present study was designed to investigate the role of central and per-
ipheral monoamines metabolism in neuropsychiatric changes in high fat
diet (HFD) fed rats.
Methods: Animals were fed on HFD (58% energy from fat) for
12 weeks. Periodically, blood was collected to estimate serum metanephr-
ine (MN) levels. After 11 weeks behavioural paradigms to assess de-
pression, locomotion and cognitive activity were performed. Central
(brain) and peripheral i.e. visceral white adipose tissue (vWAT) and
brown adipose tissue (BAT) MN levels, monoamine oxidase A and B
(MAO-A & B) and acetylcholine esterase (AChE) enzyme activity was
estimated.
Results: HFD significantly increased the body weight which was nega-
tively correlated with the serum MN concentration. However, MN con-
centration in brain was significantly decreased whereas in vWAT it was
significantly increased with no change in BAT. In obese animals immo-
bility time in forced swim test and transfer latency in elevated plus
maze was significantly increased while locomotor activity significantly
decreased. Central MAO-A and MAO-B activity was increased while it
was decreased in vWAT with no change in BAT. Brain AChE levels
were also increased significantly in obese rats.
Conclusion: Metabolism of biogenic monoamines can play a critical
role in obesity related neuropsychiatric changes.
Policy of full disclosure: None.
P-04-018 Differential effects of pharmacological and restraint
stress on effort-based decision-making
C. Bryce1, S. Floresco1. 1University of British Columbia, Vancouver, Canada
Objective: Decision-making involves choosing between several alterna-
tive possibilities after evaluation of the relative costs and benefits.
Increasing the amount of effort required to obtain a reward is one type
of cost that can diminish the subjective value of objectively larger rewards.
Repeated episodes of stress can result in depressive symptoms including
anergia, which in turn may reduce the tendency to exert effort to obtain
rewards. The goal of the present study was to examine the effects of dif-
ferent types of acute stress on effort-based decision-making.
Methods: Using an operant chamber assay, rats were required to choose
between a low effort/low reward lever (LR; 2 pellets), and a high effort/
high reward lever (HR; 4 pellets), with the effort requirement increasing
over trial blocks (2, 5, 10 and 20 presses). Normally rats will choose the
HR lever more often when the effort cost is low, reducing their preference
for this option as the amount of effort increases. Acute restraint stress, but
not increases in corticosterone, causes rats to choose the HR option less
compared to baseline performance.
Results: In a subsequent study, we assessed the effects of the alpha 2
adrenoreceptor antagonist yohimbine (1–3mg/kg, IP), which mimics
increased noradrenaline transmission induced by acute stress, on effort-
based decision-making. Our expectation was that yohimbine would de-
crease choice of the HR option, in a manner comparable to restraint stress.
In stark contrast to our expectations, we found that yohimbine increased
preference for the HR option compared to vehicle treatment.
Conclusion: This suggests that yohimbine and restraint stress produce
divergent effects on some decision-making tasks, highlighting the fact that
different types of stressors can induce opposing effects on behavior.
Whether other neurochemical changes associated with acute stress, such
as increases in corticotropin-releasing factor (CRF), mediates an increase
in effort discounting is a topic for future research.
Policy of full disclosure: None.
P-04-020 Investigating the role of picolinic acid in depression
K. Christensen1, S. Janelidze2, F. Ventorp2, L. Brundin3. 1Michigan State
University, Grand Rapids, MI, USA; 2Lund, Sweden; 3Grand Rapids, MI, USA
Objective: Picolinic acid (PIC) and quinolinic acid (QUIN) are metabolites
of the kynurenine pathway (KP) of tryptophan metabolism, which
breaks down greater than 95% of available tryptophan into NAD+ instead
of serotonin under physiological conditions. Proinflammatory cytokines
further stimulate KP activity. PIC and QUIN are produced from
2-amino-3-carboxymuconate-semialdehyde (ACMS), an intermediate
of the KP. The enzyme 2-amino-3-carboxymuconate-semialdehyde
decarboxylase (ACMSD) synthesizes PIC from ACMS while QUIN is
produced spontaneously. Additionally, QUIN causes neurotoxicity via
NMDA-receptor agonism, whereas PIC prevents this neurotoxicity with-
out affecting excitation through a currently unknown mechanism. The ob-
jective of this experiment is to investigate the influence of PIC on central
nervous system inflammation and depressive behavior.
Methods: In vitro experiments: Mouse microglia were stimulated
with lipopolysaccharide (LPS) to activate cytokine production, and were
co-treated with PIC. Supernatants were collected after 24 hours and
used to measure cytokine production. Interleukin-6 (IL6) and macrophage
inflammatory protein-1b levels were measured by ELISA. Tumor
necrosis factor-a (TNFa), IL6, IL8, and IL10 were measured by
Mesoscale Discovery (MSD) technology. In vivo experiments: Rats were
given PIC in the drinking water at different doses for 12 days. On day
10 animals received intraperitoneal LPS (1mg/kg) or saline injections.
Rats underwent open field tests (OFT) and forced swim tests (FST) before
being sacrificed. Cytokine analysis was performed on blood and cerebro-
spinal fluid using MSD assays.
Results: We found that PIC increases production of IL6 and decreases
TNFa production in vitro. PIC had no significant effect on exploratory
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behavior in the OFT beyond two hours post-LPS injection. In the FST, PIC
decreased floating behavior and increased swimming behavior.
Conclusion: These pilot data show that PIC affects microglia pro-
duction of inflammatory cytokines and mediates behavioral effects in
vivo. ACMSD and PIC could constitute future drug targets for depression,
which should be explored in future studies.
Policy of full disclosure: None.
P-04-021 Augmentation with aerobic exercise to pharmacological
treatment for Chinese inpatients with moderate to
severe depression: A single-blinded randomised
controlled study
W.S.D Chung1, C.W.H. Ho1, P.S.C. Chan1, M.J.S. Wong1, A.W.T. Cheung1,
T.F.O. Lau1. 1Tai Po Hospital, Hong Kong, Hong Kong SAR, China
Objective: Physical exercise has been found to be an effective treatment
and prevention for depression. However, there is a lack of such kind of
studies in Chinese population. This study investigates the effect of super-
vised aerobic exercise training on depressive symptoms and physical per-
formance among Chinese patients in Hong Kong with moderate to severe
depression, in their early in-patient treatment phase.
Methods: A randomised controlled study design was used. Subjects in
supervised aerobic exercise group received 30 minutes of aerobic training,
five days a week for 3 weeks. Depressive symptoms (MADRS and C-BDI)
and domains in physical performance were assessed respectively by psy-
chiatrists and physiotherapist, who were blinded to intervention, at base-
line and the end of 3 weeks as outcome measures.
Results: 40 out of 52 recruited subjects (exercise group=19, control
group=21) completed the program for analysis. After 3 weeks of training,
subjects in aerobic exercise group showed a more significant reduction in
depressive scores (MADRS) as compared with the control (between-group
mean difference in reduction=13.79±8.30; 95% CI 9.79 to 17.79; p=0.003).
The exercise group also demonstrated a significant improvement in the
sit-and-rearch flexibility test (within-group mean difference=5.19±6.36;
95% CI −8.26 to −2.13; p=0.01).
Conclusion: Aerobic exercise in addition to pharmacological inter-
vention can have a synergistic effect in reducing depressive symptoms
and increasing motor flexibility in Chinese patients with moderate to
severe depression. Introduction of exercise training in the early phase of
illness may also hasten the response to antidepressants, and subsequently
reduce the impact on our healthcare service. Limitations: This study did
not follow up subjects long enough to examine the long-term effect of
aerobic exercise, in terms of its effect size and sustainability.
Policy of full disclosure: None.
P-04-022 The efficacy of vilazodone in achieving remission in
patients with major depressive disorder: Post hoc analyses
of a phase iv trial
L. Citrome1, C. Gommoll2, X. Tang2, R. Nunez2, G. Forero2, M. Mathews2.
1New York Medical College, Clinical Professor of Psychiatry & Behavioral
Sciences, Suffern, USA; 2Jersey City, USA
Objective: In major depression disorder (MDD), symptom remission is
the goal of treatment. We evaluated the efficacy of vilazodone, a serotonin
reuptake inhibitor and 5-HT1A receptor partial agonist, in achieving dis-
ease remission using various criteria.
Methods: A post hoc analysis of a Phase IV, multicenter, randomized,
8-week double-blind, fixed-dose study (NCT01473394) comparing vilazo-
done 40mg/day with placebo. The study comprised outpatients aged
18 to 70 years with MDD and a baseline total score 526 on the
Montgomery-Asberg Depression Rating Scale (MADRS). The primary
efficacy measure was the MADRS; secondary and additional efficacy
measure included the Clinical Global Impressions-Severity (CGI-S) and
Hamilton Anxiety Rating Scale (HAMA). Post hoc analyses evaluated
the percent of patients achieving depression symptom remission
(MADRS410), complete remission (MADRS45), anxiety symptom re-
mission (HAMA47), and combined depression/anxiety symptom re-
mission (MADRS410+HAMA47). Overall disease remission was also
assessed (CGI-S=1). Additional analyses evaluated outcomes in patients
with greater depression severity (baseline MADRS 530). Odds ratios
(OR) and number needed to treat (NNT) were determined.
Results: The ITT population comprised 252 placebo and 253 vilazodone
patients. More vilazodone patients compared with placebo achieved
MADRS remission (34% vs. 22%; OR=1.82; P<0.01; NNT=9) and com-
plete remission (18% vs. 8%; OR=2.42; P<0.01; NNT=10). More vilazo-
done patients compared with placebo met criteria for HAMA remission
(49% vs. 35%; OR=1.82; P<0.01) and combined MADRS/HAMA re-
mission (32% vs. 20%; OR=1.84; P<0.01). Additionally, rates of CGI-S
remission were higher in vilazodone vs. placebo patients (24% vs. 12%;
OR=2.41; P<0.001). In patients with greater depression severity
(MADRS530), statistically significant results were seen on all remission
outcome assessments for vilazodone vs. placebo (P<0.01, all outcomes),
with larger ORs relative to the overall population (OR range: 1.92–3.46).
Conclusion: These post hoc analyses suggest that vilazodone
40mg/day is effective in achieving depression and anxiety symptom re-
mission in adult patients with MDD.
Policy of full disclosure: Supported by Forest Laboratories, Inc. The
presenting author is Giovanna Forero, an employee of Forest Research
Institute.
P-04-023 Clinical relevance of levomilnacipran er treatment in
patients with major depressive disorder: Improvements in
functional impairment categories
A. Cutler1, C. Gommoll2, C. Chen2, W.M. Greenberg2, A. Ruth3, A.
Ho Reese2. 1Florida Clinical Research Center, Maitland, USA; 2Jersey City,
USA; 3Chicago, USA
Objective: To evaluate the categorical improvement in patients with
major depressive disorder (MDD) treated with levomilnacipran
extended-release (ER) vs. placebo. Patients were analyzed for shifts from
greater severity of functional impairment at baseline to lesser severity at
end of treatment (EOT).
Methods: Data were pooled from 2 fixed- and 3 flexible-dose rando-
mized, double-blind trials of levomilnacipran ER 40–120mg/day vs. pla-
cebo in adult patients with MDD. Proportions of patients shifting from
moderate-to-high baseline impairment (score 54) to mild-to-no impair-
ment (score43) at EOT were assessed for all SDS items (representing im-
pairment in the domains of work, social life, and family/home).
Proportions of shifts from marked-to-high (score 57) at baseline to
moderate-to-no (score 46) impairment at EOT also were assessed.
Results: More levomilnacipran ER vs. placebo patients achieved
categorical SDS improvement. On the Work Item, a greater percentage
of levomilnacipran ER vs. placebo patients improved from moderate-
to-high baseline impairment (54) to mild-to-no impairment (43) at
EOT (55% vs. 40%, odds ratio [OR]=1.96, P<0.0001); more levomilnaci-
pran ER vs. placebo patients with marked-to-high baseline impairment
(57) had moderate-to-no (46) impairment at EOT (73% vs. 64%,
OR=1.81, P<0.0001). On the Social Item more levomilnacipran ER vs.
placebo patients improved from moderate-to-high impairment at baseline
to mild-to-no impairment at EOT (48% vs. 37%, OR=1.73, P<0.0001), and
from marked-to-high impairment at baseline to moderate-to-no impair-
ment at EOT (68% vs. 59%, OR=1.61, P<0.0001). On the Family/Home
Item, more levomilnacipran ER patients relative to placebo shifted from
moderate-to-high impairment at baseline to mild-to-no impairment at
EOT (51% vs. 39%, OR=1.72, P<0.0001), and from marked-to-high impair-
ment at baseline to moderate-to-no impairment at EOT (73% vs. 65%, OR
=1.47, P=0.0027).
Conclusion: These results suggest that in adult patients with MDD,
levomilnacipran ER treatment is associated with greater improvements
than placebo in all SDS-measured functional domains of work, social,
and family/home life.
Policy of full disclosure: This study was funded by Forest Laboratories,
Inc.
P-04-024 Cellular adhesion molecules and cognitive functions
in depression
D. Degmecic1, T. Bacun2, L. Glavaš-Obrovac2, V. Šeric2, S. Topic3,
A. Vcev2. 1School of Medicine Osijek, Osijek, Croatia; 2School of Medicine
Osijek, University J.J.Strossmayer, Osijek, Croatia; 3University Hospital
Osijek, Osijek, Croatia
Objective: Determine the state of cognitive functions and rate of de-
pression in population of diabetic patients and control group as well as
to determine the rate of the serum concentration of soluble cellular ad-
hesion molecules (E-selectin, ICAM-1, VCAM-1).
Methods: In a prospective study, sample consisted of 108 patients, 66 of
the patients were diagnosed with diabetes mellitus type 2, and 42 were
control group. All of them were interwied by psychiatrist and tested
with Mini Mental State Examination, Hamilton depression rating scale
and questionnaire about sociodemografic data. Also all of the patients
gave the blood for complete labaratory analysis and concentration of
the soluble cellular adhesion molecules (E-selectin, ICAM-1, VCAM-1).
SPSS Statistics version 20 statistical program has been used for the statisti-
cal analysis.
Results: In a total sample females (N=48) had more cognitive dysfunc-
tions compared with males (N=60), it was statistically significant
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(Pearsons Chi-square value 4,320; df 1; p=0,038). Results showed that de-
pressive symptoms manifested with statistical significance in the group of
patients with diabetes mellitus type 2 compared to the control study
group (Pearsons Chi-square value 8,577; d.f. 3; p=0,035). Patients with
diabetes mellitus type 2 showed statistically significant cognitive dysfunc-
tions compared with control group (Pearsons Chi-square value 10,099;
d. f. 1; p=0,001). There were no statistically significant difference between
the group of diabetic depressed patients compared with the control
group in the expression of the cellular adhesion molecules, ICAM -1
(t=1,980; p=0,055), VCAM-1 (t =0,843; p=0,200), E-selectin (t= -, 285;
p=0,778).
Conclusion: In this study we didn’t get statistically significant higher
levels of cellular adhesion molecules in these group of patients, in other
words there were no higher inflammatory response, so future studies
are needed to clear this diabetes-depression-cognitive dysfunction link
and possible innate inflammatory response.
Policy of full disclosure: None.
P-04-025 Potential antidepressant-like effect of the brain penetrant
neuropeptide Y Y2 receptor antagonist SF-11 in the rat
model of depression induced by astrocyte ablation.
H. Domin1, B. Szewczyk1, M. Wozniak1, M. Smialowska1. 1Institute of
Pharmacology PAS, Krakow, Poland
Objective: Neuropeptide Y (NPY), a widely distributed peptide in mam-
malian brain, seems to play a significant role in depression and anxiety by
acting via Y1, Y2 and Y5 receptors. Some data showed that the Y2 receptor
(Y2R) antagonists BIIE0246 and JNJ-31020028 induced antidepressant-like
behavior in olfactory bulbectomized rats.
Methods: The present study investigated the possible antidepressant-
like activity of a new Y2R antagonist SF-11 in the rat model of depression
induced by medial prefrontal cortex (PFC) astrocyte ablation by the astro-
cytic toxin L-alpha-aminoadipic acid (L-AAA). That toxin induced
depressive-like behavior in rats, reversed by the classic antidepressant
imipramine. L-AAA (100 μg/2 μl) was bilaterally microinjected into rat
PFC twice, on days 1 and 2. Afterwards, the depressive-like behavior
was assessed on day 5 by a forced swim test (FST). SF-11 was adminis-
tered intraperitoneally (3 or 10mg/kg) 1 h before the FST. On day 8, brains
were dissected and the GFAP protein level was analyzed in the PFC using
a western blot method.
Results: Our results showed that L-AAA increased immobility time in
the FST, which indicated a depressive-like effect. The Y2R antagonist
SF-11 (10, but not 3mg/kg) significantly decreased immobility time in
both control and gliotoxin-treated rats. Western blot analyses showed
that L-AAA administration significantly reduced (by 52%) the GFAP pro-
tein level in rat PFC, which was reversed by SF-11 administration.
Conclusion: The obtained results indicate that the degeneration
of astrocytes in the PFC may be a useful animal model of depression;
furthermore, they demonstrate a therapeutic potential of NPY Y2 receptor
antagonists in the treatment of depression. This study was supported by
Grant POIG.01.01.02-12-004/09.
Policy of full disclosure: None.
P-04-026 Effects of vortioxetine on cognitive symptoms of major
depressive disorder (MDD)
M. Fava1, S. Lophaven2, C. Olsen2. 1Massachusetts General Hospital, Boston,
USA; 2H. Lundbeck A/S, Valby, Denmark
Objective: Cognitive dysfunction is an important feature during the
acute phase of MDD and may persist as a residual symptom even after
remission of depression. This analysis of a short-term MDD study
(NCT01163266) investigated the effects of vortioxetine on self-rating of
cognitive symptoms by depressed patients with clinically significant cog-
nitive dysfunction at baseline.
Methods: In this double-blind study, 462 patients randomly assigned
(1:1:1) to 10 or 20 mg vortioxetine or placebo for 8 weeks were adminis-
tered the self-reported cognitive and physical functioning questionnaire
(CPFQ) [1]. To evaluate the effect in patients with significant cognitive
symptoms, a post-hoc baseline CPFQ total score >25 was introduced as
a cut-off. The CPFQ data were analyzed by ANCOVA using observed
cases for patients who had completed treatment. Path analysis assessed
to what extent improvement in cognition scores was a direct treatment
effect.
Results: In the total population, no significant differences were detected
between vortioxetine and placebo in CPFQ total score. In a post-hoc
analysis of patients with clinically relevant cognitive symptoms (81%
[371/457]), separation from placebo on the CPFQ in favor of vortioxetine
was found at Week 8, with significant reductions in the CPFQ total
score (10 mg/day), the cognitive dimension score (10 and 20mg/day),
and the four single-item scores motivation/interest/enthusiasm, ability to
remember/recall information, ability to find words (10 and 20mg/day),
and sharpness/mental acuity (10mg/day). Path analysis showed that up
to two-thirds of the effect of vortioxetine was a direct treatment effect
on cognitive symptoms, rather than an indirect effect mediated through
improvement of general depressive symptoms.
Conclusion: In this post-hoc study of MDD patients with clinically rel-
evant self-reported cognitive symptoms at baseline, vortioxetine demon-
strated a significant alleviation of the cognitive symptoms compared to
placebo that could not be accounted for solely by alleviation of depressive
symptoms.
Policy of full disclosure: An employee of H. Lundbeck A/S. This
study was funded by H. Lundbeck A/S and Takeda Pharmaceutical
Company, Ltd.
P-04-027 The efficacy of levomilnacipran er in the treatment of
patients with depression-associated fatigue symptoms
M. Freeman1, M. Fava2, C. Gommoll3, C. Chen4, W.M. Greenberg4,
A. Ruth5, J. Terner-Rosenthal4. 1Harvard Medical School, Boston, USA;
2Boston, USA; 3New Jersey, USA; 4Jersey City, USA; 5Chicago, USA
Objective: To evaluate the effects of levomilnacipran extended-release
(ER) on fatigue symptoms associated with major depressive disorder
(MDD).
Methods: Data were pooled from 2 fixed- and 3-flexible-dose, rando-
mized, double-blind, placebo-controlled studies (8 or 10 weeks) of levo-
milnacipran ER 40–120mg/day in adults with MDD. Items from the
MADRS (item 7 [lassitude]) and HAMD17 (items 7 [work and activities],
8 [retardation], and 13 [somatic symptoms general]) were used to assess
fatigue-related impairment. Analyses included change from baseline to
end of treatment (least squares mean difference [LSMD] vs. placebo)
and percent of patients without residual fatigue symptoms after treatment
(score <2 on MADRS item 7 or HAMD17 item 7; score <1 on HAMD17
items 8 or 13). Additionally, mean improvements in MADRS total score
and MADRS response rates (550% improvement) were evaluated in
patients stratified by baseline fatigue (with or without high fatigue,
MADRS item 7 score of 54 or <4, respectively).
Results: LSMD analyses indicated significantly greater improvement
with levomilnacipran ER (n=1566) vs. placebo (n=1032) on all fatigue-
related items: (MADRS item 7, −0.3; HAMD17 item 7, 0.3; HAMD17
item 8, −0.1; HAMD17 item 13, −0.1; all P<0.001). At end of treatment,
the percent of patients without residual fatigue symptoms was signifi-
cantly higher with levomilnacipran ER vs. placebo (MADRS item 7,
35% vs. 28%, P<0.001; HAMD17 item 7, 43% vs. 35%, P<0.001;
HAMD17 item 8, 46% vs. 39%, P=0.002; HAMD17 item 13, 26% vs.
18%, P<0.001). Significant mean improvements vs. placebo in MADRS
total score were found in patients with high baseline fatigue (n=1916;
LSMD=−3.1, P<0.001) and without high fatigue (n=681; LSMD=2.8,
P=0.002). Response rates were significantly greater for levomilnacipran
ER vs. placebo in both groups (high fatigue, 43% vs. 33%, OR=1.6,
P<0.001; without high fatigue, 50% vs. 39%, OR=1.6, P=0.002).
Conclusion: Levomilnacipran ER may improve fatigue symptoms asso-
ciated with MDD.
Policy of full disclosure: This study was funded by Forest Laboratories,
Inc.
P-05. Schizophrenia A
P-05-001 Switching to antipsychotic monotherapy can improve
attention and social activity in chronic schizophrenia
patients
H. Hori1, R. Yoshimura1, A. Katsuki1, A. Sugita1, K. Atake1, J. Nakamura1.
1UOEH, Kitakyushu, Japan
Objective: This study sought to examine whether switching polyphar-
macy therapy to monotherapy would improve the cognitive function
and social function of patients with schizophrenia.
Methods: Thirty-nine patients with schizophrenia who were receiving
therapy with two antipsychotics were randomly divided into a switch
to monotherapy group (switching group) and a polypharmacy continued
group (continuing group). For the patients allocated to the switching
group, the dose level of one of the two antipsychotic drugs was gradually
reduced to zero. Psychotic symptoms, cognitive function and social func-
tion scale scores were assessed immediately before and 24 weeks after
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switching, and the time courses of these scores were compared between
the two groups.
Results: Compared with the continuing group, the switching group
demonstrated significantly greater improvement in attention after switch-
ing (p=0.02). Furthermore, the improvement in daily living (p=0.038) and
work skills (p=0.04) was significantly greater in the switching group. In
an analysis of the correlation among sub-items with respect to the degrees
of improvement, a significant correlation was noted between improve-
ment in executive function and improvement in daily living (r=−0.64,
p=0.005) and between improvement in work skills and improvement in
attention (r=−0.51, p=0.038).
Conclusion: In patients with schizophrenia receiving polypharmacy,
switching to monotherapy resulted in improvements in attention.
Furthermore, improvements in executive function led to improvements
in daily living, and improvements in attention led to improvements in
work skills. Thus, switching to monotherapy is a useful option.
Policy of full disclosure: Professor Nakamura has received grant
support from Astellas Pharma, Janssen Pharmaceutical, Eli Lilly, Glaxo
Smith Kline, Pfizer, Dainippon Sumitomo Pharma Co. Ltd., Otsuka
Pharmaceutical Co. Ltd., and Chugai Pharmaceutical Co. Ltd. The other
authors report no financial relationships with commercial interest.
P-05-002 Efficacy of aripirpazole once-monthly in Asian patients
with schizophrenia: Secondary efficacy outcomes in a
multicenter, randomized, double-blind, non-inferiority
study versus oral aripiprazole
J. Ishigooka1, J. Nakamura2, N. Shimizu3. 1Tokyo Women´s Medical
University, Tokyo, Japan; 2University of Occupational and Environmental
Health, Department of Psychiatry, Kita-Kyushu, Japan; 3Otsuka
Pharmaceutical Co. Ltd., Tokyo, Japan
Objective: Non-inferiority of aripiprazole once-monthly (AOM), the
first long-acting injectable dopamine partial agonist, was confirmed in a
randomized, double-blind, non-inferiority study versus oral aripiprazole
in Asian patients with schizophrenia. Here we report the secondary
efficacy outcomes.
Methods: This study consisted of a screening phase and three treatment
phases: an oral conversion phase (<12 weeks), an oral stabilization
phase (<12 weeks) and a double-blind phase (52 weeks) in which patients
were randomized to AOM 400mg or oral aripiprazole (6–24mg/day).
Secondary outcomes from the randomized phase were mean changes in
PANSS total score and each subscale score, and CGI-S, mean CGI-I
score, the proportion of patients meeting exacerbation of psychotic symp-
toms/relapse criteria, and stabilization of psychotic symptoms/mainten-
ance criteria, time to discontinuation due to any reason.
Results: Of 455 patients randomized in the double-blind phase, 228
received AOM and 227 received oral aripiprazole. Mean PANSS total
scores at baseline of the double-blind phase were 54.4 for AOM and
53.3 for oral aripiprazole. At Week 52, changes from baseline in PANSS
total score were −2.3 for AOM and −2.7 for oral. Mean CGI-I scores at
Week 52 were 3.5 in both groups. The proportion of patients meeting
exacerbation of psychotic symptoms/relapse criteria was 6.6% in both
groups and the proportion of patients meeting stabilization of psychotic
symptoms/maintenance criteria was high (92.5% in both groups).
Discontinuation due to all reasons was 25.9% for AOM and 33.5% for
oral aripiprazole (Hazard ratio: 0.74, 95%CI: 0.52–1.0).
Conclusion: The results show that AOM is effective in maintenance
treatment of stabilized patients with schizophrenia, with comparable
efficacy and tolerability to oral aripiprazole.
Policy of full disclosure: This study was funded by Otsuka
Pharmaceutical Co., Ltd. Dr. Ishigooka has received research support or
speakers honoraria from, or has served as a consultant to, Yoshitomi,
Pfizer, Astellas, Glaxo SmithKline, Meiji Seika Pharma, Eli Lilly,
Novartis Pharma, Otsuka, Mochida, Chugai, Takeda, Shionogi,
Dainippon Sumitomo, and Tanabe Mitsubishi.
P-05-003 Hyperprolactinemia during antipsychotics treatment has
a risk of venous thromboembolism
M. Ishioka1, N. Yasui-Furukori1, N. Sugawara1, H. Furukori1, S. Kudo1,
K. Nakamura1. 1Hirosaki University, Hirosaki, Japan
Objective: Objective: The strong association between psychiatric patients
receiving antipsychotics (APs) and venous thromboembolism (VTE) is
well recognized. Although some reports suggests that hyperprolactinemia
often causes a rise coagulation factors, there are few studies on examine
the direct relationship between prolactin (PRL) elevated by APs and acti-
vated coagulation factors.
Methods: The subjects were 227 psychiatric patients (male=109, female
=118) receiving APs for at least 3 months. Markers of VTE (D-dimer,
fibrin/fibrinogen degradation products (FDP) and thrombin-antithrombin
complex (TAT)) and serum prolactin concentrations were measured. The
study was approved by the Ethics Committee of Hirosaki University
Hospital, and written informed consent to participate in this study was
obtained from the patients and their families.
Results: PRL levels were significantly correlated with logarithmic
transformation of D-dimer (r =0.311, p=0.001) and FDP levels (r=0.289,
p=0.002), but not TAT level (r=0.131, ns) in males. In females, however,
any correlation was not found between the markers of VTE and prolactin
levels. The same tendencies were confirmed using multiple regression
analyses including demographics factors and APs dosage
Conclusion: This study indicates that hyperprolactinemia is associated
with a rise coagulation factors in only male patients receiving APs. This
finding has a clinical implication that monitoring and/or modulation of
PRL level for male patients is important to decrease risk of VTE.
Policy of full disclosure: None.
P-05-004 Microglial activation in first-episode and drug-naïve
schizophrenia
Y. Iwata1, K. Suzuki1, N. Mori1. 1Hamamatsu University, School of Medicine,
Hamamatsu, Japan
Objective: A growing body of evidence suggests that neuroinflammation
underlie the pathophysiology of schizophrenia. However, to our knowl-
edge, no information is available on the alteration of microglial activation
in the brain of schizophrenia without influences of antipsychotic drugs.
We investigated activated microglia in the brain of drug-naïve schizo-
phrenia, and then to examine correlation of the microglial activation
and severity of psychotic symptom.
Methods: Twenty-two first-episode and drug-naïve patients with
schizophrenia (age range, 18-40 years; 14 men and 8 women) and 22
age- and sex-matched normal controls participated in this study.
Activation of microglia was quantified using positron emission tomo-
graphy (PET) and a radiotracer for microglia, [11C](R)-(1-[2-
chrorophynyl]-N-methyl-N-[1-methylpropyl]-3 isoquinoline carboxa-
mide)([11C](R)-PK11195). PET data were analyzed by simplified reference
tissue model. Clinical symptoms were assessed using the Positive and
Negative Symptom Scale (PANSS).
Results: [11C](R)-PK11195 binding potential (BP) values were signifi-
cantly higher in multiple brain regions in first-episode and drug-naïve
patients with schizophrenia as compared to those of controls (P<0.05, cor-
rected). Furthermore, there was a negative correlation between positive
score of PANSS and BP of [11C](R)-PK11195 in the deep white matter
of patient’s brain (Pearson’s r=−0.44, P=0.041).
Conclusion: Excessive microglia activation was present in multiple
brain regions of first-episode and drug-naïve patients with schizophrenia.
The microglial activation in the deep white matter also showed a negative
correlation with severity of psychotic symptom. The present study sug-
gests that microglia may play a protective role in the pathophysiology
of schizophrenia.
Policy of full disclosure: None.
P-05-005 Association study of H2AFZ with schizophrenia in a
Japanese case-control sample
D. Jitoku1, N. Yamamoto1, Y. Iwayama2, M. Umino1, A. Umino1,
A. Uezato1, A. Kurumaji1, T. Yoshikawa2, T. Nishikawa1. 1Tokyo Medical
and Dental University Graduate School, Tokyo, Japan; 2Laboratory for
Molecular Psychiatry, RIKEN Brain, Science Institute, Saitama, Japan
Objective: It is widely accepted that malfunction of the NMDA type glu-
tamate receptor may be involved in the pathophysiology of the major ser-
ious mental disorder, schizophrenia, because NMDA receptor antagonists
cause positive, negative and cognitive symptoms indistinguishable from
those of schizophrenia. Several recent studies on brain miRNAs have
demonstrated that expression of the glutamate system-related miR-132
and miR-212 is changed in post-mortem schizophrenic brains. In order
to obtain further insight into the relationships among the NMDA receptor,
the molecular cascades controlled by these miRNAs and schizophrenia, of
commonly predicted target genes of the two miRNAs, we focused on the
H2AFZ (encoding H2A histone family, member Z) gene whose expression
has been shown to be modified by a schizophrenomimetic NMDA antag-
onist, phencyclidine, by our screening study using a DNA microarray
technique.
Methods: In this study, we examined 4 tag single nucleotide poly-
morphisms (SNPs) (SNP01-04) located within the 10 kb up- and down-
stream regions of the H2AFZ gene for genetic association with
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schizophrenia in a case-control study of Japanese cohort with 2012 cases
and 2170 control subjects.
Results: We did not detect any significant genetic association of
these SNPs with schizophrenia in this sample set. However, we observed
a significant association of SNP02 in the male schizophrenia subjects (alle-
lic P=0.003, genotypic P=0.008). Based on a haplotype analysis, haplo-
types consisting of SNP02-SNP03-SNP04 also showed a significant
association in the male schizophrenia subjects (P=0.018). These associa-
tions remained significant even after correction for multiple testing.
Conclusion: The present findings suggest that the H2AFZ gene may
be a susceptibility factor in male schizophrenics, and that modification
of the H2AFZ signaling pathway warrants further study in terms of the
pathophysiology of schizophrenia.
Policy of full disclosure: None.
P-05-006 Functional role of serotonin 5-HT5A receptors in
cognition: Mechanism of action study with a selective
antagonist ASP5736
N. Yamamoto1, J. Yarimizu2, M. Yamazaki2, K. Harada2, M. Okabe2,
K. Ni2. 1Astellas Pharma Inc., Tsukuba, Japan; 2Astellas Pharma Inc.,
Tsukuba, Japan
Objective: We recently identified ASP5736, a novel antagonist of 5-HT5A
receptor, and reported that it had the potential for the treatment of schizo-
phrenia by mono-therapy or combination therapy with commercially
available antipsychotics. We then examined the effect of ASP5736 on
executive functions, which were impaired in schizophrenia.
Results: Sub-chronic administration of phencyclidine (PCP) to
rats selectively impaired extradimensional shifts in the attentional
set-shifting task, and ASP5736 significantly ameliorated the deficits at
0.003–0.01 mg/kg, p.o. To elucidate mechanism of action of the com-
pound, we performed multiple pharmacological studies 1) In an in vivo
receptor occupancy study, ASP5736 replaced binding of [125I]-lysergic
acid diethylamide (LSD) to 5-HT5A receptor in olfactory bulb of rats
at the behaviorally effective doses. 2) ASP5736 dose-dependently antago-
nized the 5-carboxamidotryptamine (5-CT)-induced decrease in cAMP
levels in HEK293 cells stably expressing the 5-HT5A receptor. 3)
Immunohistochemical study showed that 5-HT5A receptors were
expressed in dopaminergic (DAergic) neurons in the ventral tegmental
area (VTA), a nucleus of origin of DAergic neurons, and in parvalbumin-
positive interneurons in the medial prefrontal cortex (mPFC). 4) In in vivo
brain microdialysis study, the extracellular levels of DA and GABA were
decreased in sub-chronically PCP-treated rats.
Conclusion: From these data we have made a hypothesis that ASP5736
might increase DA and GABA releases in the mPFC by blocking 5-HT5A
receptors existing on DAergic neurons in VTA projecting to mPFC and of
GABAergic interneurons on mPFC, respectively.
Policy of full disclosure: None.
P-05-007 ASP5736, a novel serotonin 5-HT5A receptor antagonist,
ameliorates positive symptom, cognitive impairments and
mood dysfunction in animal models of schizophrenia
M. Yamazaki1, J. Yarimizu2, K. Harada2, N. Yamamoto2, M. Okabe2,
T. Shimada2, K. Ni2. 1Astellas Pharma Inc., Tsukuba, Ibaraki, Japan;
2Astellas Pharma Inc., Tsukuba, Ibaraki, Japan
Objective: The 5-HT5A receptor is a G-protein-coupled seven-
transmembrane receptor and expressed predominantly in neural tissues
such as hippocampus, thalamus, amygdala and cerebral cortex with little
expression in peripheral tissues. In addition, increased exploratory
behavior in novel environments displayed by 5-HT5A receptor KO mice
compared to wild-type mice, has suggested that the 5-HT5A receptor
is assumed to be involved in mood, affective disorder, and cognitive func-
tion, while it remains largely uncovered. We recently identified ASP5736,
a novel antagonist of 5-HT5A receptor and showed it has potential for the
treatment of Alzheimer’s disease. We then evaluated and report here that
its effects on positive symptom, cognitive impairments and mood dys-
function in several animal models of schizophrenia.
Results: ASP5736 reversed phencyclidine (PCP)- and methampheta-
mine (MAP)-induced hyperactivity in mice at 0.01–0.1 mg/kg, p.o. and
improved PCP-induced prepulse inhibition deficit in rats at 0.01–0.1 mg/
kg, p.o. Furthermore, working memory deficit in MK-801-treated mice
and visual learning deficit in neonatally PCP-treated mice were both ame-
liorated by 0.001–0.003 mg/kg, p.o. and 0.003mg/kg, p.o. of ASP5736, re-
spectively. In addition we evaluated the effect of ASP5736 on depression
model (forced swim test) using DBA/2 mice. ASP5736 significantly
decreased immobility time at doses of 0.1–0.3 mg/kg, p.o. On the other
hand, ASP5736 didn’t cause sedation, catalepsy, or increase in plasma
prolactin.
Conclusion: These results collectively suggest that ASP5736 may
benefit not only positive symptom but also cognitive impairments and
mood dysfunction, with less concerns on adverse effects in schizophrenia
patients.
Policy of full disclosure: None.
P-05-008 ASP5736, a novel serotonin 5-HT5A receptor antagonist,
ameliorates positive symptom and cognitive impairments
in animal models of schizophrenia: Combination studies
with olanzapine
J. Yarimizu1, M. Yamazaki1, K. Harada1, N. Yamamoto1, M. Okabe1,
K. Ni1. 1Astellas Pharma Inc., Tsukuba-Shi, Japan
Objective: We recently identified ASP5736, a novel antagonist of 5-HT5A
receptor. In our previous study, we reported that ASP5736 ameliorated
positive symptom and cognitive impairments in animal models of schizo-
phrenia. We then evaluated the effects of ASP5736 on positive symptom,
cognitive impairments and adverse effects in several animal models of
schizophrenia in combination with olanzapine.
Results: Although olanzapine itself failed to improve MK-801-induced
working memory deficit, ASP5736 with olanzapine significantly attenu-
ated the deficit to the same degree as ASP5736 administered alone.
Furthermore, the sedative effect of olanzapine was not enhanced by
ASP5736 at 0.003mg/kg, p.o., which is an effective dose against
MK-801-induced working memory deficit. Methamphetamine (MAP)-
induced hyperactivity was also significantly ameliorated by ASP5736
alone, and the inhibitory effect on MAP-induced hyperactivity of olanza-
pine was enhanced approximately three-fold following administration of
ASP5736 from ID50=1.18 mg/kg to ID50=0.37 mg/kg, p.o. Of note, the ad-
verse effect (catalepsy) of olanzapine was not worsened by the
co-administration of ASP5736.
Conclusion: These results collectively indicate that co-administration
of olanzapine had no influence on the memory improvement by
ASP5736, and that while the effect of olanzapine on positive symptom
model was enhanced by the treatment of ASP5736, the adverse effects
of olanzapine were not worsened by ASP5736. Present studies suggest
that a novel and potent 5-HT5A receptor antagonist ASP5736 might
have the potential to be used for the treatment of cognitive impairment
associated with schizophrenia (CIAS) in combination with commercially
available antipsychotics.
Policy of full disclosure: None.
P-05-009 Cariprazine demonstrates greater potency than
aripiprazole in animal models of psychosis, cognitive
impairment, and negative symptoms
N. Adham1, I. Gyertyan2, B. Kiss2. 1Forest Research Institute, Jersey City,
USA; 2Gedeon Richter Plc., Budapest, Hungary
Objective: Dopamine D3 receptors are thought to play a role in the regu-
lation of cognition and mood and blockade of this receptor may be benefi-
cial in treating the negative, cognitive, and mood symptoms associated
with schizophrenia. This analysis compared the potencies of aripiprazole,
a dopamine D2 receptor partial agonist, and cariprazine, a dopamine D3
and D2 receptor partial agonist with preference for D3 receptors, across
a number of animal paradigms that model different symptom domains
of schizophrenia.
Methods: The effects of different doses of cariprazine and aripiprazole
were evaluated in established rodent (rat) models of psychosis, cognitive
impairment, and negative symptoms/depression. Differences in potency
between the 2 compounds in each model were estimated using ED50
values or minimal effective doses (MED).
Results: Cariprazine occupied D2 receptors in rats with approximately
30-fold greater potency than aripiprazole (ED50: cariprazine, 0.23 mg/kg;
aripiprazole, 7.7 mg/kg); potency for D3 receptor occupancy in rats
was >70-fold higher for cariprazine vs. aripiprazole. In models of
antipsychotic-like activity, cariprazine demonstrated 20 to 30-fold greater
potency than aripiprazole (ED50 for conditioned avoidance response: car-
iprazine, 0.8 mg/kg, aripiprazole, 18 mg/kg; ED50 for amphetamine-
induced motor activity: cariprazine, 0.12 mg/kg; aripiprazole, 3.9 mg/kg).
In comparison, cariprazine showed much greater differences in potency
relative to aripiprazole in the models of cognitive impairment (cariprazine
was 25 to >250-fold more potent) and negative symptoms/depression (car-
iprazine was 85 to 100-fold more potent).
Conclusion: Cariprazine showed greater potency than aripiprazole
across a number of animal models that represent different symptom
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domains of schizophrenia. The greatest differences in potency between
cariprazine and aripiprazole were seen in paradigms of cognitive impair-
ment and negative symptoms/depression. The high affinity of cariprazine
at D3 receptors may underlie the greater potency relative to aripiprazole in
models of cognitive impairment and negative symptoms.
Policy of full disclosure: Nika Adham is an employee of Forest
Research Institute.
P-05-010 The outcome of acute transient psychotic disorders
according to 5-year follow-up
G. Aleshkina1, L. Bardenshteyn1, D. Murtazalieva1. 1Moscow State
University of Medicine, Moscow, Russia
Objective: To study the clinical, dynamic and prognostic aspects of acute
transient psychotic disorders.
Methods: We have examined 108 inpatients (61 men and 47 women,
mean age 29.3±9.7 years, range 18–55 years) with acute psychotic states
(F 23, ICD-10). Group 1: 55 inpatients with acute polymorphic psychotic
disorders without symptoms of schizophrenia (F 23.0). Group 2: 53 inpa-
tients with acute polymorphic psychotic disorders with symptoms of
schizophrenia (F 23.1). Methods used: clinical-psychopathological, clinical
follow-up, statistical. Follow-up observations period was 5 years from the
moment of psychotic symptomatology reduction.
Results: Repeated psychotic attacks over a 5-year period were observed
for 15 patients in group 1 (27.3%) and 16 patients in group 2 (30.1%). The
single relapse of illness was observed in 46.7% of cases (7 patients)
of group 1. In 8 inpatients (53.4%) of this group from 2 to 5 psychotic epi-
sodes were recorded. All relapses of the disease in group 1 were character-
ized by schizophrenic structure psychotic episodes with the identification
of specific deficit symptoms in postpsychotic period. In the group of acute
transient psychotic disorders with symptoms of schizophrenia, single
exacerbation of schizophrenia was noted in 43.7% of cases (n=7) and for
56.3% of inpatients (n=9) from 2 to 4 psychotic episodes were recorded.
Conclusion: Psychotic states in both groups were characterized by the
tendency of recurrence. The obtained preliminary data allow us to refer
27.3% of F 23.0 cases to the atypical debut of schizophrenia that presumes
supporting therapy after clinical reduction of first episode psychosis.
Policy of full disclosure: None.
P-05-011 Prefrontal GABA modulation of working memory
processes
M. Auger1, S. Floresco1. 1University of British Columbia, Vancouver, Canada
Objective: Reduced expression of markers for GABA within the pre-
frontal cortex (PFC) is consistently observed in schizophrenia, and may
lead to cognitive deficits associated with the disorder. Recent studies
have shown that blockade of prefrontal GABAA receptors increased re-
sponse latencies but did not impact accuracy in the delayed-response
task conducted on a radial maze. However, the possibility remains that
tasks which place higher demands on attention and requiring resistance
to ‘proactive interference’ may be more sensitive to PFC GABA dysfunc-
tion. Thus, the goal of this study was to explore the contribution of PFC
GABA transmission these different aspects of working memory.
Methods: Separate groups of rats were trained on one of two tasks. In
the massed-trials reference/working memory task, rats were trained to re-
trieve a food from the same 4 arms of an 8-arm radial maze, where they
received massed training designed to increase proactive interference
(5 trials per day, 1–2min ITI). The delayed non-match to position
(DNMTP) task consisted of a sample phase, in one of two levers was ex-
tended, and a choice phase, requiring selection of the opposite lever, sepa-
rated by a variable delay (1–24 s). Well-trained rats received intra-mPFC
infusions of saline and either the GABAA antagonist, bicuculline (12.5
or 50 ng), or the GABA agonists baclofen and muscimol (100 ng each).
Results: Blockade of PFC GABAA receptors caused a pronounced
increase in working and reference memory errors in both the first and sub-
sequent trials of the radial arm maze task, as has been observed in schizo-
phrenic patients. In contrast, PFC inactivation did not affect performance
of this task. PFC GABA blockade also induced delay-independent impair-
ments in accuracy on the DNMTP task.
Conclusion: Reducing PFC GABA transmission blockade produces
impairments in working memory accuracy that are distinct from the ef-
fects of PFC inactivation, and resemble those observed in schizophrenia.
Policy of full disclosure: None.
P-05-012 Aripiprazole once-monthly for long-term maintenance
treatment of schizophrenia: A 52-week open-label study
R. Baker1, T. Peters-Strickland1, R. D. McQuade1, N. Jin2, A. Eramo3,
P. P. Perry1, B. R. Johnson1, A. R. Duca2, R. Sanchez1. 1Otsuka, Princeton,
USA; 2Otsuka, Rockville, USA; 3H. Lundbeck A/S, Deerfield, USA
Objective: To evaluate the safety, tolerability, and maintenance of the
therapeutic effect of aripiprazole once-monthly (AOM) in long-term treat-
ment of schizophrenia.
Methods: This study (NCT00731549) enrolled new subjects or subjects
who participated in one of the pivotal studies (NCT00705783 Kane et al.
2012 or NCT00706654 Fleischhacker et al. 2013). The study comprised a
screening phase (if applicable), a conversion phase to oral aripiprazole
(Phase 1, if applicable), an oral stabilization phase (Phase 2), and an
AOM maintenance phase (Phase 3). New subjects who did not participate
in the pivotal studies entered at screening, proceeded to Phase 1 or 2,
depending on current treatment. Subjects who completed one of the piv-
otal studies, were re-stabilized on oral aripiprazole in Phase 2. Only sub-
jects meeting stability criteria entered Phase 3, where they received
open-label AOM administered every 4 weeks for a maximum of 52 weeks.
Results: 1,081 subjects entered Phase 3 (464 from NCT00705783, 474
from NCT00706654) and 143 new subjects]. Of these, 79.4% (858/1081)
completed 52 weeks of treatment. The most frequent primary reasons
for discontinuation were withdrawal of consent (8.2%), impending relapse
(4%) [3.4% with AEs plus 0.6% without AEs], and adverse events (2.9%).
AEs (>=5% of patients) were headache (7.6%) nasopharyngitis (7%), anxi-
ety (6.8%), and insomnia (6.6%). The proportion of subjects in Phase 3
meeting impending relapse criteria was 8.25% (89/1079).
Conclusion: Over a 52-week period, subjects participating in an open-
label trial of AOM had a high completion rate and a low rate of discon-
tinuation due to impending relapse. The safety and tolerability profile
was similar to that observed in the pivotal studies, with no new safety sig-
nals arising during long-term treatment. The results suggest that aripipra-
zole once-monthly maintains effectiveness throughout long-term
treatment.
Policy of full disclosure: Supported by Otsuka Pharmaceutical
Development & Commercialization, Inc. and H. Lundbeck A/S. Timothy
Peters-Strickland, Ross Baker, Robert D. McQuade, Na Jin, Pamela
P. Perry, Brian R. Johnson, Anna R. Duca, and Raymond Sanchez are
employees of Otsuka Pharmaceutical Development & Commercialization,
Inc. Anna Eramo is an employee of H. Lundbeck A/S.
P-05-013 Disrupted effective connectivity of emotional circuitry
in schizophrenia
F. Benedetti1, B. Vai1, G. Papa Sferrazza1, S. Poletti1, D. Radaelli1,
R. Cavallaro1, E. Smeraldi1. 1Instituto Scientifico, Ospedale San Raffaele,
Department of Clinical Neurosciences, Milan, Italy
Objective: Impaired emotional processing is a core feature of schizo-
phrenia (SKZ). Consistent findings suggested that this impairment could
be paralleled by a disrupted functional and structural integrity of fronto-
limbic areas. Moreover several studies using some connectivity techni-
ques, such as Psycho-physiological Interaction, confirmed an alterated
connectivity in SKZ. Nevertheless these techniques didn’t allow to explore
the causal relationships among the involved regions. For this reason,
using Dynamic Causal Modeling (DCM), we explored in SKZ and healthy
controls (HC) the effettive connectivity between crucial areas for emotion-
al processing: Amygdala, dorsolateral prefrontal cortex (DLPFC) and an-
terior cingulate cortex (ACC).
Methods: A 3.0 Tesla fMRI was used to study 24 SKZ patients and 38
HC during an emotional task. Six competitive DCM models were con-
structed: the ACC-Amy connection was bidirectional and DLPFC-Amy
unidirectional. We tested all the possible combinations in ACC/DLPFC
connectivity. The input enter the network from Amy and DLPFC or
from Amy only. Bayesian model selection was used to determine the
best model from a structural perspective, whereas Bayesian Model
Averaging was performed to extract DCM parameters. Afterwards the
parameters were included in a second level analyses to assess (1) differ-
ences between groups (ANOVA) and (2) correlations (Person correlation)
with scores of Positive and Negative Symptoms Scale (PANSS).
Results: In both groups the best model showed a forward connection
from DLPFC to Amy and to ACC, and a bidirectional connection between
ACC-Amy. DLPFC-Amy connection was significantly reduced in SKZ
compared to HC. The strength of ACC-Amy connection correlated signifi-
cantly with PANSS positive symptomatology rating.
Conclusion: To our knowledge this is the first study which explore the
causal relationships of the neural system involved in emotional regulation
in SKZ. Our results suggest a functional disconnection in the social brain
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network of these patients. This may contribute to the behavioral and
symptomatic outcome of the disorder and may be proposed as a possible
biomarker of treatment efficacy.
Policy of full disclosure: None.
Result DCM:
P-05-014 Risk factors for new episode of schizophrenia
A. Bravo-Mehmedbasic1, A. Kucukalic1, A. Dzubur Kulenovic1,
J. Musabegovic2. 1University Clinical Centre, Sarajevo, Bosnia and
Herzegovina; 2Sarajevo, Bosnia and Herzegovina
Objective: The goal of this research is the registration of risk factors for
new schizophrenic episodes.
Methods: The study was prospective, comparative, analytical and de-
scriptive, and was carried out in the Psychiatric Clinic University
Clinical Center Sarajevo. Subjects were divided into experimental and
control group with 50 subjects. The experimental group patients had
more than one schizophrenic episode, while the control group had only
one schizophrenic episode which should be at least a year ago. The survey
questionnaire, designed by the authors of the study, examined the follow-
ing factors: Compliance with taking prescribed therapy, interruption of
therapy, the absence of psychoeducation, age of first schizophrenic epi-
sode and number of previous episodes.
Results: Compliance with therapy shows that the respondents in the
control group was taking medications more regularly, did not stop taking
the medication when they felt better (only 4% compared to 96% of the ex-
perimental group), did not stop taking their medication if they felt worse
after taking medications (30% compared to 96% of the experimental
group) and are more familiar with the long-term benefits of the medica-
tions. Termination of antipsychotic therapy was registered in 98% of
patients in experimental and only 2% of the control group. The absence
of psychoeducation is registered in 4% of the control group and in 32%
of the experimental group patients. The respondents in the control
group, on average, later experienced first schizophrenic episode, com-
pared to the experimental group. All these differences were statistically
significant. Experimental group had an average of 6.88 schizophrenic
episodes.
Conclusion: The study demonstrated that the risk factors have a sign-
ificant impact on relapse of schizophrenic episodes. Non-compliance
with taking prescribed therapy, interruption of therapy, the absence of
psychoeducation and earlier age of first schizophrenic episodes are sign-
ificant risk factors for recurring schizophrenic episodes.
Policy of full disclosure: None.
P-05-015 Efficacy and safety of adjunctive bitopertin (10 and 20mg)
versus placebo in subjects with sub-optimally controlled
symptoms of schizophrenia treated with antipsychotics –
Results from the Phase III TwiLyte study
D. Bugarski-Kirola1, W.W. Fleischhacker2, T. Blaettler1, C. J. Edgar3,
S. Milosavljevic-Ristic1, F. Lamour1, S. Sun4, S. Kapur5. 1Basel,
Switzerland; 2Innsbruck, Austria; 3Welwyn Garden City, United Kingdom;
4Shanghai, China; 5London, United Kingdom
Objective: Current dopamine-acting antipsychotics do not work uni-
formly for all patients. NMDA receptor hypofunction has been implicated
as a potential factor in psychosis. In this study we evaluated the safety and
efficacy of bitopertin, a glycine reuptake inhibitor thought to indirectly
enhance NMDA receptor function, in patients with schizophrenia who
continued to show sub-optimally controlled psychotic symptoms despite
ongoing treatment with antipsychotics (TwiLyte; NCT01235520).
Methods: Key inclusion criteria were: age >=18 years, DSM-IV-TR diag-
nosis of schizophrenia; Positive and Negative Syndrome Scale (PANSS)
score >=70; score >=4 on >=2 psychotic PANSS items; and clinical and
antipsychotic treatment stability. Following the 4-week observation per-
iod, patients were randomized 1:1:1 to bitopertin 10mg, 20mg or placebo
once daily for 12 weeks.
Results: 560 patients (94% randomized) were included in the ITT popu-
lation. Treatment arms were comparable at baseline with PANSS total
scores and Positive Symptoms Factor Scores (PSFS; transformed to a 0 [ab-
sent] to 6 [extreme] scale) of ∼55 and ∼19 respectively for all groups, cor-
responding to moderately severe ongoing psychosis. Over 80% patients in
each group completed 12 weeks of treatment. All groups showed equi-
valent improvement at Week 12 on the PSFS (primary endpoint) and on
PANSS total (secondary endpoint), without any statistical separation.
PSFS improvements were: bitopertin 10mg -4.67 (SE, 0.329; p=0.2169),
20mg −4.81 (SE 0.330; p=0.3572), placebo −5.25 (SE 0.334). PANSS
total scores changed in a similar direction and magnitude. The adverse
event (AE) profile was similar to placebo with >=1 AE reported by
30.3%, 35.6% and 34.7% for bitopertin 10mg, 20mg and placebo groups,
respectively. There were no effects on vital signs, weight or metabolic
parameters, and there was an expected dose-dependent reduction in
haemoglobin.
Conclusion: Bitopertin was well tolerated, but we found no evidence
for efficacy against sub-optimally controlled positive symptoms. This is
the first study in this population, further studies are underway.
Policy of full disclosure: This study was supported by F. Hoffmann-La
Roche Ltd. DB-K, TB, CJE, SM-R, FL and SS are all employees of Roche.
WWF has received research grants from Otsuka, Janssen, Alkermes and
Reckitt-Benckiser, consulting honoraria from Lundbeck, Roche, BMS,
Otsuka, Janssen, Pfizer, MedAvante, Sunovion, Amgen, Endo and
Vanda, Speaker honoraria from Lundbeck, Janssen, Otsuka, Astra
Zeneca, Richter and Roche, and owns stocks in MedAvante. SK has
received grant support from GSK, GW and Roche and has served as a one-
off consultant and/or speaker for AstraZeneca, Bristol Meyers Squibb, Eli
Lilly, Envivo, Janssen – Johnson and Johnson, Otsuka, Pfizer, Takeda and
serves on the Scientific Advisory Boards for Lundbeck and Roche.
P-05-016 Minocycline add-on to haloperidol: Brain topography of
glutamatergic signaling transcripts and implications for
psychosis treatment
E. F. Buonaguro1, C. Tomasetti2, F. Marmo2, G. Latte2, L. Avvisati2,
F. Iasevoli2, A. de Bartolomeis2. 1University Federico II, Naples, Italy;
2University Federico II, Department of Neuroscience, Naples, Italy
Objective: In this study, we investigated whether the second-generation
tetracycline minocycline add-on to haloperidol may affect the expression
of two early genes, Homer1a and Arc, implicated in glutamatergic signal-
ing. The investigation was carried out in rats exposed or not to ketamine,
thus mimicking N-Methyl D-Aspartate receptor (NMDA-R) hypofunction
or naturalistic conditions, respectively.
Methods: The first group of rats received the following treatments: 1)
Vehicle+Vehicle (VEH+VEH); 2) Vehicle+Haloperidol 0.8 mg/kg (VEH
+HAL); 3) Vehicle+Minocycline 45 mg/kg (VEH+MYN); 4) Vehicle+
Haloperidol 0.8 mg/kg+Minocycline 45mg/kg (VEH+HAL+MYN). The
second treatment group received Ketamine 30 mg/kg (KET) instead of
Vehicle, resulting in the following treatment subgroups: KET+VEH;
KET+HAL; KET+MYN; KET+HAL+MYN. The topography of tran-
scripts expression was evaluated by means of in situ hybridization.
Results: Homer1a –Vehicle-experiment. Haloperidol and minocycline,
alone or in combination reduced gene expression in the insular cortex
compared with vehicle. In striatum, Homer1a expression was induced
by haloperidol in almost all subregions. –Ketamine-experiment.
Haloperidol+minocycline reduced Homer1a expression in the medial
agranular cortex and in the motor cortex compared with vehicle. In stria-
tum, haloperidol induced Homer1a expression in the ventrolateral
caudate-putamen only. Minocycline limitedly reduced haloperidol-
mediated Homer1a expression. Arc –Vehicle-experiment. Haloperidol
+minocycline reduced Arc cortical expression compared with vehicle
and haloperidol or minocycline alone increased Arc cortical expression
compared with their combination. In striatum, both haloperidol and halo-
peridol+minocycline induced Arc expression compared with vehicle,
while minocycline alone significantly reduced it. –Ketamine-experiment.
The expression pattern observed in the Vehicle-experiment was confirmed
also in the Ketamine- experiment. No significant differences in Homer1a
and Arc baseline expression where observed (i.e. VEH+VEH vs. KET+
VEH).
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Conclusion: Minocycline add-on blunted haloperidol-mediated cortical
Arc expression and cortico-striatal Homer1a expression. Minocycline has
been described to attenuate the increase in dopamine levels after
NMDA-R blockade. Therefore, minocycline may attenuate haloperidol’s
acute effect on dopaminergic and glutamatergic signaling, which may
be relevant for therapeutic efficacy and side effects.
Policy of full disclosure: None.
P-05-017 Reduced expression of both brain-derived neurotrophic
factor and reelin sensitizes to the long-term effects of
glucocorticoid stimulation on memory in mice: relevance
to schizophrenia
L. Buret1, M. van den Buuse2. 1The Florey, Melbourne, Australia; 2School of
Psychological Science, La Trobe University, Melbourne, Australia
Objective: Schizophrenia is a neurodevelopmental disease likely caused
by a combination of multiple genetic factors and environmental influences
such as stress exposure during adolescence/young- adulthood. Reelin and
brain-derived neurotrophic factor (BDNF) play an important role during
brain development and reduced levels of both proteins have been found
in schizophrenia. We then study the Reelin x BDNF x stress exposure in-
teraction in schizophrenia.
Methods: First we used Western blot to quantify mature BDNF
(mBDNF) and full-length (FL) reelin and its N-R6 and N-R2 cleavage frag-
ments in the dorsal hippocampus (DH) and ventral hippocampus (VH) of
6 week old wild-type (WT) and BDNF heterozygous (HET) mice. In a par-
allel cohort, we then simulated adolescent/young-adult stress by chronic
treatment with corticosterone (CORT) from 6–9 weeks of age. In adult-
hood at 11–12 weeks of age, we assessed short-term spatial memory
and social behaviour in a Y-maze and 3 chamber social interaction task
(SI), respectively.
Results: As expected, mBDNF levels were about 50% lower in DH and
VH of HET compared to WT. Moreover, mBDNF levels were approxi-
mately 50% lower in males compared to females. Reelin FL and N-R2
were reduced by 30% in DH of male HET compared to male WT and
females, with no differences in VH. CORT-treated HET males, but not
females, showed a significant reduction of spatial memory in the Y
maze but there were no group differences in the SI task.
Conclusion: Our results suggest that reduced levels of reelin against a
background of low BDNF expression, as observed here in the DH of
young-adult male HET, may sensitize to the effects of developmental
stress to result in cognitive deficits in adulthood. Because reduced levels
of both reelin and BDNF have been found in schizophrenia, our results
may be relevant for some of the cognitive deficits commonly observed
in this illness.
Policy of full disclosure: None.
P-05-018 Gender differences in the pharmacotherapy of
schizophrenia
E. Ceskova1, R. Prikryl2, J. Libiger3. 1CEITEC, Faculty Hospital Brno, Brno,
Czech Republic; 2Masaryk University, Brno, Czech Republic; 3Charles
University, Hradec Kralove, Czech Republic
Objective: To compare male and female patients participating in the
EUFEST (European First-Episode Schizophrenia Trial), focusing on re-
sponse to treatment.
Methods: The EUFEST trial compared four second generation antipsy-
chotics (amisulpride, olanzapine, quetiapine and ziprasidone), against
treatment with low doses of haloperidol in patients with first-episode
schizophrenia. Patients were randomly assigned by a centralized, compu-
terized online randomization system to open-label treatment. The data
were collected at baseline and then prospectively for 1 year. Treatment re-
sponse was evaluated using the PANSS (the Positive and negative syn-
drome scale).
Results: All patients from EUFEST study for whom both baseline and
12 assessment were available (n=498; 298 men and 200 women) were in-
cluded. Baseline characteristics (age and proportion of patients assigned
to individual antipsychotics) were the same between the male and female
patients with exception of ziprasidone: significantly less men than women
were assigned to ziprasidone. The total PANSS and all PANSS subscales
scores did not differ between the both groups After 3 months of treatment
a significantly more robust improvement in the total PANSS and all
PANSS subscales scores was seen in women. After 6 months the
women improved significantly more in the total PANSS and the PANSS
positive subscale, after 9 months significantly more pronounced improve-
ment was seen in the total PANSS and all the PANSS subscale scores with
exception of negative subscale, no differences after 12 months were seen.
Among all given antipsychotics only olanzapine led to significantly
greater improvement in all domains of psychopathology, the total
PANSS all the PANSS subscale scores, in women during all the follow-up
period.
Conclusion: The gender differences should be more intensively studied
and should be taken into consideration in guidelines. Strategies to deal
with these gender differences need to be considered in early intervention
program.
Policy of full disclosure: Supported by the project CEITEC (CZ.1.05/
1.1.00/02.0068) from European Regional Development Fund.
P-05-019 Genetic association between GRIA2, GRIA4 gene
polymorphisms and clinical phenotypes of schizophrenia
S. Cho1, W. S. Kang2, Y. J. Kim2, J. W. Kim2. 1Kyung Hee University Hospital,
Seoul, Republic of Korea; 2Kyung Hee University, School of Medicine, Seoul,
Republic of Korea
Objective: A glutamate dysfunction hypothesis has been proposed to
explain the pathogenesis of schizophrenia. There are increasing evidences
that AMPA receptors dysfunction may be related to increased suscepti-
bility to schizophrenia. The aim of this study was to determine whether
genetic polymorphisms of the glutamate receptor, ionotropic, AMPA re-
ceptor (GRIA) are associated with schizophrenia in the Korean
population.
Methods: Three SNPs of the GRIA2 and five SNPs of the GRIA4 gene
were genotyped. The allelic and genotypic associations between 219
schizophrenia patients and 380 healthy controls were examined.
Possible associations between these polymorphisms and the clinical
symptoms of schizophrenia such as hallucinations and delusions were
also investigated. Multiple logistic regression models (co-dominant, domi-
nant, and recessive) were performed to estimate odds ratios and p values.
A Bonferroni correction was used for multiple testing.
Results: There was significant differences in the genotype frequencies of
rs672673 of the GRIA4 gene were found between schizophrenia and con-
trols [p=0.047 in the co-dominant model (AA vs. GG), p=0.035 in the re-
cessive model (AA vs. GG/AG)]. In analysis of clinical symptoms,
significant differences were found between schizophrenia patients with
hallucinations and schizophrenia patients without hallucinations in the
GRIA4 gene [rs672673 (G/A), p=0.0034 in the recessive model (AA vs.
GG/AG)].
Conclusion: The results from the present study support the relationship
between AMPA receptor gene polymorphisms and schizophrenia symp-
toms. GRIA4 polymorphisms may be contribute to the development of
hallucinations in schizophrenia in the Korean population.
Policy of full disclosure: None.
P-05-020 Association between promoter polymorphism (-1572 T/C)
in 5-hydroxytryptamine receptor 3B and poor
concentration in schizophrenia
S. Cho1, H. J. Park2, W. S. Kang3, Y. J. Kim3, J. W. Kim3. 1Kyung Hee
University Hospital, Seoul, Republic of Korea; 2Kohwang Medical Research
Institute, Seoul, Republic of Korea; 3Kyung Hee University, School of
Medicine, Seoul, Republic of Korea
Objective: Previous studies have shown the involvement of 5-hydroxy-
tryptamine receptor 3 (HTR3) in schizophrenia. In addition, the variants
of HTR3 genes have been associated with treatment outcomes of antipsy-
chotics in schizophrenia. In this study, we investigated the associations of
the HTR3 genes with schizophrenia by analyzing the single nucleotide
polymorphisms (SNPs) of the HTR3A and HTR3B.
Methods: A total of 222 Korean schizophrenia patients and 381 control
subjects were recruited at Kyung Hee Medical Center in Seoul, Republic of
Korea. SNPs located in the promoter or exon of the HTR3B and HTR3A
were selected from the dbSNP database. Seven SNPs (rs10789970,
rs11214763, rs3758987, rs1176744, and rs2276305 in HTR3B; rs1062613
and rs1176713 in HTR3A) were selected, and genotyped using direct
sequencing. The operational criteria checklist was used to measure general
psychopathology. Multiple logistic regression analysis using codominant,
dominant, and recessive models was performed with SNPStas, adjusting
age and gender.
Results: In our study, no SNPs of the HTR3A and HTR3B were asso-
ciated with schizophrenia. However, in analysis according to the clinical
symptoms of schizophrenia, we found that rs10789970 of HTR3B was
significantly associated with poor concentration in schizophrenia patients
in the additive [TC vs. CC vs. TT; P=0.0016, odds ratio (OR)=1.95, 95%
confidence interval (CI)=1.27–2.99) and dominant models (TC/CC vs.
TT; P=0.0024, OR=2.46, 95% CI=1.37–4.42). In allele frequency analysis,
rs10789970 was also associated with poor concentration (P=0.0020, OR=
1.88, 95% CI=1.26–2.81).
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Conclusion: In conclusion, these findings imply that HTR3A and
HTR3B genes may not be directly involved in the incidence of schizo-
phrenia. But we found association with HTR3B and poor concentration
in schizophrenia patients. These results suggest that the HTR3B may be
involved in the attention problem of schizophrenia in Korean population.
Policy of full disclosure: None.
P-05-021 Preference for long-acting injectable antipsychotics of
community-dwelling patients with schizophrenia and
their caregivers in Korea
I. W. Chung1, Y.-S. Kim2, N. Y. Lee2, T. Youn1. 1Dongguk University
Hospital, Goyang-Si, Gyeonggi-Do, Republic of Korea; 2Dongguk University
Hospital, Institute of Clinical Psychopharmacology, Goyang-Si, Gyeonggi-Do,
Republic of Korea
Objective: The prescription rates of long-acting injectable antipsychotics
are very low around 1% in Korea. This study was aimed to explore the
preference of long-acting injectable antipsychotics in patients with schizo-
phrenia, who are currently living in community, and their caregivers.
Methods: The patients who were diagnosed with schizophrenia and
were registered in the 31 mental health centers of Gyeonggi province
and their caregivers were inquired the knowledge of the long-acting
injectable antipsychotics. The questionnaires contained informations
such as demographic characteristics, history of psychiatric treatment,
and knowledge and preference of long-acting injectable antipsychotics
and so on.
Results: About 8,960 subjects were registered in the community mental
health centers of Gyeonggi province in February 2012. Among them,
5,318 patients were diagnosed with schizophrenia. A total of 980 subjects
(614 of patients and 365 of caregivers) answered the questionnaires. The
mean ages (SD) of patient responders (n=604) and caregiver responders
(n=352) were 42.0 (±10.2) and 62.2 (±13.4) years old respectively. A con-
siderable number of patients (44.6% of patient responder and 43.6% of
caregiver responders) have experienced discontinuation of medications
without doctor’s consent. Only 35.9% of patient responders (n=605) and
27.1% of caregiver responders (n=358) did know about the long-acting
injectable antipsychotics. Tentative preference for long-acting injectable
antipsychotics were 35.2% and 46.8% for the patients and caregivers, re-
spectively. More analyzing results will be represented in the poster.
Conclusion: There is the huge discrepancy between the preference and
the real prescriptions of long-acting injectable antipsychotics in Korea.
Both patients and their caregivers registered in the CMHCs have a strong
commitment to live in the community. The obstacles against the benefits
of long-acting injectable antipsychotics need to be resolved.
Policy of full disclosure: None.
P-05-022 Metabolic syndrome in chronic antipsychotic treatment
of schizophrenia
I. W. Chung1, N. Y. Lee1, Y. S. Kim1, T. Youn1, S. H. Kim2, U. G. Kang2, Y.
M. Ahn1. 1Dongguk University Hospital, Goyang-Si, Gyeonggi-Do, Republic of
Korea; 2Seoul National University, Seoul, Republic of Korea
Objective:Metabolic syndrome (MetS) in patients with schizophrenia has
been reported widely, mostly in a cross-sectional data. We were aimed to
evaluate MetS changes during the maintenance antipsychotic treatment in
Korean patients with schizophrenia.
Methods: The retrospective chart review was conducted in order to ex-
plore the natural course of metabolic effects in the clinical practice of anti-
psychotic treatment. Through the review of the electronic medical record
of patients with schizophrenia of Seoul National University Hospital from
June 2007 to October 2010, patients who were measured more than twice
for all MetS components were recruited. One hundred and eighty one
patients with schizophrenia were analyzed for the metabolic data of the
American Heart Association and the National Heart, Lung and Blood
Institute adaptation of National Cholesterol Education Program Adult
Treatment Panel III#s (ATP-IIIA) definition of MetS, waist circumference
criterion of the Korean Society for the Study of Obesity.
Results: Men were 98 patients (54.1%) and mean age of patients was
34.4 (SD=9.1) years. Mean durations of illness and of antipsychotic treat-
ment were 11.2 (SD=6.5) years and 9.9 (SD=6.3) years, respectively. Mean
interval of measurements for metabolic data was 12.5 (SD=5.4) months
and the prevalence of MetS changed from 33.7% at baseline to 44.8% at
follow-up. The incidence of MetS was 30.0% and the reversal rate of
that was 26.2% between two measurement time-points. Incidence and re-
versal by clozapine were 39.0% (23/59), 31.0% (13/42) and those by other
antipsychotics were 21.3% (13/61) and 15.8% (3/19), respectively.
Conclusion: MetS was continuously increased during chronic antipsy-
chotic treatment. Simultaneously, substantial numbers of patients showed
reversal to state of no MetS in routine practice. Clozapine showed promi-
nent and dynamic change of metabolic syndrome compared to other
antipsychotics.
Policy of full disclosure: None.
P-05-023 Efficacy and safety of paliperidone ER in patients with
first episode psychosis: An open-label, prospective,
multi-center study
Y.-C. Chung1, J.-I. Park2, D.-H. Cho3, S.-W. Hahn4, C. Han5, M. H. Jung6,
J.-H. Kim7, S.-W. Kim8, K. Y. Lee9. 1Chonbuk National University, Jeonju,
Republic of Korea; 2Chonbuk National University, Medical School, Jeonju,
Republic of Korea; 3Dr Cho´s Neuropsychiatry Clinic and Research Center,
Busan, Republic of Korea; 4Soonchunhyang University College of Medicine,
Seoul, Republic of Korea; 5Korea University of College of Medicine, Ansan,
Republic of Korea; 6Hallym University Sacred Heart, Hospital, Anyang,
Republic of Korea; 7Gil Medical Center, Gachon, University, Incheon, Republic
of Korea; 8Chonnam National University, Medical School, Gwangju, Republic
of Korea; 9Eulji University College of Medicine, Eulji General Hospital, Seoul,
Republic of Korea
Objective: The aim of our study was to evaluate the efficacy and
safety of paliperidone extended-release (paliperidone ER) in patients
with first-episode psychosis.
Methods: This was an 8-week, open-label, prospective, multicenter
trial. The study population consisted of 75 patients of first-episode
psychosis. The initial recommended dose of paliperidone ER was
3–6mg/day, increasing to 12mg/day depending on treatment response.
The primary outcome measures were the PANSS and CGI-SCH; second-
ary measures included the SANS and Cognitive Assessment Interview
(CAI).
Results: Total 51 patients(68.0%) completed the study. Treatment with
paliperidone ER resulted in significant improvement in the PANSS, CGI
and SANS scores over time. The response rate (defined as >=30% decrease
in PANSS total score from baseline to last observation) was 55.3%. Using
the definition of treatment response as 20% reduction in PANSS total
scores, NPV and specificity at week-2 was higher than those of week-3.
When using 30% reduction in PANSS total scores, there was no difference
in NPV and specificity between week 2 and week-3. Overall, the most fre-
quent adverse events were akathisia (41.3%), somnolence (24.0%), EPS
(22.7%) and sedation. Adverse events were primarily observed early in
the course of treatment, at 1 or 2-weeks. No significant changes in the
scales measuring extrapyramidal symptoms (SARS, AIMS, BAS) were
observed. After 8-week treatment, there was significant increase in fasting
triglyceride, total cholesterol, prolactin level, and significant weight gain
was observed.
Conclusion: These results indicate that paliperidone ER is effective in
the treatment of first-episode psychosis and has a modest side effect bur-
den. According to the definition of treatment response, response at week-2
or 3 is shown to be a good predictor of subsequent response at week 8,
demonstrating high NPV and high specificity.
Policy of full disclosure: None.
P-05-024 Differential effects of the potential antipsychotic d,
l-govadine and its isomers on behavioural flexibility;
comparison with D1 and D2 selective compounds
G. Dalton1, C. Weidman1, S. Floresco1, A. Phillips1. 1University of British
Columbia, Vancouver, BC, Canada
Objective: Schizophrenia is associated with positive and negative symp-
toms as well as cognitive deficits. Dopamine D2 (DA D2) receptor antago-
nists are effective at treating positive symptoms yet fail to improve
cognitive impairments of the disorder. We recently described the potential
antipsychotic efficacy of the tetrahydroprotoberberine D,L-govadine, that
appears to exert both D2-antagonist and possibly D1-partial agonist
properties. This compound increases DA efflux in forebrain regions,
shows antipsychotic properties in preclinical assays relevant to schizo-
phrenia and also enhances cognitive function assessed with a delayed re-
sponse task. The current study investigated the effects of the racemic
mixture of D,L-govadine and its D and L isomers on behavioural flexibil-
ity, an executive function impaired in schizophrenia.
Methods: Rats were tested on an operant strategy-shifting task, wherein
they first learned a visual-cue discrimination. The next day, drugs were
administered prior to the set-shift, where rats learned to disregard the
visual-cue and learn a novel response discrimination strategy. The effects
of the 3 govadine compounds (0.3–1mg/kg) were compared to those
induced by the D1 agonist SKF81297 and the D2 antagonist, haloperidol.
Results: A low dose of haloperidol (0.1 mg/kg) caused non-
perseverative impairments in set-shifting, whereas a higher dose
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(0.2 mg/kg) impaired retrieval of the initial rule. Low doses of SKF81297
(0.1 mg/kg) improved shifting by decreasing perseveration. In compari-
son, D,L-govadine generally did not affect set-shifting, although the
high dose increased non-perseverative errors. L-govadine induced dose-
dependent, non-perseverative impairments, similar to haloperidol. In con-
trast, D-govadine improved performance at all doses and reduced
perseveration.
Conclusion: These data suggest that antipsychotic properties of D,
L-govadine may be attributable to the L-isomer while the cognitive en-
hancing effects may be due to D1 agonist-like actions of the D-isomer.
Further development of these types of compounds may prove useful in
devising therapies to treat both psychotic and cognitive symptoms of
schizophrenia.
Policy of full disclosure: None.
P-05-025 N-Propynyl analogs of beta-phenylethylidenehydrazine
increase brain levels of glycine and inhibit its uptake
by brain slices
K. Dhami1, E. MacKenzie1, E. Knaus1, C. Velazquez-Martinez1, K. Todd1,
G. Baker1. 1University of Alberta, Edmonton, Canada
Objective: There has been a great deal of interest in recent years in inhi-
bitors of glycine reuptake as potential antipsychotic drugs. Two analogs
of the novel neuroprotective drug beta-phenylethylidenehydrazine
(PEH) (a metabolite of phenelzine (PLZ), namely the N-bis-(2-propynyl)
and N-mono-(2-propynyl) analogs, were synthesized by us and compared
ex vivo to PEH with regard to their effects on rat brain levels of glycine.
Methods: Glycine levels were measured using high performance liquid
chromatography with fluorescence detection after derivatization. The ana-
logs were also studied in vitro in rat frontal cortex brain slices to compare
their effects to those of PEH and PLZ with regard to their ability to inhibit
the uptake of glycine; the results were compared to those of two known
inhibitors of the glycine transporter, namely sarcosine and Org-24598.
Results: The two synthetic analogs caused marked increases in brain
levels of glycine at 3, 6 and 12 hrs post-injection whereas PEH had no ef-
fect on these levels. All drugs were injected i.p. into male Sprague Dawley
rats at a dose of 0.22 mmol/kg. In the uptake studies in vitro, the
N-bis-(2-propynyl) analog caused a concentration-dependent inhibition
of 3H-glycine uptake at 100, 200 and 400microM compared to controls.
The N-mono-(2-propynyl) analog and PEH caused inhibition of
3H-glycine uptake at 200 and 400microM, however, not to the extent
seen with the N-bis-(2-propynyl) analog. PLZ caused no inhibition of
3H-glycine uptake at 50, 100, 200 or 400microM. Although the two ana-
logs were weaker than sarcosine and Org-24598, they nonetheless pro-
duced significant inhibition of 3H-glycine uptake.
Conclusion: This effect combined with their marked effect on brain
levels of glycine indicate that further studies on them as potential antipsy-
chotics are warranted. The authors are grateful to the CIHR and to Alberta
Health Services for funding.
Policy of full disclosure: None.
P-05-026 Disruption of regulated AMPA receptor endocytosis
enhances latent inhibition of two-way avoidance
C. Dias1, D. Ashby2, Y. T. Wang2, A. G. Phillips2. 1University of British
Columbia, Neuroscience, Vancouver, Canada; 2University of British Columbia,
Vancouver, Canada
Objective: The attentional deficit observed in schizophrenia can be mod-
eled in animals using a latent inhibition paradigm in which the pre-
exposure to a neutral stimulus (NS) retards subsequent learning of the as-
sociation between the NS and an unconditional stimulus (UCS).
Interfering with this learning could highlight important aspects of the
neurobiological processes involved in latent inhibition. This study
assessed the role of long-term depression (LTD) in latent inhibition.
Methods: LTD can be disrupted by an interference peptide,
Tat-GluA2-3Y which blocks alpha-amino-3-hydroxy-5-methyl-isoxazole-
4-propionic acid (AMPA) receptor endocytosis. This peptide was first
administered intravenously (2.25 nmol/g) 60 min. prior to the acquisition
of two-way avoidance. In a separate experiment, Tat-GluA2-3Y
(15 pmol) was then administered into different brain regions including
the prefrontal cortex, amygdala and nucleus accumbens.
Results: Tat-GluA2-3Y had no effect on learning the association of
NS-UCS when animals had not been pre-exposed to the NS. However,
disruption of LTD by interference with AMPA receptor endocytosis sign-
ificantly disrupted 2-way avoidance learning signaled by a CS to which
the rat had been pre-exposed This effect was replicated when
Tat-GluA2-3Y has been microinjected into the central nucleus of amygdala
but not in other structures.
Conclusion: These findings suggest that LTD in the central nucleus of
amygdala plays a crucial role in switching the diminished salience of a
pre-exposed neutral stimulus to a conditioned stimulus.
Policy of full disclosure: None.
P-05-027 Safety and tolerability of cariprazine in long-term
treatment of schizophrenia: Integrated summary of safety
data
S. Durgam1, H. A. Nasrallah, Henry A. Nasrallah2, A. Cutler3, Y. Wang4,
K. Lu4, K. Nagy5, I. Laszlovszky5. 1Forest Research Institute, Jersey City,
USA; 2St. Louis, USA; 3Bradenton, USA; 4Jersey City, USA; 5Budapest,
Hungary
Objective: Pooled data from 2 studies were analyzed to evaluate the long-
term safety and tolerability of cariprazine, a potent dopamine D3 and D2
receptor partial agonist with preferential binding to D3 receptors, in
patients with schizophrenia.
Methods: Integrated summary of safety/tolerability data from two
48-week studies of open-label, flexible-dose cariprazine in adult patients
with schizophrenia. In the first study (NCT01104792), new patients and
patients who completed double-blind treatment in 1 of 2 lead-in studies
(NCT01104766 or NCT01104779) received cariprazine 3–9mg/day. In the
second study (NCT00839852), patients who completed a double-blind
lead-in trial (NCT00694707) received cariprazine 1.5–4.5 mg/day. Safety
evaluations included adverse events, laboratory and vital signs, ECG,
ophthalmologic examinations, and assessments on the Barnes Akathisia
Rating Scale (BARS) and Simpson-Angus Scale (SAS).
Results: Of 679 patients, 40.1% completed open-label treatment. Mean
duration of treatment (days±SD) was 188.4±136.8; 211 patients (31.1%)
were exposed to cariprazine for 51 year. In patients continuing from
double-blind studies, PANSS and CGI-S scores further decreased during
open-label treatment. Treatment-emergent AEs (TEAEs) were reported
in 553 patients, the most common of which were akathisia (15.5%), insom-
nia (13.1%), headache (12.7%), and weight increase (10.5%). Serious AEs,
including 1 suicide, were reported in 79 patients (11.6%). The most com-
mon were worsening of schizophrenia (4.4%) and psychotic disorder
(2.1%). Mean increase in body weight was 2.46 kg. No clinically significant
mean changes in laboratory values (including metabolic parameters),
blood pressure, or ECGs were noted. Mean prolactin levels decreased
from baseline to the end of study. Incidences of parkinsonism (SAS >3)
and akathisia (BARS >2) were 10.7% and 17.8%, respectively.
Ophthalmologic testing revealed no clinically meaningful changes.
Conclusion: Cariprazine administered for up to 48 weeks in adults with
schizophrenia was generally safe and well tolerated, with relatively few
new AEs compared with acute treatment.
Policy of full disclosure: Supported by funding from Forest
Laboratories, Inc. and Gedeon Richter Plc. Suresh Durgam is an employee
of Forest Research Institute.
P-05-028 Effect of antipsychotic drugs on bone density and cortisol
level in schizophrenia
A. El Sheshai. Alexandria Psychiatric Center, Alexandria, Egypt
Objective: The aim of the work was to study the long term effects of anti-
psychotics on bone density and cortisol level in schizophrenic patients.
Methods: The study was conducted on 50 schizophrenic patients in
Alexandria university hospital. They were divided into two groups.
Group A: 30 patients under antipsychotic medication for more than
2 years but less than 10 years. And group B: 20 patients, medication
naïve (no medication). All patients were subjected to: Clinical psychiatric
examination to diagnose schizophrenia (DSM-IV-TR); medical and neuro-
logical examination; brief psychiatric rating scale; measurement of serum
prolactin level; measurement of cortisol level; measurement of bone den-
sity by dual- energy-X ray Absorptiometry.
Results: The result showed that bone mineral density (BMD) was inver-
sely correlated with hyper-prolactinemia caused by antipsychotic, and
also affected by cortisol level in unmedicated schizophrenics, while anti-
psychotics affect cortisol level through normalizing or lowering it.
Policy of full disclosure: None.
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P-05-029 The efficacy and safety of aripiprazole once-monthly in
obese and non-obese patients with schizophrenia; a
post-hoc analysis
A. Eramo1, M. De Hert2, W. Landsberg3, L.-F. Tsai4, R. A. Baker5.
1H. Lundbeck A/S, Chicago, USA; 2University Psychiatric Center,
Department of Neurosciences, KU Leuven, Kortenberg, Belgium; 3Otsuka,
Wexham, United Kingdom; 4Otsuka, Rockville, USA; 5Otsuka, Princeton, USA
Objective: To evaluate efficacy and safety of aripiprazole once-monthly
(AOM), an extended release injectable suspension of aripiprazole, in
obese (BMI>=30 kg/m2) and non-obese (BMI<30 kg/m2) patients with
schizophrenia.
Methods: Data from a 38-week, double-blind, active-controlled, non-
inferiority study (NCT00706654); randomisation (2:2:1) to aripiprazole
once-monthly 400/300mg (AOM-400/300mg), oral aripiprazole
(10–30 mg/day) (ARI), or aripiprazole once-monthly 50/25 mg (AOM-50/
25mg) in stable patients were analyzed post-hoc. Relapse rates in the
38-week randomized phase were compared using the Chi-squared test.
Results: 662 patients were randomized to: AOM-400/300 mg (n=265;
obese n=95 [36%]); ARI (n=266; obese n=95 [36%]); or AOM-50/25mg
(n=131; obese n=43 [33%]). In obese patients, the relapse rate was signifi-
cantly (p=0.0012) lower with AOM-400/300mg (7.4%) than with
AOM-50/25 mg (27.9%). Relapse rates with AOM-400/300mg and ARI
(8.4%) were similar. In non-obese patients, the relapse rate was signifi-
cantly (p=0.0153) lower with AOM-400/300mg (8.8%) than with
AOM-50/25 mg (19.3%). Relapse rates with AOM-400/300mg and ARI
(7.6%) were similar. For AOM-400/300mg, the most common treatment
emergent adverse events (>=10%) were insomnia (obese 12.6%, non-obese
11.2%), headache (obese 12.6%, non-obese 8.2%), injection site pain (obese
11.6%, non-obese 5.3%), akathesia (obese 10.5%, non-obese 10.6%), upper
respiratory tract infection (obese 10.5%, non-obese <5%). Increased weight
was reported in 10.5% of obese patients and 8.2% of non-obese patients.
The incidence of shifts from non-obese at baseline to obese during the ran-
domized phase was 7.6% (13/170) and from obese to non-obese was 17.9%
(17/95).
Conclusion: The efficacy and tolerability of AOM 400/300mg were
similar in both the obese and non-obese subgroups.
Policy of full disclosure: Supported by Otsuka Pharmaceutical
Development & Commercialization, Inc., and H. Lundbeck A/S. Dr. De
Hert has been a consultant for, received grant/research support and
honoraria from, and been on the speakers/advisory boards of Astra
Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck JA,
Pfizer, Sanofi Aventis and Takeda. Dr. Eramo is an employee of
H. Lundbeck A/S. Dr. Landsberg, L.-F. Tsai, and Dr. Baker are employees
of Otsuka Pharmaceutical Development & Commercialization, Inc.
P-06. Neurodegeneration A
P-06-001 ASP5736, a novel, selective and brain-penetrable
serotonin 5-HT5A receptor antagonist, ameliorates
cognitive deficits in rodent models of Alzheimer’s disease
K. Harada1, M. Okabe1, M. Yamazaki1, N. Yamamoto1, J. Yarimizu1,
M. Fujii1, K. Ni1. 1Astellas Pharma Inc., Tsukuba-Shi, Ibaraki, Japan
Objective: Although human 5-HT5A receptor was cloned 20 years ago,
very little has been unraveled about the function of the receptor in native
tissues. Findings from mRNA localization and immunolabeling studies
have revealed widespread expression in the CNS, and have provided
clues to the potential functional roles of the receptor. The lack of under-
standing of the role of the receptor has been, at least in part, caused by
the lack of available selective 5-HT5A receptor ligands. Therefore, we
have chemically optimized the functional properties of a series of com-
pounds and identified ASP5736 as a novel antagonist of 5-HT5A receptor.
In the present study, we describe our in vitro and in vivo characterization
of this compound.
Results: ASP5736 exhibited high affinity for the human 5-HT5A recep-
tor (Ki=3.6 nM) and potently antagonized 5-carboxamidotryptamine-
induced Ca2+ influx in human cells stably expressing the 5-HT5A receptor
(IC50=1.0 nM). It showed more than 200-fold selectivity over other recep-
tors, including other 5-HT receptor subtypes, enzymes and channels
except for human 5-HT7 receptor (Ki=122.9 nM). The compound pene-
trated into the brain after oral administration to mice and rats. We then
evaluated the effects of ASP5736 on rodent models of cognitive deficits
in Alzheimer’s disease. Working memory deficit in scopolamine-treated
mice was attenuated by ASP5736 treatment (0.001–0.003 mg/kg, po) as
well as by donepezil (0.25–0.5 mg/kg, po). Moreover, spatial learning
deficit in aged rats was also attenuated by ASP5736 treatment (0.001–
0.03 mg/kg, po), but not by donepezil (0.1–3mg/kg, po).
Conclusion: These studies provide compelling evidence that ASP5736
is a novel, selective and brain-penetrable 5-HT5A receptor antagonist
that is useful to elucidate the physiological function of 5-HT5A receptor
in the brain. Furthermore, they also suggest that 5-HT5A receptor antag-
onist might have utility for the symptom relief of Alzheimer’s disease.
Policy of full disclosure: None.
P-06-002 Aripiprazole for the treatment of psychotic symptoms in
patients with Lewy bodies: A case series
Y. Kikuchi1, M. Sasaki2, T. Shimomura3, T. Kanbayashi1, T. Shimizu1.
1Akita University, Akita, Japan; 2Kakunodate, Japan; 3Akita, Japan
Objective: Dementia with lewy bodies (DLB) is commonly considered the
second most common form of dementia. The purpose of this study is to
investigate the treatment effects of aripiprazole in patients with DLB.
Methods: Eleven patients who had meet the criteria for DLB partici-
pated in this study. The presence of psychotic symptoms was confirmed
by scores of either the delusions or hallucinations items of the
Neuropsychiatric Inventry (NPI) score. Patients who had 25 or more on
the Mini-mental State Examination Scale (MMSE) at the entry or having
brain damage were excluded. Aripiprazole was initiated at a low dose
(3 or 6 mg/day) and titrated to higher doses at 2-weeks intervals or
more rapidly based on investigator’s judgment. Reductions from higher
doses were permitted for tolerability. Previous medications prior to aripi-
prazole administration were not changed through this trial. Patient’s clini-
cal status was assessed at baseline, then 2-weeks during the study by
using NPI, Clinical Global Impression (CGI) and Brief Psychiatric
Rating Scale (BPRS) to measure psychotic behavioral symptoms, and
Simpson-Angus Scale (SAS) to measure parkinsonism symptoms.
Clinical Dementia Rating (CDR) and MMSE were carried out at screening
and end point to evaluate cognitive function.
Results: All patients who completed the study had a favorable re-
sponse, with a decline of more than 50% in NPI. All patients who com-
pleted the study exhibited improvement of CGI score from 4 or 5 or 6
to 1 or 2. BPRS score showed a marked decrease in psychosis and agi-
tation at week 2, and 5 of 7 responded at week 10. Three of nine patients
who completed the study exhibited improvement of CDR score, and the
other 6 patients exhibited no change.
Conclusion: This open-label trial shows that aripiprazole may be effec-
tive and well tolerated for the treatment of psychotic symptoms and agi-
tation in the patients of DLB.
Policy of full disclosure: None.
P-06-003 Studies of the mechanism of action in protective effect
against neuronal cell death of 4-phenylbutyrate and its
derivatives for therapeutic agents of neurodegenerative
disease
S. Mimori1, H. Ohtaka1, K. Kawada1, M. Kaneko2, Y. Nomura3,
Y. Okuma1, Y. Murakami1, H. Hamana1. 1Chiba Institute of Science,
Choshi, Japan; 2Gifu Pharmaceutical University, Gifu, Japan; 3Kurume
University, Kurume, Japan
Objective: Antiaggregation molecules are expected to be novel therapeut-
ics for neurodegenerative diseases such as Alzheimer and Parkinson.
Therefore, we focused on 4-phenylbutyrate (4-PBA) as a chemical chaper-
one that ensures functional folding of proteins. However, the optimization
of 4-PBA is important for better therapeutic application because currently
the high doses requirement appears to be a problem. To solve this prob-
lem, we investigated minor structural change dependent increase in bio-
logical activity dependent of 4-PBA.
Methods: We initially prepared 4-PBA derivatives by altering the
number of carbons in the fatty acids on 4-PBA. Four compounds
(3-Phenylpropionic acid: 3-PPA, 4-PBA, 5-Phenylbutyric acid: 5-PVA,
and 6-hexanoic acid: 6-PHA) showed a chemical chaperone activity in
vitro, and aggregation inhibition activity increased with an increase in
the number of carbons in the fatty acid moiety. Cytoprotective effects
against endoplasmic reticulum (ER) stress-induced neuronal death corre-
lated with the in vitro chemical chaperone activity. 3-PPA and 4-PBA sign-
ificantly reduced the neuronal death caused by the overexpression of
Parkin-associated endothelin receptor-like receptor (Pael-R).
Results: With 3-PPA or 4-PBA treatment, localization of the overex-
pressed Pael-R shifted away from the endoplasmic reticulum toward the
cytoplasmic membrane. We hypothesized that inhibition of human his-
tone deacetylase (HDAC) by 3-PPA and 4-PBA is involved in this effect.
Next, we investigated the mechanism underlying the protective effect of
4-PBA against ER stress-induced neuronal death using three simple
4-(p-substituted phenyl) butyric acids.
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Conclusion: Here, we found highly active derivatives from the proto-
type 4-PBA, which we expect to be useful for therapeutic agents of neuro-
degenerative disease.
Policy of full disclosure: None.
P-06-004 Role of vesicular release in l-DOPA-evoked increases in
extracellular dopamine in the 6-OHDA lesioned striatum
S. Ahn1, B. Ma1, A. Phillips1. 1University of British Columbia, Vancouver,
Canada
Objective: Extracellular levels of dopamine (DA) derived from exogenous
l-DOPA is largely determined by the dose of l-DOPA and severity of
nigrostriatal denervation. In earlier studies, both excessive l-DOPA
doses (+50mg/kg) and extensive terminal loss (+90%) resulted in
enhanced DA efflux that was tetrodotoxin-independent and/or unaffected
by DA transporter inhibition, suggesting a non-dopaminergic, possibly
non-neuronal, origin of DA synthesis and release. However, recent evi-
dence suggests that l-DOPA-derived DA can indeed be sequestered into
vesicles within striatal DA terminals, raising the possibility of a vesicular
mechanism of release in the denervated striatum. Specifically, we assessed
in 6-OHDA-lesioned rats whether DA derived from a relatively lower
dose of l-DOPA is sequestered into vesicles and released by Ca2
+-dependent exocytosis.
Methods: Microdialysis was used to monitor changes in DA efflux in
the dorsal striatum of rats with unilateral 6-OHDA lesions of substantia
nigra and/or medial forebrain bundle. Intra-striatal reverse-dialysis of
l-DOPA (1 uM) followed by either an omission of Ca2+ or addition of
the vesicular monoamine transporter 2 inhibitor tetrabenazine to the
perfusate.
Results: Based on prior analyses, extracellular DA concentration of
0.5 nM was indicative of a threshold lesion severity for inducing both
qualitative and quantitative differences in response to experimental
manipulations. In moderately lesioned rats (>0.5 nM), l-DOPA infusion
resulted in a significant increase in DA efflux. This increase was attenu-
ated significantly by depletion of Ca2+ or exposure to tetrabenazine,
reaching values consistently below pretreatment baseline. Rats with
severe DA depletion (<0.5 nM) also showed a significant increase in
l-DOPA-evoked DA efflux. In contrast to moderate lesions, however,
both Ca2+ omission and tetrabenazine application failed to attenuate
(i.e., maintained) the increase in DA following l-DOPA.
Conclusion: The present results suggest that synaptic regulation of DA
derived from exogenous l-DOPA is dependent on the severity of lesion.
In rats with moderate lesions, extracellular DA derived from l-DOPA is
mediated by Ca2+-dependent exocytosis of vesicles. Importantly, once
the extent of lesion crosses a threshold severity, efflux of DA is mediated
by a non-vesicular mode of release.
Policy of full disclosure: Supported by operating grants from Canadian
Institutes of Health Research to AGP.
P-06-005 Effect of the timing of acetylcholinesterase inhibitor
ingestion on sleep
W.-M. Bahk1, H. R. Song2, Y. S. Woo2, H. R. Wang2, T.-Y. Jun2, M. D. Kim3,
Y. J. Kwon4. 1Yeouido St. Mary´s Hospital, Seoul, Republic of Korea; 2Seoul,
Republic of Korea; 3Jeju, Republic of Korea; 4Chunan, Republic of Korea
Objective: Many patients with Alzheimer’s disease experience sleep
disturbances, and donepezil is usually prescribed for night-time adminis-
tration. However, increased acetylcholine is associated with cortical arou-
sal. We evaluated whether subjective sleep quality differed according to
the timing of medication administration.
Methods: Ninety-two patients with mild to moderate Alzheimer’s
disease who had taken donepezil at night (n=54) or galantamine in the
morning (n=38) were recruited for this study. Scores on the sleep visual
analogue scale (VAS) for sleep quality and daytime drowsiness were
obtained.
Results: The mean sleep-quality and daytime-drowsiness VAS scores of
the donepezil and galantamine groups differed significantly at baseline
(44.0±26.4 vs. 55.2±27.3, respectively; P<0.001 and 48.8±28.8 vs. 38.8
±25.3, respectively; P<0.001). The patients taking donepezil were then
randomly assigned to take donepezil in the morning (n=24) or at night
(n=30). Eight weeks later, VAS scores also differed among the three
groups (P<0.001 for both sleep quality and daytime drowsiness). The
VAS scores of patients taking galantamine and donepezil in the morning
were different from those taking donepezil at night at week 8. Significant
changes in VAS scores emerged only in the group taking donepezil in the
morning (4.6±26.5, P=0.046 for sleep quality; #7.1±26.1, P<0.001 for day-
time drowsiness).
Conclusion: These results suggest that taking acetylchlinesterase
inhibitors in the morning can improve the sleep states of patients with
Alzheimer’s disease.
Policy of full disclosure: None.
P-06-006 Catechin attenuates post stroke neurological
complications by suppressing NF-KB signalling pathway
in collagenase treated rats
R. Bhandari1, A. Kuhad1. 1Panjab University, Chandigarh, India
Objective: The aim of the present study was to explore the effect of cate-
chin (12.5 mg/kg, 25mg/kg, 50mg/kg) and catechin loaded nanoparticles
(12.5 mg/kg, 25mg/kg, 50 mg/kg) on neurological scoring, memory, mech-
anical hyperalgesia, allodynia, depression,oxidative-nitrosative stress
inflammation and NF-kB in collagenase-induced hemorrhagic stroke.
Methods: Catechin possesses strong neuroprotective potential but lim-
ited brain penetration. Therefore, we have also used catechin loaded in
solid lipid nanoparticles, a technology to enhance brain delivery, and
compared the neurological effects with plain catechin. Neurological scor-
ing was tested on the battery of behavioral paradigms (cylinder test, spon-
taneous motility, righting reflex, horizontal bar test, tilted cage top,
placing reaction, forelimb flexion) to evaluate neurological deficits on
3rd, 7th, 14th and 21st day after collagenase administration in caudate nu-
cleus. In addition, memory (Morris water maze), mechanical hyperalgesia
(Randall Sellitto), Allodynia (von Frey hairs), depression (forced swim
test), biochemical tests (lipid peroxidation, nitrite, superoxide dismutase,
reduced glutathione and catalase in brain homogenate) and cytokines
(TNF-alpha & IL-1β) and NF-kB were also assessed in collagenase treated
rats.
Results: Chronic treatment with plain catechin and catechin loaded in
solid lipid nanoparticles for 4 weeks starting from 2nd day after collage-
nase injection significantly attenuated neurological, behavioral, biochemi-
cal and molecular changes associated with hemorrhagic stroke. Catechin
loaded in solid lipid nanoparticles produced a pronounced effect as com-
pared to plain catechin.
Conclusion: The major finding of the study is that catechin alone ame-
liorated the post stroke neurological complications but only when it is
delivered across the blood brain barrier. Moreover, catechin not only atte-
nuated the neurological deficits associated with stroke but also reversed
post stroke neurological complications through modulation of NF-kB sig-
naling pathway in the collagenased rats and thuscatechin may find clinical
application to treat neurological complications in the stroke patients.
Policy of full disclosure: None.
P-06-007 Spontaneous head twitches in aged rats: A correlate of
late-onset psychosis?
P. Bienkowski1, A. Glebicka1, K. Karas1, M. Kolaczkowski2,
P. Mierzejewski1. 1Institute of Psychiatry, Warsaw, Poland; 2Collegium
Medicum UJ, Warsaw, Poland
Objective: Although Behavioral and Psychological Symptoms of
Dementia (BPSD) are recognized as one of the major unmet medical
needs in geriatric psychiatry, medications targeting BPSD receive little at-
tention in drug development programs. The apparent contrast between
the unmet needs and research activities may be explained, at least par-
tially, by a paucity of age-specific animal models, which could be used
to screen compounds targeting BPSD.
Methods: Head twitches (HTs) are thought to be 5-HT2A/2C receptor-
mediated responses induced by serotonin receptor agonists in mice and
rats. Spontaneous head twitches (SHTs) were consistently observed in
male Wistar rats from our colony of aged animals (>18 month-old).
Results: Large individual differences in SHTs were found with 25%
of aged rats showing <2 twitches/10 min. and another 25% showing
>12 twitches/10 min. The mean number of SHTs was 7.6±6.2 twitches/
10min. Individual differences in SHTs were stable over time with
Pearson#s r values >0.9. A 5-HT2A receptor antagonist, ketanserin
(3.0 mg/kg, i.p.) antagonized SHTs in aged rats. On the other hand,
SHTs made the observation of HTs induced by a 5-HT2A/2C agonist,
DOI impossible. The presence of SHTs in aged animals was associated
with enhanced locomotor responses to amphetamine and heightened sen-
sitivity to MK-801-induced stereotypies. SHTs were rarely observed in
3 month-old Wistar rats (the mean number: 0.2 twitches/10 min., n=72).
When scored by blind observers, SHTs in aged rats were indistinguishable
from DOI-induced HT in young animals.
Conclusion: Although exact pharmacological mechanisms standing
behind SHTs remain unclear, our pilot study may indicate that SHTs
are a marker of ‘propsychotic’ state in a subgroup of aged Wistar rats.
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Further studies are needed to find psychotropic medications which could
inhibit SHTs and reverse sensitized responses to amphetamine and
MK-801.
Policy of full disclosure: The study was supported by Adamed Ltd.,
Pienkow, Poland and Polish Agency for Enterprise Development (PARP
project no. UDA-POIG.01.04.00-14-055/10-00).
P-06-008 Impact of oxidative stress on cognition and depressive
symptoms in mild cognitive impairment in the elderly
M.A. Çinar1, E. Sertoglu2, H. Öztin3. 1TAF Rehabilitation Center, Ankara,
Turkey; 2Biochemistry Laboratory, Anittepe Dispensary, Ankara Mevki
Military Hospital, Ankara, Turkey; 3TAF Special Care Center, Ankara, Turkey
Objective: Oxidative stress is one of the most recognized hypotheses in
the theory of aging. Brain tissue is vulnerable to oxidative stress, which
proposed to lead various neurodegenerative disorders. Cognitive impair-
ment and depression are common in the elderly population. We aimed to
examine the oxidative stress impact on cognition and depressive symp-
toms in nursing home residents.
Methods: Demographic data, mini mental state examination
(MMSE), clock drawing test (CDT) and geriatric depression scale (GDS)
scores of nursing home residents were examined retrospectively.
Participants were divided into two groups as healthy controls and
patients with mild cognitive impairment. Superoxide (SPO), superoxide
dismutase (SOD) and malondialdehyde (MDA) levels were determined
in previously collected and −80 C stored serum samples, using enzyme-
linked immunosorbent assay (ELISA) method.
Results: A total of 72 participants were recruited 22.2% (n=16) of
them were male, and 77.8% of them (n=56) were female. Patients were
82±6.9 years old (mean±SD). Mean MMSE scores were 24.8±4.6 and
22.3±3.9 for healthy controls and MCI group, respectively (p<0.05).
Mean GDS scores were 11.1±3.7 and 10.7.3±2.1 for healthy controls and
MCI group, respectively (p>0.05). We found a strong correlation between
CDT scores and SOD levels (p<0.01). We also found similar correlation
between GDS scores and SPO levels (p<0.01). But we did not find any
significant difference in oxidative stress markers levels between groups.
Conclusion: In a relatively small sample size our findings partially sup-
port oxidative stress relation with cognitive functioning and depressive
symptoms. We believe oxidative stress hypotheses deserve to be investi-
gated in cellular level.
Policy of full disclosure: None.
P-06-009 Impact of drug burden on cognition and depressive
symptoms in older people
M.A. Çinar1, E. Sertoglu2, H. Kayir3, H. Öztin4. 1TAF Rehabilitation Center,
Ankara, Turkey; 2Biochemistry Laboratory, Anittepe Dispensary, Ankara Mevki
Military Hospital, Ankara, Turkey; 3Department of Pharmacology, Gülhane
Military Medical School, Ankara, Turkey; 4TAF Special Care Center, Ankara,
Turkey
Objective: Polypharmacy is common among elderly population, which
may lead risk of adverse drug reactions. Drug Burden Index was pro-
posed as useful tool to assess functional effect of drug exposure in older
population. We aimed to examine the drug burden impact on cognition
and depressive symptoms in nursing home residents.
Methods: Demographic data including medication history, mini mental
state examination (MMSE), clock drawing test (CDT) and geriatric de-
pression scale (GDS) scores of nursing home residents were examined
retrospectively. Drug Burden Index was used for total (TDB), and anticho-
linergic drug burden (AchDB) calculations. Correlation coefficients and
their significance between descriptive data, TDB, AchDB, MMSE, CDT,
GDS scores were analyzed using Pearson test.
Results: A total of 56 participants were recruited 21.4% (n=12) of them
were male, and 78.6% of them (n=44) were female. Patients were 80.1±6.7
years old (mean±SD). Mean scores for MMSE, CDT and GDS were 23.2±
4.9, 2.46±1.45, and 11.4±3.5 (mean±SD), respectively. Mean TDB and
AchDB were 0.37±0.38 and 0.48±0.45 (mean±SD), respectively. We did
not find any significant correlation between drug burden and cognitive
functioning. Also correlation analysis between depressive symptoms
and drug burden did not reveal any relationship.
Conclusion: In a relatively small sample size our findings did not sup-
port previous evidence for utility of Drug Burden Index to assess func-
tional effect of drug exposure in older population. Drug interactions
may be subtle that we could not predict by available methods. We believe
new biological methods to detect subtle drug interactions are highly
needed in older people who are at risk for adverse reactions.
Policy of full disclosure: None.
P-07. Epilepsy
P-07-001 Missense mutation of the gene encoding synaptic vesicle
protein 2A (SV2A) facilitates the kindling epileptogenesis
Y. Ohno1, T. Okumura1, S. Ishihara1, S. Shimizu1, R. Terada1,
K. Tokudome1, N. Kunisawa1, T. Mashimo1, M. Sasa1, T. Serikawa1.
1Osaka University of Pharmaceutical Sciences, Osaka, Japan
Objective: Synaptic vesicle glycoprotein 2A (SV2A) is the prototype pro-
tein specifically identified in synaptic vesicles and mediates the action
potential-dependent exocytosis of neurotransmitters. In addition, SV2A
serves as a specific binding site for the racetam-derivative antiepileptics
(e.g., levetiracetam), suggesting that SV2A is involved in pathogenesis
or treatment of epilepsy. Here, in order to elucidate the functional role
of SV2A in epileptogenesis, we created a novel rat model (SV2A mutant
rat) carrying a Sv2A-targeted mutation (L174Q) by ENU mutagenesis
and analyzed behavioral phenotypes.
Results: SV2A mutant rats exhibited normal appearance under ordi-
nary condition; however, they showed a significantly higher susceptibility
to the amygdala kindling, yielding higher seizure severity score and
longer afterdischarge duration. In addition, SV2A mutant rats were re-
markably susceptible to the PTZ kindling with higher seizure incidence.
Western blot analysis revealed no alteration in SV2A expression in any
region of the brain. However, in vivo microdialysis studies showed that
the depolarization (high K+)-induced GABA release in the amygdala
was significantly reduced by the SV2A mutation whereas the glutamate
release remained unaltered.
Conclusion: These findings suggest that the SV2A mutation impaired
the function of SV2A and specifically reduced the depolarization-induced
release of GABA in the amygdala, which facilitates the kindling epilepto-
genesis in rats.
Policy of full disclosure: None.
P-07-002 Limbic kindling impairs retrieval of fear memories and
promotes hippocampal neurogenesis and plasticity of
NPY signaling
L. Kalynchuk1, J. Botterill1, K. Brymer1, W. Marks1. 1University of
Saskatchewan, Saskatoon, Canada
Objective: Temporal lobe epilepsy is often accompanied by severe cogni-
tive, and psychiatric comorbidities that have a negative impact on quality
of life. Previous research using the kindling model of epilepsy has shown
that limbic seizures, but not non-limbic seizures, produce behavioral
comorbidities representative of the human condition. In this work, we
examine the neurobiological correlates of kindling-induced deficits in
cognition.
Methods: We characterized differences between limbic (i.e., amygdala
and hippocampus) and non-limbic (i.e., caudate nucleus) seizures on con-
ditioned fear behavior and hippocampal plasticity. Hippocampal plas-
ticity was measured through immunohistochemical analyses of the
neuronal activity marker Fos, the endogenous anticonvulsant neuro-
peptide Y (NPY), and the NPY Y2 receptor (NPY2R), which presynapti-
cally inhibits glutamate release. We also assessed adult neurogenesis
using bromodeoxyuridine (BrdU) and doublecortin (DCX).
Results: Although kindling did not affect learning of a hippocampal-
dependent fear-conditioning task, limbic but not non-limbic kindling
did impair subsequent retrieval of these fear associations. Impaired mem-
ory coincided with a general reduction of Fos protein and dramatically
increased NPY and NPY2R immunoreactivity throughout the hilus and
CA3. Further, limbic but not non-limbic kindling dramatically increased
the number of BrdU+ cells and enhanced dendritic complexity within im-
mature DCX+ neurons.
Conclusion: Limbic seizures impair retrieval of fear memories, decrease
neural activity within the hippocampus, enhance NPY signaling, and en-
hance the rate of adult neurogenesis. When combined with our previous
finding that new neurons born under conditions of recurrent seizures are
unable to functionally integrate into memory circuits, and the fact that
GABA plays an important regulatory role in neurogenesis, the overall pic-
ture suggests that seizures may impair cognition by enhancing
GABAergic mechanisms, which subsequently promotes abnormally inten-
sified hippocampal cell proliferation and maturation that can interfere
with memory circuits. These findings have implications for the develop-
ment of novel therapeutic targets for treating the behavioral comorbidities
associated with epilepsy.
Policy of full disclosure: None.
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P-08. Neuropathology; from ion channels to
cortical EEG
P-08-001 Intra-accumbal administration of endomorphin-2
decreases acetylcholine efflux via mu receptors and
increases dopamine efflux independent of mu receptors
in the nucleus accumbens of freely moving rats
Y. Aono1, H. Taguchi2, Y. Kiguchi3, T. Uchida4, K. Takada4,
N. Koshikawa5, T. Saigusa6. 1Nihon University, School of Dentistry, Tokyo,
Japan; 2Nihon University, School of Dentistry, Department of Orthodontics,
Tokyo, Japan; 3Nihon University, School of Dentistry, Department of Pediatric
Dentist, Chiba, Japan; 4Nihon University, School of Dentistry, Department of
Anaesthesiology, Tokyo, Japan; 5Nihon University, School of Dentistry,
Department of Pharmacology, Tokyo, Japan; 6Nihon University, School of
Dentistry at Matsudo, Department of Pharmacology, Chiba, Japan
Objective: We have shown that local administration of the putative
endogenous mu receptor agonists endomorphin (EM)-1 and EM-2 into
the nucleus accumbens (NAc) increased accumbal dopamine (DA) with
and without stimulating mu receptors, respectively (Okutsu et al., 2006).
Accumbal mu receptors are suggested to exert an inhibitory role on
accumbal cholinergic activity (Britt & McGehee, 2008). Therefore, we ana-
lysed the effects of EM-1 and EM-2 on extracellular acetylcholine (ACh)
and DA in the NAc using in vivo microdialysis. In order to monitor
basal ACh levels, a low concentration of physostigmine (50 nM) was
added to the perfusate.
Methods: Male Sprague-Dawley rats were used. ACh and DA levels in
accumbal perfusate samples taken every 20min were measured by
HPLC-ECD. Drugs were administered intracerebrally through the micro-
dialysis probe.
Results: The addition of physostigmine (50 nM) into perfusates allowed
detection of ACh without affecting basal DA levels. Local administration
of either EM-1 or EM-2 (6 and 30 nmol) into NAc decreased ACh in a
dose-related manner. The EM-1- and EM-2 (30 nmol)-induced reductions
in ACh were prevented by co-administration of the mu receptor antagon-
ist CTOP (3 nmol), which failed to alter basal ACh. While intra-accumbal
administration of either EM-1 or EM-2 (30 nmol) increased DA efflux,
EM-1- but not EM-2-induced DA efflux was inhibited by CTOP
(3 nmol), which failed to affect basal DA.
Conclusion: These results suggest that activation of accumbal mu
receptors by EM-1 or EM-2 inhibits accumbal ACh efflux. This study
also supports our notion that EM-1 and EM-2 enhance accumbal DA
efflux by different mechanisms when they are infused into NAc (Aono
et al., 2008). Thus, in contrast to intra-accumbal infusion of EM-1, which
increases accumbal DA efflux through mu receptors, intra-accumbal in-
fusion of EM-2 increases accumbal DA without activating mu receptors.
Policy of full disclosure: None.
P-08-002 Reduced oscillatorynatural frequencies of the frontal
cortex in schizophrenia, bipolar disorder and major
depressive disorder
F. Benedetti1, P. Canali1, G. Sferrazza Papa1, E. Smeraldi1, C. Colombo1.
1Instituto Scientifico, Ospedale San Raffaele, Department of Clinical
Neurosciences, Milan, Italy
Objective: Recent studies have demonstrated that cortical brain areas
tend to oscillate at a specific natural frequency when directly perturbed
by transcranial magnetic stimulation (TMS). Fast electroencephalographic
(EEG) oscillations, which typically originate from prefrontal regions, have
been reported to be markedly reduced in schizophrenia.
Methods: Here we employed TMS/EEG to assess the natural frequency
of prefrontal areas in a sample of 48 age-matched participants (12 each in
major depression disorder (MDD), bipolar disorder (BD), schizophrenia
(SCZ) and healthy controls). Event related spectral perturbations (ERSP)
were obtained for each subjects using wavelet decomposition.
Results: TMS resulted in a significant activation of the Beta/gamma
band response (21–50 Hz) to prefrontal cortical perturbation in healthy
control subjects. By contrast, the main frequencies of prefrontal EEG
responses to TMS were significantly reduced in patients with SCZ, BPD
and MDD (11–27 Hz) relative to healthy subjects.
Conclusion: These results support our previous findings and demon-
strate that patients with schizophrenia, bipolar disorder and major de-
pression showed a slowing in the natural frequency of prefrontal
cortico/thalamocortical circuits, suggesting a common neurobiological
impaired mechanism, which may involve GABAergic interneurons
neurotransmission.
Policy of full disclosure: None.
P-09. Pain
P-09-001 Reduced supraspinal nociceptive responses and distinct
gene expression profile in CXBH recombinant inbred
mice
S. Kasai1, K. Ikeda1. 1Tokyo Metropolitan Institute, Tokyo, Japan
Objective: Considerable variability exists in the sensitivity to analgesic
opioids across individuals, which has been an unresolved clinical issue
in pain management. CXBH mice, known as an “opioid receptor-rich”
strain, are a recombinant inbred mouse strain established by crossing
the C57BL/6By and BALB/cBy strains. In the present study, we investi-
gated nociceptive and antinociceptive sensitivity in CXBH mice and eluci-
dated the underlying molecular mechanisms.
Methods: The behavioral responses to nociceptive stimuli were exam-
ined in the tail-flick test hot-plate test, Randall-Selitto test, and abdominal
constriction test. Whole-genome gene expression profiles in the brains of
each mouse strain were analyzed with illumina Expression BeadChips.
Northern blot analysis was performed to estimate the expression levels
of the μ, δ and κ opioid receptors.
Results: CXBH mice exhibited slightly higher morphine-induced anti-
nociception compared with C57BL/6J and BALB/cBy mice in the hot-plate
test but not tail-flick test. CXBH mice exhibited a marked reduction of
nociceptive sensitivity, regardless of the type of nociceptive stimulus,
with the exception of tail stimulation. Changes in gene expression that cor-
responded to reduced nociceptive sensitivity in the brains of CXBH mice
were observed in 62 transcripts, including pain- and analgesia-related
transcripts, in a whole-genome expression assay. The total mRNA ex-
pression of opioid receptors was higher in CXBH mice than in C57BL/6J
and BALB/cBy mice. However, the expression levels of MOR-1 mRNA,
a major transcript of the μ opioid receptor gene, were not different
among the C57BL/6J, BALB/cBy, and CXBH mice.
Conclusion: Supraspinal nociceptive responses but not antinociceptive
responses were reduced in the CXBH mice, and the expression levels of
transcripts were altered in the brain of this strain.
Policy of full disclosure: None.
P-09-002 Vascular endothelial growth factor signaling in injured
nerves mediates peripheral sensitization in neuropathic
pain
N. Kiguchi1, Y. Kobayashi1, Y. Kadowaki1, F. Saika1, S. Kishioka1.
1Wakayama Medical University, Wakayama, Japan
Objective: Chronic neuroinflammation may be a critical component of in-
curable inflammatory diseases, including neuropathic pain. Because
angiogenesis due to vascular endothelial growth factor (VEGF) signaling
plays a crucial role in inflammatory response, we focused on the mechan-
isms of VEGF-regulated neuropathic pain in mice.
Methods: Neuropathic pain model was produced by partial sciatic
nerve ligation (PSL) in mice. Tactile allodynia and thermal hyperalgesia
were evaluated by von Frey test and Hargreaves test, respectively.
Blood vessels in the sciatic nerve (SCN) were visualized by ex vivo fluor-
escence imaging and immunohistochemistry using DiI fluorescence.
Results: The mRNA and protein expression of VEGFA were upregu-
lated in the injured SCN after partial sciatic nerve ligation (PSL).
VEGFAwas localized to infiltrating macrophages and neutrophils derived
from bone marrow. Upregulation of VEGFA was epigenetically mediated
by histone H3 acetylation and trimethylation in its promoter region. The
receptors of VEGF, VEGFR1 and VEGFR2, were localized to vascular en-
dothelial cells or macrophages. Progression of angiogenesis was observed
in the injured SCN after PSL and confirmed by the upregulation of CD31.
Perineural administration of pharmacological inhibitors of VEGFA or
VEGFR-associated tyrosine kinases attenuated tactile allodynia and ther-
mal hyperalgesia, which were caused by PSL. Moreover, we determined
the contribution of VEGF- and CXC-chemokine receptor 4-expressing
angiogenic macrophages to neuropathic pain.
Conclusion: Taken together, epigenetically upregulated VEGFA in
injured peripheral nerves participates in angiogenesis and prolongs pain
behaviors through its receptors. We propose that VEGFA-related compo-
nents may underlie peripheral sensitization leading to neuropathic pain.
Policy of full disclosure: None.
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P-09-003 Distinctive spontaneous neural activity in patients with
somatoform pain disorder: A resting state fMRI study
A. Yoshino1, Y. Okamoto1, Y. Kunisato2, M. Doi1, S. Yoshimura3,
N. Otsuru1, S. Yamawaki1. 1Hiroshima University, Hiroshima, Japan;
2Senshu University, Kawasaki, Japan; 3Otemon Gakuin University, Ibaraki,
Japan
Objective: Patients with somatoform pain disorder suffer from long last-
ing pain. Various neuroimaging studies have examined the mechanisms
underlying somatoform pain disorder. However, there have been few
resting-state functional magnetic resonance imaging (R-fMRI) studies of
such patients.
Methods: We examined distinctive functional network in terms of
regional homogeneity (ReHo) during the resting state, assessing nine
patients with somatoform pain disorder and 20 healthy controls. All par-
ticipants gave their written informed consent before participation, accord-
ing to a protocol approved by the Hiroshima University ethics committee.
Results: We found 1) significant ReHo increases for the left precentral
gyrus in somatoform pain disorder patients relative to healthy controls
and 2) a positive correlation between pain ratings and ReHo values for
the left precentral gyrus in patients. It has been reported that precentral
gyrus activation is associated with the amelioration of various chronic
pain syndromes.
Conclusion: These findings suggest that constant stronger resting-state
left precentral gyrus activity in patients with somatoform pain disorder
may be in some way compensatory, possibly serving to relieve the hyper-
sensitivity of pain intensity, with this linkage possibly representing a dis-
tinctive neural mechanism in somatoform pain disorder.
Policy of full disclosure: None.
P-09-004 Treatment of skin cancer pain with naltrexone in mice
locally transfected with a mutant mu-opioid receptor gene
in spinal cord
P.-L. Tao1, W.-H. Kung2, J.-H. Kao3, P.-P. Yang2, P.-Y. Law4, H. H. Loh4.
1National Health Research Institute, Zhunan, Taiwan; 2Department of
Pharmacology, National Def. Medical Center, Taipei, Taiwan; 3Graduate
Institute of Life Science, Taipei, Taiwan; 4Department of Pharmacology, UM
Medical School, Minneapolis, USA
Objective: The opioid antagonists, such as naloxone or naltrexone, exhib-
ited full agonistic properties in the mutated mu-opioid receptor,
MORS196ACSTA, in which the conserved Ser196, Thr327, Cys330 were
mutated to Ala, Ala, and Ser, respectively. In our previous study, systemic
naltrexone (10mg/kg, s.c.) elicited anti-allodynic effect without the induc-
tion of dependence and rewarding effect in mice with neuropathic pain
after the expression of MORS196ACSTA in the spinal cord by intrathecal
administration of lentivirus (LV)-MORS196ACSTA-EGFP. The objective of
this study was to further investigate whether this antinociceptive para-
digm could be effective in mice with skin cancer pain.
Methods: LV-MORS196ACSTA-EGFP was injected intrathecally into
the male C57BL/6 mice and allowed the gene expression for 4 weeks.
B16-F1 melanoma cells were then subcutaneously injected into the plantar
region of left hind paw to induce skin cancer pain. The volume of paw,
spontaneous pain and mechanical allodynia (determined by von Frey
test) were assessed before and after systemic naltrexone (10mg/kg, s.c.)
or local naltrexone (10 nmol, i.t.) from day 5 to 18 after injection of mela-
noma cells.
Results: The injection of melanoma cells into a hind paw of mice
increased the paw volume and induced spontaneous pain and allodynia
(decrease of paw withdrawal pressure) in the ipsilateral paw from day 5
to day 18. Naltrexone (10mg/kg, s.c. or 10 nmol, i.t.) elicited significant
anti-allodynic effect and improved the spontaneous pain on ipsilateral
hind paws of mice which expressed MORS196ACSTA in the spinal cord.
Conclusion: These data imply that naltrexone may have therapeutic po-
tential for skin cancer pain after the gene expression of MORS196ACSTA
in the spinal cord.
Policy of full disclosure: None.
P-10. Biomarkers (incl. Pharmacogenomics and
brain imaging) for diagnosis and treatment
response A
P-10-001 Serotonin transporter ubiquitynation is a potential
biomarker for major depressive disorder
T. Nabeshima1, A. Mouri1, M. Yokoyama1, N. Kawano2, A. Yoshimi2,
M. Ikeda3, T. Mamiya1, K. Yamada2, N. Iwata3, N. Ozaki2, Y. Noda1.
1Meijo University, Nagoya, Japan; 2Nagoya University, Nagoya, Japan;
3Fujita Health University, Toyoake, Japan
Objective: Major depressive disorder is characterized by fatigue,
diminished interest or pleasure in every day’s activities and despair.
Serotonin transporter (SERT) plays a critical role in the termination of
synaptic transmission, SERT is related to vulnerability to depression
and important targets for antidepressants. But, the metabolism of SERT
and its contribution to the depression are still unclear. Melanoma antigen
gene-D1 (MAGE-D1) plays a role of adaptor molecule in ubiqutin-
dependent degradation pathway. In vivo and in vitro immunoprecipita-
tion studies revealed that MAGE-D1 binds to SERT via necdin homology
domain. Transfection of MAGE-D1 into CHO cells expressing SERT stably
displayed intracellular colocalization of MAGE-D1 with SERT and de-
crease of serotonin reuptake and SERT protein expression with increase
of SERT ubiquitination. MAGE-D1 knockout mice showed depressive
endophenotypes without any anxiety, cognitive or motor dysfunction,
which were attenuated by antidepressants. The high potassium-induced
release of serotonin was reduced in the prefrontal cortex and hippocam-
pus of the MAGE-D1 knockout mice, which were accompanied with
hyperexpression of SERT by decrease of its ubiquitination. Thus, decrease
in SERT ubiquitination has been implicated as a causative mechanism in
depression.
Methods: In the present experiment, we used lymphoblasts derived
from the peripheral blood lymphocytes in fluvoxamine-responsive and
-resistant depression patients to quantitatively examine SERT protein ex-
pression and its ubiquitination.
Results: SERT protein was increased in the fluvoxamine-resistant
depression patients. Ubiqutinated SERT protein was decreased in the
fluvoxamine-resistant depression patients. The proteasome inhibitor
increased the expression of the SERT protein in healthy volunteer, but
failed to increase that in both fluvoxamine-responsive and -resistant de-
pression patients. Further, ubiqutinated SERT expression in platelet of
healthy subject is associated with depression-related personality trait as
harm avoidance in some indexes (anticipatory worry in men, and shyness
in women).
Conclusion: These data suggests that SERT ubiquitynation could be a
potential biomarker for major depressive disorder.
Policy of full disclosure: None.
P-10-002 The potential of DNA methylation of the SLC6A4 gene as
a surrogate index of the important characteristics in the
diagnosis and the treatment of major depression
S. Okada1, S. Morinobu2, M. Fuchikami1, Y. Okamoto1, S. Yamawaki1.
1Hiroshima, Japan; 2Kochi, Japan
Objective: Establishing biological markers for major depression (MD)
could be important for improving patient care and providing more effec-
tive treatment. Since gene-environmental interactions are closely involved
in the etiology of MD, DNA methylation profiles might serve as a useful
diagnostic biomarker. We examined the utility of DNA methylation
profiles at the CpG island of SLC6A4 (DMS) as a diagnostic biomarker
for MD. In addition, the relationship between DMS and the serotonin
transporter gene-linked polymorphic region (5-HTTLPR) allele, the sever-
ity of symptoms, number of early adversities, and therapeutic responses to
antidepressants were examined.
Methods: Genomic DNA was extracted from peripheral blood of
Japanese healthy controls and patients with MD before and after treat-
ment. DMS was analyzed using a MassARRAY Compact System. The
severity of depression was evaluated using the Hamilton Rating Scale
for Depression, and early adversity was evaluated using the Early
Trauma Inventory.
Results: We were unable to distinguish between and healthy controls,
or between unmedicated patients and medicated patients using DMS.
The 5-HTTLPR allele had no significant effect on DMS. The methylation
rates for several CpGs differed significantly after treatment. Notably, the
methylation rate of CpG 3 in patients with better therapeutic responses
was significantly higher than that in patients with poorer responses.
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Conclusion: Although further studies examining the function of specific
CpG units of SLC6A4 are required, these results suggest that the methyla-
tion rate of SLC6A4 is a useful surrogate index for therapeutic responses
to antidepressants in unmedicated patients with MD.
Policy of full disclosure: None.
P-10-003 Fronto-limbic disconnection in bipolar disorder
F. Benedetti1, G. Sferrazza Papa1, B. Vai1, D. Radaelli1, S. Poletti1,
C. Colombo1. 1Instituto Scientifico, Ospedale San Raffaele, Department of
Clinical Neurosciences, Milan, Italy
Objective: Bipolar disorder (BD) is a severe, disabling and life-threatening
illness. Several lines of evidence, coming both from neuropsychological
and brain imaging studies, suggest that disruptions in neural connectivity
could play a key role in the mechanistic explanation of the cognitive
and emotional symptoms typical of this disorder. In literature only few
studies evaluated effective connectivity (EC) with Dynamic causal model-
ing technique (DCM) in BD. In the present study we performed DCM of
functional neuroimaging data to investigate the EC in a specific cortico-
limbic network in a sample of bipolar depressed patients.
Methods: DCM was performed on fMRI activation to a face-matching
paradigm task of 52 bipolar patients during a major depressive episode,
without psychotic features, and 40 healthy subjects. EC was estimated
with DCM in a trinodal neural model including anatomically defined
regions of dorsolateral prefrontal cortex (DLPFC), anterior cingulate cor-
tex (ACC) and the amygdala (AMY). Six alternative bilinear and stochastic
models were defined for each subject.
Results: The best model was the same across all subjects, and consists in
a forward connection from DLPFC to AMY and from DLPFC to ACC and
with a bidirectional connection between ACC and AMY. However
patients with BD showed a significantly reduced endogenous connectivity
between DLPFC and Amy during the emotional processing task. There
was no significant group effect upon the others endogenous connection.
Conclusion: Both DLPFC and ACC are part of a network involved in
emotion regulation and share strong reciprocal connections with the
amygdalae. These regions are fundamental in voluntary emotion regu-
lation strategies, including reappraisal and redirection, and previous
findings showed that their irregular functioning might be involved in
the cognitive and emotional deficits characteristic of BD. Thus, our
finding of a reduced DLPFC-amygdala connectivity may reflect abnormal
modulation of mood and emotion typical of bipolar patients.
Policy of full disclosure: None.
DCM result:
P-10-004 Cortico-limbic dysfucntion in borderline personality
disorder: Adverse childhood experiences and treatment
with clozapine
F. Benedetti1, B. Vai1, G. Sferrazza Papa1, D. Radaelli1, S. Poletti1,
L. Sforzini1, E. Smeraldi1. 1Instituto Scientifico, Ospedale San Raffaele,
Department of Clinical Neurosciences, Milan, Italy
Objective: Several studies identified a dysregulation of fronto-limbic cir-
cuit during social cognition tasks in borderline personality disorder
(BPD). Clozapine successfully treats the major behavioural abnormalities
associated with BPD [2], but its effects on neural activity have never
been investigated in BPD. Here we assessed the activation of cortical
and limbic structures with BOLD fMRI, during implicit processing of
faces expressing emotions of anger and fear,exploring the effects of
6 months of combined treatment with clozapine and psychotherapy,
and also of adverse childhood experiences.
Methods: A 3.0 Tesla fMRI acquisition was used to study 30 female sub-
jects: 18 healthy control (HC), 12 BPD. At the individual level we first
compared face vs shape conditions to isolate regions engaged. Than we
performed an ANOVA with two factors: diagnosis (BPD vs. HC) and
ACE (high vs. low) to compare neural activations; controlling for age, edu-
cation and medications. We performed a second analysis ANOVA in 10
subjects (5 BPD and 5 matched controls), BPD were tested before and
after treatment.
Results: In both groups higher ACE were associated with a greater ac-
tivation of left amygdala, with BPD showing baseline hyperactivity of left
amygdala and dorsolateral prefrontal cortex. Integrated treatment caused
a broad symptomatic improvement, paralleled by a normalization of
amygdala reactivity with a further increase of DLPFC activity in BPD.
Conclusion: Results suggest an effect of ACE on fronto-limbic neural
response, which was influenced by BPD diagnosis. Greater activation in
DLPFC suggested a request for a greater control on cortico-limbic areas
which resulted, after successful treatment, in a normalization of amygdala
reactivity to aversive stimuli.
Policy of full disclosure: None.
P-10-005 Chronotherapeutic treatment efficacy and white matter
integrity: A tract-based spatial statistics study in bipolar
patients
F. Benedetti1, I. Bollettini1, S. Poletti1, D. Radaelli1, E. Smeraldi1,
C. Colombo1. 1Instituto Scientifico, Ospedale San Raffaele, Department of
Clinical Neurosciences, Milan, Italy
Objective: Bipolar disorder (BD) is a progressive and disabling psychiatric
condition. A growing body of literature suggests that bipolar symptoma-
tology may be influenced by dysfunctions in white matter (WM) integrity.
Nevertheless chronotherapeutic treatments prompt a rapid and stable
antidepressant response in bipolar depression by combining total sleep
deprivation and light therapy. Diffusion tensor imaging (DTI) allows a
non-invasive, in vivo study of the integrity of WM microstructure. The
aim of this study is to investigate a possible correlation between WM
microstructure and the response to chronotherapeutic treatment in BD.
Methods: We studied 73 patients affected by a major depressive epi-
sode with a diagnosis of BD type I. Patients who shown a reduction of
50% to Hamilton Rating Scale for Depression ratings were identified as
responders to chronotherapeutic. We compared the DTI measures of
WM integrity of responder (n=47) and no-responder (n=26) to the treat-
ment using tract-based spatial statistics on DTI measures: axial, radial,
and mean diffusivity, and fractional anisotropy. Scans were analyzed
using FSL and recorded before treatment. We accounted for the effects
of nuisance covariates that could influence WM structure.
Results: No-responder patients showed increased mean diffusivity
compared to responders in several WM fiber tracts including corpus cal-
losum, corona radiata, superior longitudinal fasciculus, inferior longitudi-
nal fasciculus, cingulum bundle, localized especially in the right
hemisphere.
Conclusion: Mean diffusivity reflects the presence of boundaries to the
free diffusion of water in each voxel, and correlates with membrane den-
sity and myelin degeneration. Damages of the myelin sheaths cause dis-
ruption in structural connectivity, with a reduction of the signal speed
and could affect the capability of neurons to communicate with each
other efficiently, thus leading to a compromised functional connectivity.
Our results suggest that WM integrity may contribute to the efficacy of
chronotherapeutic treatment, and it may represent a relevant marker for
treatment response in this disorder.
Policy of full disclosure: None.
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White matter areas where no-responder patients showed significantly
higher values of mean diffusivity than responders:
P-10-006 Imaging of high-risk adolescent myelin integrity
using DTI
J. Benoit1, A. Shafer1, M. Brown1, E. Dametto1, A. Greenshaw1, S. Dursun1,
S. Vohra1, F. Dolcos2, A. Singhal1. 1University of Alberta, Edmonton, Canada;
2University of Illinois at Urbana-Champaign, USA
Objective: Adverse childhood experiences slow the development of white
matter axon diameter and microtubule structure, and decrease the ratio of
myelinated to unmyelinated fibers in the brain’s white matter tracts. The
brain is becoming viewed more as a complex network of networks, with
each network relying on white matter integrity to function optimally.
Diffusion Tensor Imaging (DTI) provides a means of visualizing the integ-
rity of these white matter tracts. DTI scans were used to investigate
whether complex psychiatric symptoms are correlated with impaired
white matter development in adolescents.
Methods: Single DTI scans from 20 adolescent inpatients from CASA
House Edmonton were compared to 20 pair-matched (age/gender/hand-
edness) controls. Patients were diagnosed with at least two Axis-I
(DSM-IV TR) disorders; patients with a diagnosis of Fetal Alcohol
Syndrome (FAS) or Tourette’s at the time of scanning were excluded
from analysis. Tract integrity analysis was carried out using Tract-Based
Spatial Statistics, part of Oxford’s FSL software for MRI analysis. This ap-
proach extracts Fractional Anisotropy (FA) maps from the brain, which
show white matter tracts. FA maps are combined by group and compared
for differences along the core of each tract. Differences between groups
suggest a large difference in tract integrity.
Results: Following statistical corrections and confirmation of tract loca-
tions from a neurologist, we saw decreases in patient white matter integ-
rity, localized to three tracts (p<0.05): superior fronto-orbital fasciculus,
genu of the corpus callosum, and corticospinal tract.
Conclusion: Adolescent inpatients had significantly impaired white
matter development in three tracts compared to control subjects. This sug-
gests underdeveloped white matter could act as a marker for complex
psychiatric disorders. More research is needed to determine what pro-
portion of psychiatric symptoms can be accounted for by these differences
in white matter development.
Policy of full disclosure: None.
P-10-007 Analysis of serotonin transporter and 5-HT2A receptor
clusters in peripheral lymphocytes as putative biomarkers
of therapeutic efficacy in major depressive disorder
H. J. Caruncho1, T. Rivera-Baltanas2, R. C. Agis-Balboa2, E. Y. Fenton3,
L. E. Kalynchuk4, J. M. Olivares2. 1University of Saskatchewan, Saskatoon,
Canada; 2University Hospital Complex of Vigo, Vigo, Spain; 3University of
Saskatchewan, College of Pharmacy and Nut., Saskatoon, Canada; 4University
of Saskatchewan, College of Medicine, Saskatoon, Canada
Objective: To analyze the clustering of the serotonin transporter (SERT)
and the 5-HT2A receptor in the plasma membrane of lymphocytes from
non-psychiatric subjects and naive depression patients, and in these
same patients after 8 weeks of antidepressant medication; and to compare
changes in these parameters in relation to the degree of response to phar-
macological treatment.
Methods: We collected blood samples from 38 untreated and newly
diagnosed depression patients at the time of diagnose and after 8 weeks
of pharmacological treatment, and of 38 non-psychiatric subjects. We
used the Hamilton Scale to quantify the level of depression in patients
both before and after pharmacological treatment. We then used immuno-
cytochemistry to assess SERT and 5-HT2A clusters in lymphocytes.
Results: SERT clusters size, and 5-HT2A clusters size and number are
increased in lymphocytes in depression. These parameters are partially
reversed after pharmacological treatment. Analysis of the distribution of
SERT and 5-HT2A clusters size allowed the differentiation of two subpo-
pulations of naive depression patients (D-I and D-II). Initially, naive D-I
and D-II depression patients showed similar Hamilton scores. However,
D-II patients showed a better therapeutic outcome after 8 weeks of phar-
macological treatment than D-I patients, with many D-II patients showing
remission of symptoms. Pharmacological treatment alters the distribution
of SERT and 5-HT2A clusters size in D-II patients but not in D-I patients.
Conclusion: SERT and 5-HT2A clusters in peripheral lymphocytes are
altered in major depression, partially reversed by antidepressant treat-
ment, and may be considered a putative biomarker of therapeutic efficacy
in major depression.
Policy of full disclosure: None.
P-10-008 Kynurenine production is reduced by acute typtophan
depletion: Implications for cognitive impairment in
brain-gut axis disorders
J. Cryan1, P. Kennedy1, A. Allen1, E. Quigley1, A. O’Neill1, T. Dinan1,
G. Clarke1. 1University College Cork, Cork, Ireland
Objective: The specificity of acute tryptophan depletion (ATD) as a chal-
lenge of the serotonergic system has been questioned. We propose altera-
tions in the production of kynurenine, a candidate biomarker of cognitive
dysfunction in brain-gut axis disorders such as irritable bowel syndrome,
as an alternative mechanism through which ATD exerts its effects.
Methods: In a double-blind, crossover design, age-matched females
with irritable bowel syndrome (IBS; N=9) and healthy controls (HC;
N=14) were administered a tryptophan-depleting amino acid mixture
or control drink containing tryptophan. Cognitive performance was as-
sessed 5 hours post-drink using tests the Cambridge Neuropsychological
Test Automated Battery (CANTAB).
Results: In addition to reductions in plasma tryptophan availability,
ATD also reduced plasma kynurenine concentrations (HC: pre-drink:
580.78±44.49[ng/ml], post-drink: 210.05±29, p<0.001; IBS: pre-drink:
474.64±32.65, post-drink: 141.84±7.93, p<0.001). The control drink
increased kynurenine (HC: mean kynurenine pre-drink=480.67±41.82,
post-drink=1105.56±141.16, p<0.001; IBS: pre-drink=498.76±43.91, post-
drink=1732.78±424.37, p<0.05) and impaired memory performance in
the IBS cohort (paired associate learning mean errors: HC: 2.43±0.87,
IBS: 7.78±1.85, p=0.016), although ATD did not (HC: 3±0.96, IBS: 3.89±
1.81, p>0.05).
Conclusion: ATD can alter not only tryptophan but also kynurenine
production, which may regulate visuospatial memory performance in
brain-gut axis dysfunction. Targeting the kynurenine pathway may rep-
resent a viable therapeutic option to restore normal cognitive performance
in IBS.
Policy of full disclosure: The Alimentary Pharmabiotic Centre is a re-
search centre funded by Science Foundation Ireland (SFI), through the
Irish Government’s National Development Plan (NDP). The authors and
their work were supported by SFI (grant nos. 02/CE/B124 and 07/CE/
B1368, and currently via grant number SFI/12/RC/2273). GC is supported
by a NARSAD Young Investigator Grant (Grant no 20771) from the Brain
and Behavior Research Foundation. GC, JFC, TD and APA are also funded
by the Irish Health Research Board (HRB) Health Research Awards
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(grant no HRA_POR/2011/23). The authors (TD, JFC, GC and EMMQ)
received support from UCC’s Strategic Research Fund towards the pur-
chase of CANTAB software licenses. The authors wish to acknowledge
the facilities provided by the HRB Clinical Research Facility at UCC,
Mercy Hospital, Cork.
P-11. Clin. Investigator, Nat. Funding Agency,
Public-Private Partnership initiated clinical
trails
P-11-001 Mirtazapine treatment can become a preventive measure
against the long-term usage of benzodiazepines
M. Geka1, K. Inada2, Y. Geka2, Y. Takahashi2, M. Takahashi2, T. Kimura2,
J. Ishigooka2. 1Tokyo, Japan; 2Tokyo Women’s Medical University, Tokyo, Japan
Objective: Mirtazapine (MIR) is the first noradrenergic and selective ser-
otonergic antidepressant. It is known to improve sleep and appetite, par-
ticularly in patients with depression. We evaluated improvements in sleep
and appetite from the start of MIR therapy to up to 60 days.
Methods: Sleep improvement was evaluated based sleep time and the
daily dose of benzodiazepines (BZPs), as a converted-to-diazepam
equivalent, and the numbers of different BZP agents used. Quantity of
meals and body weight were measured to see changes of their appetite.
The protocol was approved by the ethics review board of Tokyo
Women’s Medical University (No. 2875).
Results: There were 51 patients with major depressive disorder
(DSM-IV) who started MIR therapy during hospitalization between
September 2009 and December 2012. When we compared the sleep time
on the first day and its average on the other days the patients received
the 15-mg dose, sleep time was extended from 4.6±2.0 to 6.3±1.9 h
(P<0.05). The difference from the other doses was not significant. The
dose of BZPs and the numbers of BZPs were decreased from 6.6±4.2 to
2.0±2.2 mg and 1.2±0.7 to 0.49±0.5 drugs, respectively (P<0.05).
Twenty-two of the 51 patients were able to withdraw their BZPs. The
patients gradually began to eat more, but their body weights did not in-
crease from the baseline measurement.
Conclusion: MIR treatment allowed to extend sleep time immediately
without increasing body weight. Almost all the patients could withdraw
or decrease BZPs. This study suggests that MIR treatment can become a
preventive measure against the long-term usage of BZPs.
Policy of full disclosure: None.
P-12. Use of traditional medicine to guidenovel
CNS drug development
P-12-001 Differential effects of d- and l-tetrahydropalmatine on
dopamine efflux in the rat nucleus accumbens
S. Ahn1, A. Phillips1. 1University of British Columbia, Vancouver, Canada
Objective: Tetrahydroprotoberberines (THPBs), including stepholidine,
govadine, and tetrahydropalmatine (THP), are key compounds found in
plant-derived traditional medicines. A growing interest in the pharma-
cotherapeutic potential of THPBs is linked to direct effects on brain dopa-
mine (DA) receptors and other key neurotransmitters. The l-enantiomers
of each of the parent racemic compounds have been shown to act as
DA D2 receptor antagonists and this in turn has been linked to the poss-
ible antipsychotic effects of l-stepholidine and l-Govadine, as well as the
sedative and analgesic properties of l-THP in humans. Preclinical assess-
ment of the d- isomer of THP indicates that it may serve as a selective
depleter of synaptic vesicles containing DA, raising the possibility that
it may act as a vesicular monoamine transporter blocker. The present
study sought to extend the examination of the pharmacological and
neurochemical properties of the d- and l-isomers of THP by employing
in vivo brain microdialysis to assess their effects on the mesolimbic DA
system.
Methods: In vivo microdialysis and high pressure liquid chromatogra-
phy with electrochemical detection was used to monitor changes in DA
efflux in the nucleus accumbens (NAc; AP +1.7 mm, ML +/−1.1 mm, DV
−8.0 mm) of rats. All experiments involved intra-NAc reverse-dialysis of
d- or l-THP (50 uM).
Results: Intra-NAc administration of the d- and l-isomers of THP had
opposite effects on DA efflux. l-THP evoked a significant increase in DA
efflux (∼+40% relative to baseline). In contrast, d-THP initially evoked a
small short-lasting increase (+30%) which then decreased below baseline
(∼−40%).
Conclusion: The present findings compliment earlier studies by
confirming that each isomer of THP can differentially modulate extra-
cellular levels of DA in the NAc. The increase in DA efflux induced
by d-THP is entirely consistent with reports that it is a selective D2
antagonist. The profile of a short-term elevation in DA efflux followed
by a decrease to levels significantly below baseline values, is very similar
to that observed with other VMAT2 antagonists including tetrabenazine
and reserpine. On-going electrophysiological studies are assessing the ef-
fects of the stereo-isomers on DA cell firing in the ventral tegmental area.
Policy of full disclosure: Supported by operating grants from the
Canadian Institutes of Health Research to AGP.
P-13. Psychoneuroimmunology and
neuroinflammation A
P-13-001 Mood-modulating drugs alter prostaglandin E2 levels in
rat brain in a region-dependent manner
A. Azab1, A. Nassar1, Y. Sharon-Granit1. 1Ben-Gurion University of the
Negev, Beer-Sheva, Israel
Objective: Accumulating evidence suggests that mood-modulating drugs
exhibit anti-inflammatory properties. However, many contradicting
findings have been reported, probably due to different experimental con-
ditions under which the drugs were investigated. This study was under-
taken to examine the effects of chronic treatment with four different
mood-modulating drugs – valproate, carbamazepine, olanzapine and imi-
pramine – on lipopolysaccharide (LPS)-induced production of prosta-
glandin E2 (PGE2) in rats’ hypothalamus and hippocampus.
Methods: Rats were treated with valproate (100mg/kg), carbamazepine
(40mg/kg), olanzapine (10mg/kg) and imipramine (20mg/kg) for 4 weeks
by a single daily intraperitonteal (ip) injection. On day 29, at 2 h post drug
treatment, rats were injected (ip) with saline or LPS (1 mg/kg). At 2 h post
LPS injection, rats were sacrificed and hypothalamus and hippocampus
were quickly excised. Hypothalamus and hippocampus were homoge-
nized and centrifuged. Supernatants were separated for determination
of PGE2 levels by ELISA.
Results: Treatment with LPS resulted in a significant increase in
hypothalamic PGE2 levels. Pretreatment with carbamazepine, olanzapine
and imipramine significantly reduced LPS-induced elevation in hypotha-
lamic PGE2 levels, while valproate led to a non-significant reduction. On
the other hand, LPS did not significantly alter PGE2 levels in the hippo-
campus. Overall, none of the tested drugs significantly affected hippocam-
pal PGE2 levels.
Conclusion: These results suggest that mood-modulating drugs exert
similar anti-inflammatory properties and that their effects on PGE2 pro-
duction are region-specific.
Policy of full disclosure: None.
P-13-003 Chronic LPS administration induces prolonged sickness
behavior in rats
C. Fischer1, N. Liebenberg1, B. Elfving1, S. Lund2, G. Wegener3. 1Aarhus
University, Risskov, Denmark; 2Department of Medical Endocrinology,
Aarhus University, Aarhus, Denmark; 3Translational Neuropsychiatry,
Aarhus University, Risskov, Denmark
Objective: Acute inflammation, e.g. by exposure to lipopolysaccharide
(LPS), produces an adaptive motivational state termed sickness behavior,
to cope with inflammatory mediators and the subsequent negative energy
balance. This response is short acting, whereas prolonged sickness beha-
vior manifest with a different survival response. Physical activity is
known to exert anti-inflammatory effect, and could serve as a unique
modulator of the immune system during chronic inflammation. The objec-
tive of this study was to investigate the behavioral, metabolic and brain
cytokine changes following chronic administration of a low dose LPS in
rats, and to explore the modulatory effects of exercise.
Methods: Sprague-Dawley rats were injected with LPS (600 μg/kg) or
saline, once or for eight weeks. Half of the rats in the chronic study had
free access to a running wheel. Sickness behavior was evaluated, includ-
ing body weight, food intake, locomotor-activity, depressive-like beha-
vior, together with cytokine and chemokine levels in frontal cortex and
hypothalamus. Energy related parameters including fasting glucose, fat
mass and liver weight was also measured.
Results: Chronic LPS administration resulted in reduced body weight
and food intake, decreased activity level and depressive-like behavior,
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similar to a single LPS injection. However, contrasting acute inflamma-
tion, chronic LPS administration induced hyperglycemia, decreased fat
mass and increased liver weight. Chronic LPS induced a specific elevation
of proinflammatory cytokines (IL-1β and IFN-γ) and chemokines (MIP-1α
and MCP-1) in frontal cortex. Exercise did not reverse the LPS-induced
sickness behavior or the altered cytokine levels.
Conclusion: Chronic administration of LPS produced prolonged sick-
ness behavior, distinct from the syndrome following a single LPS injec-
tion, which could be caused by the specific energy demand during a
chronic inflammatory disease. Exercise did not reduce the LPS-induced
sickness behavior or brain cytokine levels, suggesting that the immune-
modulatory effects of exercise are not sufficient to overcome the
LPS-induced immune response.
Policy of full disclosure: None.
P-13-005 Effects of haloperidol on lipolysaccharide-induced
inflammation in rats
A. Nassar1, Y. Sharon-Granit1, A. N. Azab1. 1Ben-Gurion University of the
Negev, Beer-Sheva, Israel
Objective: The therapeutic mechanisms of mood-modulating drugs
(mood stabilizers, antipsychotic and antidepressant drugs) are not fully
understood. Accumulating evidence suggests that inflammation plays a
role in the pathogenesis of bipolar disorder and that mood-modulating
drugs exhibit anti-inflammatory properties. This study was undertaken
to examine the effects of the antipsychotic drug haloperidol on lipopoly-
saccharide (LPS)-induced inflammation in rats.
Methods: Rats were treated with haloperidol (2 mg/kg) for 4 weeks
by a single daily intraperitonteal (ip) injection. On day 29, at 2 h
post haloperidol treatment, rats were injected (ip) with saline or LPS
(1mg/kg). At 1.5 h post LPS injection body temperature (BT) was mea-
sured. Immediately thereafter, rats were sacrificed, blood was collected,
and liver and brain regions (hippocampus, hypothalamus and frontal cor-
tex) were excised. Hippocampus, hypothalamus, frontal cortex and liver
were homogenized and centrifuged. Supernatants were separated for de-
termination of inflammatory mediators. Levels of inflammatory mediators
in plasma and supernatants of liver and brain regions were measured by
ELISA.
Results: Treatment with LPS resulted in a significant decrease in BT
(hypothermia). Pretreatment with haloperidol significantly reduced
LPS-induced hypothermia. Moreover, haloperidol significantly decreased
levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and inter-
feron (INF)-alpha in the hippocampus and hypothalamus. On the other
hand, haloperidol differently affected TNF-alpha (increased) IL-6
(decreased) and INF-alpha (not changed) levels in the frontal cortex.
Haloperidol did not alter hepatic levels of all three cytokines while it sign-
ificantly reduced plasma IL-6 levels.
Conclusion: These results suggest that haloperidol possess potent anti-
inflammatory properties, however, its effects on inflammatory mediators
production vary in different tissues.
Policy of full disclosure: None.
P-13-006 The expression of dopaminergic receptor D5 mRNA is
increased in circulating lymphocytes of children and
adolescents with tic disorders and/or
obsessive-compulsive disorder
T. Park1, Y.W. Jung2. 1Chonbuk University Medical School, Jeonju-Si,
Republic of Korea; 2College of Pharmacy, Korea University, Sejong-Si,
Republic of Korea
Objective: Tic disorders and obsessive-compulsive disorder (OCD)
are neuropsychiatric disorders in which dopaminergic dysfunction and
immune system abnormalities seem to coexist.
Methods: Using real-time PCR, we determined the mRNA expression
of dopamine receptors (DRs) D1-5 in peripheral blood lymphocytes
(PBLs) from 22 children and adolescents with tic disorders and/or OCD
and 6 healthy controls (HCs).
Results: Overall, we found that the levels of these mRNA expressions
were low or undetectable. Although it was not statistically significant,
the expression levels of DRD2 and DRD3 appear to be lower in the
lymphocytes isolated from patients compared to the ones from healthy
subjects. Most of DRD4 expressions were undetectable so that it is not
evident the role of this receptor in developing this disease. Lastly, 7 of
22 patients (32%) showed the expression of DRD5 mRNA, while no
healthy control expressed this receptor.
Conclusion: These data may suggest that DRD5 mRNA upregulation
in PBLs from children and adolescents with tic disorders and/or OCD
may represent a peripheral marker of dopaminergic dysfunction and
supports the involvement of the immune system in tic disorders and/or
OCD.
Policy of full disclosure: None.
P-13-007 Fc alpha/mu receptor (Fc alpha/mu R) mRNA
upregulation in tic disorders and/or obsessive-compulsive
disorder
T. Park1, Y.W. Jung2. 1Chonbuk University Medical School, Jeonju-Si,
Republic of Korea; 2College of Pharmacy, Korea University, Sejong City,
Republic of Korea
Objective: The pathogenesis of tic disorders and obsessive-compulsive
disorder (OCD) is still unknown. In addition to genetic factors, autoim-
mune mechanism may play an important role, as a sequela of preceding
streptococcal upper respiratory infections. Although it has been suggested
that Fc alpha/mu receptor (Fc alpha/mu R) may be associated with the
pathogenesis of tic disorder and/or OCD in children and adolescents, it
has not been found that this receptor is expressed in peripheral blood lym-
phocytes (PBLs) of children with tic disorder and/or OCD.
Methods: Using real-time PCR, we determined the mRNA expression
of Fc alpha/mu R in PBLs of tic and/or patients and compared to healthy
controls.
Results: To our surprise, almost half of patients (15 of 34) expressed this
receptor in their PBLs at least in the mRNA level. In addition, the mRNA
level of Fc alpha/mu R in the lymphocytes of tic and/or OCD patients is
higher than the one of healthy subjects, suggesting that this receptor is im-
portant to the pathogenesis of tic disorders and OCD.
Conclusion: We found that the mRNA of Fc alpha/mu receptor
(Fc alpha/mu R) was present in PBLs of children and adolescents with
tic disorders and/or OCD, and this finding may lead to new therapeutic
avenue to treat these patients.
Policy of full disclosure: None.
P-14. Autism spectrum disorders A
P-14-001 The endoplasmic reticulum stress may contribute to the
pathogenesis of the autism spectrum disorders
K. Kawada1, T. Iekumo1, R. Saito1, S. Mimori1, Y. Nomura2, Y. Okuma1.
1Chiba Institute of Science, Chiba, Japan; 2Kurume University School of
Medicine, Fukuoka, Japan
Objective: It was not elucidated the pathogenic mechanism of the autism
spectrum disorders (ASD). On the other hands, it have been previously
reported that some type of ASD might be caused by deficient of specific
genes, which regulate the synaptic development. In this study, we focused
on the endoplasmic reticulum (ER) stress, and we investigated whether
the ER stress affects the neuronal maturation such as dendrite outgrowth.
Methods: In vivo experiments, the pregnant mice were injected with
500mg/kg valproic acid (VPA) on E9.5 for establishment of animal
model of ASD. Offspring born from VPA-treated mothers were subjected
to the experiments. In vitro experiments, the neurons were differentiated
from the mouse embryonic carcinoma P19 cells using all-trans retinoic
acid. The cells were cultured in the absence or presence of tunicamycin
during differentiating for 8 days.
Results: In the animals treated with VPA, behavioral analysis of the
offspring showed a decrease in the locomotor activity, a decrease in
the cognitive ability and an increase in the aggressive social behavior.
In the cerebral cortex of the offspring, the expression of ER stress marker
GRP94 was increased. In addition, the mRNA levels of the proneural fac-
tor Hes1 and Pax6, which negatively regulate the neuronal differentiation,
were decreased in the cortex. Furthermore, the level of Math1, which posi-
tively regulates the differentiation, was increased in the cortex. In the
P19 cells, tunicamycin led to an increase in the expression of GRP78/94
during the differentiation to neuron. The number of the neuronal marker
Tuj-1-positive cells was increased by the ER stress in the differentiated
cells. On the other hands, the dendrite outgrowth of the differentiated
cells was inhibited by the ER stress.
Conclusion: We found that the brain in the animal model of ASD
was under the ER stress condition, and that ER stress induced abnormal
differentiation and neuronal maturation.
Policy of full disclosure: None.
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P-14-002 Efficacy and safety of aripiprazole used for impulsiveness
in 22q11.2 deletion syndrome with autism spectrum
disorder
M. Kawano1, T. Oshimo1, D. Hasegawa1, J. Ishigooka1. 1Tokyo Women´s
Medical University, Tokyo, Japan
Objective: 22q11.2 deletion syndrome (22q11.2DS) has an incidence esti-
mated at 1:4-5,000 and an increased risk of developing mental illnesses.
They were usually regarded as schizophrenia, but we considered it as aut-
ism spectrum disorder (ASD) and that medical treatment may be useful
for its impulsiveness. Aripiprazole is indicated overseas to use for excit-
ability in children with ASD. We treated 3 patients with ASD symptoms
and studied its efficacy and safety.
Methods: Out of patients with 22q11.2DS seen in our hospital, three
patients with ASD symptoms were consisted of men aged 14 and 17
years and a woman aged 23 years. Detailed life history and present illness
were taken and diagnosis was made according to DSM-5 along with
Autism Diagnostic Interview-Revised (ADI-R). The outcome was evalu-
ated by ABC-J, CGI-S, and CGI-I before aripiprazole administration, at
2, 4, and 8 weeks after that.
Results: At baseline prior to the dose, the mean of ABC-J irritability
was 33.3+/−2.9, lethargy 30.3+/−3.3, stereotypy 2.7+/−0.4, hyperactivity
22.3+/−10.3, and inappropriate speech 5.7+/−2.9. At the end point, the
mean of ABC-J irritability was 5.0+/−1.4, lethargy 14.0+/−3.7, stereotypy
0.7+/−0.3, hyperactivity 4+/−1.8, inappropriate speech 2.3+/−1.6, showing
improvement as well as with CGI. The three patients did not have any ad-
verse effects including insomnia, hypersomnia, and akathisia.
Conclusion: Aripiprazole appears to be effective for impulsiveness and
irritability in 22q11.2DS. Developmental disorder should be kept in mind
in evaluating 22q11.2DS patients in case of treatment, along with environ-
mental adjustment provided including social development assistance and
psychological education if necessary, it is important to select better medi-
cal treatment for them. For the limited number of such cases, further study
is warranted in the future.
Policy of full disclosure: None.
P-14-003 Lurasidone ameliorates a ketamine-induced joint visual
attention dysfunction as a possible disease model of
autism spectrum disorders in common marmosets
T. Nakako1, T. Murai1, M. Ikejiri1, T. Hashimoto1, K. Matsumoto1,
M. Kotani1, S. Manabe1, Y. Ogi1, M. Taiji1, K. Ikeda1. 1Dainippon
Sumitomo Pharma, Suita, Japan
Objective: Joint visual attention (JVA) is defined as following another
person’s pointing gesture and gaze, and the performance of JVA generally
enables infants to socially coordinate their attention with other people.
It is said that infants with autism spectrum disorders (ASD) find it
difficult to perform JVA. We have already evaluated that common mar-
mosets, small monkeys, were capable of performing JVA, and ketamine,
an NMDA receptor antagonist, impaired the JVA function. So, this
ketamine-induced JVA impaired model with common marmosets could
be a possible disease model of some aspects of ASD. Recently we have
reported that lurasidone, the latest antipsychotic agent, increased the cor-
tical efflux of glutamate. Several investigations showed that NMDA recep-
tor hypofunction was associated with ASD, so lurasidone might be
effective on JVA impairment induced by ketamine. Therefore, the present
study investigated whether lurasidone ameliorates the ketamine-induced
JVA impairment.
Methods: Five common marmosets were used. The apparatus was con-
structed using 4 white acrylic boxes (4×4×4 cm) which were attached to
4 corners of a square frame (10×10 cm). All of the boxes had a door
with a hinge and the marmoset could easily get a reward by pushing
the door. The marmoset was informed which box contained the reward
by the experimenter pointing to it. We scored in accordance with the num-
ber of incorrect choices they made.
Results: Ketamine significantly decreased JVA score as we previously
reported, and lurasidone significantly reversed the ketamine-induced
JVA impairment.
Conclusion: We showed that ketamine induced JVA dysfunction
and that lurasidone ameliorated the impairment. These findings suggest
that this experimental system could be a useful animal model of ASD
and lurasidone might be effective on some aspects of ASD.
Policy of full disclosure: None.
P-14-004 Associations between NFKB and NFKBIL1
polymorphisms and autistic-like traits in a Swedish
population of twins
N. Strenn1, D. Johansson1, L. Jonsson1, H. Anckarsäter1, P. Lichtenstein2,
A. Ekman1. 1Sahlgrenska Academy, University of Gothenburg, Gothenburg,
Sweden; 2Karolinska Institutet, Stockholm, Sweden
Objective: Autism spectrum disorders are a complex group of neurodeve-
lopmental disorders which are characterized by impairments in social
interactions and both verbal and nonverbal communication. The immune
system has been suggested to be of importance for the development of
neuropsychiatric symptoms; for example, elevated levels of cytokines
and the inflammation-related transcription factor nuclear factor kappa-B
(NFKB) have been reported in autistic individuals. The aim of this
study was to investigate possible associations between single nucleotide
polymorphisms (SNPs) in NFKB and NFKB inhibitor-like protein 1
(NFKBIL1) and autistic-like traits in a Swedish population of twins.
Methods: The subjects in this study (n=12426, 9–12 years old) are
from “The Child and Adolescent Twin Study in Sweden” (CATSS).
Their parents participated in a telephone interview where the children
were assessed by the Autism-Tics, ADHD, and Other Comorbidities
Inventory (A-TAC) where autistic-like traits are measured using a con-
tinuous scale. DNA was extracted from saliva samples and polymorph-
isms were genotyped. Statistical analyses were performed in the SAS 9.3
(SAS Institute, Inc., Cary, NC) softwear.
Results: Four out of the five investigated SNPs (NFKB: rs4648022;
NFKBIL1: rs2230365, 2239797 and rs2857605) showed significant associa-
tions with the A-TAC total autistic-like traits score.
Conclusion: To our best knowledge, polymorphisms in the genes
encoding NFKB and NFKBIL1 have not been studied previously in re-
lation to autism. These proteins may be involved in neuronal development
and our findings support the hypothesis of the immune system being im-
portant in the aetiology of neuropsychiatric symptoms.
Policy of full disclosure: None.
P-15. Attention deficit disorders A
P-15-001 Adolescent exposure to methylphenidate attenuates
successive negative contrast and evoked dopamine efflux
in the rat nucleus accumbens
S. Ahn1, G. Vacca1, A. Phillips1. 1University of British Columbia, Vancouver,
Canada
Objective: Repeated exposure to and subsequent withdrawal from psy-
chostimulants may mimic specific psychological symptoms of depression,
including decreased interest in normally rewarding stimuli. The growing
use of the psychostimulant methylphenidate (MPH) to treat attention-
deficit/ hyperactivity-disorder, especially in young children, has raised
concerns of safety and long-term consequences in adulthood. However,
to date, there is sparse evidence of mood disorders or increased incidents
of addictive behavior in individuals treated previously with MPH. The
present study examined the effects of adolescent exposure to MPH on suc-
cessive negative contrast in rats trained to lick for sucrose solutions.
Microdialysis was employed to assess any latent effects of MPH treat-
ments on dopaminergic responses evoked by a challenge dose of MPH.
Methods: Adolescent rats were trained to drink either a 4% or 32% su-
crose solution from postnatal day (PND) 36–61. During the first week
(PND 36–42), rats were also treated with daily MPH (2mg/kg, ip). For a
period of 5-days, starting at 3 days and then at 2 weeks post-MPH treat-
ment, we compared consumption of 4% sucrose in rats trained to drink 4%
with those that experienced a downshift from 32% to 4% sucrose.
Microdialysis was employed 10-days later to examine the effects of
MPH (2mg/kg, ip) on DA efflux in the nucleus accumbens.
Results: An unexpected change from a 32% to 4% sucrose solution dur-
ing the first downshift period elicited more licks in MPH-treated rats than
saline-controls, with the negative contrast effect becoming further dimin-
ished during the second period of downshift (i.e., sucrose ingestion
returned to control values more quickly in rats pre-treated with MPH).
MPH-evoked increases in DA efflux in the NAc were significantly attenu-
ated in MPH-treated rats compared to saline-controls.
Conclusion: Repeated exposure of rats to MPH during adolescence lead
in adulthood to an attenuated negative contrast effect. This finding differs
from an enhancement of ‘negative contrast’, observed in adult rats.
Furthermore, the attenuation in the magnitude of MPH-evoked DA
efflux in rats pre-exposed to MPH, suggests a long-lasting change in acti-
vation of the mesolimbic DA system that may influence motivational
responses to natural and drug rewards.
Policy of full disclosure: Supported by operating grants from Canadian
Institutes of Health Research to AGP.
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Effect of adolescent exposure to MPH on successive negative contrast:
P-15-002 Evaluation of self-perception of individuals with ADHD
before and after the use of lisdexamfetamine dimesylate
(Vyvanse)
E. Ayres1, L. Guarienti2. 1Santo Antonio Children´s Hospital, Porto Alegre,
Brazil; 2Santo Antonio Children´s Hospital, Student Guidance Center, Porto
Alegre, Brazil
Objective: This study sought to evaluate the impression of ADHD
patients in the areas of work/school, social and family life of the
Sheehan Disability Scale before and after the use of dexamphetamine
dimesylate.
Methods: Fifty eight pacients that had been previously diagnosed
with ADHD through screening, application of the SNAP-IV or ASRS-18
questionnaire and psychiatric interview and that were under treatment
withdexamphetamine dimesylate in doses of 30 or 50 mg/d for at least
one month have participated on the evaluation. The questionnaires
(SNAP IV and ASRS 18), the same utilized on the inicial screening for
the ADHD diagnostic, were sent by e-mail with questions regarding the
perception of the pacient and/or the caretaker, after the use of dexamphe-
tamine dimesylate, on matters related to work and/or study as well as
social and family life, and Sheehan Disabity Scale was used for analysis
of the answers.
Results: In our sample of 22 patients, we observed that patients,
30 days after initiation of treatment with lisdexamfetamine, reported im-
provement in symptoms measured by the scores of the spheres of the
Sheehan Disability Scale. There was a reduction in scores work/school
in 82% of cases, social life in 77% and family life 55%. Analyzing the
total, work/school sphere was the one with a higher percentage of symp-
toms reduction in their perception (82%).
Conclusion: In our sample of 58 patients, we observed that patients,
30 days after initiation of treatment with lisdexamfetamine, reported
improvement in symptoms measured by the scores of the spheres of the
Sheehan Disability Scale. There was a reduction in scores work/school
in 82% of cases, social life in 77% and family life 55%. Analyzing the
total, work/school sphere was the one with a higher percentage of symp-
toms reduction in their perception (82%).
Policy of full disclosure: None.
P-15-003 Treatment of attention in children with mild intellectual
disability
A. Djuric-Zdravkovic1, M. Japundza-Milisavljevic1, S. Gagic1. 1Faculty for
Special Education, Belgrade, Serbia
Objective: Attention deficit in children with mild intellectual disability is
being considered fundamental cognitive deficit that endangers activities
of daily living.
Methods: Aim of this research is to determine the quality of attention
components in children with mild intellectual disability and to suggest
several modes to treat this ability. Sample includes 105 subjects with
mild intellectual disability, age 10 to 15, both genders, absence of somatic,
neurological and emotional disturbances.
Results: For selectivity of attention development level assessment,
Stroop test is being used. Pearson’s coefficient of linear correlation is
determined, r=+0.73 (words) and r=+0.71 (colors), which is significant
at level 0.01. We find that longer time needed to complete the test causes
larger number of mistakes that are made. Attention flexibility research in
children with mild intellectual disability is conducted with Trail Making
Test. Low level of positive correlation is determined (r=+0.40, level
0.01) between test variables, so we conclude that examinees that do the
test more quickly, make less mistakes.
Conclusion: Treatments for improving quality of attention in children
with mild intellectual disability should be made according to symptoma-
tology of each individual. There are two basic treatment approaches: phar-
macological and behavioral. Methylphenidate therapy can efficiently
reduce attention problem in children with mild intellectual disability.
Discontinuation of medical treatment leads to interruption of benefits
that are achieved in improving this ability. Using alternative treatments
such as behavioral therapy and neurofeedback has advantages.
Symbiosis of medical and behavioral treatment gives best results in treat-
ing attention in children with mild intellectual disability.
Policy of full disclosure: Abstract represents the result of two projects:
“Creating Protocol for assessment of educational potential in children
with development difficulties as criteria for creating an individual edu-
cational programs” (No. 179025) and “Social participation of persons
with intellectual disability” (No. 179017), which are being funded by
The Ministry of education, science and technological development,
Republic of Serbia.
P-15-004 Acoustic noise benefit a common feature of the attention
deficit hyperactivity disorder phenotype? – Evidence from
motor learning in spontaneously hypertensive rats
D. Eckernäs1, G. Söderlund2, O. Holmblad1, F. Bergquist3. 1Gothenburg
University, Göteborg, Sweden; 2Sogn og Fjordane University, Songdal,
Norway; 3Gothenburg University, Department of Pharmacology, Göteborg,
Sweden
Objective: In addition to attention deficits and hyperactivity it is common
for children with ADHD to display impaired fine and gross motor skills
which increases the burden further in an academic setting. Recent findings
indicate that acoustic loud white noise (80 dBA) improves cognitive per-
formance in children with low attention. In this study, we explored
if the ADHD rat model the Spontaneously Hypertensive Rat (SHR)
displayed similar noise benefit as that observed in children with low
attention.
Methods: Effects of acoustic white noise compared to ambient silence
on skilled reach and Rotarod running were investigated in male SHR
(noise n=15, silence n=16) and Wistar SCA controls (noise n=12, silence
n=16). Each animal were trained 15 minutes in the Montoya staircase
and ran a total of four trials on the Rotarod each day for a total of
10 days. In parallel experiments the effect of methylphenidate (MPH,
SHR n=12, Wistar n=8) compared to NaCl (SHR n=12, Wistar n=12)
on motor learning was investigated using the same motor learning para-
digms. The number of pellets consumed each day and the latency to fall of
the Rotarod was used in the statistical analysis.
Results: As previously reported SHR displayed impaired acquisition of
skilled reach and Rotarod running compared to Wistar controls. Acoustic
noise restored motor learning in the SHR learning skilled reach and
Rotarod running but had no influence on learning in Wistar rats. MPH
completely restored the performance on the Rotarod but had no effect
on skilled reach learning in the SHR.
Conclusion: Results from this study suggests that rats with the ADHD
phenotype share the noise benefit previously reported in children with
low attention, the effect was in the same range as MPH medication.
Acoustic noise may be useful as an alternative treatment to stimulant
medication in the management of ADHD.
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Policy of full disclosure: Göran Söderlund is the co-founder of a com-
pany that develops a noise improvement tool to utilize the positive effects
of noise.
P-16. Anxiety disorders and phobias
P-16-001 Dependence on benzodiazepines in patients with panic
disorder: A cross-sectional study
K. Fujii1, T. Suzuki2, M. Mimura2, H. Uchida2. 1Keio University, Department
of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; 2Keio
University, School of Medicine, Tokyo, Japan
Objective: The aim of this cross-sectional study was to examine the pre-
valence of psychological dependence on benzodiazepines in outpatients
with panic disorder and elucidate demographic and clinical characteristics
associated with this condition.
Methods: This study was conducted in four outpatient clinics in
Tokyo, Japan from November, 2012 to November, 2013. Subjects were
eligible if they were outpatients aged 18 years or older and met the
diagnostic criteria for panic disorder according to the International
Classification of Diseases, 10th edition (ICD-10). The subjects received
the following assessments: the Severity of Dependence Scale, Japanese
Version (SDS), the Self-Report Version of Panic Disorder Severity Scale,
Japanese Version (PDSS-SR), and the Quick Inventory of Depressive
Symptomatology-Self Report, Japanese Version (QIDS-SR). The following
information was also collected: age, sex, ethnicity, duration of illness,
physical and psychiatric comorbidities, and details of prescribed psycho-
tropic medications.
Results: Fifty-one patients participated in this study; of these, 31
patients (60.8%) showed psychological dependence on benzodiazepines
(i.e. a total score of #5 in the SDS). The proportion of patients with depen-
dence (i.e. a total score of #4 in the PDSS) was significantly lower in remit-
ted patients (44.1%, N=15/34) than those who were not in remission
(94.1%, N=16/17) (Pearson chi-squares=11.9, p<0.001). A multiple re-
gression analysis showed that the PDSS scores showed a positive corre-
lation with the SDS total scores (#=0.60, 95% confidence interval=0.17–
0.50, p=0.0001), while other factors failed to show any significant
association.
Conclusion: These findings emphasize the need of enhanced awareness
toward benzodiazepine dependence in both patients and psychiatrists as
well as close attention especially to patients with panic disorder who pres-
ent severe symptomatology.
Policy of full disclosure: Dr. Fujii has nothing to disclose. Dr. Suzuki
has received manuscript or speaker’s fees from Astellas, Dainippon
Sumitomo, Eli Lilly, Elsevier Japan, Meiji Seika, Novartis, Otsuka,
and Weily Japan within the past three years. Dr. Mimura has received
grants and/or speaker’s honoraria from Asahi Kasei Pharma, Astellas
Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai,
Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Meiji-Seika Pharma,
Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka
Pharmaceutical, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi Pharma,
and Yoshitomi Yakuhin within the past three years. Dr. Uchida has
received grants from Pfizer, Astellas Pharmaceutical, Eisai, Otuka
Pharmaceutical, GlaxoSmithKline, Shionogi, Dainippon-Sumitomo
Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharma, Janssen
Pharmaceutical, and Yoshitomi Yakuhin and speaker’s honoraria from
Otuka Pharmaceutical, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomi
Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, Abbvie,
and Janssen Pharmaceutical within the past three years.
P-16-002 Establishment of a social interaction test using a
3-chamber system for rats
T. Yamaguchi1, H. Jingushi1, R. Fukumori1, M. Yoshioka2, T. Yamamoto1.
1Nagasaki International University, Faculty of Pharmaceutical Sciences, Sasebo,
Japan; 2Hokkaido University, Graduate School of Medicine, Department of
Neuropharmacology, Sapporo, Japan
Objective: Social interaction test has been generally evaluated as index of
social behaviors performed between two experimental animals. In this
study, we established a new social interaction test using a 3-chamber
openfield system to examine the social behavior of a rat.
Methods: A rat had been acclimated for 2 days in the square-shaped
open-field system in which two stranger cages (SCs) without rats were in-
stalled. After acclimation to the open-field system, we measured the time
required for the rat to approach the SC in which a rat was placed by visual
observation or video tracking analysis in the test trial.
Results: To evaluate the effects of lighting, social behavior was exam-
ined under dark (5 lux) and bright conditions (350 lux). Under the dark
condition, the time required for the rat to approach the SC in which a
rat was placed based on active contact was significantly longer than
that measured by visual observation under the bright condition. In ad-
dition, video tracking analysis using imaging data also showed a similar
tendency. Briefly, this result was similar to that obtained by visual obser-
vation. In the social interaction test using the 3-chamber system, the time
required for the rat to approach the SC in which a rat was housed (social
interaction time), which was measured by visual observation, was corre-
lated with that by video tracking analysis. On the other hand, anxiolytics,
tandospirone (3 mg/kg, i.p.) and diazepam (0.3 mg/kg, i.p.), significantly
increased the time required to approach the SC in which a rat was housed,
without influencing spontaneous locomotor activity.
Conclusion: In conclusion, this study showed the behavioral-
pharmacological validation of this social interaction test to measure innate
anxiety and social behavior using a 3-chamber system in rats. In addition,
this evaluation system may contribute to the development of new thera-
peutic drugs for psychiatric diseases, including anxiolytics.
Policy of full disclosure: None.
P-17. Transcultural psychopharmacology
P-17-001 Effects of antidopaminergic intervention on
catecholamine metabolites in plasma and urine in healthy
volunteers
T. Veselinovic1, H. Schorn1, M. Paulzen1, I. Vernaleken1, G. Gründer1.
1RWTH Aachen University, Aachen, Germany
Objective: The need for a better understanding of the effects of antipsy-
chotic drugs on monoaminergic neurotransmission have led to several
examinations of their influence on the relatively easily accessible catecho-
lamine metabolites in plasma and urine as possible markers for psychosis
and antipsychotic response. Up to now, such examinations, mainly per-
formed in patients with schizophrenia, resulted in inconsistent, partially
opposed results.
Methods: In this single-blind, randomized, placebo-controlled, parallel
group study we investigated the changes of the peripherally measurable
catecholamine metabolites following seven days administration of three
antipsychotics with entirely different mechanism of action (aripiprazole,
haloperidol and reserpine), and their relationship to physiology and be-
haviour in 72 healthy volunteers.
Results: A repeated measures ANOVA revealed a statistically signifi-
cant time*group interaction for homovanillic acid (HVA) (p=0.008) and
vanillic mandelic acid (VMA) (p=0.019) in urine and 3-methoxy,
4-hydroxyphenylglycol (MHPG) in plasma (p=0.003). In detail, reserpine
caused the strongest increase of HVA and MHPG, while aripiprazole
caused a most pronounced VMA increase. Further, strong positive asso-
ciations, remaining statistically significant even after Bonferroni adjust-
ment, were found for the HVA plasma concentration measured after the
pharmacological challenge and PANSS scores (PANSS total: r=0.570,
p<0.001; PANSS negative: r=0.498, p<0.001; PANSS cognitive: r=0.553,
p<0.001) as well as the HAMD score (r=0.423, p=0.003). Furthermore,
we found a strong negative correlation between the HVA concentration
and the self-assessment (rated using the visual analogue scale) of achieve-
ment potential (r=−0.466, p=0.001), the ability to concentrate (r=−0.569,
p<0.001), and the general well-being (r=−0.550, p<0.001).
Conclusion: Our results point to a robust association between different
aspects of psychopathology and catecholamine metabolites after antido-
paminergic intervention in healthy volunteers. Those metabolites rep-
resent the central monoaminergic neurotransmission only to a limited
extent. However, our observation, requiring further replication, could be
a valuable contribution to a better understanding of the neurobiological
basis of different psychopathological phenomena.
Policy of full disclosure: None.
P-18. Neuroimaging A
P-18-001 Neural basis of embarrassment of self-face recognition in
patients with social anxiety disorders: A functional
magnetic resonance imaging study
A. Kawaguchi1, T. Morita2, T. Kawaguchi1, S. Nakaaki3, N. Hashimoto1,
T. Akechi1. 1Nagoya City University, Nagoya, Japan; 2Osaka, Japan; 3Keio
University, Tokyo, Japan
Objective: Although social anxiety disorder (SAD) is highly prevalent, the
neural mechanism is yet unknown. We conducted a functional magnetic
resonance imaging (fMRI) study, using tasks involving self-conscious
emotions. In an earlier study, it was proven that, in healthy individuals,
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the emotion of embarrassment, upon viewing self-face images, increased
when they were exposed to observations by others, and the activation
in the right anterior insula was consequently increased. We had expected
that, in patients with SAD, the emotion of embarrassment would become
larger than that of healthy individuals and be further increased during ex-
posure to other’s observations, and that increases of activation in the right
anterior insula would appear more prominently.
Methods: Five patients with SAD and eight healthy individuals partici-
pated. Brain activities were measured with Siemens 3T MRI when photo-
graphic images of self-face and other-faces, which had been randomly
preselected from a video image, were presented and the subjects rated
the degree of embarrassment they felt upon viewing each image. We cre-
ated two comparison conditions, in one the participants were exposed to
other’s observations, and in the other without observations. This study
was approved by the ethic committee of Nagoya City University and all
the participants gave written informed consent.
Results: This study demonstrates that patients with SAD have stronger
emotion of embarrassment upon viewing self-face images. As a result,
self-face related brain activities increased (self-face related activities
minus other-face related activities) in the regions involved with emotion
of embarrassment (such as insula, cingulate cortex, and so on), while
we observed, by contrast, reduction in activities in the right premotor
regions involved in self-face recognition process.
Conclusion: Our data indicates that patients with SAD have strong
emotion of embarrassment of their own faces, and their abilities in the self-
face recognition process may be decreased.
Policy of full disclosure: None.
P-18-002 Structural magnetic resonance imaging study in patients
with social anxiety disorder in Japan
T. Kawaguchi1, A. Kawaguchi1. 1Nagoya City University, Nagoya, Japan
Objective: Despite the fact that social anxiety disorder (SAD) is highly
prevalent, few structural imaging studies have been conducted. Studies
using the method of region-of-interest have reported decreases of hippo-
campal/amygdala volumes in patients with SAD. We have also reported
cases in which increases of right hippocampal volumes were observed
in comparison before and after group cognitive behavioral therapy. On
the other hand, a study using the vosel-based morphometry (VBM)
(Potts et al. 1994) concluded that no significant difference was found.
However, Talati et al. reported abnormalities in the volumes of gray mat-
ters based on VBM. As described above, there has been no fixed theory
obtained in the structural imaging studies. Moreover, these studies were
conducted in European and North American subjects, although there
are cultural differences in the characteristics of SAD between Asians
and Europeans/North Americans. In the present research, we made com-
parison between Japanese patients with SAD and healthy individuals
based on VBM.
Methods: The subjects of our research were 13 patients who had been
diagnosed with SAD and 13 healthy individuals. We obtained magnetic
resonance images with Siemens 3T for VBM analysis using Statistical
Parametric Mapping 8 (SPM8). This study was approved by the ethics
committee of the Nagoya City University, and conducted with written
consent provided by all the participants.
Results: From this analysis, we did not find a significant statistical
difference at the cluster level, or observe remarkable differences in
hippocampus-amygdala regions, which had been reported in earlier
studies.
Conclusion: The fact that no significant difference was found in this
study conforms to the research result presented by Potts et al. We, how-
ever, assume that it may be because of the number of cases being small,
and that more number of cases need to be collected for reanalysis in the
future.
Policy of full disclosure: None.
P-18-003 Silexan (WS® 1265) reduces serotonin-1A receptor
binding in vivo
P. Baldinger1, R. Lanzenberger2, M. Mitterhauser3, A. Hahn2,
C. Rami-Mark3, W. Wadsak3, S. Kasper2. 1Medical University of Vienna,
Vienna, Austria; 2Medical University of Vienna, Department of Psychiatry,
Vienna, Austria; 3Medical University of Vienna, Department of Nuclear
Medicine, Vienna, Austria
Objective: Silexan (WS® 1265)*, a patented active substance comprised of
an essential oil produced from Lavandula angustifolia flowers, has been
authorized in Germany as herbal medicinal product for the treatment of
states of restlessness related to anxious mood and its effectiveness has
been shown in several forms of anxiety disorders. The serotonin-1A
receptor (5-HT1A) was shown to play a major role in the pathogenesis
and treatment of anxiety disorders.
Methods: To elucidate the effect of Silexan on 5-HT1A receptor binding,
17 healthy men (mean age±SD=25.1±3.6 years) underwent 2 positron
emission tomographies (PET) using the radioligand [carbonyl-11C]
WAY-100635 following the daily intake of 160mg Silexan or placebo
over a minimum of 8 weeks, respectively (randomized, double-blind,
cross-over design). PET scans were normalized to MNI-space (SPM8).
Quantification of 5-HT1A receptor binding potential was carried out in
PMOD 3.3 using SRTM2 and the cerebellar grey as reference region.
Results: Voxel-wise repeated-measures ANOVA including the
sequence (Silexan-placebo versus placebo-Silexan) as co-variate revealed
a significant decrease of 5-HT1A receptor binding potential following
the intake of Silexan compared to placebo in two large clusters encom-
passing the temporal gyrus and the fusiform gyrus, the hippocampus
on one hand (k=5334, peak t value=6.64, p<0.05, FWE corrected at
cluster-level) as well as the insula and the anterior cingulate cortex on
the other hand (k=4812, peak t value=6.08, p<0.05, FWE corrected at
cluster-level).
Conclusion: This PET study shows a reduced 5-HT1A receptor binding
in healthy subjects following the daily administration of 160mg of Silexan
compared to placebo. This is in agreement with SSRI- or ECT-induced re-
duction in 5-HT1A binding. These findings propose an involvement of the
5-HT1A receptor in the anxiolytic effects of Silexan. *Silexan is the active
substance of Lasea®, manufacturer: Dr. Willmar Schwabe GmbH&Co.KG,
Karlsruhe, Germany.
Policy of full disclosure: None.
P-18-004 Effect of early stress on hippocampal gray matter is
influenced by a functional polymorphism in EAAT2 in
bipolar disorder
F. Benedetti1, S. Poletti1, D. Radaelli1, C. Locatelli1, A. Pirovano1,
C. Lorenzi1, E. Smeraldi1, C. Colombo1. 1Instituto Scientifico, Ospedale San
Raffaele, Department of Clinical Neurosciences, Milan, Italy
Objective: Current views on the pathogenesis of psychiatric disorders
focus on the interplay between genetic and environmental factors, with in-
dividual variation in vulnerability and resilience being part of the devel-
opment of illness. The aim of the present study is to investigate the
effect of glutamate transporter polymorphism and exposure to adverse
childhood experiences (ACE) on hippocampal gray matter volume of
patients with bipolar disorder (BD).
Methods: Eighty-six subjects affected by BD were genotyped for
EEAT2 -181A>C and severity of ACE was rated on the Risky Families
Questionnaire. An analysis of variance, limited to the hippocampus,
with genotype and ACE as factors was performed, with age, sex, duration
of illness, number of episodes and handedness as possible confounding
factors. Statistical threshold was P<0.05 corrected for multiple compari-
sons with whole-brain family-wise error (FWE) correction.
Results: Patients exposed to higher levels of ACE had lower gray matter
volume. The effect of SLC1A2-181A>C revealed itself only among
patients exposed to lower levels of ACE, among whose T/T homozygotes
showed the lowest, and G/G the highest, gray matter volume.
Conclusion: This is the first study to show a joint effect of both ACE
and SLC1A2-181A>C on hippocampal volume. The greatest difference
between high and low exposure to ACE was observed in carriers of the
G allele which reported significantly higher gray matter volume when ex-
posed to less stress. Since the mutant G allele has been associated with a
reduced transcriptional activity and expression of the transporter protein,
we could hypothesize that after exposure to highest levels of ACE G/G
homozygotes are more vulnerable to stress and report the highest damage
to brain volume as a consequence of an excess of free glutamate.
Policy of full disclosure: None.
P-18-005 Reduced insulin sensitivity is related to less endogenous
dopamine at D2/3 receptors in the ventral striatum of
healthy non obese humans: Preliminary findings with
[11C]-(+)-PHNO
F. Caravaggio1, C. Borlido1, M. Hahn1, S. Raitsin1, E. Plitman1,
S. Nakajima1, P. Gerretsen1, A. Wilson1, G. Remington1,
A. Graff-Guerrero1. 1CAMH, Toronto, Canada
Objective: The conceptualization of obesity in relation to food addiction
remains a widely debated topic in neuroscience. Rodent models of dia-
betes suggest reduced basal dopamine levels in the nucleus accumbens,
similar to that seen in models of drug addiction. However, it is not
known whether insulin sensitivity is related to endogenous dopamine
levels in the ventral striatum (VS) of humans. Using the agonist dopamine
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D2/3 receptor (D2/3R) radiotracer [11C]-(+)-PHNO, and an acute dopa-
mine depletion challenge, we sought to determine whether baseline
D2/3R availability and estimated endogenous dopamine levels at D2/3R
in VS are related to estimates of insulin sensitivity in otherwise healthy
persons.
Methods: Eleven healthy, non-obese and non-diabetic persons (3 fe-
male) participated in the study. Eleven participants provided a baseline
[11C]-(+)-PHNO scan, while nine of these subjects also provided a scan
under acute dopamine depletion, allowing estimates of endogenous
dopamine occupying D2/3R at baseline. Acute dopamine depletion
was achieved via oral administration of alpha-methyl-para-tyrosine
(64mg/kg) as previously described by our group. The insulin sensitivity
index was estimated for each subject from fasting plasma glucose and in-
sulin using the Homeostasis Model Assessment II (HOMA2).
Results: Baseline [11C]-(+)-PHNO BPND in the right VS was negatively
correlated with estimated insulin sensitivity (r(10)= −0.65, p=0.02).
Notably, [11C]-(+)-PHNO BPND in the left VS was not correlated with in-
sulin sensitivity (r(10)=−0.35, p=0.29). In the nine subjects who also pro-
vided a scan under dopamine depletion, estimated baseline dopamine
occupancy at D2/3R in the VS was positively correlated with insulin sen-
sitivity (r(8) =0.84, p=0.005). This relationship was driven primarily by
dopamine occupancy in the right VS (r(8) =0.75, p=0.01), but not in the
left VS (r(8) =0.41, p=0.28).
Conclusion: In keeping with previous rodent studies, we demonstrate
novel findings which suggest that a decreased index of insulin sensitivity
is associated with reduced baseline endogenous dopamine levels at D2/3R
in the ventral striatum of healthy persons. Given our small sample size, it
will be important to replicate these findings in healthy persons, as well as
persons with co-morbid metabolic and neuropsychiatric diseases.
Policy of full disclosure: None.
P-18-006 Of pig and man: Analogy of response to electroconvulsive
therapy (ECT): Most do, a few don’t
D. Doudet1, C. Clark1, A. K. Alstrup2, S. Jakobsen2, A. Gjedde3,
G. Wegeners2, P. Videbech2, A. Landau2. 1University of British Columbia,
Vancouver, Canada; 2University of Aarhus, Aarhus, Denmark; 3University of
Copenhagen, Copenhagen, Denmark
Objective: ECT although recognized as the most effective treatment for
depression, still has positive response rates between 70 and 80 percent.
Reasons for this differential response rate range from the nature of the
seizure to patient presentation. We aimed to evaluate in parallel, in a con-
trolled setting and in normal minipigs, the response of the dopaminergic
(DA), noradrenergic (NA) and serotonergic (5HT) systems, to a clinical
course of ECT by PET.
Methods: Seven isofluorane-anesthetized Gottingen minipigs
underwent PET scanning with 11C-SCH23390 (tracer of DA D1 receptors),
11C-yohimbine (tracer of alpha2 adrenergic receptors) and
11C-MDL100,907 (tracer of 5HT2 serotonergic receptors) at baseline,
24–48 hrs post and 8–10 days after the end of ECT. The animals received
a clinical course of 10 bilateral ECT (Thymatron device), 3 times a week,
under ketamine sedation followed by intravenous thiopental and succinyl
choline. PET data were routinely analyzed (Logan linear analysis for
SCH23390 and yohimbine and ratio striatum/cerebellum for
MDL100,907.) For yohimbine and MDL100,907, binding was evaluated
in 7 regions: frontal, temporal and occipital cortices, thalamus, striatum,
hippocampus and amygdala. Only striatal binding was considered for
SCH23390.
Results: Binding data were analyzed using a standard repeated mea-
sures design with polynomial contrasts to determine differences in
mean levels pre- and post-ECT. However, for all three tracers, the data
violated the assumptions of the general linear model. Subsequent examin-
ation of the data indicated that two animals (28%) had almost opposite
responses to ECT in comparison to the other five (72%) for the 5HT and
NA systems. In contrast, for the DA system, all seven animals had similar
responses but varied markedly in the magnitude of response.
Conclusion: These data suggest that even in a very controlled setting,
differential responses in neurotransmitter systems to ECT are common
and may not entirely reflect stimulation parameters, seizure characteristics
or individual pathology but innate sensitivities of the monoaminergic
systems.
Policy of full disclosure: None.
P-18-007 Early changes in neural responses to emotional
information predict clinical response to antidepressant
treatment in depression
B. Godlewska1, M. Browning1, R. Norbury1, P. Cowen1, C. Harmer1.
1University of Oxford, Oxford, United Kingdom
Objective: To test whether early changes in emotional bias are predictive
of response to antidepressant treatment. Antidepressant treatment has
been shown to modulate behavioural and neural markers of negative af-
fective bias, before therapeutic changes in mood are seen. It has been
hypothesised that early changes in emotional processing are an important
mechanism which mediates clinical improvement over time by allowing a
more positive response to on-going environmental stimuli.
Methods: 32 unmedicated patients meeting DSMIV criteria for major
depression were treated with escitalopram 10mg over 6 weeks. The
neural response to emotional facial expressions was assessed both before
and after 7 days of treatment. Depression severity was measured before
treatment, 7 days and after 6 weeks using the Beck Depression
Inventory (BDI). Small volume correction was applied during fMRI ana-
lysis to assess if early change in key areas identified through previous
studies predicted clinical change after 6 weeks.
Results: BDI scores fell an average of 17.5 points after the 6 weeks treat-
ment. This response was predicted by decreased amygdala response to
fearful facial expressions after 7 days of treatment. The decreased amyg-
dala response was predictive of 6 week clinical response and survived
entering baseline or one week change in BDI scores as a co-variate.
Conclusion: SSRIs have previously been reported to decrease amygdala
response early in treatment in depressed patients and compared to a pla-
cebo control. The current study shows that these early changes are predic-
tive of later clinical response as supported by the cognitive
neuropsychological model of antidepressant drug action. These data
therefore add support to the idea that early changes in emotional proces-
sing have clinical significance which is expressed with a time delay, fol-
lowing environmental exposure and a period of learning in the context
of a reduced negative bias.
Policy of full disclosure: None.
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P-19-001 The importance of anesthetic algorism of modified ECT,
focused on strict control of intravenous anesthetic
concentration
Y. Demoto1, Y. Fujita2, A. Hiraoka3, G. Satou2, K. Mukaida4. 1Hiroshima
Haruka Clinic, Japan, Hiroshima, Japan; 2Department of Psychiatry,
Kousei-kai, Kusatsu Hospital, Hiroshima, Japan; 3Department of Medicine,
Kousei-kai, Kusatsu Hospital, Hiroshima, Japan; 4Department of
Anesthesiology, Hiroshima Prefectural, Rehabilitation Center, Hiroshima, Japan
Objective: It is important to induce qualitatively effective convulsive
brain waves under proper sedation and cardiovascular stability during
modified electroconvulsive therapy (mECT). However, many anaesthetic
agents such as propofol and thiopental used for mECT have
anti-convulsant properties and their sedative doses were differences
among individuals. We prepared an algorism to modify anesthetics dose-
setting and a level of electrical stimulus (ES energy) correlatively under
the qualitative appraisal of convulsive brain waves, and assessed the
usefulness.
Methods: Subjects included 53 patients who went through the first
one Kur of mECT between April 2013 and October 2014 after obtained
approval from institutional ethical committee. 450mECT sessions were
evalated. Anesthesia was induced with propofol and remifentanil
target-controlled-infusion (TCI) using TIVA-trainer ver. 8 and monitored
with bispectral index (BIS). Following rocuronium injection, pressure con-
trolled ventilation was adjusted to maintain the end-tidal carbon-dioxide
between 30 and 34mmHg. According to the algorism, an ES was applied
to elicit a seizure with monitoring electroencephalographic. Quality and
duration of convulsive brain waves, their relationship with BIS values,
hemodynamic change before and after ES.
Results: In 448 cases (99.6%) out of 450 cases, qualitatively effective con-
vulsive brain waves were induced. The needed number of times of ES was
1 in 434 cases, 2 in 13, and 3 in 3. Duration of convulsive brain waves was
shorter when the quality of postical suppression was high, and not corre-
lated with BIS values. On the other hand, according to anesthetics dose-
settings, significant differences were observed in hemodynamic change
before and after ES, and in the frequency of cardiovascular agonists or
antagonists injection before ES.
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Conclusion: While countermeasures to circulation fluctuations were
needed according to anesthetics dose-settings, the algorism resolved the
most important pending problems on mECT for the most part.
Policy of full disclosure: None.
P-19-002 PACAP-PAC1 signaling pathway regulates internalization
of serotonin 2A receptor in a protein kinase C and
beta-arrestin2 dependent manner
A. Hayata1, K. Moriguchi2, N. Encho2, N. Shintani2, A. Baba3,
H. Hashimoto2. 1Laboratory of Molecular Neuropharmacology, Graduate
School of Pharmaceutical, Suita, Japan; 2Osaka University, Suita, Japan;
3Hyogo University of Health Sciences, Kobe, Japan
Objective: A growing number of human genetic and animal model stu-
dies implicate the pituitary adenylate cyclase-activating polypeptide
(PACAP) signaling pathway as a risk factor for psychiatric disorders
such as schizophrenia and stress-related disorders. PACAP-deficient
mice show notable psychomotor abnormalities and neurological changes
that are thought to be endophenotypes for psychiatric disorders. Most of
them are reversed by risperidone, an atypical antipsychotic drug with
serotonin (5-HT)2 receptor and dopamine D2 receptor antagonist proper-
ties, and ritanserin, a selective antagonist for 5-HT2 receptor. These
findings indicate that 5-HT2 receptor signaling is involved in psychiatric
conditions in which PACAP signaling is dysfunctional, although the
underlying mechanisms remain unclear. Since it is known that 5-HT2A re-
ceptor functions are regulated by receptor internalization, in this study we
examined whether PACAP signaling modulates the internalization of
5-HT2A receptor.
Methods: The internalization of 5-HT2A receptor expressed in
HEK293T cells was investigated using the HaloTag system. The
HaloTag protein labeling technology is widely used for living cell imaging
and protein analysis.
Results: PACAP induced internalization of 5-HT2A as well as PAC1 re-
ceptor in a dose- and time-dependent manner. In contrast, PACAP did not
affect internalization of 5-HT1A receptor. Moreover, pretreatment with
the PKC inhibitor sphingosine considerably inhibited PACAP-induced
internalization of 5-HT2A receptor. Furthermore, beta-arrestin2 siRNA
significantly blocked PACAP-induced internalization of 5-HT2A receptor.
Conclusion: Taken together, these results suggest that the
PACAP-PAC1 pathway regulates 5-HT2A receptor internalization in a
PKC and beta-arrestin2 dependent manner. This functional crosstalk
implies the possibility that endogenous PACAP in the brain critically
regulates 5-HT2 receptor signaling, altered regulation of which may be
involved in the development of psychiatric disorders. Our results give
new insights into the mechanisms underlying the therapeutic effects of
antipsychotic drugs.
Policy of full disclosure: None.
P-19-003 Changes in extracellular contents of D-serine and
D-serine-NMDA receptor-associated amino acids by
selective suppression of serine racemase expression in
forebrain glutamatergic neurons
S. Ishiwata1, A. Umino1, D. Balu2, J. Coyle2, T. Nishikawa1. 1TMDU/Japan,
Tokyo, Japan; 2Harvard Medical School, Boston, USA
Objective: In mammalian brains, D-serine plays a pivotal role in gluta-
mate neurotransmission as an endogenous co-agonist for the N-methyl-
D-aspartate receptor (NMDAR), which is essential for the expression of
higher-order brain functions. However, the exact molecular and cellular
mechanisms underlying the regulation of the extracellular D-serine con-
tents remain unclear. Recently, Coyle and his colleagues demonstrated
that the neuron-selective deletion of the gene of a D-serine synthesizing
enzyme SR (SR) (nSRCKO) caused a significant reduction by 65% in the
tissue SR mRNA expression in the medial prefrontal cortex (mPFC) and
hippocampus (HC) and disturbed an induction of NMDA receptor-
mediated LTP in the HC. Therefore, we have studied in the nSRCKO
mouse the extracellular levels of D-serine and NMDA receptor function
in the HC or mPFC.
Methods: Male and female nSRCKO mice (Benneyworth et al. 2012)
were used. We monitored extracellular contents of various chiral and non-
chiral amino acids by applying an in vivo microdialysis technique in com-
bination with high-performance liquid chromatography with fluorometric
detection.
Results: The extracellular contents of D-serine were significantly dimin-
ished by 47% in the HC, but not mPFC. In these brain regions, there were
no significant alterations in tissue and extracellular contents of L-serine, a
precursor for D-serine, and glycine, another co-agonist for the NMDAR.
NMDA receptor function was examined by basal and NMDA-induced
levels of extracellular taurine contents before and after an intra-dialysis-
tubing infusion of NMDA. Basal extracellular taurine levels in nSRCKO
HC (before NMDA) were significantly decreased. Furthermore, the maxi-
mum absolute value of taurine after NMDA perfusion into the HC in
nSRCKO was much lower than that of control.
Conclusion: These data indicate that neuronal SR plays a substantial
role in the control of extracellular D-serine levels and that decreased
D-serine contents lead to hypofunction of the NMDAR, at least, in the HC.
Policy of full disclosure: None.
P-19-004 Impact of chemotherapy on subjective cognitive function
in patients with breast cancer: A cross-sectional study
R. Kitahata1, H. Uchida1, T. Hayashida1, S. Nakajima1, T. Maeda1,
K. Funaki1, M. Nagaoka1, T. Makiko1, H. Jinno1, M. Mimura1. 1Keio
University, Tokyo, Japan
Objective: Chemotherapy was reported to induce mild to moderate im-
pairment in cognitive function in patients with breast cancer. However,
they did not include any assessment of subjective cognitive function
while they mainly focused on objective one. Given the fact that it is
patients with breast cancer who recognized and reported this impairment
for the first time, subjective cognitive function needs to be examined to
elucidate the cognitive impairment potentially induced by chemotherapy.
Methods: This cross-sectional study included females with breast can-
cer who underwent chemotherapy within four weeks ahead of the screen-
ing. Subjective cognition was assessed using the Cognitive Failures
Questionnaire (CFQ), Dysexecutive Questionnaire (DEX), and Everyday
Memory Checklist (EMC). Objective cognitive measures included the
Behavioral Assessment of the Dysexecutive Syndrome (BADS) and
Rivermead Behavioral Memory Test (RBMT).
Results: 14 subjects were included (age=53.8±8.8 years; duration of
illness=456±954 days; stage I=2, IIa=4, IIb=3, IIIa=2, IIIb=1, IV=1,
unclear=1). The total BADS score (16.9±4.7) was comparable to normal
data (t13.6=1.20, p=0.25). The total scores in the patient-version DEX
(8.3±9.7) and family-version DEX (8.8±9.79) showed a trend correlation
(r=0.50, p=0.07). The total score in the patient-version EMC (6.1±4.5)
was lower than normal data (t82=2.38, p=0.02) and showed a trend cor-
relation with that in the family-version EMC (4.8±5.0) (r=0.52, p=0.05).
The total RBMT score (21.8±2.7) was comparable to normal data
(t82=0.27, p=0.79). The total CFQ score (25.4±10.9) was lower than the
normal (t15.5=6.80, p<0.001).
Conclusion: Patients with breast cancer did not show any significant
subjective impairment in executive function, memory, and attention with-
in four weeks after chemotherapy. Prospective studies are warranted to
explore long-term changes in subjective cognitive function in this popu-
lation following chemotherapy.
Policy of full disclosure: None.
P-19-005 A catatonia model as dysregulated glutamatergic
cortico-thalamic-cortico neurotransmission
L. Adler1, W. Regenold2, S. Doddi2. 1University of MD, School of Medicine,
Baltimore, USA; 2University of MD, School of Medicine, Department of
Psychiatry, Baltimore, USA
Objective: Development of a parsimonious neurobiological model of the
catatonic syndrome.
Methods: 1. Description and biology of catatonia associated associated
with phencyclidine (PCP) intoxication and anti-NMDA Receptor (anti-
NMDAR) antibody encephalitis 2. Review of cortico-thalamic-cortico
circuitry 3. Review of catatonia syndrome symptoms with regard to
underlying neurobiology 4. Review of catatonia treatments with regard
to the described neurobiology.
Results: 1. PCP-induced catatonia and catatonia consequent to
anti-NMDAR Ab encephalitis reflect conditions caused by hypoactivity
of NMDA receptors (1). 2. Cortical pyrimidal cells project from the frontal
cortex (FC) to the ventral tegmental area (VTA) via thalamic relays and
regulate tonic dopamine (DA) activity in the receptive fields in the
VTA. Recurrent mesocortical (MC) DA neurons feed back to pre-frontal
cortical D1 receptors. Via a polysynaptic pathway, cortical glutamatergic
(GLT) afferents project to pedunculopontine tegmental (PPT) interneurons
neurons stimulate mesolimbic (ML) and nigrostriatal (NS) D2 receptors.
MC DA neurons in the FC stimulate GLT projections to VTA and striato-
tegmental (ST) gamma-aminobutyric acid (GABA) neurons which inhibit
firing of MC and NS DA neurons (2,3). This organization provides for
co-modulation of GLT, DA, and GABA pathways (Figure 1). 3. The classic
symptoms of catatonia and putative neurologic localization are listed
in Figure 2. In terms of its neuropsychiatry, catatonia can be understood
conceptually as a psychomotor disorder. Some symptoms, such as mirror
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echopraxia (4), can be understood as reflecting mainly cortical-to-
subcortical dysregulation. Conversely, symptoms such as rigidity and im-
mobility (5) may reflect subcortical-to-cortical dysregulation. Others may
reflect more complex interactions. 4. The most effective treatments for cat-
atonia are ECT and lorazepam (6). Neuroimaging with MRS has sug-
gested that ECT results in higher cortical GLT activity (7) and enhances
GABAergic function, at least in depressed patients (8). The often immedi-
ate benefits of lorazepam (9) are consistent with collateral modulation of
SC DA activity with which then modulate cortical GLT through feedback
loops.
Conclusion: Symptoms of catatonia are consistent with dysregulated
cortico-thalamic-cortical neurotransnmission. PCP and anti-NMDAR
Abs block glutamate receptors. This blockade results in disrupted
co-modulation of dopamine activity, glutamate transmission, and GABA
function. ECT and lorazepam directly impact these disrupted circuits
and are the first line treatments for catatonia.
Policy of full disclosure: None.
P-19-006 The changes in prescription pattern of aripiprazole among
psychiatric inpatients
W.-M. Bahk1, I. H. Shim2, Y. S. Woo2, H. R. Song2, H. R. Wang2, T.-Y. Jun2,
Y. J. Kwon3, K. H. Lee4, J. S. Seo5, S.-Y. Lee6, M. D. Kim7. 1Yeouido St. Mary´
s Hospital, Seoul, Republic of Korea; 2Seoul, Republic of Korea; 3Chunan,
Republic of Korea; 4Gyeongju, Republic of Korea; 5Chungju, Republic of
Korea; 6Iksan, Republic of Korea; 7Jeju, Republic of Korea
Objective: We aimed to investigate the changes in prescription pattern of
aripiprazole among psychiatric inpatients.
Methods:We compared prescription patterns in inpatients treated with
aripiprazole between 2009–2013 and 2002–2008. The subjects’ charts were
retrospectively reviewed to ascertain the distribution of psychiatric diag-
noses and to identify other factors, such as demographic characteristics,
starting/maximum doses, and treatment regimen for diagnoses.
Results: Among the patients in the 2009–2013, the most common psy-
chiatric diagnosis was bipolar disorder, although among the patient in
2002–2008, schizophrenia and other psychotic disorder was the most com-
mon diagnosis. Patients with schizophrenia and other psychotic disorders,
major depressive disorder, and bipolar disorder in the 2009–2013 had
significantly lower starting doses than those in the 2002–2008.
Maximum doses with schizophrenia and other psychotic disorders in
2009–2013 were significantly higher than those in the 2002–2008, whereas
patients with major depressive disorder in 2009–2013 had significantly
lower than those in the 2002–2008. Aripiprazole monotherapy decreased
from 16.7% to 2.7% in schizophrenia and other psychotic disorder. The
polypharmacy increased from 21.4% to 47.3% in bipolar disorder.
Conclusion: Treatment with aripiprazole has extended in indication be-
yond schizophrenia and other psychotic disorder to mood disorder and
other diagnosis in recent years.
Policy of full disclosure: None.
P-19-007 Korean medication algorithm for depressive disorder:
Comparisons with other treatment guidelines
W.-M. Bahk1, H. R. Wang2, Y.-M. Park3, H. B. Lee2, J.-H. Jeong4, J. S. Seo5,
D.-I. Jon6, Y. S. Woo2, K. J. Min2. 1Yeouido St. Mary´s Hospital, Seoul,
Republic of Korea; 2Seoul, Republic of Korea; 3Goyang, Republic of Korea;
4Suwon, Republic of Korea; 5Chungju, Republic of Korea; 6Anyang, Republic
of Korea
Objective: The Korean Medication Algorithm Project for Major
Depressive Disorder (KMAP-MD) was developed in 2002 and then re-
vised in 2006. In 2012 it was secondly revised to reflect current changes
in pharmacotherapy for depressive disorder; Korean Medication
Algorithm Project for Depressive Disorder 2012 (KMAP-DD 2012). We
aimed to compare KMAP-DD 2012 with other recently published treat-
ment guidelines for depressive disorder.
Methods: We reviewed a total of five treatment guidelines for depress-
ive disorder that included American Psychiatric Association Practice
Guideline, Canadian Network for Mood and Anxiety Treatments
Clinical Guidelines, The National Institute for Health and Clinical
Excellence Guideline, Texas Medication Algorithm Project Procedural
Manual, and World Federation Societies of Biological Psychiatry
Guidelines. We compared the recommendations of these five guidelines
to those of KMAP-DD 2012.
Results: In terms of recommendations for initial treatment strategies,
KMAP-DD 2012 is not significantly different from the other five
guidelines. However, in case of non-response or partial response to initial
treatment, the recommendations varied across treatment guidelines. For
the maintenance therapy, the duration of maintenance therapy, and the
doses of antidepressants and antipsychotic agents differed among the
treatment guidelines. There are some discrepancies in the recommenda-
tions for each subtype of depressive disorders across treatment guidelines.
For the treatment among special population such as child-adolescent de-
pression, geriatric depression and postpartum depression, there are no
significant differences in overall recommendation across guidelines.
However, most guidelines other than KMAP-DD 2012 describe the poten-
tial risk of antidepressant such as increased suicidality among young
population.
Conclusion: This comparison identified that, by and large, the treat-
ment recommendations of KMAP-DD 2012 are similar to those of other
treatment guidelines, and reflect current changes in prescription pattern
for depression based on accumulated research data. Further studies will
be needed for several issues that the treatment guidelines reviewed here
cannot draw a definitive conclusion because of lack of evidence.
Policy of full disclosure: None.
P-19-008 Prescribing preferences in rapid tranquillisation. A survey
in Belgian psychiatrists and emergency physicians
C. Bervoets1, B. Sabbe2, M. Morrens2. 1PZ OLV Brugge and University of
Antwerp, Brugge, Belgium; 2University Antwerp, Antwerp, Belgium
Objective: The pharmacotherapeutic management of agitation is a com-
mon clinical challenge. Pharmacotherapy is frequently used, the use of
published guidelines is not known. The objective of this study was two-
fold; to describe the prescribing patterns of psychiatrists and emergency
physicians and to evaluate to which extent guidelines are used.
Methods: A cross-sectional survey in the Dutch-speaking part of
Belgium is carried out in 39 psychiatric hospitals, 11 psychiatric wards
of a general hospital and 61 emergency departments. All physicians are
asked for demographic information, their prescribing preferences, their
use of guidelines and the type of monitoring (effectiveness, safety).
Results: 550 psychiatrist and emergency physicians were invited. The
overall response rate was 20% (n=108). The number 1 preferred medi-
cation classes were antipsychotics (59.3%) and benzodiazepines (40.7%).
In non-secluded patients, olanzapine (22.2%), lorazepam (21.3%) and clo-
tiapine (19.4%) were most frequently picked as number 1 choice drug. In
secluded patients, clotiapine (21.3%), olanzapine (21.3%) and droperidol
(14.8%) were the three most frequently chosen number 1 preferred
drugs. Between-group comparisons show that emergency physicians
prefer benzodiazepines significantly more than psychiatrists do.
Zuclopenthixol and olanzapine show a particular profile in both groups
of physicians. Polypharmacy is more frequently used in secluded patients.
Published guidelines and safety or outcome monitoring are rarely used.
Conclusion: Our results show that prescription practice in Flanders
(Belgium) in acute agitation shows a complex relationship with published
guidelines. Prescription preferences differ accordingly to medical speci-
alty. These findings should be taken into account in future research.
Policy of full disclosure: None.
P-19-009 Cotard’s syndrome in glioblastoma patient
M. Curkovic1, A. Bacekovic1, A. Silic1, D. Ostojic1, V. Jukic1. 1Psychiatric
Clinic Vrapce, Zagreb, Croatia
Objective: Brain tumors are often associated with neurological as well as
with psychiatric symptoms. Cotard’s syndrome is a rare condition charac-
terized with monothematic nihilistic delusions concerning one’s own
body. It is not listed as a specific disorder in the DSM-IV or in ICD-X,
as it is typically viewed as a part of other underlying disorders.
Delusions are most commonly related to a loss of specific body part or
a body as a whole. Syndrome was described for the first time by Jules
Cotard in 1880.g as a new form of agitated melancholy. Although most
commonly described as a part of schizophrenia, bipolar disorder or psy-
chotic depression it is also associated with numerous neurological condi-
tions such as encephalitis, Parkinson’s disease, migraine, brain tumors, a-v
malformations or traumas.
Methods: In this poster we describe 37 years old patient diagnosed with
glioblastoma which developed Cotard’s syndrome in postoperative care.
Patient was operated twice, and treated in post-op care with chemo and
radiotherapy.
Results: Our patient manifested Cotard’s syndrome as negative delu-
sions, stating total absence of his heart and right arm. According to our
data search we found Cotard’s syndrome rarely associated to glioblas-
toma. His pharmacotherapy included fluvoxamine, promazine, diazepam,
phenobarbital and dexamethasone. His discharge diagnoses (ICD-XI)
were: F06.7; F91 because of C71.2 and 3; Brain tumor of right parietoocci-
pital region (PHD glioblastoma multiforme); St. post op and reop; St post
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radiotherapy; St post chemotherapy, Sensomotoric dysphasia; Right sided
hemiparesis.
Conclusion: It remains important to recognize the syndrome because
specific underlying mechanisms are present, and prognostic and thera-
peutic consequences have to be taken into account.
Policy of full disclosure: None.
Native, T1-weighted axial MRI of glioblastoma:
P-19-010 Similar American and Japanese venous endocrine
changes after tobacco smoking
E. Domino1, M. Hirasawa-Fujita1. 1University of Michigan, Ann Arbor, USA
Objective: Compared to Americans (∼18%) there are far more mu opioid
receptor (OPRM1) A118G variants in Japanese (∼50%). Since this single
nucleotide polymorphism (SNP) is important in tobacco smokers, a total
of 19 Japanese and 23 American average tobacco cigarette smokers were
recruited for a preliminary endocrine study.
Methods: Differences in venous blood nicotine, cortisol, prolactin and
dehydroepiandrosterone sulfate (DHEAS) levels were determined before
and after tobacco smoking in the overnight abstinent smokers. Adults
aged 20 to 43 years of both sexes who smoked daily for many years
were studied. The first venous blood sample was taken just before, 10
and 60min after smoking their favorite cigarette.
Results: Significant increases in nicotine, but only slight increases in
cortisol were observed 10min after smoking. Marked increases in cortisol
and prolactin levels were observed 60min after smoking. Males had
greater DHEAS levels than females. No DHEAS smoking differences
were found. There were no significant differences in blood nicotine,
prolactin, and cortisol at the 60min measurement between the
Americans and Japanese. At 10 min after smoking, the cortisol levels of
the Japanese were slightly, but significantly, greater than the Americans
(p=0.05). In addition, tobacco smoking craving scores were studied in
the American smokers in relationship to their genotype of OPRM1
A118G SNPs. Not only smoking average nicotine (avnic) cigarettes but
also smoking deniconized (denic) cigarettes significantly decreased crav-
ing. The craving scores of GG and GA (*G) carriers after avnic cigarette
smoking were more reduced than in the AA allele SNP carriers (p=0.06).
Conclusion: This preliminary study indicates no really significant endo-
crine differences were found between American and Japanese smokers.
The OPRM1 genotype SNP differences after favorite tobacco cigarette
smoking and craving reduction should be pursued comparing American
and Japanese smokers.
Policy of full disclosure: None.
P-19-011 Prevalence of vascular dementia in Upper Egypt
W. Farghaly1, H. El Tallawy1. 1Assiut University, Assiut, Egypt
Objective: The aim of this work was to study the prevalence of vascular
dementia and possible risk factors in Upper Egypt.
Methods: All inhabitants of Al Khargah district; New Valley
Governorate (n=62,583) and Al Quseir city; Red sea Governorate
(n=33,285) were screened in a door to door manner by 6 specialists
of neuropsychiatry and 15 female social workers. All subjects at the age
of 50 years and more (n=12,508) who have been living in the screened
area, for at least 6 months at the time of interview, were included in
this study. Screening was carried out using a short standardized Arabic
screening questionnaire (sensitivity 93.2% and specificity 96% respect-
ively) and modified MMSE. Suspected cases were subjected to case ascer-
tainment according to Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision, diagnostic criteria for dementia;
full clinical assessment; psychometric assessment using Cognitive
Abilities Screening Instruments, Hachinski Ischaemic Score, Instrumental
Activities of Daily Living Scale and the Geriatric Depression Scale; neuroi-
maging (computed tomography and/or mag-netic resonance imaging);
and laboratory investigations.
Results: Out of 12,508 inhabitants who aged 50 years and more 78
patients had vascular dementia with a prevalence rate of 0.62%.
Prevalence of vascular dementia increases directly with age to reach its
highest rate of 2.99% among those aged >85 years. Risk factors for vascu-
lar dementia in order of frequency were; past history of CVS (98.7%),
hypercholesterolemia (56.4%), hypertension (51.3%), diabetes mellitus
(51.3%), smoking (25.6%), hypertriglycridemia (24.4%), and hyperurice-
mia (12.8%).
Conclusion: Vascular dementia is the second cause of dementia in
Egypt with a prevalence rate of 0.62%.
Policy of full disclosure: None.
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P-20-001 Effects of pseudoginsenoside-F11 on
methamphetamine-induced behaviors related to the
dopaminergic and GABAergic neuronal system in the
nucleus accumbens
A. Nitta1, H. Lin2, K. Fu1, C. Wu2, J. Yang2, K. Uno1, Y. Miyamoto1.
1University of Toyama, Toyama-Shi, Japan; 2Shenyang Pharmaceutical
University, Shenyang, China
Objective: Addiction of methamphetamine (METH) is worldwide health
and social problems to relate serious psychiatric symptoms. Since there is
currently no effective pharmacological treatment for METH-induced ad-
diction, we investigated the effects of pseudoginsenoside-F11 (PF11),
which is isolated from Panaxquinquefolium (American ginseng), on the
methamphetamine induced-behaviors.
Methods:We carried out the locomotor sensitization, conditioned place
preference (CPP) test and in vivo microdialysis to investigate the effects of
PF11.
Results: Repeated pretreatment with PF11 attenuated METH-induced
locomotor sensitization. In the CPP test, the pretreatment with PF11 inhib-
ited METH-induced place preference. In vivo microdialysis analysis indi-
cated repeated pretreatment with PF11 prior to continuous METH
administration-prevented METH-induced increase of extracellular dopa-
mine (DA) level in the nucleus accumbens (NAc). Furthermore, microdia-
lysis analysis also revealed that repeated administration with PF11
increases extracellular GABA level in the NAc, however, single adminis-
tration would not.
Conclusion: These findings suggest that, PF11 possesses the inhibitive
effect on METH-induced increased extracellular DA level via regulating
the GABAergic neuronal system in the NAc.
Policy of full disclosure: None.
P-20-002 PCLO SNP rs13438494 regulates DA and 5-HT uptake,
accompanied with splicing efficiency and
dependence-like behaviors in genomic association studies
K. Uno1, D. Nishizawa2, S. Seo1, N. Sakai3, K. Ohi4, T. Nabeshima5,
R. Hashimoto4, N. Ozaki6, K. Ikeda7, Y. Miyamoto1, A. Nitta1.
1University of Toyama, Toyama, Japan; 2Tokyo Metropolitan Institute of
Medical Science, Tokyo, Japan; 3Hirishima University, Hiroshima, Japan;
4Osaka University, Osaka, Japan; 5Meijo University, Nagoya, Japan; 6Nagoya
University, Nagoya, Japan; 7Tokyo Metropolitain Institute of Medical Science,
Japanese Genetics Initiative, Tokyo, Japan
Objective: Piccolo (PCLO) regulates the transport of synaptic vesicles in
neuronal cells. A single nucleotide polymorphism (SNP) rs13438494 in
the intron 24 of the PCLO was reported to be associated with bipolar dis-
order in the meta-analysis of GWAS and affected PCLO gene expression
in the prefronral cortex. In this study, therefore, we have attempted to
evaluate the possible functionality of the PCLO SNP in mechanisms
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associated with uptake of neuronal transmitters of monoamines and, gen-
ome association study of dependence-like behaviors.
Methods: To characterize the intronic SNP rs13438494 in the PCLO
gene, we constructed the C allele or the A allele of the SNP plasmids con-
taining exon 24, intron 24 and exon 25. Plasmid constructs were transi-
ently transfected in SH-SY5Y cells, followed by RT-PCR analysis was
done to assess the genetic effect on splicing.
Results: The C allele and the A allele constructs displayed a different
ratio between the transcripts, indicating that the intronic SNP affect the
splicing pattern. We also generated the the C allele and the A allele plas-
mids containing C2A domain, which was reported to be one of the func-
tional parts on the DA uptake, and then transfected into HEK293 cells
with dopamine and serotonin transporters followed by DA and 5-HT up-
take analysis. In the C allele plasmid transfected cells, both DA and 5-HT
uptakes were altered compared with the A allele plasmids transfected
cells. PCLO rs13438494 has also relationship with to the symptoms of
drug dependence or related personality traits, such as the age of first ex-
posure to methamphetamine, eating disorder, tobacco dependence and
fentanyl requirement.
Conclusion: These results suggest that PCLO SNP rs13438498 regulates
DA and 5-HT uptakes and involves psychiatric disorders.
Policy of full disclosure: None.
P-20-003 Dysfunction of GABAergic system in the insular cortex is
associated with impaired decision-making in
methamphetamine-treated rats
K. Yamada1, H. Mizoguchi2, K. Fukumoto2, T. Wang2. 1Nagoya University
Hospital, Nagoya, Japan; 2Nagoya University, Research Institute of
Environmental Medicine, Nagoya, Japan
Objective: Patients with neuropsychiatric disorders such as addictive
disorders have impairments of decision making, which may be associated
with their behavioral abnormalities. The underlying neuronal mechanism,
however, remains obscure. In the present study, we examined the per-
formance of methamphetamine (METH)-treated rats in a gambling test
for rodents, and investigated the neural mechanism of impaired
decision-making.
Methods: Rats were treated with METH at 4mg/kg for 30 days and
used as METH-treated animals. The animals were subjected to the gam-
bling test for consecutive 14 days, in which the animals received 16 trials
per day. In each trial the animals chose one of four choice arms [one low
risk/low return (L-L) arm, one high risk/high return (H-H) arm and two
empty arms]. Under a standard condition, choice of the L-L arm resulted
in frequent (14/16 trials, 87.5%) small reward (1 food pellet) with in-
frequent (2/16 trials, 12.5%) punishment (1 quinine-coated food pellet).
Choice of the H-H arm resulted in infrequent (2/16) big reward (7 food
pellets) with frequent (14/16) punishment.
Results: METH-treated rats chose H-H arm more frequently than did
control animals in the gambling test, suggesting impairment of decision-
making. c-Fos immunohistochemistry revealed aberrant activation of the
insular cortex (INS) as well as nucleus accumbens in METH-treated rats.
Microinjections of GABA receptor agonists into the INS decreased the
ratio of H-H arm choice in METH-treated rats while GABA receptor
antagonists increased it in control animals. Brain microdialysis study indi-
cated the decrease of depolarization-evoked GABA release in the INS of
METH-treated rats.
Conclusion: These results suggest that INS is one of critical regions for
decision-making in normal and METH-dependent animals, in which
GABAergic dysfunction results in poor decision-making.
Policy of full disclosure: None.
P-20-004 Magnetic resonance imaging of changes in resting state
brain connectivity during recovery from alcohol use
disorder
M. Juhas1, M. Brown2, M.-A. MacKay2, J. Benoit2, T. Gillese3, E. Dametto2,
A. Aubry3, G. Walmsley3, M. Loowell3, S. Dursun2, A. Greenshaw2.
1University of Alberta, Edmonton, Canada; 2University of Alberta,
Department of Psychiatry, Edmonton, Canada; 3Alberta Health Services,
Edmonton, Canada
Objective: Alcohol use disorder is a global health problem affecting over
140 million people worldwide. The dynamic brain changes associated
with alcohol dependence, recovery, and different treatments are only
partially understood. We compared changes in functional connectivity
of resting state networks in patients undergoing residential treatment
for alcohol use disorder. This project’s objectives were to identify changes
in the resting state networks caused by chronic alcohol abuse and to com-
pare how different treatments modulated these changes.
Methods: 20 male patients (age 24–63) with alcohol use disorder
(DSM-IV) were recruited 5–10 days after detoxification and scanned be-
fore and after a 21-day residential treatment. 10 healthy volunteers
matched for age, handedness, and education level were scanned for com-
parison. The subjects were scanned using 4.7 Tesla magnetic resonance
imaging (MRI). Both scanning sessions included an anatomical scan, a
resting-state functional MRI scan, and a diffusion tensor imaging scan.
The functional data was analyzed using an independent component
analysis with SPM8, GIFT, and a custom Matlab code.
Results: Our preliminary findings revealed significant changes in sev-
eral resting state networks including the core and frontal networks. In
comparison to controls, patients had significant differences in functional
connectivity between anterior cingulate cortex and different somatosen-
sory, motor, visual, and association regions.
Conclusion: These findings suggest changes in functional connections
of anterior cingulate cortex in patients before and after undergoing treat-
ment for alcohol dependence. Due to the role of anterior cingulate cortex
in modulating execution of appropriate and suppression of inappropriate
responses, not only in higher order motor control and signal processing
but also in reward anticipation and impulse control, these results could
help us better understand dynamic changes in functional connectivity
which are closely associated with addiction, craving, and internal conflict
resolution.
Policy of full disclosure: None.
P-20-005 Neurocognitive function in internet addiction: A
comparison with alcohol dependence and healthy control
H.-Y. Jung1, Y. J. Jeon1, J.-S. Choi1, S. M. Park1, J.-Y. Lee1. 1SMG-SNU
Boramae Medical Center, Seoul, Republic of Korea
Objective: This study aimed to assess neurocognitive functions in indivi-
duals with Internet addiction, and compared those with patients with al-
cohol dependence and healthy controls.
Methods: Three groups were as following: two addiction groups
(Alcohol: n=15, 28.47±5.66 years; Internet: n=15, 20.80±5.09 years)
which consist of outpatients of Boramae Medical Center and one healthy
control group (n=15, 25.33±5.30 years). All subjects were male and young
adults. We administered traditional neuropsychological tests including
the Stroop test, trail making test (TMT), verbal fluency and also computer-
ized neuropsychological tests using the Cambridge Neuropsychological
Test Automated Battery (CANTAB).
Results: There were significant group differences in the stop signal task,
spatial span and, TMT-B among three groups. Both the Internet addiction
and alcohol dependence group showed decreased portion of successful
stop on the stop signal task compared to the healthy control group, and
that in the Internet addiction group was comparable to that in the alcohol
dependence group. With regard to spatial span, Internet addiction group
showed significantly higher scores than those in the alcohol dependence
group, although both clinical groups showed no differences of spatial
span with the healthy control group. Patients with alcohol dependence
showed poorer performances on TMT-B than those in patients with
Internet addiction and healthy controls. Furthermore, patients with
Internet addiction showed impaired visuo-spatial planning, indicated by
longer initial thinking times on the Stockings of Cambridge compared
to healthy controls. There were no significant differences in others neuro-
cognitive domains among three groups.
Conclusion: Common deficit shared by Internet addiction and alcohol
dependence was impaired response inhibition. Alcohol dependence was
associated with deficits in motor planning and cognitive shifting, whereas
Internet addiction was associated with deficits in visuo-spatial planning.
These findings suggest similarity and disparity in neurocognitive func-
tions of Internet addiction and alcohol dependence.
Policy of full disclosure: None.
P-20-006 Suicide attempters with alcohol intoxication had
equivalent suicide intent as non-drunken status suicide
attempters
B. Kim1, E.-Y. Kim1, J. Park2, Y.-M. Ahn1. 1Seoul National University
Hospital, Seoul, Republic of Korea; 2Kangwon National University Hospital,
Chuncheon, Republic of Korea
Objective: It has been known that many suicide attempts were performed
by alcohol intoxication. By this reason, it is easy to minimize sincere sui-
cide intent of suicide attempters with drunken status by impulsive beha-
vior. We aim to explore suicide intent of suicide attempters with alcohol
intoxication by comparing to non-drunken attempters.
Methods: 2,080 subjects are included from preliminary Korea national
suicide survey in 2010 and 2012. Ten medical centers joined that study
86 Poster Sessions, Tuesday 24 June 2014
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
and all subjects were interviewed by psychiatric residents in the
Emergency room and asked suicide intent by three questions, ‘just crying
for help’, ‘sincere but not-lethal’ and ‘sincere and lethal’. All demographic
data between two groups, first and multiple suicide attempters were com-
pared by student t-test and chi-square test. Multiple logistic regression
was performed to analyze differences of suicide intent between two
groups.
Results: There were more male subjects and multiple attempters in sui-
cide attempters with alcohol intoxication. Drunken status attempters used
suicide method stab wound and pesticide intoxication comparing to non-
drunken status attempters. Seriousness of suicide intent was not signifi-
cant different from two groups by performing multiple logistic regression
to compensate other variables, sex, physical illness, psychiatric history,
living status.
Conclusion: Seriousness of suicide intent of suicide attempters with al-
cohol intoxication was not significantly different from non-drunken status
attempters. This result implies that attempts with alcohol intoxication
should be managed closely.
Policy of full disclosure: None.
P-20-007 Sugar addiction: Positron emission tomography of
dopamine and opioid receptor binding in minipig brain
A. Landau1, M. Winterdahl1, A. Møller1, A. C. Schacht1, S. Jakobsen1,
A. Alstrup1, D. Bender1, J. Scheel-Kruger1, M. L. Kringelbach2. 1Aarhus
University, Aarhus, Denmark; 2Oxford University, Oxford, United Kingdom
Objective: Obesity causes serious health problems worldwide. Our work-
ing hypothesis is that obesity, in addition to being a metabolic disorder,
also consists of critical disturbances in the balance of the reward systems
in the brain, which may override the physiological controls of appetite.
Here we investigate the effects of subchronic sugar addiction on the dopa-
mine and opioid reward system in healthy Göttingen minipigs of average
weight.
Methods: Six adult female minipigs (26 kg) were anesthetized and
scanned at baseline with C-11 labeled raclopride (an antagonist to dopa-
mine D2/3 receptors) and C-11 labeled carfentanil (μ-opioid agonist) in a
Siemens PET/CT scanner. Pigs were then given access to sugar water
for one hour each morning for 12 consecutive days and were PET scanned
with carfentanil after the first sugar exposure and with both tracers after
the 12th day. Two of the minipigs were scanned again 2 weeks later, after
cessation of the sugar treatment. PET data were registered to an average
minipig MRI atlas and processed using MINC tools. The binding poten-
tials (BPND) were obtained using the Logan graphical analysis, with cer-
ebellum as a region of non-displaceable binding.
Results: On average in the six pigs, raclopride BPND was significantly
reduced in the caudate, total striatum and thalamus after 12 days of
sugar access. Carfentanil BPND was significantly reduced in the hippo-
campus after the first exposure to sugar and in the hippocampus,
putamen, amygdala and frontal cortex after 12 days of sugar. Two
weeks after the cessation of sugar treatment, the BPND of raclopride
returned toward baseline values, whereas the reduced BPND of carfenta-
nil persisted.
Conclusion: These data reinforce the importance of dopamine and
opioids in wanting and liking food, respectively, and their role in the
perpetuation of sugar addiction and obesity. Further insight into these
systems in response to palatable food could provide new approaches for
preventing addiction/obesity.
Policy of full disclosure: None.
P-20-008 Differential roles for Dopamine D1 and D2 receptors in
the basolateral amygdala in modulating risk/reward
decision making
J. Larkin1, S. Floresco2. 1University of British Columbia, Vancouver, Canada;
2University of British Columbia, Department of Psychology, Vancouver, Canada
Objective: Different aspects of cost/benefit decision making involving un-
certain rewards are facilitated by corticolimbic circuits linking regions of
the prefrontal cortex, ventral striatum and basolateral amygdala (BLA).
Dopamine (DA) also plays an integral role in promoting choice of larger,
uncertain rewards; manipulations of DA transmission in the PFC or nu-
cleus accumbens alters risky choice. Considerably less is known about
how BLA DA regulates risk-based decision making. The present study
assessed the effects of DA receptor antagonism within the BLA on risk-
based decision making, assessed with a probabilistic discounting task.
Methods: Rats were trained to choose between a small/certain lever
(1 reward pellet) and a large/risky lever (4 pellets) delivered in a probabil-
istic manner. The odds of obtaining the larger reward decreased or
increased in a systematic manner across 4 blocks of discrete-choice trials
(100-12.5% or 12.5-100%) during a daily session.
Results: In well-trained rats, blockade of BLA D1 receptors via infu-
sions of SCH23390 increased discounting of the larger/uncertain reward
and reduced risky choice, in a manner similar to D1 receptor antagonism
within the medial prefrontal cortex or nucleus accumbens. In contrast,
intra-BLA D2 blockade with eticlopride did not affect overall choice, but
did reduce reward sensitivity, as reflected by a decrease in win-stay
behavior.
Conclusion: These findings, in combination with previous data suggest
that D1 receptors in multiple DA terminal regions, including the BLA
have an important role in facilitating optimal decision making and pro-
moting choice of larger/uncertain rewards. More generally, these findings
highlight a key contribution by mesoamygdala DA in regulating certain
aspects of cost/benefit decision making, with D1 activation promoting
bias towards risky choices, and D2 receptors providing short-term feed-
back about recently rewarded actions. These findings may have important
implications for understanding mechanisms underlying alterations in de-
cision making and reward processes in psychiatric disorders linked to
dysfunction of the amygdala and DA system.
Policy of full disclosure: None.
P-20-009 MTHFR and COMP polymorphisms and serum
homocysteine levels in Korean patients with alcohol
dependence
B.-H. Lee1, Y.-M. Park2. 1Gangnam Eulji Hospital Eulji, Seoul, Republic of
Korea; 2Ilsan Paik Hospital, Inje University, Goyang, Republic of Korea
Objective: Increase of homocysteine has neurotoxic effects on dopaminer-
gic neurons, which occurs in alcohol intoxication or alcohol dependence.
The level of homocyseine is regulated by several factors including func-
tional polymorphisms within methylenetetrahydrofolate reductase
(MTHFR) and catechol-O-methyltransferase (COMT) genes. We investi-
gated single nucleotide polymorphisms (SNPs) in MTHFR and COMPT
gene and serum homocysteine levels in Korean patients with alcohol de-
pendence (AD).
Methods: Genotypes of 677C/T, 1793G/A and -393C/A in MTHFR gene
and Val108Met in COMT were determined in 243 AD patients and 130
healthy controls. Serum homocysteine levels were examined at admission
(non-abstinence state) and after 14 days of abstinence.
Results: Significant differences in genotype and allele frequencies of
MTHFR 677C/T were found between AD patients and controls. A fre-
quency of T/T genotype was significantly lower in AD patients than in
controls. However, there were no significant differences in genotype fre-
quencies of COMPT val108Met between AD patients and controls.
Serum homocysteine levels in AD patients were 24.5±15.8 #mol/l at ad-
mission and 12.2±6.7 #mol/l at 14-day abstinence, which was significant
alteration. There were no significant differences in homocysteine levels be-
tween genotypes of MTHFR and COMPT genes among AD patients.
Conclusion: This study suggests that AD patients had a lower fre-
quency of T/T genotype in MTHFR 677C/T. However, alteration of homo-
cysteine was not associated to MTHFT and COMPT gene polymorphisms
in AD patients.
Policy of full disclosure: None.
P-20-010 Predictive factors for online game addiction
Y. S. Lee1, C. Na1, K. J. Min1, D. H. Han1. 1Chung Ang Uiversity Hospital,
Seoul, Republic of Korea
Objective: Online game addiction has been increasingly recognized as a
mental disorder that seriously affects the social, academic, and/or daily
functionality of individuals. However, the predictive or causal factors
that lead to online game addiction are not well established. The aim of
this study is to identify factors which may influence the development of
online game addiction.
Methods: A total of 263 patients with problematic online gaming habits
and 153 healthy comparison subjects were recruited for participation in
the current study. All subjects were asked to fill out questionnaires regard-
ing the severity of their internet addiction, individual factors, family
environment, social interaction, and comorbidities. The cognitive func-
tioning of subjects was measured using the Wisconsin Card Sorting Test
(WCST) and the Korean-Wechsler Adult Intelligent Scale (K-WAIS).
Hierarchical logistic regression analyses among each set of variables
were conducted. Individual factors (sex and age), cognitive factors (IQ
levels and perseverative errors), psychopathological conditions (ADHD,
depression, anxiety, and impulsivity), and social interaction factors
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(family environment, social anxiety, and self-esteem) were evaluated in a
stepwise fashion.
Results: All four factors (individual characteristics, cognitive factors,
psychopathological conditions, and social interaction factors) predicted
online game addiction, with psychopathological conditions being the
strongest set of factors predicting online game addiction. In patients
with pure online game addiction (i.e., patients with online game addiction
only, with no psychiatric comorbidities), individual factors, psychological
factor (attention, mood, and anxiety), and social interactions were predic-
tive factors for the development of pure online game addiction.
Conclusion: The current study assessed risk factors for predicting
online game addiction in light of the interaction of four sets of factors, in-
cluding individual factors, cognitive functions, psychopathologies, and
social interactions. Psychopathologies, including ADHD and depression,
were the strongest factors associated with the development of online
game addiction in individuals.
Policy of full disclosure: None.
P-20-011 Characteristics of suicide attempters affected by
co-occurring serious mental illness and substance abuse
R. Martinez Riera1, G. A. Mateu Codina1, L. Diaz Digon1, C. Castillo
Buenaventura1, M. Torrens Melich1. 1INAD-Parc de Salut Mar, Barcelona,
Spain
Objective: To study the clinical characteristics of patients with Substance
Use Disorders (SUD) comorbid with non-substance related Axis I or II dis-
order, admitted to a brief dual diagnosis unit for suicidal ideation.
Methods: Data on demographic, family, and clinical factors were gath-
ered. A total of 187 patients, consecutively admitted to our dual diagnosis
unit for suicidal ideation between September 2007 and May 2013, were in-
cluded. Psychiatric disorders, substance use (SUDs) and non-substance
use disorders (non-SUDs) were diagnosed according to DSM-IV criteria.
Statistical analysis of data was performed using SPSS program.
Results: 39.6% of the sample were women, with a mean age of 40.25+8.8
years. The main SUDs diagnoses were alcohol (59.9%) and cocaine
(48.7%). The most frequent non-SUDs diagnoses were: Personality
Disorder (58.3%), Adjustment Disorder (15%), Depressive Disorder
(13.9%) and Psychosis (9.6%). 17.6% of the sample showed comorbid diag-
noses in Axis I and Axis II, whereas 50.8% had no diagnosis on Axis I. The
mean age of onset of psychiatric disorder non-related with substance use
was 26.5 +11.4. The most frequent dual diagnosis, as for Axis I, were:
Adjustment Disorder-Alcohol (7.5%), Depressive Disorder-Alcohol
(9.1%). As for Axis II, Personality Disorder-Alcohol (50%) and
Personality Disorder-Cocaine (29.8%). 63.6% had a previous history of sui-
cide attempts. Only 28.3% of the subjects had been taking a drug treat-
ment regularly and 33.2% were receiving psychiatric follow-up, during
the 6 months previous to hospital admission. 40.6% lived with family
and 27.6% lived with company or in an institution; 62% were married;
12.8% were occupationally active; 50.8% had secondary education or
higher. 35.8% had a family history of non-SUD diagnoses and 43.9%
had a family history of SUD diagnoses.
Conclusion: In a Dual Population, alcohol and cocaine are the most fre-
quent SUD disorders in patients with suicidal ideation, and the most fre-
quent non-SUD diagnoses are personality disorders, whether mood
disorders are relatively less represented. Also, factors as sex, previous sui-
cide attempts and not doing regular treatment could be associated with
suicidal ideation in these patients.
Policy of full disclosure: None.
P-20-012 Age of onset of dual schizophrenia: Is there any
relationship with severity of addiction?
G. Mateu-Codina1, J. Martí-Bonany2, M.-G. Hurtado-Ruiz2,
R. Martínez-Riera2, M. Torrens-Mèlich2. 1Sant Cugat Del Vallès, Spain;
2INAD-Parc de Salut Mar, Barcelona, Spain
Objective: Describe differences between the patients who had the onset of
a schizophrenia spectrum disorder to prior or equal to 25 years (EO<25)
compared to those whose age of disease onset was later (EO>25) in a
group patients with comorbid substance use disorders (SUD).
Methods: Sociodemographic, clinical and administrative data of all
patients diagnosed with schizophrenic disorder or schizoaffective dis-
order admitted to a dual diagnosis during 3-year period were collected.
The psychiatric diagnosis was made according to DSM-IV-R criteria.
Results: The total sample was comprised of 154 subjects (128 with
schizophrenic disorder and 26 with schizoaffective disorder).
Predominantly male (75.3%), mean age of 38.5±8.54 years. In the compari-
son (Table 1) can be seen as the EO<25 (N=98)were younger, male, un-
married and mostly had higher prevalence of secondary education.
They had lower prevalence of HIV and HCV. With regard to substance
use, in the EO<25 group the primary drug was alcohol while in the
other group was cocaine. These patients had an earlier first contact with
hypnotics, amphetamines, cocaine and nicotine as well as the age of prob-
lematic consumption of cocaine and nicotine. They also had a lower
cumulative deprivation time for both cannabis and nicotine and a higher
frequency of alcohol consumption over the past 30 days. Figure 1 shows a
comparison of the main dual reasons for admittance in both groups (psy-
chopathological main reason for admission income plus primary drug
use), while various combinations resulting from the SUD is reflected in
Figure 2. By GEP severity scale we observed that patients in the EO
group <25 had a higher family dystocia (1,43+1,17 vs 0,81+1,07; p=
0,002) and worst laboral background (1,11+1,34 vs 0,60+1,19; p=0,024).
Conclusion: Presenting a spectrum disorder of schizophrenia before
age 25 gives is associated with early consumption amb early SUD as
well as greater severity of drug addiction.
Policy of full disclosure: None.
Please see Table 1 appearing on page 89.
P-20-013 Blockade of endocannabinoid hydrolysis inhibits
cocaine-induced seizure and neurotoxicity
F. Moreira1, L. Vilela1, A. de Oliveira1, M. Moraes1. 1UFMG, Belo Horizonte,
Brazil
Objective: To test the hypothesis that the facilitation of the endocannabi-
noid system may reduce seizures and neurotoxicity induced by cocaine.
Methods: Male mice Swiss (n=9/10 per group) received intraperitoneal
injections (ip) of vehicle or inhibitor of anandamide hydrolysis (URB597),
followed by cocaine 75mg/kg. There was concomitant monitoring of
behavioral and electroencephalographic seizures. In another experiment
the animals were pretreated with AM251 (CB1 antagonist) in order to
evaluate the involvement of this receptor in the effects of URB597.
Moreover, we also investigated, through imunohistochemistry analyzes
with c-Fos protein, the neural activation induced by cocaine in hippocam-
pus of animals following seizures and effects induced by URB597 treat-
ment. Protection against cell death induced by cocaine was evaluated in
cultured hippocampal neurons and hippocampal slices by ethidium
homodimer assay. Data were subjected to ANOVA analysis followed by
Newman-Keuls multiple comparisons.
Results: Treatment with URB597 increased the latency and reduced
duration of eletroencephalografic and behavioral seizure. Pre treatment
with CB1 antagonist reversed the effect of URB597, suggesting an involve-
ment of CB1 receptor on the seizure. Immunostaining with c-Fos antibody
in hippocampus showed that URB597 administration reversed the in-
crease in the number of positive cells for c-Fos induced by cocaine.
Moreover, treatment with cocaine increased the death of hippocampal
neurons and this effect was also inhibited by URB597 effect. Again,
AM251 blocked the effects of URB597.
Conclusion: URB597 induced neuroprotective effects against
cocaine-induced convulsive seizure and cell death, both effects being
mediated by CB1 receptor. Financial support was provided by
FAPEMIG (no conflict of interest to declare).
Policy of full disclosure: None.
P-20-014 The relationship between coping styles, stressful life
events, and cannabis use in young adults
M. Sloan1, E. Yung1, N. Le Baron1, E. Dugas2, E. O’Loughlin2,
R. Wellman3, J. O´Loughlin4, N. Low1. 1McGill University, Department
of Psychiatry, Montreal, Canada; 2Montreal, Canada; 3University of
Massachusetts, Worcester, MA, USA; 4Université de Montréal, Montreal,
Canada
Objective: The latest national survey on drug use in the U.S. estimated
that one third of young adults used cannabis in 2011. The high prevalence
of cannabis use is of public health concern given the recent findings link-
ing cannabis use to the development of psychosis. The objectives are: (1)
To test if stressful life events (SLEs) in the past year are associated with
greater frequency of cannabis use. (2) To test if coping styles (i.e.,
emotion-, task-, and avoidance-oriented) modify this association.
Methods: Data were drawn from the Nicotine Dependence in Teens
Study, a longitudinal study of a school-based cohort in Montreal. The ana-
lytic sample consisted of 853 young adults (mean age=24.0 years) who
completed self-report questionnaires regarding (1) SLEs in the past year
using a modified List of Threatening Events, (2) cannabis use in the past
year and (3) coping styles using the Coping Inventory for Stressful
Situations-21. The associations between SLEs, cannabis use and coping
styles were examined in multiple linear regressions and interaction
testing.
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Results: The number of SLEs was significantly associated with fre-
quency of cannabis use (unstandardized B=0.101, p=0.000). In the pres-
ence of SLEs, task-oriented coping was associated with decreased
frequency of cannabis use (unstandardized B=−0.113, p=0.044) whereas
emotion-oriented coping was associated with increased frequency of can-
nabis use (B=0.125, p=0.029). There were no significant interactions be-
tween SLEs and avoidance-oriented coping.
Conclusion: Focusing on task-oriented coping and preventing
emotion-oriented coping may help reduce the prevalence of cannabis
use in this population.
Policy of full disclosure: None.
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P-21. Anxiety disorders B
P-21-001 Effect of curcumin on benzodiazepine related
drugs-induced anxiety-related behaviors in mice
K.-I. Tanaka1, A. Sakamoto2, S. Sakai2. 1Saitama Prefectural University,
Koshigaya, Japan; 2Shujitsu University, School of Pharmacy, Okayama, Japan
Objective: Stress manifests itself in various characteristic responses in-
cluding emotions such as fear, anxiety and impulsivity. Animals under
stress take adaptive actions that may lead to various types of behavioral
disinhibition. Such behavioral disinhibition, when expressed excessively
and impulsively, can result in harm in individuals and cause a problem
in our society.
Methods: In the present study, we examined the effect of curcumin on
benzodiazepine receptor-induced anxiety-related behaviors to clarify the
anti-anxiety activity of curcumin. Mice had free access to vehicle or curcu-
min. After four weeks, we treated with vehicle, FG7142 or diazepam intra-
peritoneally, and more thirty minutes later, we investigated the effect of
curcumin on FG7142- or diazepam-induced anxiety-related behaviors by
several behavioral tests.
Results: FG7142 shortened open area spent time in the cliff avoidance
test. However, curcumin, especially 30 mg/kg/day, significantly competed
with the reduction of FG7142-induced open area spent time. In addition,
curcumin (30mg/kg/day) significantly reduced the enhancement of
FG7142-induced glutathione in the mouse hippocampus. On the other
hand, diazepam significantly prolonged open area spent time in the cliff
avoidance test. However, curcumin, especially 30 mg/kg/day, significantly
competed with the prolongation of diazepam-induced open area spent
time. In addition, curcumin (30mg/kg/day) significantly reduced hippo-
campal glutathione content of diazepam-treated mice.
Conclusion: Therefore, it is probably that curcumin may have anti-
anxiety activity.
Policy of full disclosure: None.
P-21-002 Personality traits in patients with panic disorder
R. Muotri1, M. Bernik2. 1Institute of Psychiatry, São Paulo, Brazil; 2São Paulo,
Brazil
Objective: Using models developed by Cloninger as predictors of re-
sponse to treatment and observing the changes of the scores before and
after treatment, the objective of this study was to evaluate the prevalence
of personality dimensions in patients with panic disorder and compare
the results with those found in the literature.
Methods: Were subjected to these study 42 patients, (25 women). The
Temperament and Character Inventory Cloninger was administered to
all participants.
Results: It was found compared the scores of personality dimensions of
patients with panic disorder with healthy subjects, which were statistically
higher scores of Harm Avoidance and lower scores in Self-Direction no
differences between our results and those described in the literature.
Conclusion: The study of personality dimensions associated with psy-
chiatric disorders has grown tremendously and been shown to be useful,
both in understanding the different responses to therapy and for improve-
ment of therapeutics approach to these patients. Therefore, we believe that
outcomes of this project will help us to identify patients with the highest
potential of reply to therapy instituted, and aid the development of more
effective treatment for patients with less potential response.
Policy of full disclosure: None.
P-21-003 High baseline ‘anxiety’ in male wistar rats predicts an
‘anxiogenic’ effect of an SSRI which is dampened by
subchronic SSRI treatment
J. Näslund1, E. Studer2, H. Nissbrandt2, E. Eriksson2, O. Holmblad1.
1University of Gothenburg, Gothenburg, Sweden; 2University of Gothenburg,
Department of Pharmacology, Gothenburg, Sweden
Objective: Behavioural responses to serotonin reuptake inhibitors (SRIs)
in man depend on baseline anxiety; the anxiety-reducing effect of long-
term administration of SRIs is hence not a non-specific sedative effect,
but unique for subjects with enhanced anxiety, who are also more inclined
than others to experience anxiety-enhancing effects of acute SRI adminis-
tration. In this study, we explored if inter-individual variation within a
batch of male Wistar rats with respect to ‘anxiety’ as assessed using the
elevated plus maze (EPM) influences the response to SRIs (experiment
I), and also to what extent these inter-individual differences are influenced
by a drug arresting serotonergic transmission (experiment II).
Methods: In experiment I, 120 animals were pre-tested in the EPM.
Animals were then subjected to treatment with the SRI escitalopram
admixed to food pellets. After five weeks of treatment, animals were
given one injection of another SRI, paroxetine, and then re-tested in the
EPM. In experiment II, 65 animals were pre-tested in the EPM and
re-tested three weeks later after three days of treatment with the TPH2 in-
hibitor p-chloro-phenyl-alanine (p-CPA). In both experiments the 1/3 of
the animals displaying the highest level of baseline ‘anxiety’ were
defined as high ‘anxiety’ (HA) rats and the remaining 2/3 as low ‘anxiety’
(LA) rats.
Results: Acute administration of paroxetine, exerted an
‘anxiety’-enhancing effect in HA but not LA rats, which was eliminated
by long-term pretreatment with escitalopram. Serotonin depletion
obtained by administration of p-CPA eliminated the behavioural differ-
ence between the groups by reducing ‘anxiety’ in HA but not LA rats.
Conclusion: It is suggested that differences with respect to an ‘anxio-
genic’ impact of serotonin partly explains differences in anxiety-like be-
haviour amongst Wistar rats, and that this influence is enhanced by
acute and dampened by subchronic SRI administration.
Policy of full disclosure: None.
P-21-004 Ultra-long-term outcome of panic disorder with
clonazepam or paroxetine: A randomized, open,
systematic treatment for 3 years and a follow-up for
6 years after
A. Nardi1, R. Freire1, R. Amrein1, S. Machado1, A. Cardoso1,
M. Mochcovitch1, M. Versiani1. 1Federal University Rio de Janeiro, Rio de
Janeiro, Brazil
Objective: We aim to investigate relapse cumulative over time and re-
mission and the efficacy and safety of clonazepam or paroxetine for treat-
ing PD in a ultra-long-term follow-up.
Methods: 120 PD patients were randomized in a prospective open
study to get 2mg/day clonazepam or 40mg/day paroxetine. Patients
with an insufficient primary outcome after 8 weeks were switched to com-
bined treatment. A total of 94 patients finished long-term treatment and
underwent drug discontinuation by decreasing slowly paroxetine and
clonazepam.
Results: After two months of tapering out the drug 80% patients in the
clonazepam group, 55% on the paroxetine but by no patient in the combi-
nation group were drug free. After six months 89%/64%/44% patients
from the clonazepam/paroxetine/combination group were free of drug.
Panic attacks (PA)/mth, CGI-S, and mainly HAMAworsened slightly dur-
ing the withdrawal period and adverse events increased as compared to
the treatment period. After the withdrawal phase 66 patients were fol-
lowed annually during 6 years. 90% of patients are in average in remission
during the six-year period after drug withdrawal. 73% of patients were in
average free of PAs during the six-year follow up, 91.1% had a GCI-S
score of 1, and 38.8% had a HAMA between 5 and 10 points. 33.3% of
the patients needed drug treatment during each follow up year. The
patients not followed every year had at the end of the observation period
similar, but somewhat less favourable results, as could be expected: 88%
were in remission, 72% had no PA, 62% had a CGI-S of 1 and 30% had
a HAMA between 5 and 10 and 38.9% whereby 39% were under antipanic
treatment.
Conclusion: The relapse rate was very high. Both paroxetine or clona-
zepam had the same long-term prognosis but the clonazepam group
had a better profile of adverse events in the long-term treatment.
Policy of full disclosure: None.
P-21-005 The “anxiogenic” effect of acute escitalopram on startle
behaviour, but not that of contextual conditioning, is more
pronounced in wistar rats with high baseline reactivity
R. Pettersson1, E. Eriksson1, M. Hagsäter1. 1Neuroscience and Physiology,
Göteborg, Sweden
Objective: The acoustic startle reflex is a common measure of contextual
conditioned fear that often serves as an experimental model of anxiety.
Methods: In the present study, repeated testing was used to explore if
acute administration of a selective serotonin reuptake inhibitor (SSRI),
escitalopram (10mg/kg), influences startle in the absence or presence of
contextual conditioning in the form of foot shocks, and to what extent
the baseline startle of the animal predicts drug response.
Results: Escitalopram and contextual conditioning both increased star-
tle in male Wistar rats but did not display any synergistic effect. While ani-
mals displaying high startle at baseline showed higher susceptibility to the
influence of escitalopram in the startle paradigm, the effect of contextual
conditioning was more pronounced in those with low baseline startle.
90 Poster Sessions, Tuesday 24 June 2014
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
Conclusion:We suggest that further studies using this model may shed
light on why acute administration of SSRIs may exert anxiogenic effects in
man and why subjects with anxiety disorders are considerably more sus-
ceptible to this effect than others.
Policy of full disclosure: None.
P-21-006 Randomized, placebo-controlled effectiveness study
of Quetiapine XR in co-morbid depressive and
anxiety disorders
A. V. Ravindran1, G. Abraham2, S. Johnson3, R. Chandrasena4. 1University
of Toronto, Centre for Addiction and Mental Health, Toronto, ON, Canada;
2Canada; 3Mississauga, ON, Canada; 4Chatham, ON, Canada
Objective: Atypical antipsychotics (AAPs) are among the first-line agents
used to treat depressive and anxiety disorders. Co-morbidity of de-
pression and anxiety is highly common, but few studies have explored
the benefit of AAPs as augmentation for this group of patients.
Quetiapine is an AAP with proven efficacy, as monotherapy or augmen-
tation, for both conditions. The aim of this multi-centre, double-blind,
placebo-controlled study was to examine the efficacy, tolerability and
safety of quetiapine as augmentation in patients with depression and
co-morbid anxiety.
Methods: Seventy-four adults (18–65 years), with a primary diagnosis
of unipolar depression co-morbid with one or more anxiety disorders,
were randomly assigned to receive flexible-dose quetiapine XR 50–300
mg/day or placebo for 12 weeks, in a 2:1 ratio. Pre/post measures included
the Hamilton Depression Rating Scale (HAM-D), the Hamilton Anxiety
Scale (HAM-A), the Clinical Global Impression Scale (CGI), the Penn
State Worry Questionnaire (PSWQ), the Leibowitz Social Anxiety Scale
(LSAS), the Panic Disorder Severity Scale (PDSS), the Post-traumatic
Disorder Scale (PDS) and the Quality of Life Enjoyment and Satisfaction
Scale (QLESQ). Adverse event data was collected at each study visit.
Results: Both groups showed comparable improvement on the HAMD,
QLESQ and PSWQ, but no change on the PDSS and PDS (p>0.05).
However, quetiapine was significantly superior to placebo in improving
scores on the HAMA (p=0.048), CGI (p=0.019) and LSAS (p<0.04). The
mean dose of quetiapine was 138.5 mg/day and the mean dose of placebo
was 155.5 mg/day. Side effects were generally mild, with drop out mainly
due to lack of efficacy, and drop-out rates were similar for both groups (p
=0.066).
Conclusion: While the benefit of quetiapine augmentation was not bet-
ter for depression itself, it was significantly superior in improving anxiety
symptoms in patients with depression and co-morbid anxiety. Quetiapine
was also reasonably well tolerated.
Policy of full disclosure:
References
Maher AR, Theodore G. Summary of the comparative effectiveness review
on off-label use of atypical antipsychotics. J Manag Care Pharm. 2012;18
(5 Suppl B):S1–20.
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P-21-007 Afobazole increases binding of sigma-1 receptor selective
agonist in P2 fraction of CD-1 mice brain homogenate ex
vivo
E. Ryaskina1, M. Voronin1, S. Seredenin1. 1FSBI Institute of Pharmacology,
Moscow, Russia
Objective: Anxiolytic afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio]
benzimidazole dihydrochloride) possesses ligand properties towards
sigma-1 receptor (Sigma1R) in vitro (IC50 human T-cells =7,1*10-6M,
IC50 mice brain=1,37*10-5M) (Ryaskina et al., 2012). Afobazole and
Sigma1R agonists induce receptor’s translocation to the extracellular
space in vitro which correlates with the increase of Sigma1R in P1, P2
and P3 heavy-density fractions (Hayashi et al., 2003; Seredenin et al.,
2009). The aim of our research is to study ex vivo the influence of intraper-
itoneal injection of afobazole on Sigma1R selective agonist binding in P2
and P3 fractions of CD-1 mice brain homogenates.
Methods: In the experiments were used male CD-1 mice. Afobazole
in anxiolytic dosage 5mg/kg and vehicle saline were injected intraperito-
neally in 30 minutes before decapitation. Differential centrifugation
was used to obtain P2 and P3 fractions of brain homogenates. Sigma1R
activity was measured by radioligand binding assay using [Ring-
1,3-3H]-(+)-Pentazocine.
Results: Specific [Ring-1,3-3H]-(+)-Pentazocine binding to Sigma1R
(mean±S.D., DPM/mg of protein) in P3 fractions of mice brain homoge-
nates in control group (8799±1696) and group with afobazole pretreat-
ment (8697±1553) was significantly higher (p<0.0001, t-test) then in P2
fractions of the same groups (3976±517,9 and 4525±610,5) correspond-
ingly. These data conform to previously obtained results (McCann et al.,
1994). Afobazole (5 mg/kg i.p.) caused significant increase of [Ring-1,3-
3H]-(+)-Pentazocine binding in P2 fractions (p=0,0246, t-test) and absence
of differences between binding of the selective agonist to Sigma1R in P3
fractions (p=0,88, t-test).
Conclusion: Afobazole pretreatment increases (+)-Pentazocine binding
to Sigma1Rs in P2 fractions of mice brain homogenates ex vivo which cor-
responds to afobazole induced intacellular dynamics of Sigma1Rs in vitro
and agonistic activity determined for prototype ligands.
Policy of full disclosure: None.
P-22. Bipolar disorders B
P-22-001 Prescription of antidepressants for bipolar disorder: A
retrospective study at Tokyo Women’s Medical University
Hospital
H. Muraoka1, K. Inada1, T. Kawano1, M. Kawano1, T. Tsutsumi1,
D. Hasegawa1, J. Ishigooka1. 1Tokyo Women´s Medical University, Tokyo,
Japan
Objective: In patients with bipolar disorder, it is necessary to treat and
prevent the depression and manic phases. Antiepileptic, lithium, or anti-
psychotic drugs are typically used for this. The use of antidepressants dur-
ing the acute depressive state of bipolar disorder is suggested to be
associated with a risk of inducing changing manic phase, or causing
rapid cycling; however, no conclusive evidence has been found. We per-
formed this retrospective study to determine the clinical effects related
to the use of antidepressants to treat patients with bipolar disorder.
Methods: Patients with bipolar disorder, who were treated in the out-
patient section of the Tokyo Women’s Medical University Hospital psy-
chiatry and the department of psychosomatic medicine between January
1, 2011 and December 31, 2011, were included in this study. From these
patients’ medical records, the antidepressant prescription and the related
effects were investigated. This protocol was approved by the ethical com-
mittee of TWMU.
Results: Of the 358 patients with bipolar disorder who were included in
the study, 228 had been prescribed antidepressants. Of these, 24 showed
rapid cycling. Of the patients who did not receive antidepressants,
3 showed rapid cycling. Thus, more patients who were prescribed antide-
pressants showed rapid cycling.
Conclusion: Antidepressants are prescribed frequently to patients with
bipolar disorder. Our results suggest that using antidepressants to treat bi-
polar disorder could induce rapid cycling. However, the reasons for using
antidepressants, such as the severity of bipolar disorder and unipolar dis-
order obstacle discriminating should be considered to draw an accurate
conclusion.
Policy of full disclosure: None.
P-22-002 Patients’ preference for treatment of bipolar disorder:
An internet survey
K. Nozaki1, T. Kikuchi1, K. Watanabe1. 1Kyorin University, Tokyo, Japan
Objective: Though various clinical guidelines for bipolar disorder (BP)
have recommended monotherapy or combination of mood stabilizers
and second generation antipsychotics, it is unclear that patients’ prefer-
ence for treatment of BP which could affect adherence of those drugs.
Therefore we conducted an internet survey to elucidate the preference.
Methods: From registrants of web research monitor, 1,050 subjects who
had been diagnosed with BP and currently treated were randomly chosen.
Through screening procedures, we identified 457 participants who had ex-
perienced manic episode(s) which was evaluated by using Manic Episode
Screening Questionnaire#Kameyama, 2013). Participants were asked as to
which the current prescription they took, what bothered them in the
course of treatment, and what kind of treatment they needed in future.
Results: Majority of participants were in their 40s or 30s (41.1%, 33.5%,
respectively) and prescription which they currently took were mood sta-
bilizers (77.0%), SSRIs/SNRIs (45.1%), second generation antipsychotics
(40.3%) and first generation antipsychotics (14.7%). Things which both-
ered them in the current treatment were “Long-term therapy with taking
prescription” (65.6%), “Difficult stabilization of manic/depressive
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symptoms” (61.1%), and “Unpredictable mood switch of symptoms”
(60.2%). Their wishes for future direction of BP treatments were
“Prescription to improve symptoms rapidly” (53.0%), “Prescription
which can prevent relapse or recurrence of symptoms” (27.4%), and
“Test to diagnose BP accurately” (24.5%).
Conclusion: We clarified that preferred treatments for BP were those
with rapid improvement as well as with stabilization of symptoms. We
also elucidate that many subjects were prescribed SSRIs/SNRIs despite
the recommendation of clinical guidelines.
Policy of full disclosure: None.
P-22-003 Affective switch under antidepressants: Reality or fiction?
K. Frasch1, T. Becker2. 1Ulm University, Donauwoerth, Germany; 2Ulm
University, Guenzburg, Germany
Objective: Since decades, an association between antidepressant drug
treatment/prophylaxis and mood conversion into (hypo-)manic states in
patients with bipolar disorders is discussed. Aim of this paper is to find
methodologically sound controlled clinical studies addressing antidepres-
sant induced affective switching and to formulate corresponding recom-
mendations for clinicians.
Methods: Literature retrieval on the basis of preexisting researches by
the British NICE and the German DGPPN/DGBS.
Results: Regarding antidepressant monotherapy in acutely depressed
bipolar patients (5 studies), significantly more switches under imipramine
vs. fluoxetine were reported; other investigations found no switch rate dif-
ferences under paroxetine vs. placebo and under venlafaxine vs. lithium,
respectively. As to psychotropic drug combinations (antidepressant
plus mood stabilizer and/or antipsychotic; 6 studies), affective switches
were more frequent under venlafaxine vs. bupropione and sertraline
while between bupropione and paroxetine no differences were detected.
Furthermore, paroxetine plus mood stabilizer produced no more switches
than a combination of 2 mood stabilizers; a fluoxetine-olanzapine combi-
nation was not more frequently associated with switches than olanzapine
alone/lamotrigine/placebo. Regarding long term prophylaxis, only 2 stu-
dies were found: no different conversion rates were reported between
mood stabilizer/antipsychotic with vs. without additional antidepressant
on the one hand and fluoxetine vs. lithium on the other.
Conclusion: In acute treatment of bipolar depression, SSRI and bupro-
pione should be favoured over venlafaxine and tricyclic antidepressants.
Due to scarce data, no clear recommendations can be made with regard
to both psychotropic drug combinations including antidepressants and
long term antidepressant treatment. Regarding the lack of unambiguous
proof of efficacy of antidepressants in bipolar depression, antidepressants
should regularly be combined with mood stabilizer(s) and/or antipsycho-
tic(s) and be used with caution, especially in milder bipolar depression,
rapid cycling/mixed/bipolar I disorders and patients reporting anamnestic
switch(es). Future research should focus on the identification of predictors
for affective switching under antidepressant drug regimen.
Policy of full disclosure: None.
P-22-004 Korean medication algorithm project for bipolar disorder
2014: Rapid cycling
J.-H. Jeong1, Y. M. Jae2, D.-I. Jon3, W.-M. Bahk4. 1St. Vincent´s Hospital,
Suwon, Republic of Korea; 2Department of Psychiatry, Bong Seng Memorial
Hospital, Busan, Republic of Korea; 3Sacred Heart Hospital, College
of Medicine, Hallym University, College of Medicine, Anyang, Republic of
Korea; 4Yeouido St. Mary´s Hospital, College of Medicine, The Catholic
University of Korea, College of Medicine, Seoul, Republic of Korea
Objective: Bipolar disorder is an illness with significant morbidity and
mortality that contributes to disturb social function. Our objective for
this study is to revise Korean Medication Algorithm Project for Bipolar
Disorder 2010 for rapid cycling.
Methods: The questionnaires to survey the expert opinion of medi-
cation for rapid cycling were completed by the review committee consist-
ing of 64 Korean expert psychiatrists. We classified the experts’ opinion to
3 categories based on the lowest category in which the confidence interval
fall (6.5# for first-line and 3.5# for second-line treatment).
Results: The first-line treatment was the combination of a mood stabi-
lizer and an atypical antipsychotic. And also, monotherapy of atypical
antipsychotics was included in the first-line treatment. Additionally, a
mood stabilizer with lamotirgine therapy and an atypical antipsychotic
with lamotrigine combinations were the first-line treatment in depressive
phase. Mood stabilizer monotherapy, combination of two mood stabili-
zers, combination of mood stabilizer, atypical antipsychotics and anti-
depressants were preferred as next strategy. The first-line medications in
all cases are valproic acid, lithium, quetiapine, olanzapine and
aripiprazole. For the treatment of depressive phase, lamotrigine is the
first-line medication.
Conclusion: Compared to the surveys in 2010, the preference for atypi-
cal antipsychotics and lamotrigine were increased, and modalities as a
second-line treatment were diverse.
Policy of full disclosure: None.
P-22-005 Effects of mood-stabilizing drugs on dendritic
outgrowth and synaptic proteins levels in the primary
hippocampal neurons
Y. H. Kim1, S.W. Park2, J. H. Lee1, H. Y. Jo2, C. H. Lee2, M. K. Seo2, J.
G. Lee3, B. J. Lee1, S. J. Lee1. 1Haeundae Paik Hospital, Busan, Republic of
Korea; 2PICR, Inje University, Health Science and Technology, Busan,
Republic of Korea; 3Haeundae Paik Hospital, Health Science and Technology,
Busan, Republic of Korea
Objective: Mood-stabilizing drugs, such as lithium (Li) and valprate
(VPA), are widely used for the treatment of bipolar disorder, a disease
marked by recurrent episodes of mania and depression. Growing evi-
dence suggests that Li exerts neurotrophic and neuroprotective effects,
leading to an increase in neural plasticity. The present study investigated
whether other mood-stabilizing drugs produce similar effects in primary
hippocampal neurons.
Methods: Mood-stabilizing drugs, such as lithium (Li) and valprate
(VPA), are widely used for the treatment of bipolar disorder, a disease
marked by recurrent episodes of mania and depression. Growing evi-
dence suggests that Li exerts neurotrophic and neuroprotective effects,
leading to an increase in neural plasticity. The present study investigated
whether other mood-stabilizing drugs produce similar effects in primary
hippocampal neurons.
Results: (0.5–2mM), VPA (0.5–2mM), CBZ (0.01–0.1 mM), and
LTG (0.01–0.1 mM) significantly increased dendritic outgrowth (p<0.05
or p<0.01). The neurotrophic effect of Li and VPA was blocked by inhi-
bition of phosphatidylinositol3-kinase (PI3 K), extracellular signal-
regulated kinase (ERK), and protein kinase A (PKA) signaling (p<0.05
or p<0.01); the effects of CBZ and LTG were not affected by inhibition
of these signaling pathways. Li, VPA, and CBZ significantly prevented
B27 deprivation-induced decreases in BDNF, PSD-95, NLG1, Beta-
neurexin, and SYP levels (p<0.05 or p<0.01), whereas LTG did not.
Conclusion: Taken together, these results suggest that Li, VPA, CBZ,
and LTG exert neurotrophic effects by promoting dendritic outgrowth;
however, the mechanism of action differs. Furthermore, certain
mood-stabilizing drugs may exert neuroprotective effects by enhancing
synaptic protein levels against cytotoxicity in hippocampal cultures.
Policy of full disclosure: None.
P-22-006 Efficacy of long-acting injectable antipsychotics in the
treatment of bipolar disorder
S.-K. Lin. Taipei City Hospital, Taipei, Taiwan
Objective: Long-acting injectable antipsychotics (LAI) have been used to
treat bipolar disorder, especially for patient with poor medication adher-
ence. This study compared the first (FLAI) and second generation LAI
(SLAI) regarding the efficacy and side effects in a psychiatric hospital.
Methods: Nineteen patients with bipolar disorder receiving FLAI (1
fluphenazine, 7 haloperidol, 10 flupenthixol and 1 clopenthixol) and ten
receiving SLAI (risperidone) from outpatient department of Taipei City
Psychiatric Center were surveyed by chart review regarding their onset
of age, latency to treatment, number of mood episode and hospitalization.
Also patients were administered with questionnaire of quality of life
(WHO), drug induced extrapyramidal syndrome scale, antipsychotic side-
effect checklist, personal and social performance scale, clinical global im-
pression, lack of judgment and insight, and visual analogue of pain on in-
jection site.
Results: The mean age of study subjects was 46.4±10.3 years, with an
illness course of 22.3±9.2 years, and LAI treatment for 7.2±8.1 years.
The frequencies (times per year) of mood episodes before and after LAI
antipsychotic were 0.78±0.70 and 0.33±0.8, respectively (p<0.05); while
the frequencies of hospitalization were 0.64±0.80 and 0.06±0.20, respect-
ively (p<0.001). There is no difference between FLAI and SLAI groups
in terms of the above mentioned efficacy, quality of life, side effects, judg-
ment of insight, and pain on injection site.
Conclusion: The use of LAI, both first and second generation, can im-
prove the medication adherence and significantly ameliorate the course
of bipolar disorder. Due to the small number of study subjects, no differ-
ence was found between FLAI and SLAI in terms of efficacy and side
effects.
Policy of full disclosure: None.
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P-22-007 Impact on biomarkers of a comprehensive rehabilitation
program in bipolar disorder (PRISMA): A multimodal
approach
C. Lopez-Jaramillo1, C. Vargas Upegui1, S. Saldarriaga-Gomez1,
M. Valencia-Escobar1, J. D. Palacio1, S. Ospina2, F. Kapczinski3,
E. Vieta4. 1University of Antioquia, Medellin, Colombia; 2San Vicente
Fundation Hospital, Medellin, Colombia; 3University Rio Grande do Sul,
Porto Alegre, Brazil; 4University de Barcelona, Barcelona, Spain
Objective: Characterize actual situation of BD, and then apply a multi-
modal approach to analize the clinical, neurocognitive, neurofunctional,
psychlogic, ocupational, social effect in short-mid-long term of a multimo-
dal approach in patients with BD and to determine if it affects clinical
functionality, brain activation and its effect on specific biomarkers.
Methods: 200 BD, aged 18 to 65, were randomized to control or inter-
vention group, all subjects were assesed using psychiatric (DIGS, HRSD,
YMRS), psychologic (AQ-12, TEMPS-A, FAST, BIS-11, SAI-E), neuropsy-
chlogic (WCST, CVLT-II, WAIS III, TMT, WMS III, Rey-Osterrieth com-
plex figure), ocupational (SSI, EMES-M, EMES-C, assertiveness test,
SAD scale), familiar (FEICS, FACES-III, ECF) and general practitioner
(BRIAN, MMSE) evaluations; samples for biomarkers (NT-3, IL6, 10, 17,
BDNF, NT-3, TNF-alpha, Carbonylation of proteins, Nitration of proteins
and TBARS) were obtained and fMRI studies (3 tesla scanner) were made
in 90 patients defined randomly. Intervention comprises 12–18 specific
interventions and 10 psychoeducation sessions compared to control
group, evaluated only by psychiatry and general practitioner. All instru-
ments will be applied twice to compare data before and after intervention.
Results: Preliminary data: Evaluated to date: 172. Mean age(years):
40,22(SD: 11,742). Females: 121(70,3%). Males: 51(29,7%). FAST: 118
(68%) patients showed functional impair vs. 54(31,4%) with normal results
(Mean score: 26,71, SD: 14,097). Data will be compared after intervention.
Conclusion: Our final results will show if comprehensive rehabilitation
programs affect biomarker levels and functional and structural MRI as it
influences functional outcomes in patients with bipolar I disorder as com-
pared with standard intervention.
Policy of full disclosure: None.
P-22-008 A preclinical model and human genetic studies implicate
abnormal development of monoaminergic neurons in
bipolar disorder
V. Jukic1, C.-R. Tania2, V. Jovanovic3, K. Zega3, O. Kofman3, E. Binder4,
C. Brodski5. 1Zagreb, Croatia; 2Munich, Germany; 3Be’er Sheva, Israel; 4Max
Planck Institute for Psychiatry, Munich, Germany; 5Ben-Gurion University of
Negev, Be’er Sheva, Israel
Objective: Subtle mood fluctuations are normal emotional experiences.
However, when very drastic, mood swings can be a clinical manifestation
of bipolar disorder. Despite the importance for normal and pathological
behavior, the mechanisms underlying endogenous mood instability are
largely unknown. A major obstacle preventing progress of our under-
standing of this behavior has been the lack of appropriate animal models.
Previously, we demonstrated that the suggested susceptibility genes for
bipolar disorder Otx2 together with Wnt pathway members are upstream
regulators of genes specifying monoaminergic neurons. Here we behavio-
rally phenotyped mouse mutants overexpressing Otx2 in the hindbrain,
resulting in an increased number of dopaminergic neurons and decreased
numbers of serotonergic neurons. Combining these preclinical experi-
ments with human genetic studies we further investigate the significance
of the development of monoaminergic neurons for bipolar disorder.
Methods: Using a translational approach we combine behavioral
experiments in mouse mutants with a pathway analysis tool for genome-
wide association studies.
Results: During one month of monitoring home cage activity, control
animals showed stable locomotor activity levels, while mutants showed
extended periods of elevated or decreased activity relative to their individ-
ual average. Repeated measurements in the open field demonstrated for
mutants increased intra-individual fluctuations in locomotor activity, ha-
bituation, risk-taking behavioral parameters and social interaction. In the
sugar preference test, mutants showed increased intra-individual changes
in hedonic-like behavior. Olanzapine, lithium, carbamazepine and the
serotonin receptor agonists quipazine and CP-809101 improved beha-
vioral alterations of mutants. Testing the relevance of our findings for bi-
polar disorder in humans, we used an interval-based enrichment analysis
tool for genome-wide association studies. We found that genes specifying
dopaminergic and serotonergic neurons exhibit a significant level of
aggregated association with bipolar disorder.
Conclusion: Our results suggest that an abnormal development of
monoaminergic neurons leads to affective instability and is implicated
in bipolar disorder.
Policy of full disclosure: The authors declare no competing financial
interests.
P-22-009 Short- and longer-term treatment with lurasidone in
patients with bipolar I depression: Effect on metabolic
syndrome
S. McElroy1, A. Pikalov2, J. Cucchiaro2, J. Hsu2, H. Kroger2, D. Phillips2,
A. Loebel2. 1Cincinnati, USA; 2Fort Lee, USA
Objective: To evaluate the effect of lurasidone on the prevalence of meta-
bolic syndrome in bipolar I depression.
Methods: Data were pooled from 3 short-term studies in patients with
bipolar I depression were randomized to 6 weeks of once-daily, double-
blind, placebo-controlled treatment with lurasidone (20–120mg/d), either
as monotherapy (one study, N=499), or adjunctive therapy with lithium
(Li) or valproate (VPA; two studies, combined N=694). Patients complet-
ing the three 6-week studies continued to receive 6 months of additional
treatment with lurasidone 20–120mg/d in an open-label extension study
(N=494). NCEP criteria (JAMA 2001;285:2486–2497) for metabolic syn-
drome were used. Change at 6 months (for completers) was calculated
from double-blind baseline of the 6-week acute study.
Results: At baseline, the prevalence of metabolic syndrome was
similar in the adjunctive studies (lurasidone, 14.8%; placebo, 13.5%) and
in the monotherapy study (lurasidone, 14.3%; placebo, 15.5%). After
6 weeks of adjunctive therapy, the prevalence of metabolic syndrome in
the lurasidone vs. placebo groups was 17.0% vs. 12.4% (LOCF); after
6 weeks of monotherapy, the prevalence was 15.8% vs. 17.7% (LOCF).
For patients who completed 6 months of extension phase treatment, the
prevalence of metabolic syndrome was 23.8% (adjunctive therapy) and
17.9% (monotherapy). For the subgroup with metabolic syndrome at base-
line in the adjunctive therapy studies (n=31), the following median
changes were observed (completer analysis): weight (0.0 kg), cholesterol
(−6.0 mg/dL), triglycerides (+11.0 mg/dL), and glucose (+2.0 mg/dL). For
the subgroup with metabolic syndrome at baseline in the monotherapy
study (n=30), the following median changes were observed: weight
(−0.3 kg), cholesterol (−4.0 mg/dL), triglycerides (−22.0 mg/dL), and
glucose (−2.0 mg/dL).
Conclusion: In patients with bipolar depression, 7 months of treatment
with lurasidone was associated with minimal metabolic changes. In at-risk
patients with metabolic syndrome at baseline, treatment with lurasidone
was not associated with worsening of metabolic parameters.
Policy of full disclosure: Dr. McElroy is a consultant to, or member of
the scientific advisory boards of Alkermes, Shire, and Sunovion; she is (or
has been) a principal or co-investigator on research studies sponsored by
the Agency for Healthcare Research & Quality (AHRQ); Alkermes,
AstraZeneca, Brackett, Cephalon, Corcept, Eli Lilly and Company,
Marriott Foundation, NIMH, Orexigen Therapeutics, Inc., Pfizer, Shire,
Takeda Pharmaceutical Company Ltd, and Transcept Pharmaceutical,
Inc.; she also holds a patent for the use of sulfamate derivatives for treat-
ing impulse control disorders and has received payments from Johnson &
Johnson Pharmaceutical Research & Development, L.L.C., which has ex-
clusive rights under the patent. Drs. Pikalov, Cucchiaro, Hsu, Kroger,
Loebel, and Ms. Phillips are full-time employees of Sunovion
Pharmaceuticals Inc.
P-22-010 The effect of childhood abuse and neglect on clinical
severity in mood disorders
G. Kraus1, N. Lebaron1, X. Zhang1, A. Iskric1, E. Yung1, J. Lober1, N. Low1.
1Allan Memorial Institute, Montreal, Canada
Objective:Mood disorders are common psychiatric disorders which affect
20% of the population during their lifetime. They are characterized by
early onset, chronic nature, and severe consequences, including suicide
attempts. Childhood adversity (CA) has been investigated as a major
risk factor for the development of mood disorders, increasing the risk
by 2–3-fold. However, significant knowledge gaps remain in the associ-
ation between CA and mood disorders, especially regarding the impact
of specific types of CA on specific indicators of mood disorder severity.
Therefore, this study tests whether different types of childhood adversity
are associated with worse disease severity in mood disorder patients as
indicated by age of first psychiatric treatment and first psychiatric hospi-
talization, number of psychiatric hospitalizations, and suicidal behavior.
Methods: Data were drawn from the Mood Disorders Program of
McGill University Health Centre. The analytic sample includes 77 adults
with a DSM-IV diagnosis of a mood disorder (Bipolar Disorder or
Major Depression). Participants filled out self-report questionnaires, in-
cluding the Childhood Experience of Care and Abuse questionnaire
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(CECA-Q) which assesses childhood adversity, and underwent the
Structured Clinical Interview for DSM-IV (SCID).
Results: Individuals who had experienced at least one form of child-
hood sexual abuse had a 13-fold increased likelihood of being hospitalized
for psychiatric reasons during their lives. Parental loss or separation dur-
ing childhood was associated with an earlier age of first psychiatric ad-
mission. Furthermore, severity and frequency of maternal psychological
abuse, as well as physical abuse during childhood, was associated with
a later age of first psychiatric admission.
Conclusion: Physical, sexual, and psychological abuse, as well as separ-
ation from parents, all appear to have longstanding negative effects in
those with mood disorders. It is very important that the presence and
types of childhood adversity be systematically reviewed in initial psychi-
atric assessments as this may help prognosticate the treatment and sever-
ity of illness.
Policy of full disclosure: None.
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P-23-001 Spatiotemporal activation during verbal fluency task in
remitted patients with major depression: An MEG study
K. Shishida1, N. Kanayama1, A. Hashizume1, H. Yamashita1,
Y. Okamoto1, K. Kurisu1, S. Yamawaki1. 1Hiroshima University,
Hiroshima, Japan
Objective: The thought symptoms of major depression could be classified
into two categories: decrement in the amount or speed of thought (e.g.
psychomotor retardation), and altered contents of thought (e.g. pessi-
mistic thought or suicidal ideation). In previous study using fMRI, we
have demonstrated that patients with major depression show limited
amount of elevation in cerebral perfusion during verbal fluency task,
even in the remitted state. However, using hemodynamic methods, it is
difficult to estimate the altered pattern of activation during verbal task
in depression with a high temporal resolution. In the present study, we
aimed to compare the neural activity during the performance of verbal
fluency task, using magnetoencephalography (MEG).
Methods: Twelve remitted patients with major depression and twelve
age- and sex-matched healthy volunteers participated. The task consisted
of three conditions namely verbal generation, verbal repetition and rest
condition, presented alternately (at least 30 epochs for each condition).
In verbal generation condition, one of three Japanese syllabaries was ran-
domly presented for 7 sec and subjects were required to covertly generate
words which begin with those letters. In verbal repetition condition, sub-
jects were required to articulate a Japanese word covertly. Magnetic field
was recorded with whole-head 306ch neuromagnetometer. Within each
subject#s MRI, source current was estimated using spatial filter technique,
and event-related spectral perturbation of beta band (18∼24 Hz) activities
were calculated with bandpass filter. The processed data was spatially
normalized, and statistically compared in the two subject groups.
Results: In verbal generation condition, both groups showed similar ac-
tivation pattern, first in the occipital area around 200ms after stimulus
presentation, followed by left lateral prefrontal and somatosensory area
occurring around 300ms. However, the depression group showed greater
activation in somatosensory area and in right occipital area.
Conclusion: Patients with major depression might recruit different
strategy to conduct a verbal task.
Policy of full disclosure: None.
P-23-002 How often have depressed patients received
psychoeducation about antidepressants treatment? The
survey of 424 outpatients in Japan
K. Shuhei1, Y.-F. Norio2, S. Norio2, S. Yasusi3, F. Akira4, T. Tetu5,
I. Msamiti1, T. Koji1, N. Taku5, N. Kazuhiko1. 1Hirosaki University,
Hirosaki-Si, Aomori-Ken, Japan; 2Hirosaki University, Graduate School of
Medicine, Department of Neuropsychiatry, Hirosaki-Si, Aomori-Ken, Japan;
3Seihoku Chuoh Hospital, Goshogawara-Si, Aomori-Ken, Japan; 4Mutu
General Hospital, Mutu-Si, Aomori-Ken, Japan; 5Odate Municipal General
Hospital, Odate-Si,Akita-Ken, Japan
Objective: Recently many studies have suggested that successful psychoe-
ducation to depressed patients is associate with improvement of antide-
pressant adherence, a decrease in the symptom and an effectiveness in
the relapse prevention of depression. However, there is little information
how often depressed patients receive the adequate psychoeducation.
Therefore, we surveyed outpatients in Japan about the subjective experi-
ence that received psychoeducation.
Methods: The subjects were 424 outpatients recruited according to the
following inclusion criteria: (a) outpatient; (b) who have been a
depressive, or depressive now; (c) who have taken antidepressant, or tak-
ing now. We use self-administered questionnaires. Questionnaires is
formed in 8-items from A to H: (A) Depressive symptoms, (B) The course
of the depression, (C) The onset mechanism of the depression, (D)
Treatment plan, (E) Duration of taking antidepressants, (F) How to dis-
continue antidepressants, (G) Side effect of antidepressants and (H)
Psychotherapy. For each item, we questioned “Have you received an ex-
planation by doctor in charge?” and “How much do you understand
about it?” Understanding for each item is rated 11 anchor points (0
through 10).
Results: Ratios of person receiving explanations were 62% for (A), 49%
for (B), 51% for (C), 57% for (D), 46% for (E), 29% for (F), 51% for (G) and
37% for (E). Understanding scores in patients with receiving explanations
were significantly higher than those without receiving explanations in all
items. Average understanding scores were relative low around 5.5 to 6.4
even in patients with receiving explanations, while those without receiv-
ing explanations were 2.0 to 3.7. Significant negative correlations were
found between understanding scores and age or onset age.
Conclusion: We concluded that adequate psychoeducation is not suffi-
ciently performed. It is required to provide an effective, quick, and easy
psychoeducational method for depressed patients to general physician
and psychiatrist.
Policy of full disclosure: None.
P-23-003 Baseline difference between patients’ and clinicians’ rated
illness severity scores and subsequent outcomes in major
depressive disorder: Analysis of the STAR*D Data
M. Tada1, T. Suzuki1, T. Abe2, B. G. Pollock3, M. Mimura1, H. Uchida1.
1Department of Neuropsychiatry, Keio University School of Medicine, Tokyo,
Japan; 2Center for Clinical Research, Keio University, School of Medicine,
Tokyo, Japan; 3Geriatric Mental Health, Centre for Addiction and Mental
Health, Toromto, Canada
Objective: Data have been scarce on the association of the difference be-
tween subjective and objective severity of the illness with the subsequent
response to antidepressant treatment in Major Depressive Disorder
(MDD), which was addressed in this study.
Methods: This was a post hoc analysis of the data from level 1 of the
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
study, in which non-psychotic MDD patients were treated with 10–60
mg/day of citalopram for 12–14 weeks and evaluated with the 16-item
Quick Inventory of Depressive Symptomatology, Clinician Rating
(QIDS-C16) and the 16-item Quick Inventory of Depressive
Symptomatology, Self-Report (QIDS-SR16). A baseline QIDS difference
score was defined as a value of a baseline QIDS-SR16 score minus a base-
line QIDS-C16 score. Remission was defined as both QIDS-SR16 and
QIDS-C16 scores of #5 at the treatment exit. Logistic regression analysis
was performed to examine correlation between the baseline QIDS differ-
ence score and the subsequent remission.
Results: Of the evaluable 2872 participants, 28.0% (n=803) remitted. A
baseline QIDS difference score ranged from −16 to +10 (mean±SD, −0.7±
3.1). A higher QIDS difference score at baseline was significantly asso-
ciated with a lower remission rate after controlling demographic and clini-
cal variables (odds ratio=0.953, 95% confidence interval=0.925–0.982, p=
0.002).
Conclusion: Patients who perceived their illness to be more severe than
assessed by clinicians were less likely to achieve remission. These findings
suggest the importance of taking caution for such patients who regard the
symptomatology as more negative before starting antidepressant therapy
in an effort to improve treatment outcomes for MDD.
Policy of full disclosure: None.
P-23-004 The evolution of antidepressant switch and augmentation
therapy in the treatment of depression: A chart review
R. Tarumi1, H. Uchida2, T. Suzuki2, H. Tani2, R. Den1, N. Sawada2,
A. Ohtani2, H. Sakurai2, C. Tsutsumi-Ozawa2, M. Mimura2. 1Komagino
Hospital, Hachiouji, Japan; 2Tokyo, Japan
Objective: The objective of this study was to examine the evolution of
antidepressant switch and augmentation therapy (i.e. concomitant use
of a mood stabilizer or an antipsychotic) in the real-world from a longi-
tudinal perspective.
Methods: A systematic chart review of longitudinal prescriptions was
conducted regarding 633 patients with major depressive disorder for up
to two years after their first visit to one of six psychiatric clinics in
Japan between July, 2010 and June, 2011. Patients who had already
received antidepressants for the current episode were excluded. Reasons
for prescription changes were examined.
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Results: 22.6% (N=143) of the patients completed or continued the out-
patient treatment over the two years while 27 (4.3%), 23 (3.6%), and 439
(69.4%) patients discontinued it due to hospitalization, referral to another
clinic, and loss to follow-up, respectively. A total of 324 episodes of anti-
depressant switch or discontinuation were identified; the most frequent
reason for the regimen change was ‘symptomatic improvement’ (35.8%,
N=116) followed by ‘ineffectiveness’ (32.7%, N=106) and ‘side effects’
(26.5%, N=86). In the 106 episodes of antidepressant switch or discontinu-
ation due to ineffectiveness, 84.0% (N=89) of the regimen change were
commenced even before the maximum dosages in package inserts were
tried. Fifty patients (7.9%) received augmentation therapy; it was
employed after a median of only one antidepressant had been tried.
Conclusion: These preliminary findings raise a concern that psychia-
trists may be hasty in performing an antidepressant switch or augmen-
tation therapy in the treatment of depression.
Policy of full disclosure: None.
P-23-005 The study of treatment response in depressive patients
with alcohol use disorders by using HAM-D
M. Tayama1, E. Hashimoto1, T. Saito1. 1Sapporo Medical University, Sapporo,
Japan
Objective: It is known that high rate of comorbidity exists between mood
disorders and alcohol use disorders. We have previously reported that
depressive patients with comorbid alcohol use disorders showed poorer
response to antidepressant treatment. In this study, we assessed the
change of the HAM-D 17-items from baseline to study endpoint
(week12) to evaluate treatment-resistant depression symptoms in those
patients with alcohol use disorders.
Methods: Fifty-eight participants with depression were divided into
2 groups: non-alcohol use disorder (NAUD) group (n=36) and alcohol
use disorder (AUD) group (n=22) according to Alcohol Use Disorder
Identification Test (AUDIT) score (NAUD<12, AUD#12). Depression
was assessed by the Mini-International Neuropsychiatric Interview (M.I.
N.I). The effect of medication on depressive symptoms was monitored
at 2, 4, 8 and 12 weeks using the HAM-D.
Results: The baseline score of HAM-D sleep item was higher in
AUD group than in NAUD group. AUD group showed significantly
less improvement in the HAM-D sleep items from baseline to endpoint
compared to NAUD group. Benzodiazepine medications (dose of benzo-
diazepines used was equivalent to greater than 10mg of diazepam)
resulted in significant baseline to endpoint improvement in insomnia
early item of HAM-D in NAUD group. On the other hand, there was
no significant improvement in HAM-D sleep items after treatment in
AUD group. The overall response rate was greater in NAUD group
than in AUD group.
Conclusion: These results suggest that alcohol use disorder may
negatively affect depression treatment outcomes not only in the overall
response rate but also in the efficacy of benzodiazepines for sleep
disturbance.
Policy of full disclosure: None.
P-23-006 The influence of 5- HTTLPR genotypes on the association
between paroxetine plasma concentrations and their
therapeutic effects in patients with major depressive
disorder
T. Tomita1, N. Yasui-Furukori1, T. Nakagami1, S. Tsuchimine1,
M. Ishioka1, A. Kaneda1, S. Kaneko1. 1Hirosaki University, Hirosaki, Japan
Objective: The efficacy of treatment with selective serotonin reuptake
inhibitors in patients with major depressive disorder (MDD) can differ
depending on serotonin transporter-linked polymorphic region
(5-HTTLPR) genotype, and the efficacies of plasma concentration mea-
surements can also differ. We aimed to investigate the differences in the
associations between paroxetine plasma concentrations and clinical
responses in patients with different 5-HTTLPR genotypes.
Methods: Fifty-one patients were enrolled in this study. The
Montgomery-Asberg Depression Rating Scale (MADRS) was used to
evaluate patients at 0, 1, 2, 4, and 6 weeks. The patients# paroxetine
plasma concentrations at week 6 were measured using high-performance
liquid chromatography. And their 5-HTTLPR polymorphisms (alleles S
and L) were analyzed using polymerase chain reaction with specific pri-
mers. We divided the participants into two groups based on their L hap-
lotype: the SS group and the SL and LL group. We used single and
multiple regression analyses to investigate the associations between
MADRS improvement and paroxetine plasma concentrations or other cov-
ariates for each group.
Results: There were no significant differences between the two groups
with regard to demographic or clinical data. In the SS group, the paroxe-
tine plasma concentrations were significantly negatively correlated with
improvement in MADRS at week 6. In the SL and LL group, the paroxe-
tine plasma concentration was significantly positively correlated with im-
provement in MADRS at week 6 according to the results of single
regression analysis, but it was not significantly correlated with improve-
ment in MADRS at week 6 according to the results of multiple regression
analysis.
Conclusion: For the patients with MDD who does not respond to par-
oxetine, a lower plasma concentration or an oral dose of paroxetine might
be more effective in patients with the SS genotype, and a higher that might
be more effective in patients with the SL or LL genotype.
Policy of full disclosure: None.
P-23-007 Decreased serum levels of polyunsaturated fatty acids and
folate, but not brain-derived neurotrophic factor, in
adolescent depression
S. Tsuchimine1, N. Yasui-Furukori1, M. Saito1, S. Kaneko1. 1Hirosaki
University, Aomori, Japan
Objective: Evidence from observational studies suggests that there is an
association between depression and brain-derived neurotrophic factor
(BDNF), polyunsaturated fatty acids (PUFAs), and folate; however, this
association has yet to be examined in adolescent depression. The objective
was to determine whether the BDNF, PUFAs, and folate in serum differ
between first-episode adolescent depressed patients and healthy controls.
Methods:Wemeasured the serum levels of BDNF, PUFAs, and folate of
cases admitted to the hospital for depression (n=28) and compared it to
that of controls (n=24). Subjects and their parents were informed about
the nature and the purpose of this study, and a consent form was signed
by parents. The ethics committee of Hirosaki University Graduate School
of Medicine approved the study protocol.
Results: There were significant differences in the docosahexanoic
acid (DHA), arachidonic acid (AA), and folate levels between cases and
cintrols. Serum levels of DHA, AA, and folate levels in the patients
group were statistically lower than those in the control group (p<0.001,
p=0.001, and p=0.01, respectively), while serum levels of BDNF were
not different between cases and controls.
Conclusion: These results are in line with findings of previous studies
involving adult and elderly subjects, demonstrating lower levels of
PUFAs and folate in depressed patients than healthy controls. However,
further studies using larger sample size are warranted.
Policy of full disclosure: None.
P-23-008 Antidepressant dose increase or stay in early
non-responders with depression
F. Ueno1, T. Suzuki2, S. Nakajima3, M. Mimura2, H. Uchida2. 1Kurihama
Medical Center, Yokosuka, Japan; 2Tokyo, Japan; 3Toronto, Canada
Objective: The primary objective of this study is to compare 6-week out-
comes between increasing the dose of mirtazapine versus maintaining the
same dose in patients with depression who failed to show initial treatment
response.
Methods: Data from a 6-week double-blind placebo-controlled rando-
mized trial of mirtazapine in subjects with major depression were used
for this post-hoc analysis. Percentages of subjects who achieved remission
(i.e. a HAMD-score of#7) and changes in the 17-item Hamilton Rating
Scale for Depression (HAM-D) scores from baseline at week 6 were com-
pared between the following two groups, respectively: (1) subjects who
failed to show a #20% decrease in the HAM-D total scores at week 1
but were assigned to continue 15mg (N=21), and (2) those who failed
to show a #20% decrease in the HAM-D total scores at week 1 and were
assigned to increase the dose to 30 mg for another 5 weeks (N-23).
Differences between groups were tested using a Student t-test or
Fisher’s exact test for categorical variables.
Results: The remission rate in subjects who experienced a dose in-
crement to 30mg was numerically higher than those who continue the in-
itial dose (15mg) although the difference did not reach any statistical
significance (14.3% [3/21] vs. 34.7% [8/23], p=0.17). The 30 mg group
showed a greater decrease in the HAM-D total score than the 15mg
group (mean±SD, 12.4±8.7 vs. 10.0±5.8); however, again, no statistically
significant difference was observed (p=0.31).
Conclusion: No significant dose-response relationship was observed in
mirtazapoine, possibly due to the small sample size. However, although
not statistically significant, these wide differences may suggest the
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possible clinical utility of antidepressant dose increase in patients with de-
pression who failed to respond to an initial dosage.
Policy of full disclosure: None.
P-23-009 Leukocyte gene expression-based diagnostic test for major
depressive disorder: A pilot and replication study
S. Watanabe1, J.-I. Iga1, S. Numata1, S. Shimodera3, H. Fujita2, K. Ishii3,
T. Ohmori1. 1Tokushima, Japan; 2Kochi, Japan; 3Tokyo, Japan
Objective: To establish biological and easy-to-use diagnostic test for MDD
can help to make early diagnosis and provide adequate treatment. In the
present study, we examined the biological diagnostic test for MDD based
on the leukocytes gene expression.
Methods: 25 drug-naive MDD subjects and 25 age-and-sex matched
healthy subjects participated in the pilot study. The replication study
involved 19 MDD subjects and 18 healthy subjects. We selected 40 candi-
date genes under the following criteria. 1) Genes whose expression levels
were reported to be altered in the leukocytes of MDD, 2) Genes whose ex-
pression levels were found to be altered after lithium administration. 3)
Candidate genes for neurobiology of MDD expressed enough in human
leukocytes. We examined the level of these gene expressions using
custom-made PCR array plates to differentiate MDD subjects from
healthy subjects based on the gene expression profiles.
Results: Among 40 candidate genes, we identified a set of 13 signifi-
cantly changed genes in MDD subjects in the pilot study. In the pilot
study, the discrimination analysis based on these 13 gene expression
levels demonstrated a sensitivity and specificity of 80% and 92%, respect-
ively, in differentiating between the two groups. The replication study
yielded nearly identical sensitivity and specificity (85% and 83%, respect-
ively). We also found that the most significant 6 genes among 13 genes
could yield the identical results.
Conclusion: Using leukocyte gene expression profiles, we could differ-
entiate MDD subjects from healthy subjects with adequate sensitivity and
specificity. Further research is needed to confirm the performance of the
test across various psychiatric diseases. Additional markers not yet iden-
tified can further improve the performance of this test.
Policy of full disclosure: None.
P-23-010 Effect of repeated restraint stress on glucocorticoid
receptor function in the rat brain
M. Yoshioka1, R. Ghebreab1, T. Yoshida1, T. Izumi1, Y. Ohmura1.
1Hokkaido University, Sapporo, Japan
Objective: The objective of this study was to investigate the effect of re-
peated restraint stress on depression- and anxiety-like behaviors in male
rats and the impact of this stress on HPA axis system.
Methods: Rats were subjected to restraint stress for seven consecutive
days (3 h/day) (RS7) or once as acute restraint stress (RS1). Two weeks
after the last restraint stress, elevated plus maze (EPM) and forced swim
tests (FST) as well as protein assay were conducted. Plasma corticosterone
was also measured to assess HPA axis function.
Results: The expression of glucocorticoid receptors (GR) and FK 506
binding protein 51 (FKBP5), a co-chaperone of GR, in medial prefrontal
cortex (mPFC), amygdala and hippocampus were analyzed by western
blot. RS7 rats but not RS1 showed decreased time spent in open arms of
EPM. Both RS7 and RS1 increased immobility time in FST. Plasma level
of corticosterone in RS7 group was still increased two weeks after the
last restraint stress but not altered by acute restraint stress. RS7 had no ef-
fect on GR in any brain regions analyzed, but increased FKBP5 expression
in amygdala.
Conclusion: These results suggest the alteration of GR function induced
by increment of FKBP5 in amygdala may mediate repeated restraint
stress-induced depressive-like and anxiety-like behaviors.
Policy of full disclosure: None.
P-23-011 Efficacy and safety of vilazodone 20mg and 40mg in
major depressive disorder: A randomized, double-blind,
placebo- and active-controlled trial
C. Gommoll1, M. Mathews2, D. Chen2, R. Nunez2, A. Khan3. 1Forest
Research Institute, Jersey City, USA; 2Jersey City, USA; 3Bellevue, USA
Objective: This study (NCT01473381) assessed the efficacy and safety
of once-daily vilazodone (VLZ) 20mg and 40mg in adults with major de-
pressive disorder (MDD).
Methods: This was a 10-week randomized, double-blind study in MDD
patients comparing VLZ 20mg/d and VLZ 40mg/d with placebo (PBO);
citalopram 40mg/d (CIT) was included for assay sensitivity. Primary
efficacy outcome was change in Montgomery-Åsberg Depression Rating
Scale (MADRS) score; secondary outcomes were change in Clinical
Global Impressions-Severity (CGI-S) and MADRS sustained response
rate (score412 for at least the last 2 consecutive visits). Safety assessments
included adverse events, laboratory and vital signs, ECG, and Changes in
Sexual Functioning Questionnaire (CSFQ).
Results: The safety population comprised 281 PBO, 288 VLZ 20mg,
287 VLZ 40mg, and 282 CIT patients; discontinuation rates were 25%,
31%, 34%, and 29%, respectively. MADRS scores improved significantly
more than PBO for VLZ 20mg (LSMD, −2.57; adjusted P=0.0073),
VLZ 40mg (LSMD, −2.82; adjusted P=0.0034), and CIT (LSMD, −2.74;
P=0.0020). Reduction in CGI S scores were significantly greater than
PBO for VLZ 20mg (LSMD, −0.35; adjusted P=0.0073), VLZ 40mg
(LSMD, −0.33; adjusted P=0.0097), and CIT (LSMD, −0.35; P=0.0025).
MADRS sustained response rates were higher in VLZ 20mg (29.9%),
VLZ 40mg (33.5%), and CIT (31.1%) groups versus PBO (26.3%); differ-
ences were not statistically significant. Treatment-emergent AEs (TEAEs)
were similar for VLZ 20mg (72.2%), VLZ 40mg (77.4%), and CIT
(77.0%) and PBO (63.3%). TEAEs occurring in 55% of VLZ patients
and twice PBO were diarrhea, nausea, vomiting, and insomnia. Most
TEAEs were mild/moderate in severity. Serious AEs were reported in 2
PBO, 4 VLZ 20mg, 4 VLZ 40mg, and 6 CIT patients. VLZ groups
improved more than CIT on the CSFQ; differences were not statistically
significant.
Conclusion: These results support the efficacy, safety, and tolerability
of VLZ 20mg and 40mg for the treatment of MDD in adults.
Policy of full disclosure: Supported by funding from Forest
Laboratories, Inc. Carl Gommoll is an employee of Forest Research
Institute.
P-23-012 Agomelatine’s efficacy in positive and negative affects
in depression
P. Gorwood1, G. Vaiva2, E. Corruble3, P.-M. Llorca4, F. J. Bayle5,
M. D. Carmen Munoz Sanz6, P. Courtet7. 1Centre Hospitalier Sainte-Anne,
Paris, France; 2Michel Fontan Hospital, Department of Psychiatry, Lille,
France; 3Bicêtre Hospital, Department of Psychiatry, Le Kremlin Bicêtre,
France; 4University Hospital, Department of Psychiatry, Clermont-Ferrand,
France; 5Centre Hospitalier Sainte-Anne, Department of Psychiatry, Paris,
France; 6Servier International, Suresnes Cedex, France; 7CHU Montpellier,
Department of Emergency Psych., Montpellier, France
Objective: Agomelatine is an antidepressant with a novel mechanism of
action releasing dopamine and noradrenaline specifically in the limbic
regions without affecting brain serotonin levels. Depressed patients
given agomelatine have shown early improvement of interest and plea-
sure. The present study evaluated the effects of agomelatine on positive
and negative emotions since their improvement in depression is important
to obtain recovery.
Methods: 1565 adult outpatients with major depressive disorder receiv-
ing agomelatine were assessed using the QIDS-C, CGI, and MATHYS
scales at inclusion, week 2 (W2) and week 6 (W6). The MATHYS is a self-
rated visual analogue scale proposing five dimensions and 7 emotions
rated according to their frequency.
Results: All negative emotions significantly decreased from inclusion to
W2 and from W2 to W6. The emotional tone scores at inclusion, W2, and
W6, respectively, were 2.77, 2.15, and 1.90 for sadness, 2.81, 2.20, and 1.97
for anxiety, 1.70, 1.35, and 1.15 for panic, 2.08, 1.85 and 1.70 for irritability,
and 1.48, 1.37, and 1.27 for anger. Joy increased from 0.87 to 1.00 at W2
and 1.13at W6 and exaltation remained stable at around 0.65. All dimen-
sions of the scale improved significantly (p<0.001) from inclusion to W2
and from W2 to W6 (p<0.001): emotional reactivity (from 5.36 to 5.58
and 5.60), cognitive speed (from 4.56 to 4.95 and 5.08), psychomotor func-
tion (from 2.86 to 3.86 and 4.24), motivation (from 2.36 to 3.65 and 4.09),
and sensory perception (from 4.67 to 4.93 to 5.07). These changes were
correlated with significant decreases of the QIDs-C and CGI scales after
2 and 6 weeks of treatment.
Conclusion: These results show an improvement of negative but also
positive emotions with agomelatine that is significant as soon as the se-
cond week of treatment. This improvement may be an asset to obtain
more complete functioning recovery.
Policy of full disclosure: Unrestricted grant from Servier.
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P-23-013 Glutamate complex and BDNF concentration of
depressive patients with cognitive dysfunction
C. Han1, S.-H. Kim2. 1Korea University, Ansan City, Republic of Korea; 2Korea
University, Guro Hospital, Seoul, Republic of Korea
Objective: Decreased BDNF levels have been reported in Alzheimer’s dis-
ease and regarded as a contributor to neurodegenerative change and cog-
nitive impairment. Changes of BDNF levels in depressive patients also
have been reported. So we aimed to find differences in biological markers
like Glutamate and BDNF in MCI patient with and without depression,
which may promote our understanding in the relationship between de-
pression and cognitive impairment.
Methods: 163 patients diagnosed as MCI by subjective complaints and
neurocognitive tests were divided into a depression group and a non-
depression group. Serum BDNF levels were tested by blood sampling,
and the level of glutamate in the anterior cingulate gyrus was tested by
Magnetic resonance spectroscopy. A Students’ T-test was performed to
compare level of BDNF and glutamate between the depression group
and the non-depression group.
Results: There were no significant differences in serum BDNF levels be-
tween depression and non-depression groups. Glutamate levels in the an-
terior cingulate gyrus were significantly lower in the depression group
than in the non-depression group.
Conclusion: A decrease in glutamate levels was specific to depression
in MCI patients. It suggest that depression may contribute to cognitive im-
pairment and its progression independently, rather than just share same
risk factor or being an early symptom of dementia, and that glutamate
may play a role in cognitive decline. Future studies should confirm
whether MCI with depression shows a higher conversion rate to dementia
than MCI without depression, and longitudinally follow glutamate level
and cognitive function under the treatment of depression.
Policy of full disclosure: None.
P-23-014 The alleged ineffectiveness of SSRIs in depression is an
artefact caused by the use of an inappropriate measure of
efficacy
F. Hieronymus1, J. F. Emilsson1, S. Nilsson2, E. Eriksson1. 1Gothenburg
University, Gothenburg, Sweden; 2Chalmers University, Gothenburg, Sweden
Objective: Many studies have questioned if summation of the scores of
the 17 disparate items constituting the Hamilton Depression Rating
Scale (HDRS-17) is a reliable index of severity in depression; yet the cur-
rent questioning of the efficacy of antidepressant drugs is to a large extent
based on the assumption that response to treatment is reliably reflected by
this instrument. We aimed to investigate the possibility that the shortcom-
ings of the HDRS may contribute to the failure of antidepressants to out-
perform placebo in many trials.
Methods: We analyzed thirteen industry-sponsored trials of selective
serotonin reuptake inhibitors (SSRIs) comprising twenty-four drug-
placebo comparisons and including patient-level data from 5381 subjects
(administered paroxetine, citalopram, fluoxetine, or placebo), the aim
being to assess what the outcome would have been if the single item de-
pressed mood (rated 0–4) had been used as measure of efficacy.
Results: While 12 out of 24 comparisons (50%) revealed a significant
difference between active drug and placebo at week 6 with respect to re-
duction in HDRS-17-sum, 23 out of 24 comparisons (96%) showed the ac-
tive drug to be superior to placebo in reducing depressed mood.
Correspondingly, a pooled analysis of all cases showed the effect size
when assessed using the HDRS-17-sum to be 0.30, whereas it, when mea-
sured using the depressed mood item alone, was 0.42.
Conclusion: While not claiming that measuring one item only is the
most appropriate way of recording symptom severity in depression, we
do suggest that the inclusion of a number of varying symptoms in the as-
sessment, some of which may be side-effects of treatment and/or are unre-
lated to the disorder, reduces the sensitivity to detect a difference between
active drug and placebo. This lack of sensitivity of HDRS-17 might partly
explain why a high fraction of antidepressant trials fail to reveal a signifi-
cant difference between treatment groups.
Policy of full disclosure: None.
P-23-015 Abnormality of fractional amplitude of low frequency
fluctuation (fALFF) in drug naive patients with major
depressive disorder
M. Huang1, L. Yu2, Y. Xu3. 1First Affiliated Hospital, Zhejiang University,
Hangzhou, China; 2Anesthesiology and Pain, Hangzhou, China; 3First
Affiliated Hospital, Hangzhou, China
Objective: Recent resting-state fMRI studies on major depressive disorder
(MDD) have found altered temporal correlation between low-frequency
oscillations (LFOs). However, changes on the amplitudes of these LFOs re-
main largely unknown.
Methods: Male or female Han Chinese patients (18 to 45 years of age)
with MDD and age, gender and education matched control subjects
(n=26) were were recruited. Resting-state fMRI was obtained by using
an echo-planar imaging sequence and the fractional amplitude of low-
frequency fluctuations (fALFF) was calculated to investigate the ampli-
tude of LFOs in the resting state.
Results: The depression group exhibited lower fALFF values in the left
superior frontal gyrus, left middle frontal gyrus, left inferior frontal gyrus,
bilateral superior parietal gyrus regions, left parahippocampal gyrus,
right cerebrum, and left insula. Higher fALFF values in the depression
group were observed in left inferior temporal gyrus, right caudate and
right parahippocampal gyrus.
Conclusion: These findings indicated LFOs abnormalities in MDD and
the fALFF analysis might be a potential approach in further exploration of
this disorder.
Policy of full disclosure: None.
P-23-016 Brain serotonin transporter may predict patient with
suicide attempts in drug-naïve major depressive disorder
S.-Y. Huang1, Y.-W. Yeh2, P.-S. Ho3. 1Tri-Service General Hospital, Taiepi,
Taiwan; 2Tri-Service General Hospital, National Defense Medical Center,
Taiepi, Taiwan; 3Tri-Service General Hospital, Bei-Tou Branch, Taiepi, Taiwan
Objective:Much evidence suggests that the serotonergic system may play
an important role in the pathophysiology of major depressive disorder
(MDD) and suicide behaviors. The aim of this study was to examine
whether the serotonin transporter (SERT) availability is associated with
severity of MDD and a possible prediction of suicide attempt.
Methods: SERT availability was investigated in 17 drug-naïve
MDD patients and 17 age-gender matched healthy controls using
4-[18F]-ADAM as a SERT radiotracer in PET brain imaging. Subjects
underwent PET/CT after intravenous administration of 4-[18F]-ADAM.
SERT availability was measured by PMOD software to demarcate the
region-of-interest in the midbrain, thalamus, striatum, and prefrontal cor-
tex (PFC). The 21-item Hamilton Depression Rating Scale (HDRS21) and
Beck Scale for Suicide Ideation (BSS) were used to assess the severity of
depression and intent of suicide idea prior to brain image.
Results: A significant differences of SERT availability were found be-
tween in drug-naïve MDD and controls in midbrain, thalamus, and stria-
tum. SERT availability in midbrain had a linear correlation with HDRS21
in MDD group. The SERT ratio between serotonergic projection area
(PFC) and raphe nuclei (midbrain) was significantly higher in suicide
attempters, but no difference was noted between depressed non-suicide
subjects and controls.
Conclusion: This study suggests regional SERT availability in the mid-
brain, thalamus, and striatum was significantly lower in drug naïve MDD
than in healthy controls, and this effect was more pronounced in suicide
attempters. Non-synchronous reduction of brain serotonin transporter
may predict suicide attempts in drug-naïve patients with major depressive
disorder.
Policy of full disclosure: None.
P-23-017 A phase 3, long-term, open-label extension study
evaluating the safety and tolerability of 15 and 20mg
vortioxetine in subjects with major depressive disorder
P. L. Jacobsen1, L. Harper2, M. Serenko3, S. Chan3, A.
R. Mahableshwarkar3. 1Takeda Development Center Americas, Deerfield,
USA; 2Orlando, USA; 3Deerfield, USA
Objective: Vortioxetine is a recently approved antidepressant for adults
with major depressive disorder (MDD). We evaluated its long-term safety,
tolerability, and clinical effectiveness in MDD patients.
Methods: This 52-week flexible-dose open-label extension (OLE)
trial (NCT01152996) enrolled subjects who completed 1 of 3 short-term
studies (NCT01153009, NCT01163266, or NCT01179516). All subjects
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switched to vortioxetine 10mg/day for week 1, and increased to 15 or 20
mg/day based on investigator judgment. Safety and tolerability were
assessed by treatment-emergent adverse events (TEAEs), laboratory
values, and physical examination. Efficacy measures included the
Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton
Anxiety Scale (HAM-A), Clinical Global Impressions of Severity
(CGI-S), and Sheehan Disability Scale (SDS).
Results: Of 1075 subjects enrolled, 538 (50.0%) completed the OLE
study. Of 537 who withdrew, 115 (10.7%) discontinued due to TEAEs.
TEAEs were reported by 854 subjects (79.6%), with 34 serious adverse
events (SAEs) reported by 29 subjects (2.7%),11 (1.0%) of whom withdrew.
SAEs reported by >1 subject included acute cholecystitis (n=2; unrelated),
breast cancer (n=3; unrelated), and suicide attempt (n=2; 1 possibly re-
lated, 1 unrelated). No deaths occurred. Long-term treatment was well tol-
erated. TEAEs reported by 55% of subjects included nausea (24.0%),
headache (12.7%), diarrhea (7.5%), nasopharyngitis (6.3%), vomiting
(6.3%), viral upper respiratory tract infection (URTI) (6.2%), constipation
(6.1%), weight increase (6.1%), URTI (5.6%), and insomnia (5.2%).
Laboratory values and physical examinations revealed no clinical trends.
Mean MADRS total score and HAM-A score were 32.8 and 18.8 before the
initial studies, 19.9 and 11.5 at the OLE start, and 11.9 and 7.8 after week
52 (observed cases), respectively. Maintenance of improvement was also
seen in mean CGI-S and SDS scores.
Conclusion: After 52 weeks’ OLE treatment, vortioxetine 15 and 20mg
were safe and well tolerated, with subjects continuing to improve on de-
pression, anxiety, and disability symptoms.
Policy of full disclosure: This study was funded by the Takeda
Pharmaceutical Company, Ltd and H. Lundbeck A/S. Paula L. Jacobsen
is an employee of Takeda Development Center Americas, Inc.
P-23-018 Initial response to medication predicts early improvement
after 2 weeks in patients with major depressive disorder
S. Jang1, Y. Jae1. 1Bongseng Memorial Hospital, Busan, Republic of Korea
Objective: A number of large-scale study and meta-analyses suggested
that some current antidepressant treatments can exert some beneficial ef-
fect within the first week. Early improvement (more than 20% improve-
ment of symptoms severity at 2 weeks) was a highly sensitive predictor
of response or remission and so was a positive prognostic sign. With ear-
lier prediction, we can avoid time wasting with unpromising medications
and optimize medication for MDD patients. We investigated whether in-
itial clinical change (ICC) and initial subjective response (ISR) can predict
early improvement of antidepressant pharmacotherapy.
Methods: The symptoms of depression were assessed on the Hamilton
Rating Scale for Depression (HAMD-17). ISR was checked by a Korean
translation of the Modified Van Putten and May scale. CGI-I was used
to assess ICC. Ratings were made at baseline, day 1, 2, 4, and 14 after
treatment initiation. We employed Pearson’s correlation analysis and
multivariate logistic regression analyses. Sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV) and receiver
operating characteristic (ROC) curves were calculated.
Results: Among 33 MDD patients, 72.7% of patients achieved early im-
provement on HAMD-17. Significant correlation between initial response
(ICC or ISR on 2, 4 and 7 day) and early improvement were found. CGI-I
score of # 3 (sensitivity 79.2%, specificity 77.8%) and change in Modified
Van Putten and May scale score of # 9 (sensitivity 62.6%, specificity 77.8%)
on day 7 predicted later HAMD-17 early improvement at 2 weeks.
Conclusion: The findings show that ICC and ISR might be significant
predictors of early improvement in MDD pharmacotherapy. By using
ICC and ISR as an indicator for the future treatment outcome, we can de-
termine the optimal medication for MDD patient as early as within 7 days
of treatment initiation.
Policy of full disclosure: None.
P-23-019 The relationship between low self-esteem and suicide
attempt in patients with major depressive disorder:
A pilot study
D.-I. Jon1, H. Jeon1, H. J. Hong1, N. Hong1, E.-H. Park1, M. H. Jung1.
1Hallym University Hospital, Anyang, Republic of Korea
Objective: Depression is a major risk factor for suicide, and several
psychological factors such as low self-esteem are involved on suicide.
The aim of this study was to investigate the difference in self-esteem be-
tween non-suicide attempters (NSA) and suicide attempters (SA) with
major depressive disorder (MDD).
Methods: The study subjects consisted of 52 patients who received
inpatient or outpatient treatments at the Hallym University Sacred
Heart Hospital. All participants were diagnosed as MDD by Korean ver-
sion of the Mini-international Neuropsychiatric Interview (K-MINI).
Columbia Suicide Severity Rating Scale (C-SSRS) was used to evaluate
patient’s suicide attempt. They completed a questionnaire that included
Rosenberg Self-Esteem Scale (RSES), Beck Depression Inventory (BDI)
and Beck Scale for Suicide Ideation (BSI).
Results: A total of 52 subjects were evaluated by C-SSRS, and among
them, 32 were NSA and 20 were SA. Compared to NSA, SA showed sign-
ificantly lower levels of self-esteem (t=3.49, p=0.001) and higher levels
of BSI (t =−4.89, p<0.001). Although there was no significant difference
between two groups for severity of overall depressive symptoms, negative
attitude subscale of BDI was higher in SA than NSA (t=−2.596, p=0.014).
A stepwise multivariate logistic regression analysis showed that low self-
esteem was significant association with suicide attempt after adjusted by
negative attitude subscale of BDI and BSI (odds ratio=0.78, p=0.04).
Conclusion: The present study indicated that low self-esteem plays a
significant role in SA with MDD. Assessment of suicide risk should in-
clude not only suicide ideation and severity of overall depressive symp-
toms but also low self-esteem.
Policy of full disclosure: None.
P-23-020 Modelling the cycling of mood in a preclinical model
of depression
L. Kalynchuk1, K. Lebedeva1, E. Fenton1, H. Caruncho1. 1University of
Saskatchewan, Saskatoon, Canada
Objective: Major depression is a recurrent condition. Almost without ex-
ception, animal models of depression have not addressed the sensitization
that develops over the course of subsequent depressive episodes, and
therefore, they do not provide means to understand the neurobiological
mechanisms by which depression becomes autonomous of stress. In our
recent work, we have attempted to recapitulate the cyclical course of
human depression in a preclinical animal model of depression.
Methods:We assessed depression-like behavior in rats through 3 cycles
of treatment with and recovery from the stress hormone corticosterone
(CORT). Each cycle of treatment comprised 21 days of CORT injections
(either 10mg/kg, 20 mg/kg, or 40 mg/kg) followed by 21 days of stress-free
recovery. Depression-like behavior was measured in the middle and end
of each CORT treatment and at the end of each recovery period using the
forced swim test. We also collected brain tissue at each behavioral time
point so we could analyze the number and maturation rate of immature
neurons within the granule cell layer of the dentate gyrus.
Results: CORT administration produced increasingly greater effects
on depression-like behavior through each cycle of treatment. In the first
cycle, CORT increased depression-like behavior after 21 days of treatment,
which then normalized after the recovery period. In the second and third
cycles however, CORT induced an early manifestation of depression-like
behavior after only 10 days of treatment. In addition to these behavioral
changes, CORT also produced physiological alterations indicative of de-
pression: decreased body weight gain (1st cycle) and body weight loss
(2nd and 3rd cycles) and accumulative decreases in the number and den-
dritic complexity of immature granule neurons.
Conclusion: These results present a promising model for better under-
standing the mechanisms of chronic and recurring depression.
Policy of full disclosure: None.
P-23-021 Serum mirtazapine monitoring in the Korean
psychiatric patients
J. Y. Kim1, J.-H. Jang1, W. Myung1. 1Samsung Medical Center, Seoul, Republic
of Korea
Objective: Mirtazapine is a tetracyclic antidepressant that acts by enhanc-
ing serotonergic and noradrenergic neurotransmission. This study aimed
to evaluate mirtazapine pharmacokinetic (PK) data from Korean psychi-
atric patients on long-term mirtazapine treatment, and to understand po-
tential factors affecting its steady-state concentrations in a clinical setting.
Methods: Total 337 steady-state mirtazapine concentrations from 189
adult psychiatric outpatients were evaluated. Serum mirtazapine con-
centrations were measured by HPLC-MS/MS as a routine. We retrospec-
tively collected data including patients’ demographics, mirtazapine
dosing history, and concurrent medications.
Results: Median mirtazapine concentration was 42.3 ug/L (range:
2.9∼199.3) at the 7.5 to 60mg daily dosage range. At steady state,
mirtazapine dose had positive correlation with the drug concentration
(r=0.498, P<0.0001). However, even at a constant dose, large intra- and
inter-individual variations in the drug concentrations were observed;
individual C/D ratio ranged from 0.06 to 5.52 and maximum to minimum
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concentration ratio in an individual with a constant dose was shown up
to 11 fold. In elderly patients, dose-adjusted serum concentrations
were higher than those of the younger ones. Body weight, sex, and
co-medications (eg. paroxetine, venlafaxine, diazepam, sertraline, fluoxe-
tine) did not reach statistical significance in correlation with dose-adjusted
drug concentrations. In addition, treatment responsiveness was not asso-
ciated with initial mirtazapine concentration.
Conclusion: This study presented therapeutic drug monitoring data of
mirtazapine and pharmacokinetic variations in a routine outpatient set-
ting. Considering the large inter- and intra-individual variability and
poor compliance in psychiatric patients, therapeutic drug monitoring of
mirtazapine would be helpful to improve pharmacotherapy.
Policy of full disclosure: None.
P-23-022 Aripiprazole augmentation for major depressive disorder:
Dosing patterns in a naturalistic treatment setting
J. Kim1, S.-H. Kim2, C.-U. Pae3. 1The Catholic University, Seoul, Republic of
Korea; 2Korea University Medical Colle, Guro Hospital, Seoul, Republic of
Korea; 3The Catholic University, College of Medicine, Seoul, Republic of Korea
Objective: This study investigated the dosing patterns for aripiprazole
augmentation for major depressive disorder (MDD) in a naturalistic treat-
ment setting.
Methods: Between 1 January 2009 and 31 March 2012, patients with a
diagnosis of MDD who were receiving aripiprazole augmentation in con-
junction with an ongoing antidepressant were recruited for this study. The
electronic medical records and clinical data for a total of 276 patients were
reviewed up to a year.
Results: The mean duration of aripiprazole augmentation was 5 months;
the mean time to the first increase of aripiprazole was about 3 weeks; and
the mean initial, first up-titrated, maximal, and maintenance doses were
3.4, 4.2, 4.7, and 4.4 mg/day, respectively. The most frequent adverse
events were insomnia, followed by anxiety and sedation.
Conclusion: The current results indicate that the actual doses of aripi-
prazole augmentation with ongoing antidepressant for MDD should be
lower than the doses used in placebo-controlled clinical trials and those
recommended by the US Food and Drug Administration. Adequately
powered and well-controlled prospective studies are needed to better
understand the exact role of low doses of aripiprazole augmentation in
the treatment of MDD, particularly in routine practice.
Policy of full disclosure: None.
P-23-023 Decreased quality of life in elderly patients with
subsyndromal depression
M.-D. Kim1, K.-H. Lee2, S. Lee3. 1Jeju National University Hospital, Jeju,
Republic of Korea; 2Dongguk University Hospital, Kyungju, Republic of
Korea; 3Chonbuk University Hospital, Jeonju, Republic of Korea
Objective: Non-major depression with fewer symptoms than required for
a DSM-IV diagnosis of major depressive disorder (MDD) has consistently
been found to be associated with functional impairment. In this study, we
aim to estimate the quality of life in elderly patients with subsyndromal
depression (SSD) compared with non-depressive elderly (NDE).
Methods: The Korean version of Mini International Neuropsychiatric
Interview was administered to 194 of outpatients with depression and
108 of normal control group. SSD is defined as having five or more current
depressive symptoms with core depressive symptoms (depressive mood
or loss of interest or pleasure) during more than half a day and more
than seven days over two weeks. Depression was evaluated by the
Korean form of Geriatric Depression Scale of a 15-item short version
(KGDS-15). Global cognition was assessed by the Korean Version of
Revised form of Hasegawa Dementia Scale (K-HDS) and Mini-Mental
State Examination in the Korean version of CERAD assessment packet
(MMSE-KC). Subjective cognitive impairment was assessed Subjective
Memory Complain Questionnaire (SMCQ). Quality of life was evaluated
by The Korean Version of Short-Form 36-Item Health Survey (SF-36).
Results: The scores of physical component summary (PCS)(F=9.274,
p=0.003, ANCOVA) and mental component summary (MCS) (F=53.166,
p<0.001, ANCOVA) in the SSD group were lower than those in NDE
group with adjustment for age, gender, and education.
Conclusion: Subjects with SSD, as well as those with MDD, were
experienced low quality of life in both physical and mental aspects, com-
pared to NDE group.
Policy of full disclosure: None.
P-23-024 Infanticide in psychiatry: Theoretical concepts and
clinical practice
M. Kolenic1, K. Moravcik1, J. Pristasova1. 1Faculty Hospital Prešov, Presov,
Slovak Republic
Objective: Infanticide committed by women suffering from mental dis-
order is a serious medical, social and ethical issue. We present theoretical
concepts of this topic as well as case reports of such incidents. We also
deal with therapeutic implications and possibilities of re-entry into normal
life. Transcultural socio-legal differences in terms of this issue is also
investigated.
Methods: Our work analyze and sumarize theoretical concepts of infan-
ticide committed by women suffering from mental disorder. Case reports
from our practice are atteched.
Results: It is often very difficult, from forensic point of view, to deter-
mine the extent of distortion control and cognitive abilities at the time
of committing the incriminating act. The result of this assessment has ser-
ious legal consequences and a tremendous influence on the fate of the
patient. However, regardless of verdict of the court, many other factors
are no less important for the woman: psychological support to cope
with the event after resolving of psychotic symptoms; attitude of partner
and close relatives; psychopharmacological treatment; social attitudes
towards this issue and toward mental disorders per se etc. These factors
together participate on the quality of next life and course of mental illness.
Conclusion: Psychotic symptoms give rise to the infanticide in many
cases – Transcultural differences in the approach to the infanticide are evi-
dent – Postapartum psychosis as a risk factor of infanticide.
Policy of full disclosure: None.
P-23-025 Female transgenic mice with conditional glucocorticoid
receptor deletion in noradrenergic system display
depressive-like behavior reversed by desipramine and
fluoxetine
G. Kreiner1, P. Chmielarz1, I. Nalepa1. 1Institute of Pharmacology PAS,
Krakow, Poland
Objective: Hyperactivity of hypothalamic-pituitary-adrenal system
(HPA) is believed to be one of the major contributors to depression path-
ology. The activity of HPA is controlled by glucocorticoid receptors (GR)
which function may be impaired in depression, resulting in reduced
GR-mediated negative feedback on the HPA axis. Animals carrying muta-
tions of GR reveal alterations in the HPA comparable to those observed in
depressed patients. The aim of this study was to investigate if conditional
inactivation of GR narrowed to noradrenergic system (an important target
for antidepressant therapy) may evoke depressive-like behavior in mice.
Methods: The experiments were carried out on male and female mice
lacking GR selectively in noradrenergic neurons. Ablation of GR in nora-
drenergic system was achieved using the Cre/loxP approach by crossing
transgenic mice hosting the Cre recombinase under the dopamine beta-
hydroxylase promoter with animals harboring the floxed GR gene. Mice
were screened for anxiety- and depressive-like behavior in Light/Dark
Box Test and Tail Suspension Test (TST). Desipramine (20mg/kg, i.p.)
and fluoxetine (10mg/kg, i.p.) were administered in single dose 30 min-
utes before test.
Results: Resulting GRDBHCre mice were born at expected rates, viable
and showed no obvious physical impairment regarding life span, fertility,
weight gain and locomotor activity. Interestingly, female GRDBHCre mice
showed anxiety-like behavior (increased latency to enter light box com-
partment), and depressive-like behavior (increased immobility time in
TST) while no changes were observed in male mutants. This depressive-
like behavior was reversed after single dose of desipramine and fluoxe-
tine. However, we observed that the effect of fluoxetine was more pro-
nounced in female mutant mice than in their littermate controls, while
the effect after desipramine treatment remained similar despite of
genotype.
Conclusion: Female GRDBHCre mice may represent an interesting
novel genetic model to study depression. Moreover, our results emphasize
the gender variability in depression often neglected in experimental study.
Policy of full disclosure: None.
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P-23-026 Molecular analysis of prefrontal cortex in mice exposed to
chronic mild stress; the influence on lipid and
carbohydrate metabolism under depressive state
M. Motoyama1, K. Yamanishi1, N. Doe2, M. Sumida2, Y. Watanabe3,
M. Yoshida3, H. Yamamoto1, W. Li1, H. Yamanishi3, H. Okamura1,
H. Matsunaga1. 1Hyogo College of Medicine, Nishinomiya, Hyogo, Japan;
2Section of Behavioral Science, Kouiken Co. Ltd., Akashi, Hyogo, Japan;
3Hirakata General Hospital, Hirakata, Osaka, Japan
Objective:Major depressive disorder (MDD) is a common disorder and is
responsible for considerable disability, anorexia, and physical comorbid-
ity. Recently, there have been some researches regarding the relationship
between MDD and metabolic disorders such as dyslipidemia. As a risk
factor of developing MDD, additionally, the oral hypoglycemic agents
such as sulfonylureas should be noted and certain causal relations be-
tween MDD and diabetes may exist. In this study, we generated
depression-like behavior in mice animal models by chronic mild stress
(CMS) according to the standardized procedure to investigate the rela-
tions between MDD and metabolic disorders focusing on molecular
mechanism.
Methods: C57BL/6N mice that had been received CMS for four weeks
showed several kinds of depression-like behavioral changes. We per-
formed comparative analysis of the gene expression profile of the pre-
frontal cortex between CMS mice and the controls using microarray and
Quantitative real-time PCR (qRT-PCR). For further analysis, we categor-
ized the genes by using two web-based bioinformatics analysis tools.
The 1st tool consisted of the Database for Annotation, Visualization and
Integrated Discovery (DAVID), which looked for significantly enriched
genes, and categorized them by Gene Ontology#(GO) terms. The 2nd
one was network explorer of ingenuity pathway analysis (IPA), which
looked for the functions, interactions, and diseases of these extracted
genes particularly. We confirmed the expression level of mRNA and pro-
tein of some genes by qRT-PCR and Western blotting analysis,
respectively.
Results: According to the microarray results, 494 genes were differen-
tially expressed. The two kinds of web tools suggested that many differ-
entially expressed genes were significantly related to dyslipidemia and
to diabetes.
Conclusion: We found a number of isolated genes with significant dif-
ferences and direct interactions between MDD and metabolic disorders.
Further examinations focusing on the roles of these genes in the PFC
should be needed for strengthening the possibility of novel drug develop-
ment for MDD.
Policy of full disclosure: None.
P-24. Eating disorders
P-24-001 Exploring cognitive function in obesity: Assessment of
5-choice serial reaction time task performance in
leptin-knockout rats
W. Adams1, A. D´Souza1, J. Sussman1, T. Kieffer1, C. Winstanley1.
1University of British Columbia, Vancouver, Canada
Objective: Impulse control deficits may contribute to excessive food in-
take in some individuals with obesity. In addition to its role in regulating
appetite and energy expenditure, leptin also directly modulates the ac-
tivity of central dopaminergic circuits. While dopamine is involved in
mediating impulsivity, the influence of leptin on this cognitive domain re-
mains unclear. Here, we explored the performance of leptin-knockout
(leptin-KO) rats in the 5 Choice Serial Reaction Time task (5CSRT), a
rodent analogue of the Continuous Performance Test used clinically to as-
sess impulse control and attention.
Methods: Male leptin-KO (n=7) and wild type (n=11) rats were food
restricted under standard conditions and trained in the 5CSRT. Animals
learned to respond to a brief light stimulus presented in one of five loca-
tions to earn a food reward. Responses made before stimulus presentation
provided an index of motor impulsivity, while other variables measured
attentional ability and motivation to perform the task. Performance was
assessed at baseline, after 4-week’s consumption of high-fat diet, and
after acute amphetamine challenge.
Results: Leptin-KO rats showed a mild learning deficit compared to
controls, yet there were no differences in baseline performance once the
task was acquired. Prolonged consumption of a high-fat diet did not affect
5CSRT performance in either group. In contrast, leptin-KO rats showed
enhanced impulsive responding following amphetamine treatment com-
pared to controls, while other behavioural variables remained unchanged.
Conclusion: Leptin deficiency slowed the rate at which animals learned
the 5CSRT but did not alter performance at baseline or after high-fat diet
consumption. A genotype effect on motor impulsivity was prominently
observed after amphetamine treatment, with leptin-KO rats showing
potentiated premature responses; however, the caveat that both groups
had been consuming high-fat diet limits our interpretation of these data.
Molecular assays of dopaminergic markers are ongoing and may shed
light on the mechanisms underlying these findings.
Policy of full disclosure: None.
P-24-002 Effects of high-fat diet and binge-like food intake on
cognitive performance in the 5-choice serial reaction
time task
J. Sussman1, W. Adams1, C. Winstanley1. 1University of British Columbia,
Vancouver, Canada
Objective: Compulsive overeating, as seen in binge-eating or obese indi-
viduals, may involve abnormalities in reward, motivation and impulse
control circuits akin to those seen in drug addiction. While rats preferen-
tially consume high-fat foods, the behavioural effects of chronically con-
suming a high-fat diet have yet to be thoroughly investigated. This
study explored the effect of a high-fat diet on attention, motivation for
food rewards and impulsivity in rats, in states of hunger and after
binge feeding.
Methods: 31 male Long-Evans rats received restricted daily allotments
of either a high-fat (n=15) or control (n=16) diet, and trained on the
5-Choice Serial Reaction Time task (5CSRT). In this task, animals must re-
spond to a brief light stimulus to receive a food reward; accuracy (%cor-
rect responses) indexes attention, reward collection latencies and
omitted trials index motivation, and premature responses index motor
impulsivity. Once animals were trained, they were allowed to binge for
2 hours/week on control food (5 weeks), and then on high-fat food
(5 weeks). The basal effects of high-fat diet consumption, as well as the
influence of binge feeding, on task performance were assessed.
Results: Rats maintained on a high-fat diet omitted fewer trials at base-
line, and showed a blunted increase in omissions in sessions after binge-
feeding, than rats maintained on a control diet. High-fat diet animals also
collected food rewards more quickly than controls. However, diet or bin-
geing did not affect other 5CSRT variables.
Conclusion: Our results indicate that long-term consumption of high-
fat diets increases motivation for food rewards and attenuates the acute
demotivating effects of bingeing. As such, these data suggest that indivi-
duals who chronically consume high-fat foods may continue to seek and
eat food even when physically satiated. Molecular analyses of brain
regions involved in motivation and reward may help clarify the neurobio-
logical mechanisms underlying these behavioural changes.
Policy of full disclosure: None.
P-25. Schizophrenia B
P-25-001 Metabolic risk and status with continuous antipsychotic
treatment in chronic schizophrenia patients between
2-year period
K. Kawabe1, S. Ochi1, Y. Yoshino1, T. Ishimaru1, Y. Mori1, H. Onuma1,
H. Osawa1, S.-I. Ueno1. 1Japan, Toon, Ehime, Japan
Objective: The prevalence of diabetes mellitus in schizophrenic patients
is several times higher than that of the general population. In addition,
common side effects of atypical antipsychotic treatments for schizo-
phrenia are weight gain and lipid metabolism abnormality. In our pre-
vious study of 68 chronic schizophrenic patients using atypical
antipsychotics, we reported relatively high levels of resistin and a signifi-
cant correlation between body mass index (BMI) and Homeostasis Model
Assessment-Insulin Resistance (HOMA-IR). We expanded this research
in our current 2-year study, examining metabolic laboratory values
in chronic schizophrenia patients who used continuous antipsychotic
treatment.
Methods: This study was a prospective cohort study. The participants
were 42 schizophrenic patients (22 males, 20 females; aged 25–79 years,
mean age 52.6±13.4). The Brief Psychiatric Rating Scale (BPRS) and the
Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) were used for
medical assessment. Changes in carbohydrate metabolism (C-peptide,
resistin, insulin levels, lipid metabolism, HOMA-IR) and changes in physi-
cal characteristics (BMI, abdominal girth, the number of metabolic syn-
drome conditions) were studied over a 2-year period. In addition, single
nucleotide polymorphisms (SNP) in the transcriptional regulatory region
of the resistin gene were examined.
Results: We found no changes in the mental state of the participants.
Moreover, physical changes, such as changes in BMI and abdominal
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girth, were not observed. The SNP-420 genotype was not associated with
any data. However, there were statistically significant decreases in the
mean values of total cholesterol and hemoglobin A1c levels after 2 years.
Conclusion: There were almost no changes in the blood examinations
and the physical states of patients with chronic schizophrenia after
2 years of treatment. Research studies observing longer treatment periods
are needed to examine how adverse metabolic effects change over time in
schizophrenia patients who use continuous antipsychotic treatment.
Policy of full disclosure: None.
P-25-002 Effects of clozapine on dopamine dynamics in the
amygdala of stress-sensitive animals
M. Kawano1, H. Muraoka1, T. Kawano1, M. Yamada1, J. Miyagi1,
H. Oshibuchi1, K. Inada1, J. Ishigooka1. 1TWMU/Japan, Tokyo, Japan
Objective: Stress can flare up schizophrenic symptoms to cause hypersen-
sitivity in emotional handling the event, so it is meaningful to study the
effects of relevant drugs on the dopamine dynamics in the amygdala.
We have so far studied using stress-sensitive animals with a special refer-
ence to schizophrenia and found that anti-psychotic drugs suppress the
dopamine release provoked by fearsome stimulation in the amygdala.
To clarify the effects of clozapine commonly given for treatment-refractory
schizophrenia, we using animals under conditioned fear stress application
attempted to study how clozapine affects the dopamine regulation during
fear stimulation in the amygdala.
Methods: Chronic administration of methamphetamine (MAP)
results in MAP-sensitization, and we used MAP-sensitized rats as surro-
gate for stress vulnerability in schizophrenia. Fear conditioning can be
formed during stressful environment according to the classical condition-
ing theory and was widely applied for research of psychiatric disorders.
The variations of dopamine levels in the amygdala were measured
with time using microdialysis and HPLC (high-performance liquid
chromatography).
Results: A single dose of clozapine was identified to suppress the fear
stimulation-induced excess of dopamine release in the amygdala more
significantly in the stress-sensitive model than in the saline control.
However, clozapine did not affect any baseline dopamine levels in the
stress-sensitive models.
Conclusion: In our series of studies we have so far demonstrated that
anti-psychotic agents suppress the fear stimulation-induced excess of
dopamine release in the amygdala either in normal or MAP-sensitized
rats. However, these agents suppress dopamine excessive release after
fear stimulation conditioning by changing the dopamine baseline levels.
In stress-sensitive models, clozapine suppresses the excessive release of
dopamine after stimulation conditioning without changing the dopamine
baseline levels, suggesting that the results were different from other anti-
psychotic drugs. We have already reported similar results with valproate
(VPA), and it is warranted to compare clozapine with VPA to elucidate
the emotion-stabilizing action of these agents.
Policy of full disclosure: None.
P-25-003 Seizures, EEG abnormalities, and clinical response during
clozapine therapy in Japanese patients with schizophrenia
Y. Kikuchi1, K. Ataka1, K. Yagisawa1, Y. Omori1, T. Kanbayashi1,
T. Shimizu1. 1Akita University, Akita, Japan
Objective: Clozapine is effective against treatment-resistant schizophrenia
and was introduced to Japan in 2009. Clozapine-induced seizures are
more frequent than agranulocytosis, and electroencephalography (EEG)
abnormalities are even more common. Because clozapine efficacy varies
among individuals and races, there is a need to determine the predictive
factor of treatment-response and side effects of clozapine in a Japanese
population. Here, we describe EEG abnormalities and seizures associated
with clozapine treatment in Japanese schizophrenia and compare EEG
results and total score of positive and negative syndrome scale (PANSS
(T)) before and after treatment.
Methods: Twenty patients with treatment-resistant schizophrenia ac-
cording to Diagnostic and Statistical Manual of Mental Disorders IV cri-
teria were enrolled in this study, including 4 males and 16 females.
EEGs were obtained prior to clozapine treatment, when seizures occurred,
and every 4 weeks. PANSS (T) were used to determine clozapine treat-
ment outcome and were compared at baseline and last observation.
Results: All patients had normal baseline EEGs, and 10 patients (50%)
later showed EEG abnormalities. There were no significant differences be-
tween the EEG normal and EEG abnormal groups in mean age, gender,
mean clozapine dose, or length of treatment with clozapine. Six patients
(30%) experienced seizures; one with both tonic-clonic and myoclonic,
one with tonic-clonic and four with myoclonic seizures. The mean base-
line PANSS (T) scores were not significantly different between the EEG
normal and EEG abnormal groups, but the mean score in the EEG abnor-
mal group was significantly lower than that in the EEG normal group at
the final follow-up. The response rate of the EEG abnormal group was
higher, albeit not significantly, than that of the EEG normal group.
Conclusion: Clozapine is more likely to cause seizures in the Japanese
population. EEG abnormalities appeared after clozapine treatments are
associated with a good clinical response to clozapine.
Policy of full disclosure: This work was supported by Health and
Labor Sciences Research Grant Number 3000000301.
P-25-004 Association study of methamphetamine- and
phencyclidine-responsive gene, WD repeat domain 3,
in schizophrenia
M. Kobayashi1, N. Yamamoto1, D. Jitoku1, Y. Iwayama2, T. Yoshikawa2,
T. Nishikawa1. 1Tokyo Medical and Dental University, Tokyo, Japan;
2RIKEN Brain Science Institute, Saitama, Japan
Objective:Methamphetamine, an indirect dopamine agonist, and phency-
clidine, an antagonist of the N-methyl-D aspartate type glutamate recep-
tor, are known to cause schizophrenia-like symptoms only after
adolescent period. Previously, by using a microarray technique, we
found that cortical gene expression of WD repeat domain 3 (WDR3) pro-
tein was up-regulated in the adult but not in infant rats by these schizo-
phrenomimetics. WDR3 and other related proteins are the nuclear
proteins presumably involved in various cellular activities, such as cell
cycle progression, signal transduction, apoptosis, and gene regulation.
To further elucidate molecular pathophysiology of schizophrenia, we
have examined genetic association of WDR3 in schizophrenia.
Methods: We examined 11 single nucleotide polymorphisms (SNPs) of
human WDR3 gene, using an 1808 schizophrenics and 2170 matched con-
trols from Japanese population. Additionally, for the family-based associ-
ation study 204 patients and their parents were examined. All the study
was approved by ethics committees of the institutes. All participants
gave informed and written consent to participate in the study.
Results: In a genotypic test a nominally significant association with
schizophrenia was observed in one SNP. By additional stratification
analysis, we found one SNP showed a significant correlation with female
schizophrenia. Furthermore, four SNPs displayed nominally significant
association with certain onset-age groups of schizophrenia in female
and male schizophrenics. In a block-based haplotype analysis, one block
showed nominal association with schizophrenia. In female, same block
showed a significant association.
Conclusion: Our findings suggest that WDR3 gene may be a suscepti-
bility factor of female and inclinable specific onset ages of schizophrenia.
One SNP, which is located in CTCF binding site of 5’ upstream of WDR3
gene, showed a significant association with female schizophrenics. The
polymorphism of this site might be linked to the insulator function/dys-
function of the WDR3 and flanking cluster genes. In conclusion, WDR3
might be involved in the molecular basis of schizophrenic pathology.
Policy of full disclosure: None.
P-25-005 Transcriptomic evidence for immaturity of the prefrontal
cortex in patients with schizophrenia
T. Miyakawa1, H. Hagihara1, K. Ohira1, K. Takao2. 1Fujita Health
University, Toyoake, Japan; 2Okazaki, Japan
Objective: Schizophrenia, a severe psychiatric disorder, has a lifetime
prevalence of 1%. The exact mechanisms underlying this disorder are
still unknown, though theories abound. Recent studies suggest that par-
ticular cell types and biological processes in the schizophrenic cortex
have a pseudo-immature status, in which the molecular properties are
similar to those in normal immature brain. However, whether the matura-
tional state of a certain brain region as a whole is affected in schizophrenia
is not known. Here, we show that the schizophrenic prefrontal cortices
(PFC) resemble juvenile PFC in terms of genome-wide expression profile.
Methods: We conducted a gene expression meta-analysis in which ex-
pression patterns that are altered in the dorsolateral PFC (DLFC) and the
medial PFC (MFC) of schizophrenia patients were compared with those in
the corresponding regions of developing normal human brains.
Results: We found that overall gene expression patterns in the schizo-
phrenic PFC resemble those in the normal immature PFC. Furthermore,
we showed that more than half of the common gene alterations in schizo-
phrenic and developing PFC could be derived from maturational abnor-
malities of fast-spiking interneurons, astrocytes, and oligodendrocytes.
Additionally, we found that developing human PFC shows a gene ex-
pression pattern similar to that of the PFC of naive Schnurri-2 knockout
101P-25. Schizophrenia B
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
mice, an animal model of schizophrenia with good face and concept val-
idity, suggesting that the juvenile-like gene expression patterns observed
in the schizophrenic PFC may not be due to medication.
Conclusion: Collectively, our results provide strong evidence that
pseudo-immaturity of PFC resembling that of the juvenile brain is an
endophenotype for schizophrenia.
Policy of full disclosure: None.
P-25-006 Effects of n-acetylcysteine on clinical symptoms in
subjects with at-risk mental state: A case series
N. Miyake1, S. Miyamoto2, Y. Yamashita2, Y. Ninomiya2, J. Arai2,
S. Tsukahara2, Y. Ito2, M. Tadokoro2, T. Iwakura2, H. Nakamura3,
N. Yamaguchi2. 1St. Marianna University School of Medicine, Kawasaki,
Japan; 2St. Marianna University School of Medicine, Department of
Neuropsychiatry, Kawasaki, Japan; 3St. Marianna University School of
Medicine, Department of Radiology, Kawasaki, Japan
Objective: The safer preventive intervention of psychosis in subjects with
at-risk mental state (ARMS) is warranted. Given that N-acetylcysteine
(NAC), a glutathione precursor, has neuroprotective effects, its preventive
use in psychosis merits investigation.
Methods: Four subjects with subthreshold psychosis were given
NAC (2000mg/day) as supplementation for 12 weeks. Clinical evaluations
were conducted at baseline, 12- and 24-weeks. The primary outcome
measure was changes in the Scale of Prodromal Symptoms (SOPS).
Secondary outcome measures included the Brief Assessment of
Cognition in Schizophrenia-Japanese language version (BACS-J), the
Schizophrenia Cognition Rating Scale (SCoRS), UCSD Performance-
based Skills Assessment-Brief (UPSA-B), Schizophrenia Quality of Life
Scale-Japanese version (SQLS-J) and magnetic resonance spectroscopy.
This work was supported by JSPS Grant-in-Aid for Young Scientists (B)
24791239. This study protocol was approved by the bioethics committee
of St. Marianna University School of Medicine, and written informed con-
sent was received from all participants.
Results: NAC improved the SOPS total score from baseline to endpoint
(43.0±13.0 to 22.8±22.2). Three subjects no longer met the criteria of
ARMS at endpoint. In addition, improvements in the BACS-J
composite z-score (from −0.58±1.17 to 0.16±0.91), the SCoRS and the
SQLS-J score were observed, but the UPSA-B score did not change. The
N-acetylaspartate/creatine ratio in the dorsolateral prefrontal cortex was
higher in subjects who didn’t meet the criteria of ARMS at endpoint com-
pared with that in subjects who remained ARMS. No serious adverse
events were observed during the trial.
Conclusion: This is the first report which examined the effects of NAC
on clinical symptoms in subjects with ARMS. NAC may have beneficial
effects on psychophathological symptoms, cognitive functions, functional
capacity and subjective QOL. Thus, NAC may offer a safe and efficacious
strategy for improving clinical symptoms in subjects with subthreshold
psychotic states.
Policy of full disclosure: Dr. Miyake has received speaker’s
honoraria from Dainippon Sumitomo and Otsuka, and has received re-
search support from KAKENHI and research group for schizophrenia.
Dr. Miyamoto has received advisory board honoraria from Dainippon
Sumitomo. Dr. Yamaguchi has received advisory board and/or speaker’s
honoraria from Daiichi Sankyo, Eizai, Eli Lilly, Janssen, Otsuka, and
Takeda. No other authors have any conflicts of interest.
P-25-007 Clinical and biological correlates of resilience in patients
with schizophrenia: A cross-sectional study
Y. Mizuno1, T. Suzuki2, A. Hofer3, W.W. Fleischhacker3, T. Uchida4,
K. Yoshida5, H. Sakurai2, K. Watanabe6, M. Mimura5, H. Uchida5. 1Keio
University, School of Medicine, Tokyo, Japan; 2Inokashira Hospital,
Department of Psychiatry, Tokyo, Japan; 3Medical University Innsbruck,
Department of, Psychiatry and Psychotherapy, Innsbruck, Austria; 4Kawasaki
Municipal Hospital, Department of Neuropsychiatry, Kawasaki, Japan; 5Keio
University, School of Medicine, Department of Neuropsychiatry, School of
Medicine, Tokyo, Japan; 6Kyorin University, School of Medicine, Department
of Neuropsychiatry, Tokyo, Japan
Objective: Resilience refers to the process of adapting well in the face of
significant risk and adversity (e.g. traumatic life events). However, little
is known about factors that bring about resilience in patients with severe
mental illness. The objective of this cross-sectional investigation was to
identify clinical and biological correlates of resilience in patients with
schizophrenia.
Methods: Clinically stable outpatients with schizophrenia (DSM-IV)
were included. Subjective resilience was assessed using the Resilience
Scale (Wagnild and Young 1993). Other clinical variables included
sociodemographic data, premorbid adjustment, premorbid intelligence,
duration of illness, psychopathology, insight, chlorpromazine-equivalent
doses of antipsychotics, drug attitude, personal and social performance,
hopelessness, internalized stigma, quality of life (QOL), and self-esteem.
Furthermore, as candidate biomarkers of resilience, blood samples were
assessed for adrenocorticotropic hormone (ACTH), cortisol, and high-
sensitivity C-reactive protein (hs-CRP) levels, while saliva samples were
assessed for alpha-amylase concentrations.
Results: Fifty-six outpatients were assessed between April 2013
and January 2014 (mean±SD age, 45.9±10.0 years; duration of illness,
19.4±10.6 years; 22 males; all Japanese). On a scale of 25–175 with higher
scores indicating higher resilience, mean±SD total scores of resilience
amounted to 110±25 (range: 46–170). Spearman’s rank correlation coeffi-
cient showed that resilience was positively correlated to self-esteem and
QOL, while negatively correlated with internalized stigma, hopelessness,
and poor premorbid adjustment. Other variables, including biological
markers, showed no statistically significant correlations with resilience.
In a stepwise multiple regression analysis, the model including self-
esteem (Beta=0.746, p=0.000) and hs-CRP (Beta=0.255, p=0.009) best
explained resilience, with the adjusted R-squared amounting to 0.530.
Conclusion: Resilience in patients with schizophrenia correlated posi-
tively with self-esteem and QOL, and negatively with internalized stigma,
hopelessness, and poor premorbid adjustment. Further studies with larger
sample sizes are warranted to elucidate the theoretical construct and bio-
logical bases of resilience in patients with schizophrenia.
Policy of full disclosure: None.
P-25-008 Effect of aripiprazole on cognitive function and functional
capacity in antipsychotic-naïve first-episode
schizophrenia: First report
Y. Ninomiya1, S. Miyamoto1, T. Tenjin1, N. Miyake1, S. Ogino1,
H. Harada1, Y. Yamashita1, Y. Kaneda2, T. Sumiyoshi3, N. Yamaguchi1.
1St. Marianna University School of Medicine, Kawasaki City, Kanagawa,
Japan; 2Tokushima, Japan; 3Tokyo, Japan
Objective: Cognitive impairment is a core feature of schizophrenia and is
present early in the course of the illness. Impairments in cognitive func-
tioning are correlated with impaired functional capacity. The purpose of
this study was to evaluate the short-term effects of aripiprazole, an atypi-
cal antipsychotic, on cognitive function and functional capacity in
first-episode schizophrenia.
Methods: Thirteen antipsychotic-naïve patients with first-episode
schizophrenia participated in the study. Aripiprazole (3–30mg/day) was
given in an open label design for 8 weeks. Clinical evaluations were con-
ducted at baseline and 8 weeks after the start of treatment. The main out-
come measure was change in cognitive function assessed by the Brief
Assessment of Cognition in Schizophrenia (BACS-J). Secondary outcome
measures included the Schizophrenia Cognition Rating Scale (SCoRS),
UCSD Performance-based Skills Assessment-Brief (UPSA-B), the Positive
and Negative Syndrome Scale (PANSS) and the Clinical Global
Impression-Severity of Illness Scale (CGI-S). This study protocol was
approved by the bioethics committee of St. Marianna University School
of Medicine, and written informed consent was received from all
participants.
Results: Ten patients (3 males and 7 females; mean age, 32.2±6.4 years)
completed the study. One patient dropped out, and two patients are in
progress. The mean daily dose of aripiprazole was 6.9±6.6 mg/day at
8 weeks. Significant improvements from baseline to endpoint were
observed for verbal memory and verbal fluency on the BACS-J, the com-
munication domain on the UPSA-B, the SCoRS score, and all subscales on
the PANSS and CGI-S (p<0.05).
Conclusion: These results suggest that aripiprazole can improve psy-
chopathological symptoms and some types of cognitive function and
functional capacity which may be associated with verbal communication
in first-episode schizophrenia. We will present the data of more cases in
the congress.
Policy of full disclosure: None.
P-25-009 Blonanserin ameliorates phencyclidine-induced
impairment of visual recognition memory (2):
Involvement of dopamine-D1 receptor-PKA signaling
Y. Noda1, H. Hida1, A. Mouri1, K. Mori1, K. Yamada2, N. Ozaki2,
T. Nabeshima1. 1Meijo University, Graduate School Pharm., Nagoya, Japan;
2Nagoya University, Graduate School of Medicine, Nagoya, Japan
Objective: Blonanserin exhibits higher affinity for dopamine-D2/3 than for
serotonin 5-HT2A receptors. It ameliorates cognitive impairment by aug-
mentation of dopaminergic neurotransmission due to inhibition of both
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dopamine-D3 and serotonin 5-HT2A receptors of the medial prefrontal cor-
tex (mPFC) in mice administered phencyclidine [PCP; a non-competitive
N-methyl-D-aspartate (NMDA) receptor antagonist] repeatedly, as an
animal model of schizophrenia. Cognitive impairments in mice adminis-
tered PCP repeatedly, which is accompanied by dysfunction of the
dopamine-D1 and/or NMDA receptors in the mPFC. However, the mol-
ecular mechanism of ameliorating effect of blonanserin remains unclear.
In the present study, we investigated the postsynaptic mechanisms
underlying the effect of blonanserin on cognitive impairment in
PCP-administered mice.
Methods: The visual recognition memory and the levels of phosphory-
lated NR1 (an essential subunit of NMDA receptors) [Ser897 and Ser896
phosphorylate by a protein kinase A (PKA) and PKC, respectively] in
the mPFC were evaluated by the novel object recognition test (NORT)
and western blot analysis, respectively.
Results: The ameliorating effect of blonanserin on PCP-induced cogni-
tive impairment was antagonized by SCH23390, a dopamine-D1 receptor
antagonist, and H-89, a PKA inhibitor. The levels of NR1 phosphorylated
at Ser897 by PKA in the mPFC of PCP-administered mice after a NORT
training session were significantly decreased, compared to those in saline
control mice. The phosphorylation levels in the PCP-administered mice
were raised by blonanserin, the effect being blocked by SCH23390.
There were no differences in the levels of NR1 phosphorylated at Ser896
by PKC in any group.
Conclusion: Our findings suggest that dopamine-D1 receptor-PKA sig-
naling is required for the ameliorating effect of blonanserin on cognitive
impairment. Additionally, activation of NMDA receptors in the mPFC
through dopamine-D1 receptor-PKA, but not PKC, signaling is also critical
for recognition memory in PCP-administered mice.
Policy of full disclosure: None.
P-25-010 Translating study results into real-world psychiatric
practice: An experience in a male, locked, non-acute
unit serving for persistently ill patients over one year
T. Suzuki1, H. Uchida2, K. Tsunoda2, M. Mimura2. 1Inokashira Hospital,
Tokyo, Japan; 2Tokyo, Japan
Objective: The authors, previously reported on the effectiveness of anti-
psychotic augmentation strategies in severely afflicted populations, herein
describe an experience in a male, closed psychiatric unit over one year.
Methods: The unit is a non-acute one serving for persistently
and severely ill patients in serious needs. This study was approved
by Inokashira Hospital. Psychopharmacotherapy of 60 patients
(53 with schizophrenia (ICD-10), mean+/−S.D. age 58.4+/−13.0 y.o., dur-
ation of illness 30.5+/−15.0 years, approximate duration of admissions
19.1+/−14.4 years) who gave informed consent and were treated for
more than three consecutive months in the unit during F.Y. 2013 will be
critically evaluated. Clinical evaluation was routinely performed with
the CGI and FACT-Sz.
Results: Thus far, compared to the baseline (March 2013 or at the time
of admission to the ward), the number and dose of antipsychotics was
reduced from 1.80 to 1.03 and 923mg to 580mg, respectively. The number
of total psychotropics was also significantly minimized from 4.75 to 2.12.
Overall, the CGI-Severity and FACT-Sz improved slightly from 5.80 to
5.45 and 29.2 to 33.4, respectively. Likewise, the CGI-Improvement was
4 (i.e., no change) for 36 patients, 3 (minimally better) for 19 patients,
and 2 (much better) for 5 patients. Twenty-one patients were successfully
treated with an antipsychotic with/without a benzodiazepine (prescribed
in 28 patients, mostly lorazepam) or an antiparkinsonian drugs (pre-
scribed in only three patients). Twenty-one patients needed adjunctive
valproate (average blood levels 95.9+/−22.1 microg/ml) and nine patients
used lithium (0.631+/−0.255 mEq/l). However, only seven patients (11.7%)
needed two antipsychotics simultaneously.
Conclusion: Optimization of psychopharmacotherapy is possible in the
real-world for difficult patients and, while augmentation of an antipsy-
chotic with mood stabilizers is frequently needed, antipsychotic polyphar-
macy should be exceptional even in a challenging population.
Policy of full disclosure: The authors have declared that there are no
conflicts of interest in relation to the subject of this study. Dr. Suzuki
has received manuscript or speaker#s fees from Astellas, Dainippon
Sumitomo, Eli Lilly, Elsevier Japan, Janssen, Meiji Seika, Novartis,
Otsuka, and Weily Japan. Dr. Uchida has received grants from Pfizer,
Astellas Pharmaceutical, Eisai, Otsuka Pharmaceutical, GlaxoSmithKline,
Shionogi, Dainippon-Sumitomo Pharma, Eli Lilly, Mochida
Pharmaceutical, Meiji-Seika Pharma, Janssen Pharmaceutical, and
Yoshitomi Yakuhin and speaker#s honoraria from Otsuka
Pharmaceutical, Novartis Pharma, Eli Lilly, Shionogi, GlaxoSmithKline,
Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma,
and Janssen Pharmaceutical within the past three years. Dr. Tsunoda
has nothing to disclose. Dr. Mimura has received grants or speaker#s hon-
oraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo,
Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Janssen
Pharmaceutical, Meiji-Seika Pharma, Mochida Pharmaceutical, Novartis
Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, and Yoshitomi
Yakuhin within the past two years.
P-25-011 Effect of antipsychotics on telomere length in the
hippocampus
K. Toriumi1, M. Miyashita1, T. Ichikawa1, A. Kobori1, I. Nohara1, M. Arai1,
N. Obata1, M. Itokawa1. 1Tokyo Metropolitain Institute of Medical Science,
Tokyo, Japan
Objective: Recently, leukocyte telomeres in schizophrenia patients have
been reported to be shorter than that in healthy subjects. Several lines of
evidence suggested that telomere shortening was induced by biophysical
and psychological stress, especially during neurodevelopmental period
that is thought to be causative for schizophrenia. Additionally, chronic
stress exposure to mice suppressed neurogenesis in the hippocampus ac-
companied with decrease of telomerase expression, leading to depression-
like and negative symptom-like behaviors. The behavioral deficits were
also induced by treatment of telomerase inhibitor in hippocampus.
Although these findings suggest the association between telomere and
schizophrenia, the molecular mechanism remains unclear.
Methods: We checked leukocyte telomeres in 42 patients with schizo-
phrenia (Male/Female=23/19, Ave. age=49.81) and 56 healthy subjects
(Male/Female=30/26, Ave. age=46.84). Telomere length was measured
by quantitative PCR as described previously (Cawthon et al. 2009) with
minor modifications. In mice study, C57BL/6J mice were administrated
with antipsychotics and some antagonists for 2 weeks from the age of
8 weeks.
Results: We first investigated the lengths of leukocyte telomeres using
Japanese schizophrenia patients and discovered that the telomeres were
indeed shortened as previous reports in American and European subjects
with schizophrenia. Next, to evaluate the effect of antipsychotics on telo-
mere length, we had treated mice with several types of antipsychotics
for 2 weeks and found that treatment of atypical antipsychotics, such as
risperidone, olanzapine and aripiprazole, but not typical antipsychotics,
haloperidol, elongated the telomere length in the hippocampus.
Moreover, we found that the effect of atypical antipsychotics on telomere
length might be regulated by serotonin system.
Conclusion: Our findings suggest the possibility that atypical antipsy-
chotics improve negative symptom, at least partially, through the modu-
lation of telomere length.
Policy of full disclosure: None.
P-25-012 Is sustained dopamine D2 receptor blockade above 65%
necessary for maintenance treatment of schizophrenia? A
single-blind, randomized, controlled study
T. Tsuboi1, T. Suzuki2, R. R. Bies3, G. Remington4, B. G. Pollock4,
J. Hirano1, M. Mimura1, H. Uchida1. 1Keio University, School of Medicine,
Tokyo, Japan; 2Tokyo, Japan; 3Indianapolis, USA; 4Toronto, Canada
Objective: While 65–80% blockade of dopamine D2 receptors with anti-
psychotics optimizes therapeutic efficacy in the acute phase of schizo-
phrenia, it is unclear as to whether it is necessary to keep D2 blockade
within this therapeutic window for the maintain treatment. The objective
of this study was to examine whether this therapeutic window also would
apply for the maintain treatment.
Methods: In this single-blind, 52-week, randomized controlled trial,
clinically stable patients with schizophrenia (DSM-IV) treated with risper-
idone or olanzapine were randomly assigned to the continuous D2 block-
ade group (i.e. a trough D2 blockade of >65%) or intermittent D2 blockade
group (i.e. a peak D2 blockade of >65% with a trough level of <65%).
Plasma antipsychotic concentrations at trough that are expected to result
in 65% D2 blockade are 15.2 ng/mL and 19.3 ng/mL for risperidone
and olanzapine, respectively, according to the model that we recently de-
veloped. Oral doses that correspond to those plasma antipsychotic con-
centrations at trough will be estimated for each individual, using
the mixed effect population pharmacokinetic approach. According to
the group assigned, antipsychotic doses were individually titrated.
Psychopathology and side effects were assessed at the baseline and one
year with the Positive and Negative Syndrome Scale (PANSS), the
Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BAS),
and the Abnormal Involuntary Movement Scale (AIMS).
Results: Sixty-eight patients were enrolled (mean±SD age, 55.4±14.9;
41 men; 33 and 35 subjects on risperidone and olanzapine, respectively).
26 (76.5%) and 31 (91.2%) subjects successfully completed the study in
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the continuous D2 and intermittent D2 groups, respectively, without any
significant difference. No significant differences were found in changes in
PANSS total score (−0.6 vs. −1.5), SAS, BAS or AIMS between the con-
tinuous D2 and intermittent D2 groups.
Conclusion: Sustained dopamine D2 blockade above 65% may not be
necessary for the maintain treatment of schizophrenia.
Policy of full disclosure: None.
P-25-013 Postnatal development of patterns of basal and
schizophrenomimetic phencyclidine-induced gene
expression in the rat neocortex
M. Umino1, A. Umino1, N. Yamamoto1, T. Nishikawa1. 1Tokyo Medical and
Dental University, Bunkyo-Ku, Tokyo, Japan
Objective: The onset of schizophrenia and the schizophrenomimetic ef-
fects of N-methyl-D-aspartate (NMDA) receptor (NMDAR) antagonists
usually occur after adolescence. These clinical observations indicate sug-
gest that schizophrenia-related neuron circuits and molecules in the
brain could exhibit development-dependent responses to NMDAR
antagonists.
Methods: To get an insight into the molecular mechanisms underlying
the above clinical observations and onset of schizophrenia, we have stud-
ied developmental changes in the patterns of brain gene expression fol-
lowing no treatment (basal expression) or systemic application of
phencyclidine (7.5 mg/kg, subcutaneously) in the developing rats from
postnatal days 8 to 77. To this end, we employed a DNA microarray
and a quantitative RT-PCR method. The present animal experiments
have been approved by the ethics committees of the Tokyo Medical and
Dental University.
Results: DNA microarray analyses have revealed that prominent
changes in overall gene expression profiles after the PCP injection occurs
across the critical period around postnatal weeks 3 for the development of
adult-type PCP-induced abnormal behavior that has been considered to
be a model for schizophrenia. PCP, at least, caused an increase (PCP/saline
control ratios more than 1.2) and decrease (PCP/saline control ratios less
than 0.8) in the expression of 18 and 18 genes, respectively, in the neocor-
tex only after the critical period. The overall patterns of basal gene ex-
pression in the neocortex also displayed an inflection period around
postnatal week 3.
Conclusion: These data further support our view that the neocortical
genes exhibiting the critical period-related alterations in basal expression
and responsiveness to PCP could compose the molecular cascades that
are involved in the pathophysiology of schizophrenia. These genes
might malfunction in the schizophrenia-related neocortical circuits after
adolescence,
Policy of full disclosure: None.
P-25-014 The improvement of social functioning in schizophrenic
patients treated with paliperidone extended-release:
12-month observational surveillance in real clinical
practice with 1405 patients
A. Wakamatsu1, A. Tanimura1, K. Morita1, T. Ohnishi1, K. Tooriyama1,
T. Yamaoka1, H. Usui1, Y. Ogawa1, T. Kubo1, A. Fujino1. 1Janssen
Pharmaceutical KK, Tokyo, Japan
Objective: To demonstrate the effectiveness of PAL-ER on social function-
ing of schizophrenia in the real world, we conducted a 12-month
observational surveillance in real clinical practice with 1405 Japanese
schizophrenic patients.
Methods: This open-label, observational, multicenter surveillance in
real clinical practice was performed for a 12-month observation period.
The primary endpoint was changes of social functioning estimated by
Social and Occupational Functioning Assessment Scale (SOFAS) from
baseline to the end of observation period (using last-observed-carried for-
ward: LOCF). Secondary endpoint was improvement of symptoms esti-
mated by Clinical Global Impression-Schizophrenia (CGI-SCH). All
treatment-emergent adverse events (TEAEs) and adverse drug reactions
were also collected. The protocol was reviewed by internal review
board members including the ethical point of view and was approved
by Pharmaceuticals and Medical Devices Agency.
Results: Discontinuation rate calculated by Kaplan-Meier method was
34.7%. In this surveillance, we found that PAL-ER treatment significantly
improved the social functioning of schizophrenia patients assessed by
SOFAS (p<0.001 by signed Wilcoxon test). Among the treated patients,
52.8% were improved and 5.6% were worsened in SOFAS score. The
patients who had more than 60 in SOFAS score represented slightly dis-
able but generally well in social functioning, and this proportion of
patients increased from 3.3% at baseline to 24.0% at 12-month by the
treatment. Also, 55.3% of PAL-ER treated patients showed improvement
of more than 1 scale in CGI-SCH at LOCF compared to baseline.
Adverse drug reactions were reported in 414 (29.5%) patients in total;
most common were hyperprolactinemia (6.4%), somnolence (5.2%), fati-
gue (4.2%), and akathisia (2.6%). Twelve deaths were occurred and serious
TEAEs were reported in 8.8% patients. No new safety concerns were
observed.
Conclusion: This is a first report showing that PAL-ER treatment
improved the social functioning in Japanese schizophrenic patients in
real clinical practice.
Policy of full disclosure: All authors are employees of Janssen
Pharmaceutical K.K.
P-25-015 Effects of escitalopram on the amygdala dopamine release
in emotional processing: A specific effect in the
methamphetamine-sensitized rats
M. Yamada1, H. Muraoka1, M. Kawano1, T. Kawano1, T. Tsutsumi1,
J. Miyagi1, H. Oshibuchi1, K. Inada1, J. Ishigooka1. 1Tokyo Women’s
Medical University, Tokyo, Japan
Objective: Escitalopram (ESCIT) has the highest affinity for the human
serotonin transporter. Although SSRI typically used in the treatment of
depression and anxiety disorders, how such distinguish profile account
for their therapeutic action has not been fully clarified yet. In this study,
to investigate the effect of SSRI in emotional processing, we examined
the effects of the ESCIT on the dopamine (DA) levels and on excessive in-
crease of DA levels in response to a conditioned fear stimulus (CS) in the
amygdala of methamphetamine (MAP) -sensitized rats, in which model
animals the excessive increase of DA levels are a biological marker of
hypersensitivity and vulnerability to psychological stress.
Methods: Male Sprague-Dawley rats received 2mg/kg/day of MAP for
10 days, and then a fear-conditioning was performed in which tone con-
ditioned stimulus was paired with electrical foot shock. The extracellular
DA levels in the amygdala were measured using in vivo microdialysis.
During microdialysis, rats were injected to ESCIT (5mg/kg) intraperitone-
ally and then after 80min followed by CS.
Results: The basal extracellular DA levels were higher in the amygdala
of MAP-sensitized rats compared to un-sensitized rats. ESCIT treatment
significantly increased the DA levels in the amygdala in un-sensitized
rats. However, the increased DA elicited by ESCIT was not shown in
the MAP-sensitized rats. The CS subjection significantly increased amyg-
dala DA levels, which was greater for MAP-sensitized rats than for
un-sensitized rats. ESCIT treatment significantly suppressed the CS
induced excess DA release in the amygdala of MAP-sensitized rats.
Conclusion: These results suggest that the therapeutic effect of SSRI on
depression and anxiety disorders may involve modulation of amygdala
DA release in emotional processing. In addition, the specific effect of
SSRI on DA levels shown in MAP-sensitized rats may imply a part of
mechanisms for beneficial effect on vulnerability to psychological stress.
Policy of full disclosure: None.
P-25-016 Identification of developmentally regulated NMDA
receptor antagonist phencyclidine-responsive transcripts
in the rat brain
N. Yamamoto1, H. Takebayashi1, A. Umino1, T. Nishikawa1. 1Tokyo
Medical and Dental University, Tokyo, Japan
Objective: Schizophrenic and similar psychotic symptoms induced by an
NMDA-type glutamate receptor antagonist, phencyclidine (PCP), usually
develop during or after adolescence. Adult-type behavioral disturbance
following NMDA receptor antagonist application in rats is observed as
well only after a critical period at around 3 postnatal weeks. To obtain
further insights into the molecular basis of schizophrenia, we have inves-
tigated the gene expression profiles after acute PCP injection at different
developmental stages in rats.
Methods: Male Wistar rats at different postnatal days (PD) were admi-
nistered with PCP. After 1 h, total RNA in cerebral neocortex and thala-
mus of the animals was isolated and applied for DNA microarray
analysis to determine the development-dependent PCP-induced genes.
All the study was approved by the ethical committee for animal experi-
ments of the Institute.
Results: We have identified several PCP-responsive genes from the
rat brain regions only after the developmentally critical period as novel
candidates for the schizophrenia-related molecules. We next character-
ized a PCP-responsive non-coding transcript, prt6. The prt6 mRNA in
thalamus of adult rats was rapidly enhanced and peaked at 1–6 hours,
then returned to the basal level within 24 hours. By the acute injection
of another non-competitive NMDA receptor antagonist, MK-801, and a
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schizophrenomimetic dopamine agonist, methamphetamine, the ex-
pression level of prt6 mRNA was significantly increased.
Conclusion: The present study indicates that prt6 may be a key mol-
ecule in the pathophysiology of the onset of schizophrenic symptoms.
Possible miss regulation of the target gene(s) expression for microRNA
and/or other non-coding RNA fragments in the prt6 transcript may be
mutually associated with maturation of certain brain neuron circuits
and molecular networks in schizophrenia.
Policy of full disclosure: None.
P-25-017 Effect of aripiprazole on subjective experience in
antipsychotic-naïve first-episode schizophrenia: First
report
Y. Yamashita1, S. Miyamoto1, T. Tenjin1, Y. Ninomiya1, N. Miyake1,
S. Ogino1, H. Harada1, Y. Kaneda2, T. Sumiyoshi3, N. Yamaguchi1.
1St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan;
2Iwaki Clinic, Tokushima, Japan; 3National Center of Neurology and
Psychiatry, Tokyo, Japan
Objective: Subjective experience under antipsychotic treatment may be
associated with adherence and functional outcome in schizophrenia.
The purpose of this study was to evaluate the short-term effects of aripi-
prazole on subjective experience in first-episode schizophrenia.
Methods: Thirteen antipsychotic-naïve patients with first-episode
schizophrenia participated in the study. Aripiprazole (3–30mg/day) was
given in an open label design for 8 weeks. Clinical evaluations were con-
ducted at baseline and 8 weeks. The primary outcome measure was
changes in subjective well-being assessed by the Subjective well-being
under neuroleptic drug treatment short form-Japanese version
(SWNS-J). Secondary outcome measures included the Schizophrenia
Quality of Life Scale-Japanese version (SQLS-J) and the Positive and
Negative Syndrome Scale (PANSS). Safety assessments included labora-
tory tests, body weight, Body Mass Index (BMI), and the Drug Induced
Extra-Pyramidal Symptoms Scale (DIEPSS). This study protocol was
approved by the bioethics committee of St. Marianna University School
of Medicine, and written informed consent was received from all
participants.
Results: Ten patients (3 males and 7 females; mean age, 32.2±6.4 years)
completed the study. One patient dropped out, and two patients are in
progress. The mean daily dose of aripiprazole was 6.9±6.6 mg/day at
8 weeks. Significant improvements from baseline to endpoint were
observed for self-control and social integration on the SWNS-J, psycho-
social score on the SQLS-J, and all subscales on the PANSS. In the labora-
tory tests, high-density lipoprotein cholesterol significantly increased, and
fasting blood sugar significantly decreased from baseline within the nor-
mal range. Although mean body weight and BMI increased from baseline,
the rate of weight gain was only 0.4%. There was no significant change in
the DIEPSS score.
Conclusion: These results suggest that aripiprazole can improve
psychopathological symptoms and some types of subjective experience
in first-episode schizophrenia. We will present the data of more cases in
the congress.
Policy of full disclosure: None.
P-25-018 Interaction between paliperidone and carbamazepine
N. Yasui-Furukori1, K. Kubo1, M. Ishioka1, S. Tsuchimine1, Y. Inoue1,
K. Nakamura1. 1Hirosaki University, Hirosaki, Japan
Objective: This aim of this study was to determine the impact of carbama-
zepine on the pharmacokinetics of paliperidone.
Methods: Six schizophrenic patients initially received a 6–12mg/day
dose of paliperidone alone. Subsequently, a 200mg/day dose of carbama-
zepine was administered, and the carbamazepine dose was increased to
400mg/day and then 600mg/day. Plasma concentrations of paliperidone
before and after carbamazepine co-administration were quantified using
LC/MS/MS.
Results: Carbamazepine significantly reduced the plasma concentration
of paliperidone. The plasma concentration of paliperidone at baseline and
with co-administration of 200, 400, and 600mg/day were 45.8±11.7, 26.9±
13.7, 17.1±8.2, and 15.9±7.6 ng/ml, respectively. The concentration of pali-
peridone with carbamazepine co-administration at doses of 200, 400, and
600mg/day were 55.7±20.7, 36.1±12.2, and 33.6±10.4%, respectively, of
baseline. This effect occurred even at the carbamazepine dosage of 200
mg/day and reached a plateau at dosages higher than 400mg/day.
However, carbamazepine co-administration exacerbated the psychotic
symptoms in some patients.
Conclusion: The results of the present study suggest that adjunctive
treatment with carbamazepine reduces the concentration of paliperidone
in a dose-dependent manner, most likely because of the induction of sev-
eral drug metabolyzing enzyme and several drug transporters.
Policy of full disclosure: None.
P-25-019 The differences of cognitive deficits in chronic
schizophrenia on long-term treatment with typical and
atypical antipsychotics
M. Han1, X.-F. Huang2, X. Y. Zhang3. 1University of Wollongong,
Wollongong, Australia; 2University of Wollongong, Schizophrenia Research
Institute, Wollongong, Australia; 3Baylor College of Medicine, Beijing
HuiLongGuan Hospital, Houston, USA
Objective: Cognitive deficits have been presented in the prior to the onset
of other symptoms of schizophrenia and generally persisted during the
course of the disease. Whether cognitive function is affects by antipsycho-
tic treatment during the course of schizophrenia is still debated. This
study aimed to examine the effect of long-term treatment of antipsychotic
drugs on cognitive function in patients with chronic schizophrenia.
Methods: The study assessed cognitive function in 395 healthy controls
and 438 patients with chronic schizophrenia on long-term treatments with
antipsychotics, including mainly monotherapy with clozapine (n=224),
risperidone (n=99) and typical antipsychotics (n=115).
Results: Cognitive test scores were significantly lower in all patient
groups than healthy controls on all scales (all p<0.001) except for visuos-
pitial/constructional index. Clozapine treatment had significantly lower
immediate memory and delayed memory than typical antipsychotics
(all p<0.01). Clozapine treatment had better language index than risperi-
done (p<0.01).
Conclusion: Patients with chronic schizophrenia performed significant
cognitive deficits than healthy controls in all examined cognitive domains
except for the visuospitial/constructional index. Cognitive deficits in
patients with chronic schizophrenia were significantly influenced by dif-
ferent type’s antipsychotics treatment. Clozapine treatment had worse im-
mediate memory and delayed memory than typical antipsychotics, and
better language performance than risperidone.
Policy of full disclosure: None.
P-25-020 Effect of pharmaceutical care by pharmacists on
medication therapy in patients with chronic schizophrenia
Y. Hashimoto1, M. Tensho2. 1Kobe Gakuin University, Kobe, Japan; 2Sawa
Hospital, Osaka, Japan
Objective: Despite of contradictory evidence for effectiveness, use of two
or more antipsychotics, antipsychotics polypharmacy, is given in about
one third patients with chronic schizophrenia. Polypharmacy is raised
some problems, including adverse effects and patient safety. On the
other hand, pharmacists have responsibility to check the prescription
and discuss with physician and other health-care providers, and then
pharmacists should propose the optimal formulation. If these functions
of pharmacists work precisely, the problems may be prevented.
Therefore, in this study, we examined whether continuous pharmaceutical
cares are useful for the physicians’ prescriptions in patients with schizo-
phrenia or not.
Methods: Subjects are 78 in-patients with chronic schizophrenia treated
to antipsychotics therapy in Sawa hospital in Osaka, Japan. The partici-
pants were divided into two groups; continuous pharmaceutical inter-
vention group (n=26) and non-intervention group (n=52). The
pharmaceutical cares are as follow; patients’ education about medicine
and disease, monitoring side effects, up to these points for patients. To
physicians, request the blood test, discuss to prescription formula. We per-
formed intervention as appropriate. The items of survey are as follow;
the doses of antipsychotics, anti-Parkinsonian, and benzodiazepines, the
number of antipsychotics and anti-Parkinsonian, and the rate of concur-
rent anti-Parkinsonian, benzodiazepines, and mood stabilizers.
Results: In this study, continuous intervention for a year, the dose and
the number of antipsychotics and the number of anti-Parkinsonian was
significantly lower in intervention than in non-intervention.
Conclusion: Medication therapy is one of the most important treat-
ments for schizophrenia although there are some problems in medication
therapy such as adverse effects. Pharmaceutical intervention by pharma-
cists could make prescriptions by physicians optimize and/or simplify, in-
cluding in the medicines for the adverse effects and adjuvant medications.
As indicated above, it might be suggested that clinical practice should be
taken full advantage of pharmacists’ ability to medication therapy for
schizophrenia.
Policy of full disclosure: None.
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P-25-021 Blonanserin ameliorates phencyclidine-induced
impairment of visual recognition memory (1):
involvement of dopamine-D3 receptors
H. Hida1, Y. Matsumoto1, A. Mouri1, T. Seki2, K. Mori1, K. Yamada3,
N. Ozaki4, T. Nabeshima2, Y. Noda1. 1Meijo University, Graduate School
Pharm., Nagoya, Japan; 2Meijo University, Faculty of Pharm., Nagoya, Japan;
3Nagoya University, Graduate School of Medicine, Nagoya, Japan;
Objective: Blonanserin shows a binding profile unique among the atypi-
cal antipsychotic drugs (APDs) in that it exhibits a higher affinity for
dopamine-D2/3 receptors than for serotonin 5-HT2A receptors. Clinically,
blonanserin exhibits APD properties, with efficacy against positive symp-
toms, negative symptoms, and cognitive impairments in schizophrenia. In
animal studies, blonanserin has shown activity in reducing several psy-
chobehavioral abnormalities in animal models of schizophrenia.
However, the effect of blonanserin on the cognitive impairment and in-
volvement of dopamine-D3 receptors in its effect remain unclear. In the
present study, we investigated the effect of blonanserin on cognitive im-
pairment in the animal model of schizophrenia, in comparison with that
of olanzapine, and elucidated further the involvement of dopamine-D3
receptors in this model.
Methods: The mice received phencyclidine (PCP), a non-competitive
NMDA receptor antagonist, (10 mg/kg/day, s.c.) once a day for 14 con-
secutive days, as an animal model of schizophrenia. The visual recog-
nition memory and extracellular dopamine levels in the medial
prefrontal cortex (mPFC) were evaluated by the novel object recognition
test (NORT) and microdialysis experiment, respectively.
Results: Blonanserin (3mg/kg, p.o.), as well as olanzapine (3mg/kg, p.
o.), significantly ameliorated PCP-induced impairment of visual recog-
nition memory, as demonstrated by NORT, and increased the extracellular
dopamine levels in the mPFC. Both these effects of blonanserin were
antagonized by DOI, a serotonin 5-HT2A receptor agonist, and
7-OH-DPAT, a dopamine-D3 receptor agonist, whereas the effects of olan-
zapine were antagonized by DOI, but not by 7-OH-DPAT.
Conclusion: Our conclusion is that blonanserin ameliorates
PCP-induced cognitive impairment by antagonizing dopamine-D3 recep-
tors, in addition to serotonin 5-HT2A receptors, and thereby stimulates re-
lease of dopamine in the mPFC, and shows a unique pharmacological
efficacy different from that of olanzapine.
Policy of full disclosure: None.
P-25-022 Schizophrenic patients have a high prevalence of clinical
and laboratory markers of low plasminogen activators
and/or plasmin activity
S. Hoirisch-Clapauch1, A. E. Nardi2. 1Rio de Janeiro, Brazil; 2Institute of
Psychiatry, Federal University, RJ, Rio de Janeiro, Brazil
Objective: To assess the prevalence of markers of reduced activity of plas-
minogen activators/plasmin in schizophrenics. Schizophrenics exhibit hip-
pocampal atrophy. Plasminogen activators and plasmin mediate different
processes that culminate in neuronal excitotoxicity prevention and hippo-
campal neurogenesis.
Methods: Study population consisted of 70 schizophrenics (DSM-IV)
and 98 age-matched controls without psychiatric diagnosis. Exclusion
criteria for patients and controls comprised pregnancy, puerperium, estro-
gen use or anticoagulation within one month preceding sampling.
Twenty-nine outpatients and 41 inpatients, aged 18–72 years (mean 42
+/−11), were recruited at a university hospital. Thirty percent were taking
atypical antipsychotics.
Results: Clinical indicators suggestive of reduced activity of plasmin-
ogen activators/plasmin, highly prevalent among schizophrenics, in-
cluded: a history of ischemic stroke <50 years or deep-venous
thrombosis (14% versus 2% of controls), severe dysmenorrhea during
early adolescence (50% versus 12%), and any stillbirth or preterm delivery
due to severe placental insufficiency in psychotropic-naïve women (50%
versus none). All but three patients had positive laboratory markers
(1–6, mean 2.1), including persistent antiphospholipid antibodies, usually
lupus anticoagulant or IgM anticardiolipin antibody in medium/high titer
(30% versus none); low free-protein S (22% versus none, range 32–66%);
>20% increase in fasting insulinemia with normal glucose levels (44%
versus 11%, range 13.8–119 mcU/mL); >20% increase in homocysteine
levels (27% versus 5%, range 13.6–59 mcmol/L); and a PAI-1 4G allele
(60% versus 48%). Of the hyperhomocysteinemic patients, 25% had two
or more alleles of the methylenetetrahydrofolate reductase C677T or
A1298C polymorphisms. Schizophrenics studied during acute episodes
and refractory patients exhibited the highest number of laboratory
markers. Non-significant variables were: heterozygous prothrombin
G20210A (2% versus 1%), heterozygous factor V Leiden (3% versus 2%),
antithrombin III and protein C deficiency (not detected).
Conclusion: Our findings suggest that protocols aiming at normalizing
plasminogen activators/plasmin activity may offer new pharmacological
tools for treating schizophrenia (Faperj E.26/110.643/2012).
Policy of full disclosure: None.
P-25-023 Sustained psychosis remission with warfarin therapy
S. Hoirisch-Clapauch1, A. E. Nardi2. 1Rio de Janeiro, Brazil; 2Institute of
Psychiatry, Federal University, RJ, Rio de Janeiro, Brazil
Objective: To explain why five patients with schizophrenia or schizoaffec-
tive disorders (DSM-IV) and recurrent deep vein thrombosis attained re-
mission of psychotic symptoms after months on warfarin therapy and
remain free of psychotropic medication from 2–11 years. None of these
patients displayed any ischemic brain injury on neuroimaging studies.
Methods: The model that better explains the reduction of hippocampal
volume, commonly seen in patients with schizophrenia and schizoaffec-
tive disorders, includes a trigger and a predisposing condition. The trigger
is exemplified by illicit drugs or traumatic events that promote release of
substances harmful to the neurons, such as glucocorticoids or noradrena-
lin. Predisposing factors comprise inherited or acquired factors that may
impair hippocampal neurogenesis or neuronal plasticity. The Medical
Subject Headings hippocampus AND “neuronal plasticity” OR neurogen-
esis were entered in Pubmed with every component of the coagulation
and fibrinolytic pathways to search for proteins capable of preventing
thrombotic events and also of mediating hippocampal regeneration.
Results: The search yielded only one match: tissue-plasminogen acti-
vator (tPA). Clot-buster tPA is involved with synaptic remodeling, neuro-
nal plasticity and hippocampal neurogenesis required for brain repair
after stress. All five patients had more than one thrombophilia diagnosis
associated with reduced activity of tPA, including fasting hyperinsuline-
mia, hyperhomocysteinemia, prothrombin G20210A polymorphism,
PAI-1 4G allele or antiphospholipid antibodies, such as a strong lupus
anticoagulant. Biochemical abnormalities seen in schizophrenia and re-
lated to low tPA activity include: deficient dopamine transmission at D1
receptors in the prefrontal cortex, impaired cleavage of brain-derived neu-
rotrophic factor precursor (pro-BDNF) to antiapoptotic mBDNF, abnor-
mal N-methyl-D-aspartate receptor-mediated signaling, reduced Akt
phosphorylation, and abnormal activation of reelin. An increased preva-
lence of both thromboembolic and psychotic events is seen in conditions
characterized by low tPA activity, such as the puerperium, confinement
and chronic inflammatory disorders. Warfarin increases tPA levels.
Conclusion: Our findings suggest that normalization of tPA activity
may provide a new strategy for the treatment of schizophrenia.
Policy of full disclosure: None.
P-25-024 Contributions of medial prefrontal cortex and
dorsomedial striatum to working memory capacity in rats
J. Howland1, D. Davies1, Q. Greba1, J. Selk1, F. Syed1. 1University of
Saskatchewan, Saskatoon, SK, Canada
Objective: Working memory enables storage and manipulation of
information necessary for higher order cognition and is disrupted in
psychiatric disorders such as schizophrenia. Capacity, one facet of
working memory, has been identified as requiring more basic research
before being included in the translational battery of the Cognitive
Neuroscience Treatment Research to Improve Cognition in
Schizophrenia (CNTRICS) initiative. Working memory capacity is often
assessed by measuring the span or number of stimuli that can be retained
in working memory. The objective of the present experiments was to test if
temporary inactivation of medial prefrontal cortex (mPFC) or dorsomedial
striatum (dmSTR) reduced working memory capacity using an odor span
task (OST) in rats.
Methods: Male Long Evans rats were trained to perform the OST.
Briefly, the task requires rats to remember an increasing span of different
odors to receive food reward using a serial delayed non-matching to sam-
ple procedure. Following training, rats were implanted with cannulae
dorsal to the mPFC and dmSTR. The rats were then tested on the OST fol-
lowing infusions of either saline or the GABA receptor agonists muscimol
and baclofen into the mPFC (bilateral), dmSTR (bilateral), or a unilateral
infusion into each area in opposite hemispheres (disconnection procedure)
in a counterbalanced order.
Results: Rats showed average spans between 8 and 12 odors at the end
of training and following saline infusions. Temporary inactivation of
either the mPFC (2.67 odors) or dmSTR (5.64 odors) profoundly impaired
performance of the task only on the day of infusion. Critically, the
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disconnection procedure also significantly reduced odor span (1.74 odors).
Latency to retrieve the food reward during the task was not affected by
any of the treatments.
Conclusion: These data define a neural circuit including the mPFC and
dmSTR that supports odor span capacity in rats.
Policy of full disclosure: None.
P-25-025 NS1738, a positive allosteric modulator of Alpha7
nicotinic receptors, as adjunctive treatment in
schizophrenia. An experimental study
K. Jardemark1, Å. Konradsson-Geuken2, K. Feltmann2, V. Ivanov2,
B. Schilström2, M.M. Marcus2, T. Svensson1. 1Karolinska Institutet,
Department of Physiology and Pharmacology, Stockholm, Sweden; 2Sweden
Objective: Preclinical and clinical studies with α7 nicotinic acetylcholine
receptor (nAChR) agonists show promising results for the treatment of
cognitive deficits in schizophrenia, but positive allosteric modulators
(PAMs) of the α7 nAChR may provide a rational alternative. Here we
examined in the rat, the effects of the α7 PAM NS1738 on brain dopami-
nergic and noradrenergic cell firing and cognitive functioning. Adjunctive
treatment with NS1738 to risperidone was examined for antipsychotic
efficacy and effects on cortical glutamatergic NMDA receptor-mediated
neurotransmission.
Methods: We examined antipsychotic efficacy using the CAR test, the
effect on cognition using the novel object recognition (NOR) test, the effect
on cell firing in the ventral tegmental area (VTA) and locus coeruleus (LC)
using extracellular single-cell recording in vivo and the effects on NMDA
receptor-mediated currents in pyramidal neurons in the medial prefrontal
cortex (mPFC) using intracellular electrophysiological recording in vitro.
Results: NS1738 increased both firing rate (0.1 mg/kg i.v.) and in par-
ticular burst firing (0.05–0.1 mg/kg i.v.) of dopaminergic cells in the
VTA, whereas no effect was seen on noradrenergic cells in the LC.
Furthermore, NS1738 (1mg/kg s.c.) significantly improved recognition
memory. Addition of NS1738 (1mg/kg s.c.) to a low dose of risperidone
(0.25 mg/kg i.p.) enhanced the antipsychotic-like effect in the CAR
model. Whereas neither risperidone (10 nM) nor NS1738 (500 nM) pro-
duced any effect when administered alone, the combination potentiated
NMDA-induced currents in pyramidal cells in the mPFC.
Conclusion: The present results propose that in combination with an α7
PAM, a dose reduction of antipsychotic drugs such as risperidone may
be achieved, yet with maintained antipsychotic effect. Moreover, the com-
bination of NS1738 and risperidone in concentrations which were ineffec-
tive when given alone, enhanced cortical glutamatergic NMDA
receptor-mediated transmission, an effect which may contribute to im-
prove cognition and negative symptoms.
Policy of full disclosure: Grants/research support of Torgny
H. Svensson: The Swedish Research Council, The Karolinska Institutet,
Stockholm (Sweden), The Brain Foundation (Sweden), AstraZeneca,
Organon, Schering-Plough, Merck Sharp and Dome, Lundbeck, Otsuka,
Astellas; Consultant/advisory board: AstraZeneca, Janssen, Lundbeck,
Otsuka, Merck Sharp and Dome, Organon, Pfizer, Carnegie Health Care
Funds (Sweden).
P-25-026 Association between FAT gene and schizophrenia in the
Korean population
Y.-E. Jung1, T.-Y. Jun2. 1Jeju National University, Jeju, Republic of Korea;
2The Catholic University of Korea, Seoul, Republic of Korea
Objective: The aim of this study was to investigate the genetic association
of the FAT gene with schizophrenia in the Korean population, as well as
analyzing the association of FAT gene with clinical variables.
Methods: Four variants within the FAT gene were investigated in 189
patients with schizophrenia and 119 healthy controls(rs2306987 A/C,
rs2306990T/C, rs2637777 G/T, and rs2304865 G/C).
Results: Significant association at the rs273777 with schizophrenia was
observed; however, rs2306987, rs2306990, and rs2304865 were not asso-
ciated with schizophrenia. Haplotype analyses revealed that the haplo-
type A/T/T/G was associated with a significantly protective effect.
Sliding window analysis (rs2637777 G/T and rs2304865 G/C) revealed
the more common T/G haplotype, included in the A/T/T/G protective
combination, showed a small protective effect, in particular the effect was-
due to the rs273777T variant (minor allele).
Conclusion: The present finding suggests that FAT polymorphism may
play a putative role in the susceptibility to schizophrenia in the Korean
population. Further studies using a larger number of subjects should be
performed to determine whether the FAT gene polymorphism may be
truly involved in the development of schizophrenia.
Policy of full disclosure: None.
P-25-027 Disturbance of facial mimicry in schizophrenia
K. Kim1, G. Ju1, J. W. Son1, S. I. Lee1, C. J. Shin1, S. K. Kim1, H.-R. Ghim1,
J.-S. Eom1, E. Moon1, Y. O. Park1, Y.-U. Cheon1. 1Chungbuk National
University Hospital, Chungcheongbuk, Republic of Korea
Objective: Emotional facial expression is an important mechanism con-
tributing to the experience of empathy, identified as a key predictor of
social function. Although the existence of empathy dysfunction in schizo-
phrenia is generally accepted, direct evidence exists very limitedly. The
aim of this study was to evaluate the disturbance of empathy through
rapid facial mimicry by using electromyography.
Methods: 25 patients with schizophrenia were enrolled in the study.
They were presented with stimuli portraying happy, angry, sad facial
expressions. Participants were requested to recognize the stimuli while
electromyographic activities of corrugator, zygomaticus muscles were
recorded. The EMG activity and heart rate were compared with those of
24 control subjects matched for age, duration of education, IQ and gender.
Empathic abilities of the participants were assessed with the empathy
contagion scale and interpersonal reactivity index. A neuropsychological
battery, including positive and negative syndrome scale, the Korean –
Weschler adult intelligence scale was also administered.
Results: There was no significant difference in any of the demographic
variables of the two groups. The patients with schizophrenia had a sign-
ificant deficiency in empathy based on the IRI and the EC. The healthy
control group displayed a distinct pattern of EMG responding consistent
with a typical mimicry response such as greater zygomaticus activity in
response to happy faces, and greater corrugator activity to angry and
sad faces. In contrast to controls, schizophrenia patients did not show elec-
tromyographic response to happy, angry, sad facial expressions. The ac-
tivity of zygomaticus muscle was negatively correlated with personal
distress in angry face, and positively correlated with personal distress in
happy face. A negative correlation was observed between PANSS score
and EC.
Conclusion:We could identify that schizophrenia patients are impaired
in capacity of facial mimicry, as indicator of affective empathy in both
positive and negative emotions. These results suggest that a considerable
proportion of decreased facial mimicry in schizophrenia might be
influences to social interaction.
Policy of full disclosure: None.
P-25-028 Associations of obsessive-compulsive symptoms with
clinical features and neurocognitive functioning in
patients with schizophrenia according to the stage of
illness
S.-W. Kim1, B.-O. Jeong1, J.-M. Kim1, I.-S. Shin1, Y.-H. Lee2, M. Hwang3,
M. Berk4, P. McGorry5, J.-S. Yoon1. 1Chonnam National University,
Gwangju, Republic of Korea; 2St. John Hospital, Gwangju, Republic of Korea;
3New York, USA; 4Geelong, Australia; 5Melbourne, Australia
Objective: To investigate the associations of comorbid obsessive#compul-
sive symptoms (OCS) with neurocognitive functioning and psychopath-
ology in people with schizophrenia according to stage of illness.
Methods: A total of 163 people with schizophrenia who were receiving
risperidone monotherapy were enrolled. Comorbid OCS were assessed
using the Yale#Brown Obsessive Compulsive Scale (YBOCS), and subjects
with a score of 10 or higher constituted the OCS group. Neurocognitive
functioning, psychopathology, and quality of life were compared accord-
ing to the presence of OCS in the total population and among populations
with<5 and #5 years of illness duration.
Results: A total of 30 patients (18.4%) had OCS. In the early-stage
group (duration of illness<5years), the learning index on the verbal learn-
ing test was significantly higher in the OCS than in the non-OCS group. In
the chronic-stage group (duration of illness#5 years), the backward digit
span was significantly lower in the OCS than in the non-OCS group.
In both stages of illness groups, scores on positive and general psycho-
pathology subscales and total Positive and Negative Syndrome Scale,
Calgary Depression Scale for Schizophrenia, and Beck Depression
Inventory scores were significantly higher in the OCS than the non-OCS
subgroup. Additionally, the Subjective Well-being under Neuroleptic
Treatment-Short Form score was significantly lower in the OCS than in
the non-OCS group.
Conclusion: The relationship between OCS and neurocognition in
patients with schizophrenia is dependent on stage of illness. However,
schizophrenia patients with OCS had greater psychotic and depressive
symptoms and poorer quality of life regardless of illness stage.
Policy of full disclosure: This work was supported by a grant
(CRI10012-1) of the Chonnam National University Hospital Research
Institute of Clinical Medicine. Data collection was supported in part by
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investigator-initiated grants from Korea Otsuka Pharmaceutical,
Sanofi-Aventis Korea, and Janssen Korea. The funding sources had no
further role in study design; in the analysis and interpretation of data;
in the writing of the manuscript, and in the decision to submit the article
for publication.
P-25-029 Comparison of attitudes toward long-acting injectable
antipsychotics among psychiatrists and patients
S.-W. Kim1, Y.-H. Lee2, J.-E. Jang1, T. Yoo1, J.-M. Kim1, I.-S. Shin1,
J.-S. Yoon1. 1Chonnam National University, Gwangju, Republic of Korea;
2St. John Hospital, Gwangju, Republic of Korea
Objective: The current prescription rate of long-acting injectable antipsy-
chotics (LAI) is <1% in Korea. This study aimed to investigate the reason
for LAI underuse by surveying the attitudes toward LAI among psychia-
trists and patients receiving LAI.
Methods: A total of 173 psychiatrists and 99 patients receiving LAI
participated in the survey. Participating psychiatrists were divided into
two groups according to experience with prescribing LAI to at least 10
patients.
Results: The two psychiatrist groups did not differ significantly in
terms of sociodemographic characteristics and clinical practice patterns.
However, the group with higher experience more frequently provided
explanations regarding LAI to their patients and was more satisfied
with the use of LAI than the group with less experience. Acceptance
rates of patients to the recommendation for LAI treatment and satisfaction
of psychiatrists with the outcome of LAI were also significantly higher in
the group with higher experience. Psychiatrists with less experience with
LAI were more negative toward LAI than patients receiving LAI as well as
psychiatrists with higher experience.
Conclusion: Attitudes of psychiatrists toward LAI were closely related
to the use of LAI. The negative attitude and reluctance of psychiatrists,
rather than patient resistance, may contribute to the underuse of LAI.
To enhance the use of LAI, more information based on scientific evidence
should be provided to psychiatrists to reduce their prejudice against LAI,
and the positive experiences of both patients receiving LAI and colleagues
should be shared with them.
Policy of full disclosure: This study was supported in part by an
investigator-initiated grant from Janssen Korea Co. Ltd. The funding
source had no further role in study design; in the analysis and interpret-
ation of data; and in the decision to submit the article for publication.
Representatives of the company were allowed to comment on the report,
but the final approval of content was retained by the investigators
exclusively.
P-25-030 Effects of antipsychotic drugs on the expression of
synapse-associated proteins in the frontal cortex of rats
subjected to immobilization stress
Y. H. Kim1, S.W. Park2, Y. S. You1, C. H. Lee2, M. K. Seo2, H. Y. Jo2,
J. G. Lee1, B. J. Lee1, J. H. Baek1, S. J. Lee1. 1Haeundae Paik Hospital, Busan,
Republic of Korea; 2PICR, Inje University, Busan, Republic of Korea
Objective: Regulation of synaptic plasticity has been implicated in the
cognitive impairment and treatment of schizophrenia. The present study
examined the effects of three antipsychotic drugs, olanzapine, aripipra-
zole, and haloperidol, on the expression of synapse-associated proteins
in the frontal cortex of rats with and without immobilization stress.
Methods: Rats were subjected to immobilization stress 6 h/day for
3 weeks. The effects of two atypical antipsychotic drugs, olanzapine
(2mg/kg) and aripiprazole (1.5 mg/kg), on expression of serine9-
phosphorylated GSK-3 beta, Beta-catenin, BDNF, PSD-95, and synapto-
physin were determined by Western blotting. A typical antipsychotic
drug, haloperidol (1.0 mg/kg), was used for comparison.
Results: Immobilization stress significantly decreased the expression
of phosphorylated GSK-3 beta, Beta-catenin, BDNF, PSD-95, and synapto-
physin in the frontal cortex (all p<0.01). Chronic administration of
olanzapine and aripiprazole significantly attenuated the immobilization
stress-induced decrease in the levels of these proteins (p<0.05 or
p<0.01), whereas chronic administration of haloperidol did not in this
regard. Additionally, chronic administration of olanzapine (p<0.05) and
aripiprazole (p<0.01) significantly increased levels of phosphorylated
GSK-3 beta under normal conditions without stress, and chronic adminis-
tration of aripiprazole also increased BDNF levels under this condition
(p<0.01).
Conclusion: These results indicate that two atypical antipsychotics,
olanzapine and aripiprazole, and one typical one, haloperidol, differen-
tially regulate the levels of synapse-associated proteins in the rat frontal
cortex. These findings may contribute to neurobiological basis of how
olanzapine and aripiprazole improve the cognitive symptoms of patients
with schizophrenia by suggesting that their mechanism of action involves
up-regulation of synapse-associated proteins.
Policy of full disclosure: None.
P-25-031 Effect of add on aripiprazole on antipsychotic induced
hyperprolactinemia
V. Kumar Kg1, G. Venkatasubramanian1, S. Varambally1. 1NIMHANS,
Bengaluru, India
Objective: To study the effect of add on aripiprazole on antipsychotic
induced hyperprolactinemia in patients with schizophrenia/Bi Polar
Affective Disorder (BPAD).
Methods: In patients of schizophrenia/BPAD, with clinically suspected
antipsychotic induced hyperprolactinemia, serum prolactin levels were
measured. For patients who had higher serum prolactin levels (N-10) tab-
let aripiprazole was added and subsequently serum prolactin levels were
repeated over next few months. Standardized mean difference between
serum prolactin levels before and after aripiprazole was calculated, with
a 95% confidence limit interval.
Results: Aripiprazole had statistically significant effect on reducing the
serum prolactin levels [Pre 89.55 ng/ml (SD: 56.42 ng/ml); post 36.42 ng/ml
(SD: 24.44 ng/ml; t-3.950; SD: 42.52 ng/ml; p<0.005)] in patients with anti-
psychotic induced hyperprolactinemia on paired sample T test.
Conclusion: Aripiprazole is efficacious in treating antipsychotic
induced hyperprolactinemia. Results have to be repeated in studies with
larger sample size.
Policy of full disclosure: None.
P-25-032 Treatment patterns of long-acting injectable
antipsychotics in the province of quebec
J. Lachaine1, M.-E. Lapierre1, N. Abdalla2, A. Rouleau3, E. Stip4.
1University of Montreal, Montreal, Canada; 2Lundbeck Canada, Montreal,
Canada; 3Lundbeck France, Issy-les-Moulineaux, Paris, France; 4CR-CHUM,
University of Montreal, Montreal, Canada
Objective: The objective of this study was to assess the treatment patterns
of long-acting injectable antipsychotics (LAI-AP), notably in terms of
treatment persistence and compliance, in a real life setting, using the prov-
incial public drug reimbursement program database of the Régie de l#as-
surance maladie du Québec (RAMQ).
Methods: Patients with a diagnosis of schizophrenia/schizoaffective
disorder, who were incident users (no use in the previous 12 months) of
a LAI-AP prescribed between January 1st 2008 and March 31st 2012, at
least 20 years old, and with continuous enrolment in the database during
the study period were selected. Concomitant use of oral antipsychotics
and treatment adherence with LAI-AP were analyzed. Persistence was
estimated in terms of treatment duration. Compliance was calculated
during the year after the initiation of the LAI-AP using the medication
possession ratio (MPR). Patients were considered compliant if they had
a MPR of at least 0.80. Treatment compliance to oral antipsychotics
used in the year prior the initiation of the LAI-AP was also evaluated.
Results: A total of 1,992 patients met the inclusion criteria. The mean
age was 43.5 years (SD=14.3) and 66.2% of the patients were male. A
total of 546 patients (27.4%) received an oral antipsychotic at the first
date of dispensation of LAI-AP. The average persistence with LAI-AP
was 217.2 days (SD=144.2). The mean MPR over the one-year period
following the initiation of LAI-AP was 0.58 (SD=0.35) for the overall co-
hort. 37.5% of patients were compliant, with a MPR of 0.80 or more,
while in the year before the initiation of LAI-AP, the compliance with
oral antipsychotics was 29.0% (p<0.001).
Conclusion: Treatment persistence and compliance represent signifi-
cant issues in the treatment of schizophrenia/schizoaffective disorders.
The initiation of a LAI-AP significantly improved treatment compliance
versus oral antipsychotics among these patients.
Policy of full disclosure: This study was supported by Lundbeck.
P-25-033 Healthcare costs before and after initiation of long-acting
injectable antipsychotics in the province of Quebec
J. Lachaine1, M.-E. Lapierre1, N. Abdalla2, A. Rouleau3, E. Stip4.
1University of Montreal, Montreal, Canada; 2Lundbeck Canada, Montreal,
Canada; 3Lundbeck France, Issy-les-Moulineaux, Paris, France; 4CR-CHUM,
University of Montreal, Montreal, Canada
Objective: The purpose of this study was to describe the resource use be-
fore, and after, initiation of long-acting injectable antipsychotics (LAIAP)
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using the provincial public drug reimbursement program database of the
Régie de l’assurance maladie du Québec (RAMQ).
Methods: Patients who were incident users (no use in the previous
12 months) of a LAIAP prescribed between January 1st 2008 and March
31st 2012, at least 20 years old, with a diagnosis of schizophrenia/schizoaf-
fective disorder and with continuous enrollment during the study period
were selected. Resource utilization and associated costs were analyzed
both during the year before LAIAP initiation (preinitiation period) and
the year after (postinitiation period).
Results: A total of 1992 patients met the inclusion criteria. The average
age was 43.5 years (SD=14.3). In pre-initiation period, 1484 patients had
at least one hospitalization, compared to 958 in post-initiation period
(p<0.001), and the number of days hospitalized was reduced by half
(40 days [SD=40] vs. 21 days [SD=30]; p<0.001). The number of patients
having at least one emergency room visit decreased from 1372 to 813
patients (p<0.001), but the number of patients with at least one outpatient
clinic visit increased from 1572 to 1726 patients (p<0.001). The pre-
initiation inpatient costs were CDN$21312 (SD=27303), compared to
CDN$7199 (SD=16419) in post-initiation period (p<0.001). The outpatient
costs were CDN$1209 (SD=1173) during the pre-initiation period, and
CDN$1296 (SD=1284) in the post-initiation period (p=0.002), while cost
of medication were CDN$1861 (SD=2515) vs. CDN$4595 (SD=3910)
(p<0.001). Total cost of health care resource, including LAIAP, were
CDN$24382 (SD=27234) in the pre-initiation period, compared to CDN
$13090 (SD=16987) in the post-initiation period (p<0.001).
Conclusion: The initiation of LAIAP resulted in significantly lower
health care resource and cost reduction, with the primary driver being a
reduction in number of hospitalizations, days of hospitalization and visits
to the emergency room.
Policy of full disclosure: This study was supported by Lundbeck.
P-25-034 Improvement on dyslipidemia and negative symptoms by
ziprasidone augmentation in clozapine-resistant patients
with schizophrenia
H.-B. Lee1, S.-J. Yim1, M. Sim1, H.-K. Kang1. 1Seoul National Hospital, Seoul,
Republic of Korea
Objective: The object of this study was to evaluate the effectiveness of
ziprasidone as an augmentation agent for improving dyslipidemia, psy-
chotic symptoms, and functional outcome in clozapine-resistant patients
with schizophrenia.
Methods:A6-month, prospective, open-label clinical trialwas conducted
in clozapine-resistant patientswith schizophrenia. In every enrolledpatient,
ziprasidone was added-on to clozapine while maintaining or reducing the
daily doses of clozapine during the study period. Dyslipidemia-improving
effects were assessed by the mean changes in fasting triglyceride (TG),
HDL-cholesterol, and TG to HDL cholesterol ratio(TG/HDL-C).
Symptomatic improvement was measured by the mean change of BPRS
scores. Improvement in functional outcome was assessed using GAF and
PSP sclae.
Results: 48 patients were enrolled (mean aged 42.5±7.5 years; 31.3%
women; mean clozapine dose of 431.3±107.0mg/day) and 39 patients
completed this study. The mean augmented dose of ziprasidone was
108.3±43.6 mg/day. Daily dose of clozapine was reduced to 84.5% from
the baseline dose in 20 patients, whereas 28 patients maintained the
same dose of clozapine. There were significant improvements in lipid
profile, with mean changes of −73± mg/dL in fasting TG and 2.25± in
TG/HDL-C, in particular patients with metabolic syndrome at baseline
(p=0.005). These changes in fasting TG and TG/HDL-C were consistent re-
gardless of whether the daily dose of clozapine was reduced or not. The
mean change in BPRS scores was −6.2±5.8 (p<0.001). Especially, negative
symptoms and affect subscale scores were much more improved; in conse-
quence, functional outcome was improved as well.
Conclusion: Ziprasidone is suggested as a suitable agent for augmen-
tation in clozapine-resistant patients with schizophrenia, in particular
those with insulin resistance and dyslipidemia. Additionally, ziprasidone
augmentation of clozapine appears to be safe and effective in improving
negative-affect symptoms and functional outcome.
Policy of full disclosure: None.
Comparison of the changes in TG to HDL-cholesterol ratio over
6months between patients who reduced daily dose of clozapine and
patients who maintained the same dose of clozapine with a separate
analysis for patients with MetS and patients without MetS at:
P-25-035 Metabolic syndrome and its impact on health related
quality of life and body image in Korean patients with
schizophrenia
S. Y. Lee1, S. K. Chung2. 1Wonkwang University Hospital, Iksan, Republic of
Korea; 2Chonbuk National Univerity, Hosptial, Jeonju, Republic of Korea
Objective: The use of antipsychotic drugs led to an unequivocal improve-
ment in the medical treatment of schizophrenia. However, treatment with
these drugs is associated with important side effects such as metabolic
syndrome. Therefore screening and management of metabolic syndrome
are important for quality of life in schizophrenia patients. This study
aimed to study the prevalence of metabolic syndrome and its impact on
health related quality of life (HRQoL) in patients with schizophrenia.
Methods: The subjects were 81 in-patients with schizophrenia who
were diagnosed as schizophrenia by DSM-IV criteria. For each subject,
anthropometric index and laboratory parameters were measured.
Metabolic syndrome defined by NCEP ATP III and HRQoL were mea-
sured by Short-Form 36 Health Survey-Korean (SF-36-K). Body image
was measure by Body Image Index. Statistical analysis was done using
SPSS 12.0 for Window. Statistical significance was set at p<0.01.
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Results: Of patients, 24.7% had metabolic syndrome. Metabolic syn-
drome was associated with long duration of illness. The patients with
metabolic syndrome showed poor QoL., especially role physical and
bodily pain in SF-36-K. Also, the patients with metabolic syndrome had
negative body image, especially body feature, compared to the patients
without metabolic syndrome.
Conclusion: This study suggested that metabolic syndrome is common
among patients with chronic schizophrenia. Also it may lead to lowering
of QoL and deterioration of body image. So, clinicians should be cautions
to aware the increased risk for the metabolic syndrome and intervene ac-
tively to prevent and treat metabolic morbidity among chronic patients
with schizophrenia.
Policy of full disclosure: None.
P-25-036 Effects of environmental context and drug dose on
MK-801 sensitisation in rats
E. Lefevre1, D. Eyles1, T. Burne1. 1Queensland Brain Institute, Brisbane,
Australia
Objective: The behavioural and neurochemical adaptations associated
with N-methyl-D-aspartate (NMDA) receptor antagonist – induced sensi-
tisation are thought to be relevant to the glutamate pathophysiology of
schizophrenia. External factors that modulate sensitisation, including
drug dose and environmental context, have not been addressed in the
MK801 sensitisation rat model. The objective of this study was to deter-
mine the impact of these external factors on MK801 sensitisation.
Methods: The first cohort of Sprague-Dawley rats (n=10/group) was
assigned to one of four dose treatment groups: saline or MK801 (0.1,
0.25 and 0.5 mg/kg). To induce sensitisation rats were administered
7 daily injections of MK801 and a challenge dose of the drug after a
5-day period of abstinence. The second cohort of rats (n=8/group)
received 7 daily injections of MK801 (0.25 mg/kg) in one of two environ-
mental contexts, test or home cage, and was challenged with either
MK801 (0.25 mg/kg) or saline in the test cage. Additionally, we analysed
the protein expression of the NR1, NR2A & 2B NMDA receptor subunits
in the nucleus accumbens, a key region associated with expression of
sensitisation.
Results: MK801 induced sensitisation was significantly affected by
dose (p<0.05), whereby only the intermediary (0.25 mg/kg MK801)
treatment group developed locomotor sensitisation. However, there was
no effect of context on locomotor sensitisation to MK801 (0.25mg/kg).
Furthermore, conditioned locomotion was not evident in rats treated
with MK801 in the test cage and challenged with vehicle. MK801 induced
locomotor activity did not correlate to the protein expression of NR1,
NR2A or 2B subunits.
Conclusion: These results demonstrate that MK801 induced sensitis-
ation is highly dependent on the drug dose but not the environmental
context in which the drug is administered. Future studies aim to elucidate
the role of non-NMDA glutamatergic receptors in MK801 sensitisation,
which may pave the way for a better understanding of glutamates role
in schizophrenia.
Policy of full disclosure: None.
P-25-037 Long-term effectiveness and safety of blonanserin in
patients with first-episode schizophrenia: A one-year
open-label study
T. Tenjin1, S. Miyamoto1, Y. Ninomiya1, N. Miyake1, S. Ogino1,
H. Harada1, Y. Yamashita1, Y. Kaneda2, T. Sumiyoshi3, N. Yamaguchi1.
1St. Marianna University, School of Medicine, Kawasaki City, Kanagawa,
Japan; 2Iwaki Clinic, Anan City, Tokushima, Japan; 3National Center,
Neurology and Psychiatry, Kodaira City, Tokyo, Japan
Objective: Schizophrenia is a chronic and debilitating disorder character-
ized by positive, negative, cognitive, and affective symptoms. The pur-
pose of this study was to evaluate the long-term effectiveness and
safety of blonanserin, a second-generation antipsychotic drug developed
in Japan, in patients with first-episode schizophrenia.
Methods: Twenty-three antipsychotic-naïve patients with first-episode
schizophrenia were treated within an open-label, one-year, rater-blind
prospective trial of blonanserin (2–24mg/day). Clinical evaluations were
conducted at baseline and 2-, 6-, and 12-months after the start of treat-
ment. The main outcome measures were changes in subjective well-being
and subjective quality of life, as assessed by the Subjective Well-being
under Neuroleptic treatment scale Short form-Japanese version
(SWNS-J) and the Schizophrenia Quality of Life Scale-Japanese language
version (SQLS-J), respectively. Secondary outcome measures included
the Positive and Negative Syndrome Scale (PANSS), the Brief
Assessment of Cognition in Schizophrenia-Japanese language version
(BACS-J), laboratory tests, body weight, and extrapyramidal symptoms.
This study protocol was approved by the bioethics committee of
St. Marianna University School of Medicine, and written informed con-
sent was received from all participants.
Results: Fourteen patients (60.9%) completed the study. In the intention
to treat analysis, significant improvements were observed in several sub-
scales on the SWNS-J, SQLS-J, and BACS-J, and in all subscales on the
PANSS. Improvement in depressive symptoms with blonanserin treat-
ment was positively correlated with improvements in subjective well-
being and subjective quality of life, as well as certain domains of cognitive
function. No significant changes were noted for any safety measure dur-
ing the one-year study period.
Conclusion: Blonanserin was well tolerated and effective for the treat-
ment of first-episode schizophrenia in terms of subjective wellness, cog-
nition, and a wide range of pathological symptoms. Thus, blonanserin
may be a promising candidate as a first-line antipsychotic for first-episode
schizophrenia.
Policy of full disclosure: Dr. Tenjin has received speaker’s honoraria
from Dainippon Sumitomo. Dr. Miyamoto has received advisory board
honoraria from Dainippon Sumitomo. Dr. Miyake has received speaker’s
honoraria from Dainippon Sumitomo, Eli Lilly, Mitsubishi Tanabe,
Otsuka, and Yoshitomi. Dr. Sumiyoshi has received advisory board
and/or speaker’s honoraria from Dainippon Sumitomo, Eli Lilly,
Mitsubishi Tanabe, Yoshitomi, and Takeda. Dr. Yamaguchi has received
advisory board and/or speaker’s honoraria from Daiichi Sankyo, Eizai,
Eli Lilly, Janssen, Otsuka, and Takeda. No other authors have any confl-
icts of interest.
P-25-038 Impact of once- versus twice-daily risperidone and
olanzapine dosing on clinical outcomes: Findings from
the catie schizophrenia study
H. Takeuchi1, G. Fervaha1, J. Lee1, O. Agid1, G. Remington1. 1Yeouido
St. Mary’s Hospital, Seoul, Republic of Korea; 2Seoul, Republic of Korea;
3Gyeongju, Republic of Korea; 4Naju, Republic of Korea
Objective: The objective of this study was to evaluate the impact of once-
vs. twice-daily dosing of risperidone and olanzapine on clinical outcomes
in patients with schizophrenia.
Methods: Data from phase 1 of the Clinical Antipsychotic Trials
of Intervention Effectiveness (CATIE) schizophrenia study were used
in this post hoc analysis. Patients with schizophrenia (DSM-IV) were
randomly allocated to treatment with risperidone (1.5–6.0 mg/day) or
olanzapine (7.5–30mg/day), and were also randomly assigned to once-
daily (N=173 or 169, respectively) or twice-daily (N=168 or 167, respect-
ively) dosing and followed over 18 months. Discontinuation rate and time
to discontinuation were used as primary outcome measures to compare
the two groups. The following secondary outcome measures were also
analyzed; efficacy: symptoms and quality of life, safety: extrapyramidal
symptoms, body weight, and adverse events, other: medication adher-
ence, attitude toward medication, and concomitant psychotropic
medications.
Results: We found no significant difference in discontinuation rates
and time to discontinuation between once- and twice-daily dosing
groups (P>0.05) in total patients receiving risperidone and olanzapine,
or patients receiving risperidone or olanzapine. Once-daily dosing
group demonstrated significantly lower mean daily doses of risperidone
and olanzapine across phase 1 (P=0.046 and 0.003, respectively), and a
lower rate of sleepiness in total patients (P=0.004) compared to twice-
daily dosing group. No significant differences were found in any other
outcome measures between once- and twice-daily dosing groups in total
patients.
Conclusion: We found no differences in effectiveness and efficacy out-
comes between once- and twice-daily dosing for risperidone and olanza-
pine. However, in view of the lower mean dose and better side effect
profile, it may be advisable to adhere to a once-daily dosing regimen.
Policy of full disclosure: Dr. Takeuchi has received fellowship grants
from CAMH foundation, the Japanese Society of Clinical
Neuropsychopharmacology, and Astellas Foundation for Research on
Metabolic Disorders, speaker’s fees from Dainippon Sumitomo Pharma,
Eli Lilly, GlaxoSmithKlein, Janssen Pharmaceutical, Meiji Seika Pharma,
and Otsuka Pharmaceutical, and manuscript fees from Dainippon
Sumitomo Pharma within the past 5 years. Mr. Fervaha has no competing
interests to disclose. Dr. Lee has received consultant fee from Roche within
the past 5 years. Dr. Agid has received speaker’s honoraria from, Eli Lilly,
Janssen-Ortho (Johnson & Johnson), Lundbeck, Novartis, Sepracor Inc.
US., and Sunovion, and consultant fees from BMS, Eli Lilly,
Janssen-Ortho (Johnson & Johnson), Lundbeck, Novartis, Otsuka, Roche,
Sepracor, and Sunovion, and research support from Janssen-Ortho
(Johnson & Johnson), Otsuka, and Pfizer, Inc. within the past 5 years.
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Dr. Remington has received research support from Novartis, Medicure,
and Neurocrine Bioscience, consultant fees from Roche, and speaker’s
fees from Novartis. He holds no commercial investments in any pharma-
ceutical company within the past 5 years.
P-26. Post-traumatic stress disorders
P-26-001 Atypical antipsychotics in the treatment of posttraumatic
stress disorder
W.-M. Bahk1, H. R. Wang2, Y. S. Woo2, K. H. Lee3, B.-H. Yoon4. 1Yeouido
St. Mary´s Hospital, Seoul, Republic of Korea; 2Seoul, Republic of Korea;
3Gyeongju, Republic of Korea; 4Naju, Republic of Korea
Objective: This study reviewed extant published articles on the efficacy
and safety of atypical antipsychotics for the treatment of posttraumatic
stress disorder.
Methods: We performed a literature search using PubMed, EMBASE,
and the Cochrane database in January 2013. Selection criteria for this re-
view included prospective, controlled studies using validated rating scales
of posttraumatic stress disorder symptoms in the management of post-
traumatic stress disorder.
Results: A total of 12 prospective, controlled studies were included in
this review. This review found that atypical antipsychotics are effective
and safe in treating posttraumatic stress disorder, even though there
were some negative findings. In particular, atypical antipsychotics also
seem to be effective in treating anxiety, depression and psychotic symp-
toms frequently accompanied by PTSD.
Conclusion: This review found that atypical antipsychotics appeared
to be effective and tolerable in the management of PTSD, even though
the evidence was limited.
Policy of full disclosure: None.
P-26-002 Association between D2 Dopamine Receptor(DRD2)
gene and posttraumatic stress disorder
H. Chung1, T. Kim1, J. Choi1, H. So1, S. Kang1. 1VHS Medical Center, Seoul,
Republic of Korea
Objective: Evidences from recent studies support the role of a genetic
factor in Posttraumatic Stress Disorder (PTSD) development. The first
aim of this study is to investigate the association between Dopamine D2
receptor (DRD2) TaqI A polymorphism and PTSD. The second aim is to
examine the association between DRD2 TaqI A polymorphism with clini-
cal symptoms in PTSD.
Methods: 189 Vietnam veterans were collected for this study, among
whom 99 were PTSD patients and 90 were control subjects. DRD2 TaqI
A polymorphism were determined by PCR method. Several standardized
research scales were used for the clinical assessment of PTSD, including
the combat exposure scale (CES), clinician administered PTSD scale
(CAPS), Beck depression inventory(BDI), clinical global impression (CGI).
Results: In this study, the PTSD patients were not significantly different
from the controls in respect to the DRD2 genotype distribution, the fre-
quency and prevalence of A1 allele, or the frequency of heterozygotes.
In PTSD patients, patients group with A1 allele (A1A1, A1A2) had higher
scores for the total CAPS score (p=0.044), avoidance symptoms score of
CAPS (p=0.016) and BDI (p=0.024) than those without A1 allele (A2A2).
Conclusion:We couldn’t find association between Dopamine D2 recep-
tor (DRD2) TaqI A polymorphism and PTSD. But A1 allele of DRD2 seem
to have influence on avoidance symptoms in PTSD patients.
Policy of full disclosure: None.
P-26-003 PTSD, outcome and its up to date treatments
H. Rabbani. Paris, France
Objective: Based on our teaching experiences, observations and clinical
researches in the Mental Health Center, we present the psychopathologi-
cal and psycho-social effects of post-traumatic stress disorder (PTSD)
(caused by wars or catastrophic stressful life events) then its different
methods of treatment.
Methods: Since world war II, large studies were made in France, USA,
Canada and in some other European countries by researchers (Goldberger
L. 1982, Lazarus R.S. 1985, Lomranz J.1990 and others) on this area.
Recently the study of PTSD has become one of the principal themes of
congresses.
Results: The therapy of the patients, particularly women (Rabbani
H. San Francisco 1998) in some cases: eg. divorce, forced immigration,
(Rabbani H. 1991) and separation or faced to the catastrophic events
(human or natural) and suffering from depression and trauma, is not so
easy. In one side, the medical and psycho pharmacotherapy (antidepres-
sants with their chemical substances), and psychosocial treatments:
music, occupational therapy, sports, physical activities etc. on the other
side, are recommended. Today, depression and trauma resulting from
many factors (Rabbani H. Salpêtrière 2007) are widespread in the world.
Alas! because of so many reasons: sociopolitical and environmental
changes, acts of terrorism, injustice, wars and violence (Rabbani H.
Istambul 2003 Mc Gill 2012) etc. there is likelihood that the frequency of
anxiety, depression and trauma will increase in the future. The efficiency
of some antidepressants such as imipramine, paroxetine (Rabbani H. 2008
Munich) and others (eg. antidepressant properties of ketamine) recently
presented by H. Lôo R. Gaillard et al 2014, is well established; however,
medical treatment, in spite of its side effects, as indicated also several
authors (Stein H.B. et al 2002, Gourion D. et al 2007) is pertinent.
Conclusion: Meanwhile, in parallel of medical and pharmacotherapy,
we must note that the psychosocial and family cares in collaboration
with psychologists and social workers can be more efficient in reduction
or improvement of PTSD.
Policy of full disclosure: None.
P-26-004 The effect of early post-stressor intervention with
agomelatine on behavioral and molecular responses in
an animal model of post-traumatic stress disorder
J. Zohar1, H. Cohen1. 1Chaim Sheba Medical Center, Tel Aviv, Israel
Objective: Long-term behavioral, molecular and morphological
effects of agomelatine, a melatonergic agonist (MT1/MT2) and 5HT2C
antagonist with antidepressant and anxiolytic and re-synchronizing
effects were assessed in an animal model of posttraumatic stress disorder
(PTSD).
Methods: Adult male Sprague-Dawley rats were exposed to the pred-
ator scent stress (PSS) (10min), and 1 h later treated acutely with agome-
latine (50 mg/kg i.p.) or vehicle on Day1 (D1). Rats were assessed in the
Elevated plus-maze (EMP) and acoustic startle response (ASR) on D8,
freezing behavior after situational reminder cue was done on (D9) and
rats were sacrificed 24 h after. Serum corticosterone and the dexametha-
sone suppression test were used to assess the stress response and HPA
axis feedback inhibition. Neurons from hippocampus (CA1, CA3, and
DG) were reconstructed and Sholl analysis and spine density estimation
evaluated. Brain expression of BDNF and Per1, Per2 clock genes was
analysed.
Results: Agomelatine reversed time spent in the open arms (EPM)
decrease and mean startle amplitude increase observed in PPS vehicle-
treated rats. Moreover agomelatine decreases prevalence rates of indivi-
duals displaying extreme behavioural responses (PTSD-like), cue-induced
freezing and PPS#induced corticosterone increases. Agomelatine also nor-
malized BDNF decreases observed in the DG, cortex (layer III), and baso-
lateral amygdala (BLA) of PPS rats. In line with this, agomelatine-treated
stressed animals displayed significantly increased DG and CA1-apical
dendritic length and number and reversed the hippocampal neuronal
retraction observed in PSS vehicle-treated rats. As regards clock genes
expression, agomelatine normalized Per1 increases observed in the CA3,
Suprachiasmatic nucleus (SCN) and BLA of PPS rats and Per2 increases
observed in the CA1, SCN and BLA of PPS rats.
Conclusion: The data provides initial evidence that a single dose of ago-
melatine administered in the acute aftermath of stress promotes recovery
while promoting enhanced neuronal and synaptic plasticity and connec-
tivity in the secondary prevention of PTSD in this model.
Policy of full disclosure: None.
P-27. Neurodegeneration B
P-27-001 Pharmaceutical therapy for behavioral and psychological
symptoms of dementia (BPSD) in inpatients
J. Uno. Fujita Kokoro Care Center, Toyoke Aichi, Japan
Objective: Although Behavioral and Psychological Symptoms of
Dementia (BPSD), such as hallucination, delusion, aggressiveness, dis-
quieting are treated with central symptoms of dysfunction of recognition
by pharmaceutical therapy in dementia, there is few repots of clinical sur-
vey. This article reports the survey of pharmaceutical therapy for BPSD
with inpatients in our hospital and we reexamined the pharmaceutical
therapy in BPSD.
Methods: The patients with dementia (ICD-10: F0) hospitalized at
Okehazama Hospital Fujita Kokoro Care Center between 1/4/2012 and
31/3/2013 were enrolled in the survey. The symptoms of BPSD and the
111P-27. Neurodegeneration B
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
names of the drugs and doses for the treatment of BPSD were studied
from the patient’s case record.
Results: The subjects number (M/F) who were enrolled in the study
were 150 (72/78), and average age was 78.5 (46#99) and average hospita-
lized days were 147(2#3, 516). BPSD were recorded in 64.0% of subjects
and main symptoms were below: agitation, hallucination, abnormal beha-
vior, and resistance. The drugs for the treatment of dementia were pre-
scribed in 31.1% of the subjects and antipsychotics, Yokukansan,
anxiolytics/hypnotics, and mood stabilizers were below: 82.3%, 34.4%,
19.8%, 22.9%, respectively. The prescription rate of antipsychotics were
higher in order: Risperidone>Quetiapine>Olanzapine>Aripiprazole.
Conclusion: The study revealed that about 64.0% in inpatients with
dementia in our hospital have symptoms of BPSD and they have short
hospitalized periods also. If we could control the symptoms of BPSD,
they can leave out the hospital as soon as possible. The main symptoms
of BPSD were agitation, hallucination, abnormal behavior, so the drugs
to treat BPSD were mainly used antipsychotics for the purpose of sed-
ation. As FDA revealed that the use of antipsychotics makes the death
rates higher, we pharmacists engaged in psychiatric care should actively
commit themselves as a professional of drugs to ensuring appropriate pre-
scriptions in order to get maximum merits of antipsychotics.
Policy of full disclosure: None.
P-27-002 Epidemiological and clinical profile of Alzheimer’s
dementia in Upper Egypt
H. El Tallawy1, W. Farghaly1. 1Assiut University, Assiut, Egypt
Objective: Objective of this work was to estimate the prevalence of AD
in Upper Egypt and the associated possible risk factors.
Methods: Subjects and methods: All subjects at the age of 50 years
and more (n=12,508) who have been living in Al Khargah district; New
Valley Governorate (n=8,173 out of 62,583) or Al Quseir city; Red sea
Governorate (n=4,335 out of), for at least 6 months, at the time of inter-
view were included in this study. All inhabitants were screened in a
door to door manner using a short standardized Arabic screening ques-
tionnaire and modified MMSE, by 6 specialists of neuropsychiatry.
Suspected cases were subjected to full clinical examination, psychometric
assessment using the Cognitive Abilities Screening Instrument,
Instrumental Activities of Daily Living Scale, Geriatric Depression Scale,
Hachinski Ischemic Score, DSMIV- TR diagnostic criteria, neuroimaging,
and laboratory investigations when indicated.
Results: One hundred twenty six cases were diagnosed as having
AD with a prevalence rate of 1% for population aged 50 years and
more. It was estimated that 7.9% of the cases were early onset dementia
(<65 years of age), while 92.1% were late onset AD (>65 years). The pre-
valence increased steeply with age to a maximum of 9.74% for those
aged >80 years. It was higher among females (1.265%) than males
(0.93%). Staging of dementia cases revealed that 41.3% of cases are of
mild severity. Probable associated risk factors in order of frequency
were hypertension (14.3%), positive family history of AD (13.5%), smok-
ing (10.3%), diabetes mellitus (8.7%), epilepsy prior to dementia (5.6%).
Among symptomatic presentation impaired self care was recorded
among 88.1% of cases, memory impairment in 84.1%, while behavioral
changes were reported among 48.4%.
Conclusion: Prevalence of AD in Upper Egypt was 1% with more than
40% of cases are of mild severity. Door-to-door survey is the best method
in, developing countries, for early detection of those mild cases.
Policy of full disclosure: None.
P-27-003 Blood endotoxin in patients with AD, acetyl choline
metabolic enzymes, BDNF level changes and significance
of research
B. Han1, F. Wu2, D. Han2, Q. Sun1, X. Shan1. 1The General Hospital of CAPF,
Peking, China; 2Shanxi Medical University, Taiyuan City, China
Objective: Observe whether accompanied by IETM in patients with AD,
further explore AChE, ChAT, and the role of BDNF in AD mechanism,
proved to play an important role in AD. Provide new way for the onset
of the new prevention and treatment of AD.
Methods: Research object and grouping: from August 2011 to October
2012 will conform to the standard of from Department of Outpatient and
Ward of Department of Neurology or Department of Outpatient and
Ward of Department of Psychiatry in Shanxi Province, 70 old people as
the research object, such as divided into AD group and control group.
Neuropsychological tests: MMSE and ADAS-cog. LPS level was detected
by Chromogenic End-point Tachypleus Amebocyte Lysate (CE TAL),
AChE, ChAT and BDNF level was detected by ELISA.
Results: MMSE scores in the AD group were significantly lower than
the control group; ADAS-Cog scores in the AD group was significantly
higher than the control group. LPS levels in AD group was significantly
higher than the control group; AChE levels higher than the control
group, ChAT level significantly lower than the control group; Serum
BDNF levels in AD group was significantly lower than the control
group. The AD group LPS, BDNF, ChAT, and content of AChE after stat-
istical analysis found that the LPS under 0.20 Eu/ml, BDNF, ChAT and
AChE content fell sharply, while LPS above 0.20 Eu/ml, BDNF, ChAT
and AChE content basic similar. By control LPS, BDNF, ChAT and
AChE content statistics analysis, found that among various variables
found no correlation exists between variables.
Conclusion: In the AD patients with IETM. The experiment based
on the research of the AChE, ChAT, BDNF and combining the research
previously of TNF alpha and A beta and Tau protein of observation,
put forward the “IETM may be AD A new risk factor in the process of
happen?” Key words Intestinal endotoxemia; Alzheimer’s disease; LPS;
AChE; ChAT; BDNF.
Policy of full disclosure: None.
P-27-004 Effect of endotoxin on brain cell apoptotic in aging rats
B. Han1, F. Wu2, N. Zhao2, Q. Sun1, X. Shan1. 1The General Hospital of
CAPF, Peking, China; 2Shanxi Medical University, Taiyuan City, China
Objective: To study dyofunction clearing endotoxin and its effect on brain
cells in aging rats.
Methods: Endotoxin and tumor necrosis factor-# content of plasma
were determined in normal and after endotoxin infection of 24 month
old and 6 month old rats. Effect of endotoxin and tumor necrosis factor-#
on free Ca## in brain cells were observed in vitro, and apoptosis of brain
cells were examined by flow cytometer.
Results: The level of endotoxin in plasma were much higher in
24 month old rats than those of 6 month old rats in both normal and
after endotoxin injection groups, buttumor necrosis factor-# was increased
significantly only after endotoxin injection. Tumor necrosis factor-# was
elevated significantly free Ca## in brain cells, and after endotoxin injection
via portal vein apoptosis of brain cells were developed.
Conclusion: Increased plasma endotoxin toxin and tumor necrosis
factor-# in 24 month old rats contributed to elevation of [Ca##]i in brain
cells and apoptosis, and the mechanism might involes changes of brain
microecological environment induced by altered cytokins. [Key words]
Endotoxin; tumor necrosis factor-#;Apoptosis; Rat.
Policy of full disclosure: None.
P-27-005 Effects of IETM on learning memory ability and
hippocampal gene expression of APP and PS1 in rats with
Alzheimer’s disease
B. Han1, F. Wu2, D. Han2, Q. Sun1, X. Shan1. 1The General Hospital of CAPF,
Peking, China; 2Taiyuan City, China
Objective: To investigate the effect of intestinal endotoxemia (IETM) on
learning and memory ability in rats with Alzheimer’s disease (AD) and
its possible mechanisms.
Methods: The AD model of wistar rats were produced by injecting
D-galactose and AlCl3 intraperitoneally for 90 days. Subsequently, learn-
ing and memory ability of the rats were evaluated by Morris water maze;
the level of lipopolysaccharide (LPS) and tumor necrosis factor-# (TNF-#)
were determined by ELISA; the apoptotic neuron was detected by
(TUNEL); hippocampal gene expression of amyloid precursor protein
(APP) and presenilin1 (PS1) was tested by RT-PCR.
Results: Compared with the normal control group, the model
group had longger latency (P<0.01) and more error times (P<0.05) in
Morris water maze test; LPS, TNF-# and PD in AD rats were increased
(P<0.05); the expression of APP and PS1mRNA in hippocampus were
increased (P#0.05).
Conclusion: The rat model of Alzheimer#s disease is accompanied
IETM and that may plays an important role in the development of AD.
[Key words] Alzheimer’s disease (AD); Intestinal endotoxemia (IETM);
Lipopolysaccharide (LPS); Tumor necrosis factor-# (TNF-#); Amyloid
beta-protein precursor (APP); Presenilin1 (PS1)
Policy of full disclosure: None.
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P-27-006 The change of endotoxin, AchE, ChAT and Tau protein
in patients with Alzheimer’s disease
B. Han1, F. Wu2, D. Han2, N. Zhao2, Q. Sun1, X. Shan1. 1The General
Hospital of CAPF, Peking, China; 2Shanxi Medical University, Taiyuan City,
China
Objective: To investigate the change of endotoxin, AchE, ChAT and Tau
protein in patients with Alzheimer’s disease (AD).
Methods: From January 2011 to January 2012, subjects of patients with
AD and healthy elderly were collected from hospital and nursing homes
from Taiyuan City, China. Subsequently, cognitive function of the two
group subjects were assessed by MMSE and ADAS-Cog. The level of
endotoxin was determined by TAL, AchE, ChAT and Tau protein were
determined by ELISA.
Results: MMSE score in the patients with AD were significantly lower
than the healthy elderly (P<0.001), ADAS-Cog score in patients with AD
were significantly higher than the healthy elderly (P<0.001); patients with
AD endotoxin, AchE, ChAT and Tau protein were significantly higher
than the healthy elderly (P<0.05).
Conclusion: Patients with AD were all accompanied intestinal endo-
toxemia and that may be a risk factors in the development of AD. [Key
words] Alzheimer’s disease; Intestinal endotoxemia; endotoxin; AchE;
ChAT; Tau protein.
Policy of full disclosure: None.
P-27-007 The role of P38, JNK and NF-KB in LPS activating
microglia in Alzheimer disease’s rats
B. Han1, F. Wu2, D. Han2, Q. Sun1, X. Shan1. 1The General Hospital of CAPF,
Peking, China; 2Shanxi Medical University, Taiyuan City, China
Objective: The study was to explore the role of P38, JNK and NF-KB
in LPS activating microglia in Alzheimer disease (AD) Rats which were
established by D-galactose and aluminum trichloride (AlCl3).
Methods: Adult Wistar rats were subjected to 90 days of intraperitoneal
injection weth D-galactose and AlCl3 to establish the AD model. After
the administration, the level of Lipopolysaccharide (LPS) in the serum
was determined by tachypleus amebocyte lysate method; the experession
of P38, JNK, NF-KB and OX-42 in the brain were determined by
Western-blot and Immunofluorescence method.
Results: The expression of OX-42 in the brain of Alzheimer Disease’s
rats and the control group both have positive fluorescent particles, fluor-
escence intensity compared the two groups difference have statistical sign-
ificance. The expression of OX-42 in the brain of AD’s rats and the control
group both expressed, the difference between groups was not statistically
significant; Compared with the control group, the expression of p-P38,
p-JNK in the brain of AD’s rats were markedly increased. Compared
with the control group (34.7±4.6)%, the expression of NF-KB in the
brain of AD’s rats (51.9±7.6)% were markedly increased, difference have
statistical significance.
Conclusion: The P38, JNK and NF-KB played a important role in
LPS activating microglia in the AD’s rats model which were established
by D-galactose and AlCl3. [Key words] Intestinal endotoxemia,
Lipopolysaccharide, Alzheimer’s disease, P38, JNK, NF-KB.
Policy of full disclosure: None.
P-27-008 Recovery of old (lost) memories in mice genetically
designed to mimic Alzheimer’s disease
S. Josselyn1, A. Yiu1, V. Mercaldo1, D. Sargin1, A. Rashid1, J. Epp1,
P. Frankland1. 1Hospital for Sick Children, Toronto, Canada
Objective: The clinical hallmark of Alzheimer’s disease (AD) is progress-
ive cognitive decline. Patients first show difficulty forming new memories,
then deficits in retrieving older memories. Beta-amyloid (Ab) is implicated
in AD and chronically high Ab may induce cell death. This neurodegen-
eration readily accounts for memory and cognitive impairment observed
in later stages of AD. In early stages of AD, however, patients show
deficits in forming new memories and high Ab but no detectable cell
death. This suggests that high Ab may directly interfere with the synaptic
plasticity required for normal memory formation. How Ab impairs mem-
ory is unknown. In vitro, high Ab decreases synaptic strength by promot-
ing internalization of postsynaptic AMPA-type glutamate receptors
(AMPARs), suggesting some of the memory deficits in AD may be due
to excessive AMPAR internalization. Here we investigated the role of
AMPAR internalization in the memory deficits observed in several
types of mice genetically designed to recapitulate important aspects
of AD.
Methods: We examined the effects of acutely or chronically increasing
Ab on the ability of mice to form stable memories. We also examined
the role of AMPAR internalization in these memory deficits.
Results: Acute or chronic increases in Ab impaired the ability of mice to
form stable long-term memory. Importantly, transiently interfering with
AMPAR internalization was sufficient to reverse the memory deficits pro-
duced by either acute or chronic overexpression of Ab. Memories, even
after consolidation, are modifiable. The process of remembering is thought
to reactivate memory representations in the brain. The reactivated mem-
ory is re-stored in a second wave of consolidation (reconsolidation).
Strikingly, similarly disrupting AMPAR endocytosis during a memory re-
minder enabled the recovery of an otherwise inaccessible memory in mice
with chronically high Ab.
Conclusion: Our findings raise the possibility that targeting AMPAR
trafficking could restore both the ability to form new memories as well
as enable recovery of lost past memories in AD patients.
Policy of full disclosure: None.
P-27-009 Novel 5-HT6 receptor antagonists/D2 receptor partial
agonists targeting behavioral and psychological
symptoms of dementia
M. Kolaczkowski1, M. Marcinkowska2, A. Bucki2, M. Pawlowski2,
A. Wesolowska2, P. Mierzejewski3, P. Bienkowski3. 1Adamed Ltd.,
Czosnow, Poland; 2Jagiellonian University, College of Medicine, Krakow,
Poland; 3Institute of Psychiatry and Neurology, Warsaw, Poland
Objective: All dementia patients suffer from impairment of cognitive
functions and up to 90% of them show also behavioral and psychological
symptoms (BPSD) such as: depression, anxiety, agitation, aggression,
irritability or psychosis. Those symptoms were found to be even more dis-
turbing than cognitive decline and are the most common cause of patients’
institutionalization. In view of lack of specific treatments, BPSD have been
commonly treated using antipsychotic drugs, which display only partial
efficacy. Moreover, they were found to exacerbate preexisting cognitive
deficits, as well as cause serious cardiovascular and motor side effects,
and thus are not approved for the treatment of BPSD. Therefore, develop-
ment of an effective and safe therapy of BPSD remains an increasing
clinical and social unmet need. Pharmacological studies revealed procog-
nitive role of 5-HT6 receptor (5 HT6R) antagonists, and indicated their po-
tential anxiolytic and antidepressant-like activity Moreover recent clinical
findings confirm their utility in treatment of Alzheimer’s disease.
Similarly, a growing body of evidence suggests the high therapeutical po-
tential of D2 receptor (D2R) partial agonists as both antipsychotic and
antidepressant agents, with a favorable safety profile.
Methods: Design, synthesis and pharmacological evaluation of a set of
innovative, hybrid molecules acting as 5HT6R antagonists and D2R par-
tial agonists was presented. The series was evaluated for affinity towards
5-HT6, D2 and M1 receptors as well as hERG channels. The lead molecule
was tested in models of antidepressant-like (Porsolt test) and anxiolytic-
like (Vogel test) activity.
Results: The most promising compounds displayed a desired profile
of 5-HT6/D2 activity with negligible affinity for antitargets. The lead com-
pound was significantly active in rat tests, in doses lower than the refer-
ence compounds, representing components of its mechanism of action
(i.e. selective 5-HT6 antagonism and partial D2 agonism).
Conclusion: These observations provide compelling validation of the
applied approach and warrant further studies on this mechanism of
action.
Policy of full disclosure:MK is employee of Adamed Ltd. Studies were
financed by Adamed Ltd. and Polish Agency for Enterprise Development
(PARP). Project nr UDA-POIG.01.04.00-14-055/10-00.
P-28. Neuropathology/post mortem studies
P-28-001 Abnormal fatty acid composition in the frontopolar cortex
of affective disorders –Kraepelin’s dichotomy still alive
Y. Tatebayashi1, Y. Matsuda1, N. Kikuchi-Nihonmatsu1. 1Tokyo
Metropolitain Institute of Medical Science, Tokyo, Japan
Objective: Conventional neuropathological studies for psychiatric disor-
ders have so far provided some but only limited evidence to implicate
for their etiologies. We have tackled these challenges using novel analytic
methods developed by ourselves and a well-characterized set of post-
mortem brains provided by the Stanley Foundation Neuropathological
Consortium.
Methods: Frozen unfixed postmortem brains (Brodmann Area (BA)10
& BA20) from patents with schizophrenia, bipolar disorder, or major
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depressive disorder or from normal controls were analyzed. Total fatty
acid (FA) composition (Fig. A) was analyzed using a novel statistical
method. The validity of these methods and the influence of confounding
factors were carefully checked by animal and statistical studies.
Results: We found that gamma linoleic (18:3n-6) and docosapentaenoic
acids (22:5n-3) abnormally accumulate in the FPC of patients suffering
from affective disorders but not from schizophrenia (Fig C, D). No change
was found in the levels of docosahexaenoic acid (22:6n-3) (Fig. B). In the
affective disorder FPC, the levels of oleic acid (18:1n-9) (Fig. E) and the
ratios of oleic to stearic acids (18:1n-9/18:0) (Fig. F), which presumably
represent stearoyl-coenzyme A desaturase activities, were also signifi-
cantly downregulated. These abnormalities were all aggravated in a my-
elin level-dependent manner, suggesting their close relationship with
myelination (Fig. C–F). Animal studies have further revealed that chronic
antidepressant treatment induces robust changes in brain FA metabolism
(Fig. C), but contributes only part of the abnormalities found in the affect-
ive disorder brains.
Conclusion: These findings identify a novel neuropathological hall-
mark of affective disorders that not only supports biologically
Kreapelin#s nosological dichotomy, but which also suggests that the
pathogenesis of affective disorders involves a certain lipid-related pertur-
bation in association with cortical myelination in the adult FPC that may
serve as a novel diagnostic and therapeutic target.
Policy of full disclosure: None.
Abnormal FA composition in affective disorders:
P-28-002 Cytokine expression in cingulate cortex in major
depressive disorder with and without psychosis
C. Beasley1, C. Ma1, L. Shao1. 1UBC, Vancouver, Canada
Objective: Mounting evidence suggests that depression is associated
with chronic, low-grade inflammation. Furthermore, it has been postu-
lated that changes in the inflammatory system may also be present in
other psychiatric disorders, including psychotic disorders. Raised levels
of pro-inflammatory cytokines have previously been reported in serum
and plasma from patients with major depressive disorder (MDD) and
schizophrenia. However, few studies have specifically examined cytokine
expression in brain tissue, with inconsistent results. In this study we
examined expression of several cytokines in post-mortem cingulate cortex
in psychotic and non-psychotic MDD subjects and controls.
Methods: Gene expression levels of the pro-inflammatory cytokines
interleukin (IL)-1beta, IL-6, and tissue necrosis factor (TNF)-alpha and
the anti-inflammatory cytokines IL-10 and IL-13 were quantified in the
cingulate cortex from control subjects (n=12), MDD subjects without
psychotic features (n=12), and MDD subjects with psychotic features
(n=12), using quantitative PCR.
Results: ANCOVA results indicate that mRNA expression of IL-1beta
differed significantly between groups, being lower in MDD subjects
with psychosis compared to both control subjects and MDD subjects with-
out psychosis. IL-6, IL-10, IL-13 and TNF-alpha were not significantly
altered in MDD subjects with or without psychosis.
Conclusion: Our data are not consistent with with prior reports of
increased pro-inflammatory cytokine expression in MDD and psychotic
disorders. However, given previous findings that antipsychotics can re-
duce peripheral IL-1beta expression, we suggest that lower IL-1beta
mRNA expression in the cingulate in MDD patients with psychosis may
reflect modulation of brain cytokine levels by antipsychotic medications.
Policy of full disclosure: This study was supported by the Michael
Smith Foundation for Health Research, the Canadian Institutes of
Health Research, and a Coast Capital Savings Depression Research
Award. Postmortem brain tissue was donated by the Stanley Medical
Research Institute#s brain collection.
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P-28-003 Frontal white matter measures are unchanged in adult
rats exposed to a 4-day alcohol binge protocol
C. Beasley1, C. Hercher1, L. Shao1, T. Bendyshe-Walton1, S. Fazeli1,
C. MacRae1, D. Lang1. 1UBC, Vancouver, Canada
Objective: Excessive alcohol consumption is associated with negative
short- and long-term health consequences including brain toxicity. Data
from human studies indicates that decreased white matter volume, abnor-
mal white matter integrity and lower expression of myelin-associated
proteins are present in subjects with chronic alcoholism. In addition, neu-
ronal degeneration, gliosis and neuroinflammation have previously been
reported in temporal cortex and hippocampus in adult rodents following
short-term binge protocols. Currently, it is not clear whether binge alcohol
exposure exerts deleterious effects on white matter. In this study we exam-
ined frontal white matter volume, myelin-associated protein levels and
markers of gliosis following a 4-day binge alcohol exposure protocol in
adult rats.
Methods: Two cohorts of adult female Long-Evans rats were adminis-
tered ethanol three times/day for four days. Brains were subsequently
harvested; in the first cohort tissue was perfused for neuroanatomical
examination while in the second cohort frontal white matter was extracted
and tissue frozen for biochemical analyses. Frontal white matter volume
anterior to the genu of the corpus callosum was measured using stereolo-
gical techniques. Density of microglial cells and glial fibrillary acidic pro-
tein (GFAP) immunoreactivity was quantified by immunocytochemistry
and computer assisted image analysis. Expression of myelin-associated
proteins was determined using western blotting.
Results: We observed no difference in white matter volume, microglial
cell density, GFAP immunoreactivity, or levels of myelin-associated pro-
teins between groups.
Conclusion: Our data indicate that frontal white matter is not signifi-
cantly affected by short-term binge alcohol exposure in adult rats.
Policy of full disclosure: This study was funded by the Mind
Foundation of BC. CB also receives funding from the Michael Smith
Foundation for Health Research and the Canadian Institutes of Health
Research.
P-28-004 Trace amine-associated receptor, type 1 (TAAR1) as
prospective target receptor for neuroleptics: From
D-neuron study in postmortem brains of schizophrenia
K. Ikemoto. Iwaki Kyoritsu General Hospital, Iwaki, Japan
Objective: The role of trace amines in the etiology of mental disorders has
been underestimated due to paucity of trace amines in mammalian brains.
However, recent pharmacological studies have shown the importance
of trace amine-associated receptor, type 1 (TAAR1), a subtype of trace
amine receptors, as a prospective target receptor for novel neuroleptics.
The author shows a novel hypothesis for etiology of schizophrenia, in
which TAAR1 and trace amines are involed, and emphasized the import-
ance of TAAR1 ligands as novel neuroleptics.
Methods: Endogenous ligand producing neuron of TAAR1 is the
D-neuron, i.e., trace amine neuron, defined as “the aromatic L-amino
acid decarboxylase neuron, not containing dopamine (DA) nor serotonin”.
The author’s group found significant reduction of D-neurons (trace amine
neurons) in the nucleus accumbens (Acc) of autopsy brains of patients
with schizophrenia (Ikemoto et al. 2003). The author reviewed recent rele-
vent publications focued on TAAR1 and D-neurons, and showed invole-
vement of them in etiology of schizophrenia.
Results: Animal model studies have shown that reduced TAAR1 stimu-
lation to DA neurons in the midbrain ventral tegmental area (VTA)
increased firing frequency of VTA DA neurons (Wolinsly et al., 2007,
Bradaia et al., 2009). Thus, D-neuron reduction and consequent trace
amine reduction, causing TAAR1 stimulation decrease on terminals of
midbrain VTA DA neurons would be molecular basis of mesolimbic
DA hyperactivity of schizophrenia. D-neuron reduction in Acc of post-
mortem brains is due to neural stem cell (NSC) dysfunction in the subven-
tricular zone of lateral ventricle located in the marginal area of Acc
(cf. NSC dysfuction hypothesis of schizophrenia). The new “trace amine
hypothesis” (“D-cell hypothesis”), of schizophrenia in which D-neuron
and TAAR1 is involved, is in agreement with recent reports showing ef-
fectiveness of TAAR1 ligands for schizophrenia model animals (Revel
et al., 2013).
Conclusion: The “trace amine hypothesis” (“D-cell hypothesis”) links
DA hypothesis of schizophrenia with NSC dysfunction hypothesis.
D-neuron reduction in Acc, an anatomical area known for antipsychotic
acting site, would let us conclude TAAR1 ligand searching study being
pivotal in novel neuroleptic discovery.
Policy of full disclosure: ”The method for visualizing human D-cells”
is under requiring an international patent.
P-28-005 Changes in phospholipase c beta 1 expression in the
dorsolateral pre-frontal cortex in schizophrenia and
suicide
M. Udawela1, E. Scarr1, B. Dean1. 1University of Melbourne, Department
of Psychiatry, Florey Institute, Parkville, Australia
Objective: Phospholipase C, beta 1 (PLCB1) is a downstream signalling
protein for various receptor systems implicated in schizophrenia (Sz).
We recently showed decreased PLCB1 mRNA in Brodmann’s Area (BA)
46 from subjects with Sz, while protein levels remained unchanged [1].
PLCB1 protein has been reported to be decreased in BA8 and 9 in ado-
lescent suicides [2], which led us to determine whether PLCB1 mRNA
and protein were altered in BA9 from subjects with Sz, a disorder asso-
ciated with an increased rate of suicide.
Methods: Quantitative PCR was used to measure mRNA for PLCB1
variants a and b, and Western blots were used to measure PLCB1a and
b protein, in BA9 from 38 subjects with schizophrenia, of which 12 had
died by suicide, and 20 controls with no history of psychiatric illness.
Results: Compared to age/sex matched controls, PLCB1 a and b mRNA
were not altered in subjects with schizophrenia. By contrast, PLCB1a, but
not b, protein was lower in Sz (p=0.001) whereas PLCB1b protein was
lower (p=0.028) and PLCB1b mRNA was higher (p=0.018) in subjects
who had died by suicide.
Conclusion: We have shown that PLCB1 variant a protein is lower in
BA9 from subjects with schizophrenia whereas that of variant b is lower
in those with the disorder who died by suicide. Understanding the poten-
tial role of PLCB1 signalling in Sz and suicide risk should be a priority as
this signalling pathway is targeted by antipsychotic drugs.
Policy of full disclosure: None.
References
1. Udawela, et al. Aust N Z J Psychiatry (2011) 45: 140.
2. Pandey, et al. Am J Psychiatry (1999) 156: 1895.
P-28-006 Gene coexpression analysis in the frontal cortex of bipolar
patients and controls
L. Toker1, P. Pavlidis1. 1University of British Columbia, Vancouver, Canada
Objective: Several large scale gene expression analyses addressed the
question of genes differentially expressed in bipolar patients. While the
list of candidate genes is continuously growing, the reproducibility of
the results at gene level, is relatively low. More systemic approach for ana-
lysing expression data is based on clustering the genes based on common
characteristics e.g. pathways, cellular localization, function etc. While this
approach appears to provide more robust results, it is limited to our cur-
rent knowledge regarding the genes and their products. As such it is
biased towards the more studied terms and might neglect important
but less examined connections. Coexpression analyses possess the poten-
tial to uncover previously unknown interactions and functional connec-
tions between proteins, and thus, are not as biased by prior knowledge.
Methods: We performed coexpression analyses of several publicly
available gene expression data sets from frontal cortex of bipolar patients
and controls. We were specifically interested in the coexpression of sub-
sets of genes previously reported to be related to lithium treatment or
to bipolar disorder, but lacking known connections between them.
Results: We show that such genes while not consistently showing dif-
ferential expression among studies, are highly coexpressed.
Conclusion: Our results suggest existence of yet unknown physical and
functional interactions between the genes’ products. Such interactions
might be relevant to the pathophysiology of bipolar disorder and might
relate to the patient’s responsiveness to the different treatments.
Policy of full disclosure: None.
P-28-007 Pyruvate dehydrogenase beta subunit expression within
the schizophrenia’s
N. Thomas1, E. Scarr1, B. Dean2. 1University of Melbourne, Melbourne,
Australia; 2University of Melbourne, Department of Psychiatry, Florey
Institute, Parkville, Australia
Objective: A recent microarray study by our group showed a significant
decreased in the expression of Pyruvate dehydrogenase beta subunit
(PDHB) in the dorsolateral prefrontal cortex (BA 9) from people with
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schizophrenia (Sz) compared to that in age/sex matched, healthy controls.
PDHB is the catalytic component of PDH that plays an essential role in its
ability to convert pyruvate to acetyl-CoA, a rate limiting step in the pro-
duction of energy from glucose. Changes in levels of PDHB in BA 9
could therefore have profound effects on energy utilisation in that CNS re-
gion from people with Sz. The potential importance of changes in PDHB
in Sz has led us to validate our microarray data.
Methods: Quantitative PCR was used to measure levels of PDHB
mRNA whilst Western blotting was used to measure levels of PDHB pro-
tein in BA 9 from 30 subjects with Sz and 30 controls.
Results: mRNA for PDHB was significantly increased between
people with Sz (0.8796±0.04 units) compared to controls (0.7628±0.04
units; p=0.05). Protein levels were not significantly different between
the two groups (Sz=0.708±0.05 vs. Controls=0.6333±0.03; p=0.30).
Conclusion: Our data argues that changes in levels of PDHB expression
at the level of mRNA in BA9 from people with Sz do not extend to
changes in levels of protein level. However, relatively minor variations
in levels of PDHB could impact on PDH activity and therefore functional
assays will be employed to investigate the activity of the PDH in this
cohort.
Policy of full disclosure: None.
P-28-008 Class II metabotropic glutamate receptors are
downregulated in major depressive disorder
C. McOmish1, S. Hopper1, G. Pavey1, M. Udawela1, E. Scarr2, B. Dean3.
1Florey Institute of Neuroscience and Mental Health, Melbourne, Australia;
2University of Melbourne, Melbourne, Australia; 3Molecular Psychiatry Lab,
FINMH, Howard Florey Laboratories, Melbourne, Australia
Objective: Major Depressive Disorder (MDD) affects ∼10% of the world’s
population (WHO). Yet, despite high prevalence rates, major aetiological
questions remain unanswered, and better therapeutic strategies are
urgently needed. Emerging results aimed at identifying the mechanism
of action of ketamine, an NMDA receptor antagonist that shows rapid
and and effective antidepressant activity, reveal a role for mGlu2/3 in
the signaling pathways thought to underlie the antidepressant effects,
necessitating further investigations into mGlu2 and 3, and their involve-
ment in MDD. In this study, we investigated the expression of mGlu2/3
receptors in the anterior cingulate cortex (BA24) of people with MDD.
Methods: Saturation binding curves for [3H]LY341495 were established
in human cortical tissue. Based on these curves, a concentration of 3nM
[3H]LY341495 was chosen for autoradiography. Sections were incubated
in 3nM [3H]LY341495, postfixed, and apposed to plates for 3 days prior
to being imaged on a BAS system, and analysed using AIS software.
BA24 was selected for analysis in MDD, schizophrenia (SCZ), bipolar
(BPD) and controls (N=14–15).
Results: mGlu2/3 were found to be expressed across the brain, in
regions of relevance to psychiatric disorders. Strong binding was observed
in cortical regions (BA9 and BA10), caudate putamen, and hippocampus.
Consistent with an important role for mGlu2/3 in MDD, [3H]LY341495
binding was significantly decreased in BA24 of MDD relative to control,
but unchanged in the same region in SCZ and BPD.
Conclusion: The emergence of ketamine as a treatment for depression
has shifted the focus of affective research programs, underscoring the
need for increased insight into glutamate’s contribution to the aetiology
and treatment of psychiatric disease. We demonstrate dysregulation of
mGlu2/3 in MDD, however the dissociation of mGlu2 from mGlu3 is a
critical next step in precisely identifying the disruption. Understanding
how these receptors are involved in psychopathology will allow for the
development of more targeted treatment strategies.
Policy of full disclosure: None.
P-29. Neurophysiology; from ion channels to
cortical EEG B
P-29-001 Neurofunctional activation of human visual cortex in
amblyopiainduced by S/NRI treatment and sensory
stimulation. A case report
S. Izzo1, G. Arduino1, D. Di Meglio1, D. Di Blasio1. 1Aerospace Medical
Institute, Rome, Italy
Objective: To demonstrate the neuroplasticity process in the underdevel-
oped adult brain visual cortex induced by the combination of long term
antidepressant administration (S/NRI duloxetine) and sensory stimu-
lation. A model of neuronal restored plasticity has been so far demon-
strated only in the visual cortex of amblyopic adults rodents treated
with the SSRI fluoxetine.
Methods: Measurements at T0 and T1 (respectively 0–18 months) of: –
Eyesight: UnCorrected/Best Corrected Visual Acuity (UC/BCVA); –Visual
Evoked Potentials (VEPs), with pattern reversal of 15° and 60°. Daily ex-
posure for one/two hour/s of the amblyopic eye to visual stimulation, such
as watching TV, for 18 months; Duloxetine intake, 60mg/die, as pre-
scribed, for 18 months.
Results: Measurements at T1 in the amblyopic left eye, showed: – in-
crease of BC VA from 4/10 to 7/10 (Fig.1); – decrease of VEPs P100
Latency peak time from 117.77 to 111.91 msec in 15°pattern (Fig.2) and
from 112.5 to 102.5 in 60°pattern (Fig. 3); – increase of VEPs N75- P100
Amplitude from 0.42 to 4.14 μV in 15°pattern (Fig. 4) and from 3.76 to
5.33 in 60°pattern (Fig. 5).
Conclusion: The clinical and the experimental results (improvement of
BCVA, increase of N75-P100 Amplitude, decrease of P100 Latency, re-
mission from dysthymia), seem to confirm other findings and to demon-
strate that also the human adults neuronal cortex can be shaped, after
proper stimulation, in order to support its natural and specific function,
as showed for the contralateral eye (Fig. 6-7-8-9). The functional/structural
adaptations observed might be explained through the mechanism of
neuroplasticity, likely enhanced simultaneously by the duloxetine related
production of BDNF and the active visual-sensory stimulation (watching
TV). Since adaptation can occur also in cortical area never properly devel-
oped before (as the amblyopic one), a potential clinical application might
be investigated in several neurological circumstances, where the neural
network/functions has formerly been unexpressed or compromised.
References: see attached file.
Policy of full disclosure: None.
Figures 1-2-3-4-5-6-7-8-9-references:
P-29-002 Modulation of the error-related negativity by emotional
interference in obsessive-compulsive disorder
C.-H. Kim1, D. Roh1. 1Severance Mental Health Hospital, Gwangju-Si,
Republic of Korea
Objective: Patients with obsessive-compulsive disorder (OCD) typically
view perceived inadequacy or error in daily activities and often feel that
compensatory action is needed to rid themselves of this perception.
Enhanced error monitoring provides evidence for the fronto-striatal
model of OCD, typically examined by measuring error-related negativity
(ERN). This study examined ERN in OCD patients and compared it with
that in healthy subjects through affective modulation induced by
task-irrelevant emotional stimuli (fearful faces).
Methods: A modified version of the flanker task with task-irrelevant
emotional face stimuli was performed by 22 OCD patients and 22 healthy
subjects while EEG signals were recorded from 65 electrodes. To quantify
response-locked ERN, a mean amplitude of 20#120 msec post-response
was computed.
Results: During trials with fearful face stimuli, the patients with OCD
showed more significantly enhanced ERN amplitude(#4.05±4.44) than
did the control (#1.03±3.67, t=2.292, p=0.028). The difference between
ERN following fearful and neutral face stimuli was larger in the OCD
patients than in the control group. Only the OCD patients exhibited
significantly increased ERN amplitude under fearful face conditions com-
pared with neutral face conditions (F=11.130, p=0.003). The OCD patients
exhibited signficantly larger and correct-related negativity amplitudes
than did the controlin both fearful and neutral conditions. Across the
entire sample, the ERN amplitude enhancement between fearful and
neutral condition was significantly correlated with feeling of incomplete-
ness (r=−0.339, p=0.025).
Conclusion: These data provide further support for the view that per-
formance monitoring is overactive in OCD. These findings also suggest
that emotional interference using emotionally valent facial images modu-
lates performance monitoring processes in OCD. On the basis of ERN as a
stateaffect-independent property, changes in performance monitoring
associated with emotional interference suggest that affective function in
the fronto-striatal network be considered in understanding the neural
bases of OCD.
Policy of full disclosure: None.
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P-29-003 Acute effects of smoked cannabis on brain EEG power,
coherence and sLORETA current density –A pilot study
T. Palenicek1, F. Tyls1, M. Viktorinova1, R. Androvicova1, T. Melicher1,
M. Brunovsky1, P. Novakova1, L. Kaderabek1, J. Horacek1. 1Prague
Psychiatric Center, Prague, Czech Republic
Objective: The acute effects of cannabis and delta-9-tetrahydrocanabinol
(THC) have been reported to induce psychotic symptoms. However, the
relation of its psychotropic effects on how acute cannabis changes brain
EEG activity during resting is limited. Therefore, we have examined the
effects of smoked cannabis on EEG power spectra, coherence and on cur-
rent density using sLORETA (standardized low resolution brain electro-
magnetic tomography).
Methods: We used an ecologically valid approach where recreational
cannabis users were allowed to smoke their own cannabis in a dose suffi-
cient to produce an appropriate high. We controlled the content and
amount of THC in the drug they used and in in the serum. The brief psy-
chiatric rating scale (BPRS) and altered state of consciousness scale (ASCs)
were used to evaluate the psychopathology and characterize the high.
Data were compared to a group of nonsmokers.
Results: Smokers scaled significantly higher than the controls on
both psychometric scales. Cannabis induced a moderate increase of the
mean EEG power in the alpha1 band (8–10 Hz), a robust increase of
the power in the gamma band (30–40 Hz) and on the contrary a moderate
decrease in the alpha2 band (10–12 Hz). EEG coherence was mainly
decreased across the whole spectrum, with the most robust changes
being present in the beta (12–25 Hz) and high beta (25–30 Hz) bands.
sLORETA analysis showed a robust gamma current density increase
in the frontal and temporal lobes and a small decrease of alpha2
activity in the middle cingulate and premotor cortex (Brodman area 6
and 24).
Conclusion: Since some parallels can be seen when compared to EEG
findings in acutely psychotic patients, our findings have implications for
acute THC as a model of psychosis. This work is supported by projects
VG20122015080, VG20122015075, NT13897, PCP00023752, ECGA278006
and PRVOUKP34.
Policy of full disclosure: None.
P-29-004 Dread of ego dissolution experience during cannabis
intoxication correlated with decrement of activity in
default mode network: A LORETA study
F. Tyls1, T. Palenicek1, M. Brunovsky1, M. Viktorinova1, M. Fujáková1,
J. Horacek1. 1Prague Psychiatric Center, Prague, Czech Republic
Objective: Cannabis intoxication is known to induce characteristic altered
state of consciousness (ASC) (Gouzoulis-Mayfrank, 1998). We wanted to
find EEG correlates of different parameters of cannabis-induced changes
in the ASC scale (ASCS).
Methods: 45 minutes after smoking the usual amount of cannabis,
a group of occasional cannabis users underwent resting state EEG record-
ing. Only those subjects, who had levels higher than 4 ng/ml were in-
cluded in EEG analysis (N=13). The psychopathology during the
experiment was assessed by subjects themselves with ASC scale and by
the experimenter with BPRS (Brief Psychiatric Rating Scale) 120 minutes
after drug use. Regression analysis was performed using sLORETA to as-
sess whether the activity changes in brain regions interrelate with ASCS
and BPRS.
Results: Our main finding was a negative correlation (r=−0.78, p<0.05)
between Dread of ego-dissolution (DED) subscale of ASCS and sLORETA
activity in beta 3 frequency band in Cingulate gyrus and Precuneus (BA
7,24,31). Furthermore, we found another negative correlation (r=−0.72,
p<0.05) between anxiety/depression subscale of BPRS and sLORETA ac-
tivity in similar brain structures in beta 2, beta 3 and gamma frequency
bands.
Conclusion: The decrement of brain activity in midline parietal
structures in higher frequency bands correlated with subjectively
experienced DED (fear, self-disorganization, derealization), as well as
with the scores of anxiety/depression rated by the experimenter. These
brain structures are thought to be involved in default mode network
(DMN) (Raichle, 2001), where deactivations were reported in relation to
different ASC (Cavanna and Trimble, 2006). One of the main hub of
DMN, the precuneus, is involved in representation of self and external
world (Gusnard and Raichle, 2001), therefore its deactivation should re-
sult in self-disorganization and changes in representation of external
world (as observed by increased scores of DED). These dreadful experi-
ences were shown to correspond to clinically observable anxiety
(Gouzoulis-Mayfrank, 1998).
Policy of full disclosure: This work was supported by projects
VG20122015080, MHCZ-DRO (PCP, 00023752), PRVOUK P34.
P-29-005 Effects of acute THC intoxication on cognitive functions
and vigilance in recreational and chronic cannabis users
M. Viktorinova1, M. Brunovsky1, T. Palenicek1, F. Tyls1, M. Fujakova1,
J. Horacek1. 1Prague Psychiatric Centre, Prague, Czech Republic
Objective: The aim of the present study was to assess neurocognitive
performance in recreational and chronic cannabis users during acute
THC intoxication and determine its effects on cognitive performance as
well as vigilance.
Methods: Computer-based neuropsychological tests (Trail Making
Test – TMT, Continuous performance test –CPT) were administered to a
group of 21 recreational, 27 chronic THC users and 19 matched controls
30 and 240 minutes after intoxication by their usually smoked amount
of cannabis. To allow for comparison between users, blood levels of
THC were measured at regular time intervals and the sample smoked
by each individual was subject to genetic analysis. In addition, a
10-minute EEG of a car ride watched from driver’s perspective was
recorded 60 minutes after intoxication and analyzed by means of spectral
analysis (theta/beta ratio; TBR) of 60 consecutive 10 s epochs.
Results: While both groups of THC users performed equally well in
terms of their psychomotor speed, the accuracy rates differed significantly
between recreational users and controls (p<0.05) at 30 minutes after in-
toxication. Chronic users did not differ from controls in reaction times
nor did they differ in accuracy rates. In terms of vigilance, analysis in
progress reveals differences in TBR with chronic users showing the fastest
vigilance decrement.
Conclusion: In line with previous findings, our data provide support to
impairment in visuomotor accuracy in recreational cannabis users after
acute THC intoxication. Although we did not find any behaviorally man-
ifested impairment in chronic users, their differences in vigilance have im-
portant implications for cannabis use and traffic safety.
Policy of full disclosure: None.
P-30. Sleep disorders
P-30-001 Evaluation of the efficacy and adverse effect (unpleasant
taste) of eszopiclone in Japanese patients
K. Matsumura1, A. Akahane1, N. Hamaichi2, E. Ikebuchi1. 1Teikyo
University, School of Medicine, Tokyo, Japan; 2Mimura Hospital, Hokkaido,
Japan
Objective: Eszopiclone is a non-benzodiazepine hypnotic with anti-
anxiety, sedative, as well as sleep-promoting actions. Also, as it has no
major adverse effects except for an unpleasant taste (primarily bitterness),
it is considered to be a hypnotic that can be used safely in patients with all
kinds of insomnia, including that associated with physical and psychiatric
disorders and old age, as well as primary insomnia. It was approved in
Japan about 7 years after approval in the United States, and evidence con-
cerning this novel hypnotic is being accumulated in Japan. In this study,
we investigated the efficacy of Eszopiclone and its unpleasant taste, the
most common complaint associated with it, in daily clinical use.
Methods: A questionnaire survey concerning the efficacy and adverse
effect 2 weeks after the beginning of the administration of Eszopiclone
was carried out in 68 patients who were administered Eszopiclone as
the initial treatment for insomnia or as a substitute for other hypnotics.
Results: Frequent diagnoses were mood disorder, schizophrenia, and
neurotic disorder. As for concomitant medications, other psychotropic
drugs were used in 64. The sleep-inducing effect was considered satisfac-
tory by 58.8% of the patients. However, only 36.8% replied that they had a
feeling of having slept well, and 63.2% felt lingering sleepiness. Bitterness
was reported by 10 patients (14.7%), with 1 of them answering that it was
impossible to continue taking the drug.
Conclusion: Eszopiclone was suggested to be effective for the treat-
ment of insomnia, particularly sleep-onset insomnia, associated with psy-
chiatric disorders. The incidence of an unpleasant taste (bitterness) as
an adverse effect was observed less frequently in this study (14.7%)
than in previous studies (21–36%), but whether or not this low incidence
was related to the primary diseases and concomitant medications, the
presence of which is a characteristic of this study based on daily clinical
practice, is unknown.
Policy of full disclosure: None.
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P-30-002 Suppression of limbic neural activity in the sleep apnea
model using obese diabetic mice
Y. Ohno1, T. Mukai1, Y. Nagao1, S. Nishioka1, S. Shimizu1, K. Tokudome1,
R. Kato1, Y. Matsumura1, T. Hayashi1. 1Osaka University of Pharmaceutical
Sciences, Osaka, Japan
Objective: Patients with sleep apnea (SA) exhibit not only sleep distur-
bances, but also neurocognitive impairments and/or psychoemotional dis-
orders. To explore the changes in neural activities related to SA syndrome,
here, we examined the effects of intermittent hypoxia (IH) on brain Fos ex-
pression in obese diabetic db/db mice.
Methods:Male db/db mice were exposed to IH stimuli (repetitive 6-min
cycles of 1 min with 5% oxygen followed by 5min with 21% oxygen) for
8 hours (80 cycles) per day or normoxic condition (control group) for
14 days. Fos protein expression was immunohistochemically examined
one day after the last IH exposure.
Results: Mapping analysis revealed a significant reduction of Fos ex-
pression by IH in the limbic and paralimbic structures, nucleus accumbens
and amygdala. In the brain stem regions, Fos expression was region-
specifically reduced in the ventral tegmental area while other regions
were relatively resistant against IH. In addition, db/db mice exposed to
IH showed a trend of sedative and depressive behaviors.
Conclusion: The present results illustrate that SA in the obese diabetic
model causes neural suppression preferentially in the limbic and paralim-
bic regions, which may be related to the neuropsychological disturbances
associated with SA.
Policy of full disclosure: None.
P-30-003 Evaluation of efficacy and safety of an occlusal splint vs.
gabapentin in the treatment of sleep bruxism
E. Abdollahian1, M. Azangou1. 1MUMS, Mashhad, Islamic Republic of Iran
Objective: The objective of this study was to compare the efficacy and
safety of an occlusal splint vs. Gabapentin in the treatment of this
problem.
Methods: Twenty subjects with sleep bruxism were divided into
occlusal splints and gabapentin treatment groups. Sleep laboratory
recordings by polysomnography were made before and 2 months
after the interventions to assess the effectiveness of each treatment
and in 4 subjects of each group on the third night after two weeks of
wash-out, to evaluate the stability of treatment results. Data analysis
was done by Harmonie 6.0 software. For statistical analysis, Willcoxon
test was used.
Results: Greater reduction in these parameters were found in
Gabapentin group. Occlusal splint was effective in reduction of massetter
muscle activity (EMG). Moreover, the subjects treated with Gabapentin
showed a significant improvement in the total sleep time and sleep
efficiency.
Conclusion: Gabapentin showed more improvement in duration of
bruxism, whereas occlusal splint showed more reduction of massetter
muscle contractions during sleep bruxism so Gabapentin can be an effec-
tive treatment modality in sleep bruxism especially in those with poor
sleep quality.
Policy of full disclosure: None.
P-30-004 Status of associated factors for the quality of sleep in
patients with dementia: An epidemiological assessment
T. H. Huang1, C.-E. Chang2, T. Yang3, Y.-C. Chou4, S.-C. Lin4, C.-A. Sun5.
1Chang Bing Show Chwan Hospital, Changhua County, Taiwan; 2Fu-Jen
Catholic University, College of Medicine, Department of Public Health,
College of Medicine, New Taipei City, Taiwan; 3Mei-ho University, Pingtung
County, Taiwan; 4National Defense Medical Center, Taipei City, Taiwan;
5Fu-Jen Catholic University, New Taipei City, Taiwan
Objective:Most of the previous studies in patients with dementia explore
a combination of behavioral and psychological symptoms, cardiovascular
disease, and the impact on the patients and caregivers# quality of life.
People with dementia commonly complain of sleep disturbances, there-
fore, the purpose of this study is to understand the factors in sleep quality
that relate to dementia in patients.
Methods: Data was collected from the Sleep Center of Chang Bing
Show Chwan Memorial Hospital. One hundred and seven participants
with dementia and the four hundred twenty eight participants without
dementia were matched by age and gender. Responses to a clinically
structured questionnaire contains demographic variables, Pittsburgh
Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Athens
Insomnia Scale (AIS), and patients were measured during overnight
polysomnography (PSG). Diagnosis of dementia was made by means of
DSM-IV criteria. Statistical analysis using SPSS 20.0 software.
Differences in percentages were assessed by the chi-squared test. The as-
sociation between sleep quality and dementia was evaluated using mul-
tiple logistic regression models.
Results: Insomnia syndrome was present in 84.1% of subject with
dementia and 79.2% of subject without dementia. Participants without
dementia has significantly good exercise habits than dementia patients
(41.6% [n=178] vs 30.8% [n=33]; odds ratio [OR]=0.63; 95% confidence
interval [CI]=0.40–0.99). From the multiple logistic regression analysis,
daytime sleepiness (OR=2.13, 95%CI=1.36–3.33) and sleep efficiency
(OR=1.90, 95% CI=1.02–3.54) had significantly higher risks of dementia
after adjusted for exercise habits. Increased sleep latency was not statisti-
cally significant in association with increased risk of dementia. Otherwise,
dementia patients had lower arousal index and periodic leg movements
index.
Conclusion: Subjects with excessive daytime sleepiness and poor sleep
efficiency have a higher likelihood of dementia in population. Insomnia,
the most common sleep problem in our study, is not associated with
the presence of dementia. Furthermore, good exercise habits may decrease
the risk of dementia.
Policy of full disclosure: None.
P-30-005 Risk predictors for hypnosedative-related complex sleep
behaviors in adult psychiatric outpatients
T.-J. Hwang1, C.-Y. Hsu1, M. H. Hsieh1, H.-C. Chen1, C.-A. Yao1,
W.-J. Liu1, C.-C. Liu1, C.-M. Liu1. 1National Taiwan University Hospital,
Taipei, Taiwan
Objective: Previously we reported a higher dose of zolpidem was the
most important risk predictors for complex sleep-related behaviors
(CSBs) in psychiatric outpatients taking hypnosedative drugs. Here we
aimed to validate this finding by using another sample with a larger size.
Methods: A total of 634 subjects using hypnosedatives were enrolled
from the adult psychiatric outpatient clinics of a medical center in
Taiwan from June 2011 to November 2012. All subjects completed a ques-
tionnaire, which included demographic data, current and childhood sleep
habits, and CSBs after taking hypnosedatives. CSBs were defined as som-
nambulism with object manipulation, sleep related eating and other
amnestic sleep-related behaviors. A cohabitant was contacted to confirm
the existence of CSBs. Demographic and clinical variables were compared
in those with CSBs and those without. Then multiple logistic regression
analyses were performed in order to identify significant risk predictors
for CSBs.
Results: The diagnoses of 634 subjects were as follows: depressive dis-
order (n=194, 30.6%), schizophrenia (n=166, 26.2%), sleep disorder (n=
106, 16.7%), bipolar affective disorder (n=71, 11.2%), anxiety disorder
(n=71, 11.2%) and others (n=26, 4.1%). Preliminary analyses showed
that, out of the 634 subjects, 49 (7.7%) had CSBs, 207 (33%) took zolpidem
and 36 (73.5%) of those having CSBs took zolpidem. Univariate analysis
showed that those with CSBs were significantly more likely to be younger
(P=0.023), to take zolpidem (P<0.001), to receive antidepressant treatment
(P=0.007), to have fewer medical comorbidities (P=0.002) and not to go to
bed immediately after taking a hypnotic agent (P=0.013). Multiple logistic
regression analyses revealed that zolpidem was the strongest significant
predictor of CSBs (OR=7.6; 95% CI, 3.9–14.9; P<0.001), followed by anti-
depressant use (OR=2.9; 95% CI, 1.5–5.7; P=0.002) and having fewer
medical comorbidities (OR=1.2; P=0.045).
Conclusion: The results of this study validate our previous findings and
indicate that zolpidem use is the most important risk predictor for CSBs in
adult psychiatric outpatients.
Policy of full disclosure: The study was sponsored by the National
Science Council, Taiwan (NSC 101-2314-B-002 -189 and NSC
102-2314-B-002 -157 -MY2).
P-31. Traumatic brain injury and mental health
P-31-001 The effect of cognitive and behavioral therapy on
depression among patients with traumatic brain injury
C. Shao1, X. Wu2, Z. Wang2, Y. Bai2, S. Shi2, Y. Wu2. 1Huashan Hospital,
Fudan University, Shanghai, China; 2Huashan Hospital, Shanghai, China
Objective: Depression is very common following traumatic brain injury
(TBI). It is very important to recognize depression after TBI because of
the association with poor global and psychosocial outcome and cognitive
deficits. The purpose of the study is to explore if cognitive and behavioral
therapy (CBT) could reduce depressive symptoms after TBI.
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Methods: This randomized, controlled study was conducted in a
general hospital setting. We recruited 72 patients with symptoms of de-
pression after a traumatic brain injury. All participants were randomized
to the 8-week cognitive and behavioral therapy group or to the control
group. The primary outcome measure was symptoms of depression
using the Patient Health Questionnair-9items (PHQ-9).
Results: Compared with the control group, the reduction of PHQ-9 was
greater in the CBT group (P<0.05). The improvement of PHQ-9 scores was
maintained at the 8 week follow-up. Most of the patients (80%) preferred
this kind of intervention.
Conclusion: CBT is an effective therapy to improve the depressive
symptoms after TBI. Also, it is a more preferred treatment for depression
among TBI patients.
Policy of full disclosure: Supported by Shanghai health bereau found-
ing of Shanghai, China. The approved number is 20114358.
P-32. Biomarkers (incl. pharmacogenomics and
brain imaging) for diagnosis and treatment
response B
P-32-001 Altered face inversion effect in schizophrenic patients
treated with typical vs atypical antipsychotics
T. Tsunoda1, M. Uenoyama1, S. Nomura1, H. Toda1, M. Nagamine1,
K. Shimizu1. 1National Defense Medical College, Tokorozawa, Japan
Objective: There is accumulating evidence that schizophrenics may have
deficits in facial recognition, which has been related to disease-specific dis-
turbances in normal social interaction. Neurophysiologically, face inver-
sion results in an amplitude increase of the event-related potential (ERP)
component N170. This face inversion effect (FIE) presumably reflects a
disruption of face-specific configuration processing. The present study
investigated FIE between typical antipsychotics (TAPs)-treated patients
and patients treated with other atypical antipsychotics (ATAs).
Methods: The subjects consisted of 20 schizophrenics. Event-related
potentials (ERPs) to upright and inverted neutral faces and cars were
recorded. We assessed the relationships between typical or atypical anti-
psychotics and upright or inverted faces or cars in schizophrenics.
Results: ATAs patients exhibited a significant FIE of the N170 ampli-
tude compared to TAPs. In both groupss, no inversion effect was observed
for car stimuli. For face stimuli, TAPs patients showed significant bilateral
N170 reduction compared to ATAs.
Conclusion: These results indicate face-specific configuration proces-
sing deficits in schizophrenia and associations between FIE or face-N170
reduction and TAPs or ATAs.
Policy of full disclosure: None.
P-32-002 Proteomic analysis of the lymphoblastoid cell line derived
from Japanese schizophrenic patients
A. Yoshimi1, S. Kunimoto2, S. Yamada2, B. Aleksic2, A. Hirakawa2,
T. Nagai2, N. Ozaki2. 1Nagoya University, Graduate School of Medicine,
Nagoya, Japan; 2Nagoya, Japan
Objective: Schizophrenia is a chronic and disabling mental disorder with
a lifetime prevalence of approximately 1% worldwide. Although a num-
ber of studies have shown several convincing candidate genes or mole-
cules, the pathophysiology of schizophrenia has not been completely
elucidated. Optimal therapy based on pathophysiology should be per-
formed as early as possible to improve functional outcome and prognosis.
Therefore the identification of biomarkers for schizophrenia is necessary
to provide timely diagnosis and effective therapy. To explore biomarkers
for schizophrenia, we employed the florescence two-dimensional differen-
tial gel electrophoresis (2D#DIGE) for proteomic analysis.
Methods: A 2D-DIGE approach was performed to investigate the alter-
ation of protein expression profiles in the lymphoblastoid cell lines (LCLs)
(29 schizophrenics and 29 controls). Spot detection and matching were
performed using the PDQuest 8.0. Differentially expressed protein spots
were sequenced by LC-MS/MS and identified using Mascot program.
The identified proteins were confirmed by Western blotting (WB).
Receiver operating curve analysis including the area under the curve
(AUC) and multivariable logistic regression were investigated to identify
an optimal combination of biomarkers to create a diagnostic model.
Results: A total of ∼1200 protein spots was identified on a typical LCL
gel (schizophrenia mean 1103±11.7; control mean 1103±13.3), and 20
spots were differentially expressed in a 2D-DIGE analysis. These spots
were selected for sequencing and 22 unique proteins were identified.
Eight out of 22 was confirmed the direction of change by WB. Among
the 8 promising biomarkers, the optimal 4-marker model comprised
MX1, GART, UROD, and GLRX3. The AUC for the accuracy of predicting
schizophrenia by 4-marker model was 0.86, implying good discriminative
ability.
Conclusion: As a result, differentially expressed proteins might be asso-
ciated with molecular mechanisms that contribute to the pathophysiology
of schizophrenia. These findings might provide insight into the pathophy-
siology of schizophrenia and potentially provide diagnostic and prognos-
tic biomarkers.
Policy of full disclosure: This research was supported by the
Grant-in-Aid for Young Scientists B (No. 25860999) from Japan Society
for the Promotion of Science (JSPS), the Adaptable & Seamless
Technology Transfer Program through Target-driven R&D (A-STEP:
AS2511400P) from Japan Science and Technology Agency (JST), and the
Strategic Research Program for Brain Sciences from Ministry of
Education, Culture, Sports, Science and Technology (MEXT), Japan.
P-32-003 Effects of NSI-189, a neurogenic compound, on
quantitative electroencephalography (qEEG) in patients
with major depressive disorder (MDD) during a phase 1b
randomized, double-blind, placebo controlled, multiple
ascending dose study
B. English1, J. Johnstone2, K. Johe3, L. Gertsik4, M. Sherman1, M. Fava5,
L. Ereshefsky1. 1PAREXEL International, Glendale, USA; 2Q-Metrx,
Glendale, USA; 3Neuralstem Inc., Rockville, USA; 4California Clinical Trials,
Glendale, USA; 5Massachusetts General Hospital, Department of Psychiatry,
MGH Clinical Trials Network, Boston, USA
Objective: NSI-189, a novel molecule (Neuralstem Inc) for the treatment
of MDD has been shown to stimulate neurogenesis of human
hippocampus-derived neural stem cells in vitro and in mouse hippocam-
pus in vivo. In a Ph1b, double-blind, placebo-controlled, multiple-
ascending-dose study, patients with symptomatic MDD were randomized
to receive NSI-189 40, 80, 120mg daily or placebo for 28 days, QEEG was
used to characterize pharmacodynamic effects of NSI-189.
Methods: In addition to safety, pharmacokinetic, and behavioral
ratings scales, qEEG measurements were obtained 6 hrs post-dose on
Day 14 and 28 for 20 minutes at rest. EEGs were recorded using
19-standard International 10/20 System scalp locations plus EMG. and
eye movement monitoring. Digital EEGs recorded using Cadwell
Laboratories instrumentation, were reviewed to identify the presence of
physiological and instrumentation prior to analyses. Artifacts were re-
moved from EEG files manually by an experienced technologist. Epocs
of EEG data are submitted to power spectral analyses using Brain
Vision Analyzer software.
Results: Safety EEGs recordings pre vs. post dose showed no new
findings by visual inspection. Results of qEEG analyses using amplitude
and coherence measures, pre vs 6 hrs post-dose on Day 14 and Day 28,
show increased HF alpha with active treatment and lower HF alpha
with placebo. This effect is particularly prominent in the left posterior
temporal and parietal regions in patients receiving NS-189 and is similar
when comparing baseline to Day 14 or 28. Significant univariate effects
comparing amplitude from baseline to safety are seen only for changes
within the active treatment group. Changes within the placebo group
for these measures were not significant.
Conclusion: These findings demonstrate a measurable impact of
NSI-189 on the qEEG of patients with MDD. The largest effect seen in
the active treatment group was HF alpha in the left posterior temporal re-
gion. This finding is consistent with improvement in left temporal lobe
function and may also reflect changes in activity in left mesial temporal
lobe and hippocampus. Neuropsychological correlates of these changes
mind include modulating context regulation of affect and clinical re-
sponse, i.e., fluoxetine, increased alpha activity in posterior regions of
the head were associated with clinical response.
Policy of full disclosure: None.
P-32-004 Basal prolactin levels as a predictor of response to
antidepressant treatment
A. Faron-Górecka1, M. Kusmider1, K. Szafran1, M. Kolasa1, P. Gruca1,
M. Papp1, D. Zurawek1, J. Solich1, P. Pabian1, M. Dziedzicka-
Wasylewska1. 1Institute of Pharmacology PAS, Krakow, Poland
Objective: The relationship between response to antidepressant (ADs)
and prolactin (PRL) levels has been studied. It has been shown that base-
line cortisol, prolactin and L-tryptophan (TRP) availability may influence
response to ADs treatment. Considering mentioned reports we aimed to
verify whether the response to antidepressant treatment depends on the
endogenous level of PRL in plasma.
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Methods: In our study we used the Chronic Mild Stress (CMS) # the an-
imal model of depression. Rats are exposed to CMS procedure for 2 weeks
and subsequently to CMS in combination with imipramine (IMI) treat-
ment for 5 consecutive weeks. Behavioral results obtained in CMS experi-
ments showed that after 2 weeks of mild stress, anhedonia in rats is
manifested by reduced consumption of sucrose solution. Next 5 weeks
of stressful stimuli maintained this effect, and the administration of anti-
depressant drugs reversed anhedonia. Some animals (ca.30%) did not re-
spond to antidepressant therapy and were considered treatment-resistant.
The plasma of animals responding and not responding to therapy was col-
lected from the tail at two time points: before starting the CMS procedure
and after seven weeks of stress procedure plus five weeks of IMI admin-
istration. Concentrations of peptide in plasma were determined in dupli-
cates using commercially available ELISA kits for rat prolactin (SPIbio,
Germany). The inter-assay coefficient of variation was less than 15% for
rat plasma samples in the concentration range of 8 to 1000 ng/ml.
Results: We observed significant negative correlation between basal
levels of PRL before CMS procedure and behavioral response to IMI ad-
ministration (difference in the sucrose intake dsucrose intake=after
IMI treatment before IMI administration). The Spearman Rank
Coefficient, rs is −0.5929, p<0.0198, (Statistica, StatSoft, USA).
Conclusion: The obtained results indicate that the basal level of PRL
can be a good predictor of response to treatment in depression.
Policy of full disclosure: This work was financially supported
by grants from MNiSW nr NN 401 067438, DeMeTer POIG.01.01.02-
12-004/09.
P-32-005 Adverse drug reactions and CYP2D6 genotypes in
patients with mood disorders
A. Holck1, A.-L. Zackrisson2, M. Reis3, Å. Westrin1. 1Clinical Sciences,
Lund, Sweden; 2Department of Forensic, Genetics, Forensic and Toxicology,
Linköping, Sweden; 3Clinical Pharmacology, Linköping University, Linköping,
Sweden
Objective: The polymorphic gene CYP2D6 encodes for the CYP2D6 en-
zyme that is involved in the metabolism of a number of drugs. The four
genotypes (poor metabolizer, intermediate metabolizer, extensive meta-
bolizer, and ultra-rapid metabolizer) display different metabolic activity.
The specific objective of this pilot study was to investigate if the frequency
of adverse drug reactions (ADRs) was related to different CYP2D6 geno-
types in depressed patients treated with an antidepressant drug.
Methods: Patients with a depressive disorder or bipolar depression
were genotyped for CYP2D6, examined and asked to fill in the self-rating
version of the UKU Side Effect Rating Scale.
Results: 54 patients were included. The analysis was limited to the two
most frequent genotypes: intermediate metabolizer (n=24) and extensive
metabolizer (n=27). When only the patients treated with one or more
drugs metabolized by CYP2D6 were analyzed (n=41), autonomic and
psychological ADRs were significantly more frequent in intermediate
metabolizers than in extensive metabolizers.
Conclusion: The results suggest that among patients treated for de-
pression, intermediate metabolizers are more likely to experience auto-
nomic or psychological ADRs than patients who are extensive
metabolizers if treated with one or more drugs metabolized by the
CYP2D6 enzyme. Genotyping of psychiatric patients who experience
ADRs may be of great value, since it could guide the physician to a
new antidepressant with a different metabolic pathway. The novel
finding of this study was thus that genotyping may help prevent ADRs
not only in poor metabolizing patients, as has been suggested earlier,
but also in intermediate metabolizers of CYP2D6. However, more and lar-
ger studies are needed.
Policy of full disclosure: None.
P-32-006 Investigation of dopaminergic and serotonergic receptors
for their association with antipsychotic response in north
Indian schizophrenia patients
A. Jajodia1, H. Kaur1, R. Chadda2, K. Kumari2, S. Jain3, R. Kukreti1.
1CSIR-IGIB, Delhi, India; 2AIIMS, Delhi, India; 3NIMHANS, Bengaluru, India
Objective: Schizophrenia is a debilitating psychiatric illness with varying
degree of symptoms. Understanding of the genetic variation underlying
the varying degree of response towards antipsychotic will help towards
safe and effective medication and to develop novel diagnostic with im-
provement in current therapeutics.
Methods: Here, we genotype 331 patients from northern India enrolled
as per as DSM-IV criteria. Patients were evaluated by CGI(I) during
enrollment and followed up for period of three months and reassessment
was performed. The definition of response to treatment was based on
rating of 2 or two point reduction of CGI(I) scale from baseline otherwise
patients classified as incomplete responders. Following the criteria 159
subject were categorized as complete responders and 158 as incomplete
responders. Total 40 single nucleotide polymorphisms (SNPs) from
12 genes of dopaminergic and serotonergic receptors known targets for
antipsychotics were investigated using Illumina GoldenGate customized
array.
Results: We observed statistical significant difference among
complete responders and incomplete responder for polymorphisms
of HTR1A (rs878567- OR=2.41, 95% CI=1.33–4.39; rs1423691-2.04,95%
CI=1.16–3.58), HTR3B (rs2276307-OR=1.96, 95%CI=1.22–3.17), HTR3B
(rs1176744-OR=1.69, 95% CI=1.03–2.79). We identified a significant
three marker “GGC” haplotype (rs1423691-rs878567-rs6295) of HTR1A
and “CGG” (rs1176744-rs2276307-rs2276308) of HTR3B significantly asso-
ciated with disease with p-value 0.03 and 0.02 respectively. None of the
associations withstands multiple correction. However, the individual
role of these genes in antipsychotic response cannot be ignored.
Conclusion: HTR1A haplotype consist SNPs of 5#UTR and 3#UTR re-
gion suggesting regulatory potential. Moreover, HTR3B haplotype consist
of nonsynonymous variant (rs1176744;Tyr129Ser) which altered protein
structure. This study demonstrates the potential of variants from serotonin
receptor that could identify drug response predictors that mediate the ef-
fect of antipsychotics.
Policy of full disclosure: None.
P-32-007 PAPA – Pharmacokinetics in pregnancy and
antidepressant drugs
A. Josefsson1, M. Reis1. 1Linköping University, Linköping, Sweden
Objective: Background. The pregnant woman is unique with regard to the
dramatic physiological changes that occur during 40 weeks as well as sub-
sequent pharmacokinetic (PK) changes. Concern for the effects of antide-
pressant drugs on the fetus is great. Still the mother has to be treated and
kept healthy since the impact of psychiatric illness is high on the fetus/
child. There is an acute shortage of studies of continuous PK-change in
pregnant women not least with respect to antidepressant drugs. Specific
objective: The main aim was to elucidate if, how, when and why PK
changes of specific antidepressants occur during pregnancy, their metabo-
lites and, if applicable, the enantiomers.
Methods: The study was a hypothesis generating, prospective and
naturalistic pharmacokinetic study of 5 antidepressant drugs; citalopram,
sertraline, mirtazapine, venlafaxine, and escitalopram. Pregnant women
medicated with an antidepressant were identified during their first
visit to antenatal care (gestational week 6–10). They were genotyped for
genes (CYP2D6, CYP2C19) coding for crucial drug metabolic enzymes.
Antidepressant drug serum concentration was taken as well as several
blood samples for physiological markers. At gestational week 15, 20, 25,
35 and at partus the procedure was repeated and umbilical cord drug con-
centration was taken. Concomitant medication, weight changes and
smoking habits were observed throughout the pregnancy.
Results: Preliminary results. Seventy-six women were included; antide-
pressant PK-data were obtained from 39 completed pregnancies. The most
common drugs were sertraline and citalopram. The mean ratio for drug
concentration umbilical cord/mother was 0.73 for citalopram (n=12);
and 0.40 for sertraline (n=20). The mean ratio s-albumin at partus/first
visit was 0.7; the orosomukoid ratio 0.9; and the cystatin C ratio 1.9.
Conclusion: In order to optimize antidepressant treatment an increased
understanding of the continuous pharmacokinetic changes in the preg-
nant body is vital. The results of this study fill some of the knowledge
gaps.
Policy of full disclosure: None.
P-32-008 A deep sequencing study of circulating microRNA levels
in peripheral whole blood following ECT for severe
depression
E. Kolshus1, G. Blackshields1, D. McLoughlin1, K. Ryan2. 1St. Patrick’s
Hospital, Dublin, Ireland; 2TCIN, Trinity College, Dublin, Ireland
Objective: A discovery phase study to assess alterations in microRNA
expression following treatment with electroconvulsive therapy (ECT).
Methods: 16 patients (8 females; age 63.7 (SD=13.1) with a major
depressive episode (DSM-IV) and who showed a good response to ECT
were selected from a larger cohort participating in a randomised con-
trolled trial of ECT for depression (ISRCTN23577151). Depression
severity was assessed using the Hamilton Depression Rating Scale
(HDRS). We also measured: general cognition using the Addenbrooke’s
Cognitive Examination-Revised (ACE-R); frontal-executive function
120 Poster Sessions, Tuesday 24 June 2014
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
using Trail-making (TMT-B) and fluency tests; working memory using
Digit Spans; and verbal memory using the Buschke Selective Reminding
Test (BSRT). Early morning fasting whole blood samples were taken be-
fore and after completing the allocated ECT course using the PaxGene sys-
tem (Qiagen) and then purified using PaxGene kits. Deep sequencing was
performed using the SOLiD platform (Applied Biosystems). Bioinformatic
analysis of deep sequencing data was performed to identify differentially
expressed miRNAs. With 16 patients we have 80% power to detect a
2-fold change in miRNA levels. Correlation analyses of pre/post-ECT
changes in miRNA abundance with clinical data were performed.
Results: Pre and post ECT HDRS scores were 30.4(5.7) and 7.1(4.1). The
quality of the miRNA samples was good (RIN>6) for sequencing, which
revealed several miRNAs with altered levels post ECT. These data and
further bioinformatic analyses of target mRNAs will be presented along
with results of clinical association studies.
Conclusion: MicroRNAs may have a role as a biomarker in depression.
Policy of full disclosure: None.
P-33. Psychoneuroimmunology and
neuroinflammation B
P-33-001 A cytokine study in children and adolescents with tic
disorders and/or OCD
T. Park1, Y.W. Jung2. 1Chonbuk University Medical School, Jeonju-Si,
Republic of Korea; 2College of Pharmacy, Korea University, Sejong-Si,
Republic of Korea
Objective: Although earlier studies indicated a possible relationship be-
tween and the cytokines and tic disorders and/or OCD, it still remains
to be determined the expressions of proinflammatory cytokines in the
sera of the patients.
Methods: 43 children and adolescents with tic disorders and/or OCD
and 17 healthy comparison subjects were enrolled. These samples were
analyzed for the concentration of proinflammatory cytokines by enzyme-
linked immunosorbent assay (ELISA).
Results: Among these cytokines, little or no expressions of IL-2 and IL-6
were found in both tic patients and healthy subjects. In addition, IL-12,
IL-17A, CCL2 and IL-1b were detectable from most samples, but the
expressions of these cytokines were comparable between these two
groups. On the other hand, the expression of tumor necrosis factor
(TNF)-alpha was significantly higher in the sera of the patients compared
to the ones of healthy controls.
Conclusion: Findings suggest a role for TNF-alpha in tic disorders and/
or OCD. TNF-alpha can be a good target to develop new therapy to treat
these patients.
Policy of full disclosure: None.
P-33-002 CCL2 is associated with hippocampal and amygdala
volume in females with major depressive disorder
J. Savitz1, W. Drevets2, C. Smith1, T. Victor3, B. Wurfel1, P. Bellgowan1,
J. Bodurka1, K. Teague3, R. Dantzer4. 1LIBR, Tulsa, USA; 2Titusville,
USA; 3Tulsa, USA; 4Houston, USA
Objective: Major depressive disorder (MDD) has been associated with
altered peripheral concentrations of pro-inflammatory cytokines and che-
mokines including CC chemokine ligand-2 (CCL2; MCP-1) which is se-
creted by tissue macrophages and dendritic cells as well as by neurons,
astrocytes and microglia. MDD-associated reductions in hippocampal vol-
ume that are thought to reflect dendritic atrophy have been reported.
Nevertheless, the possibility that morphometric abnormalities of the
brain are associated with peripheral immune alterations has not been
investigated in the context of MDD.
Methods: Here we tested for an association between plasma concentra-
tions of CCL2 and gray matter (GM) volumes of the hippocampus in
unmedicated, moderately-to-severely depressed females with MDD (n=
28, age=35.1±9.6, BMI=26.7±4.8) and healthy controls (HC, n=12, age=
35.8±10.8, BMI=28.0±5.0). CCL2 was measured using ELISA from
plasma samples taken within 3 days of scanning. T1-weighted 3T MRI
scans optimized for brain tissue contrast were acquired and GM volumes
were segmented using FreeSurfer.
Results: The MDD and HC groups did not differ significantly from
each other with respect to CCL2 concentration, total GM volume, and
hippocampal volume. Within the MDD group, CCL2 was positively
correlated with the Hamilton Depression Rating Scale (Ham-D) score
(rs=0.4, p<0.05) as well as hippocampal volume (rs=0.4, p<0.05), but
not total GM volume. CCL2 showed a similar magnitude of correlation
with hippocampal GM volume in the HC although the results were not
significant, possibly because of the smaller sample size.
Conclusion: Our preliminary results are consistent with a role for
CCL2 in neuroprotection and neuroplasticity and they call for a larger,
more systematic study of the relationship between CCL2 and brain
morphometry.
Policy of full disclosure: Wayne Drevets is an employee of Janssen
Pharmaceuticals. Jonathan Savitz has received funding from Janssen
Pharmaceuticals. The other authors have no disclosures to make.
P-33-003 Effects of mood-modulating drugs on
lipopolysaccharide-induced hypothermia and elevation
in plasma cytokines levels in rats
Y. Sharon-Granit1, A. Nassar1, A. N. Azab1. 1Ben-Gurion University of the
Negev, Beer-Sheva, Israel
Objective: Accumulating evidence suggests that mood-modulating drugs
exhibit anti-inflammatory properties. Numerous studies examined the ef-
fects of mood-modulating drugs on plasma levels of inflammatory cyto-
kines in bipolar patients, however, these studies revealed various
(sometimes antagonizing) findings for specific cytokines, even under
treatment with the same drug. This study was undertaken to examine
the effects of chronic treatment with lithium (LIT), valproate (VPA), carba-
mazepine (CBZ), olanzapine (OLZ) and imipramine (IMI) on lipopolysac-
charide (LPS)-induced production of tumor necrosis factor (TNF)-alpha,
interleukin (IL)-6 and IL-10 in rats.
Methods: Rats were treated with LIT (50 or 100mg/kg), VPA (50 or
100mg/kg), CBZ (20 or 40mg/kg), OLZ (5 or 10mg/kg) and IMI (5 or
20mg/kg) for 4 weeks by a single daily intraperitonteal (ip) injection.
On day 29, at 2 h post drug treatment, rats were injected (ip) with saline
or LPS (1 mg/kg). At 1.5 h post LPS injection, body temperature (BT)
was measured and immediately thereafter rats were sacrificed and
blood was collected. Plasma levels of TNF-alpha, IL-6 and IL-10 were
measured by ELISA.
Results: Treatment with LPS resulted in a significant decreased in BT
(hypothermia). All mood-modulating drugs significantly decreased
LPS-induced hypothermia. Moreover, treatment with LPS led to a signifi-
cant increase in plasma levels of TNF-alpha, IL-6 and IL-10. Overall, pre-
treatment with LIT, CBZ and OLZ significantly reduced LPS-induced
elevation in plasma levels of TNF-alpha, IL-6 and IL-10. On the other
hand, VPA and IMI did not alter IL-6 and IL-10 while significantly
decreasing TNF-alpha levels.
Conclusion: These results suggest that mood-modulating drugs
exert different anti-inflammatory properties and that their effects on
inflammatory mediators production are not identical. The mechanism
underlying the ant-hypothermic effect of the drugs is currently under
investigation.
Policy of full disclosure: None.
P-34. Autism spectrum disorders B
P-34-001 Mouse models of tuberous sclerosis complex show
autism-related behavioral deficits severer in Tsc2 than
Tsc1 haploinsufficiency
A. Sato1, Y. Takamatsu2, S. Kasai2, T. Kobayashi3, O. Hino3, K. Ikeda2,
M. Mizuguchi4. 1Tokyo Metropolitan Institute of Medical Science, Tokyo,
Japan; 2Addictive Substance Project, Tokyo Metropolitan Institute of Medical
Science, Tokyo, Japan; 3Department of Molecular, Pathogenesis, Juntendo
University, Tokyo, Japan; 4Department of Developmental Medical Sciences,
The University of Tokyo, Medical Sciences, Tokyo, Japan
Objective: Exaggerated mTOR-mediated signaling is considered as one of
the molecular pathomechanisms in autism spectrum disorder (ASD). This
underlies human diseases that are highly related to ASD, such as tuberous
sclerosis complex (TSC). Haploinsufficiency in the TSC1 or TSC2 genes
cause TSC and the patients with TSC2mutations are likely to have severer
neurological complications including ASD. We previously showed the
impaired social interaction in mouse models of TSC and the therapeutic
efficacy of an mTOR inhibitor rapamycin (Sato et al., Nat Commun,
3;1292:2012). We further analyzed these models for ASD-related beha-
vioral deficits, paying special attention to correlation between genotype
and phenotype.
Methods: We crossed Tsc1+/− and Tsc2+/− mice to obtain wild-type
(WT), Tsc1+/− (Tsc1HZ), Tsc2+/− (Tsc2HZ) and Tsc1+/−;Tsc2+/− (TscD) mice
on the same genetic background. These mice were assessed with social
interaction test (SIT), 3-chamber social test (3CST) and self-grooming
test (SGT). Then rapamycin (5 mg/kg) or vehicle was injected to the
mice intraperitoneally for 2 days. The mice were tested using with SIT
and 3CST.
Results: Tsc1HZ, Tsc2HZ, and TscD mice showed a reduced interest in
a novel mouse in SIT and an intense self-grooming behavior in SGT. In
3CST, the mutant mice as well as WT mice preferred a novel mouse
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over an inanimate object. However, when the cagemate was presented in-
stead of the object, WT and Tsc1HZ mice preferred the novel mouse while
Tsc2HZ and TscD mice did not. Rapamycin reversed the above abnor-
malities in Tsc1HZ, Tsc2HZ and TscD mice.
Conclusion: ASD-related abnormal behavior was severer in Tsc2 than
Tsc1 haploinsufficiency. This finding will contribute to elucidate the mol-
ecular mechanism of ASD in TSC and other disorders associated with
mTOR dysregulation.
Policy of full disclosure: None.
P-34-002 A higher ratio of omega-6/omega-3 fatty acid remarkably
improved the core symptom of autism spectrum disorders
via upregulation of signaling: Comparison with
risperidone solution
K. Yui1, H. Yamanouchi2. 1Ashiya University, Ashiya, Japan; 2Saitama
Medical University, Department of Pediatrics, Morohongo, Japan
Objective: The deviant developmental trajectory may lead to the core
social and behavioral impairments of autism spectrum disorders (ASD).
Impaired signaling due to reduced long-distance functional connectivity
may contribute to the pathophysiology of ASD. There is a few drugs for
treatment of core social impairment. Polyunsaturated fatty acid (PUFA),
docosahexaenoic acid (DHA) and arachidonic acid (ARA) promote neural
function. Particularly, omega-6/omega-3 ratio of 4/1 is associated with
favorable outcome of neuronal function (Yahuda, 2003). In addition, ris-
peridone solution has been reported to improve social and behavioral
impairments.
Methods: We compared the efficacy of supplementation with omega-6/
omrga-3 ratio of 4/1 (omega-6 supplementation) (N=10), and risperidone
solution (N=9) in 19 individuals with ASD (mean age±SD=12.8±7.5
years) in a 16-week open-label treatment. To investigate the relationship
between efficacy of these medical regimens and PUFAs derived signaling,
we examined plasma levels of ceruloplasmin which is protecting the brain
from various neurodegeneration, and superoxide dismutase and transfer-
rin, both of which are modifier of signaling. The outcome measures were
the Aberrant Behavior Checklist (ABC) and the Social Responsiveness
Scale (SRS).
Results: Repeated measures ANOVA revealed that the omega-6
supplementation significantly improved the SRS-measured mannerisms
compared to the risperidone solution during the treatment. Moreover,
the omega-6 supplementation significantly improved four of each five
subscales of the ABC and SRS, respectively from the baseline at the end
of treatment. Plasma ceruloplasmin levels were significantly increased
from the baseline at the end of treatment. Risperidone solution reduced
all of the ABC and SRS subscale scores, however, there were no statistical
significance in score changes on the ABC and SRS, and on plasma levels of
signaling biomarkers from the baseline at the end of treatment. Both treat-
ment regimens did not induce any aversive effects.
Conclusion: Supplementation with omega-6/omega-3 ratio of 4/1
remarkably improved the ASD symptoms and upregulation of signaling.
Policy of full disclosure: None.
P-35. Attention deficit disorders B
P-35-001 Risk factors for Attention-Deficit/Hyperactivity Disorder
(ADHD) in Al-Queir City, Red Sea governorate, Egypt
O. A. Elmagd Elkhouli. Faculty of Medicine, Alexandria, Egypt
Objective: To identify the possible risk factors responsible for attention-
deficit/hyperactivity disorder.
Methods: In this study, risk factors for ADHD were assessed in 144
patients with ADHD, aged 4- 18 years, in Al- Quseir city- Red Sea gover-
norate. Those patients were diagnosed and assessed for possible risk
factors, I.Q, and blood levels of heavy metals using the following tools:
Conner’s Rating Scales-Revised, The Stanford-Binet Intelligence Scale:
Fourth Edition, DSM-IV- TR diagnostic criteria for ADHD, Social scale
assessment, and a special questionnaire to assess possible risk factors
for ADHD.
Results: 144 patients had been diagnosed as having ADHD. Risk factors
for ADHD in this study are: large family size (31.3%, P<0.007), first birth
order (15.3%, P<0.003), neonatal jaundice (16%, P<0.01) and separation
from one parent where living with divorced mothers was a significant
risk factor (4.8%, P<0.006). High blood levels of heavy metals (lead, cop-
per, manganese, cadmium and magnesium) showed significant differ-
ences in comparison to the control group for all subtypes of ADHD,
(P<0.005).
Conclusion: Large family size, first birth order, neonatal jaundice, sep-
aration from one parent and exposure to heavy metals are the most risk
factors for ADHD.
Policy of full disclosure: None.
P-35-002 Methylphenidate improves handwriting of children with
ADHD; a systematic review of controlled clinical trials
M. Ghanbari1, A. Ghanizadeh2. 1Shiraz, Islamic Republic of Iran; 2Research
Center for Psychiatry, Shiraz, Islamic Republic of Iran
Objective: While many studies compared handwriting ability of children
with ADHD and those children without ADHD, contribution of medica-
tions on handwriting in children with attention deficit hyperactivity dis-
order (ADHD) has been sparse. No systematic review examined the role
of stimulants in this regard.
Methods: Literature was searched according to a planned search strat-
egy using the electronic databases PubMed and Google scholar. Inclusion
criteria were interventional studies investigating the effects of stimulants
on handwriting quality in children and adolescents diagnosed with
ADHD. Those articles without the intervention were excluded.
Results: Only nine out of 64 retrieved articles met inclusion criteria. The
assessments used for handwriting was very heterogeneous to perform a
pooled data analysis. Five articles reported double blind control clinical
trials. All the controlled and non-controlled clinical trials administered
methylphenidate. These trials reported that methylphenidate improved
handwriting quality.
Conclusion: Current evidence supports that the use of methylphenidate
is an effective option for the treatment of handwriting in children and
adolescents with ADHD. Recommendations for future studies considering
current literature limitations are provided.
Policy of full disclosure: None.
P-35-003 The effectiveness of neurofeedback in reducing
symptoms of attention deficit and hyperactivity in adults
with attention deficit disorder/hyperactivity
L. Heydarinasab1, A. Madani1. 1Shahed University, Tehran, Islamic Republic
of Iran
Objective: Attention deficit/hyperactivity disorder, is a common psycho-
logical disorder in persons, that begins in childhood and continues into
adulthood and leads to problem in various aspects of life, such as per-
sonal, social, professional life, and executive function such as working
memory and concentration and other aspects of individual performance.
The aim of the present research was to investigate the effectiveness of
neurofeedback in reducing symptoms of attention deficit/hyperactivity
disorder in adults with ADHD.
Methods: Research design was experimental with pre-test and
post-test and control group. The population study are formed of adults
with attention deficit/hyperactivity disorder that refer to the Atieh clinic
in Tehran. Among the statistical population, 8 persons in 2 groups, one ex-
perimental group and one control group of patients that referred to the
Atieh clinic, based on purposive sampling was selected. The research
instruments were the Beck Anxiety Inventory, Beck Depression
Inventory, Inventory adult attention deficit/hyperactivity disorder of
Barkley, IVA test and CNSVS test. Data analysis, through SPSS software
using U Mann-Whitney was performed.
Results: The results showed that neurofeedback led to a significant in-
crease in attention and concentration and significant reduction in impul-
sivity in experimental group compared with the control group.
Policy of full disclosure: None.
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P-36. Foetal-alcohol spectrum disorders
P-36-001 Therapeutic Drug Monitoring (TDM) in maternal serum,
amniotic fluid and umbilical cord blood during pregnancy
and delivery
M. Paulzen1, T. Veselinovic1, N. Frergsen1, T. Goecke1, C. Hienke2,
G. Gründer1. 1RWTH Aachen University, Aachen, Germany; 2University of
Mainz, Mainz, Germany
Objective: Treatment of psychiatric diseases during pregnancy is compli-
cated by the concern for the safety of the unborn child because all psycho-
tropic medications more or less cross the placenta. Fetal outcome is
influenced by various factors and – among others – the effects of a specific
drug itself depend on the concentration in maternal and fetal serum as
well as on its concentration in amniotic fluid.
Methods: The present study is a naturalistic prospective investigation
of different psychotropic drug concentrations in maternal serum (MS)
and amniotic fluid (AF) of 14 women and umbilical cord blood (UC)
of nine newborns. The women were treated with different doses of psy-
chotropic drugs such as antidepressants, antipsychotics, anticonvulsants
and others.
Results: Patients received thirteen different psychotropic drugs. Results
are available for five antidepressants (citalopram, paroxetine, sertraline,
fluoxetine and venlafaxine), 3 anticonvulsants (valproic acid, levetirace-
tam, lamotrigine), 2 benzodiazepines (diazepam, clobazam), as well as
for olanzapine, methadone and methylphenidate.
Conclusion: Concentrations of different psychotropic drugs were found
in maternal plasma, amniotic fluid an umbilical cord blood in highly vari-
able concentrations suggesting that fetal exposure is continual and may
occur through a variety of paths accounting for increased fetal exposure.
Policy of full disclosure: None.
P-37. Neuroimaging B
P-37-001 Neural correlates of antidepressant response to
escitalopram in patients with major depressive disorder:
A preliminary fMRI study
M. Takamura1, Y. Okamoto1, G. Okada1, S. Toki1, T. Yamamoto2,
T. Matsumoto1, S. Yamawaki1. 1Hiroshima University, Hiroshima, Japan;
2Hiroshima University, JSPS, Hiroshima, Japan
Objective: Selective serotonin reuptake inhibitors (SSRIs) are popular
medications for major depressive disorder (MDD), and MDD involves
deficits in the reward system. However, not much is known about the ef-
fects of SSRI on reward system and which biological changes are needed
to recover from a major depressive episode. The aim of the present study
was to elucidate the underlying mechanism of SSRI treatment and to
evaluate the relationship between clinical outcome and changes in brain
activation during anticipation of incentives.
Methods: In this preliminary study, twelve patients with MDD under-
went functional magnetic resonance imaging (fMRI) during a monetary
incentive delay task at baseline and following 6 weeks treatment with
escitalopram, an SSRI. Severity of depression was measured with the
Hamilton Rating Scale of Depression.
Results: There was no significant main effect of SSRI treatment in any
brain area. We noted a significant interaction between treatment response
and changes in the brain activation during anticipation of reward.
Specifically, improvement in depression ratings was positively correlated
with change in the activation of striatum and left lateral prefrontal cortex.
Conclusion: These results suggest that successful treatment with escita-
lopram may be associated with modulation of brain activity in regions
within the reward network.
Policy of full disclosure: None.
P-37-002 Therapeutic window of antipsychotic occupancy at
dopamine D2/3 receptors in older patients with
schizophrenia: A longitudinal clinical PET study
A. Graff1, T. K. Rajji1, B. H. Mulsant1, S. Nakajima1, F. Caravaggio1,
T. Suzuki2, H. Uchida3, P. Gerretsen1, T. Arenovich1, B. G. Pollock1,
D. C. Mamo4. 1CAMH, Toronto, Canada; 2CAMH, Tokio, Japan; 3Tokio,
Japan; 4Malta, Malta
Objective: Patients with schizophrenia are aging. Reports suggest that
older patients will double by 2030 to equal the population of younger
ones. Clinical guidelines for patients with schizophrenia recommend
using lower antipsychotic doses. These guidelines are based on limited
empirical data that do not take into account mechanistic processes
involved in age-associated medication sensitivity. The aim of the current
study was to establish a clinically effective therapeutic window of antipsy-
chotic occupancy at striatal dopamine D2/3 receptors in older patients
with schizophrenia.
Methods: The current longitudinal and prospective study included 35
clinically stable older patients with schizophrenia (age=60.1±7.0 years)
treated with the same dose of oral olanzapine (20.8±6.6 mg/day) or risper-
idone (4.7±2.9 mg/day) for at least 6 months. Patients were scanned with
[11C]-raclopride before and after a 40% reduction of their dose and were
monitored clinically for at least three months after reaching the final dose.
D2/3R occupancies were estimated using 53 controls to derive an
age-and-sex matched non-displaceable binding potential as an antipsy-
chotic free condition.
Results: The relative decrease in striatal D2/3 occupancy was 7%; 85%
of the patients remained clinically stable. Clinical deterioration was only
observed in patients without extra-pyramidal symptoms (EPS) at baseline.
The lowest D2/3 occupancy associated with clinical stability was 45%. EPS
were more likely with D2/3 occupancies higher than 60%. EPS and serum
prolactin levels decreased following dose reduction. No changes were
found in the mean total, positive, negative, and general psychopathology
subscale scores of the PANSS; or in the mean total scores of the BPRS and
CGI-S over the course of the study.
Conclusion: Antipsychotic dose reduction is feasible in older patients
with schizophrenia and improves antipsychotic associated side effects.
The therapeutic window for D2/3 antipsychotic occupancy appears
lower in older patients with schizophrenia (45%–60%) than previously
reported in younger patients (65%–80%).
Policy of full disclosure: Dr. Graff-Guerrero has received research sup-
port from the following external funding agencies: CIHR, US NIH,
Ontario Mental Health Foundation, Mexico ICyTDF and CONACyT.
Other authors have no financial or other relationship relevant to the sub-
ject of this manuscript. Dr. Rajji has received research support from Brain
and Behavior Research Foundation (previously known as NARSAD),
Canadian Foundation for Innovation, Canadian Institutes of Health
Research (CIHR), Ontario Ministry of Health and Long-Term Care,
Ontario Ministry of Research and Innovation, US National Institute of
Health (NIH), and the W. Garfield Weston Foundation. Dr Mulsant cur-
rently receives research support from the Canadian Institutes of Health
Research, the US National Institute of Health (NIH), Bristol-Myers
Squibb (medications for a NIH-funded clinical trial) and Pfizer (medica-
tions for a NIH-funded clinical trial). Within the past five years he has
received research support from Eli-Lilly (medications for a NIH-funded
clinical trial) and some travel support from Roche. He directly own stocks
of General Electric (less than $5,000). Dr. Nakajima has received a fellow-
ship grant from the Nakatomi Foundation and Japan Society for the
Promotion of Science and manuscript fees from Dainippon Sumitomo
Pharma and Kyowa Hakko Kirin. Fernando Caravaggio has not conflict
of interest to declare Dr. Suzuki has received manuscript or speaker’s
fees from Astellas, Dainippon Sumitomo, Eli Lilly, Elsevier Japan,
Janssen, Meiji Seika, Novartis, Otsuka, and Weily Japan. Dr. Uchida has
received grants from Pfizer, Astellas Pharmaceutical, Eisai, Otsuka
Pharmaceutical, GlaxoSmithKline, Shionogi, Dainippon-Sumitomo
Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharma, Janssen
Pharmaceutical, and Yoshitomi Yakuhin and speaker’s honoraria from
Otsuka Pharmaceutical, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomi
Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, Abbvie,
and Janssen Pharmaceutical within the past two years. Dr. Gerretsen
has not conflict of interest to declare Tamara Arenovich has not conflict
of interest to declare Dr. Pollock receives research support from the
National Institute of Health, Canadian Institutes of Health Research,
American Psychiatric Association, and the Foundation of the Centre for
Addiction and Mental Health. Within the past five years he has been a
member of the advisory board of Lundbeck Canada (final meeting was
May 2009). He was also a member of the advisory board of Forest
Laboratories (final meeting was March 2008). Dr. Pollock has served
one time as a consultant for Wyeth (October 2008) and Takeda (July
2007). He was also a faculty member of the Lundbeck International
Neuroscience Foundation (LINF) (final meeting was April 2010).
Dr. Mamo has received research support from the following external
funding agencies: CIHR, the US NIH, Ontario Ministry of Health and
Long Term Care. He has also received grants or consultant fees from
the Bristol-Myers Squibb and Pfizer and has received speaker’s honoraria
from AstraZeneca.
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P-37-003 Dopamine transporter gene on prediction of brain
dopamine activity and cognitive function in patient with
alcohol dependence?
S.-Y. Huang1, C.-H. Yen2, C.-C. Huang1, Y.-W. Yeh1, S.-C. Kuo1.
1Tri-Service General Hospital, Taiepi, Taiwan; 2Tri-Service General Hospital,
Neurology, Taiepi, Taiwan
Objective: Evidence has suggested that the dopamine transporter (DAT)
plays a role in the pathogenesis of alcohol dependence (AD) and de-
pression and that polymorphisms of the DAT may influence the brain
availability. This study evaluated the differences in DAT availability/cog-
nitive function between healthy controls and AD patients, and evaluated
the impact of DAT polymorphisms both on DAT availability and cogni-
tive function.
Methods: Thirty healthy controls and thirty-five patient with AD were
recruited. DAT availability was measured in vivo with single photon
emission computed tomography and 99mTc-labeled TRODAT-1 in the
striatum, caudate, putamen. Cognitive function such as TMT, WCST,
Stroop test were investigated before image study. Each subject was geno-
typed for the DAT polymorphism.
Results: Compared to healthy controls, there was a significantly lower
availability of DAT in the striatum, caudate and putamen among patients
with AD. Significant disturbances of working memory and executive
functions were noted in patients with alcohol dependence. In addition,
AD patients had worse results of TMTA,B, Stroop test RIT,NIT,RIC,
NIC, WCST total errors. Of patients with anxiety, depression and alcohol
dependence (ANX/DEPALC), the carriers of one ten repeat allele showed
a significantly higher availability of DAT in the striatum compared to non-
ten repeat carriers. After Bonferroni correction, these significances van-
ished. There were no significant differences in DAT availability between
controls and ANX/DEP ALC.
Conclusion: The results suggest that alcoholics may have lower DAT
availability in the Striatum; the DAT polymorphism may influence DAT
availability in patient with AD. These findings may serve as a springboard
for future large-scale studies.
Policy of full disclosure: None.
P-37-004 Dopamine transporter reduction associated the
development of heroin dependence and poor cognitive
function
S.-Y. Huang1, C.-S. Liang2, C.-H. Yen3. 1Tri-Service General Hospital, Taiepi,
Taiwan; 2Tri-Service General Hospital, Beitou Branch, Taiepi, Taiwan;
3Tri-Service General Hospital, Department of Neurology, Taiepi, Taiwan
Objective: Much evidence suggests that the Dopamine system may play
an important role in the pathophysiology of Heroin dependence (HD)
and cognitive function. This study sought to investigate the changes in
striatal dopamine transporter density in opioid-dependent individuals
and assess their cognitive function.
Methods: Single photon emission computed tomography with
99mTc-TRODAT-1 as ligand measured striatal dopamine transporter
levels in 20 opioid-dependent individuals without a history of methadone
or methamphetamine exposure and 20 age- and sex-matched healthy con-
trols. Wisconsin Card Sorting Test was performed to assess neurocogni-
tive function.
Results: Opioid-dependent individuals showed significant striatal
dopamine transporter reduction, with the greatest severity in left caudate,
and poorer performance on the Wisconsin Card Sorting Test, including
total amount, total errors, perseverative response, perseverative errors
and non-perseverative errors. Striatal dopamine transporter levels corre-
lated with non-perseverative errors in either opioid group or control
group.
Conclusion: These results demonstrate that in human repeated opioid
exposure may reduce striatal dopamine transporter density that was asso-
ciated with non-perseverative errors. We suggest that non-perseverative
error may be a more sensitive parameter to identify striatal DAT
density-associated dysfunction of working memory maintenance.
Policy of full disclosure: None.
P-37-005 Effects of hormone replacement therapy on cerebral
serotonin-1A receptor binding in postmenopausal women
examined with [carbonyl- 11C]WAY-100635
G. Kranz1, C. Rami-Mark1, U. Kaufmann1, P. Baldinger1, A. Hahn1,
M. Savli1, P. Stein1, W. Wadsak1, M. Mitterhauser1, R. Lanzenberger1,
S. Kasper1. 1Medical University of Vienna, Vienna, Austria
Objective: Preclinical research points to a strong modulatory influence of
gonadal hormones on the serotonin system. However, human data corro-
borating this association remains scarce. The aim of this study was to
examine the effects of hormone replacement therapy on 5-HT1A receptor
binding in postmenopausal women using positron emission tomography
(PET) and the radioligand [carbonyl-11C]WAY-100635.
Methods: In this randomized, double-blind, longitudinal study,
30 postmenopausal women underwent treatment with either a combi-
nation of oral 17#-estradiol valerate and micronized progesterone
(group 1, n=10), oral 17#-estradiol valerate (group 2, n=10), or placebo
(group 3, n=10). Two PET measurements were performed, the first on
the day before treatment start and the second after at least eight weeks
of treatment. Plasma levels of estradiol (E2), progesterone (P4), sex
hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate
(DHEAS), follicle stimulating hormone (FSH) and luteinizing hormone
(LH) were collected prior to PET measurements.
Results: As expected, hormone replacement therapy led to a significant
increase in E2 and P4 plasma levels in group 1 and to a significant increase
in E2 levels in group 2. The 5-HT1A receptor binding did not change
significantly after estrogen, combined estrogen/progesterone treatment
or placebo in any of the investigated brain regions. There were no signifi-
cant correlations between changes in E2 or P4 values and changes in
5-HT1A receptor binding.
Conclusion: Although we were not able to confirm effects of gonadal
hormone treatment on 5-HT1A receptor binding, our data do not preclude
associations between sex steroid levels and serotonin, the neurotransmit-
ter implicated most strongly in the pathogenesis of affective and anxiety
disorders.
Policy of full disclosure: None.
P-38. Others B
P-38-001 Optogenetic activation of dorsal raphe serotonin neurons
enhances patience for future rewards
K. Miyazaki1, K. Tanaka2, A. Yamanaka3, A. Takahashi4, K. Doya5.
1Okinawa, Japan; 2Keio University, Tokyo, Japan; 3Nagoya University,
Nagoya, Japan; 4National Institute of Genetics, Mishima, Japan; 5OIST,
Okinawa, Japan
Objective: The classic theory on serotonin states that it opposes dopamine
and inhibits behaviors when aversive events are predicted. However, the
therapeutic effects of serotonin signal-enhancing medications have been
difficult to reconcile with this theory. Recent recording and pharmacologi-
cal inhibition studies of serotonin neurons in the dorsal raphe nucleus
(DRN) have shown that these neurons play roles in promoting actions
for future rewards.
Methods: Here we developed mice that express channelrhodopsin-2 in
the serotonin neurons and showed that the selective activation of the sero-
tonin neurons in the DRN enhanced the mice’s patience in waiting for
both the conditioned reinforcer tone at a tone site and the food reward
at a food site.
Results: Optogenetic activation of DRN serotonin neurons while the
mice waited for the tone by keep nosepoking at the tone site significantly
reduced the number of tone wait errors. When the duration of the tone
delay was increased, the reduction in the number of the tone-wait errors
was more effective with the longer tone delays. When serotonin neurons
were activated during the variable delay periods when the mice waited
for the food by keep nosepoking at the food site (3, 6, or 9 sec or infinity,
i.e., omission), the reward wait errors were significantly reduced in the
9 sec waiting trials. In the reward omission trials, the waiting time of
the mice was significantly longer (17.5 sec; mean) in the serotonin acti-
vation trials compared with the trials with no activation (12.0 sec).
Prolonged waiting time with optogenetical stimulation would not due
to a reinforcing effect induced by serotonin neural activation. Durations
of spontaneous nosepoking at the food site were not significantly different
between with and without serotonin neural activation.
Conclusion: These results indicate that the temporally precise activation
of the serotonin neurons during waiting facilitates patience for delayed
rewards.
Policy of full disclosure: None.
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P-38-002 Effect of quetiapine on DNA methylation in
neuroblastoma cells
H. Sugawara1, M. Bundo2, T. Asai2, F. Sunaga2, J. Ueda3, J. Ishigooka1,
K. Kasai2, T. Kato3, K. Iwamoto2. 1Tokyo Women´s Medical University,
Tokyo, Japan; 2University of Tokyo, Tokyo, Japan; 3RIKEN BSI, Wako, Japan
Objective: Epigenetic regulation may be involved in the pathophysiology
of mental disorders, such as schizophrenia and bipolar disorder, and in
the pharmacological action of treatment drugs. We previously reported
the hypermethylation of serotonin transporter, SLC6A4 in patients with
bipolar disorder (BD), and the methylation level in the same region was
decreased in human neuroblastoma cells treated with three mood stabili-
zers (lithium, valproate and carbamazepine). Characterizing the epigen-
etic effects of treatment drugs is an important step to optimal treatment.
Methods: We performed genome-wide DNA methylation analysis of
using human neuroblastoma cells treated with quetiapine (QTP) using
Infinium HumanMethylation 27 BeadChip. We also examined common
methylation changes with other three mood stabilizers by QTP treatment.
Furthermore, we performed bisulfite sequencing analysis to examine the
effect of QTP on the DNA methylation level of the promoter region of
SLC6A4.
Results: A total of 1,173 genes showed altered DNA methylation.
Altered DNA methylation dominantly occurred as hypomethylation with-
in the CpG island. Gene ontology analysis revealed that these genes were
related to the cellular process of intracellular protein binding. There was
no common effect of QTP with other three mood stabilizers. However,
common DNA methylation changes in seven genes, including
ADRA1A, which encodes alpha 1A-adrenoceptor, were found with que-
tiapine and lithium treatment. Finally, we detected the decreased DNA
methylation level of the promoter region of SLC6A4 by bisulfite-
sequencing analysis, which was consistent change with other three
mood stabilizers.
Conclusion: QTP altered DNA methylation levels at a subset of CpG
sites, preferentially located within CpG islands Although whether these
effects are directly related to drug efficacy remain unknown, decreased
methylation of the promoter region of SLC6A4 suggests the mood
stabilizer-like role of QTP. Future studies such as gene expression analysis
and animal model experiments will be required.
Policy of full disclosure: M.B., F.S., and K.I. are employed by the
Department of Molecular Psychiatry, Graduate School of Medicine, The
University of Tokyo, Tokyo, Japan, which is endowed by Astellas
Pharma, Dainippon Sumitomo Pharma, and Yoshitomiyakuhin.
P-38-003 Convulsive liability of cefepime and meropenem in
normal and corneally kindled mice
A. Tanaka1, K. Takechi1, S. Watanabe1, M. Tanaka1, H. Araki1. 1Toon, Japan
Objective:We previously reported that the prevalence of convulsions was
significantly higher in patients treated with cefepime than in patients trea-
ted with meropenem. Additionally, cefepime-associated convulsions
occur only in patients with brain disorders, not in those with renal failure.
In this study, we examined the convulsive liability of cefepime and mer-
openem in normal mice and in corneally kindled mice with a low seizure
threshold.
Methods: We assessed the proconvulsive liability of cefepime and mer-
openem in mice using pentylenetetrazol (PTZ) injection, electroconvulsive
shock at low stimulus currents and corneal kindled. In addition, we mea-
sured electroencephalogram (EEG) activity 1 min after injection of the
antibiotics.
Results: Cefepime and meropenem, administered by intravenous injec-
tion, at 250 or 500mg/kg, had no effect on PTZ-induced convulsions in
normal mice. In mice with seizures induced by electroconvulsive shock
at low stimulus currents, mean seizure duration in animals administered
500mg/kg cefepime was significantly greater than in animals adminis-
tered saline. Furthermore, EEG spikes were present in animals injected
with 500mg/kg cefepime. In corneally kindled mice, mean seizure dur-
ation in animals given cefepime was significantly greater than in mice
given meropenem.
Conclusion: The convulsive liability of cefepime was significantly
greater than that of meropenem in normal and corneally kindled mice.
These findings suggest that cefepime may have substantial neurotoxicity
in patients with a low seizure threshold.
Policy of full disclosure: None.
P-38-004 Psychotropic drug utilization in child and adolescent
psychiatry inpatients of a university hospital
A. Kamath1, S. Hadigal1, P. Kamath1, A. Shenoy1. 1Kasturba Medical
College, Mangalore, Karnataka, India
Objective: With a predominantly younger population, psychiatric mor-
bidity in children in India is relatively high. Studies from around the
world show an increase in the use of psychotropic medication in children.
The patterns of drug utilization vary internationally and within regions.
The objective of our study was to determine the psychotropic drug utiliz-
ation pattern in child and adolescent psychiatry inpatients in a university
hospital in India and determine the presence of any gender difference.
Methods:Hospital records of all psychiatry inpatients less than or equal
to 18 years of age admitted over a period of one year were studied. Drugs
prescribed before hospitalization, during hospital stay and on discharge
were recorded. The drug classes were delineated as follows - antidepres-
sants, antipsychotics, mood stabilizers, anxiolytics/hypnotics and
stimulants.
Results: Of the 82 patients admitted, 59.8% were males. The mean age
was 11.47±5.09 years in males and 13.67±4.09 years in females (p<0.05).
Adjustment disorder was the commonest psychiatric illness followed by
anxiety disorder. 54.88% of the patients did not receive any psychotropic
drugs. 18.3% were prescribed antidepressants, 24.4% antipsychotics and
36.6% anxiolytics. Lorazepam was the most commonly prescribed drug
followed by olanzapine (22% and 9.8% respectively). Use of antidepres-
sants, antipsychotics and anxiolytics was significantly more in females
(p<0.05). 26.6% of the patients were prescribed more than one psycho-
tropic drug on discharge.
Conclusion: The age and gender presentation was similar to those
reported by other studies. Anxiolytics and antipsychotics were the most
commonly prescribed psychotropic drugs. No psychostimulants were pre-
scribed. No significant difference in the drug use was seen on admission
and discharge. Polypharmacy seen in our study is less than those reported
by other studies among psychiatry inpatients. A gender difference in the
use of psychotropic medications was seen which could be due to the dif-
ference in the pattern of psychiatric morbidity.
Policy of full disclosure: None.
P-38-005 Treatment of neuroleptic malignant syndrome in child
and adolescent: A case report
M.-D. Kim1, K.-H. Lee2, S. Chung3. 1Jeju National University Hospital, Jeju,
Republic of Korea; 2Dongguk University Hospital, Kyungju, Republic of Korea;
3Chonbuk University Hospital, Jeonju, Republic of Korea
Objective: Neuroleptic Malignant Syndrome is a rare clinical syndrome
occurring due to idiosyncratic reaction after use of neuroleptics.
Recently, the use of antipsychotics has been increasing in the field of
child and adolescent psychiatry especially in psychosis, mood disorder,
and destructive behavior disorders.
Methods: Case: A 14-year-old male patient, diagnosed with schizo-
phrenia. He was prescribed with 6mg/day of risperidone in combination
with 300mg/day of quetiapine. The 3 days before the onset of neuroleptic
malignant syndrome, all oral medications were stopped along with NPO
for treatment due to manifestation of paralytic ileus from worsening of
underlying constipation; in addition, IM injection of haloperidol was
only allowed for the symptom control. The day before the onset, an IM
injection of 15mg of haloperidol and 10mg of lorazepam resulted in
vomiting, headache, fever of 39°, systemic tremor and stiffness, confusion,
tachycardia and sweating. Blood work-up performed on day of admission
at ICU indicated CPK 2836 IU/L and myoglobulin 337.2 ng/ml, and CPK,
after peaking at 4493 IU/L, continuously decreased and was normalized
by the 18th day at ICU. Diazepam, dantrolene, domperidone, L-Dopa/
benserazide and cold blanket were applied.
Results: Normalization of hematologic abnormalities were followed by
stabilization of tremor, stiffness, and high fever on the 18th day.
Conclusion: Neuroleptic malignant syndrome is an exigent condition
which may cause fatal outcomes in the field of psychiatric treatment.
Cautious pre-evaluation of risk factors in patients requiring neuroleptics
are critical in order to prevent fatal complications.
Policy of full disclosure: None.
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P-38-006 Prenatal maternal stress from a natural disaster predicts
hippocampal volumes in boys at age 11: Project Ice Storm
S. King1, R. Dufoix2, D. P. Laplante3. 1Department of Psychiatry, McGill
University, Douglas Mental Health University Institute, Verdun, Quebec,
Canada; 2Montreal, Canada; 3Douglas Hospital Research Centre, Montreal,
Canada
Objective: The hippocampus develops primarily during the fetal
period and plays a pivotal role in learning and memory. Non-human
primate studies have demonstrated that early and late in utero exposure
to maternal stress result in reduced hippocampal volumes. However,
no human prospective studies of the effects of prenatal maternal
stress (PNMS) on the hippocampal development have been conducted.
Our objective was to determine whether in utero exposure to disaster-
related PNMS is associated with altered hippocampal volumes in
11½ year-old children. We hypothesized that higher maternal objective
or subjective PNMS levels would be related to smaller hippocampal
volumes.
Methods: Measures of maternal objective exposure and subjective dis-
tress were obtained after the 1998 Quebec Ice Storm. We obtained a 3D,
1×1×1 mm3, T1-weighted Magnetization Prepared Rapid Gradient Echo
sequence (TR/TE/TI=2300/2.98/900ms) of 33 male and 32 female 11½
year-olds. Hippocampal segmentation from native MRI scans was per-
formed by a collaborator who was blind to all other subject data using
the fully automatic SACHA method. The number of obstetric complica-
tions was determined by maternal recall at 6 months postpartum and ver-
ified using hospital records.
Results: More obstetric complications were related to smaller right hip-
pocampal volumes (RHCV) in both male and females. Higher levels of
maternal objective exposure were related to smaller RHCV in males
only. Objective exposure and obstetric complications and their interaction,
explained 34.6% of variance in males’ RHCV: males exposed to high levels
of objective exposure or obstetric complication or both had smaller RHCV
compared to males exposed to low objective hardship and obstetric
complications.
Conclusion: Our results suggest that higher levels of disaster-related
objective hardship, but not subjective distress are related to smaller
RHCV in male but not female children. It remains to be determined
whether this alteration in RHCV of 11.5 years old males is related to ob-
servable phenotypes.
Policy of full disclosure: none
P-38-007 Prenatal maternal stress and toddler stress reactivity at
2½ years of age: The Iowa flood study
S. King1, E. Ping Yong2, M.W. O´Hara3, D. P. Laplante2. 1Department of
Psychiatry, McGill University, Douglas Mental Health University Institute,
Verdun, Quebec, Canada; 2Douglas Hospital Research Centre, Montreal,
Canada; 3Iowa City, USA
Objective: Prenatal maternal stress (PNMS) has been found to affect
domains of cognitive, behavioural, emotional, and psychosocial develop-
ment in offspring. Studies suggest dysregulated activity of the hypothala-
mic pituitary adrenal (HPA) axis may underlie such manifestations. Given
that PNMS is associated with an influx of maternal glucocorticoids, which
are transmitted to the fetus via the placenta, researchers are interested in
examining how PNMS in turn affects the development of the fetal HPA
axis. Moreover, how these effects present themselves throughout post-
natal development. While animal and human studies have found PNMS
exposure to be associated with dysregulated HPA axis activity in off-
spring, results are inconsistent and at times contradictory. The objective
of this study was to determine the association between the severity of
disaster-related prenatal maternal stress (Iowa flood of 2008) and infant
stress reactivity.
Methods: Women were recruited shortly after 100-year floods in Iowa,
USA in June 2008, and their objective exposure to the floods and subjec-
tive distress assessed. A sample of 88 mother-toddler dyads participated
in a laboratory assessment that involved a brief maternal-toddler separ-
ation to invoke a stress response in the toddler. Salivary cortisol samples
were collected four times throughout the assessment. Percent change in
cortisol and area under the curve were computed to assess the toddlers#
stress response.
Results: Results from regression analyses show that the subjective rat-
ing of PNMS was a significant predictor of percent change and area
under the curve, but was moderated by infant sex: greater subjective
PNMS was associated with hyper-secretion of cortisol in females and a
blunted response in males. These results persisted after controlling for
time of day of the assessment and baseline cortisol levels.
Conclusion: The results from the present study suggest that
in-utero exposure to PNMS can have long-term implications for the
functioning of the stress response system, evident throughout early
childhood.
Policy of full disclosure: None.
P-38-008 Prenatal maternal exposure to a natural disaster predicts
more masculine 2d:4d finger length ratio in girls: Project
ice storm
S. King1, P. L. Hurd2, A. Liu3, D. P. Laplante4. 1Department of Psychiatry,
McGill University, Douglas Mental Health University Institute, Verdun,
Quebec, Canada; 2Edmonton, Canada; 3Douglas Hospital Research Centre,
Verdun, Canada; 4Douglas Hospital Research Centre, Montreal, Canada
Objective: Prenatal maternal stress appears to have masculinizing
effects on some systems and feminizing on others. Most experimental
research is conducted in animals. We capitalized on a natural disaster
in January 1998 in Quebec, Canada to study the effects of stress
exposure in pregnant women on their unborn children. The ratio of
the lengths of the 2nd and 4th fingers (2D:4D ratio), a sexually
dimorphic trait, reportedly reflects in utero testosterone exposure. Our
objective was to determine the extent to which the pregnant women’s
objective degree of exposure to the 1998 Quebec Ice Storm crisis, and
their level of subjective distress about the storm, influenced their
children’s 2D:4D ratio.
Methods: Subjects were 115 French-Canadian women who were preg-
nant during the ice storm, or conceived within 3 months of the storm;
their children (58 girls, 57 boys) at age 5 ½ years; a matched comparison
group of 47 girls and 50 boys; and 111 adult French Canadians (60
women, 51 men). Women were recruited 4-5 months after the ice storm
and completed a questionnaire about objective stress exposure
(Storm32) and their subjective distress about the storm (Impact of Event
Scale # Revised; IES-R). Finger lengths of children and comparison adults
were measured with digital calipers.
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Results: Prenatal ice storm exposed girls had more masculine 2D:4D
than their male peers (p<0.05) while comparison children and adults
had ratios in the expected direction. Ice storm girls had significantly
more masculine 2D:4D than comparison girls; ice storm boys had slightly
more feminine ratios than comparison boys. Timing in gestation of the
stress exposure had effects for both boys and girls.
Conclusion: Prenatal maternal stress exposure, randomly distributed
by a natural disaster, influences a sexually dimorphic trait in children,
resulting in an overall masculinization of girls. Effects of timing and of ob-
jective or subjective stress differed by sex.
Policy of full disclosure: None.
2D:4D Finger lengths in prenatally stressed children and unstressed
controls:
P-38-009 COMT genotype moderates effects of prenatal maternal
stress due to a natural disaster on birth outcomes: The
Iowa flood study
S. King1, K. N. Dancause2, L. Cao2, M.W. O´Hara3, D. P. Laplante2.
1Department of Psychiatry, McGill University, Douglas Mental Health
University Institute, Verdun, Quebec, Canada; 2Douglas Hospital Research
Centre, Montreal, Canada; 3Iowa City, USA
Objective: Prenatal maternal stress (PNMS) is a risk factor for adverse
birth outcomes. These effects vary by timing of exposure and newborn
sex, and perhaps by genotype. However, our understanding remains lim-
ited because of the challenges of designing human studies of PNMS. We
investigate PNMS by studying pregnant women exposed to natural dis-
asters. Disasters provide excellent models of PNMS because the exact tim-
ing of the stressor can be identified, and exposure tends to be randomly
distributed. Our goal was to determine whether and how the timing
and severity of exposure to PNMS due to a natural disaster influences
gestational age and growth measures at birth and whether genotype mod-
erates the effect of maternal stress.
Methods: We assessed objective hardship and subjective distress
among 144 women exposed to severe flooding in Iowa in June 2008 dur-
ing pregnancy. The children’s DNA provided their COMT genotype. We
analyzed associations between objective and subjective PNMS levels and
birth outcomes, and PNMSxCOMT interactions.
Results: Earlier timing of flood exposure predicted lighter birth
weights. More severe PNMS predicted shorter birth lengths among
girls, but longer birth lengths among boys. For babies with the COMT
AA (Met/Met homozygous) genotype, greater PNMS predicts larger size
at birth, while PNMS predicted smaller size at birth in GG (Val/Val)
babies.
Conclusion: Timing of PNMS from a natural disaster during pregnancy
affected birth weight, and severity of PNMS affected birth length with
variations by infant sex and by genotype. These effects were independent
of other maternal characteristics, suggesting that PNMS is an independent
predictor of birth outcomes. Differences between boys and girls might
reflect sex-specific effects of hormones such as testosterone on fetal
growth. More research is necessary to clarify the effects of exposure to
moderately stressful events on birth outcomes, and the underlying
mechanisms.
Policy of full disclosure: None.
P-38-010 Prenatal maternal stress increases the risk for asthma
in 12 year old girls
S. King1, A.-M. Turcotte-Tremblay2, R. Lim3, D. P. Laplante4, L. Kobzik5,
A. Brunet4. 1Department of Psychiatry, McGill University, Douglas Mental
Health University Institute, Verdun, Quebec, Canada; 2University of
Montreal, Montreal, Canada; 3Harvard School of Public Health, Children’s
Hospital Boston, Boston, USA; 4Douglas Hospital Research Centre, Montreal,
Canada; 5Harvard School of Public Health, Brigham and Women’s Hospital,
Montreal, Canada
Objective: Asthma is a chronic lung disease characterized by the inflam-
mation and tightening of the airways. Affecting 11% of Canadian children,
asthma increases physical inactivity, school absences, hospitalizations and
premature deaths. Animal and human studies suggest that non-genetic in
utero factors may shape the physiological systems involved in the devel-
opment of asthma in children. Large quantities of cortisol may be released
in the blood stream following a highly stressful event, causing alterations
in the fetus’ stress response system. However, limitations exist in the
literature. First, results on animal studies are not directly applicable to
humans. Second, stressful events are generally not independent of the
mothers’ characteristics (e.g. divorce and job loss). Lastly, objective and
subjective stress are often not differentiated. This study examined whether
higher levels of prenatal maternal stress (PNMS) due to a natural disaster
would increase the risk of having asthma in 11 year old offspring.
Methods: In 1998, we assessed severity of objective hardship and sub-
jective distress in women pregnant during the January 1998 Quebec
Ice Storm. Data was collected on potential confounding variables (e.g.,
maternal trait anxiety, life events, obstetric complications, and socio-
economic status). Lifetime asthma symptoms, diagnoses, and corticoster-
oid utilization were assessed when the children were 12 years old (N=68).
Results: The findings suggest that subjective distress increases the risk
of asthma in girls. More specifically, we found that, in girls only, higher
levels of prenatal maternal subjective distress predicted greater lifetime
risk of wheezing (OR=1.11; 90% CI=1.01–1.23), mother-reported asthma
(OR=1.11; 90% CI=1.00–1.23), doctor-diagnosed asthma (OR=1.09; 90%
CI=1.00–1.19) and lifetime utilization of corticosteroids (OR=1.12; 90%
CI=1.01–1.25).
Conclusion: Further research is required to understand the mechanism
by which gender may mediate the relation between PNMS and the devel-
opment of asthma in children.
Policy of full disclosure: None.
P-38-011 Endocannabinoids in CSF and serum from borderline
personality disorder patients
D. Koethe1, E. Schwarz2, C. Schaefer2, F. Enning3, J. K. Mueller3,
J. M. Bumb2, S. Herpertz1, C. Schmahl3, M. Bohus3, F. M. Leweke2.
1Heidelberg University, Department of General Psychiatry, Heidelberg,
Germany; 2Central Institute of Mental Health, Heidelberg University,
Psychiatry and Psychotherapy, Mannheim, Germany; 3Central Institute of
Mental Health, Heidelberg University, Psychosomatic Medicine, Mannheim,
Germany
Objective: The endocannabinoid system plays an important role in the
pathophysiology of psychiatric disorders. Due to its neuromodulatory
potential, its role in emotion regulation and in extinction of aversive mem-
ory, the endocannabinoid system might be another potential candidate
system, affecting a broad range of psychopathology in both, posttraumatic
stress disorder (PTSD) and/or borderline personality disorder (BPD).
Methods:We addressed this question by analyzing serum and cerebro-
spinal fluid (CSF) levels of the endocannabinoids anandamide and
2-arachidonoyl-sn-glycerol (2-AG) and related endogenous lipids oleoy-
lethanolamide and palmitoyletnanolamide. Based on our previous ap-
proach we developed and validated a specific and sensitive method
using high performance liquid chromatography coupled with tandem
mass spectroscopy (HPLC-MS/MS). We analyzed human serum samples
from patients suffering from BPD (n=23) or PTSD (n=21) as well as
matched healthy controls (n=34). In addition, we measured these and
the neuropeptides oxytocin (OXT) and vasopression (VPA) in CSF and
serum samples in an independent cohort of 27 BPD patients and 26
matched controls.
Results: Serum levels of anandamide and 2-AG were significantly
elevated in BPD, while oleoylethanolamide was significantly elevated in
PTSD when compared to controls. In CSF, levels of anandamide as well
as oleoylethanolamide and palmitoyletnanolamide were significantly
decreased in BPD, while 2-AG was not affected.
Conclusion: Our data rise evidence that the endocannabinoid system
may play an independent functional role in the pathophysiology of BPD
and warrant further investigation of this contribution.
Policy of full disclosure: None.
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P-38-012 Structure of psychotropic drugs prescribed by therapists
of primary care (territorial polyclinics)
M. Kunetsova. 1MNIIP, Research Institute of Psychiatry, Moscow, Russia
Objective: Of the study was to determine how often and what kind of
drugs are prescribed therapists in primary health care (territorial
polyclinics).
Methods: Study was conducted on the basis of the territorial
polyclinic of Moscow. The study involved 12 doctors. The average age
was 46,1±12,7 years, average service record was 22,7±12,9 years. Were
analyzed 679 prescription forms. In the month subscribed about 48,5 titles
of psychotropic drugs, per physician accounted for about 4 recipes.
Frequency of assignments by different specialists ranged from 0,7 to 9,8
drugs per month.
Results: Most commonly prescribed psychotropic drugs were
benzodiazepine tranquilizers 57,7% (n=392). There were fenazepam
39,5% (n=155), clonazepam − 24,5% (n=96), alprazolam − 13% (n=51),
diazepam − 9,2% (n=36) nozepam − 6,1% (n=24), tazepam − 5,6%
(n=22), mezapam − 2% (n=8), lorazepam − 0,5% (n=2). Sedatives other
groups (ataraxia, grandaxinum) were discharged in 1,5% of cases (n=10).
Widely prescribed drugs containing phenobarbital. A second group of
frequency assignments became hypnotics − 23,1% (n=157), zopiclone is
prescribed in 64,3% (n=101), zolpidem in 35,7% (n=56). Preparations of
other groups discharged significantly less: neuroleptics − 2,5% (n=17),
antidepressants − 2,4% (n=16), nootropics − 1,3% (n=9), mood stabilizers
/ anticonvulsants - 0 3% (n=2) of the total prescriptions.
Conclusion: Therapists do not always correctly and efficiently dis-
charged psychotropic drugs. They preferred tranquilizers and hypnotics.
However, general practitioners (primarily therapists) have high potential
and wide range of opportunities for providing pharmacological assistance
to patients with mental disorders.
Policy of full disclosure: None.
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P-39-001 D- and l-govadine block d-amphetamine conditioned
place preference
M. Nesbit1, C. Dias2, A. Phillips2. 1UBC, Vancouver, Canada; 2Department of
Psychiatry, University of British Columbia, Vancouver, Canada
Objective: Tetrahydroprotoberberines (THPB) derived from traditional
Chinese medicine have been extensively evaluated for targeting dopamine
D1 and D2 receptors and have potential as novel treatments for drug
addiction. Govadine is a THPB derivative and recent findings have iden-
tified both similarities and differences in the neuropsychopharmacological
properties of d- and l-stereoisomers (Lapish et al., 2014).The present study
assessed the effects of d- and l-Govadine on the acquisition of
amphetamine-induced conditioned place preference (CPP).
Methods: CPP was established in rats by pairing d-amphetamine
(d-AMPH, 1.5 mg/kg, i.p.) or saline with a specific environmental context.
The rats received d-Govadine (1mg/kg, s.c.) or vehicle 5 min prior to
d-AMPH administration during the acquisition phase. CPP was assessed
as time spent in the d-AMPH- and the saline-paired contexts. We also
evaluated the effect of l-Govadine on d-AMPH-induced CPP using the
same protocol.
Results: Preliminary results show that both d- and l-Govadine inhibit
the induction of d-AMPH CPP.
Conclusion: It appears that both stereoisomers block the rewarding
effects of d-AMPH suggesting therapeutic potential for drug addiction.
Investigations into the effect of d-Govadine on the expression, extinction
and reinstatement of d-AMPH-induced CPP are ongoing.
Reference
Lapish CC, et al.(2014). Selective effects of d- and l- Govadine in preclini-
cal tests of positive, negative, and cognitive symptoms of schizo-
phrenia. Neuropsychopharmacology. Advance online publication.
Retrieved 30 January 2014. doi:10.1038/npp.2014.23.
Policy of full disclosure: None.
P-39-002 Tolerance to different types of frustration in alcohol
dependent patients and healthy controls as related to
anxiety and impulsivity
P. S. Netter1, M. Baars2. 1University of Giessen, Giessen, Germany; 2University
of Zurich, Department of Psychiatry, Zurich, Switzerland
Objective: Since anxiety has been found to be related to susceptibility
to punishment and impulsivity to susceptibility to reward (J.A.Gray,
1981), it was investigated, if these associations are also valid with respect
to frustration by application of negative stimuli (neg+) versus by with-
drawal of rewards, (pos-), and if this relationship equally applies to
alcohol dependent persons and healthy controls according to their differ-
ences in anxiety and impulsivity.
Methods: 60 male alcohol dependent patients and matched healthy
controls, each divided according to high and low anxiety and impulsivity
scores were compared for their questionnaire scores on sensitivity to pun-
ishment and reward and for their depressive and aggressive responses to
questionnaire items representing the two types of frustrations (QDF, Baars
et al., 2011).
Results: All participants were more frustrated by neg+ than by pos-
conditions, and both types of frustration correlated more clearly with
sensitivity to reward than with sensitivity to punishment. No general dif-
ference in tolerance to either type of frustration emerged between alcohol
dependent patients and controls, but in controls high scorers on anxiety
exhibited significantly higher levels of predominantly depressive
responses in particular to neg+ items than low scorers (interaction
p=0.018) confirming expectations, whereas impulsivity did not predict
tolerance to frustration. In alcohol dependent patients, on the other
hand, impulsivity was a better predictor of intolerance to both types of
frustration than anxiety, in particular when comparing aggressive
responses.
Conclusion: Frustration from withdrawal of rewards does not reflect
sensitivity to reward and is not more pronounced in alcohol dependent
patients than in controls, but in alcohol dependent patients frustration
in general is more determined by impulsivity as a personality trait than
in controls leading to predominantly aggressive responses. This suggests
to consider trait impulsivity for the prognosis of a successful therapy of
alcoholics.
Policy of full disclosure: None.
P-39-003 Nicotine replacement therapy in our patients: Are they
getting the right nicotine dose?
P. Philippe Vincent1, L. Desbiolles2, V. Savard2, S. Tremblay2, B. Rouleau2.
1Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada;
2Jewish General Hospital, Montreal, Canada
Objective: This trial evaluated the impact of optimizing nicotine
replacement therapy on agitation levels in subjects admitted to the inpa-
tient psychiatric unit of a university affiliated hospital. A pre-post
quasi-experimental design was used.
Methods: All consenting patient admitted to the psychiatry ward were
eligible to participate. Agitation levels were assessed with the PANSS-EC
rating scale. Pharmacy residents were scoring patients with direct inter-
view and with chart review. Group 1 patients were only allowed a nic-
otine transdermal patch; group 2 subjects could also use nicotine gums
and inhalers in addition to the patch.
Results: Most patients were suffering from psychotic disorders (56%).
In the first 48 hours post-admission, the scores on the PANSS-EC were
16.9 in group 1 (n=18) and 13.6 in group 2 (n=19). The between group dif-
ference in evolution from baseline was 5.4 points (p=0.0002). This differ-
ence is very clinically significant. Sensitivity analysis did not show any
confounding factors.
Conclusion: Some studies show that such an effect is stronger than
what is observed when a patient receives the usual antipsychotic +benzo-
diazepine combo for agitation.The addition of nicotine gums and inhalers
to the nicotine transdermal patch greatly reduced agitation levels in psy-
chiatric inpatients and should be considered in the treatment plan.
Policy of full disclosure: None.
P-39-004 An open-label naturalistic study: Mirtazapine orally
disintegrating tablets treatment for depression in
heroin-addicts
C. Shao1, S. Zhu2, Z. Wang2, S. Shi2. 1Huashan Hospital, Fudan University,
Shanghai, China; 2Huashan Hospital, Shanghai Mental Health Center,
Shanghai, China
Objective: Heroin dependence is often complicated by depression requir-
ing antidepressant treatment. Mirtazapine is an established antidepressant
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with well-documented efficacy. The objective of the present study is to in-
vestigate the efficacy and tolerability of the new formulation of mirtaza-
pine, Orally Disintegrating Tablets (ODT) for depression among
heroin-addicts.
Methods: This prospective, open-label, naturalistic study was conduc-
ted in the Outpatients Department of a general hospital. 24 depressed
heroin-addicts were recruited, of whom 22 were followed up for 17
weeks. All patients initially received mirtazapine ODT 15mg/day and
the dose was titrated to 30mg or 45mg when response was not significant
and in the absence of obvious adverse effects. Efficacy was the primary
measure using the total score of the Hamilton Depression Rating
Scale-17(HAMD-17). Tolerability was mainly assessed by the incidence
of treatment-emergent adverse events. Patients were evaluated at baseline,
at weeks 1, 5, 9, 13 and 17.
Results: among the 22 patients (14 female and 8 male) who finished the
study, the mean total (SD) HAMD-17 score decreased significantly from
29.2(4.1) to 7.2(4.1) (P<0.05). At each visit, the mean HAMD-17 score
was significantly lower than that at the preceding visit. At the endpoint
(week 17), remission (HAMD-17 score<or=7) was achieved in 12(55%)
patients. Among those patients, four reported at least one adverse effect
during Treatment, but those adverse effects were described as mild to
moderate and lasted just several days. The most majority of the patients
preferred the new formulation of mirtazapine.
Conclusion:Mirtazapine ODT was an effective, well-tolerated and pref-
erable formulation for the treatment among heroin-addicts with
depression.
Policy of full disclosure: Supported by National Natural Science
Foundation in China. The number of approved is 81201033.
P-39-005 Benzodiazepine receptor system of the human and rat’s
brain under chronic influence of alcohol
T. Shushpanova1, V. Semke1, A. Solonsky1, N. Bokhan1, V. Udut2. 1Mental
Health Research Institute, Tomsk, Russia; 2Pharmacology Research Institute,
Tomsk, Russia
Objective: Alcohol abuse induces neuroadaptive alterations of benzodia-
zepine receptors (BDR), that modulate GABAAR, and GABA mediation in
brain regions, associated with reward function in the brain, that serve al-
cohol addictions. Properties of BDR in synaptosomal and mitochondrial
membranes from different brain areas (prefrontal cortex, n.caudatus and
cerebella cortex) of alcohol abused patients and brain cortex of male rats
with different preference to alcohol were studied.
Methods: Properties of BDR “synaptosomal” (CBR) and “mitochon-
drial” (MBR) types were examined in respective membrane fractions
obtained from different brain areas of alcohol abused patients and non-
alcoholic persons (early postmortem material) by radioreceptor assay
(RRA) with [3H]flunitrazepam and [3H]PK-11195. Properties of BDR in
rat brain cortex were examined in such as membrane fractions by RRA
with [3H]flunitrazepam and [3H]Ro5–4864.
Results: Comparative study of kinetic parameters (Kd and Bmax) of
[3H]flunitrazepam and [3H]PK-11195 binding with synaptosomal and
mitochondrial membranes obtained from autopsy samples has shown,
that affinity of BDR was decreased and capacity was increased in different
areas of human brain under influence of alcohol abuse. More alterations of
BDR appeared in prefrontal cortex, less - in n.caudatus and cerebella cor-
tex. Finding results showed that alcohol addiction induces more altera-
tions in MBR than CBR, that agree with physiological and maintaining
function of MBR in CNS under influence of toxic factors.
Conclusion: Affinity of [3H]flunitrazepam and [3H]Ro5–4864 binding
with membranes from rats brain was decreased, but capacity of receptors
was increased in brain cortex of “heavy drink” and “non-heavy drink”
male rats compared with “non-prefer” alcohol rats. Administration of
anticonvulsant meta-chloro-benzhydryl-urea (m-chBHU) increased
affinity of BDR in brain cortex of “heavy drink” rats. So, m-chBHU has
a normalizing effect on GABA - receptor function.
Policy of full disclosure: None.
P-39-009 Opioid dependence disrupts cocaine reward by
disrupting GABAergic chloride homeostasis mediated by
activated microglia
A. Taylor1, A. Castonguay2, A. Ghogha3, P. Vayssiere3, A. Pradhan3, Y. De
Koninck2, C. Evans3, C. Cahill4. 1UCI, Los Angeles, USA; 2Laval University,
Quebec, Canada; 3UCLA, Los Angeles, USA; 4UCI, Irvine, USA
Objective: Opioid dependent states are associated with adaptations with-
in the mesocorticolimbic dopaminergic system that contribute to the nega-
tive affective state when the drug is absent (withdrawal). Here, we
analyze molecular adaptations in the ventral tegmental area (VTA) and
their effect on drug reward.
Methods: C57Bl/6 mice were made opioid dependent with increasing
injections of morphine (10–40mg/kg, i.p) twice daily for 4 days.
Results: Opioid dependent animals displayed significant microglial ac-
tivation in the VTA and blocking microglial activation decreased BDNF
expression. Chronic morphine exposure decreased expression of the pot-
assium/chloride (Cl-) co-transporter, KCC2, within VTA GABAergic neu-
rons, which resulted in a loss of Cl- extrusion as measured by fluorescent
lifetime imaging. Interfering with BDNF signaling recovered Cl- extrusion
in morphine-dependent GABAergic neurons. Loss of Cl- extrusion is
known to undermine GABAergic inhibitory potential, which translates
into an increased inhibition in dopaminergic VTA neurons. In support
of this, cocaine reinforcement (as measured using the conditioned place
preference paradigm) was diminished in opioid dependent animals.
Cocaine place preference was restored in opioid dependent animals by
cotreatment with microglial inhibitors.
Conclusion: This study provides evidence for disrupted reward circui-
try in opioid dependent animals that is driven by microglial activation
within the VTA. Reactive microglia release BDNF that precipitates a
shift in EGABA within VTA GABAergic inhibitory interneurons leading
to dysregulation of dopaminergic circuitry.
Policy of full disclosure: None.
P-39-010 Repeated amphetamine sensitizes dopaminergic
modulation of the basolateral amygdala neurons:
Physiological, behavioural, and molecular analyses
M. Tse1, S. Kaur1, P. Cocker1, C. Winstanley1, S. Floresco1. 1University of
British Columbia, Vancouver, Canada
Objective: Chronic abuse of psychostimulants such as amphetamine
(AMPH) impairs cognitive processes associated with the limbic system.
Rodent studies showed that repeated AMPH causes behavioural, neuro-
chemical, and physiological changes in mesolimbic dopamine (DA)
modulation on various regions of the limbic circuit (e.g., prefrontal cortex,
nucleus accumbens). However, relatively little is investigated in the baso-
lateral amygdala (BLA). We therefore examined how repeated AMPH
(2mg/kg i.p. every 48hr, 5 injections, two-week washout) may alter beha-
vioural, neurophysiological, and molecular properties of the BLA.
Methods: We conditioned rats to pair previously neutral stimuli to
delivery of sugar pellets (15-day training), followed by AMPH injection
regimen described above. Rats subsequently were trained to acquire a
novel instrumental response for conditioned stimuli paired with food.
In a separate experiment, we extracellularly recorded changes in BLA neu-
ron activity in response to DA manipulation in anesthetized rats, as well
as western blot analysis to assess DA-related proteins within the BLA.
Results: Rats received repeated AMPH showed reduced instrumental
respond to stimuli previously paired with food reward. In addition,
BLA neurons demonstrated increased sensitivity to the inhibitory effects
of endogenous phasic DA. Burst stimulation of the ventral midbrain
causes reliable suppression of putative BLA principle neuron firing. This
DA hypersensitivity appeared to be dependent on increased D2 receptor
sensitivty, as low dose (0.02 mg/kg, i.v.) of D2 agonist quinpirole can sup-
press BLA neurons firing in AMPH-treated rats but not in control. These
results were complemented by a western blot experiment, where
AMPH-treated rats showed increased D2 and DARPP-32 expression in
the BLA.
Conclusion: Collectively, these findings provide behavioural, physio-
logical, and molecular evidence suggesting repeated AMPH increases
D2 receptor and downstream DA effector protein, DARPP-32, expression,
causing an enhanced inhibitory tone within the BLA. Furthermore, they
suggest that impairments in reward-related functions observed in psy-
chostimulant abusers may be at least in part due to D2 receptor hyperac-
tivity of the BLA.
Policy of full disclosure: None.
P-39-011 Recovery of substance-induced psychotic disorder
following an olanzapine treatment in patients with
cannabis addictive disorder and the emergence of panic
disorder, after stabilization of the psychosis
P. Zuleta1, V. Sanchez1, G. Oviedo2, R. Carolina1, J. Navarro1. 1Clínica
Nuestra Señora de la Paz, Bogota, Colombia; 2P. Universidad Javeriana,
Bogota, Colombia
Objective: To show the development of Panic Disorder symptoms after
the stabilization of substance induced psychosis, especially the anticipat-
ory anxiety related to reappearance of psychosis.
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Methods: In our drug rehab program we registered which patients had
psychosis. Those that developed psychosis continued treatment with olan-
zapine. Once stabilized, we found panic disorder with strong anticipatory
anxiety. We used the EASE scale (Examination of Anomalous Self
Experience) to measure the psychotic compromise when the Panic symp-
toms appeared (measured by the scale ESAP). The measurements were
presented in graphics.
Results: After the improvement of psychosis, the ESAP scale shows de-
velopment of Panic Disorder symptoms. We characterized those symp-
toms by using the patients’ narrative and by applying the ESAP
measurement.
Conclusion: The psychotic experience is very traumatic. Although the
recovery of hallucinations and delusions is decisive, the memory of the
psychosis may condition a panic response. Use of clonazepam allows
psychotherapy to work and create enough insight; it permits the critique
of psychosis and of the panic symptoms. These patients were able to con-
tinue occupational therapy without the symptoms reappearance.
Policy of full disclosure: None.
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P-40-001 Prediction error demarcates the transition from retrieval,
to reconsolidation, to new learning
D. Sevenster1, T. Beckers1, M. Kindt1. 1University of Amsterdam, Amsterdam,
Netherlands
Objective: Retrieval-induced plasticity (reconsolidation) does not necess-
arily occur when a memory is reactivated. Recently, we demonstrated that
reconsolidation depends on prediction error (PE) - a discrepancy between
what is expected and what actually occurs on a given learning trial. It may
however be questioned whether PE is a sufficient condition for reconsoli-
dation, given that PE can also give rise to new learning instead (e.g. extinc-
tion learning). It has indeed been demonstrated that extinction training
puts a constraint on reconsolidation. During extinction training, repeated
or prolonged unreinforced exposure generates multiple PEs. We tested
whether the transition from reconsolidation to the formation of a new
memory trace occurs long before the expression of the inhibitory extinc-
tion memory can be observed.
Methods: In a human differential fear conditioning paradigm, we cre-
ated three groups in which fear acquisition was partially reinforced
(50%; reinforcement on all even trials). One day later the memory was
reactivated with one (no PE, n=18), two (single PE group, n=18) or four
unreinforced reminder trials (multiple PEs group, n=16), followed by ad-
ministration of the noradrenergic beta-blocker propranolol (40 mg).
Expression of the fear memory was measured with the fear potentiated
startle, while declarative US-expectancy ratings served to index PE. On
day 3, all groups underwent an extinction and reinstatement procedure
to test the absence of fear memory expression.
Results: The beta-adrenergic receptor antagonist propranolol erased the
startle fear response 24 h after reactivation only when memory retrieval
induced a single PE but not when there was no PE or multiple PEs, as
indicated by post-retrieval changes in US-expectancy.
Conclusion: 1) PE is a necessary but not a sufficient condition for mem-
ory reconsolidation. 2) Too little and too much PE mark a boundary con-
dition of memory reconsolidation. 3) Reconsolidation is prevented long
before fear extinction can be observed.
Policy of full disclosure: None.
P-40-002 Psychotropic effects profiles of benzodiazepines and
atypical anxiolytics in the treatment of uncomplicated
generalized anxiety disorder
T. Syunyakov1, S. Syunyakov1, E. Teleshova1, O. Dorofeeva1, M. Metlina1,
N. Bogdanova1, G. Neznamov1. 1FSBI Zakusov Institute of Pharmacology
RAMS, Moscow, Russia
Objective: Generalized anxiety disorder (GAD) is the prevalent chronic
disorder often complicated by comorbid conditions worsening outcomes.
It is crucial to treat GAD on early, uncomplicated stages of disorder.
To achieve symptomatic remission and improve long-term outcomes it
is important to address treatment to full set of therapeutic targets.
Atypical anxiolytics (AA) and benzodiazepines (BDZ) are options for
GAD treatment and most effective in uncomplicated cases. The aim of
this study is to compare effectiveness and psychotropic effects profiles
of AA and BDZ in the treatment of uncomplicated GAD to assess how
it comply the therapeutic needs of these patients.
Methods: GAD patients without comorbity and with duration of illness
less than 2 years were included. The study utilized Hamilton Anxiety
Rating Scale (HARS), Clinical Global Impression (CGI) scale and Scale
for Evaluation of Severity of Symptoms (SESS) that allows assessing
changes in severity of psychopathological symptoms reflecting anxiolytics
clinical effects. After 7-day placebo lead-in period to eleminate
placebo-responders 65 patients received AA (mercaptobenzimidazole
derivate Afobazole or peptide anxiolytic Selank derivate of tuftsin) and
32 patients received BDZ (phenazepam or medazepam).
Results: Patients treated with BDZ and AA had comparable back-
ground characteristics. Treatments didn’t differed on either HARS or
CGI-Severity score changes after 2 weeks. Though CGI therapeutic effect
was greater in AA group. Both BDZ and AA significantly reduced anxi-
ety, insomnia and autonomic symptoms domains of SESS. Hypnotic effect
was more evident with BDZ. Despite similarities BDZ and AA differed in
terms of action on asthenia symptoms domain. AA improved asthenia
while BDZ showed undesirable sedative and muscle relaxant properties.
Conclusion: Improved therapeutic effect of AA in uncomplicated GAD
despite more robust anxiolytic action of BDZ may be due to that fact that
their psychotropic effects profile is closer to match full set of therapeutic
needs of GAD patients.
Policy of full disclosure: None.
P-40-003 Augmentation strategies in treatment resistant anxiety
disorders: Meta-analysis and systematic review
M. Van Ameringen1, B. Patterson2. 1McMaster University, Hamilton,
Canada; 2McMaster University, MacAnxiety Research Centre, Hamilton,
Canada
Objective: Anxiety disorders are associated with high rates of non or par-
tial response to first-line treatment with selective serotonin reuptake inhi-
bitors. The primary objective was to examine the potential benefits of
using medication augmentation strategies compared to control treatments
in patients who have had a partial or non-response to initial treatment for
generalized anxiety disorder(GAD), social anxiety disorder(SAD) and
panic disorder(PD) by meta-analysis of a pooled dataset.
Methods: Double-blind, controlled (placebo or active comparator) trials
of medication augmentation in treatment resistant anxiety disorders were
systematically reviewed by independent raters for inclusion, quality and
risk of bias. MEDLINE, EMBASE, PsycINFO, The Cochrane Library and
conference proceedings were searched to identify trials. Effect estimates
were calculated using random effects modeling; heterogeneity and sensi-
tivity analyses were completed.
Results: Six studies(3 in GAD, 1 in SAD, 2 in PD) were included in the
meta-analysis. Five studies had small samples; a study of pregabalin in
treatment resistant GAD had a largest sample and was given the greatest
weight in the analyses. Augmentation was not associated with an
increased risk of response, (CGI-I # 2) versus placebo RR=1.08, 95% CI
0.94 to 1.24. A small, significant effect was found in reduction in symptom
severity: Standard Mean Difference −0.32, 95% CI −.56 to −0.08. No sign-
ificant differences were found between augmentation with medication
versus placebo in functional impairment and drop-outs due to adverse
events.
Conclusion: Augmentation does not appear to be beneficial in treat-
ment resistant anxiety disorders. These results may be limited by small
study samples, and a small number of overall studies in the analysis.
Policy of full disclosure: Dr. Van Ameringen has received grant/re-
search support from personal fees from Canadian Foundation for
Innovation (CFI), Forest Laboratories, Janssen-Ortho Inc., National
Institutes of Health, Pfizer Inc., Servier, and Wyeth-Ayerst . He is on
the speaker#s bureau for Biovail, GlaxoSmithKine, Janssen-Ortho Inc.,
Lundbeck, Pfizer Inc., and Shire. He has received consultant frees from
and is on advisory boards of Astra Zeneca, Biovail, Eli Lilly, Forest
Laboratories , Janssen-Ortho Inc., Labo Pharm, Lundbeck, Pfizer Inc.,
and Shire. Beth Patterson has nothing to disclose.
P-40-004 Technology-based communication in individuals with
social phobia
M. Van Ameringen1, B. Patterson2, W. Simpson2, J. Turna2. 1McMaster
University, Hamilton, Canada; 2McMaster University, MacAnxiety Research
Centre, Hamilton, Canada
Objective: There is emerging literature examining the effects of increased
internet use on social behavior, however the results have been equivocal
with some studies indicating benefit and some indicating harm. Social
phobia is an anxiety disorder which has a profound impact on communi-
cation. In addition, Social phobics (SPs) have been found to be high inter-
net users. The impact of internet use on the social functioning of SPs was
examined via an internet survey.
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Methods: A survey was posted on the website of an anxiety research
centre about the reasons for and time spent on the internet during leisure
time. Participants also completed an anxiety and depression screener,
measures of severity and impairment.
Results: The survey was completed by 513 participants; 62% had social
phobia (SP) 54% had major depressive disorder and only 18% of the sam-
ple did not meet criteria for a mental disorder. Over 1/3 spent less than
2 hours/day online and 34% had met friends online. Those with SP
were compared to those without social phobia (NoSP) and to those with-
out any diagnosis (controls). SPs reported higher rates of functional im-
pairment compared to NoSPs or Controls. Compared to NoSP and
Controls, SPs were significantly more likely to send a text message or
use the computer to avoid face to face (FTF) (p<0.001) or telephone(p<
0.001) contact. SPs vs. NoSPs and Controls reported significantly higher
rates of avoiding making friends, shopping, banking, obtaining infor-
mation and ordering food FTF due to the ability to access information
and services online. SPs reported feeling significantly less close to the peo-
ple they socialize with compared to NoSPs and Controls. If available
online, 67% would be motivated to obtain treatment.
Conclusion: Given the high use of the internet by SPs for social interac-
tion, technology based treatments may improve access to treatment and
improve social functioning.
Policy of full disclosure: Dr. Van Ameringen has received grant/re-
search support from personal fees from Canadian Foundation for
Innovation (CFI), Forest Laboratories, Janssen-Ortho Inc., National
Institutes of Health, Pfizer Inc., Servier, and Wyeth-Ayerst. He is on the
speaker’s bureau for Biovail, GlaxoSmithKine, Janssen-Ortho Inc.,
Lundbeck, Pfizer Inc., and Shire. He has received consultant frees from
and is on advisory boards of Astra Zeneca, Biovail, Eli Lilly, Forest
Laboratories , Janssen-Ortho Inc., Labo Pharm, Lundbeck, Pfizer Inc.,
and Shire. Beth Patterson has nothing to disclose William Simpson has
nothing to disclose Jasmine Turna has nothing to disclose.
P-40-005 Generalized anxiety disorder and ACTH plasmatic
concentrations
L. Vavrusova. IInd Clinic of Psychiatry, Slovac Health Care University,
Bratislava, Slovak Republic
Objective: ACTH plasmatic concentrations in MDD are frequently
increased, however how is it in the most prevalent group of anxiety dis-
orders - GAD?
Methods: 24 patients high level of anxiety in general anxiety disorder
participated in the study. Age 21 – 25 years. ACTH and cortisol plasma
concentrations were followed in regular intervals (week 10,12,14,16) in
patients who did not respond to 8 weeks of antidepressant treatment.
All pacients were switched from various SSRI and SNRI antidepressants
to paroxetine 40 mg. In addition to the clinical interview, the HAMA
Rating Scale was used to assess general anxiety symptomology and the
Hamilton Depression Rating Scale a standard measure of depressive
symptoms, was also administered. Study participants underwent an in-
itial evaluation, which included collection of demographic information,
self-reported current and past medical history and medication use, and
the Structured Clinical Interview for DSM-IV Axis I Disorders. GAD sub-
jects with a secondary diagnosis of comorbid depression, panic disorder,
social phobia, or specific phobia were not included. All subjects were
excluded from this analysis if had a history of psychosis, unstable medical
illness, or alcohol or substance abuse. Participants were also excluded if
they were currently using corticosteroids and female participants were
excluded if they were on hormone replacement therapy.
Results: We did not find correlation between ACTH plasmatic concen-
tration and severity of symptomatology measured by HAM-A ACTH
plasmatic concentrations in women and men remained unchanged despite
of improvement in HAM-A score or introducing the treamtment. Our
findings show that highly anxious females exhibited higher cortisol re-
lease than highly anxious males, however in the range of normal values.
Cortisol plasmatic concentrations in women decreased with the improve-
ment of HAM-A score and did not change with improvement of HAM-A
score in men, they remained low.
Conclusion: GAD does not seem to be connected with increased ACTH
plasmatic concentrations during acute state.
Policy of full disclosure: None.
P-40-007 Selected G alpha proteins are involved in
morphine-induced impairment of fear memory
A. Zelek-Molik1, M. Costanzi2, K. Rafa-Zablocka1, G. Kreiner1,
J. Vetulani1, A. Roman1, V. Cestari2, I. Nalepa1. 1Institute of Pharmacology
PAS, Krakow, Poland; 2Cell Biol. & Neurobiology IBCN, National Research
Council CNR, S. Lucia Foundation, Rome, Italy
Objective: Fear conditioning (FC) is an animal model of anxiety disorders,
where the ability to learn and remember an association between aversive
experience and environmental cues is measured. It has been shown that
the hippocampus mediates contextual fear conditioning and opioid recep-
tors (OR) become involved in this process. However, the molecular mech-
anism mediating fear memory by OR remains unknown. The aim of this
study was twofold. Firstly we wanted to assess whether morphine, admi-
nistered immediately after FC, influences mice fear behavior (freezing)
induced by exposure to conditioned context (CTX) or cues (CUE) applied
23 hr after a footshock. Secondly, we assessed the influence of FC training
and CTX/CUE retrieval on mRNA expression of alpha subunits of G(i/o),
G(s), G(q), G(11) and G(12) proteins in the mouse hippocampus.
Methods: C57BL/6J mice were subject to 1-day FC procedure, morphine
(1mg/kg/ip) was injected immediately after learning. Freezing behavior
was measured during FC training and during CTX/CUE test. mRNA ex-
pression was assessed 24 hr after footshock and 1 hr after CTX/CUE test
using RealTime PCR with TaqMan probes.
Results: Behavioral results showed that the immediate post-training ad-
ministration of morphine prevented CTX- and CUE-triggered freezing.
Biochemical analysis revealed the increase in Galpha(11) as a FC conse-
quence. Galpha(11) was also elevated after exposure to CTX and CUE.
However, morphine treatment prevented the increase in Galpha(11) trig-
gered by FC and CTX. Morphine also prevented the CTX induced increase
in Galpha(12). Galpha(s) was differently regulated, as its mRNA
decreased after FC. This was still observed after CTX but only in mice
treated with morphine.
Conclusion: Our data demonstrate the involvement of G11-, Gs-
and G12- dependent signaling pathways in murine hippocampus in the
development of fear memories. Moreover OR stimulation with morphine
immediately after fear exposure can prevent the fear-triggered neuroadap-
tations responsible for fear memory.
Policy of full disclosure: Study originated in the frame of cooperation
between the Italian National Research Council and the Polish Academy of
Sciences and supported by statutory funds of the Institute of
Pharmacology PAS.
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P-41-003 Combined treatment: Impact of optimal psychotherapy
and medication in bipolar disorder
S. Parikh1, V. Velyvis2, L. Hawke3. 1University of Toronto, Toronto, Canada;
2University of Toronto, Toronto Western Hospital, Toronto, Canada; 3Université
de Saint-Boniface, Winnipeg, Canada
Objective: To investigate the longitudinal course of symptoms in bipolar
disorder among individuals receiving optimal treatment combining phar-
macotherapy and psychotherapy, as well as predictors of the course of
illness.
Methods: One hundred and sixty participants with bipolar disorder
(BD-I: n=115, BD-II: n=45) received regular pharmacological treatment,
complemented by a manualized, evidence-based cognitive-behavioral
therapy or psychoeducation. Participants were assessed at baseline and
prospectively for 72 weeks using the Longitudinal Interval Follow-up
Evaluation (LIFE) scale scores for mania/hypomania and depression, as
well as comparison measures (clinicaltrials.gov identifier: NCT00188838).
Results: Over a 72-week period, patients spent, on average, about
two-thirds of the time well. Symptoms were experienced more than
50% of the time for about a quarter of the sample. Depressive symptoms
strongly dominated over (hypo)manic symptoms, while subsyndromal
symptoms were more common than full diagnosable episodes for both
polarities. Mixed symptoms were rare, but present for a minority of par-
ticipants. Participants who had fewer depressive symptoms at intake, a
later age of onset and no history of psychotic symptoms spent more
weeks well over the course of the study.
Conclusion: Combined pharmacological and adjunctive psychosocial
treatments appear to provide an improved course of illness compared to
previous studies. Efforts to further improve the course of illness beyond
that provided by current optimal treatment regimens will require a sub-
stantial focus on both subsyndromal and syndromal depressive
symptoms.
Policy of full disclosure: None.
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P-41-004 Bipolar disorder is more virulent in the United States than
many European countries
R. Post1, L. Altshuler2, G. Leverich1, W. Nolen3, R. Kupka4, H. Grunze5,
M. Frye6, T. Suppes7, S. McElroy8, P. Keck9, M. Rowe1. 1Bipolar
Collaborative Network, Bethesda, USA; 2VA Medical Center, Los Angeles,
USA; 3Universitair Medisch Centrum, Groningen, Netherlands; 4VU
University Medical Center, Amsterdam, Netherlands; 5Newcastle University,
Newcastle-upon-Tyne, United Kingdom; 6Department of Psychiatry, Mayo
Clinic, Rochester, USA; 7Stanford University, Palo Alto, USA; 8Lindner
Center of HOPE, Cincinnati, USA; 9University of Cincinnati, Cincinnati, USA
Objective: Controlled and naturalistic studies reveal a high degree of
treatment resistance in patients with bipolar disorder from the US. We
examined factors that might be associated with this adverse course of
illness.
Methods: 968 outpatients with bipolar disorder average age 41 gave
informed consent for participation in a treatment outcome network and
provided detailed demographic, family history, and course of illness in-
formation on a questionnaire. Data from 676 patients from 4 sites in the
US were compared with 292 from 3 sites in the Netherlands and
Germany (abbreviated Europe).
Results: Virtually every aspect of bipolar disorder was more frequent or
severe in those from the US compared to Europe. This included: genetic
vulnerability (more parents and other relatives with bipolar disorder
and a range of other psychiatric illnesses); psychosocial vulnerability
(childhood verbal, physical, and sexual abuse, as well as more stressors
accumulating over the course of illness); 31.1% vs 5.6% with childhood
onset (< 12 yrs.); greater time delay to first treatment; more anxiety dis-
order comorbidity; rapid cycling; 20 or more episodes; medical comorbid-
ities (including obesity); and twice the percent with a history of alcohol
abuse and of drug abuse.
Conclusion: Almost all of these characteristics that are worse in the US
vs Europe are associated with a poor long-term outcome, and we found a
greater incidence of non-response to prospective naturalistic treatment in
those from the US. The greater accumulation of 1) stressors, 2) episodes,
and 3) substance use contributes to illness progression as each is asso-
ciated with sensitization effects (increasing behavioral responsivity upon
repetition) and cross-sensitization to the others. A paradigm shift toward
earlier and more consistent treatment may help prevent these progressive
processes, likely based on epigenetic mechanisms, and lessen the asso-
ciated great illness burden, disability, and early demise associated with bi-
polar disorder in the US.
Policy of full disclosure: None.
P-41-005 Biochemical and genetic correlates of homocysteine in
bipolar disorder
J. Rybakowski1, J. Dorszewska2, M. Skibinska3, M. Dmitrzak-Weglarz3,
A. Permoda-Osip4. 1Poznan University of Medical Sciences, Poznan, Poland;
2Poznan University of Medical Sciences, Laboratory of Neurobiology,
Department of Neurology, Poznan, Poland; 3Poznan University of Medical
Sciences, Psychiatric Genetic Unit, Poznan, Poland; 4Poznan University of
Medical Sciences, Department of Adult Psychiatry, Poznan, Poland
Objective: An increased level of homocysteine (HCY) has been observed
in bipolar mood disorder and an association of the polymorphisms
of methylene-tetrahydrofolate reductase (MTHFR) gene with bipolar
disorder was postulated. We studied clinical and biochemical factors in re-
lation to hyperhomocysteinemia in patients with bipolar disorder during
depressive episode and also investigated a possible association between
5 polymorphisms of four genes coding enzymes of HCY metabolism.
Methods: One-hundred and twelve patients (24 male, 88 female), aged
20 to 78 (mean 51±14 years) with bipolar disorder were included. The
assays of serum concentrations of HCY, vitamin B12, folic acid as well
as markers of endothelial function such as E-selectin and intracellular
adhesion molecule-1 (ICAM-1) were made during depressive episode.
Genotyping was performed for C677 T (rs1801133) and A1978C
(rs1801131) polymorphisms of MTHFR gene, T833C polymorphism
(rs5742905) of cystationine beta-synthase (CBS) gene, A2756 G poly-
morphism (rs1805087) of homocysteine methyltransferase (MTR) gene
and A66 G polymorphism (rs1801394) of methionine reductase synthase
(MTRR) gene, and compared with 167 healthy control subjects (81 male,
86 female).
Results: During depressive episode, hyperhomocysteinemia (>15mM/l)
was found in 50 patients (45%), significantly more frequently in male
(67%) than in female subjects (39%). A significant inverse correlation
between HCY and concentration of folic acid and vitamin B12 as well
as with E-selectin and ICAM-1 was observed. An association with bipolar
disorder was found for the T833C polymorphism (rs5742905) of CBS gene.
No relationship with bipolar disorder was obtained for the remaining
polymorphisms studied.
Conclusion: The results show a significant prevalence of hyperhomo-
cysteinemia in bipolar depressed patients during acute episode and cor-
roborate the correlation between increased concentration of HCY and
lower level of vitamin B12 and folic acid. They are also pointing to a poss-
ible association between T833C polymorphism (rs5742905) of cystationine
beta-synthase gene and bipolar disorder.
Policy of full disclosure: None.
P-41-006 Phosphoinositols accumulation following lithium
treatment is mimicked by IMPA1 knockout and
intracerebroventricularly IP3 administration results in
lithium-like behavior
Y. Sade1, Y. Bersudsky2, G. Agam3. 1Ben Gurion University, Beer-Sheva,
Israel; 2Mental Health Center, Beer-Sheva, Israel; 3Ben Gurion University,
Mental Health Center, Beer-Sheva, Israel
Objective: In agreement with the inositol depletion hypothesis of lithium
(Li)’s mechanism of action IMPA1 (coding for inositol monophospha-
tase1) knockout (KO) mice exhibit Li-like behavior in the forced-swim
test (FST) and in the pilocarpine-induced seizures paradigm. We hypothe-
sized that similarly to Li’s effect bi-allelic IMPA1 knockout results in brain
phosphoinositols accumulation and that this accumulation mediates Li’s
behavioral effects.
Methods: 3H-inositol was administered intracerebroventricularly (icv)
to determine its conversion into phosphoinositols (separated by anion
exchange chromatography) and phosphoinositides (extracted by
chloroform:methanol:HCl 100:200:1). IP3/IP1 was administered icv in
lyposomes.
Results: Chronic Li treatment and ablation of IMPA1 resulted in several
fold increased frontal cortex and hippocampal radiolabeled phosphoinosi-
tols; acute Li treatment led to a trend of increased 3H-phosphoinositols
levels. icv administration of 150 ug IP3 in liposomes decreased immobility
in the forced-swim test (FST) and attenuated the hyperlocomotion re-
sponse to amphetamine without affecting motor behavior. Administration
of the same amount of IP1 had no effect. Administration of 500 μg IP1
induced sickness. Intriguingly, chronic Li treatment combined with ad-
ministration of IP3 receptor antagonist (IP3Ra) induced a synergistic effect
in the FST.
Conclusion: Li has been reported to downregulate IP3Rs. A possible in-
terpretation of the behavioral results is that IP3 administration induced
IP3Rs desensitization and that IP3Ra blocked the remaining IP3Rs follow-
ing Li treatment. Overall, our results support the notion that Li’s thera-
peutic effect is mediated by its intervention in inositol metabolism.
Policy of full disclosure: None.
P-41-007 Behavioural characterisation of ebselen; a potential
lithium-mimetic
N. Singh1, S. Vasudevan1, A. Sharpley1, I. Antoniadou1, T. Sharp1,
P. Cowen1, G. Churchill1. 1University of Oxford, Oxford, United Kingdom
Objective: To characterise the behavioural effects of ebselen, a potential
lithium-mimetic in animal models and healthy volunteers.
Methods: Ebselen was tested in animal models in which lithium has an
established phenotypic effect. Ebselen was injected intra-peritoneally (i.p.)
into male, C57Bl/6 mice that were then tested for behavioural effects in the
open-field test, the amphetamine-induced hyperactivity test, the forced
swim test, and the dimethoxy-4-iodoamphetamine (DOI) induced head
twitch. In a randomised, double-blind, parallel group, placebo-controlled
healthy volunteer (n=40) study, we administered 3×600mg ebselen over
two days and tested the effects on tasks of emotional processing.
Additionally, we assessed the ebselen effects on brain myo-inositol levels
using magnetic resonance spectroscopy and on the architecture of the
sleep polysomnogram in a double-blind, randomised, cross-over study.
Results: In mice, ebselen caused a reduction in exploratory behaviour in
the open field, as well as in the hyperactivity that followed administration
of amphetamine. In the DOI head twitch model, ebselen caused an attenu-
ation of the head-twitches. These effects are consistent with effects pre-
viously reported with lithium. In the forced swim test, a sub-cutaneous
injection of ebselen caused a reduction in immobility, also consistent
with literature on both ebselen and lithium. In healthy volunteers, some
antidepressants have been shown to bias emotional processing in posi-
tively. Lithium has been shown to increase slow-wave sleep in the poly-
somnogram although its effects on brain myo-inositol levels are
inconsistent. At present, we are near completion of the studies, but are
still blind to the treatment. The data analysis will be complete by April
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and will be presented. Ebselen has been found to be well-tolerated and
safe at the doses that we are administering.
Conclusion: Ebselen shows various behavioural effects in mice that are
consistent with it being a novel mood-stabiliser and a potentially safer
alternative to lithium.
Policy of full disclosure: None.
P-41-008 A pilot, open-label, 8-week study evaluating the efficacy
of adjunctive minocycline for the treatment of bipolar I/II
depression
J. Soczynska1, S. H. Kennedy1, M. Alsuwaidan2, R. Mansur1, M. Li1,
M. P. McAndrews1, E. Brietzke3, V. Taylor4, R. S. McIntyre1. 1University
Health Network, Toronto, Canada; 2Kuwait, Kuwait; 3San Paulo, Brazil;
4Toronto, Canada
Objective: To evaluate if 8 weeks of adjunctive minocycline treatment will
reduce the severity of depressive symptoms in individuals with bipolar
I/II disorder.
Methods: A total of 29 individuals between the ages of 18 and 65 who
met DSM-IV-TR criteria for a major depressive episode as part of bipolar I
or II disorder were enrolled in an 8-week, open-label study with adjunc-
tive minocycline (100mg b.i.d). A total of 27 subjects were included in
the intent to treat sample. Efficacy was evaluated with the mixed-effects
model for repeated measures (MMRM).
Results: Adjunctive minocycline treatment was associated with signifi-
cant change from baseline to week 8 on the Montgomery Asberg
Depression Rating Scale (MADRS), Hamilton Depression Rating Scale
17 item (HAMD-17), and Clinical Global Impression Severity (CGI-S)
(p=0.002, <0.001 and p=0.002, respectively). Significant improvement
was observed as early as week 1 on the MADRS and HAMD-17 and
week 2 on the CGI-S (p=0.017, p=0.007 and p=0.006, respectively).
Conclusion: This pilot study suggests that adjunctive minocycline may
be an efficacious antidepressant for individuals with bipolar depression.
These results provide a rationale for testing minocycline’s efficacy in a lar-
ger randomized, placebo-controlled trial.
Policy of full disclosure: Joanna K. Soczynska is a recipient of the Eli
Lilly Canada Fellowship, Ontario Graduate Scholarship, and Joseph
Bazylewicz Fellowship. Sidney H. Kennedy has received research support
from Bristol-Meyers Squibb, Brain Cells Inc., Clera Inc., Eli Lilly,
Lundbeck, Pfizer, Servier, St Jude Medical Inc, and Canadian Institutes
of Health Research. Roger S. McIntyre Eli Lilly has received research sup-
port from Janssen-Ortho, Shire, Astra-Zeneca, Pfizer and Lundbeck.
P-41-009 Lurasidone treatment for bipolar I depression: Effect on
core depression symptoms
M. Thase1, J. Tsai2, H. Kroger2, A. Pikalov3, J. Cucchiaro3, A. Loebel3.
1Philadelphia, USA; 2Marlborough, USA; 3Fort Lee, USA
Objective: To evaluate the antidepressant effect of lurasidone using the
6-item MADRS subscale which has been shown to be a unidimensional
measure of “core” depressive symptoms (Bech et al., Psychopharm
2002;163:20–25).
Methods: Patients with bipolar I depression were randomized to
6 weeks of double-blind treatment with lurasidone in a monotherapy
study with fixed-flexible doses of 20-60 mg/d and 80–120mg/d vs.
placebo (total N=485); and in an adjunctive therapy study of lurasidone
(20–120mg/d) with either lithium or valproate vs. placebo (total
N=664). The criterion for severe depression: baseline MADRS score530.
Results: Lurasidone monotherapy resulted in significantly greater
Week 6 improvement on the MADRS-6 for the 20–60mg and 80–120mg
dose groups vs. placebo (−10.4 and −10.4 vs. −6.9; P<0.001 for both com-
parisons). In the severe depression group, lurasidone therapy (combined
doses vs. placebo) was associated with significantly greater Week 6 im-
provement on the MADRS (−17.3 vs. −11.8; P<0.001) and on the
MADRS-6 (−11.7 vs. −7.5; P<0.001). Week 6 effect size was larger for
the severe (vs. less severe) depression group on the MADRS (0.56 vs.
0.44), and the MADRS-6 (0.62 vs. 0.44). Treatment with adjunctive lurasi-
done was associated with significant improvement on the MADRS-6
(P=0.003), but effect sizes were smaller for the severe depression group
(0.25 vs. 0.49).
Conclusion: Treatment of bipolar I depression with lurasidone was
associated with significant improvement in core depressive symptoms.
In patients with severe depression, treatment with lurasidone was asso-
ciated with larger effect sizes in the monotherapy study.
Policy of full disclosure: During the past 3 years, Dr. Thase has been an
advisor or consultant to Adolor Corp; Alkermes; AstraZeneca;
Bristol-Myers Squibb; Eli Lilly and Company; Forest Pharmaceuticals,
Inc; GlaxoSmithKline; Johnson & Johnson (including Janssen
Pharmaceuticals, Inc and Ortho-McNeil); Lundbeck; MedAvante, Inc;
Merck (formerly Organon and Schering- Plough); Neuronetics, Inc;
Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical,
Inc; Pamlab; Pfizer Inc (formerly Wyeth Research); PGx; Rexahn
Pharmaceuticals; Shire; Supernus Pharmaceuticals; Takeda
Pharmaceutical Company Ltd; and Transcept Pharmaceuticals, Inc.
During the same time frame, he has received grant support from the
Agency for Healthcare Research and Quality; Eli Lilly and Company;
Forest Pharmaceuticals, Inc; GlaxoSmithKline; the National Institute of
Mental Health; Otsuka America Pharmaceutical, Inc; and Sunovion
Pharmaceuticals Inc (formerly Sepracor Inc). During the past 3 years,
Dr. Thase has been on the speakers’ bureaus of AstraZeneca,
Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, and
Pfizer Inc (formerly Wyeth), and holds equity in MedAvante, Inc. Dr.
Thase has received royalties from American Psychiatric Publishing,
Guilford Publications, Herald Publishing House, and W.W. Norton &
Company. Drs. Tsai, Kroger, Pikalov, Cucchiaro, and Loebel are full-time
employees of Sunovion Pharmaceuticals, Inc.
P-41-011 Safety and tolerability of cariprazine in patients with
acute bipolar mania: Pooled analysis of 3 phase II/III
pivotal studies
L. Yatham1, E. Vieta2, K. Lu3, K. Nagy4, I. Laszlovszky4, W. Earley3,
S. Durgam3. 1Vancouver Coastal Health and Providence Healthcare,
Department of Psychiatry, Vancouver, Canada; 2University of Barcelona,
Barcelona, Spain; 3Forest Research Institute, Jersey City, USA; 4Gedeon
Richter Plc, Budapest, Hungary
Objective: The efficacy and tolerability of cariprazine, a D3-perferring
dopamine D3 and D2 receptor partial agonist, was assessed in 3
randomized, double-blind, placebo-controlled, 3-week, Phase II/III studies
in patients with bipolar mania (NCT00488618, NCT01058096,
NCT01058668). Here we report an integrated summary of safety and tol-
erability data from these studies.
Methods: Cariprazine doses from 3 studies were pooled (3–12mg/d);
additional analyses evaluated the 3–6 and 9–12mg/d groups. Safety
assessments included adverse events (AEs), laboratory values, vital
signs, weight, electrocardiograms (ECGs), Columbia-Suicide Severity
Rating Scale, and extrapyramidal symptom scales.
Results: The pooled safety population comprised 1065 patients (pla-
cebo, n=442; cariprazine, n=623); approximately 70% of patients com-
pleted the study. The most frequently reported treatment-emergent AEs
(TEAEs) (>=5% and twice placebo) were akathisia (placebo, 5%; caripra-
zine, 20%), extrapyramidal disorder (5%; 13%), restlessness (2%; 6%)
and vomiting (4%; 9%). The incidence of serious AEs was similar between
groups. AEs leading to discontinuation occurred in (7% of placebo and
12% of cariprazine patients. There was 1 death in the cariprazine group
(pulmonary embolism; considered unrelated to treatment). TEAEs of sui-
cidal ideation were infrequent (placebo, 4; cariprazine, 2); there were no
suicide attempts. Mean changes in weight were small (placebo, 0.17; car-
iprazine, 0.54 kg); the proportion of patients with >=7% increase in weight
were similar between groups (both 2%). Mean changes in blood pressure
and pulse were slightly greater with cariprazine and indicative of a
dose-relationship. Cariprazine was not associated with mean increases
in ECG parameters except for a slight increase in ventricular heart rate
vs placebo (5.0 and 0.9 bpm, respectively). Mean changes in metabolic
parameters (eg., lipids, glucose) were generally small and similar between
groups. Prolactin levels decreased in both groups.
Conclusion: In this pooled analysis, treatment with cariprazine for up
to 3 weeks was generally safe and well-tolerated.
Policy of full disclosure: Supported by funding from Forest
Laboratories, Inc. and Gedeon Richter Plc. Lakshmi Yatham has received
research grants from Forest, Otsuka, Roche, Shire; is a consultant to:
Genentech, Janssen, Merck, Teva Novartis, Sunovion, Gruenthal,
Boehringer- Ingelheim, Lundbeck; and is a speakers bureau member for
Janssen, Merck, Novartis, Sunovion.
P-42. Depression C
P-42-001 The effect of group therapy on the depression, quality of
life, stress hormone, immunity and heart rate variability
in Korean patients with breast cancer
S. Y. Lee1, M.-D. Kim2, W.-M. Bahk3, D.-I. Jeon1. 1Wonkwang University
Hospital, Iksan, Republic of Korea; 2Jeju National University, Hospital, Jeju,
Republic of Korea; 3Seoul, Republic of Korea
Objective: The aim of this study was to examine the effect of group ther-
apy on the depression, quality of life, stress hormone, immunity and heart
rate variability.
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Methods: The subjects were 52 patients with breast cancer who com-
pleted surgery and adjuvant therapy more than 2 years ago at the
Department of Surgery from at Wonkwang University Hospital. The
Beck depression inventory (BDI), Spielberger State-Trait Anxiety
Inventory (STAI), Visual analogue scale for pain (VAS), Somatic
Symptoms Inventory(SSI), Cancer coping questionnaire(CCQ), Social sup-
port rating Scale (SSRS) and Short Form Health Survey-36-Korean
(SF-36-K) were used. Venous blood from patients were collected for asses-
sing immunity and stress hormones at the same time before and after
group therapy. Heart rate variability (HRV) were measured by SA-6000
(Medicore, Korea) for assessing adapation for stressful situation.
Seventeens of subjects among 52 patients were selected according to the
patients’ informed consent of participation in group therapy. The patients
completed 14 weeks treatment program which was compose of 90 min-
utes session per week. Psychological parameters and biological para-
meters were compared before and after group therapy.
Results: 1) The prevalence of depression in patients with breast cancer
was 36.4%. 2) The group therapy for Korean patients with breast cancer
decreased depression and increased role physical and general health
perception of SF-36-K. 3) The group therapy increased level of T cell
and T helper cell, and significantly decreased norepinephrine level. 4)
The group therapy increased Standard Deviation NN interval(SDNN)
and Total Power(TF) in HRV.
Conclusion: These results suggest that group therapy for Korean
patients with breast cancer could decrease depression and increase quality
of life as well as increase immune function and HRV. Group therapy will
be a treatment program for patients with breast cancer in Korea.
Policy of full disclosure: None.
P-42-002 The antidepressant vortioxetine does not disrupt
sleep-wake rhythms during sub-chronic treatment with
clinically-equivalent doses - an electroencephalographic
polysomnography study in rats
S. Leiser1, D. Iglesias-Bregna1, L. Westrich1, C. Sanchez1. 1Lundbeck,
Paramus, USA
Objective: With few exceptions, antidepressants are reported to disrupt
sleep architecture. Vortioxetine is an antidepressant that acts through
5-HT3, 5-HT7 and 5-HT1D receptor antagonism, 5-HT1B receptor partial
agonism, 5-HT1A receptor agonism and inhibition of the 5-HT transporter
(SERT). In depressed patients treated with vortioxetine, the incidence of
sleep-related adverse events was 2.0–5.1% compared to 4.4% in patients
who received placebo (Baldwin et al., IJPCP, 2013). A sleep-EEG study
of vortioxetine and paroxetine in healthy subjects indicated that at a
given SERT occupancy, vortioxetine affected rapid eye movement
(REM) sleep to a lesser degree than paroxetine (Wilson et al., Eur
Neuropsychopharmacol, 2013). Here we investigated clinically equivalent
doses of vortioxetine on sleep-EEG in rats.
Methods: Cortical EEG, neck EMG, and locomotor activity were
recorded in male Sprague Dawley rats in home cages using telemetric
implants. Recordings were made 90 minutes before and 4 hours after a
10 a.m. acute dose and continued for 2 weeks in rats receiving normal
chow or chow containing vortioxetine 0.6 g/kg food, which corresponds
to 80–90% SERT occupancy in the brain. Sleep stages were manually
scored into Active Wake, Quiet Wake, and Non-REM and Paradoxical
(REM) sleep.
Results: Acute vortioxetine, 1, 3, 5, 10mg/kg, increased latency to the
first REM episode and 10mg/kg also increased non-REM sleep latency.
Sub-chronic administration of vortioxetine resulted in a normal sleep-
wake rhythm comparable to that of rats receiving normal chow (measured
on days 3, 7, 10, 14).
Conclusion: Our data appears consistent with clinical findings that
vortioxetine does not greatly alter sleep-wake patterns during treatment.
Based on literature showing 5-HT1A agonism promotes wakefulness
while 5-HT3 and 5-HT7 antagonism regulates REM sleep, it seems
vortioxetine’s overall modest effect on sleep architecture is due to its
multimodality. Further work is needed to substantiate this.
Policy of full disclosure: All authors were full time employees or
consultants of Lundbeck at the time of the study.
P-42-003 Effects of chronic social instability stress during
adolescence on social and cognitive functions
J. Li1, X. Wang2, Y. Su1, T. Si1. 1Institute of Mental Health, Beijing University,
Beijing, China; 2Department of Neurobiology, School of Medicine, Zhejiang
University, Hangzhou, China
Objective: Adolescence is a critical developmental period. The neuro-
developmental plasticity during this period may make it particularly
vulnerable to perturbations from adverse life events such as chronic stress,
which may cause behavioral abnormalities and eventually contribute to
the onset of psychiatric disorders. Considering the stressors involved in
human stress-associated disorders are mostly of social nature, in this
study, we used a chronic stress model of social instability to investigate
the effects of chronic social stress during adolescence on social and cogni-
tive functions.
Methods: The chronic stress procedure was performed with adolescent
male C57BL/6 mice. Starting at postnatal day 28, the group composition in
each cage was changed twice per week for seven weeks, so that each time
four mice from different cages were put together in a new cage. Control
mice remained with the same cage mates throughout the experiment. At
the end of treatment, all mice were single housed for seven days before
subject to a series of behavioral testing, including open field, social ap-
proach, social preference, social recognition and Y-maze spontaneous
alternation tests.
Results: We first replicated previous findings by showing that stressed
animals displayed anxiety-related behaviors in the open field test.
For social behaviors, we found that chronic social stress did not alter ani-
mals’ latency to approach a novel mouse, but induced greater sociability
in the social preference test and a defect in a preference for social novelty
in the social recognition test. Besides, stressed animals showed poorer per-
formance in the spontaneous alternation test, indicating a deficit in spatial
working memory.
Conclusion: These findings suggest that chronic social instability stress
during adolescence results in increased anxiety and impaired social and
cognitive behaviors. Further studies are needed to investigate biochemical
changes to obtain a better understanding of the mechanisms underlying
such deficits.
Policy of full disclosure: None.
P-42-004 Recovery of age-related memory impairment in mice by
vortioxetine is associated with activation of genes related
to the neurotrophic factor signaling
Y. Li1, A. Abdourahman1, J. A. Tamm1, C. Sanchez1, M. Gulinello2.
1Lundbeck Research USA, Paramus, USA; 2Albert Einstein College of
Medicine, Neuroscience Department, Behavior Core, Bronx, USA
Objective: Changes in intracellular signal transduction may be involved
in memory decline during aging. Antidepressants have been shown to
modulate signal transduction in rodent disease models, but it is not
clear if this also occurs in otherwise healthy old mice. Furthermore, anti-
depressants with different mechanisms of action have not been systemati-
cally examined in old mice regarding cognitive function and signal
transduction. We compared the effects of aging and two different antide-
pressants (the SSRI fluoxetine and the multimodal-acting antidepressant
vortioxetine) on visuospatial memory and expression levels of genes re-
lated to signal transduction in old mice. Vortioxetine is a 5-HT3, 5-HT7
and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist,
5-HT1A receptor agonist and inhibitor of the serotonin transporter.
Methods: Female C57BL/6 mice at 11 months of age received the fol-
lowing treatments for 1 month: vortioxetine (10mg/kg/day in food), fluox-
etine (16 mg/kg/day in drinking water) or vehicle (plain tap water and
normal rodent chow). Vehicle treated three-month old female mice were
included as age control. Visuospatial memory was evaluated by object
placement test. Expression levels of genes were measured in hippocampus
using quantitative PCR. Results were compared to vehicle treated old
mice and p<0.05 was considered significant.
Results: Visuospatial memory deficit in old mice was significantly
improved by vortioxetine, whereas fluoxetine was ineffective. In hippo-
campus, expression of TrkB, NF-kB1, JAK2, mTOR, CaMK2A, Arc,
CREB1, and c-FOS was significantly decreased in old versus young
mice. Vortioxetine, but not fluoxetine, significantly increased the ex-
pression of TrkB, NF-kB1, RELA, CaMK2A, Arc and c-FOS in old mice.
Conclusion: In otherwise healthy old female mice, deficits in visuo-
spatial memory were accompanied by decreased expression of genes
involved in signal transduction. Vortioxetine improved age-related defic-
its in visuospatial memory, which was associated with increased ex-
pression levels of genes related to neurotropic factor signaling.
Policy of full disclosure: This study was supported by H. Lundbeck
A/S.
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P-42-005 Vortioxetine restores memory function and reverses
depression-like behavior in ovariectomized rats
Y. Li1, C. Sanchez1, M. Gulinello2. 1Lundbeck Research USA, Paramus, USA;
2Albert Einstein College of Medicine, Neuroscience Department, Behavior Core
Facility, Bronx, USA
Objective: Ovariectomy (OVX) causes spatial memory deficits and
depression-like behavior in rodents (Kiss et al., 2012). However, it is
unclear if other cognitive domains are affected. Estrogen has been
shown to alleviate these symptoms and modulation of the serotonergic
system has been proposed as a possible underlying mechanism (Kiss
et al., 2012; Osterlund 2010). However, it is not known if antidepressants
with direct serotonergic receptor modulating properties are also effica-
cious in this model. We used a battery of behavioral tests to characterize
the OVX rat model and to test the effects of vortioxetine in the behavioral
domains in which OVX rats displayed deficits. Vortioxetine is an antide-
pressant with multimodal activities: a 5-HT3, 5-HT7 and 5-HT1D receptor
antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and
inhibitor of the serotonin transporter.
Methods: Female Sprague-Dawley rats underwent ovariectomy at
10 weeks of age. Gonadally intact age-matched female rats were included
for determining the behavioral consequences of OVX. To test effects of
vortioxetine, OVX rats were fed with vortioxetine-containing chow
(doses equivalent to 10mg/kg/day) for 4 weeks and were compared to
OVX rats fed with plain chow. The behavioral test battery included the ob-
ject placement test (for visuospatial memory), social preference test, social
memory test and forced swim test (for depression-like behavior).
Results: OVX rats exhibited deficits in visuospatial memory and
increased immobility in the forced swim test, while social preference
and social memory were not affected. Chronic vortioxetine treatment
significantly (p<0.05) improved visuospatial memory performance and
decreased immobility in the forced swim test comparing to the vehicle-
treated OVX group.
Conclusion: Ovariectomy induces specific memory deficits and
depression-like behavior in rats and may be valuable as an animal
model of cognitive dysfunction comorbid with depression. Vortioxetine
reversed memory deficits and exhibited antidepressant-like efficacy in
this model.
Policy of full disclosure: This study was supported by H. Lundbeck
A/S.
P-42-006 Pontine microbleeds and depression in stroke
X. Liu1, W. K. Tang2, Y. Chen3, J. Abrigo4, W. C. Wing Chu4, V. C. Tong
Mok5, G. S. Ungvari6, K. S. Wong1. 1CUHK, Hong Kong, Hong Kong SAR,
China; 2Department of Psychiatry, CUHK, Hong Kong SAR, China;
3Department of Neurology, Dongguan People’s Hospital, Dongguan,
Guangdong, China; 4Department of Imaging and Interventional Radiology,
CUHK, Hong Kong, Hong Kong SAR, China; 5Department of Medicine and
Therapeutics, CUHK, Hong Kong, Hong Kong SAR, China; 6The University
of Notre Dame, Perth, Australia
Objective: This study was designed to determine the relationship between
cerebral microbleeds (CMBs) and poststroke depression (PSD).
Methods: A cohort of 229 patients with acute ischemic stroke admitted
to the Acute Stroke Unit of the Prince of Wales Hospital between June
2004 and Oct 2010 was recruited. Depressive symptoms were assessed
using the Geriatric Depression Scale (GDS).PSD was defined as a GDS
score of 7 or above at three months following the subjects’ index stroke.
The presence and location of CMBs were evaluated with magnetic reson-
ance imaging (MRI).
Results: Compared with the non-PSD group, PSD patients were more
likely to have pontine CMBs (32.0% versus 18.2%; p=0.019). Pontine
CMBs remained an independent predictor of PSD in the multivariate
analysis, with an odds ratio of 2.24 (p=0.015).
Conclusion: The results suggest that pontine CMBs may play a role in
the development of PSD. The importance of CMBs in the pathogenesis of
PSD in stroke survivors as well as general elderly population warrants
further investigation.
Policy of full disclosure: None.
P-42-007 Syndrome of inappropriate antidiuretic hormone
secretion secondary to antidepressants: Fact or fiction?
M. Llobet1, J. M. Ginés1, J. León1, M. Martín2, S. Ramos1, A. Sabaté1,
L. Gómez1, S. Latorre1, V. Pérez1. 1Hospital del Mar, Barcelona, Spain;
2University Germans Trias i Pujol, Badalona, Spain
Objective: Analyze incidence of SIADH secondary to antidepressants in
hospitalized patients.
Methods: Retrospective review of all consultants to psychiatric service
between 2012 and 2013 (n=1393). Repeated consultations were removed
(n=458). From the resulting, patients who initiated antidepressant treat-
ment before admission were analyzed and, in these, if they had signs of
hyponatremia suggestives of SIADH, having ruled out other possible
causes.
Results: 30,38% (n=74) of patients received antidepressants. Of them,
10,81% (n=8) had hyponatremia suggestive of SIADH. 57% (n=4) were fe-
male. The average age was 74,85 years. Antidepressant were SSRIs in 68%
(n=5); dual-action antidepressants in 26% (n=2); and, 1 patient (13%) was
taking risperidone (see Table).
Conclusion: According to literature, most cases described were older
people with diuretic treatment. Our incidence was 11%. Unfortunately,
the actual incidence cannot be calculated because of a significant bias,
we only could analyzed people hospitalized. Increase awareness of this
disorder is necessary, especially due to the aging of population and in-
creasing use of antidepressants. We believe appropriate to do analytical
monitoring in patients over 65 years that begin antidepressant treatment
and have other risk factors for developing SIADH. The relative risk of
hyponatremia associated with each SSRIs drug needs to be determined,
for that, more research is needed.
Policy of full disclosure: None.
P-42-008 Phenelzine increases rat brain levels of L-tyrosine, an
effect apparently mediated by its active metabolite
beta-phenylethylidenehydrazine
D. Matveychuk1, E. Nunes1, N. Ullah1, C. Velázquez-Martínez1, G. Baker1.
1University of Alberta, Edmonton, Canada
Objective: Phenelzine is a monoamine oxidase inhibitor (MAOI) with
antidepressant, anxiolytic and neuroprotective properties. In addition to
increasing the concentrations of biogenic amine neurotransmitters by inhi-
biting MAO, phenelzine has additional effects on brain amino acids, in-
cluding increases in GABA, alanine and ornithine and decreases in
glutamine levels, which may contribute to its therapeutic effects.
Phenelzine is a unique MAOI in that it is also a substrate for the enzyme,
with beta-phenylethylidenehydrazine (PEH) being one of the metabolites
formed. While PEH itself is a weak MAOI, it produces alterations in rat
brain levels of the aforementioned amino acids that are comparable to
those of phenelzine. These effects on amino acids are reversed for
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phenelzine, but not for PEH, when the animals were pre-treated with
another MAOI, suggesting that they are dependent on the
MAO-catalyzed formation of PEH. We now report that phenelzine and
the E- and Z- geometric isomers of PEH also increase rat whole brain con-
centrations of L-tyrosine.
Methods: Rat whole brain L-tyrosine levels were measured by HPLC
with electrochemical detection following a 30mg/kg intraperitoneal ad-
ministration of phenelzine, E-PEH and Z-PEH. To investigate whether
this effect on L-tyrosine was MAO-dependent, animals were pre-treated
with a 1mg/kg intraperitoneal dose of the MAOI tranylcypromine prior
to administration of phenelzine or racemic PEH.
Results: Phenelzine, E-PEH and Z-PEH increased rat whole brain
L-tyrosine levels at 3 and 6 hours, reaching maximum levels of
265-305% of vehicle-treated controls at 3 hours. MAO inhibition with tra-
nylcypromine abolished the increase in L-tyrosine for phenelzine, but not
for PEH, suggesting that PEH is responsible for the tyrosine-elevating
property of phenelzine.
Conclusion: Since L-tyrosine is a precursor for dopamine and noradre-
naline, these results suggest that PEH may be a useful adjunctive drug to
consider in a number of neurological and psychiatric disorders. Funded
by CIHR(MOP:86712).
Policy of full disclosure: None.
P-42-009 The efficacy of vortioxetine in adult patients with a
recurrent major depressive episode (MDE): A
randomized, double-blind, placebo-controlled study
R. McIntyre1, S. N. Lophaven2, C. K. Olsen2. 1University of Toronto, UHN -
Toronto Western Hospital, Toronto, Canada; 2Copenhagen, Denmark
Objective: To present secondary analyses of depressive efficacy endpoints
after acute treatment of vortioxetine 10 mg/day and 20mg/day versus pla-
cebo in patients with a recurrent MDE.
Methods: Patients (18–65 years) with a current MDE53 months, and a
MADRS526 were eligible for this randomized, double-blind, placebo-
controlled, multi-national, 8-week study (FOCUS: NCT01422213).
Pre-defined secondary efficacy outcomes assessing depressive symptom
severity included change from baseline to Weeks 1, 4, and 8 in MADRS
total score and Clinical Global Impression CGI scores using MMRM.
Results: Patients had a mean baseline MADRS total score of 31.6±3.7
and a CGI-S score of 4.6±0.6. After 8 weeks, the mean MADRS decreased
(improved) by 10.9 (placebo), 15.6 (vortioxetine 10mg) and 17.6 (vortiox-
etine 20mg) points. The difference to placebo (n=194) in mean change
from baseline to Week 8 in the MADRS total score (FAS, MMRM)
was −4.7 (n=193, p<0.001) for vortioxetine 10mg and −6.7 (n=204,
p<0.001) for vortioxetine 20mg. The clinical relevance of these outcomes
was supported by the CGI results, with separation from placebo for the
CGI-S of −0.08 at Week 1 (p=0.077), −0.27 at Week 4 (p=0.004) and
−0.65 at Week 8 (p<0.001) for vortioxetine 10mg and −0.18 at Week 1,
−0.43 at Week 4 and −0.85 at Week 8 (p<0.001 for all) for vortioxetine
20mg. Separation from placebo for the CGI-I for vortioxetine 10 mg was
−0.15 at Week 1 (p=0.020), −0.41 at Week 4 (p<0.001) and −0.61
at Week 8 (p<0.001) and for vortioxetine 20mg was −0.28 at Week 1
(p<0.001), −0.54 at Week 4 (p<0.001) and −0.86 at Week 8 (p<0.001).
Conclusion: In this study, both vortioxetine doses separated from pla-
cebo with respect to depressive symptom severity and clinical global
assessments. The difference to placebo in the MADRS total score was
greater for the 20mg dose than the 10 mg dose.
Policy of full disclosure: Dr. McIntyre does not have any financial
conflicts of interests to disclose. This study was funded by H. Lundbeck
A/S and Takeda Pharmaceutical Company, Ltd.
P-42-010 Neurohormonal response to psychosocial stress and food
consumption in depression: The association of cortisol,
leptin and ghrelin
M. McKay1, R. Levitan2, K. Zakzanis2, F. Vaccarino2, T. da Silva2,
A. V. Ravindran3. 1University of Toronto, Toronto, ON, Canada; 2Toronto,
ON, Canada; 3University of Toronto, Centre for Addiction and Mental Health,
Toronto, ON, Canada
Objective: Obesity is frequently co-morbid with depression and can com-
plicate treatment and prognosis. Altered stress perceptions and eating
behaviours (particularly emotional eating, or increased food consumption
in response to stress or negative affect), as well as neurohormonal
mediation, had been suggested as shared pathophysiologies. The aim of
this investigation was to examine the association of stress and appetite
hormones with stress response and eating behaviour in individuals with
depression.
Methods: Patients with major depression and matched healthy controls
(18–65 years) underwent two physiological challenges, i.e., psychosocial
stress (the Trier Social Stress Test), and food ingestion. Serial plasma sam-
ples were collected with both challenges to assess secretion of cortisol
(associated with stress) and ghrelin and leptin (associated with hunger
and satiety processes, respectively). Eating behavior and stress perception
were also measured.
Results: 18 depressed patients and 17 matched healthy controls were
recruited. In response to both physiological challenges, lepin levels were
higher in depressed participants compared to controls, with greater elev-
ation associated with longer duration of illness. There were no group dif-
ferences in cortisol or ghrelin response to either challenge. Emotional
eaters in the combined sample (patients and controls) exhibited signifi-
cantly lower levels of ghrelin in response to food than non-emotional
eaters. Elevated leptin levels, negative affect and emotional eating were
also significantly noted.
Conclusion: The results of this study indicate that depression is asso-
ciated with abnormal leptin concentrations, and that this may be partly
due to the influence of stress. The association of depressive chronicity
and higher leptin levels is also notable, as it may indicate a vulnerability
to obesity for those with chronic depression. Similarly, emotional eating
may also increase risk of weight gain for individuals with this tendency.
Policy of full disclosure:
References
Lu X.Y. (2007). The leptin hypothesis of depression: a potential link
between mood disorders and obesity? Current Opinion in
Pharmacology, 7, p648–652.
Schanze A., Reulbach U., Scheuchenzuber M., Groschl M., Kornhuber J.
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P-42-011 Broader conceptualization of remission assessed by the
remission from depression questionnaire and its
association with symptomatic remission
A. Montoya1, J. Lebrec2, K.M. Keane3, I. Fregenal4, A. Cuidad4,
M. Zimmerman5. 1Lilly Research Laboratories, Toronto, Canada; 2Eli Lilly
and Company, Bad Homburg, Germany; 3Eli Lilly and Company,
Windlesham, Surrey, United Kingdom; 4Eli Lilly and Company, Madrid,
Spain; 5Eli Lilly and Company, Providence, USA
Objective: The primary objective of this prospective, multicenter, observa-
tional study was to evaluate the association between a broader conceptua-
lization of remission in Major Depressive Disorder (MDD), based on the
Remission from Depression Questionnaire (RDQ) score at baseline, and
being in symptomatic remission, based on the Hamilton Rating Scale
for Depression (HAM-D17) score at study end following 6 months of
observation.
Methods: Patients #18 years of age who previously experienced an
acute period (12±2 weeks ago) for the current MDD episode but were
in symptomatic remission at baseline were included. In addition to base-
line RDQ total score, further factors potentially influencing remission sta-
tus (HAM-D17) at 6 months were considered: baseline severity of
depression (determined by HAM-D17), age, gender, employment status,
years since diagnosis, family history of depression, history of MDD, treat-
ment duration for current episode, and somatic comorbidities. A back-
wards selection strategy was used to statistically model remission status
and determine factors with the strongest association.
Results: The study included 613 patients with a mean age of
46.6±13.48 years (years±standard deviation). Most subjects (77.3% at
baseline and 66.3% at 6 months) were still treated for their episode of
MDD. Of 575 patients completing the study, 54 were no longer in symp-
tomatic remission at 6 months. Statistical modeling indicated that an in-
crease in baseline HAM-D17 score of 1 unit decreased the odds of being
in remission by 18% (odds ratio 0.82, p=0.017, 95% confidence interval
(CI) 0.70#0.96). Increasing RDQ by 1 unit did not change the odds of
being in remission at 6 months (odds ratio 1.00, 95% CI 0.98#1.02).
Conclusion: After adjustment for baseline severity of depression mea-
sured by HAM-D17, there was no association between baseline RDQ
score and remission status, ie HAM-D17, at 6 months.
Policy of full disclosure: Alonso Montoya, Jeremie Lebrec, Karen Mary
Keane, Irene Fregenal, and Antonio Ciudad are employees of Eli Lilly and
Company.
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P-42-012 Changes in alpha(1)-adrenergic receptor subtypes in the
prefrontal cortex of rats subjected to chronic mild stress
and imipramine treatment
I. Nalepa1, A. Bielawski2, K. Rafa-Zablocka2, A. Zelek-Molik2, P. Gruca3,
M. Papp1, A. Roman2. 1Institute of Pharmacology PAS, Krakow, Poland;
2Institute of Pharmacology PAS, Department Brain Biochemistry, Krakow,
Poland; 3Institute of Pharmacology PAS, Department of Pharmacology,
Krakow, Poland
Objective: The alpha(1)-adrenergic receptor (alpha(1)-AR) is important
target of many psychoactive substances, including antidepressants.
Three subtypes of alpha1-AR (alpha1A, alpha1B, alpha1D) are widely
expressed in brain, though the functional difference among individual
subtypes is still not well understood. We investigated alterations in the
alpha(1)-ARs subtypes at their mRNA and protein levels in the prefrontal
cortex of male Wistar rats subjected to the chronic mild stress (CMS) pro-
cedure followed by treatment with antidepressant drug, imipramine (IMI).
Methods: Five groups of animals were studied: sham-saline; stress-
saline; sham-IMI; stress-IMI-responders and stress-IMI-nonresponders,
i.e., the stressed animals resistant to IMI treatment as indicated by anhe-
donia test. The receptors mRNA level was measured using RT-qPCR
and SybrGreen dye, and the protein level was assessed by Western
blotting.
Results: The changes found at mRNA level concerned mainly the alpha
(1B) expression. The CMS procedure decreased the alpha(1B) expression
(by 39 % vs. sham-saline group). Surprisingly, a similar effect was
observed in stressed animals that responded behaviourally to IMI treat-
ment, but not in the IMI-nonresponders group. However, these mRNA
changes were not followed by alterations in the alpha(1B) receptor protein
level. Whereas the alpha(1A)-AR mRNA was not influenced by any pro-
cedure, the alpha(1D) was increased in stressed rats that did not respond
to IMI (by 28 % vs. saline-sham group). In the latter group, an opposite
change was seen in the alpha(1D) protein level which was decreased in
comparison to the stress-IMI-responders (by 20 % vs. saline-sham).
Moreover, IMI alone caused the decrease in protein expression levels of
alpha(1A)- and alpha(1B)-AR.
Conclusion: Our results indicate that though all three alpha(1)-ARs
seem to be involved in mechanism of IMI action, the individual alpha
(1)-AR subtype may differ in its vulnerability to stress in CMS model of
depression.
Policy of full disclosure: None.
P-42-013 Levomilnacipran inhibits both norepinephrine and
serotonin reuptake across the clinical dose range
J. O´Connor1, L. Chen1, C. Gommoll1, S. Zukin1. 1Forest Research Institute,
Jersey City, USA
Objective: Levomilnacipran extended-release (ER) is a potent and
selective SNRI approved for the treatment of major depressive disorder
(MDD) in adults. In vitro, levomilnacipran ER shows greater potency
for inhibition of NE relative to 5-HT reuptake. The objective of this ana-
lysis was to characterize the pharmacokinetic (PK) profile of levomilnaci-
pran ER 40, 80, and 120mg/d and to use the PK data to estimate 5-HT and
NE reuptake inhibition over the levomilnacipran ER dose range.
Methods: PK data were collected from approximately 15% of adult
patients with MDD who participated in an 8-week placebo-controlled,
fixed-dosed trial of levomilnacipran ER 40, 80, and 120mg/day. Blood
samples were collected predose, and at 2, 4, 6, 8, 12, and 24 hours
postdose. Plasma samples were analyzed using a validated LC-MS/MS
method. To evaluate 5-HT and NE inhibition over the levomilnacipran
ER clinical dose range, unbound levomilnacipran ER plasma concentra-
tions obtained over a 24-hour period were plotted against previously
determined in vitro 5-HT and NE reuptake inhibition profiles, which
had been generated using human recombinant transporters expressed in
HEK cells.
Results: Levomilnacipran steady state PK profiles were linear and dose
proportional following oral administration. The Cmax was 92.8 ng/mL,
180.4 ng/mL, and 297.2 ng/mL, for the 40, 80, and 120-mg doses. The
average plasma concentrations at steady state for levomilnacipran
ER were 63.3 ng/mL for 40 mg/day, 122.3 ng/mL for 80mg/day, and
199.9 ng/mL for 120mg/day. The average unbound plasma concentrations
for levomilnacipran that were reached in MDD patients treated with
levomilnacipran ER 40, 80, or 120mg/day exceeded the concentration
which showed 90% and 80% inhibition of NE and of 5-HT reuptake, re-
spectively, in vitro.
Conclusion: These data suggest that levomilnacipran ER strongly
inhibits both NE and 5-HT across the clinically effective dose range.
Policy of full disclosure: This study was funded by Forest
Laboratories, Inc.
P-42-014 Serotonin 5-HT4 receptor agonist is able to promote
erythropoietin expression and cell proliferation in
hippocampal neural progenitor cells
D. H. Oh1, H. Son2. 1Hanyang University Medical Center, Seoul, Republic
of Korea; 2Department of Biochemistry, College of Medicine, Hanyang
University, Seoul, Republic of Korea
Objective: Serotonin (5-hydroxytryptamine, 5-HT), a monoamine neuro-
transmitter, plays important roles in in the regulation of various functions,
such as emotional status, sleep, feeding, sexuality and pain. There are
numerous evidences that 5-HT and its receptors are involved in the action
of antidepressants. Our previous study showed that fluoxetine (selective
serotonin reuptake inhibitor) recovers the down-regulation of EPO in
the hippocampus of chronic unpredictable stress-induced depression
model rats.
Methods: The present study was undertaken to investigate the effect of
5-HT and 5-HT receptor agonists (8-OH-DPAT, 5-HT1A receptor agonist;
RS67333, 5-HT4 receptor agonist) on EPO expression and cell proliferation
in cultured hippocampal neural progenitor cells (NPCs).
Results: EPO expression was increased time dependent manner being
significant at 3, 4 and 5 days after 5-HT treatment as determined by
reverse transcription-polymerase chain reaction (RT-PCR) and Western
blotting (P<0.05). Four days treatment of 5-HT and 5-HT receptor agonists
on NPCs significantly increased EPO expression and the fraction of bro-
modeoxyuridine (BrdU, proliferation marker)-positive cells co-labeled
with microtubule-associated protein 2 (MAP2, neuronal marker) com-
pared with those in the control groups (P<0.05). The most prominent ef-
fect was demonstrated by RS67333.
Conclusion: In summary, these results provide evidences that 5-HT and
5-HT receptor agonists promote EPO expression and hippocampal cell
proliferation. These suggest that 5-HT4 receptor agonist could be a good
candidate for treating mental illness such as depression and anxiety asso-
ciated with neuronal atrophy and reduced hippocampal neurogenesis.
Policy of full disclosure: None.
P-42-015 The role of the vagus nerve in the anti-inflammatory
action of antidepressants in rats
K. Ondicova1, A. Tillinger2, L. Mikova3, N. Hegedusova1, J. Pecenak1,
B. Mravec3. 1Faculty of Medicine, Bratislava, Slovak Republic; 2Institute Exp.
Endocrinology SAS, Bratislava, Slovak Republic; 3Faculty of Medicine,
Institute Exp. Endocrinology SAS, Bratislava, Slovak Republic
Objective: Signalization by the vagus nerve influences different processes,
including both peripheral and central inflammation. The decreased vagal
activity was found in depressed individuals. We suggest that some
antidepressants may exert their antiinflammatory effect at least partially
by activation of antiinflammatory pathway of the vagus nerve. In our
study this concept has been evaluated in animal model.
Methods: Sprague-Dawley rats were assigned to subdiaphragmatic
vagotomy (SV; n=30) or sham operation (SHAM; n=29). After 4 weeks
of recovery period, the effect of acute fluoxetine (Fx) treatment on
LPS-induced plasma cytokine and corticosterone secretion, splenic cyto-
kine expression, c-fos mRNA, and cytokine (TNFa, IL1b) gene expression
in brain areas was studied. Rats were injected intraperitoneally (i.p.) with
saline or Fx (10mg/kg) 30 minutes before i.p. injection of lipopolysacchar-
ide (LPS; 50 μg/kg) or saline. After three hours rats were sacrificed and
samples were collected.
Results: Acute injection of Fx significantly attenuated LPS-induced in-
crease of plasma cytokine and corticosterone levels and caused a marked
reduction in TNFa, IL1b and IL6 mRNA expression in the spleen in
SHAM rats. Vagotomy restricted this inhibitory effect on the periphery.
Centrally, immune challenge with LPS induced significant changes of
c-fos and cytokine gene expression in brain areas (Paraventricular
Nucleus; PVN, Nucleus Tractus Solitarii; NTS) with mean c-fos mRNA
levels 2.0 and 5.5fold higher in LPS-treated SHAM rats than in saline-
treated controls. TNFa and IL1b mRNA levels were also significantly
higher in the PVN and NTS of LPS-treated SHAM rats. In vagotomized
rats, LPS produced a slight increase in the expression of c-fos, and cyto-
kine mRNA, which was not influenced by the Fx treatment.
Conclusion: We found that fluoxetine blocked systemic LPS-induced
increase in peripheral cytokines and this effect was reduced by subdiaph-
ragmatic vagotomy. These data indicate that peripheral antiinflammatory
effect of fluoxetine is mediated also via the vagus nerve.
Policy of full disclosure: None.
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P-42-016 Vortioxetine does not affect sexual behavior in a male
rat model for sexual dysfunction
R. Oosting1, J. Chan2, A. Pehrson3, Y. Li4, C. Sanchez3, B. Olivier1. 1Utrecht
University, Utrecht, Netherlands; 2Utrecht University, Pharmacology, Utrecht,
Netherlands; 3Lundbeck Research USA, Paramus, New Jersey, USA; 4Utrecht
University, Lundbeck Research USA, Paramus, New Jersey, USA
Objective: Antidepressants acting via inhibition of the serotonin (5-HT)
transporter (SERT) inhibit sexual behavior. Vortioxetine, an antidepres-
sant with a multimodal mechanism of action, is an inhibitor of the
SERT, a 5-HT3A, 5-HT7 and 5-HT1D receptor antagonist, a 5-HT1A recep-
tor agonist and a 5-HT1B receptor partial agonist. Since modulating 5-HT
receptor subtypes (e.g., 5-HT1A, 5-HT1B receptors) and transporter may
affect sexual function differently, we compared the effects of vortioxetine
and a selective serotonin reuptake inhibitor (SSRI), paroxetine, on the sex-
ual behavior of male rats.
Methods: The effects of vortioxetine (1 and 10mg/kg/day), paroxetine
(10mg/kg/day) and vehicle were compared acutely and after 1 and
2 weeks of dosing on various measures of male rat sexual behavior,
i.e., latency and number of ejaculations, mounts and intromissions.
Since the affinity of vortioxetine for the rat 5-HT1A receptor is
approximately10-fold lower than for the human 5-HT1A receptor, vortiox-
etine was also tested in the presence of flesinoxan (2.5 mg/kg) to mimic the
human level of 5-HT1A receptor activation. Vortioxetine was dosed via
the food, paroxetine and flesinoxan were administered as s.c. injections.
Antidepressant exposures were determined as SERT occupancy using ex
vivo autoradiography.
Results: Neither vortioxetine nor vortioxetine plus flesinoxan affected
sexual behavior, whereas 2-weeks paroxetine dosing impaired sexual
behavior significantly (P<0.05) in several measures. Vortioxetine, 1 and
10mg/kg, corresponded to 50 and 88% SERT occupancy, which matched
occupancies seen at clinical doses (5–20mg/day) as shown in human PET
studies. Paroxetine produced approximately 90% SERT occupancy.
Flesinoxan alone increased sexual performances acutely and after
1 week, but not after 2 weeks of treatment.
Conclusion: Vortioxetine at clinically relevant levels of SERT occupancy
did not affect male rat sexual performance. Thus, it appears that one or
more of vortioxetine’s receptor activities counteract the serotonin-
mediated inhibition of sexual performance produced SERT inhibition.
Policy of full disclosure: The research was funded by Lundbeck USA.
P-42-017 Aripiprazole augmentation, antidepressant combination
or switching therapy in patients with major depressive
disorder who are partial- or non-responsive to current
antidepressants: A multi-center, naturalistic study
C.-U. Pae1, S. Ahn1, C. Han2. 1Bucheon St. Mary´s Hospital, Bucheon,
Republic of Korea; 2Ansan Hospital, Korean University, Ansan, Republic of
Korea
Objective: There has been no studies comparing the clinical benefits of
aripiprazole augmentation (AT), antidepressant combination (AC), and
switching to a different antidepressant (SW) in patients with major de-
pressive disorder (MDD) patients partially or not responding to an initial
antidepressant. AT, AC, or SW was chosen by patients.
Methods: The primary efficacy measure was the proportion of patients
showing an improvement in the Clinical Global Impression-Clinical
Benefit (CGI-CB) score at week 8. Secondary efficacy measures included
changes in CGI-CB, CGI-Severity (S) and subjective satisfaction scores.
Remission and responder analysis were also employed.
Results: A total of 295 patients were enrolled. The most preferred strat-
egy was AT (n=156, 52.9%), followed by AC (n=93, 31.5%) and SW (n=46,
15.6%). The improver was significantly higher in AT (74.1%) compared
with AC (48.1%; p<0.001) and similar to SW (73.5%, p=0.948), whereas
no significant difference was found between AC and SW. Similar results
were also found in the most secondary endpoint measures proving a su-
periority of AT over AC without differences between AT and SW.
Tolerability profiles were similar across the three groups; however, the
mean weight gain for SW (−0.1 kg) was significantly less than that for
AC (1.3 kg, p<0.05). Patients preferred AT to AC or SW when an antide-
pressant was ineffective in treating their depression.
Conclusion: Among the three treatment strategies, overall AT yielded
greater clinical benefit than did AC and SW. Adequately powered, well-
controlled clinical trials are strongly warranted to confirm our findings
due to methodological shortcomings.
Policy of full disclosure: None.
P-42-018 Agomelatine treatement in outpatient depressives: A short
effectiveness study
G. Papageorgiou1, G. Avraam1, S. Dimou1. 1Evangelismos Hospital, Athens,
Greece
Objective: Assessment of efficacy and safety of agomelatine alone or in
combination in outpatients with DSM-IV major depressive episode of
variable duration.
Methods: To 40 outpatients (18 males, 22 females) with DSM-IV major
depression, agomelatine 25mgs omni nocte was prescribed, with a poss-
ible increase to 50mgs omni niocte after two weeks. Efficacy was assesed
with the dministration of 17-item HAM-D in 0, 2,4,8 and 12 weeks. Side
effects were assessed through clinical observation or self reports.There
was a separate analysis of efficacy for both monotherapy (25or 50mgs
of agomelatine) and polypharmacy patiens and also for older (>65 years
of age) and younger patients. A liver biochemistry profile was adminis-
terd in week 0 and week 12 to 33 patients.
Results: After 12 weeks a mean reduction of 10,2 points in HAM-D for
both groups was observed. A greater reduction (11, 6 points) was found in
the group under 50mgs/day but the difference was marginally statistically
significant. Another interesting finding was that a better outcome was
observed in monotherapy patients (− 11 units) compared with polyphar-
macy patients (−8,4)), a non-significant finding. . The most common
reported adverse event was headache (14,6 %). Two patients had a non
significant rise of ALT (16 and 23 units at the end of the study).
Conclusion: Agomelatine proved to be an effective treatment choice for
outpatients with major depression.
Policy of full disclosure: None.
P-42-019 The effects of 3 weeks repetitive transcranial magnetic
stimulation on the P200 amplitude in patients with
medication-resistant major depression
J. E. Park1, H. J. Huh2, J.-H. Chae2. 1Keyo Hospital, Uiwang, Republic of
Korea; 2Seoul St. Mary’s Hospital, Seoul, Republic of Korea
Objective: Previous studies have reported that the repetitive transcranial
magnetic stimulation (rTMS) would be able to induce neuronal plasticity
in the brain. Although event-related potential (ERP) is an expecting tool
for exploring, a study of rTMS effects on ERPs in patients with major de-
pression has not been fully explored. The aim of this study is to prove that
rTMS treatment induces changes in brain function of patients with
medication-resistant major depression using ERP.
Methods: Eighteen patients with medication-resistant major depression
(five males and thirteen females) participated in this study. The patients
received rTMS treatment for three weeks. All patients completed clinical
scales including Hamilton Depression Rating Scale (HAM-D), Hamilton
Anxiety Scale (HAM-A), Beck Depression Inventory (BDI), State-Trait
Anxiety Inventory (SAI, TAI), Ruminative Response Scale (RRS),
Emotion Regulation Questionnaire (ERQ), and Cognitive Emotion
Regulation Questionnaire (CERQ), and EEG assessment including ERP
auditory oddball task, at their first visit (baseline) and second visit
(3-weeks).
Results: In rating scales, HAM-D, HAM-A, BDI, SAI, and ‘blaming
others’ scale of CERQ decrease significantly after rTMS treatment. In
ERP auditory oddball task, when FP1, FP2, FZ, FCZ, CZ, and PZ channels
were analyzed, P200 amplitudes showed a main effect for time of measure
and increased after 3-weeks rTMS treatment. Standardized low-resolution
brain electromagnetic tomography (sLOREA) showed significant acti-
vation in left middle frontal gyrus.
Conclusion: This study suggests that long-term rTMS treatment
induces changes of brain function in patients with medication-resistant
major depression, which can be identified using ERP.
Policy of full disclosure: None.
P-42-020 The association between serum lipid levels, suicide
ideation, and central serotonergic activity in patients with
major depressive disorder
Y.-M. Park1, B.-H. Lee2. 1Goyang, Republic of Korea; 2Seoul, Republic of Korea
Objective: There is some evidence that low lipid levels cause suicide in
depressed patients. The purpose of this study was to identify whether
low serum lipid levels are associated with suicide ideation or are corre-
lated with central serotonin function.
Methods: Auditory processing for the loudness dependence of auditory
evoked potentials (LDAEP) was measured in 73 outpatients with major
depressive disorder. The Hamilton Depression Rating Scale (HAMD)
and Beck Depression Inventory (BDI) were administered on the same
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day as measurement of the LDAEP. In addition, serum levels of total chol-
esterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL),
and triglyceride (TG) levels were measured. All subjects had received anti-
depressant monotherapy.
Results: The depressed subjects were divided into those with and with-
out suicide ideation according to the score for HAMD item 3 or BDI item
9. TG levels differed significantly between the two groups, whereas body
mass index (BMI), total cholesterol, LDL, HDL, and LDAEP did not. The
scores for HAMD item 3 and BDI item 9 were negatively correlated with
TG levels (p=0.049 and 0.027, respectively). The LDAEP was negatively
correlated with TG levels (p=0.012). Although there was tendency toward
a negative correlation between the LDAEP and serum LDL, it did not
reach statistical significance (p=0.068).
Conclusion: The findings of this study revealed a relationship between
TG and suicide ideation that is independent of both BMI and body
weight. Furthermore, serum lipid levels were associated with central ser-
otonergic activity, as assessed using the LDAEP.
Policy of full disclosure: This study was supported by a grant from
National Research Foundation of Korea (NRF), funded by Ministry of
Education and Science Technology (MEST) (NRF-2011-0010562). They
support authors in financial aspect.
P-42-021 Concentrations of different antidepressants in plasma and
cerebrospinal fluid under naturalistic conditions
M. Paulzen1, S. Groppe1, T. Veselinovic1, S. C. Tauber1, C. Hiemke2,
G. Gründer1. 1RWTH Aachen University, Aachen, Germany; 2RWTH
Aachen University, Mainz, Germany
Objective: Aim of this study was to investigate whether drug concentra-
tions of different antidepressants in plasma can be considered as a surro-
gate marker of concentrations in brain/cerebrospinal fluid (CSF).
Methods: The present study is a naturalistic prospective investigation of
48 depressive patients treated daily doses of venlafaxine (16), citalopram
(16) and mirtazapine (16). Patients underwent lumbar puncture (LP) for
medical reasons and not for the purpose of this study. Blood was collected
in at the same time as lumbar puncture was done. LP was done as part of
the clinical routine without placing a special emphasis on trough levels of
the ingested drug.
Results: The correlation between venlafaxine, O-desmethylvenlafaxine
and AM in plasma and CSF was highly significant (p<0.001).
Mirtazapine in plasma and CSF were just trend-wise correlated
(r=0.441, p=0.088) and no relation of daily dose and CSF levels of mirta-
zapine could be observed (r=0.313, p=0.238). Citalopram-levels showed a
high correlation between plasma and CSF _r=0.890, p<0.001,
Conclusion: 3 different antidepressants show highly variable pen-
etration ratios into CSF. The poor correlation of dose to concentrations
in body fluids and the highly significant correlation of plasma to CSF con-
centrations indicate that plasma concentration is a much better marker of
drug concentration in brain than the dose.
Policy of full disclosure: None.
P-42-022 Vortioxetine treatment reverses cognitive impairment
induced by long-term dysregulation of glutamate
neurotransmission in rats
A. Pehrson1, J. Waller1, N. Plath2, C. Sanchez1. 1Lundbeck Research USA,
Inc., Paramus, USA; 2H. Lundbeck A/S, Valby, Denmark
Objective: Vortioxetine is a multimodal-acting antidepressant that in-
directly modulates glutamate neurotransmission via serotonergic mechan-
isms. Preclinical evidence suggests that vortioxetine ameliorates
impairments in memory and cognitive flexibility. However, there is little
evidence directly tying vortioxetine’s cognitive effects to glutamate modu-
lation. Our objective was to assess whether vortioxetine ameliorates cog-
nitive deficits induced by long-term glutamate dysregulation using a
glutamatergic NMDA receptor antagonist.
Methods: Subchronic phencyclidine (SubPCP): Male rats were treated
with saline or PCP (5mg/kg ip bid) for 7 days followed by a 7 day wash-
out. After washout, rats were assessed in the attentional set-shifting task
(AST) 1 h after vortioxetine (0, 1, 3, 10mg/kg sc) or 30min after modafinil
(64 mg/kg po). A separate cohort was assessed in the novel object recog-
nition (NOR) task 1 h after vehicle or 10mg/kg vortioxetine. A third co-
hort had free access to vehicle or vortioxetine-infused food (0.22 or 1.8 g
vortioxetine/kg food) during the 14-day SubPCP administration/washout
period. On day 15, rats were assessed in the AST. Frontal cortex tissue was
analysed for altered GABA- and glutamate-related protein expression
using western blots.
Results: SubPCP impaired AST performance in the extradimensional
shift and extradimensional reversal subtests (F(30,383)=1.519, p<0.05).
The SubPCP-induced extradimensional shift deficit was reversed by mod-
afinil, and all vortioxetine doses. The extradimensional reversal deficits
were normalized by 10mg/kg vortioxetine. SubPCP also impaired NOR
performance (F(2,31)=5.46, p<0.01), and 10mg/kg vortioxetine reversed
this deficit. Subchronic vortioxetine blocked SubPCP-induced impairment
in AST performance at both concentrations (F(30,417)=2.29, p<0.001).
Rats in the high subchronic vortioxetine group had significant increases
in GAD67 (F(2,32)=4.91, p<0.05) and NR2B (F(2,32)=5.06, p<0.05) ex-
pression vs controls.
Conclusion: Vortioxetine administration reversed subchronic
PCP-induced deficits in memory and executive function, suggesting that
vortioxetine may be able to normalize dysregulated glutamate
neurotransmission.
Policy of full disclosure: Alan Pehrson, Jessica Waller, and Connie
Sanchez are employees of Lundbeck Research USA, Inc. Niels Plath is
an employee of H. Lundbeck A/S.
P-42-023 Synaptic and neuroplastic mechanisms of chronic
lurasidone treatment in the chronic mild stress model
M.A. Riva1, F. Macchi1, A. C. Rossetti1, M. Papp2, R. Molteni1. 1University
of Milan, Milan, Italy; 2Institute of Pharmacology, Polish Academy of Sciences,
Krakow, Poland
Objective: It is well-established that major depression is associated with
impaired synaptic function and reduced neuronal plasticity in selected
brain structures, and that such changes represent an important target of
pharmacological intervention. In the present study we have investigated
the ability of the second-generation antipsychotic drug lurasidone to
modulate neuroplastic alterations in the chronic mild stress (CMS)
model of depression.
Methods: Male Wistar rats were exposed to CMS for 2 weeks and
sucrose consumption was used to distinguish between susceptible and
non-susceptible animals in order to identify the molecular alterations
that are relevant for stress susceptibility. Control and CMS-susceptible
rats were then randomized to receive chronic vehicle or the novel antipsy-
chotic drug lurasidone for 5 more weeks, while continuing the stress pro-
cedure, in order to evaluate the antidepressant properties and molecular
changes set in motion by chronic drug treatment.
Results: After 2 weeks of CMS, we found reduced expression of the
pool of BDNF transcripts with long 3#UTR that may be targeted to the
synaptic compartment, suggesting the contribution of the neurotrophin
to the behavioral dysfunction produced by CMS. The down-regulation
of BDNF expression persisted until the end of the stress procedure in
vehicle-treated rats, whereas chronic lurasidone treatment was able to re-
vert the depressive-like behavior and normalized the BDNF mRNA levels
in the prefrontal cortex of CMS rats. Moreover, we found that stressed rats
display significant defects in the post-synaptic compartment, as shown by
the reduced expression of PSD-95 but not of synapsin I, and that these
changes were also normalized by chronic lurasidone treatment.
Conclusion: Our results demonstrate that lurasidone show antidepres-
sant properties in the CMS model through the modulation synaptic and
neuroplastic proteins. The adaptive changes produced by sub-chronic
treatment with lurasidone may contribute to the amelioration of func-
tional capacities, which are deteriorated in patients with major depression
and stress-related disorders.
Policy of full disclosure: M.A. Riva has received honoraria or research
support from Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Eli
Lilly, Servier and Sunovion. All the other authors have no financial confl-
icts to declare.
P-42-024 Neurobiological correlates of anhedonia: Findings based
on the dimensional anhedonia rating scale
S. Rizvi1, A. Cyriac1, A. Strafella1, B. Sproule2, S. Kennedy1. 1University
Health Network, Toronto, Canada; 2CAMH, Toronto, Canada
Objective: To identify the brain regions and dopamine receptor binding
associated with anhedonia in treatment resistant depression patients.
Methods: Patients with treatment resistant depression (n=15) under-
went two positron emission tomography (PET) scans at baseline as part
of a Deep Brain Stimulation trial: glucose metabolism using
18F-fluorodeoxyglucose and extrastriatal dopamine D2/D3 binding
using 11C-FLB 457. On the day of the D2 scanning, patients completed
the Dimensional Anhedonia Rating Scale (DARS), a novel questionnaire
to measure anhedonia (maximum possible score: 68, where a high score
reflects less anhedonia), and the Snaith Hamilton Pleasure Scale
(SHAPS; maximum possible score: 14, where a high score reflects more
anhedonia). Patients also completed measures of depressive symptoms
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and physical activity. A group of healthy controls completed the scales
but not the PET imaging (n=99).
Results: There was a statistically significant difference between
depressed patients and healthy controls on the DARS (15.4+/−6.6 vs.
51.8+/−11.6, t =11.5, p<0.0001). There was a similar group difference
based on the SHAPS (9.9+/−2.6 vs. 1.6+/−2.8, t=−10.6, p<0.0001).
Neuroimaging correlates based on glucose metabolism and dopamine
binding potential will be discussed.
Conclusion: Anhedonia is prominent in treatment resistant depression.
Further research should aim to identify this symptom as a potential diag-
nostic and treatment biomarker.
Policy of full disclosure: The PET scan data used in this study
were from a Deep Brain Stimulation clinical trial sponsored by St. Jude
Medical. SJR has received travel funding from Eli Lilly and St. Jude
Medical. SHK has received honoraria/research funding from
AstraZeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Canadian
Institute of Health Research, Lundbeck, Ontario Brain Institute, Pfizer,
Servier, and St. Jude Medical. AC, APS and BAS declare no conflicts.
P-42-025 Clinical depression predicts paranoia in high-risk patients
R. K. R. Salokangas1, T. From1, M. Heinimaa1, J. Hietala1, H. Graf von
Reventlow2, D. Linszen3, P. Dingemans3, M. Birchwood4, P. Patterson4,
S. Ruhrmann5, J. Klosterkötter5. 1University of Turku, Turku, Finland;
2Bochum, Germany; 3Amsterdam, Netherlands; 4Birmingham, United
Kingdom; 5Cologne, Germany
Objective: Since the nineteenth century, causal connection between affect-
ive disorders and paranoid thinking has been one of the most interesting
questions in psychiatric psychopathology. Patients with affective disor-
ders or symptoms may have non-psychotic or psychotic paranoid symp-
toms. On the other hand, paranoid patients often reveal depressive or
anxiety symptoms. In cross-sectional studies, causal direction between af-
fective disorders and paranoia can not been evaluated. In a prospective
follow-up study, we aimed to study whether clinical depressive or anxiety
disorders predict occurrence of paranoid-like symptoms in clinical high-
risk (CHR) patients.
Methods: In the EPOS project, 245 young help-seeking CHR patients
were examined and prospectively followed for 18 months. At baseline,
patients’ current clinical SCID diagnoses, depressive and anxiety symp-
toms, premorbid adjustment and childhood and adolescence traumatic
and distress experiences were assessed. Persecutory/paranoid symptoms
were assessed by the Structured Interview for Prodromal Syndromes at
baseline and at the 9 and 18 months follow-up. Baseline paranoid symp-
toms were subtracted from follow-up paranoid symptoms (follow-up
paranoia). The association between premorbid and baseline factors and
follow-up paranoia were analysed with hierarchical linear model.
Results: From clinical diagnoses, depressive, anxiety and somatisation
disorders, as well as depressive and anxiety symptoms associated signifi-
cantly with follow-up paranoia. Likewise, poor premorbid adjustment,
and emotional and sexual abuse had a significant association with follow-
up paranoia. In multivariate hierarchical modelling, clinical depressive
and somatisation disorder, premorbid adjustment and sexual abuse pre-
dicted significantly follow-up paranoia. In post hoc analyses, also anxiety
symptoms were entered into the predictive model.
Conclusion: From clinical disorders, depression and somatisation are
the major predictors of paranoid symptomatology in CHR subjects.
Also anxiety symptoms, especially excessive social anxiety, play a signifi-
cant and independent role in occurrence of paranoid symptoms. From
early developmental factors, poor premorbid social adjustment and child-
hood/adolescence sexual abuse may increase vulnerability to paranoid
experiences.
Policy of full disclosure: None.
P-42-026 Vortioxetine, a multimodal-acting antidepressant with
distinct pharmacological properties - A comparative
preclinical study vs. SRIs
C. Sanchez1, E. Dale1, Y. Li1, S. C. Leiser1, M. Gulinello2. 1Lundbeck
Research, Paramus, USA; 2Albert Einstein College of Medicine, Bronx, USA
Objective: The antidepressant vortioxetine is a 5-HT3, 5-HT7 and 5-HT1D
receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor
agonist and inhibitor of the 5-HT transporter (SERT). The aim of this
investigation was to compare vortioxetine with SSRIs or SNRIs in rat
assays predictive of anxiolytic and antidepressant activity and cognitive
enhancement.
Methods: Effects on 5-HT-induced spontaneous inhibitory post-
synaptic currents (sIPSCs) were recorded in CA1 pyramidal cells of
hippocampus slices using whole cell patch recordings. Since theta
rhythms are involved in memory formation and 5-HT3 receptor-
expressing interneurons regulate the strength of theta rhythms by control-
ling the output of pyramidal cells, theta rhythms were recorded in vivo
using electroencephalographic recordings. Acute anxiolytic activity was
measured as reduction of conditioned fear-induced ultrasonic vocalization
and increase of social interaction time under unfamiliar aversive light con-
ditions. Antidepressant activity was measured by means of the forced
swim test in female rats during a progesterone withdrawal (PWD) phase.
Results: Vortioxetine blocked 5-HT-induced sIPSCs, likely through
blockade of 5-HT3 receptors on interneurons; escitalopram was inactive.
Vortioxetine increased theta power during the active wake state; escitalo-
pram and duloxetine were inactive. Vortioxetine showed acute anxiolytic
activity in both assays; duloxetine and paroxetine were inactive in the con-
ditioned fear and social interaction tests, respectively. Chronic dosing
with vortioxetine, but not fluoxetine or duloxetine, produced an
antidepressant-like effect during PWD. Furthermore, in rats chronically
treated with fluoxetine and subsequently exposed to PWD, addition of
a 5HT1A receptor agonist or a 5-HT3- or 5-HT7-receptor antagonist failed
to produce antidepressant-like activity. The latter suggests that a complex
interaction between SERT inhibition and > 1 receptor activity is involved
in the antidepressant-like activity of vortioxetine in this model.
Conclusion: Vortioxetine differs from SSRIs and SNRIs in preclinical
assays of anxiolytic and antidepressant activity and cognitive enhance-
ment. This supports a crucial role for vortioxetine’s receptor activities.
Policy of full disclosure: CS, ED, YL, SCL are fulltime employee at
Lundbeck Research. MG is a consultant to Lundbeck Research.
P-42-027 Cognitive impairment in depression
E. Serfaty1, S. M. Zanone2. 1Universidad de Buenos Aires, Buenos Aires,
Argentina; 2Novain Neurociencias Group, Buenos Aires, Argentina
Objective: To study cognitive function in depressed patients, between 18
to 45 year old.
Methods: It were studied 28 patients with depression and 10 healthy
controls during six months, using MINI, MADRS and Cognitive test to de-
termine cognitive level, visual memory and executive function, as well as
problems related at work and concentration to read and do homework.
Results: Eighty percent of patients with depression (minor, mild and
major depression had cognitive impairment, and 20 percent of healthy
people had it too. Statistical analysis was done with SPSS.
Conclusion: Most of the patients with depressed mood had cognitive
impairment (visual attention and executive function) with a correlation
with social problems at home and work. It would neccessary to sensibilize
mental health professionals to explore cognitive function in depressed
patients, asking about it or using appropiate scales of measure. To
know about the degree of cognitive impairment will be usefull to deter-
mine psychopharmaology and psychotherapy treatment.
Policy of full disclosure: None.
P-42-028 Having difficulty concentrating or making decisions is
a useful clinical cue for depression
N. Ship1, A. Thompson2. 1Lundbeck Canada, Toronto, Canada; 2Institute for
Health Economics, Edmonton, Canada
Objective: To determine which symptoms within the DSM criteria for a
Major Depressive Episode (MDE) might have the most utility for clinical
decision making among practitioners.
Methods: Interview data were collected by telephone from randomly
selected working adults in Alberta, Canada, in 2009. Step-wise regression
models were built from those reporting depressed mood or loss of inter-
est. The independent variables are the seven remaining depressive symp-
toms. The following dependent variables were considered relevant to
clinical decision making: (1) a sufficient number of symptoms for an
MDE, (2) significant distress or impaired ability to function, (3) hopeless-
ness, and (4) previous help-seeking for a mental health problem.
Results: Of the sample, 26% (N=743 of 2817) reported a period of de-
pressed mood or loss of interest. A single symptom, “Difficulty concen-
trating or making decisions”, captured 52% of the variance in modeling
a sufficient number of symptoms for an MDE. As expected, this model
improved incrementally with each additional depressive symptom (67%,
76%, 83%, 92%), since these define the threshold. “Difficulty concentrating
or making decisions” captured 27% of the variance in modeling distress or
impairment (33%, 38%, 39%, incrementally). “Feelings of worthlessness or
guilt” captured 20% of the variance in modeling hopelessness (29%, 31%,
32%, incrementally). Help-seeking for a mental health problem could not
be modeled (8%, with 1 symptom, 13% with 4).
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Conclusion: In working adults, the use of a single depressive item was
most useful in modeling a sufficient number of symptoms for an MDE,
was somewhat useful in modeling distress/impairment and hopelessness,
but was not useful in modeling help-seeking. Most of the utility of the
step-wise models was captured with the first depressive item.
“Difficulty concentrating or making decisions” yielded the most infor-
mation and may be a worthwhile clinical cue for practitioners presented
with a working adult.
Policy of full disclosure: Noam Ship is a full time employee of
Lundbeck Canada Inc.
P-42-029 Resilience and vulnerability are dose-dependently related
to corticosterone treatment in adult but not adolescent rats
T. Si1, Y. Li1, J. Li1, X. Liao1, Y. Zhao1, Y. Su1. 1Institute of Mental Health,
Beijing, China
Objective: Adolescence is a key developmental transition period charac-
terized by highly plasticity, which renders heightened risks for stress-
related disorders. Little is known about the effect of different severity of
adolescent stress on the development of vulnerability and resilience.
Methods: Both adolescent (postnatal days (PND) 30) and adult (PND
70) male rats were allocated into three treatment regimens, receiving
daily injections of either high (40mg/kg) or low (5mg/kg) doses of
CORT or vehicle consecutively for 21 days. Both short-term and long-term
effects of treatment regimens on behaviors, cognition and HPA axis
activity were assessed.
Results: Adulthood 40mg/kg, but not 5 mg/kg CORT treatment signifi-
cantly decreased sucrose preference/intakes, heightened startle reflexes,
decreased central exploration, impaired spatial learning, caused adrenal
atrophy and decreased endogenous plasma CORT within 1-week
of CORT cessation. After 4-week recovery, 5 mg/kg CORT pretreatment
significantly increased central exploration and spatial learning, 40mg/kg
CORT impaired reversal learning in adult rats. Although adolescent
40mg/kg CORT also caused adrenal atrophy and reduced plasma
CORT, no deficit in behaviors were found in short-term and long-term.
Both 5mg/kg and 40mg/kg CORT significantly increased short-term
sucrose intakes/preference, reduced startle reflexes and enhanced
pre-pulse inhibition in adolescent rats. After 4-week recovery, while
adolescent 5mg/kg CORT pretreatment significantly enhanced reversal
learning, 40mg/kg pretreatment significantly enhanced pre-pulse inhi-
bition and spatial learning.
Conclusion: CORT exert an inverted U-shape effect on adult rats.
40mg/kg CORT induced depressive-like behaviors, anxiety-like beha-
viors, and deficits in cognitive ability in short-term while 5mg/kg
CORT enhanced spatial learning in long-term. However, this dose-effect
relationship did not exist in adolescent rats. Both adolescent 5mg/kg
and 40mg/kg CORT treatment appeared to favor behavioral functioning.
This study opened the possibility of using stress inoculation effects to pro-
mote building resilience in adolescence.
Policy of full disclosure: None.
P-42-030 Alterations of the cortisol and dehydroepiandrosterone
(DHEA) in perinatal depression
H.-S. Suh1, R.-S. Ahn2, K.-S. Lee3, C.-H. Kim4. 1School of Medicine, CHA
University, Seoul, Republic of Korea; 2School of Medicine, CHA University,
Complementary Alternative Medicine, Seoul, Republic of Korea; 3School of
Medicine, CHA University, Psychiatry, Seoul, Republic of Korea; 4College of
Medicine, Yonsei University, Psychiatry, Seoul, Republic of Korea
Objective: The purpose of this study is to investigate the alterations of the
hypothalamic–pituitary–adrenal (HPA) axis hormones, especially salivary
cortisol and dehydroepiandrosterone (DHEA) in perinatal depression.
Methods: 44 patients with depression and 217 normal subjects in peri-
natal period were included in this study. Edinburgh Postnatal Depression
Scale (EPDS) and Beck Depression Inventory II (BDI-II) were performed.
The subjects below 10 points of EPDS score or below 13 points of BDI-II
score were classified to normal subjects. Among the subjects more than
11 points of EPDS score or more than 14 points of BDI-II score were diag-
nosed depression by DSM-IV TR by psychiatrists. All subjects were to col-
lect their saliva in each 4 collecting tubes, immediately upon awakening
(IA), 30 minutes after awakening (30A), 60 minutes after awakening
(60A) and before bedtime (BB).
Results: The number of subjects in antenatal period were 103, and ante-
natal depression (AD) patients were 21, antenatal normal (AN) subjects
were 82. The number of subjects in postnatal period were 114, and post-
natal depression (PD) patients were 23, postnatal normal (PN) subjects
were 91. Salivary cortisol levels in subjects with AD collected IA, 30A
and 60A were lower than with AN subjects significantly except BB.
Salivary cortisol levels in subjects with PD collected 60A only were
lower than with PN subjects significantly. Salivary DHEA levels in sub-
jects with both AD and PD were lower than with normal subjects signifi-
cantly. Also cortisol/DHEA ratio (F/D ratio) in subjects with both AD and
PD were much higher than with normal subjects significantly.
Conclusion: These results suggest that the blunted response was shown
in AD, and the characteristics between AD and PD are different. Also the
differences of salivary DHEA levels and F/D ratio between subjects with
PD and normal subjects are suggested the one of the key points of differ-
ence among both groups.
Policy of full disclosure: None.
P-42-031 A clinical case of velaxin therapy in a teenager
E. Valzdorf. BNUEL, Irkutsk, Russia
Objective: To briefly characterize the state of mental health in a teenager
with a revealed mild depressive episode and assess antidepressant
Velaxin in the therapy used for the treatment.
Methods: The clinical-psychopathological and pathopsychological
methods.
Results: After the first administration of the medication the patient in
conversation complained about the frequent and pronounced effect of
“déjà vu” that lasted for 10–15 seconds and manifested itself 3–4 times
a week. Also he complained about low spirits, apathy, loss of appetite
and deterioration of memory. Doctor prescribed him antidepressant
Velaxin (the dosage of 300mg per day divided into two doses),
Nootropil (the dosage of 1600mg per day divided into two doses) and
Mexidol (the dosage of 125mg once a day in the evening). During the
third week of the Velaxin therapy the patient showed some improvements
in his condition: the spirits improved, apathy disappeared. The effect of
“déjà vu”manifested itself 1–2 times a week and became less pronounced.
At the same time the decision was made to leave the same dosage of the
main medication, Velaxin. During the sixth week of the therapy the men-
tal health of the teenager remained good. After the next talk, in order to
avoid the withdrawal syndrome it was decided to gradually decrease
the Velaxin dosage by 50mg in the next week of the therapy. When the
dosage of the antidepressant was reduced to 37.5 mg per day the with-
drawal syndrome was not revealed. During the twelfth week of the ther-
apy the patient stopped taking the antidepressant, the effect of “déjà vu”
did not occur anymore.
Conclusion: Velaxin can be applied in the therapy of such a mental dis-
order as mild depressive episode in the teenage patients. The treatment
should start with a dosage of 300mg per day with its gradual reduction
to 37.5 mg per day against the background of a good mental health.
Policy of full disclosure: None.
P-42-032 The cognitive effects of vortioxetine are associated with
increased expression of neuroplasticity markers
J. Waller. Lundbeck Research USA, Paramus, USA
Objective: The antidepressant vortioxetine acts as an antagonist at 5-HT3
and 5-HT7 receptors, partial agonist at 5-HT1B receptors, agonist at
5-HT1A receptors, and a SERT inhibitor. In contrast to typical SSRIs, vor-
tioxetine enhances long-term potentiation, the cellular basis of memory, in
hippocampal slices and improves cognitive performance in preclinical
studies [1,2]. In addition, recent clinical studies reveal a role for vortioxe-
tine in alleviating cognitive dysfunction in depressed subjects [3].
However, the underlying molecular mechanism by which vortioxetine
augments memory performance remains unknown. We examined the ef-
fect of vortioxetine and the putative antidepressant ketamine on mRNA
and protein expression of various synaptic markers that play a central
role in protein synthesis and plasticity.
Methods: Transcription of neuroplasticity-related genes was measured
by quantitative PCR and protein levels assessed by western blot analysis
in frontal cortex and hippocampus at various time points following acute
vortioxetine (10mg/kg, i.p.) or ketamine (10mg/kg, i.p.) treatment in adult
male rats.
Results: Vortioxetine and ketamine treatment increased mRNA levels
of mTOR, spinophilin, mGluR1, and HOMER3 in the frontal cortex 8 h
post-injection. Levels of phospho-mTOR at Ser2448, a marker of mTOR ac-
tivation, were elevated in the frontal cortex 24 h following acute vortiox-
etine treatment. Moreover, protein levels of some glutamate markers,
including phospho-Tyr1472 of the GluN2B subunit of the NMDA recep-
tor, a site implicated in stabilization of receptors at the synaptic mem-
brane, were increased in the frontal cortex relative to vehicle-injected
animals.
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Conclusion: Together, these results suggest that vortioxetine affects
pathways involved in protein translation and glutamatergic signaling at
the synapse. The direct activity of vortioxetine at multiple 5-HT receptors
may trigger activation of these signaling cascades, leading to improve-
ment of cognitive dysfunction [1].
References
1. du Jardin et al. Eur Neuropsychopharmacol 2013: PMID: 23916504.
2. Mork et al. Pharmacol Biochem Behav 2013: PMID: 23380522.
3. McIntyre et al. Neuropsychopharmacol 2013;38:S380–S381.
Policy of full disclosure: Employee of Lundbeck Research USA.
P-42-033 Randomised, double-blind study of vortioxetine versus
venlafaxine in adults with major depressive disorder
(MDD)
G. Wang1, M. Gislum2, G. Filippov2. 1Beijing Anding Hospital, Beijing,
China; 2Lundbeck, Copenhagen, Denmark
Objective: This randomised, double-blind 8-week comparator study
compared efficacy and tolerability of fixed-dose treatment with
multimodal-acting antidepressant vortioxetine 10mg/day and venlafaxine
XR 150mg/day (SNRI) in MDD patients from Asia (China, South Korea,
Taiwan and Thailand).
Methods: Eligible patients aged 18–65 years with a diagnosis of MDD
and a Montgomery-Åsberg Depression Rating Scale (MADRS) total
score >=26 were randomised (1:1). The primary endpoint was change
from baseline to Week 8 in MADRS total score analysed by ANCOVA
(FAS, LOCF), using a non-inferiority test margin of±2.5 MADRS points.
Pre-defined secondary endpoints included MADRS response and re-
mission rates, anxiety symptoms (HAM-A), global clinical judgment
(CGI), overall functioning (SDS), and health-related quality of life
(Q-LES-Q).
Results: On the primary efficacy endpoint at Week 8, non-inferiority
was established with a difference between vortioxetine (n=211) and ven-
lafaxine (n=226) of −1.2 MADRS points in favour of vortioxetine (95% CI:
-3.0 to 0.6; p=0.1989). The MADRS total score decreased (improved)
from 32.3±4.6 at baseline to 13.6±9.6 (vortioxetine) and from 32.3±4.5
to 14.8±10.4 (venlafaxine) (FAS, LOCF). At Week 8, the HAM-A and
SDS total scores, CGI and Q-LES-Q scores, and response and remission
rates demonstrated similar improvement for vortioxetine and venlafaxine,
with MADRS response rates of 66.5% (vortioxetine) vs 61.4% (venlafaxine)
and remission rates of 43.1% (vortioxetine) vs 41.4% (venlafaxine) (LOCF).
Fewer vortioxetine than venlafaxine patients withdrew for any reason
(18.0% versus 27.4%) or for adverse events (6.6% vs 13.7%). The most fre-
quent adverse events were nausea, dizziness, dry mouth, and decreased
appetite.
Conclusion: Vortioxetine was at least as efficacious as venlafaxine in
this MDD study and was safe and better tolerated than venlafaxine.
Policy of full disclosure: This study was sponsored by H. Lundbeck
A/S.
P-42-034 Effects of levomilnacipran er on measures of attention in
a phase III trial of major depressive disorder
K. Wesnes1, C. Gommoll2, C. Chen2. 1Bracket, Reading, United Kingdom;
2Forest Research Institute, Jersey City, USA
Objective: To evaluate changes in cognitive measures in patients with
major depressive disorder (MDD) treated with levomilnacipran ER
(LVM) versus placebo (PBO), and assess relationships between cognitive
changes and depression symptoms.
Methods: In an 8-week study of LVM 40–120mg versus PBO in
adult patients with MDD (NCT00969709), cognitive assessments included
change from baseline on the Bond-Lader Visual Analog Scales (VAS) of
Mood and Alertness and the Cognitive Drug Research (CDR) System.
The CDR tests speed and accuracy on 3 computerized tasks (Simple
Reaction Time, Digit Vigilance, and Choice Reaction Time); test results
are used to derive 4 composite scores: Power of Attention (PoA),
Continuity of Attention (CoA), Cognitive Reaction Time (CogRT), and
Reaction Time Variability (RTV). Post hoc analyses evaluated relation-
ships between changes in cognitive measures and baseline depressive
symptoms (as measured by MADRS Total and Item 6 [Difficulty
Concentrating] scores). Relationships between MADRS response (550%
improvement) and changes in cognitive measures were assessed.
Results: Of 429 ITT patients, 187 PBO and 182 LVM patients had
valid Week 8 cognitive assessments and were included in the analyses.
Greater improvement for LVM versus PBO in depressive symptoms
was accompanied by greater improvement over PBO in all measures of at-
tention (CoA, P=0.0016; PoA, P=0.0382; RTV, P=0.0237;) except CogRT
(P=0.3409). There was no significant correlation between change in atten-
tion measures and baseline (or change in) MADRS scores. However, LVM
MADRS responders experienced significant improvements from baseline
in PoA, CoA, and RTV; in contrast, LVM non-responders and PBO
patients did not show significant improvements in cognitive measures (ex-
cept for significant improvement in PoA for PBO responders).
Conclusion: LVM treatment was associated with significant improve-
ment over PBO in depressive symptoms and cognitive measures.
MADRS response in LVM-treated patients was associated with significant
improvement on most cognitive measures.
Policy of full disclosure: This study was funded by Forest
Laboratories, Inc.
P-42-035 An international study of the grid-hamd: Has it fulfilled
its promise?
J. Williams1, M. Ondrus1, M. K. Rishton1, J. Persson1, M. Popescu1,
R. Valjakka1. 1MedAvante, Hamilton, USA
Objective: An international group developed the GRID-HAMD to ad-
dress many critiques of the HAM-D and improve its administration.
The GRID-HAMD provides novel grid scoring, structured interview
guide and scoring conventions on the same page as each item, and revised
anchor points for problematic or inconsistently rated items. The purpose
of this study was to assess the success of this effort.
Methods: A survey distributed to 74 experienced clinical trial raters in-
cluded 20 questions about the usability and ease of use of the GRID-
HAMD, rated from strongly disagree to strongly agree. Raters were also
asked to compare the GRID-HAMD with the SIGH-D by responding to
four statements with answers ranging from 1=GRID-HAMD to 7=SIGH-D.
Results: Sixty questionnaires were completed (81%). Most raters agreed
that wording of GRID-HAMD questions made it easy to administer (80%),
the conventions were clear (85%) and helpful (90%), and guidelines for
rating symptom intensity were clear (82%). Fewer rated it “easy to decide
on a frequency level” (65%). A large majority (87%) thought “having the
scoring conventions integrated into the interview guide has made scoring
easier.”More than half (57%) of 46 raters who had used both preferred the
graphical layout. However, slightly more preferred the SIGH-D for its
“ease of use” (52% vs. 41%) and “efficiency” (40% vs. 34%), and expressed
“overall preference for the SIGH-D” (47% vs. 40%).
Conclusion: The raters evaluated the clarity and ease of use of the
GRID-HAMD positively. They prefer the graphical layout that places
each item with its interview questions and conventions all on the same
page. Surprisingly, the raters did not indicate overall preference for the
GRID-HAMD versus the SIGH-D. The respondents indicated several
areas of improvement and highlighted the #most difficult# items for
both instruments.
Policy of full disclosure: Authors are affiliated with MedAvante.
P-42-036 Correlation analysis of hair cortisol levels in female
depressions
X. Yang1, X. Ma2. 1Sichuan University, Chengdu, China; 2Sichuan University,
West China Hospital, Psychiatric Laboratory, Chengdu, China
Objective: To detect the hair cortisol level and the cumulative and retro-
spective hypothalamic-pituitary- adrenal (HPA) axis function in the
first-episode and recurrent female patients with depression.
Methods: We used the Hamilton Depression Scale (HAMD), Hamilton
Anxiety Scale (HAMA) to evaluate the clinical symptoms of 35 female
depressions (22 cases of first-episode, 13 cases of recurrent) and 30 healthy
controls. We collected the hair samples by scissoring hair as close as poss-
ible to the scalp of the particepates. Since the hair grows approximately 1
centimeter per month, we used the 1 centimeter length interception of hair
close to the scalp as the representation of cortisol level of patients during
the episode duration and baseline in controls. We selected 1 centimeter
length after the episode of disease and scissored 1centimeter length inter-
ception to represent the hormone levels of patients before the disease epi-
sode. Electrochemiluminescence immunoassay was used to measure the
hair cortisol hormone levels. And we compared the differences of hair cor-
tisol levels among first-episode and recurrent patients with depression
and control subjects.
Results: Before the disease episode, the hair cortisol levels
in first-episode patients are lower than that in control subjects (t=2.280,
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p=0.027).No significant differences were found between the hair cortisol
levels of recurrent patients compared to the control subjects and
first-episode patients(t1=−1.332,p1=0.190; t2=0.678 ,p=0.503). During
the illness, the hair cortisol levels in first-episode patients are higher
than that in control subjects (t=3.284,p=0.002). No significant differences
were found between the hair cortisol levels of recurrent patients compared
to the control subjects (t=0.830,p=0.412). Moreover, the hair cortisol levels
in first-episode patients was significant higher than that in recurrent
patients in the duration (t =2.209,p=0.034). We found no correlation
between the hair cortisol levels and the HAMD/HAMA scale scores
(HAMD: r=−0.203,p=0.319;HAMA:r=−0.002,p=0.991).
Conclusion: The function of adrenal gland has changed in female
patients with depression which might be different between the
first-episode and recurrent patients. These findings suggest that measure-
ment of cortisol in hair could serve as a retrospective biomarker of
hypothalamic-pituitary-adrenal (HPA) axis function in female depression.
Policy of full disclosure: None.
P-42-037 Herbal medicine for hospitalized patients with severe
depressive episode: A non-randomized controlled study
Z.-J. Zhang1, L.-Y. Liu2, B. Feng2, J. Chen3. 1The University of Hong Kong,
Hong Kong SAR, China; 2Tongde Hospital of Zhejiang Pr., Hangzhou,
Zhenjiang, China; 3The University of Hong Kong, Hangzhou, Zhejiang, China
Objective: The purpose of this retrospective study was to evaluate the ef-
fectiveness and safety of herbal medicine used in hospitalized patients
with severe depressive episode.
Methods: In this retrospective, nonrandomized controlled study, 146
patients with severe depressive episode were hospitalized between
September 2009 and November 2013. While all of them were treated
with conventional psychotherapeutic agents, 78 received additional herbal
medicine. The severity of depressive symptoms was measured using
24-item Hamilton Rating Scale for Depression (HAMD-24) on a weekly
basis. Clinical response, remission rate and incidence of adverse
events were compared between patients treated with (n=78) and without
(n=68) herbal medicine.
Results: The two groups had similar average length of hospital stay
with approximately 28 days and were not different in the use of psy-
chotherapeutic agents during hospitalization. However, survival analysis
revealed that patients with herbal medicine exhibited significantly
higher clinical response (RR=2.179, P<0.001) and remission rate (RR=
5.866, P<0.001) compared to those without herbal medicine. Herbal
medicine-treated patients experienced remarkably lower incidences of
physical tiredness, headache, palpitation, dry mouth and constipation,
but had a significantly higher incidence of digestive discomfort compared
to patients without herbal medicine.
Conclusion: Additional herbal medicine is capable of enhancing antide-
pressant response and reducing certain adverse effects associated with
psychotherapeutic agents. Herbal medicine can be considered as an effec-
tive and relatively safe therapy for severe depressive episode (Trial
Registration: ChiCTR-OCH-13003864).
Policy of full disclosure: None.
P-43. Schizophrenia C
P-43-001 White matter alterations in first-episode deficit and
non-deficit schizophrenia patients and their first-degree
relatives - a combining TBSS and VBM study
W. Lei1, W. Deng1, T. Li1. 1Sichuan University, Chengdu, China
Objective: Clinically and genetically heterogeneity has been greatly con-
tributed to the lack of progress in our understanding of schizophrenia.
The categorization of deficit schizophrenia (DS), differ from the nodeficit
schizophrenia (NDS), is regarded as one of the most promising attempts
to reduce the heterogeneity within schizophrenia. Present study aimed
to investigate the differences in white matter (WM) alterations between
first-episode DS and NDS patients and explore the potential endopheno-
type of subgroups.
Methods: Structural MRI and diffusion tensor imaging data of
first-episode DS (n=44) and NDS (n=44) patients, their unaffected first de-
gree relatives (n=67), and age-and sex matched health controls (n=84)
were collected (table 1). Both the WM integrity measures and WM volume
(WMV) were examined using tract-based spatial statistics (TBSS) and
voxel-based morphometry (VBM) analysis.
Results: 1) Both DS and NDS patients showed WMV reduction in
cerebellum posterior lobe and WMV enlargement in bilateral fronto-
parietal regions, while 2) DS patient showing selective WMV reduction
in bilateral posterior limb of internal capsule (PLIC), when compared
with both healthy controls and NDS patients(figure 1,2). Moreover, 3)
the first degree relatives of DS patients shared the WMV deficit in
right insula (part of right PLIC cluster) with probands, representing an
endophenotype in DS(figure 3). In addition to volumetric alterations, 4)
DS patients also showing more sever white matter integrity deficit,
indexed by fractional anisotropy(FA) reduction, in bilateral sub_gyral
of parietal lobe and left precuneus than NDS patients do(figure 4). 5)
The WMV of bilateral PLIC and right insula, as well as the FA value
in left precuneus were inversely correlated with negative symptoms in
patients.
Conclusion: These results suggested that significant WM disruption, es-
pecially volume deficit in PLIC, may represent a neurobiological marker
of DS.
Policy of full disclosure: None.
Figure 1. WMV alterations in first-episodic DS (left panel) and NDS (right panel) patients when compare with sex- and
age-matched healthy controls:
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P-43-002 Gray matter alterations in first-episode patients with
deficit or non-deficit schizophrenia and their first-degree
relatives
W. Lei1, W. Deng1, M. Li1, N. Zhang2, T. Li1. 1Sichuan University, Chengdu,
China; 2Center for Neural Engineering, Department of Bioengineering,
Chengdu, China
Objective: Different patterns of gray matter (GM) abnormalities in deficit
schizophrenia (DS) and non-deficit schizophrenia (NDS) have been
reported. The aim of the present study was to examine the structural
brain alterations in first-episode DS/NDS patients and to explore the po-
tential difference in genetic risk of DS and NDS.
Methods: The structural magnetic resonance imaging (sMRI) was per-
formed in 132 first-episode patients with schizophrenia (44 DS and 88
NDS), 67 of their first-degree relatives and 84 healthy controls (44 and
40 matched with patients and relatives, respectively). GM volume
(GMV) was assessed by using Voxel-based Morphometry (VBM) and
compared between groups. Correlation analysis was also carried out be-
tween GMV and clinical symptoms in patients.
Results: DS patients displayed more severe GMV reduction in the cer-
ebellar culmen than NDS patients. The GMV reduction in cerebellar cul-
men was also observed in the first-degree relatives of DS patients but
not in the relatives of NDS patients, suggesting possible different genetic
risk in DS and NDS. Moreover the right supramarginal gyrus (rSMG) was
significantly smaller in DS patients than both NDS patients and healthy
controls, while NDS patients did not show any significant GMV difference
compared to health controls in this area. In addition, The GMV of rSMG
was inversely correlated with negative symptoms.
Conclusion: The present study revealed distinct spatial patterns of gray
matter alterations and possible different genetic risks in DS and NDS.
Policy of full disclosure: None.
Figure 3. Endophenotype of DS:
Figure 2. DS patients showing selective WMV reduction in bilateral PLIC (defined as the overlapped regions of HC1>DS and
NDS>DS) when compare with NDS patients (yellow) and HC1 (red):
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Figure 4. Voxel-wise comparison of FA maps:
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P-43-003 The contingent negative variation in patients with deficit
schizophrenia and or bipolar I disorder patients with
psychotic features measurement and correlation with
clinical characteristics
Z. Li1, W. Deng1, X. Liu1, Z. Zheng1, M. Li1, X. Ma1, Q. Wang1, T. Li1.
1West China Hospital, Chengdu, China
Objective: The purpose of this study was to assess contingent negative
variation (CNV) in patients with first episode and drug-naïve deficit
schizophrenia (DS) or bipolar I disorder (BP I) with psychotic features.
The study also investigated correlations between CNV and clinical charac-
teristics in DS and BP I.
Methods: We elicited a CNV using an alarm (S1)-imperative (S2) para-
digm in patients with DS (n=30) or BP I with psychotic features (n=33)
and in healthy controls (n=40). A general linear model was used to com-
pare CNV potentials among the three groups, and partial correlation was
used to investigate the relationship between CNV features and clinical
characteristics of patients with DS or BP I.
Results: CNV amplitude was significantly smaller and reaction time
significantly longer in the DS and BP I groups than in healthy controls.
Post-imperative negative variation (PINV) interval was significantly
shorter in the DS group than in healthy controls. The onset latency of
CNV expectancy wave was significantly longer and PINV area signifi-
cantly smaller in the DS group than in the other groups. In the DS
group, CNV amplitude and PINV interval correlated negatively with
the subscale of negative symptoms on the PANSS; CNV amplitude also
correlated negatively with disease duration. In the BP I group, CNV am-
plitude and reaction time showed no correlation with clinical features.
Conclusion: CNV amplitude is a common trait marker for psychosis.
The onset latency of CNV expectancy wave appears to be a specific trait
marker and may be used to identify candidate genes for DS.
Policy of full disclosure: None.
P-43-004 Effects of the putative antipsychotics D- and L-govadine
on disrupted performance of the touchscreen-based
paired associates task following acute MK-801 in rats
B. Lins1, A. Phillips2, J. Howland1. 1University of Saskatchewan, Saskatoon,
Canada; 2University of British Columbia, Vancouver, Canada
Objective: Tetrahydroprotoberberines, such as D- and L-govadine, are
novel compounds derived from traditional medicine that have shown
promise in treating some symptoms of schizophrenia. The present experi-
ments assessed the effects of D- and L-govadine on the Paired Associates
Learning (PAL) task in rats. The PAL task is part of the CANTAB battery
and is impaired in patients with schizophrenia and has been adapted for
use with rodents using touchscreen-equipped operant chambers with the
hope of unifying preclinical and clinical research. The specific objectives of
this study were to: 1) examine the effects of acute NMDA receptor antag-
onism as a model for schizophrenia on performance of the PAL task; and
2) test the effects of the putative antipsychotics, D- and L-govadine on the
effects of NMDA receptor antagonism on the task.
Methods: Male Long-Evans rats were trained to perform the PAL task
in touchscreen-equipped operant chambers. Following training, they were
treated with saline, the NMDA receptor antagonist MK-801 (0.15 mg/kg;
i.p.), D-govadine (1mg/kg; s.c.), L-govadine (1mg/kg; s.c.) or a combi-
nation of MK-801 and one isomer of govadine in a counterbalanced order.
Results: Acute MK-801 significantly reduced the number of trials com-
pleted, impaired accuracy, and increased the number of errors in the PAL
task. Administration of L-govadine, but not D-govadine, prior to MK-801
significantly improved accuracy and reduced errors compared to MK-801
alone. L-govadine alone, but not D-govadine, reduced errors compared to
vehicle. L-govadine, but not D-govadine, also significantly increased
latency to make a selection in the task.
Conclusion: These data establish disruptive effects of acute MK-801
treatment on performance of the PAL task and suggest that L-govadine
may have properties consistent with a compound useful in the treatment
of the cognitive symptoms of schizophrenia.
Policy of full disclosure: None.
P-43-005 Neuroimmunoendocrine interrelationships in long-term
treatment of schizophrenic patients with quetiapine
O. Lobacheva1, T. Vetlugina1, A. Semke1, Y. Maltseva1. 1Mental Health
Research Institute, Tomsk, Russia
Objective: Nervous, immune and endocrine systems are integral parts of
general adaptation, and peculiarities of neuroimmunoendocrine interac-
tions to significant extent determine individual organism’s adaptation.
Objective was detection of peculiarities of neuroimmunoendocrine
interrelations in schizophrenic patients under long-term treatment with
neuroleptic quetiapine.
Methods: We examined 11 paranoid schizophrenic patients aged
from 20 to 45 years, 5 men and 6 women. Patients received antipsychotic
quetiapine (Ketilept, Hungary) both as maintenance therapy for not less
than 6 months and in the process of inpatient treatment. The psychometric
scale PANSS was used to estimate the dynamics of psychopathological
symptomatology during treatment. The immunological examination
included the definition of phenotypes of surface receptors of immunocom-
petent cells with method of flow cytometry (cytoflow meter FacsCalibur,
Becton Dickinson, USA), cortisol, and prolactin and thyroid hormones
levels with enzyme immunoassay. The research was carried out in two
points: first - at admission, second - in 6 weeks of treatment.
Results: Alteration of subpopulation composition of blood lymphocytes
with reduction of number of CD3+- (p=0,040) and CD3+CD4+-cells (p=
0,007), increase of number of CD3+HLADR+- (p=0,004) and CD3+CD16
+56+-lymphocytes (p=0,000002), level of cortisol (p=0,000001) and thy-
roid hormones (TSH, p=0,008; T3, p=0,000007; T4, p=0,000331) as com-
pared with healthy persons was revealed. In the process of treatment,
positive dynamic of psychopathological symptoms was accompanied by
positive dynamic of CD3+- and CD3+CD4+-lymphocytes, level of cortisol
and thyroid-stimulating hormone remained high against the background
of trend to further heightening of level of prolactin.
Conclusion: Thus, it has been identified that acute period of
schizophrenia after long-term maintenance treatment with quetiapine is
accompanied by immune-hormonal imbalance with cellular immunodefi-
ciency and activation of thyroid gland function, heightening production
of thyroid hormones that heighten metabolic activity and sensitivity of
organism’s tissues to circulating in blood catecholamines. Findings dem-
onstrate that deviations in neuroimmunoendocrine regulation system
are a united mechanism of endogenous disorders development.
Policy of full disclosure: None.
P-43-006 Evaluation of daytime sleepiness in patients with
schizophrenia treated with atypical antipsychotics:
Results from a randomized, double-blind,
placebo-controlled trial
A. Loebel1, C. Siu2, J. Cucchiaro1, A. Pikalov1, P. Harvey3. 1Sunovion
Pharmaceuticals Inc., Fort Lee, USA; 2Data Power Inc., Flemington, USA;
3University of Miami, Miami, USA
Objective: The aim of this post-hoc analysis was to compare the effects of
2 atypical antipsychotic agents, lurasidone (80mg/d or 160mg/d) and
quetiapine XR (600mg/d), on daytime alertness, and to evaluate the ef-
fects of daytime sleepiness (also known as daytime somnolence or sed-
ation)on treatment outcomes in patients with an acute exacerbation of
schizophrenia.
Methods: Patients who met DSM-IV-TR criteria for schizophrenia were
randomized to 6-weeks of double-blind treatment with fixed doses of lur-
asidone 80mg/d (n=125), lurasidone 160mg/d (n=121), quetiapine XR
600mg/d (n=119), or placebo (n=121), all dosed once-daily in the evening,
with food. Daytime sleepiness was assessed using the Epworth Sleepiness
Scale at baseline, week 3, and week 6 visits. A mediation regression ap-
proach was applied to explore the effect of daytime sleepiness on changes
in agitation (assessed by PANSS-EC), cognition (assessed by CogState
Computerized Schizophrenia Battery), and functional capacity (assessed
by UPSA-B score).
Results: Daytime sleepiness improved in the lurasidone and placebo-
treated groups but worsened in the quetiapine XR treatment group
when compared to placebo (p=0.001) and to either dose of lurasidone
(both p<0.01). Sedation associated with quetiapine XR treatment
mediated an improvement in agitation and a worsening in functional ca-
pacity; these mediating relationships were not observed for the lurasidone
or placebo treatment groups.
Conclusion: In this 6-week double-blind study, treatment with lurasi-
done 80mg or 160mg, administered once-daily in the evening, was asso-
ciated with a reduction in daytime sleepiness similar in magnitude to
placebo, while quetiapine XR 600mg/d was associated with a significant
increase in daytime sleepiness. Daytime sleepiness was associated with
improvement in agitation and worsening in functional capacity for quetia-
pine XR, but not lurasidone or placebo-treated patients. Our findings sug-
gest that daytime somnolence may have a significant impact on cognitive
and functional outcomes in patients with schizophrenia.
Policy of full disclosure: Drs. Cucchiaro, Loebel and Pikalov are
employees of Sunovion Pharmaceuticals Inc. Dr. Siu has received pay-
ment for consulting from Pfizer Inc., and Sunovion Pharmaceuticals Inc.
Dr. Harvey serves as a consultant/advisory board member for Abbvie,
Boeheringer Ingelheim, Bristol-Myers-Squibb, Forest Labs, Genentech,
Roche, Shire, Sunovion, and Takeda.
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P-43-007 BDNF polymorphisms are associated with schizophrenia
onset and cognitive performance
M. Lv1, X. Zhang1. 1Beijing Hui-Long-Guan Hospital, Beijing, China
Objective: Accumulating evidence has shown that BDNF may be
involved in the pathogenesis of schizophrenia. Moreover, the BDNF gen-
etic variant, especially the Val66Met polymorphism may influence specific
aspects of human cognition. This study aimed to investigate the potential
association of BDNF gene polymorphisms with susceptibility to schizo-
phrenia, the psychopathological symptoms and cognitive impairments
in patients with schizophrenia in a Han Chinese population.
Methods: Four polymorphisms (rs6265, rs12273539, rs10835210 and
rs2030324) of the BDNF gene were analyzed in a case-control study of
1892 Han Chinese individuals (849 patients and 1043 controls).
Cognitive function was measured using the repeatable battery for the as-
sessment of neuropsychological status (RBANS) in 598 patients and 434
controls. We assessed 825 patients for psychopathology using the
Positive and Negative Syndrome Scale.
Results: In single marker analyses the rs10835210 mutant A allele was
significantly associated with schizophrenia. Haplotype analyses revealed
higher frequencies of haplotypes containing the mutant A allele of the
rs10835210 in schizophrenia than controls. We also found that this poly-
morphism rs10835210 was associated with positive symptoms, and the
patients carrying the mutational allele A showed more positive symp-
toms. Further, we found that the BDNF rs12273539 played a stronger
role in cognitive performance among both schizophrenics and healthy
controls, especially on attention and language; however, the BDNF
rs10835210 had a weak effect on language performance in schizophrenia.
Conclusion: These findings suggest the role of these BDNF gene var-
iants in susceptibility to schizophrenia, in clinical symptom severity and
in some aspects of cognitive function.
Policy of full disclosure: None.
P-43-008 Divergent quantitative and qualitative changes in
amphetamine-induced hyperlocomotion in BDNF
heterozygous mice following chronic methamphetamine
exposure
E. Manning1, A. Halberstadt2, M. van den Buuse1. 1The Florey Institute of
Neuroscience and Mental Health, Parkville, Australia; 2Department of
Psychiatry, University of California, San Diego, USA
Objective: Methamphetamine (METH) abuse is associated with increased
risk of developing psychotic disorders that closely resemble schizo-
phrenia. Altered brain-derived neurotrophic factor (BDNF) signalling
has been implicated in both schizophrenia and the effects of METH. In
mice, locomotor hyperactivity following challenge with psychostimulant
drugs is used to model aspects of the positive symptoms of schizophrenia,
as this behaviour is associated with enhanced subcortical dopamine re-
lease similar to what is thought to contribute to psychosis. However, sim-
ple measurements of hyperactivity may not adequately describe the
effects of psychostimulant drugs on behaviour.
Methods: We compared quantitative and qualitative locomotor activity
measures to assess the effects of chronic METH pretreatment on hyperac-
tivity following amphetamine challenge in BDNF heterozygous mice
(HETs) and wild-type controls (WT). Starting in late adolescence, BDNF
HETs and WTs were treated for three weeks with escalating doses of
METH or saline. Following a 2-week drug withdrawal, mice were chal-
lenged with saline or amphetamine, and locomotor behaviour was mea-
sured using photocell activity chambers. Both quantitative (distance
moved) and qualitative (spatial D and entropy) analysis were performed.
Results: In addition to the expected increase in locomotor distance
moved, amphetamine reduced spatial D and increased entropy, indicative
of straighter locomotor paths and more random locomotor paths, respect-
ively. At 3mg/kg amphetamine, locomotor hyperactivity was enhanced in
METH-treated WT mice, but not BDNF HETs (METH x genotype x dose x
time block, p=0.008). In contrast, METH pretreatment reduced the effect
of amphetamine to increase entropy in BDNF HETs, but had no effect
in WT mice (dose x METH x genotype, p=0.012) or on spatial D changes.
Conclusion: These studies demonstrate divergence between quantitat-
ive and qualitative aspects of amphetamine-induced changes in locomotor
behaviour in BDNF HETs following METH treatment. This finding sup-
ports the value of analysing qualitative measures of locomotion when
studying the effects of psychostimulant drugs.
Policy of full disclosure: None.
P-43-009 An open-label extension study of lurasidone safety and
efficacy in patients with schizophrenia previously
randomized to lurasidone or risperidone
G. Mattingly1, M. Tocco2, J. Cucchiaro3, J. Xu3, A. Loebel3. 1Midwest
Research Group, St. Charles, USA; 2Marlborough, USA; 3Fort Lee, USA
Objective: To evaluate the safety and efficacy of lurasidone in patients
with chronic schizophrenia who continued on lurasidone (LUR-LUR) or
switched from risperidone (RIS-LUR).
Methods: Patients completing a 12-month, randomized, double-blind
study evaluating flexibly dosed lurasidone (40-120mg/d) versus risperi-
done (2–6mg/d) entered a 6-month, open-label extension (OLE) study
with flexibly dosed lurasidone (40–120 mg/d). Descriptive statistics evalu-
ated safety and efficacy using last observation carried forward (LOCF)
and observed case (OC) approaches.
Results: Among 223 patients (136 LUR-LUR, 87 RIS-LUR) who contin-
ued into the OLE study, overall discontinuation rates were 19.9% for
LUR-LUR and 25.3% for RIS-LUR. Mean change in weight from OLE
baseline to endpoint (OC) was −0.6 kg for LUR-LUR and −2.9 kg for
RIS-LUR patients. Median changes in metabolic parameters from
OLE baseline to endpoint (OC) for LUR-LUR vs RIS-LUR patients
were: −4.0 mg/dL vs 4.5 mg/dL for total cholesterol, −4.5 mg/dL vs
−5.5 mg/dL for triglycerides, and 0.0 mg/dL vs −3.0 mg/dL for glucose.
Prolactin levels showed little median change in LUR-LUR patients and
decreased in RIS-LUR patients (−17.1 ng/mL). During the OLE, extrapyra-
midal symptom-relatedTEAEswerenoted in 8.1%of LUR-LURand 6.9%of
RIS-LUR patients. Discontinuation from theOLEdue to a TEAE occurred in
5.1% of LUR-LUR and 6.9% of RIS-LUR patients. At OLE baseline, mean
scores on the Positive and Negative Syndrome Scale (PANSS) and
Clinical Global Impression-Severity (CGI-S) were 55.5 and 2.9, respect-
ively, for all patients. In both the LUR-LUR and RIS-LUR groups,
mean change from OLE baseline (LOCF) was 1.0 on the PANSS and
0.0 on the CGI-S.
Conclusion: Switching to lurasidone after 12 months of treatment with
risperidone was generally safe and well tolerated, with improvement in
weight and prolactin levels, in this 6-month OLE study. Patients who tran-
sitioned from risperidone to lurasidone maintained clinical stability.
ClinicalTrials.gov identifier: NCT00641745.
Policy of full disclosure: Dr. Mattingly has no real or apparent conflicts
of interest to disclose. All other authors report being employees of
Sunovion Pharmaceuticals Inc.
P-43-010 Early response to risperidone treatment in the first
episode of schizophrenia (FES) patients and its predictive
value to subsequent response
M. Mayerova1, L. Ustohal2, I. Stehnova1, R. Prikryl2, E. Ceskova2,
T. Kasparek2. 1Faculty Hospital Brno, Brno, Czech Republic; 2Faculty
Hospital Brno, CEITEC, Brno, Czech Republic
Objective: The time-course of response to AP treatment is important
for management of acute treatment of schizophrenia patients. The aim
of the study was to investigate whether early response in the second
week can predict response in the fourth week of FES patients treated
with risperidone.
Methods: FES patients were rated by PANSS in four consecutive weeks
of monotherapy with risperidone. Early responders=at least 20% decrease
of total PANSS after two weeks of therapy. Later responders=at least 30%
decrease of total PANSS after four weeks of therapy.
Results: a) Demographic data: 35 FES patients, average age 25, average
duration of schizophrenia 4 months, average total PANSS beginning score
134. b) Response rate to risperidone therapy: 63% (N=22) later responders,
37% (N=13) later non-responders. c) The relationship between early and
later response (RESP)/nonresponse (NONRESP): After two-week therapy
- Decrease of total PANNS #20% After four-week therapy 27 early RESP
21 RESP, 6 NONRESP 8 early NONRESP 7 NONRESP, 1 RESP After two-
week therapy # Decrease of total PANSS # 30% After four- week therapy
19 early RESP 18 RESP, 1 NONRESP 16 early RESP 4 RESP, 12 NONRESP
A 20% decrease of total PANSS is adequate criteria for the prediction of
nonresponse after four weeks. For the prediction of response, the criteria
should by higher # 30% decrease of total PANSS. d) Differences in PANSS
decrease between later responders and later non-responders: viz grafs
(red=nonresponders, green=responders, blue=all)-
Conclusion: FES patients are characterized by the high reactivity to the
risperidone therapy. The most noticeable improvement of schizophrenic
symptomatology occurs during the first two weeks of treatment. Early re-
sponse/nonresponse in the second week predicts consecutive response/
nonresponse in the fourth week of the therapy.
Policy of full disclosure: None.
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P-43-011 The electronic schizophrenia treatment adherence
registry-e-STAR. Results from Romania
I. V. Miclutia1, D. M. Podea2, L. Damian3, I. D. Craciun4, R. Ciungu5.
1University of Medicine, Clujnapoca, Romania; 2University of Medicine, Arad,
Romania; 3County Hospital Borsa, Borsa, Romania; 4Emergency County
Hospital Cluj, Clujnapoca, Romania; 5Janssen Romania, Bucharest, Romania
Objective: To assess prospectively (2 years) the medication usage patterns
in schizophrenia patients; to document clinical efficacy and long-term
treatment outcomes of Risperidone Consta (RLAI) in a naturalistic setting;
to collect 2 years retrospective data in order to a more accurate compari-
son of the evolution after initiation with RLAI; to prospect reasons for in-
itiation of RLAI.
Methods: e-Star is part of an international non-interventional observa-
tional registry on the usage of RLAI in daily clinical practice. 290
Romanian patients from 50 sites were enrolled. Inclusion criteria were
the start or switch to a new antipsychotic medication either RLAI or
oral antipsychotics. A secured web-based system was employed to cap-
ture 24 months retrospective and 24 months prospective data regarding
demographics, duration of diagnosis treatment and hospitalization his-
tory, reasons for initiating the new treatment, periodic assessment of
severity of illness-CGI, functioning-GAF and reports of adverse events,
dosing regimen, and concomitant treatments.
Results: The duration of the diagnosis was 7.5 years in RLAI, respect-
ively 9.5 years in the oral group. Over 61% of patients were not working.
Number and lengths of hospitalizations dropped after the new treatment
in both groups. Inpatients initiated on RLAI, showed a statistically de-
crease of hospital stays in all follow-up intervals of interest, compared
to the retrospective period (all p values<0.009). Mean CGI-S scores gradu-
ally decreased over time, reaching changes at the end of the 24 months of
1.63 (SD=1.25) in the RLAI group, and 1.51 (SD=1.23) in the oral antipsy-
chotic group. Subjects were more often switched to RLAI due to insuffi-
cient efficacy and compliance issues.
Conclusion: The Romanian sub study of e-STAR emphasized the
fact that although more sever patients were treated with RLAI, they regis-
tered more evident improvements, lower hospitalizations and discontinu-
ation rates.
Policy of full disclosure: The Romanian e-STAR sub study has been
initiated and supported by Janssen Romania.
P-43-012 Prospective naturalistic survey of safety of risperidone
long acting injectable (RLAI) in Romanian schizophrenia
patients
I. V. Miclutia1, D. M. Podea2, M. Vrabie3, R. Ciungu4. 1University of
Medicine, Clujnapoca, Romania; 2University of Medicine, Arad, Romania;
3Psychiatric Hospital Bucharest, Bucharest, Romania; 4Janssen Romania,
Bucharest, Romania
Objective: To confirm the safety of risperidone long-acting injectable
under marketed conditions. Secondary objectives were to investigate
the reasons of initiation of treatment, effectiveness of RLAI, and clinical
outcome.
Methods: 1354 subjects were recruited by 253 investigational sites in
Romania. Subjects, consenting to participate in the study, were either
patients requiring a switch from previous antipsychotic medication, or
patients at onset of schizophrenia. Data was collected at baseline 1, 3, 6
and 12 month later. Alongside to the psychiatric and hospitalization his-
tory and collection of demographic data, dosing of RLAI, concomitant
medication, reasons for initiation, adverse events; following tools were ap-
plied: CGI, CGI improvement, GAF.
Results: Reasons for initiation ofRLAI were insufficient efficacy (46.4%)
and non-compliance to the previous medication. 31.2% of the patients
experienced a treatment-emergent AE. The most common reported AEs
were insomnia, anxiety, depression and psychotic disorder. Other
reported AEs included extrapyramidal symptoms, weight gain, and endo-
crine disorders (amenorrhea, galactorrhea). All parameters assessing drug
efficacy showed a statistical significant improvement except for the num-
ber and the duration of hospitalizations, which increased compared to the
6 months pre-study period. CGI increased significantly (p<0.001) from
baseline to both 6 and 12 months. GAF score improved significantly
(p<0.001) from baseline to both 6 and 12 months, with an average increase
of 22.8 and 39.7 points, respectively.
Conclusion: Treatment-emergent AEs observed during this study were
consistent with the established safety profile of risperidone long-acting
injectable. In addition, treatment with risperidone long-acting injectable
resulted in the expected, statistically relevant improvement of psychiatric
status in subjects eligible for such treatment.
Policy of full disclosure: the current study has been initiated and sup-
ported by Janssen Romania.
148 Poster Sessions, Wednesday 25 June 2014
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article/17/Supplem
ent_1/1/900273 by Faculty of Life Sciences Library user on 28 August 2020
P-43-013 Lurasidone in contrast to other antipsychotics does not
produce deficits in social exploration and social
recognition in the rat
P. Mierzejewski1, N. Nowak1, A. Glebicka1, K. Karas1, M. Kolaczkowski1,
P. Bienkowski1. 1Institute of Psychiatry, Warsaw, Poland
Objective: Social deficits are believed to be important predictor of func-
tional outcome in schizophrenia. Although currently used antipsychotics
are effective in treating positive symptoms of schizophrenia, social deficits
are still one of the major unmet medical needs. Animal models of social
behavior and social memory are thought to be useful tools in the search
for new psychoactive medications for schizophrenia, depression, and
other neuropsychiatric disorders in which social deficits are seen. In the
present study, we compared first-generation antipsychotic (haloperidol)
and second-generation antipsychotics (olanzapine, aripiprazole, cloza-
pine, sertindole, lurasidone) as well as escitalopram and diazepam in
terms of their influence on social behavior and social memory in the rat.
Methods: The social exploration and recognition test consisted of two
trails. During the first trial, an unknown juvenile rat (100–150 g) was
placed into the home cage of an adult rat (500–550 g). The time spent
by the adult in active social investigation (close following, sniffing, groom-
ing, crawling over or under juvenile rat) was measured. Each adult rat was
re-exposed to the same juvenile fifteen minutes later and again social in-
vestigation time was measured (trial 2). Social recognition was defined
as a difference between investigation times during trial 1 and trial 2.
Results: Except lurasidone, all the tested drugs significantly suppressed
social exploration. Significant changes were observed for haloperidol
(Minimal Effective Dose: 0.1 mg/kg), olanzapine (10mg/kg), aripiprazole
(10mg/kg), clozapine (3mg/kg), sertindole (1 mg/kg), escitalopram
(30mg/kg), and diazepam (10mg/kg). Interestingly, none of the tested
antipsychotics influenced social recognition. In contrast, escitalopram
and diazepam produced considerable recognition deficits at the dose of
10mg/kg and 3mg/kg, respectively.
Conclusion: In conclusion, our data indicate that lurasidone do not im-
pair social behavior in the rat and suggest that the drug can be a good
treatment choice for patients with social deficits.
Policy of full disclosure: The study was supported by Adamed Ltd.,
Pienkow, Poland and Polish Agency for Enterprise Development (PARP
project no. UDA-POIG.01.04.00-14-055/10-00).
P-43-014 Effect of long-term treatment with lurasidone or
risperidone on metabolic syndrome status in patients
with schizophrenia
J. Newcomer1, A. Pikalov2, K. Watabe2, J. Cucchiaro2, K. Rajagopalan3,
A. Loebel2. 1Florida Atlantic University, Boca Raton, USA; 2Fort Lee, USA;
3Marlborough, USA
Objective: This post hoc analysis evaluated the effect of long-term treat-
ment with lurasidone or risperidone on metabolic syndrome status.
Methods: Outpatients with clinically stable schizophrenia were
randomized 2:1 to flexibly dosed, once-daily lurasidone (40–120mg/d)
or risperidone (2–6mg/d) in a 12-month, multiregional, double-blind
study followed by an open-label extension (flexibly dosed lurasidone
40–120mg/d for up to 6 months). International Diabetes Federation
criteria were used to evaluate metabolic syndrome, defined as
elevated waist circumference (using ethnic group-specific norms) or
BMI >30 kg/m2 plus 52 of the following: triglycerides 5150mg/dL,
HDL cholesterol <40mg/dL in men or <50mg/dL in women, blood press-
ure 5130/85 mmHg, or blood glucose 5100mg/dL.
Results: The prevalence of metabolic syndrome at baseline of the
double-blind phase was similar for the lurasidone (32.5%; 134/412) and
risperidone (32.7%; 65/199) groups. After 12 months of treatment, the
prevalence of metabolic syndrome (observed cases) was 31.5% (47/149)
with lurasidone and 44.1% (41/93) with risperidone (p<0.05). For patients
taking lurasidone in the double-blind phase who continued on lurasidone
in the open-label phase (n=109), the prevalence of metabolic syndrome
was 33.3% at double-blind baseline and 26.6% after 18 months of treat-
ment. In a similar analysis of risperidone-treated patients switched to
open-label lurasidone after 12 months (n=65), the prevalence of metabolic
syndrome was 42.9% at double-blind baseline, 48.4% at open-label base-
line (after 12 months of risperidone), and 38.5% after 6 months of open-
label lurasidone.
Conclusion: Treatment with lurasidone was associated with a lower
prevalence of metabolic syndrome compared with risperidone treatment.
The prevalence of metabolic syndrome remained stable over 18 months of
continuous treatment with lurasidone, in contrast to increased prevalence
during 12 months of treatment with risperidone. The prevalence of
metabolic syndrome decreased in risperidone-treated patients who were
switched to lurasidone for 6 months. ClinicalTrials.gov identifier:
NCT00641745
Policy of full disclosure: Dr. Newcomer reports financial involvement
with Bristol-Myers Squibb Company, Merck & Co., Inc., and VIVUS Inc.;
and research grants from Pfizer Inc. All other authors report being
employees of Sunovion Pharmaceuticals Inc.
P-43-015 Tolerability and safety profile of aripiprazole
once-monthly in the treatment of schizophrenia: A pooled
analysis from the safety database of 11 completed or
ongoing trials
A.-G. Nylander1, R. A. Baker2, P. Hertel1, N. Jin3, A. Eramo4, R. Duffy2,
R. D. McQuade2, T. Peters-Strickland2. 1Lundbeck A/S, Valby, Denmark;
2Otsuka, Princeton, USA; 3Otsuka, Rockville, USA; 4Lundbeck A/S, Deerfield,
USA
Objective: To evaluate the long-term tolerability and safety profile of ari-
piprazole once-monthly (AOM).
Methods: Data from the safety database of 11 completed or ongoing
AOM trials in subjects with schizophrenia were pooled; 2 completed
phase 3 trials (pivotal), 4 ongoing phase 3/3b trials (as of 02 April 2012),
4 completed phase 1/1b trials, 1 ongoing phase 1b trial. Exposure and
treatment emergent adverse event (AE) data are summarized for
AOM-400/300mg, and the sub-therapeutic doses <AOM-300mg.
|Results: 1,539 subjects received AOM-400/300mg and 168 received
AOM<300mg (ie, 15mg, 25 mg, 50mg, 100mg, or 200mg; 131 received
25/50 mg). 995 subjects received at least 7 aripiprazole injections (ie
6 months of exposure), 784 subjects at least 13 injections (ie 12 months
of exposure), and 244 subjects at least 26 injections (ie 2 years of exposure).
Treatment-emergent AEs resulted in trial discontinuation for 9.4%
(145/1539) of AOM-400/300mg treated subjects and 14.9% (25/168) of a
subjects treated with AOM<300mg. Treatment-emergent AE (>=10%
of AOM-400/300mg subjects) was insomnia 11.0% (n=169/1539).
Treatment-emergent AEs (<10% to >=5% of AOM-400/300-mg subjects)
were headache 9.6% (n=147/1539,), anxiety , 8.8% (n=136), increased
weight 7.7% (n=119), nasopharyngitis 7.5% (n=115), akathisia 7.1%
(n=109), injection site pain 7.0% (n=108), and upper respiratory tract in-
fection 5.5% (n=84). The incidences of these events were comparable
with AOM<300mg except for injection site pain [AOM-400/300mg 7.0%
(n=108/1539); AOM<300mg, 3.0% (n=5/168)]. The majority of treatment
emergent AEs were either mild or moderate in severity.
Conclusion: A substantial number of patients have been actively
monitored for side effects after treatment with aripiprazole once-monthly
for >=1 year, and some for >=2 years. The long-term tolerability and
safety profile was consistent with the known safety profile of oral
aripiprazole.
Policy of full disclosure: Supported by Otsuka Pharmaceutical
Development & Commercialization, Inc., and H. Lundbeck
A/S. R. Baker, N. Jin, R. Duffy, R. McQuade, and T. Peters-Strickland
are employees of Otsuka Pharmaceutical Development &
Commercialization, Inc. P. Hertel, AG Nylander, and A Eramo are
employees of H. Lundbeck A/S.
P-43-016 The effect of previous dose of oral aripiprazole (10 or
30 mg/day) on the efficacy and tolerability of aripiprazole
once-monthly: Post-hoc analysis of two double-blind,
randomized, controlled trials
A.-G. Nylander1, A. Eramo2, R. Baker3, L.-F. Tsai4, T. Peters-Strickland3,
R. Sanchez3. 1Lundbeck A/S, Valby, Denmark; 2Lundbeck A/S, Deerfield,
USA; 3Otsuka, Princeton, USA; 4Otsuka, Rockville, USA
Objective: To present the efficacy and tolerability of aripiprazole once-
monthly (AOM) in patients stabilized on 10 or 30mg/day oral aripiprazole
(ARI) before switching to aripiprazole once-monthly AOM.
Methods: Data from 2 pivotal double-blind, placebo- or active-
controlled trials assessing AOM in patients with schizophrenia (study
246, NCT00705783; study 247, NCT00706654) were analyzed post-hoc.
Efficacy was evaluated by change from baseline in the Positive and
Negative Syndrome Scale (PANSS) Total Score at 4 weeks after initiation
of AOM. Tolerability was measured as common adverse events in this
period.
Results: 841 stable patients (study 246: n=576, study 247: n=265)
received AOM-400/300mg. Of these, 105 had been stabilized on
10mg/day ARI (study 246: n=75, study 247: n=30) and 212 on
30mg/day ARI (study 246: n=147, study 247: n=65). In each study,
AOM maintained stability of symptoms: 246 study, change in PANSS
total from baseline to Week 4: 10mg group=0, 30mg group=−0.18; 247
study 10mg group=−1.03, 30 mg group=−1.83. The most common
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adverse events (>=5%) were injection site pain (range: 9.3% [10mg/study
246] to 0% [30mg/study 247]); insomnia (9.2% [30mg/study 247] to 2.7%
[10mg group/ study 246]); weight increase (8.2% [30mg/study 246] to
1.3% [10 mg/study 246]); agitation (6.2% [30 mg/study 247] to 0% [10
mg/study 247]); dizziness (5.3% [10mg/study 246] to 0% [30mg/study
246 and 10mg/study 247]); akathisia (7.7% [30mg/study 247] to 2.7%
[10mg/study 246]); and anxiety (6.7% [10mg/study 247] to 1.5% [30mg/
study 247]).
Conclusion: Aripiprazole once-monthly maintained stability of symp-
toms in the month after initiation regardless of whether patients had
been stabilized on 10 or 30 mg/day oral aripiprazole. Adverse events oc-
curred at similar rates (none exceeding 10%) for patients converted from
oral aripiprazole 10 or 30mg/day; and were similar to the entire study
population.
Policy of full disclosure: Supported by Otsuka Pharmaceutical
Development & Commercialization, Inc., and H. Lundbeck
A/S. A. Eramo and AG Nylander are employees of H. Lundbeck
A/S. R. Baker, L-F Tsai, T. Peters-Strickland, and R. Sanchez are employees
of Otsuka Pharmaceutical Development & Commercialization, Inc.
P-43-017 Defects of neurocognitive performance and social
functioning in non-prodromal individuals with high
genetic loading for schizophrenia
J. W. Park1, S. N. Kim1, T. Y. Lee1, C. Lee1, Y. S. Shin1, J. S. Kwon1,
D.-H. Kang1, J. H. Jang1, N. Y. Shin1. 1Seoul National University Hospital,
Seoul, Republic of Korea
Objective: Neurocognitive dysfunction in unaffected relatives of indivi-
duals with schizophrenia was regarded as evidence of an endophenotype
and examined in relation to social functioning. Although previous re-
search has investigated this relationship, these studies included relatives
at the prodromal stage. Given recent clinical high-risk studies showing
that such individuals may have neurocognitive or neurobiological altera-
tions similar to, albeit less serious than, those observed in schizophrenia,
this relationship remains unclear. This study examined neurocognitive
and social functioning in non-help-seeking individuals with genetic load-
ing but without psychosis-risk syndrome (GHR) to determine whether
neurocognitive deficits account for social functioning impairment.
Methods: The GHR group included unaffected individuals with high
genetic loading for schizophrenia, and were compared with the healthy
control group. GHR individuals fulfilling the psychosis-risk syndrome
criteria were excluded. Measures of neurocognitive and social cognitive
function, as well as Social Functioning Scale, were administered.
Results: The GHR group showed significant impairment on the Trail
Making Test and the Wisconsin Card Sorting Test(WCST) compared
with healthy control group even after controlling for general intelligence,
age, and education. Subscores of the Social Functioning Scale were found
to be significantly lower in the GHR subjects. Categories completed from
the WCST significantly predicted impairment on the social functioning
scale in the GHR group, but not in the healthy control group.
Conclusion: These result suggest that neurocognitive impairment, es-
pecially executive dysfunction, plays an important role in social function-
ing impairment in GHR subjects without psychosis-risk syndrome.
Policy of full disclosure: None.
P-43-018 The change of polyunsaturated fatty acid (PUFA)
concentration during paliperidone extended-release
treatment and the plasma concentration of paliperidone
ER at week-2 and week-3
J.-I. Park1, Y.-C. Chung1, B.-J. Lee2, S.-H. Lee3, S. J. Lee4, B. Nam5,
T. Sumiyoshi6. 1Chonbuk National University, Jeonju, Republic of Korea;
2Inje University College of Medicine, Busan, Republic of Korea; 3Pochon CHA
Medical School, Seongnam, Republic of Korea; 4Kyungpook National
University, Daegu, Republic of Korea; 5Konkuk University College of
Medicine, Chungju, Republic of Korea; 6Toyama Graduate School Medicine
and Pharmaceutical Science, Toyama, Japan
Objective: The aim of our study was to investigate the change of polyun-
saturated fatty acid (PUFA) concentration during 8 week treatment of
paliperidone extended-release(paliperidone ER). We also investigate the
plasma concentration of paliperidone at week-2 and week-3.
Methods: This study was conducted as a part of the Efficacy and Safety
of Paliperidone ER in Patients with First Episode Psychosis. The study
population consisted of 75 patients of first-episode psychosis. The initial
recommended dose of paliperidone ER was 3–6mg/day, increasing up
to 12mg/day depending on treatment response. Plasma PUFA concentra-
tions were measured using a gas chromatography system at baseline
(n=62) and week-8(n=42). For assay of plasma concentration, blood sam-
ples were taken on week-2(n=30) and week-3(n=29).
Results: Baseline PUFA concentration didn’t show significant
association with PANSS, SANS, GAF, and the Cognitive Assessment
Interview (CAI). After 8-week treatment, PUFA concentration did not
show significant change except for an increase in eicosapentaenoic
acid (EPA) concentration. At week-2 and week-3, the mean plasma
concentration of paliperidone was significantly associated positively
with 9-hydroxy risperidone. The mean plasma concentration was
17.08±9.30 ng/ml at a daily oral dosage of 7.96±2.59 mg (week-2), and
21.51±14.82 ng/ml at 8.50±2.77 mg(week-3). At week-2 or week-3, the
mean plasma concentration of non-response group was significantly
higher than that of response group. When defining the treatment response
as >=30% decrease in PANSS0-6 total score from baseline, plasma concen-
tration at week-3 significantly associated negatively with treatment re-
sponse at week-8.
Conclusion: After 8-week treatment with paliperidone, there was sign-
ificant increase in EPA concentration. However, the effect of paliperidone
on PUFA concentration warrants further investigation. The response rate
at week-8 was negatively associated with higher plasma concentration of
paliperidone at week-3.
Policy of full disclosure: None.
P-43-019 Convergence of clozapine induced ErbB1-ERK and
ErbB4-PI3 K/AKT signalling in prefrontal cortical
neurons: Relevance to therapeutic efficacy
A. Pereira1, Y.-S. An1, R. Sethi1, P. Malcolm1, S. Sundram1. 1The Florey
Institute, The University of Melbourne, Melbourne, Australia
Objective: Dysregulation of the epidermal growth factor (EGF) system,
implicated in synaptic plasticity, long-term potentiation and dendritic
spine connectivity has been linked to schizophrenia. For instance, in
patient brain and blood low EGF levels resulting in compensatory
up-regulation of the EGF receptor (ErbB1) is postulated to represent
a hypofunctioning signalling state. Consistent with this hypothesis our
preclinical in-vitro and in-vivo data demonstrate that the antipsychotic
drug clozapine increases ErbB1 signalling via GPCR transactivation of
the extracellular signal-regulated kinase (ERK) pathway in cortex and
striatum. Here we investigate whether ERK intersects with the AKT path-
way via the mediators PI3 K, Src, beta-arrestin and Ca2+ which may gov-
ern the ErbB1 transactivation mechanism induced by clozapine, since both
pathways are implicated in schizophrenia through cell and genetic based
studies.
Methods: Frontal cortical neurons were exposed to wortmannin (PI3 K
inhibitor), (BMK120, pan-Class I PI3 K inhibitor), monodansylcadaverine
(MDC) (receptor endocytosis inhibitor) and BAPTA-AM (Ca2+ inhibitor),
and the effect on clozapine-mediated ErbB1-ERK, ErbB4-PI3 K/AKT and
Src phosphorylation examined to assess pathway cross-talk.
Results: AKT phosphorylation was significantly inhibited by clozapine
in the absence of changes in PI3 K p110delta isoform expression.
Wortmannin caused significant dose-dependent inhibition of ERK1/2
phosphorylation in the presence of clozapine while beta-arrestin or intra-
cellular calcium release were not involved. BMK120 had limited effect
on ERK phosphorylation but further reduced AKT phosphorylation
upon exposure to clozapine contingent on dose. Parallel detection of Src
phosphorylation indicated a time disconnect with ERK phosphorylation.
Conclusion: Our data demonstrate convergence of ERK and PI3 K/AKT
signalling induced by clozapine through mediators such as Src and PI3 K
contingent on cell and tissue type. We therefore propose that there is a
complex reciprocal relationship between ErbB1 and ErbB4 signalling to
ERK1/2 and PI3 K in neurons that may be disrupted in schizophrenia
and ameliorated by clozapine.
Policy of full disclosure: None.
P-43-020 Efficacy and tolerability of paliperidone palmitate
long-acting injectable antipsychotic in first-episode
schizophrenic patients
D. Petric1, V. Racki2, M. Graovac1, A. Kastelan1, T. Grahovac1,
M. Vucic-Peitl1, T. Franciskovic1. 1Clinical Centre Rijeka, Rijeka, Croatia;
2Faculty of Medicine, University of Rijeka, Rijeka, Croatia
Objective: Aim of the paper is to assess the therapeutic efficacy and toler-
ability of paliperidone palmitate long-acting injectable antipsychotic in
first-episode schizophrenic patients. The management of patients with a
first-episode of psychosis remains a challenge. Treating patients with pali-
peridone palmitate avoids the issue of non-compliance.
Methods: The research included 17 patients aged 16 to 22 years who
were diagnosed in accordance with the Diagnostic and Statistical
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Manual of Mental Disorders, Fourth Edition. All patients were assessed
six times over six months using the following clinical scales: Positive
and Negative Syndrome Scale, Clinical Global Impression - Severity and
Improvement Scale, Personal and Social Performance Scale. Primary
safety measures included incidence of adverse events.
Results: In this six months analysis 88.2% of patients with first-episode
psychosis achieved remission, which was significantly associated with
early treatment response. Patients achieving remission demonstrated a
trend towards greater improvement in function, health status and
productivity.
Conclusion: All doses of once-monthly paliperidone palmitate were
efficacious and generally tolerated. Earlier application of paliperidone
palmitate results in lower relapse rates, better reaction to therapy, achiev-
ing remission and full recovery.
Policy of full disclosure: None.
P-43-021 A mirror-image study to compare the efficiency of
paliperidone palmitate with oral antipsychotics in
schizophrenic patients
P. Philippe Vincent. Institut Universitaire en Santé Mentale de Montréal,
Montreal, Canada
Objective: We aimed to compare the efficiency of paliperidone palmitate
(PP) with usual oral antipsychotic therapy in a psychiatric hospital in
Quebec. Specific objectives were to compare total annual hospitalisation
days and the annual cost of both treatments.
Methods: We undertook a retrospective mirror-image study where one
year of hospitalisation days on oral antipsychotics was compared to one
year of hospitalisation days on PP. Patients were selected if they had
received the 3rd dose of PP, if they were prescribed oral antipsychotics
one year before, and if they consented to the study. They were excluded
if they had received clozapine, if they switched to PP from another long
acting antipsychotic, or if they were known to be refractory to treatment.
Mean possession ratios (MPR) were obtained from community
pharmacists.
Results: Seventeen patients were recruited from a pool of 200 candi-
dates. Principal reasons for exclusion was use of clozapine or another
long acting therapy in the year prior enrolment. Mean patient demo-
graphics were 36 years, 76% male, 76% paranoid schizophrenia, 24% of
community treatment orders, 41% of substance abuse disorder, and 52%
of anterior exposure to risperidone. The most frequent reason to switch
to PP was acute psychotic episode and non adherence. Mean annual hos-
pitalisation days was 55 (range 21–116) and 11 (range 0–62) for the one
year before and one year after periods, respectively (p<0, 01). MPR was
60% (range 0–100%) with oral therapy and 90% with PP. 741 days of hos-
pitalisation were saved for those patients, making savings of 9422 $ per
patient per year after controlling for drug cost.
Conclusion: PP is clinically more efficient than oral therapy, as it
diminishes patient suffering and total spending for the treatment of
schizophrenia, but the present results cannot be distinguished from
improved adherence, or simply use of long acting injectable antipsychotic.
Policy of full disclosure: This study was done with a non-restrictive
educational grant from Janssen.
P-43-022 Prefrontal GABA-blockade and decision making:
Relevance for schizophrenia
P. Piantadosi1, S. Khayambashi1, A. Cywinska1, M. Schluter1, S. Floresco1.
1University of British Columbia, Vancouver, Canada
Objective: The prefrontal cortex (PFC) plays a critical role in decision
making, and is thought to be an area of pathology in schizophrenia.
Individuals with schizophrenia display alterations in cost/benefit decision
making involving evaluations of a variety of costs (uncertainty, delays, ef-
fort). PFC neurotransmission is thought to be compromised in the dis-
order, including hypofunction of GABA interneurons. Given that these
neurons are thought to be critical for cognitive functioning, we sought
to test how decreasing GABA function affects different forms of decision
making that are perturbed in schizophrenia.
Methods: Male rats were well-trained on separate decision making
tasks. To assess the impact of GABAergic hypofunction (intended to
mimic part of the PFC pathology observed in schizophrenia), rats received
intra-medial PFC infusion of the GABA-receptor antagonist bicuculline
(50 ng) or saline prior to a test session. On each task, rats chose between
one, ‘low cost’ lever that gave an immediate, certain reward (sucrose pel-
lets) after one press and a high-cost lever that delivered a larger reward
associated with a form of cost; 1) uncertainty, delivering the reward in a
probabilistic manner 2) delays to receiving the reward or 3) requiring
more effort to obtain the larger reward.
Results: PFC GABA-blockade decreased risky choice, similar to the
risk-averse phenotype observed in schizophrenia. These treatments did
not affect delay discounting, but did cause a slight decrease in preference
for the large/delayed reward when it was not delayed. PFC GABA block-
ade also reduced slightly the preference for larger rewards associated
with greater effort costs. Control experiments suggested that mPFC
GABA-blockade does not affect basic motivational process, but does
cause mild deficits in preference for larger vs. smaller rewards.
Conclusion: GABA-blockade of the mPFC produces discrete alterations
in some forms of cost/benefit decision making, some of which may be re-
lated to those observed in schizophrenia.
Policy of full disclosure: None.
P-43-023 Extracellular matrix metabolism was unveiled in
physiophology of schizophrenia by interacted
genome-wide association study and consequent
downstream analysis
H. Ren. West China Hospital of Sichuan, Chengdu, China
Objective: To capture common variants of schizophrenia by using quan-
titative trait, DMS (delay matching to sample) and to detect possible func-
tional network meditating effect of captured genes on schizophrenia.
Methods: 100 first-episode schizophrenia patients and 140 healthy con-
trols were recruited for DMS test, linear regression model was built to as-
sociate DMS test results and SNP×diagnosis, geneMANIA was applied to
predict more genes sharing smiliar function with query genes and to plot
functional pathway most relevant to the query genes from early associ-
ation study.
Results: 32 SNPs located in 26 genes reached P-value threshold of as-
sociation significance (5×10–5) with the highest P-value generated from
FHIT in chromosome 3(3.69×10–8) when interacted with DMS_PC_A
and DMS_PEGC. Downstream functional analysis showed that most
genes found from association test are enriched in metabolic pathway of
extracellular matrix.
Conclusion: Genes passing significance threshold after using DMS as
quantitative traits were most relevant to chondrontin metabolic process,
proving DMS as a viable intermediate phenotype for GWAS of schizo-
phrenia and also suggesting possible mechanism DMS deficits exerted
on in schizophrenia pathology.
Policy of full disclosure: None.
Significance of GWAS Genotyped SNPs of the 400 kb region in
chromosomal region of FHIT., adapted from LocusZoom output:
Please see diagram appearing on page 152.
P-43-024 Efficacy of lurasidone in the treatment of schizophrenia
with prominent negative symptoms: A post-hoc analysis
of short-term trials
N. R. Schooler1, A. Pikalov2, J. Hsu2, J. Cucchiaro2, R. Goldman3,
A. Loebel2. 1Brooklyn, USA; 2Fort Lee, USA; 3Marlborough, USA
Objective: To evaluate the efficacy of lurasidone in patients with promi-
nent negative symptoms (PNS).
Methods: This post-hoc analysis utilized pooled data from three
6-week, double-blind, placebo-controlled trials of patients (N=1206)
with an acute exacerbation of schizophrenia who were randomized to lur-
asidone 40–160mg/d. Patients with PNS at baseline were identified based
on the following criteria: a PANSS negative subscale score 525 (median)
and a PANSS positive score <26 (median). MMRM analyses were per-
formed for change in PANSS total, negative subscale, and CGI-S scores.
Responders were defined as reduction from baseline in PANSS total of
520%, 530%, or 540% (LOCF-endpoint).
Results: A total of 20.5% patients met criteria for PNS. Treatment of
the PNS group with lurasidone (vs placebo) was associated with signifi-
cantly greater week-6 improvement in the PANSS total score (−23.1 vs
−16.2; p<0.01), PANSS negative subscale score (−6.7 vs −4.5; p<0.01),
and CGI-S (−1.4 vs −1.0; p<0.01). Treatment of the PNS group with
lurasidone (vs placebo) was associated with significantly greater endpoint
response using the PANSS total 520% improvement criterion (71.3% vs
52.5%; p<0.01), 530% criterion (55.1% vs 37.5%; p<0.01), and 540%
criterion (42.5% vs 28.8%; p<0.05). In the group without PNS, treatment
with lurasidone was also associated with significantly greater (P<0.01)
endpoint responder rates using these PANSS criteria. Discontinuation
due to adverse events, for lurasidone vs placebo, respectively, was low
in both the PNS group (5.4% vs 1.2%) and the group without PNS
(5.9% vs 4.7%). In the prominent negative symptom group, the 3 most
common adverse events reported for lurasidone vs placebo were head-
ache (22.2% vs 18.8%), somnolence (22.2% vs 2.5%), and akathisia
(15.0% vs 3.8%).
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Conclusion: Patients presenting with PNS responded well to lurasidone
with significant improvement in PANSS total and negative subscale
scores. Treatment with lurasidone was generally safe well-tolerated in
the PNS group.
Policy of full disclosure: Dr Schooler has received grants from Otsuka,
Neurocrine and Genentech. She has participated in advisory boards
to provided other consultation to Abbott, Eli Lilly, Shire, Janssen
Psychiatry, Amgen, Lundbeck and Roche. Dr. Pikalov, Hsu, Cucchiaro,
Goldman, and Loebel are full-time employees of Sunovion
Pharmaceuticals, Inc.
P-43-025 Pitfall of using absolute Framingham Risk Score for
primary prevention strategy in schizophrenia
C. Siu1, C. Brambilla2. 1Data Power, Flemington, USA; 2Milan, Italy
Objective: In a Lancet Comment published on 30–11–2014, Ridker and
Cook reported that the new ACC/AHA prediction algorithm systemati-
cally overestimated the absolute risk for atherosclerotic cardiovascular
disease in 5 cohorts, which featured better smoking, cholesterol and
blood pressure profiles compared to the cohorts used in deriving the
guidelines. The objective of this paper was to examine the recalibration
procedure for absolute risk survival model, using the Framingham Risk
Score (FRS) risk estimate in the CATIE study as an example.
Methods: We recalibrated the FRS risk estimates for the CATIE study
population, and applied a risk ratio approach to improving the risk pre-
diction algorithm, defined as the absolute risk divided by the absolute
risk for an optimal risk profile (i.e. a total cholesterol 170mg/dL,
HDL-cholesterol 50mg/dL, and untreated systolic blood pressure
110mm Hg, nonsmoker and without diabetes).
Results: We compared the mean for each of the categories of the FRS
risk factors in CATIE and FHS studies: mean age 40 in CATIE versus 49
in FHS, total cholesterol >=240mg/dL is 20% in CATIE versus 26% in
FHS, HDL<35mg/dL is 25% in CATIE versus 11% in FHS, Stage I-IV hy-
pertension 28% in CATIE versus 32% in FHS, Diabetes mellitus (women
16% and men 11%) in CATIE versus (women 4% and men 5%) in FHS,
and smoker (women 56% versus men 73%) in CATIE versus (women
38% and men 40%) in FHS. Unlike the substantially marked contrast in ab-
solute risk scores, virtually identical risk ratios would be obtained for both
the FHS and the new recalibrated models for CATIE.
Conclusion: Our findings suggest that risk ratio (relative to low risk
state) instead of absolute risk might be more appropriate for prediction
of cardiovascular risk in schizophrenia patients using Framingham
Scoring Model.
Policy of full disclosure: C Siu is a consultant to Sunovion
Pharmaceuticals. No conflict of interest for C Brambilla.
P-43-026 Insight into illness and uncooperativeness in chronic
schizophrenia
C. Siu1, O. Agid2, M. Waye3, C. Brambilla4, J. W.-Kit Choi5,
G. Remington2, P. Harvey6. 1Data Power, Flemington, USA; 2CAMH,
Toronto, Canada; 3Hong Kong, China; 4Milan, Italy; 5Castle Peak Hospital,
Hong Kong, China; 6University of Miami, Miami, USA
Objective: The objective of this study was to examine factors that might
influence insight, uncooperativeness, and self-assessment of quality-of-life
using the large National Institute of Mental Health Clinical Antipsychotic
Trials of Intervention Effectiveness CATIE dataset.
Methods: Insight was assessed by the Insight and Treatment
Attitudes Questionnaire (ITAQ) and PANSS item G12 “lack of judgment
and insight”. Social and occupational functioning was assessed using
the Heinrichs-Carpenter Quality of Life (HCQoL) scale, while self-report
well-being overall was assessed with the Lehman QoL Interview
(LQOLI). Uncooperativeness was assessed by PANSS item G8
(#Uncooperativeness#).
Results: : Consistent with previous reports, we found better insight into
illness was associated with higher functioning (p<0.05), greater neurocog-
nitive composite (p<0.05) and reasoning (p<0.05) performance, but there
was an inverse correlation to lower self-report well-being overall (p<0.05)
and a higher level of depressive symptoms (p<0.05) in patients with
chronic schizophrenia. We also found the inverse relationship at baseline
between insight and self-report LQOLI was explained, in part, by levels of
depressive symptoms (p<0.001) and neurocognitive reasoning impair-
ment (p<0.05). Overall cognitive performance was not significant after
adjusting for depression effect (p>0.05). Among subjects with mild or
no depressive symptoms on all 9 items of the Calgary Depression Scale
(N=839), better self-report well-being overall (LQOLI) was associated
with poorer insight (p<0.05) and lower cognitive reasoning performance
(p<0.05) after adjusting for age and symptom severity (CGI-S). Improved
insight into illness over time was longitudinally associated with reduc-
tions in uncooperativeness symptoms (PANSS G12) (p<0.001).
Conclusion: Our findings suggest that poorer insight and attitudes
toward treatment had significant associations with higher level of unco-
operativeness, lower level of neurocognitive reasoning, and less de-
pression, which in turn impacts self-report assessment of well-being
overall. These results suggest the importance of reducing insight and cog-
nitive impairments both for functional improvement and willingness to
accept treatments.
Policy of full disclosure: C Siu: a consultant to Sunovion; O. Agid:
consultant to Eli Lilly Inc. Canada, Eli Lilly USA, Janssen-Ortho Inc.,
Pfizer, Inc.; G Remington: Research support from Novartis, Medicure,
and Neurocrine, Speaker for Norvatis, Consiltant to Roche; P Harvey
serves as a consultant/advisory board member for Abbvie, Boeheringer
Ingelheim, Bristol-Myers-Squibb, Forest Labs, Genentech, Roche, Shire,
Diagram reference P-43-023
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Sunovion, and Takeda. No conflict of interest for M Waye, C Brambilla
and WK Choi.
P-43-027 Inhaled loxapine and intramuscular lorazepam in healthy
volunteers: Results of a randomized, placebo-controlled
drug-drug interaction study
D. A. Spyker1, J. V. Cassella1, R. R. Stoltz2, P. P. Yeung3. 1Alexza
Pharmaceuticals Inc., Mountain View, CA, USA; 2Covance Clinical Research
Unit, Evansville, IN, USA; 3Teva Pharmaceuticals, Frazer, PA, USA
Objective: Inhaled loxapine administered via the Staccato® system
reduces agitation in patients with schizophrenia or bipolar I disorder.
This study compared the pharmacodynamic effects and safety of single-
dose inhaled loxapine and intramuscular (IM) lorazepam vs. each agent
alone in healthy volunteers. (NCT01877642).
Methods: Randomized, double-blind, cross-over study. Primary end-
points were maximum effect (minimum value) and area under the
curve (AUC) from baseline to 2hr post treatment for respirations/min
and pulse oximetry with: concomitant inhaled loxapine 10mg+IM loraze-
pam 1mg compared with either inhaled loxapine 10mg+IM placebo, or
IM lorazepam 1mg+Staccato® placebo. LS-means [90% CI] for ratios of
values for concomitant treatment vs. either agent alone were derived
and equivalence confirmed by 90% CI within 0.8–1.25. Subjects were ex-
posed to each treatment in random order, with a 3-day washout between.
Blood pressure (BP), heart rate, and sedation (100mm visual analog scale
[VAS]) were assessed, and AEs recorded.
Results: All 18 subjects (mean 20.4 years; 61% male) completed the
study. No significant interaction was seen for inhaled loxapine+ IM
lorazepam on respiration or pulse oximetery vs. either agent alone
during the 12hr post-dose period, with 90% CI for AUC and Cmin
ratios confirming equivalence. BP and heart rate were unchanged for
12hr post-dose with inhaled loxapine+ IM lorazepam vs. either agent
alone. Results clearly demonstrated the central nervous system sedative
effects of IM lorazepam, inhaled loxapine, and the combination of inhaled
loxapine+ IM lorazepam in healthy volunteers. No deaths, serious AEs,
premature discontinuations due to AEs, or treatment-related AEs were
reported.
Conclusion: No effects on respiration or vital signs were seen for
inhaled loxapine+ IM lorazepam vs. each drug alone. There was greater
sedation with inhaled loxapine+ IM lorazepam compared with either
drug administered alone in these healthy volunteers.
Policy of full disclosure: Study funded by Alexza Pharmaceuticals.
Medical writing support, funded by Teva Pharmaceuticals, was provided
by Annie Rowe, PhD, of Excel Scientific Solutions. DAS and JVC are
employees of Alexza Pharmaceuticals, Inc. RRS is an employee of
2Covance Clinical Research Unit. PY is an employee of Teva
Pharmaceuticals.
P-43-028 Quality of life and first epizode of schizophrenia
I. Stehnova1, M. Sisrova2, L. Ustohal3, M. Mayerova3, D. Berankova4.
1Faculty Hospital of St. Anne, Brno, Czech Republic; 2Faculty Hospital Brno,
Regional Hospital Liberec, Brno, Czech Republic; 3Faculty Hospital Brno,
Brno, Czech Republic; 4Faculty Hospital of St. Anne, Faculty Hospital
Ostrava, Ostrava, Czech Republic
Objective: Quality of life in first epizode schizophrenia patients, who suf-
fer weighty mental illnesses is without question influence in important
way. Return to normal life functioning is very often difficult and protrac-
ted. Studying of this problematic can offer ideas on which parts need to be
rehabilitated and thereby may return pacients back to normal functional
life quickly and effectively.
Methods: Our research group is formed by 40 patients who have
been investigated during first epizode schizophrenia and by 80 healthy
controls. Patients were invited after one year period to the control inves-
tigation. Questionaire Subjective Quality of Life Analysis SQUALA was
chosen as an indicator of subjective level of quality of life. Patients were
divided to 3 categories according to used medication (olanzapine, risper-
idone and other).
Results: Results show that patients with schizophrenia have demon-
strably lower level of quality of life than healthy controls. Same phenom-
enon was detected in areas of health, close relationships, free time
activities and abstract qualities. Only part of basic needs feel these patients
same as healthy controls. We also detected that quality of life, especially
part of close relationships, corelate negatively with thought and percep-
tion disorder, while performance in executive tasks corelate negatively
with level of perception of basic needs, which contain evaluation of sur-
rounding and housing, finance and food. In case of increase of subjec-
tively perceived depresivity patients reffer worse quality of functioning
in close relationships. In connection with psychopharmacological treat-
ment were not found any statistically significant relationships. After one
year from first epizode remains level of subjective quality of life without
any chase, even though that presence of positive symptoms and global
scale of psychopatology is statistically lower.
Conclusion: From the mentioned findings is obvious, that quality of
life of patients with schizophrenia is lower in comparison with healthy
controls and this deficit is unfortunatelly stabile in time.
Policy of full disclosure: None.
P-43-029 Cognition and schizophrenia: Neuropsychological profile,
dynamics, psychopatology and pharmacotherapy
I. Stehnova1, M. Sisrova2, L. Ustohal3, M. Mayerova3, D. Berankova4.
1Faculty Hospital of St. Anne, Brno, Czech Republic; 2Faculty Hospital Brno,
Regional Hospital Liberec, Brno, Czech Republic; 3Faculty Hospital Brno,
Brno, Czech Republic; 4Faculty Hospital Brno, Faculty Hospital Ostrava,
Ostrava, Czech Republic
Objective: Maping of cognitive abilities in schizophrenia pacients is indi-
visible part of psychodiagnostics of this disease. Neuropsychological clini-
cal scan is still not fully clear and studies dedicated to this topic offer
many diferent information. Aim of this study is to map this issues and
bring new information about cognitive functioning and dynamics in
schizophrenia.
Methods: Our research group is formed by 41 in patients who were
observed during first epizode schizophrenia in Clinic of Psychiatry at
Faculty hospital Brno. One year after the first epizode were performed
controling investigations. After retreat of acute psychotic proces durig
first epizode the patients undergone complex neuropsychological investi-
gation including submission of questionaires maping quality of life and
depresion. Patients were also scaled by the method PANSS and divided
into 3 categories acording to the used medication (olanzapine, risperidone
and other).
Results: Results show that in the first epizode schizophrenia patients
partial cognitive deficit is present. This deficit is the strongest in verbal
memory abilities (phase imprinting and recall), visual memory and psy-
chomotor speed. Cognitive weaknesses include most of attention compo-
nents as working memory, verbal fluency and distribution of attention.
Improvement of cognitive capacity in area of working memory, visual
memory, verbal memory in phase recall and quality of conception think-
ing was evidenced after one year from the first. At the same time has not
been found statisticaly significant dependance between types of pharma-
cotherapy and cognition quality. Contrariwise we have found negative co-
relation between rate of positive symptoms and flexibility of thinking,
negative symptoms and quality of attention, short-term memory and glo-
bal cognitive functioning. General psychopatology corelate positively
with level of subjective depression and negatively with flexibility of think-
ing, distribution of attention and short-term memory.
Conclusion: From the perspective of psychopatology cognitive func-
tioning is fundamentally influenced by negative and general symptoms.
Policy of full disclosure: None.
P-43-031 A double-blind, placebo-controlled, randomized
withdrawal study of lurasidone for the maintenance of
efficacy in patients with schizophrenia
R. Tandon1, A. Loebel2, D. Phillips2, A. Pikalov2, D. Hernandez2, Y. Mao2,
J. Cucchiaro2. 1University of Florida College, Gainesville, USA; 2Fort Lee, USA
Objective: To evaluate lurasidone for maintenance treatment of patients
with schizophrenia.
Methods: Adult patients experiencing an acute exacerbation of schizo-
phrenia were enrolled in the 12- to 24-week open-label stabilization phase
of the trial and treated with lurasidone (40–80mg/d, flexibly dosed).
Patients who maintained clinical stability during the initial open-label
study phase for 512 weeks were subsequently randomized to placebo
or lurasidone (40–80mg/d, flexibly dosed) at baseline of the 28-week,
double-blind study phase. The primary efficacy endpoint was time to
relapse in the double-blind phase. Secondary efficacy measures
included the Positive and Negative Syndrome Scale (PANSS) and
Clinical Global Impression–Severity (CGI-S). Safety assessments included
treatment-emergent adverse events, discontinuations due to AEs, and lab-
oratory measures.
Results: Of 676 enrolled patients, 285 met protocol-specified stabiliza-
tion criteria and were randomized to lurasidone (N=144) or placebo
(N=141). Relapse occurred in a greater proportion of patients receiving
placebo (41.1%) than lurasidone (29.9%). Time to relapse was significantly
longer for lurasidone compared with placebo (log-rank test, p=0.039).
Lurasidone was associated with a 33.7% reduction in risk of relapse versus
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placebo (Cox hazard ratio [95% confidence interval], 0.663 [0.447, 0.983];
p=0.041). Patients receiving placebo demonstrated significantly greater
worsening on PANSS and CGI-S scores compared to lurasidone-treated
patients (PANSS mean change, +12.4 vs +8.3, p=0.029; CGI-S mean
change, +0.7 vs +0.4, p=0.015; analysis of covariance with the last obser-
vation carried forward). The discontinuation rate due to adverse events
during the double-blind phase was 13.9% for lurasidone and 15.6% for
placebo. Minimal changes in weight, prolactin, lipid, and glucose para-
meters were observed in both groups during the double-blind phase.
Conclusion: This placebo-controlled, randomized withdrawal study
demonstrated the efficacy of lurasidone for the maintenance treatment
of patients with schizophrenia. Lurasidone was generally well tolerated,
with minimal effects on weight and other metabolic parameters.
ClinicalTrials.gov identifier: NCT01435928
Policy of full disclosure: Dr. Tandon reports serving as a consultant for
Sunovion Pharmaceuticals Inc. All other authors report being employees
of Sunovion Pharmaceuticals Inc.
P-43-032 Risperidone monotherapy influences cortical inhibition in
patients with first episode of schizophrenia: A TMS study
L. Ustohal1, R. Prikryl1, M. Mayerova1, I. Stehnova1, H. Prikrylova
Kucerova1, E. Ceskova1, T. Kasparek1. 1Masaryk University, Brno, Czech
Republic
Objective: Cortical inhibition is a neurophysiological mechanism
whereby GABA interneurons attenuate the activity of other neurons.
The inhibitory and excitatory mechanisms can be assessed using trans-
cranial magnetic stimulation (TMS). One of the inhibitory paradigms is
known as cortical silent period (CSP). Recent metanalysis did not find
significant differences in CSP in patients with schizophrenia. But there
are several studies showing that CSP is shortened in patients with schizo-
phrenia and antipsychotic medication (especially clozapine) can cause its
prolongation. The aim of our study was to assess the ability of risperidone
to influence CSP in patients with first episode of schizophrenia (FES).
Methods: Drug-naive patients with FES were included to our study
(N=13). They were treated with risperidone monotherapy. The CSP dur-
ation was measured using TMS before the treatment and after four weeks
of risperidone monotherapy. The psychopathology was assessed using
Positive and Negative Syndrome Scale (PANSS). The CSP duration was
obtained in moderately tonically active musculus abductor digiti minimi
by stimulating the motor cortex with an intensity of 150% of motor thresh-
old. CSP was defined as a time between the initiation of motor-evoked
potential (MEP) and return of any voluntary EMG activity.
Results: Mean CSP duration increased during the treatment from
134.2 ms (SD=41.8) to 162.9 ms (SD=62.0) which was statistically signifi-
cant (p<0.05). We did not find any correlation with the PANSS total
score or its subscores.
Conclusion: We found in our study that risperidone monotherapy can
influence cortical inhibition in drug-naive patients with FES.
Policy of full disclosure: This work was supported by the project
‘CEITEC–Central European Institute of Technology’ (CZ.1.05/1.1.00/
02.0068) from European Regional Development Fund and by the project
(Ministry of Health, Czech Republic) for conceptual development of re-
search organization 65269705 (University Hospital Brno, Czech Republic).
P-43-033 Polydipsia in a patient with a chronic, severe mental
illness
D. Volochniouk1, F. Iftene1. 1Queens University, Kingston, ON, Canada
Objective: Disturbances of water homeostasis among psychiatric clients
have been noticed, particularly the consumption of excessive quantities
of liquid (“polydipsia”). Purpose: To describe the particularities of a poly-
dipsic patient with schizoaffective disorder, the risk factors involved, the
possible mechanisms, reasons delaying diagnosis, and the screening
strategies.
Methods: Data collection includes: chart review and structured inter-
views. We did weight measurements and urine collections twice daily
on three different days, at two weeks interval.
Results: The case studied was that of DG, diagnosed with
Schizoaffective Disorder 25 years ago. He has been living in a home for
special care for 20 years. He has been presenting permanent excessive
drinking behavior for the last 15 years, along with episodic aggressive
behavior and urine incontinence. He stated that he drinks around 6 liters
of water per day.
Conclusion: Possible risk factors involved in triggering DG#s water
seeking behavior are: treatment with Lithium for the last 20 years, long
term classic neuroleptic treatment, and heavily drinking and smoking
behavior. The water drinking pattern was interesting–he was waking
up at 2 am and drinking large quantities of water to the point that his
maximum body weight per day was at 8 in the morning, with a baseline
at 8 p.m. He admitted having a psychological reason # dizziness and #feel-
ing high,# along with thirst. This patient was only recently diagnosed with
polydipsia. In this presentation, we are discussing some potential screen-
ing strategies for polydipsia in order to avoid this situation in the future.
Policy of full disclosure: None.
P-43-034 Vitamin C as an adjunct in schizophrenia treatment: A
literature review of the theoretical bases and clinical
applications
D. Volochniouk1, F. Iftene1. 1Queens University, Kingston, ON, Canada
Objective: Schizophrenia is a devastating illness thought to result from
a combination of genetic and environmental factors. Its etiology and
treatment remain under active investigation. There is a growing body of
evidence that perioxidative neuronal damage is a contributing factor. In
this review, we focused on the results of the existing Vitamin C sup-
plementation trials in Schizophrenia and the theoretical bases for con-
sidering the role of oxidative stress in its pathophysiology.
Methods: We searched the available English language literature in
PubMed/Medline, Embase, Cochrane and Web of Science, using key
words such as schizophrenia, vitamin C, ascorbic acid, antioxidant sup-
plementation, oxidative stress, adjunctive treatment for schizophrenia.
Bibliographies from primary sources and reviews were used to sup-
plement our search.
Results: Supplementation of antipsychotic regimens with antioxidants
was found beneficial in several trials. In particular, Vitamin C has been in-
corporated into NICE guidelines for treatment resistant schizophrenia,
among adjunctive treatment options. It was found to improve brief psy-
chiatric rating scale scores, and appears to be a useful, inexpensive and
safe option. However, the clinical trials of Vitamin C supplementation re-
main scarce.
Conclusion: Vitamin C is an inexpensive and safe adjunctive option to
supplement schizophrenia treatment. It has sound theoretical basis behind
it and has shown promise in the existing clinical investigations. However
clinical trials remain scarce and more research is needed to delineate the
extent of its usefulness.
Policy of full disclosure: None.
P-43-035 How does the NSA-4 compare to the NSA-16?
J. Williams1, L. Garzio1, D. Osman1, D. Popp1. 1MedAvante, Hamilton, USA
Objective: The 16-item Negative Symptom Assessment (NSA-16) is
increasingly used as a validated measure to track response to treatment
of negative symptoms of schizophrenia. The NSA-4 has been proposed
as a reliable and valid alternative. Alphs et al., examined the psychometric
properties of the NSA-4 in two randomized clinical trials. The current
study is an effort to replicate their findings.
Methods: Subjects with prominent negative symptoms of schizophrenia
were interviewed by videoconferencing Blinded remote raters adminis-
tered the PANSS immediately followed by the NSA-16. Correlation coeffi-
cients between NSA-16 and NSA-4 were calculated for the NSA global
rating, the PANSS negative and positive subscales, and several PANSS
Marder factors. Cronbach#s alpha and interrater reliability (calculated as
an ICC) were determined for the NSA-16 and NSA-4.
Results: The NSA-16 was administered 2804 times by 29 Central Raters,
to a total of 483 subjects at 13 visits, including end point. Overall, the cor-
relation between the total scores of the NSA-4 and NSA-16 was high
(0.86). Good convergent validity of the NSA-4 was demonstrated by cor-
relations between the NSA-4 and the NSA global rating (r=0.67), as well
as the PANSS negative subscale (r=0.73) and the PANSS negative symp-
toms Marder factor (r=0.73). Divergent validity was demonstrated by low
correlations between the NSA-4 and PANSS Marder factors anxiety/de-
pression (r=−0.11), disorganized thought (r=0.29), hostility/excitement
(r=0.03), and PANSS positive symptoms (r=0.13). Cronbach’s alpha was
lower for NSA-4 (#=0.65) compared to NSA-16 (#=0.87). Finally, the inter-
rater reliability estimates for NSA-4 and NSA-16 were 0.94 and 0.97,
respectively.
Conclusion: The NSA-4 had very good overall agreement with the
NSA-16, and even higher convergent and divergent validity with the
selected PANSS subscales and interrater reliability than was demonstrated
by Alphs et al.,
Policy of full disclosure: Authors are affiliated with MedAvante.
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P-43-036 Effects of 17beta-estradiol on spatial memory and protein
expression of BDNF and parvalbumin in WT mice are
absent in BDNF heterozygous mice
Y. C. Wu1, X. Du2, M. van den Buuse2, R. Hill2. 1Florey Institute of
Neuroscience & Mental Health, Melbourne, Australia; 2Behavioural
Neuroscience Laboratoy, Florey Institute of Neuroscience & Mental Health,
Melbourne, Australia
Objective: Cognitive impairments are a core feature of schizophrenia
which are poorly responsive to current antipsychotics. Brain-derived neu-
rotrophic factor (BDNF) and estradiol (E2) are known for their cognitive
enhancing effects. We sought to determine the consequences of ovari-
ectomy (OVX) and hormone replacement on memory performance and
expression of proteins implicated in cognitive function at young adult-
hood in wild-type (WT) and BDNF heterozygous (+/−) mice.
Methods: Prepubescent OVX and hormone replacement (E2 or pro-
gesterone (P4)) were conducted in 5 week old female WT and BDNF+/−
mice. Spatial memory and recognition memory were examined at
10–11 weeks of age using Y-maze and novel object recognition tasks,
respectively. Protein expression of BDNF and parvalbumin (PV) were
measured by Western blot in the dorsal (DHP) and ventral (VHP) hippo-
campus at 12 weeks.
Results: OVX significantly impaired spatial and recognition memory
in WT mice while E2 replacement only restored the Y-maze deficit.
BDNF+/− intact mice showed a significant deficit in spatial, but not recog-
nition memory compared to WT intact controls. However, OVX improved
this spatial memory deficit in BDNF+/− mice as they performed signifi-
cantly better than WT OVX. Furthermore, E2 replacement reversed this
positive effect of OVX in BDNF+/− mice. BDNF and PV expression
were significantly reduced in DHP of WT OVX mice compared to intact
controls. E2 replacement effectively maintained BDNF and PV expression
in WT OVX mice. By contrast, BDNF and PV expression were significantly
lower in BDNF+/− compared to WT mice, however OVX and E2 replace-
ment had no further impact on their expression.
Conclusion: These data confirm the cognitive enhancing effects of E2 on
spatial memory, and suggest that BDNF and PV expression may mediate
this effect in WT mice. Conversely, the effects of E2 are absent in BDNF
+/− mice indicating an altered neuroendocrine status in these animals.
Policy of full disclosure: None.
P-43-037 Gray matter volume correlates with comt gene val158met
polymorphism in first-episode treatment-naïve patients
with schizophrenia
B. Xiang. Sichuan University, Chengdu, China
Objective: Catechol-O-methyltransferase (COMT) plays an important role
in modulating cortical dopaminergic catabolism and has been associated
with schizophrenia. However, it remains unclear if the variations in dopa-
mine signaling affect the gray matter (GM) structural maturation in typi-
cally developing individuals, and whether such effect are disrupted in
schizophrenia patients. The aims of this study are: (1) to explore the re-
lationship between the functional polymorphisms Val158Met of COMT
gene and GM volume in first-episode treatment-naïve patients with
schizophrenia and healthy controls, (2) to investigate the relationship
among GM volume and psychiatric symptoms.
Methods: Whole GM volume which was computed by an automated
voxel based morphometry by statistical parametric mapping and clinical
performances were evaluated in 150 first-episode treatment-naïve patients
with schizophrenia and 100 healthy controls. In addition,2-sample t-tests
was used to explore the main effect of diagnostic group, a full factorial
model was used to obtain genotype-by-diagnostic interaction in the vol-
ume of GM according to genotypes of the mentioned polymorphism,
and multiple regression was used to explore the correlation between
whole GM volume and clinical syndromes, with age and sex as
covariance.
Results: GM volume was significantly reduced in the right precentral
gyrus[MNI: 37 −16 70], right cerebellum anterior lobe [MNI: 6 −56 26]
and left Postcentralgyrus[MNI: −8 −36 80](P<0.05, FWE corrected) in
schizophrenia. There was also a strong group×genotype interaction on
the right precuneus(P<0.001, uncorrected). A significant positive corre-
lation of the GM volume over the cluster located at middle frontal
gyrus [MNI: 36 60 15] with PANSS subscales for general psychopatho-
logical symptoms within schizophrenic patients, the negative correlation
of the GM volume over the cluster located at parahippocampagyrus
[MNI: 27 −10 −25] with PANSS subscales for negative symptoms within
schizophrenic patients (FDR correction at p<0.05).
Conclusion: These _ndings suggest that COMT Met variant was asso-
ciated with disruption of dopaminergic influence on GM maturation
and may be the pathogenesis of schizophrenia, and maybe that the abnor-
mal GM structure were association with clinical syndromes.
Policy of full disclosure: None.
P-43-039 A randomized, placebo-controlled repeat-dose thorough
QT study of inhaled loxapine in healthy volunteers
P. Yeung1, J. V. Casella2, D. A. Spyker2. 1Southeastern, PA, USA; 2Alexza
Pharmaceuticals Inc., Mountain View, CA, USA
Objective: Single-dose administration of inhaled loxapine via the
Staccato® system was not associated with clinically relevant QT pro-
longation, but the effect of repeat dosing of inhaled loxapine on QTc pro-
longation has not been previously studied. This study was therefore
conducted to investigate potential effects on cardiac repolarization
(QT-interval) of 2 consecutive doses of inhaled loxapine administered
2 hours apart (NCT01854710).
Methods: This randomized, double-blind, positive-controlled, cross-
over study was conducted in healthy volunteers (18–65 years of age).
Each subject received: 2 doses of inhaled loxapine (10mg)+oral placebo;
2-doses of inhaled placebo+oral placebo; or 2 doses of inhaled placebo
+oral moxifloxacin (400mg; [positive control), with >3-days washout be-
tween treatments. Inhaled doses were spaced by 2 hours. Primary out-
come was maximum effect of inhaled loxapine on QTc interval duration
vs. placebo at 12 preselected time points across the 24-hour post-dose
interval.
Results: Of 60 enrolled subjects (mean 33.8 years; 52% male), 45 (75%)
completed the study. Inhaled loxapine did not increase QT interval
across 24-hour post-dose follow-up, as demonstrated by a maximum
mean increase in the placebo-corrected change in QTc from baseline of
4.04 msec with the upper 95% CI of 6.31 msec at 5 minutes post second-
dose. As a positive control, the lower one-sided 95% CI for moxifloxacin
effect was >5 msec at all 4 predefined post-dose time points.
Conclusion: No clinically relevant change in QTc was seen with mul-
tiple doses of inhaled loxapine in this population of healthy volunteers.
Inhaled loxapine did not significantly prolong the QTc interval in this
study. These findings suggest that inhaled loxapine is not associated
with cardiac re-polarization liability.
Policy of full disclosure: Study funded by Alexza Pharmaceuticals.
Medical writing support, funded by Teva Pharmaceuticals, was provided
by Annie Rowe, PhD, of Excel Scientific Solutions. JVC and DAS are
employees of Alexza Pharmaceuticals, Inc. PPY is an employee of Teva
Pharmaceuticals.
P-43-040 The psychometric properties of night eating questionnaire
in Korean schizophrenic outpatients
B.-H. Yoon1, S.-H. Nam1, Y.-H. Sea1, J.-H. Song1, H.-R. Jeong1, K.-M. Kim1.
1Naju National Hospital, Naju, Republic of Korea
Objective: The purpose of this study was to evaluate psychometric
properties of the Night Eating Questionnaire (NEQ) as a measure of the
Night Eating Syndrome (NES) in schizophrenic outpatients.
Methods: The behavioral and psychological symptoms of NES were
assessed with the 14-item self-reported questionnaire (NEQ). Body
weight and height were measured to assess the body mass index (BMI).
Subjective estimates of depression, binge eating patterns, sleep quality
and weight-related quality of life were evaluated using Beck’s
Depression Inventory (BDI), Binge Eating Scale (BES), Pittsburgh Sleep
Quality Index (PSQI) and Korean version of Obesity-related Quality of
Life scale (KOQoL).
Results: Results Among 223 schizophrenic outpatients who completed
the NEQ, 25 (11.2%) patients screened as having NES (total NEQ >25).
NEQ demonstrated high internal consistency (Crobach’s alpha=0.74)
and item-total correlations (r=0.29∼0.75; p<0.001, respectively) were ac-
ceptable except morning anorexia. Principal components analysis revealed
the presence of four factors (nocturnal ingestions, evening hyperphagia,
mood/sleep, and morning anorexia), explaining 56.8% of total variance.
Although total score of NEQ was not correlated with BMI, age at onset,
duration of illness, use of atypical antipsychotics, it was significantly cor-
related with total scores of BDI, BES, PSQI and KOQoL. Test-retest re-
liability was also good (r=0.74, p<0.001).
Conclusion: Our results showed that NEQ appears to be an efficient,
valid measure of NES in Korean schizophrenic outpatients.
Policy of full disclosure: None.
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P-43-041 Antipsychotics promote the differentiation of
oligodendrocyte progenitor cells by regulating
oligodendrocyte lineage transcription factors 1 and 2
Y. Zhang1, H. Zhang2, J. Wang2, X.-M. Li3. 1University of Saskatchewan,
Saskatoon, Canada; 2Shantou University, Shantou, China; 3Faculty of
Medicine, Department of Psychiatry, University of Alberta, Edmonton, Canada
Objective: Oligodendrocyte/myelin abnormalities may be an important
component of the pathogenesis found in schizophrenia. The aim of this
current study was to examine the possible effects of the antipsychotic
drugs (APDs) haloperidol (HAL), olanzapine (OLA), and quetiapine
(QUE) on the development of oligodendroglial lineage cells.
Methods: CG4 cells, an oligodendrocyte progenitor cell line, were
treated with various concentrations of HAL, OLA, or QUE for specific
periods. The proliferation and differentiation of the CG4 cells were mea-
sured. The regulation of CG4 cell differentiation by oligodendrocyte lin-
eage transcription factors 1 and 2 (Olig1 and Olig2) was examined.
Results: The APDs used in this study had no effect on the proliferation
of CG4 cells. The APDs elevated the expression of 2′,3′-cyclic nucleotide
3′-phosphodiesterase (CNP), a specific marker of oligodendrocytes, and
promoted the CG4 cells to differentiate into CNP positive oligodendro-
cytes. QUE and OLA increased the expression of both Olig1 and Olig2
whereas HAL only increased the expression of Olig2.
Conclusion: Our findings suggest that oligodendrocyte development
is a target of HAL, OLA, and QUE and provide further evidence of the
important role of oligodendrocytes in the pathophysiology and treatment
of schizophrenia. They also indicate that the expression level of oligoden-
drocyte/myelin-related genes could be profoundly affected by APDs,
which should be considered in future studies aiming to measure the oligo-
dendrocyte/myelin-related gene expressions in schizophrenia patients.
Policy of full disclosure: Dr.Xin-Min Li receives research grants from
Pfizer Canada Inc., Astrazeneca Canada. Dr.Yanbo Zhang receives fellow-
ship from The Rx&D Health Research Foundation (HRF). Drs. Handi
Zhang and Junhui Wang have no conflict of interest.
P-43-042 Differences in weight education programs, eating habits,
energy levels, and physical activities of patients with
schizophrenia or bipolar disorder treated with olanzapine
across four countries
T. Treuer1, W. Montgomery2, W. Y. Ye3, Z. Kadziola4, D. Novick5,
S. Hu Wu3, H. B. Haber Xue3, J.-F. Joyce Yeh6, I. Ruiz7. 1Eli Lilly &
Company, Budapest, Hungary; 2Eli Lilly, NSW, Australia; 3Eli Lilly,
Shanghai, China; 4Eli Lilly, Vienna, Austria; 5Eli Lilly, Windlesham, United
Kingdom; 6Eli Lilly, Taipei, Taiwan; 7Eli Lilly de Mexico, Mexico
Objective: This post hoc analysis of a multinational observational study
assessed the use of weight education programs, eating habits, energy
levels, and physical activities in patients initiating or switching to oral
olanzapine for the treatment of schizophrenia or bipolar disorder.
Methods: Outpatients with schizophrenia or bipolar disorder from
China, Mexico, Romania, and Taiwan who initiated or switched to oral
olanzapine (N=622) were assessed monthly (#6 months). A general linear
model adjusting for patient baseline characteristics, country, and partici-
pation in a weight education program was used to estimate weight
changes in relation to program participation.
Results: Less than half of patients participated in a weight education
program (China 153/330 patients [46.4%]; Mexico 39/91 [42.9%];
Romania 49/151 [32.5%]; Taiwan 11/50 [22.0%]). At the first program
visit, most programs were delivered as individual sessions (range:
72.7%−86.3%); lifestyle/behavioral consultation were used commonly in
China (40.5%/37.3% of programs) and Romania (40.8%/34.7%), but rarely
in Mexico (7.7%/5.1%); nutritional consultation was used most commonly
in Taiwan (72.7%). The potential consequences of weight gain were com-
monly discussed in China (64.7%) and Romania (65.3%), but rarely in
Mexico (2.6%). The least squares mean increase from baseline in weight
was significantly higher (P<0.05) in patients who did not participate in
a program than in those who did in China (1.06 kg) and Romania
(2.78 kg). Program compliance significantly improved (P<0.05) during
the study in China and Romania. There were some country differences
in eating habits, energy levels, and physical activities.
Conclusion: Awareness of country differences in weight education
programs, eating habits, energy levels, and physical activities may help
clinicians identify those patients who would benefit most from these pro-
grams after initiation of antipsychotic treatment. Results should be inter-
preted conservatively due to the observational design.
Policy of full disclosure: Funding source: Eli Lilly and Company.
P-44. Neurodegeneration C
P-44-001 Protective role of 17#-estradiol on glucose transporter and
mitochondrial enzymes in brain of aging female rats
P. Kumar1, R. Kale2, N. Baquer2. 1Jawaharlal Nehru University, New Delhi,
India; 2Jawaharlal Nehru University, School of Life Sciences, New Delhi, India
Objective: Aging is a multifactorial process involving neurodegenerative
changes in cell morphology and biochemistry. Aging in females and males
is considered as the end of natural protection against age related diseases
like osteoporosis, coronary heart disease, diabetes, Alzheimer’s disease
and Parkinson’s disease. These changes increase during menopausal con-
dition in females when the level of estradiol is decreased.
Methods: The objective of this study was to observe the changes in ac-
tivities of mitochondrial enzymes (monoamine oxidase (MAO), Na+K+
ATPase and Ca+ATPase), DNA degradation, and glucose transporter 4
(GLUT4) expression in brains of female rats of 3 months (young),
12 months (adult) and 24 months (old) age groups, and to see whether
these changes are restored to normal levels after exogenous administration
of estradiol (0.1 μg/gm body weight for one month).
Results: The results obtained in the present work revealed that normal
aging was associated with significant decrease in the activity of Na+K
+ATPase, Ca+ATPase and GLUT4 levels in the brains of aging female
rats, and an increase in DNA degradation and MAO activity. The present
study showed that estradiol treatment significantly decreased DNA
degradation, and MAO activity in brain of aging rats, and a reversal of
Na+K+ATPase, Ca+ATPase and GLUT4 levels was achieved.
Conclusion: It can therefore be concluded that estradiol’s beneficial ef-
fects seemed to arise from its antilipofuscin, antioxidant, antilipidperoxi-
dative effects, implying an overall anti-aging action. The results of this
study will be useful for pharmacological modification of the aging process
and applying new strategies for control of age related disorders.
Policy of full disclosure: None.
P-44-002 Pharmacogenetics of angiotensin-converting enzyme
inhibitors in patients with dementia due to Alzheimer’s
disease
F. Oliveira1, P. Bertolucci2, E. Chen3, M. Smith3. 1Escola Paulista de
Medicina, UNIFESP, São Paulo, Brazil; 2Escola Paulista de Medicina,
Discipline of Neurology, São Paulo, Brazil; 3Escola Paulista de Medicina,
Discipline of Genetics, São Paulo, Brazil
Objective: The angiotensin-converting enzyme is an amyloid-beta-
degrading enzyme, with ACE gene polymorphisms rs1800764 and
rs4291 accountable for higher angiotensin-converting enzyme activity
and local boosting effects upon angiotensin-converting enzyme levels,
while showing the most significant effects for risk and age of onset of de-
mentia due to Alzheimer’s disease (AD). We aimed to investigate whether
rs1800764 and rs4291 are also associated with cognitive change in patients
with AD who have systemic hypertension under treatment with
angiotensin-converting enzyme inhibitors.
Methods: Participants with late-onset AD according to National
Institute on Aging – Alzheimer’s Association criteria were screened with
Mini-Mental State Examination (MMSE) and Clinical Dementia Rating
Sum-of-Boxes (CDR-SB) and followed for one year. Genotypingwas under-
taken with TaqMan® Real-Time PCR technology for rs1800764 and rs4291,
and also for APOE haplotypes. Presence of each ACE gene polymorphism
was correlated with APOE haplotypes and treatment using angiotensin-
converting enzyme inhibitors. Mann-Whitney test and two-way ANOVA
were employed for statistical analysis, significance at p<0.05.
Results: A total of 182 consecutive patients were included, with minor
allele frequencies of 0.49 (rs1800764 – C) and 0.34 (rs4291 – T). Overall 173
patients (95.1%) used cholinesterase inhibitors, whereas 149 (81.9%) had
systemic hypertension, and 120 (65.9%) used angiotensin-converting en-
zyme inhibitors. Patients with the APOE-e4/e4 haplotype had earlier
onset of AD (p<0.007), while rs1800764 and rs4291 genotypes had no
influence over age of dementia onset (p>0.07). All patients who used
angiotensin-converting enzyme inhibitors had slower cognitive decline ac-
cording to the MMSE (p=0.012). Carriers of the rs4291 – TT genotype
had slower worsening of CDR-SB scores when they used angiotensin-
converting enzyme inhibitors (p=0.019), as well as carriers of the
rs1800764 – CC : rs4291 – TT haplotype (p=0.007).
Conclusion: Angiotensin-converting enzyme inhibitors may slow the
cognitive decline of patients with AD, more remarkably for carriers of
specific ACE gene polymorphisms.
Policy of full disclosure: This work was supported by CAPES -
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. The
authors report the following disclosures: 1. Fabricio Ferreira de Oliveira,
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MD, MSc, is a PhD student at the Federal University of São Paulo -
UNIFESP in São Paulo, Brazil; he receives a scholarship for academic re-
search from CAPES – Coordenação de Aperfeiçoamento de Pessoal de
Nível Superior, a governmental agency in Brazil, and receives personal
compensation for acting as a Healthcare Council Member for Gerson
Lehrman Group. 2. Paulo Henrique Ferreira Bertolucci, MD, MSc, PhD,
is a professor at the Department of Neurology and Neurosurgery of the
Federal University of São Paulo – UNIFESP in São Paulo, Brazil; he has
received personal compensation for acting as a consultant for Janssen,
Lundbeck, Novartis, Pfizer and Support. 3. Elizabeth Suchi Chen, MSc,
PhD, is a professor at the Department of Morphology and Genetics
of the Federal University of São Paulo – UNIFESP in São Paulo,
Brazil. 4. Marilia de Arruda Cardoso Smith, MSc, PhD, is a full professor
at the Department of Morphology and Genetics of the Federal University
of São Paulo – UNIFESP in São Paulo, Brazil; she receives support for re-
search activities from the following Brazilian public agencies for research:
FAPESP – The State of São Paulo Research Foundation, CNPq - Conselho
Nacional de Desenvolvimento Científico e Tecnológico, and CAPES -
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Effects of angiotensin-converting enzyme inhibitors over
Mini-Mental State Examination scores within one year for patients
with dementia due to Alzheimer’s disease:
P-44-003 Neurotranslational analysis of the role of
cholesterol-lowering drugs over cognitive change in
Alzheimer’s disease
F. Oliveira1, P. Bertolucci2, E. Chen3, M. Smith3. 1Escola Paulista de
Medicina, UNIFESP, São Paulo, Brazil; 2Escola Paulista de Medicina,
Discipline of Neurology, São Paulo, Brazil; 3Escola Paulista de Medicina,
Discipline of Genetics, São Paulo, Brazil
Objective: To investigate whether polymorphisms of LDLR and CETP
genes are associated with cognitive change in patients with dementia
due to Alzheimer’s disease (AD) who have hyperlipidemia under treat-
ment with statins or Ezetimibe.
Methods: Participants with late-onset AD according to National
Institute on Aging – Alzheimer’s Association criteria were screened with
Clinical Dementia Rating Sum-of-Boxes (CDR-SB) and Mini-Mental
State Examination (MMSE) and followed for one year. Genotyping was
undertaken with TaqMan® Real-Time PCR technology for CETP poly-
morphisms I422 V and TaqIB, and also for APOE, rs5930 (LDLR10),
rs11669576 (LDLR8) and rs5925 (LDLR13). Presence of each LDLR or
CETP polymorphism was correlated with APOE haplotypes and treat-
ment using Simvastatin, Atorvastatin, Rosuvastatin and/or Ezetimibe.
Mann-Whitney test and two-way ANOVA were employed for statistics,
significance at p<0.05.
Results: A total of 148 consecutive patients were included, considering
101 females (68.2%) and 47 males (31.8%), with minor allele frequencies of
0.07 (rs11669576 – A), 0.35 (rs5930 – A), 0.47 (rs5925 – C), 0.36 (I422 V – G)
and 0.37 (TaqIB – A). Carriers of the I422 V-AA genotype had later onset
of AD (p=0.0035), while carriers of the APOE-e4/e4 haplotype had earlier
dementia onset (p=0.0121). According to CDR-SB scores, statins slowed
the cognitive decline of patients who were APOE4- (p=0.013), and also
of carriers of the haplotype rs11669576 – GG: rs5925 – CC who were
APOE4+ (p=0.044). According to MMSE scores, statins led to faster
cognitive decline for carriers of the haplotype I422 V – AA : TaqIB – GG
(p=0.012). Use of Ezetimibe was unrelated with cognitive change, regard-
less of any genotypes or haplotypes.
Conclusion: Statins may differentially affect the cognitive decline of
patients with AD who carry specific genetic profiles.
Policy of full disclosure: This work was supported by CAPES –
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. The
authors report the following disclosures: 1. Fabricio Ferreira de Oliveira,
MD, MSc, is a PhD student at the Federal University of São Paulo –
UNIFESP in São Paulo, Brazil; he receives a scholarship for academic
research from CAPES – Coordenação de Aperfeiçoamento de Pessoal de
Nível Superior, a governmental agency in Brazil, and receives personal
compensation for acting as a Healthcare Council Member for Gerson
Lehrman Group. 2. Paulo Henrique Ferreira Bertolucci, MD, MSc, PhD,
is a professor at the Department of Neurology and Neurosurgery of the
Federal University of São Paulo – UNIFESP in São Paulo, Brazil; he has
received personal compensation for acting as a consultant for Janssen,
Lundbeck, Novartis, Pfizer and Support. 3. Elizabeth Suchi Chen, MSc,
PhD, is a professor at the Department of Morphology and Genetics of
the Federal University of São Paulo – UNIFESP in São Paulo,
Brazil. 4. Marilia de Arruda Cardoso Smith, MSc, PhD, is a full professor
at the Department of Morphology and Genetics of the Federal University
of São Paulo - UNIFESP in São Paulo, Brazil; she receives support for re-
search activities from the following Brazilian public agencies for research:
FAPESP - The State of São Paulo Research Foundation, CNPq – Conselho
Nacional de Desenvolvimento Científico e Tecnológico, and CAPES –
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Effects of statins for carriers and non-carriers of rs11669576 - GG:
rs5925 - CC according to APOE status:
P-44-004 A case study of primary progressive aphasia, logopenic
type – 3 years longitudinal follow-up in a frontotemporal
neurocognitive disorder, possible (DSM V)
M.-C. Sarpe1, M. Ladea2, M. Bran3, D. Prelipceanu3. 1Spitalul Dumbraveni,
Comuna Dumbraveni, Romania; 2Obregia Hospital of Psychiatry, III
Departement, Bucharest, Romania; 3Obregia Hospital of Psychiatry, Bucharest,
Romania
Objective: PPA (primary progressive aphasia) was initially described by
Mesulam and diagnosis can now be made in any patient who has a lan-
guage disorder (aphasia) that is due to a neurodegenerative disease (pro-
gressive) and in whom the aphasia is initially the most salient feature of
the clinical picture (primary). PPA have been the focus of several studies
during the past decades. The progression occurs in the course of years
rather than months, and the primary nature of the aphasia is demon-
strated by showing that memory for recent events, the recognition of
familiar faces and objects, reasoning, and basic aspects of comportment
are relatively preserved at the initial stages. Dementia may develop later
in the course, but the aphasia predominates. There are now described 3
variants: agrammatic/dysfluent, semantic, and logopenic. The logopenic
variant is characterized by interruptions of fluency due to frequent
word finding pauses but relatively intact syntax and word
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comprehension. Anomia is present in all variants but may become the
principal feature of the logopenic subtype. We report a 57-years old
woman suffering from problems in recalling names of objects for 2,3
years (2011). Screening measures showed mild cognitive decline in 2011,
and important now. We discuss the various diagnoses that the patient
had during 3 years, and the difficulty to find the correct one in such cases.
Methods: Clinical, neuro-imagistic aspects, lab results, as well as evol-
ution and treatment are being discussed.
Results: The final diagnosis was PPA, logopenic type – Frontotemporal
Neurocognitive disorder, Possible (DSM V).
Conclusion: In this moment there is no treatment approved for the
treatment of this disorder but there are some studies related to the effect
of mementine, so we have started this treatment and symptomatic treat-
ment (antipsychotics, anxiolytics). The prognosis is 6–11 years since the
first apparition of the symptoms.
Policy of full disclosure: None.
P-44-005 A common target in type 2 diabetes mellitus and
Alzheimer’s disease (AD)
M.-S. Song1, C. Learman1, T. Hall1, A. Clarey1, P. Wachowiak1, A. Loftus1,
M. Field1, G. Dunbar1. 1Field Neurosciences Institute, Saginaw, USA
Objective: AD is characterized by the presence of senile plaques, neurofi-
brillary tangles, and neuronal loss in defined regions of the brain. Type 2
Diabetes Mellitus (T2DM) has been shown to be highly correlated with
AD development. Pathologies common to both diabetes and AD include
vascular impairment, neurodegeneration and plaque accumulation, and
these AD symptoms may be exacerbated by T2DM. However, the precise
mechanism by which T2DM is associated with AD remains unclear. To
address this question, we induced a diabetic complication, using a phar-
macological drug, streptozotocin (STZ) to study the mechanisms of insu-
lin signaling impairments in the context of how T2DM may contribute to
AD pathologies. We further targeted insulin-related potential signaling
molecules, glucagon like peptide-1 (GLP-1) and glycogen synthase kinase
3 beta (GSK3#).
Methods: Peritoneal injection of STZ was performed to induce T2DM in
APP/PS1 mice. Blood glucose level was measured using ELISA for vali-
dation of STZ- induced diabetes, and immunohistochemistry and micro-
scopic methods were used for characterizing cerebrovascular integrity,
neurodegeneration and glia-induced inflammation.
Results: Cerebrovascular impairment was associated with plaques in
APP/PS1 mouse brains, while there were no signs of comparable damage
in WT mice. This impairment was accompanied by excessive activation of
astrocytes, a sign of inflammation. Our immunoblotting data showed that
the expression of glucose transporter (GLU-T), a marker for blood vessel
integrity, was decreased in APP/PS1 mouse brain. This measure of
reduced GLU-T levels, was associated with damaged cerebrovascular sys-
tem, was supported by GLU-T immunohistochemistry. We conclude that
these pathologies are accelerated by STZ-induced diabetes and GLP-1,
demonstrating the potential links between diabetes and AD.
Conclusion: Our data indicate that vascular damage is accompanied by
excessive activation of astrocytes, associated with accumulated plaques.
STZ-induced diabetes provides a valid animal model to study
diabetes-associated AD, and as a model for sporadic cases of AD.
Policy of full disclosure: None.
Vascular impairment in APP/PS1 mouse brain:
P-44-006 Dopamine D2/3 agonist ropinirole medication
differentially affects decision-making under risk or
uncertainty on rodent models of gambling behaviour
M. Tremblay1, J. G. Hosking2, C. A. Winstanley2. 1University of British
Columbia, Vancouver, Canada;
Objective: The more traditional drug treatment for Parkinson’s Disease
(PD), L-DOPA, has shown over time to produce debilitating side-effects
such as dyskinesia. Selective dopamine agonists that act on the D2/3
receptors such as pramipexole and ropinirole have been used to treat
the motor symptoms of PD, but these drugs may lead to a variety of
Impulse Control Disorders (ICDs) including pathological gambling in
some patients. Few studies have looked at the effect of ropinirole on im-
pulsive or risky behaviours.
Methods: Rats learned either the rat gambling task (rGT)- a rodent ana-
logue of the Iowa Gambling Task used clinically to assess decision-
making under risk, where rats chose between four options, each asso-
ciated with differing probabilities of reward and punishment, or the
Betting task- a paradigm which captures irrational decision-making
under uncertainty in which rats choose between a guaranteed reward ver-
sus a 50:50 chance of double that reward or nothing. The behaviour of 24
rats on each task was assessed before and following implantation of an os-
motic mini-pump delivering either ropinirole at 5mg/kg/day or a saline
solution for 28 days.
Results: Chronic ropinirole increased premature responses on the rGT,
but did not affect choice of the risky option. In the Betting task, chronic
administration of ropinirole led to an increase in choice of the uncertain
lever regardless of the baseline preference characteristic of each rat.
Conclusion: This bias towards uncertainty produced by chronic ropi-
nirole medication may explain why some PD patients treated with selec-
tive dopamine medication develop gambling and other risky and
maladaptive behaviours. We intend to follow up these findings by deter-
mining the impact of chronic ropinirole in a dorsostriatal 6-hydroxydopa-
mine (6-OHDA) lesion model of PD. These studies will help characterise
the specific type of impairments experienced by PD patients taking dopa-
mine agonist therapy and provide knowledge of the neurological mechan-
ism underlying them.
Policy of full disclosure: None.
P-45. Biomarkers (incl. Pharmacogenomics and
brain imaging) for diagnosis and treatment
response C
P-45-001 Haplotype analysis of genetic polymorphism in antisocial
alcoholism
R. Kongsakon1, B. Lertaumnuachoke2. 1Faculty of Medicine, Bangkok,
Thailand; 2Faculty of Medicine, Ramatibodi Hospital, Bangkok, Thailand
Objective: To evaluate the promoter region, exon 8 and exon 14 of
MAO-A gene in antisocial alcoholism subjects (cases).
Methods: The normal control and cases were Thai males with more
than 18 years old. The normal control subjects were screened using Al-
cohol Use Disorder Identification Test (AUDIT) (<8) and Tridimensional
Personality Questionaire (TCI) and 77 subjects passed the criteria. For
the cases, they were screened using Alcohol Use Disorder Identification
Test (AUDIT) (>8), Mini-International Neuropsychiatric Interview (M.I.
N.I) (type 1 and 2) and Tridimensional Personality Questionaire (TCI).
There were 2 groups of the cases; type 1, the alcoholics who started to
drink alcohol #25 years of age and had no antisocial behavior (n=125).
Type 2 was the alcoholics who started to drink alcohol <25 years of age
and had antisocial behavior (n=126).
Results: For MAO-A promoter study, genomic DNA was amplified in
vitro, 3 alleles of 30-bp repeat polymorphism were detected for 3, 4 and
5 repeated polymorphisms. Three repeated polymorphisms of MAO-A
promoter in normal control, type 1 and type 2 cases were 54.5, 53.6 and
51.6%, respectively. Four repeated polymorphisms of MAO-A promoter
in normal control, type 1 and type 2 cases were 45.5, 45.6 and 48.8%, re-
spectively. Five repeated polymorphisms of MAO-A promoter was
detected only in type 1 cases (0.8%). However these results were non-
significant different between controls and cases both type 1 and 2 by
using X2-test. For exons 8 and 14 of MAO-A gene study using PCR and
cutting amplicon of exons 8 and 14 with Fnu4HI and EcoRV, respectively.
Conclusion: The results showed that DNA polymorphism of exons
8 and 14 in control and cases both types 1 and 2were non-significant differ-
ent by using X2-test. Haplotype distribution of these 3markers was studied
and results were non-significant different between controls and cases.
Policy of full disclosure: None.
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P-45-002 Clinical predictors of drug response in patients with
obsessive-compulsive disorder
M.-S. Koo1, C. H. Kim2. 1Kwandong University, Gwangmyung, Republic of
Korea; 2Yonsei University, Seoul, Republic of Korea
Objective: The aim of this study was to evaluate which clinical variables
might influence the antiobsessional response to proserotonergic drugs in a
sample of patients with obsessive-compulsive disorder (OCD).
Methods: Two hundred forthy-nine patients with DSM-IV OCD
underwent mean 13-month treatment with selective serotonin reuptake
inhibitors. According to treatment response, defined as a reduction of
the Yale-Brown Obsessive Compulsive Scale total score >35% and CGI 1
or 2, patients were divided into two groups.
Results: One hundred fourteen patients responded to treatment and
one hundred thirty five patients did not. Responders had a significant
high long duration of treatment, short duration of pre-treatment medi-
cation and higher frequency of drug naïve cases and lower baseline
Y-BOCS scores.
Conclusion: The pre-treatment factors including pre-treatment period,
drug naïve or not and baseline OCD symptoms and the factor of duration
of treatment may influence drug treatment response in OCD patients.
Policy of full disclosure: None.
P-45-003 Plasma clomipramine levels in obsessive-compulsive
disorder
D. Marazziti1, S. Baroni1, L. Dell´Osso1. 1Università di Pisa, Pisa, Italy
Objective: The aim of this study was to explore the possible relationship
between plasma clomipramine (CMI) and its major metabolite
N-desmethylclomipramine (DMCMI) levels and related parameters, and
clinical features in OCD patients.
Methods: Twenty-six OCD outpatients (13 men, 13 women), suffering
from OCD were consecutively enrolled in the study. The severity of
OCD was assessed by the Yale-Brown Obsessive Compulsive Scale
(Y-BOCS). The measurements were carried out after four weeks and six
months from the beginning of the treatment. The drug levels were mea-
sured by a HPLC method developed by us. The correlations between
biological and clinical parameters were analyzed by means of the
Spearman#s correlation coefficient. The Mann-Whitney test was used for
comparing biological and clinical variables between men and women.
Results: The results showed that CMI levels were related to the doses at
the two assessment times. A significant and positive correlation was
detected at the beginning between the DMCMI ratio and the Y-BOCS
total score, however this was true only for men, where the similar correla-
tions were measured also with the Y-BOCS subscale. After six months of
CMI, men showed a significant improvement of the compulsions.
Conclusion: These findings would highlight the potential impact of
assessing CMI plasma levels and their relationships with specific symp-
toms, as well as the influence of the gender on the drug response.
Policy of full disclosure: None.
P-45-004 Abelson helper integration site-1 gene variants on major
depressive disorder and bipolar disorder
C.-U. Pae1, S. Ahn1, A. Serretti2, S. Porcelli1, C. Han3. 1Bucheon St. Mary´s
Hospital, Bucheon, Republic of Korea; 2Bologna, Italy; 3Ansan, Republic of Korea
Objective: The present study aimed to explore whether 4 single nucleo-
tide polymorphisms (SNPs) within the AHI1 gene could be associated
with major depressive disorder (MD) and bipolar disorder (BD), and
whether they could predict clinical outcomes in mood disorders.
Methods: One hundred and eighty-four (184) patients with MD, 170
patients with BD and 170 healthy controls were genotyped for 4 AHI1
SNPs (rs11154801, rs7750586, rs9647635 and rs9321501). Baseline and
final clinical measures for MD patients were assessed through the
Hamilton Rating Scale for Depression (HAM-D). Allelic and genotypic
frequencies in MD and BD subjects were compared with those of each dis-
order and healthy group using the #2 statistics. Repeated measures
ANOVA were used to test possible influences of SNPs on treatment
efficacy.
Results: The rs9647635 A/A was more represented in subjects with BD
as compared with MD and healthy subjects together. The rs9647635 A/A
was also more presented in patients with MD than in healthy subjects.
With regard to the allelic analysis, rs9647635 A allele was more repre-
sented in subjects with BD compared with healthy subjects, while it was
not observed between patients with MD and healthy subjects.
Conclusion: Our findings provide potential evidence of an association
between some variants of AHI1 and mood disorders susceptibility but
not with clinical outcomes. However, we will need to do more adequately-
powered and advanced association studies to draw any conclusion due to
clear limitations.
Policy of full disclosure: This study was supported by a grant from the
Korean Health Technology R&D Project, Ministry of Health & Welfare,
Republic of Korea (A120004).
P-45-005 Reduction in serum brain derived neurotrophic factor
concentration with subcallosal deep brain stimulation
treatment for refractory depression
R. Ramasubbu1, H. Vecchiarelli1, M. Hill1, Z. Kiss1. 1University of Calgary,
Calgary, Canada
Objective: Subcallosal cingulate (SCC) deep brain stimulation (DBS) is a
promising experimental treatment for treatment resistant depression
(TRD). Given the role of brain derived neurotrophic factor (BDNF) in
neuroplasticity and antidepressant efficacy, we examined the effect of
SCC-DBS on serum BDNF in TRD.
Methods: Four patients with TRD underwent SCC-DBS treatment.
Following a double-blind stimulus optimization phase of 3 months,
patients received optimal continuous stimulation in an open label fashion
for 6 months. Clinical improvement in depressive symptoms was evalu-
ated bi-weekly for 6 months using Hamilton Depression Rating Scale
(HDRS). Mature serum BDNF levels were measured 1 week before and
9 months post-DBS.
Results: Out of four patients, three responded to SCC-DBS with two
showing full clinical response (50% reduction in HDRS scores) and one
showing partial response (35% reduction in HDRS scores) at the clinical
endpoint. Interestingly, all 4 patients showed reduction in serum BDNF
concentration from pre-DBS baseline.
Conclusion: SCC-DBS for TRD may be associated with decreased levels
of serum BDNF. Longitudinal studies with multiple measurements in a
larger sample are required to determine the role of BDNF as a biomarker
of SCC-DBS and its antidepressant efficacy.
Policy of full disclosure: Supported by Hotchkiss Brain Institute (HBI),
Calgary, Calgary Health Region, & Alberta Innovates and Health
Solutions (AIHS).
P-45-006 Elevated serum amyloid a in depressive patients and its
potential use as a clinical biomarker
A. Sauro1, E. Achtyes2, L. Smart3, S. Halstead3, L. Brundin4. 1Michigan
State University, Grand Rapids, USA; 2Michigan State University, Pine Rest
Mental Health, Grand Rapids, USA; 3Pine Rest Mental Health, Grand
Rapids, USA; 4Michigan State University, Van Andel Institute, Grand
Rapids, USA
Objective: The biology of depression is becoming more understood, how-
ever, the need for reliable biomarkers remains evident. Studies have
shown marked elevations in the cerebral spinal fluid (CSF) and plasma
of inflammatory cytokine levels of depressed and suicidal patients.
Serum Amyloid A (SAA) proteins are regulated in liver cells by the
pro-inflammatory cytokines IL‐1, IL-6, and TNF‐α. These acute-phase
SAAs (A-SAAs) are implicated in several chronic inflammatory diseases,
and have also been shown to be elevated following administration of bac-
terial lipopolysaccharide (LPS) in mice. In this study, we show significant
correlations with depressive symptoms and SAA levels in human plasma.
These findings could implicate SAA as a potential biomarker for de-
pression in the clinical setting.
Methods: 89 male and female patients, ages 18–67 with varying psychi-
atric histories were enrolled in this study. Plasma samples were analyzed
utilizing the electrochemiluminescent technology of Mesoscale Discovery.
Growth Factor 4-plex, Vascular Injury II 4-plex, Pro-inflammatory 9-plex,
and Chemokine 9-plex assays were run on the SI6000 machine. Depressive
symptoms and suicidality were evaluated using the Patient Health
Questionnaire 9 (PHQ9), The Center for Epidemiological Studies
Depression Scale (CES-D), Hamilton Depression Rating Scale (HAM-D),
and SCID-1.
Results: Significant correlations between lnSAA and depressive symp-
toms were found. Crying spells, loss of appetite, feeling tired or having
little energy, were among the positive correlations with peripheral SAA.
Raw sampling also showed a positive correlation with suicidal intent
and SAA levels. Furthermore, SAA levels correlate with IL-6 in these
patients.
Conclusion: This study shows direct evidence of increased SAA levels
in patients with depressive symptoms. Utilizing this protein for monitor-
ing peripheral inflammation could prove advantageous in developing a
panel of biomarkers for depression.
Policy of full disclosure: None.
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P-45-007 QEEG biomarkers of sustained response to rapid
antidepressant effect of NMDA antagonist in major
depressive disorder
P. Sos1, M. Klirova1, T. Novak1, M. Brunovsky1, J. Horacek1, M. Bares1,
C. Hoschl1. 1Prague Psychiatric Centre, Prague, Czech Republic
Objective: A series of clinical studies demonstrated that QEEG (quantitat-
ive electroencephalography) prefrontal theta cordance value decreases
after one week of treatment in responders to antidepressants and precedes
clinical improvement. Ketamine, a non-competitive antagonist of NMDA
receptors, has a unique rapid antidepressant effect but its influence on
QEEG measures is still unknown. To date wasn’t studied predictive
value of cordance in response to single infusion of ketamine in depressive
subjects.
Methods: In a double-blind, cross-over, randomized, placebo-
controlled experiment we studied the influence of ketamine (0.54 mg/kg)
on theta cordance in a group of 27 right-handed hospitalized depressive
patients on stable antidepressant medication. QEEG cordance values in
theta frequency band were calculated according to UCLA algorithm.
Results: Responders (n=11) to ketamine in compare to non-responders
(n=16) showed significant difference in cordance values at the end of keta-
mine infusion (Spearman, p=0.039). The cordance decrease, measured be-
tween the end of infusion and next day, positively correlated with
ketamine antidepressant response (MADRS decrease) fourth day after in-
fusion (two-tailed Fisher’s Exact test, df=1, p=0.0076) with NPV 90.9%
(95% CI 64.3%–99.5%) and PPV 62.5% (95% CI 44.2%–68.4%).
Conclusion: Our data indicate that ketamine infusion immediately
induces similar changes as monoaminergic-based antidepressants do
gradually after a series of downstream signalling steps. The reduction in
theta prefrontal cordance could serve as a biomarker of sustained antide-
pressant response, a hypothesis that should be tested in larger depressive
population.
Policy of full disclosure: This study was supported by IGA MH CR:
NT13403-4, NT12024-5; PRVOUK P34 and RVO-PCP/2012. The study
was registered with EU Clinical Trials Register [EudraCT number
2009-010625-39].
P-45-008 Association of BDNF promoter methylation and genotype
with suicidal ideation in elderly Koreans
J.-S. Yoon1, J.-M. Kim2, H.-J. Kang Kang2, K.-Y. Bae2, S.-W. Kim2,
I.-S. Shin2, H.-R. Kim3, M.-G. Shin4. 1Chonnam National University,
Gwangju, Republic of Korea; 2Department of Psychiatry, Chonnam National
University, Medical School, Gwangju, Republic of Korea; 3Brain Korea 21
Project, Center for Biomedical Human Research, Chonnam National
University, Medical School, Gwangju, Republic of Korea; 4Department of
Laboratory Medicine, Chonnam National University, Medical School,
Gwangju, Republic of Korea
Objective: Brain-derived neurotrophic factor (BDNF) has been considered
a risk factor for suicidal behavior in adult populations. BDNF secretion is
influenced by epigenetic (DNA promoter methylation) and genetic (val66-
met polymorphism) profiles. We investigated the independent and inter-
active effects of BDNF methylation status and val66met polymorphisms
on late-life suicidal ideation.
Methods: In total, 732 Korean community residents aged 65+ were eval-
uated; of 639 without suicidal ideation, 579 (90.6%) were followed up
2 years later. The prevalence and incidence of suicidal ideation were ascer-
tained using the Geriatric Mental State Schedule. Socio-demographic and
clinical covariates included age, gender, education, depressive symptoms,
cognitive function, and disability. The independent effects of BDNF
methylation status on the prevalence and incidence of suicidal ideation
were investigated using multivariate logistic regression models. The two-
way interactions of BDNF methylation status and val66met polymorph-
ism on suicidal ideation were assessed using the same models.
Results: Higher BDNF methylation status was significantly associated
with both prevalence and incidence of suicidal ideation, independent of
potential covariates. No significant methylation-genotype interaction
was found.
Conclusion: The BDNF hypothesis and the epigenetic origin of the sui-
cidal behavior were supported, even in old age. BDNF promoter methyla-
tion status may be useful as a biological marker for suicidality in late life.
Policy of full disclosure: This study was supported by a grant of the
Korean Health Technology R&D Project, Ministry of Health & Welfare,
Republic of Korea (A120051). The Ministry of Health and Welfare of
Korea had paper publication design; in the collection, analysis and in-
terpretation of data; in the writing of the report; or in the decision to sub-
mit the paper for publication.
Figure1:
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P-46-001 Nicotine’s effects on cognitive effort are dependent upon
individual differences: Acetylcholine manipulation on a
rodent cost/benefit decision-making task
J. Hosking1, F. Lam1, C. Winstanley1. 1University of British Columbia,
Vancouver, Canada
Objective: All individuals are confronted with choices that require weigh-
ing potential benefits against their associated costs. Animal models of
such cost/benefit decision-making have typically focused on dopaminer-
gic contributions to choice. Acetylcholine is heavily interconnected with
the dopaminergic system, and has also been demonstrated to be essential
element in many cognitive processes. Despite this, its contribution to cost/
benefit decision making remains poorly understood, especially within the
realm of effort.
Methods: Here we utilize a rat Cognitive Effort Task (rCET) to probe
acetylcholine’s contribution to effortful decision making. In the rCET, ani-
mals can choose either an easy trial, where the visuospatial attentional de-
mand is low but the potential reward (sugar) is small, or a difficult trial on
which both the attentional demand and available reward are greater.
Following the establishment of baseline behaviour, four drug challenges
were administered via intraperitoneal injection: nicotine, mecamylamine,
oxotremorine, and scopolamine.
Results: As per previous studies, animals were divided by their base-
line preferences, with “workers” choosing high-effort/high-reward
options significantly more than “slackers”. Nicotine dose-dependently
caused slackers to choose even fewer high-effort trials than at baseline,
but had no effect on the choice of workers, which was near ceiling.
Despite these opposing effects on choice, nicotine greatly increased
motor impulsivity for all animals. Interestingly, nicotine did not affect ani-
mals’ ability to perform the task, i.e. did not benefit or impair their visuo-
spatial attention.
Conclusion: Nicotine appears to exacerbate existing choice preferences
for mental effort expenditure. Acetylcholine’s contribution to decision
making may therefore be best understood as a function of the individual
differences in sensitivity to effort costs. As such, this research suggests
novel therapeutic strategies based on individuals’ underlying preferences.
Policy of full disclosure: None.
P-46-002 The effect of chronic atomoxetine treatment during
adolescence on decision making and impulsive action
in adulthood
M. Silveira1, C. Winstanley2. 1UBC, Vancouver, Canada; 2Vancouver, Canada
Objective: Atomoxetine, the first nonstimulant drug approved for the
treatment of attention deficit hyperactivity disorder (ADHD), is a selective
norepinephrine reuptake inhibitor (SNRI) that is efficacious in reducing
the hyperactive, inattentive, and impulsive symptoms that characterize
the disorder. Treatment for ADHD is administered chronically during
adolescence, a time when the frontal brain regions necessary for executive
function and impulse control are undergoing extensive maturation.
Having previously shown that chronic atomoxetine treatment during ado-
lescence decreases impulsive choice in adulthood, we set out to investigate
its putative long-term effects on more complex decision-making processes
using the rodent gambling task (rGT).
Methods: 24 Long-Evan rats were administered saline or 1.0 mg/kg ato-
moxetine daily from postnatal day 40–54, a time period reflecting rodent
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adolescence. Two weeks following treatment, all animals were trained and
assessed in the rGT. In this task, rats must choose between four response
options that are each associated with the delivery of a different amount of
reward, as well as different probabilities of receiving said reward. The rGT
is also a sensitive measure of impulsive action, whereby premature
responses made prior to stimulus onset are recorded.
Results: Regardless of the treatment administered during adolescence,
rats learned to favour the advantageous options characterized by small,
low penalty rewards in lieu of the larger, higher penalty reward options.
rGT performance was then assessed following acute treatment with ato-
moxetine (0.1–1.0 mg/kg) or amphetamine (0.3–1.5 mg/kg). Across groups,
the highest dose of atomoxetine decreased choice of the most advan-
tageous choice option, and decreased premature responding at all doses
tested. Amphetamine also impaired choice performance, but increased
premature responding across groups.
Conclusion: These data suggest that chronic atomoxetine treatment
during adolescence does not affect complex decision-making in adult-
hood, but that acute treatment with atomoxetine, while reducing impul-
sive action, can impair optimal decision-making.
Policy of full disclosure: None.
P-46-003 The efficacy of atomoxetine in treating adult ADHD: A
meta-analysis of placebo-controlled trials
S. Vedalaveni Chowdappa1, V. Ravishankar1, K. Muralidharan1,
V. Benegal1. 1NIMHANS Bangalore, Bangalore, India
Objective: To study the efficacy of atomoxetine in the treatment of adult
attention deficit hyperactivity disorder [ADHD] compared to placebo.
Methods: We performed a Medline, search for English language publi-
cations of Randomized Controlled Trials (RCTs) comparing atomoxetine
to placebo for adult ADHD using the keywords ‘adult ADHD’, ‘atomox-
etine’ and ‘placebo’. A total of 45 RCTs were returned of which we in-
cluded eleven relevant RCTs reporting data on 2692 patients with adult
ADHD in the analysis. Standardized mean difference between atomoxeti-
neand placebo for the mean baseline-to-endpoint change in total ADHD
scores, impulsivity/hyperactivity and inattention scores was calculated,
with a 95% confidence limit.
Results: Atomoxetine had superior efficacy than placebo in treating
adult ADHD [−0.40; 95% CI −0.48, −0.32; overall effect p<0.00001].
Atomoxetine was superior to placebo on both the domains of inattention
[−0.39; 95% CI −0.47, −0.31; overalleffect p<0.00001] and impulsivity/
hyperactivity [−0.34; 95% CI −0.42, −0.26; overall effect p<0.00001].
Conclusion: Atomoxetine is efficacious in treating adult ADHD com-
pared to placebo, though the efficacy is marginally superior for inattention
than hyperactivity/impulsivity.
Policy of full disclosure: None.
P-47. Gender and mental health
P-47-001 First onset postpartum psychosis and first line treatment:
Series of five case studies remitted with olanzapine
M. Curkovic1, A. Bacekovic1, A. Silic1, D. Ostojic1, V. Jukic1. 1Psychiatric
Clinic Vrapce, Zagreb, Croatia
Objective: Postpartum psychosis [PPP] is rare disorder with an estimated
prevalence in the general population of 1–2 per 1,000 childbirths. PPP is
a psychiatric emergency that requires inpatient psychiatric treatment be-
cause it can have negative consequences for the mother, infant, and entire
family.
Methods: We present five patients diagnosed with first onset PPP
treated with olanzapine during the last year (2013th) in our Intensive
care unit. All of our patients experienced clear phenomenological pre-
dominance of psychotic symptoms with no evidence of neither manic
nor depressive symptoms.
Results: Median age of our patients was 31 years (range 27–40; inter-
quartile range [IQR] 10), all of them were primiparous, and experienced
some of the obstetrical complications during delivery. None of our patient
had previous history of psychiatric illnesses, and only one had positive
family history. The median onset of psychotic symptoms that led to hos-
pitalization occurred at 12 days postpartum (range 8–25; IQR 10, 5).
Median duration of hospitalization was 11 days (range 6–38, IQR 20.5).
One patient was discharged prior to achieving full remission because of
the infectious complications, although she showed clear response to treat-
ment prior to demission. We treated all patients with olanzapine, and
we used bromocriptine for every patient to achieve ablactation.
Supplementary therapy was used according to symptomatology and the
progress of treatment, namely low doses of typical antipsychotics (n=3),
and benzodiazepines (n=4). Two of our patients had a typical antipsycho-
tic still included in discharge therapy, and three of them had
benzodiazepines.
Conclusion: According to out database search there are no clear guide-
lines regarding the treatment of first onset PPP in the patients with no
prior history of psychiatric illnesses. According to our data, olanzapine
proved itself as a valuable first line treatment. At this point there is a
definite need for further investigations of preferably prospective design
for the full understanding and possibly developing clear guidelines
for PPP.
Policy of full disclosure: None.
P-47-002 The effect of depression on long-term risk incidence
of cardiovascular diseases in female population aged
25–64 in Russia: Based on monica-psychosocial
epidemiological study
V. Gafarov1, D. Panov1, E. Gromova1, I. Gagulin1, A. Gafarova1. 1FBI Inst.
Internal Med.SB RAMS, Novosibirsk, Russia
Objective: To explore the influence of depression (D) on relative risk
of myocardial infarction (MI), arterial hypertension (AH) and stroke in fe-
male population of 25–64 years in Russia.
Methods: Under the third screening of the WHO “MONICA-
psychosocial” (MOPSY) program random representative sample of
women aged 25–64 years (n=870) were surveyed in Novosibirsk. D was
measured at the baseline examination by means of test MOPSY. From
1995 to 2010 women were followed for 16 years for the incidence of
AH, MI and stroke. Cox proportional regression model was used for as-
sessment of relative risk (HR) of cardiovascular diseases.
Results: The prevalence of D in women aged 25–64 years was 55.2%.
Over 16 years of study MI was developed in 2.2% of women, stoke - in
5.1%. 16-years risk of MI development in women having D was
2.53-fold (95% CI:1.26–24.34; p<0.05), HR of stroke was 4.63-fold (95%
CI:1.03–20.89; p<0.05) higher compared to those without D. HR of AH
in women with D over the first 5 and 10 years of study was 1.6-fold
(95.0%CI:0.86–2.98; p<0.05) and 1.74-fold higher (95.0%CI:1.01–3.01;
p<0.05) compared to those without D, respectively. MI, AH and stroke
rates were more likely in married women having D with average
educational level. Rates of AH was higher in first-line managers
(chi-square=4.38 df=1 p<0.05) and easy manual laborers with D
(chi-square=4.61 df=1 p<0.05). Similar tendencies in occupational class
were typical for MI and stroke.
Conclusion: The prevalence of D in women aged 25–64 years is more
than 50%. Over 16 years women with D have significantly higher risk
of AH, MI and stroke than without D, especially in married women
whose job positions were manager and physical worker.
Policy of full disclosure: None.
P-47-003 Maternal mental health: A prospective naturalistic study
of the outcome of pregnancy in women with major
psychiatric disorders in an African country - Update on
fetal outcome
D. Niehaus1, E. du Toit1, L. Koen1, E. Thomas1, G. Harvey1, J. Leppanen2.
1University of Stellenbosch, Tygerberg, South Africa; 2University of Tampere,
Tampere, Finland
Objective: There is a general consensus that mothers suffering from pre-
existing mental illness are at an increased risk for pre-and post partum
complications. The extent of the risk to the fetus has not been studied
fully in Sub-Saharan Africa. A collaborative network of state and private
practice clinics in Cape Town, South Africa monitor mothers suffering
from mental illness. The aim is to address the paucity of data on the out-
come of pregnancy in women with major psychiatric disorders in
Sub-Saharan Africa.
Methods: This update reports on the first 75 pregnant female mental
health users managed at the maternal mental health clinic at Stikland
Hospital (one of the network of clinics) in this prospective study design.
Data are collected as part of patient reviews during care-as-usual visits
and for the purposes of this report we focus on fetal outcome (i.e.
mortality).
Results: The 1st 75 participants (mean age 29 years) presented on aver-
age at 16 weeks pregnancy duration, with 20 of the cases being primigra-
vida. The most common primary psychiatric diagnoses were major
depressive disorder (n=25), bipolar mood disorder (n=21) and schizo-
phrenia spectrum disorders (n=11). Pregnancy outcome data are available
on 59 pregnancies (16 pregnancies ongoing at time of this report) at time
of this report and shows 8 unsuccessful pregnancies including two volun-
tary abortions (8 and 10 weeks), four miscarriages (8, 21, 22 and 25 weeks),
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one stillborn baby (>28 weeks), one death at day 5 post partum. Poor ad-
herence to post partum follow-up was a common occurrence.
Conclusion: This update on fetal outcome in mental health users show
a number of complicated pregnancies and this is compounded by irregu-
lar contact with psychiatric services. Effort should be made to improve
adherence to regularly scheduled follow-up as the risk for a complicated
pregnancy outcome is significant.
Policy of full disclosure: National Research Foundation of South
Africa, Faculty of Health Sciences, University of Stellenbosch
P-48. History of neuropsychopharmacology
P-48-001 LSD treatment in Danish psychiatry, especially
emphasizing the neurotoxic potentials of LSD. A
follow-up study of 151 patients
J. K. Larsen1, B. B. Bendsen2. 1University Hospital of Aarhus, Risskov
Psychiatric Hospital, Brønshøj, Denmark; 2University Hospital of CPH,
Psychiatric Centre FRB, Frederiksberg, Denmark
Objective: The purpose of the present study was to evaluate the long-term
outcome of LSD-treatment in a population of Danish psychiatric patients.
We aimed at estimating possible beneficial and damaging effects of the
LSD-treatment. Finally the aim was to find evidence for the neurotoxic
potentials of LSD.
Methods: From 1959 around 400 patients were treated with LSD in
Denmark, the majority in the early and mid-1960’ies. In 1986 the LSD
Damages Law was passed, and thereby patients treated with LSD could
apply for compensation. Each application was dealt with in a tribunal
under the Ministry of Social Affairs. The total material including hospital
case records, applications, medical and psychiatric certificates and evalu-
ation sheets of the tribunal was later on referred to the Danish State
Archives. This material including 151 of the 154 applicants has been care-
fully studied.
Results: Already during the first years of treatment one homicide, two
suicides and four attempted suicides were reported. However, a review
published in 1964 of the first 129 patients within a broad spectrum of
diagnoses found 45 % unchanged and 55 % improved. In total all 154
applicants being treated with LSD received economic compensation for
LSD inflicted damages. In 151 applicants 5 % later on went through
psychosurgery, 14 % developed a psychotic/schizophrenic breakthrough,
14 % developed recurrent or chronic depression, 69 % suffered from per-
sistent flashback experiences and around 66 % reported increased chronic
anxiety.
Conclusion: In the 1960’ies international warnings of the medical use
of LSD were ignored. Even if the 154 applicants of this study are not rep-
resentative of the total LSD material, the high incidence of serious
damages in this subset is worrying. There is no conflict between the
acute stimulating effect seen in a few patients and lasting serious damages
observed in this sample. LSD is considered to possess neurotoxic
potentials.
Policy of full disclosure: None.
P-49. Pharmacoeconomics
P-49-001 The importance of tardive dyskinesias in schizophrenia
based on 21 cases. Tests run in psychiatry department of
the military hospital of Marrakesh – Morocco
A. Benali1, F. Oueriagli Nabih1, W. Hikmat2. 1Service de Psychiatrie,
Marrakech, Morocco; 2Service de Psychiatrie, Hôpital Ibn Naffis, Marrakech,
Morocco
Objective: We are going to analyze the occurrence processes according to
incriminated therapeutic generation. We will also discuss the epidemio-
logical and clinical features of tardive dyskinesia before focusing on
therapeutical paharmaco-logics (and not pharmacologic) perspectives.
Methods: Through a retrospective study based on observations about
21 schizophrenic male patients suffering from a tardive dyskinesia of an
iatrogenic origin, at the psychiatric department of the military hospital
of Marrakesh between 2010 and 2012.
Results: In practice, tardive dyskinesias set up after many years of ex-
posure to high antipsychotic dosages. However, they can occur – rarely
indeed – rapidly and at low dosages (Correl CU et al, 2004). The late dys-
kinesias show resistance toward therapeutics causing social stigmatization
by their « rabbit syndrome » aspect. They substantially decrease the qual-
ity of life and increase mortality and morbidity (Tarsy D et al, 2006). The
extra pyramidal symptoms make the psychological suffering worse at the
psychotic and depressive levels. The patients suffering from dyskinesia
show more positive and negative psychotics symptoms compared to con-
trol schizophrenic patients. The tardive dyskinesias are associated to un-
successful therapeutical prognosis in schizophrenia (Spivak B et al, 1997).
Conclusion: Dyskinesias induced by neuroleptics are a common side
effect, regardless of the generation therapeutic complained, combining
both classical neuroleptics that atypical antipsychotics. Prevention is the
best prescription adequately carefully weighing the risk-benefit ratio, es-
pecially concerning the prescription of “hidden neuroleptics.”
Policy of full disclosure: None.
P-49-002 Hyperprolactinemia and antipsychotic treatments:
Screening and treatment strategy, based on 25 cases.
Experiences run by the psychiatry department of the
military hospital of Marrakesh-Morocco
A. Benali1, F. Oueriagli Nabih1, W. Hikmat2. 1Service de Psychiatrie,
Marrakech, Morocco; 2Service de Psychiatrie, Hôpital Ibn Naffis, Marrakech,
Morocco
Objective: The study aims to analyze the discoveries circumstances, the
clinical and biological features of hyperprolactinemia induced by those
psychotropic drugs in addition to their evolving particularities, in order
to set up recommendations about the neuroleptics prescription and the
patients follow up procedures.
Methods: It is a retrospective study based on 25 cases of male patients
suffering from hyperprolactinemia treated at the psychiatry department of
the military hospital in Marrakesh, between 2005 and 2012, and who were
put under antipsychotics.
Results: Clinical signs of sexual circumstance was the most
common finding (Haddad PM et al, 2004). The average value of the
PRL was 62±24 ng / mL. Pharmacological classes were encountered ris-
peridone alone (07 cases), Olanzapine alone (03 cases), Haloperidol
alone (07 cases), Olanzapine levomepromazine+ (05 cases) and 03 cases
of patients under neuroleptic treatment delay based Fluphenazine.
Magnetic Resonance Imaging hypothalamic pituitairy was requested for
all patients and no hypothalamic-pituitary abnormalities were detected.
A combination with other therapeutics was revealed in 06 cases (antihy-
pertensives and antihistamines). Dosages of psychotropic treatments
were reduced in 18 cases, the change to other antipsychotic less hyperpro-
lactinemia was observed in 07 cases. The normalization of the PRL was
obtained on average in three months. No dopamine agonist therapy
was prescribed in these cases. Treatment with injectable testosterone
was required in two cases where a biological hypogonadism was
confirmed.
Conclusion: The HPRL induced by antipsychotics is undervalued de-
spite its frequency and yet not without clinical consequences. In addition
to sexual disorders often factors of poor adherence to treatment, there is a
potential long-term somatic development-related bone abnormalities and
a possible increased risk of breast cancer or prostate cancer. For all these
reasons, hyperprolactinemia must be careful research, through a pretreat-
ment assessment and monitoring of patients, integrating in the analysis of
risk / benefit ratio of antipsychotic treatment.
Policy of full disclosure: None.
P-49-003 Atypical Antipsychotic (AAP) use & cost trends in Indiana
medicaid (MA) children & teens (2004–2012)
A. Goddard1, K. Schwartz1, K. Hendrix1, E. Hancock2, L. David2,
S. Downs1, R. Marc1. 1Indiana University, Indianapolis, USA; 2Indiana
Medicaid Office, Indianapolis, USA
Objective: The US Agency for Healthcare Research and Quality (AHRQ)
and Rutgers U formed a 16-state consortium (including IN) to study the
rapid escalation of antipsychotic (AP) use in MA youth. On average
1.6% (2007 data) were exposed to at least 1 AP (range 0.6–4%). Another
key finding was the high rate (12%) of AP exposure in MA foster children.
The goal of the present study was to replicate and extend the AHRQ/
Rutgers study to include IN claims data from 2004 through 2012.
Extension features included a primary focus on AAPs (vs all APs), ana-
lysis of both FFS and non-FFS groups, evaluation of cost trends, and the
effect of recent IN MA program changes on AAP utilization and cost.
Methods: IN children (<19 years old) who had MA coverage for at least
one month during any calendar year of the study period (January 2004 –
June 2012) were eligible for inclusion (1.4 million unique cases). An
exhaustive list of AAPs was used to search this data base. To evaluate
the impact of several IN MA program changes on AAP utilization &
cost, we examined 75 monthly time points over three time periods: before,
during, and after key program changes.
Results: AAP utilization rates varied between 2–3%. We also observed
high rates of AAP prescribing in MA Fosters (10–15%). MA program
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changes occurring after 2007 were associated with plateauing AAP utiliz-
ation from 2008–2012. There was a significant difference in utilization be-
tween pre-intervention and during-intervention (ANOVA p<0.0001), and
between pre-intervention and post-intervention time periods (p<0.0001).
Conclusion: Our in-state AAP utilization trends were generally consist-
ent with the earlier findings of the AHRQ-Rutgers consortium document-
ing rapid growth in AAP use and cost in MA youth. A series of
containment strategies appeared effective in addressing these trends.
Policy of full disclosure: Professor Goddard: NAUREX clinical trial,
site PI
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P-50-001 Differential effects of clozapine exposure compared to
standard second-generation antipsychotics on
hippocampal volumes in chronic schizophrenia
D. Lang1, D. Warburton2, B. Humphries3, W. Su4, O. Leonova5, R. White5,
A. Thornton6, W. Honer7. 1University of British Columbia, Vancouver,
Canada; 2University of British Columbia, School of Kinesiology, Unit II
Osborne Centre UBC, Vancouver, Canada; 3University of British Columbia,
Department of Radiology, CFRI - BCMHARI BCCH Site, Vancouver, Canada;
4University of British Columbia, Department of Psychiatry, CFRI -
BCMHARI BCCH Site, Vancouver, Canada; 5University of British Columbia,
Department of Psychiatry, BC Psychosis Program, Vancouver, Canada;
6Simon Fraser University, Department of Psychology, CFRI Bldg BCMHARI,
BCCH Site, Vancouver, Canada; 7University of British Columbia, Department
of Psychiatry, Vancouver, Canada
Objective: Hippocampal volume deficits are one of a number of highly
replicated observations in persons with schizophrenia. These volumetric
deficits have been associated with memory impairment, negative symp-
tom severity and deficits in executive functioning. The efficacy of current
atypical antipsychotics in addressing functional deficits of the hippocampi
is unestablished. Individual atypical antipsychotics on may exert differen-
tial effects on hippocampal volumes, particularly clozapine versus other
standard second-generation antipsychotics. In a group of chronically trea-
ted patients, we investigated potential differential effects of clozapine ver-
sus standard atypical medications.
Methods:We examined total hippocampal volumes (L+R) using high-fi
eld imaging in a cohort of 23 refractory schizophrenia and schizoaffective
disorder patients, 13 who had received mainly clozapine treatment (mean
dose 304.8 mg/d) and 10 who had received either 1 or more of aripripazole
(mean dose 15mg/), olanzapine (mean dose 12.5 mg/d), risperidone (mean
dose 1.8 mg/d), quetiapine (mean dose 605 mg/d), loxapine (mean dose
80mg/d), flupenthixol (mean dose 5.3 mg/d) or palliperidone (mean
dose 83.3 mg/d).
Results: Total hippocampal volumes were significantly smaller in the
mainly clozapine treated group (F(1,22)=4.7, p. =0.044. No group differ-
ences in age, length of illness, total PANSS score (Positive and Negative
Syndrome Scale), ESRS score (Extrapyramidal Symptoms Rating Scale),
CDS score (Calgary Depression Scale), HAMAS score (Hamilton
Anxiety Scale) or WTAR score (Wisconsin Test of Adult Reading) were
observed; all p-values >0.25.
Conclusion: Previous animal investigations on the effects of clozapine
exposure on cell proliferation in the hippocampus were negative and
did not induce neuroplasticity. The current results suggest that alternate
atypical antipsychotics with higher D2 affinities may exert neurotrophic
effects on the hippocampus, whereas clozapine does not.
Policy of full disclosure: None.
P-50-002 Autoradiographic characterization of [3H]JNJ-54235012, a
radiolabelled allosteric potentiator of the M1 muscarinic
acetylcholine receptor: A new tool for studying central
cholinergic system
X. Langlois1, I. Lenaerts1, I. Fonteyn1, K. De Wapenaert1, J. Leenaerts1,
F. Rombouts1. 1Janssen Research & Development, Beerse, Belgium
Objective: Compounds activating the M1 muscarinic acetylcholine recep-
tor (mAChR) may have therapeutic benefit in treating cognitive deficit
associated with schizophrenia or dementia. Activation of the M1
mAChR by small molecules can be produced either by binding at the
orthosteric acetylcholine binding site or by interacting with the allosteric
site of this receptor. However, compounds belonging to the first category
lack some selectivity and are causing cholinergic side effects whereas the
allosteric potentiators of the M1 mAChR, showing a higher degree of sel-
ectivity, are expected to be better tolerated. Due to this reason, numerous
drug discovery programs looking for positive allosteric modulators
(PAM) of M1 mAChR have been initiated. In order to deepen our
understanding of such molecule, a highly potent PAM of the M1
mAChR JNJ-54235012 was radiolabelled and characterized.
Methods: Binding properties of [3H]JNJ-54235012 were assessed on
membranes prepared from human M1 mAChR-recombinant cell line
and on rat brain sections.
Results: Initial binding experiments on membranes have shown a high
acetylcholine dependency of [3H]JNJ-54235012 binding to the human M1
mAChR. In saturation experiment and in presence of 1 μM acetylcholine,
Kd of [3H]JNJ-54235012 was equal to 4 nM. In rat brain sections, similar
acetylcholine dependency was observed and the pattern of binding sites
visualized by autoradiography was very similar to the known distribution
of M1 mAChR. Due to the acetylcholine dependency of [3H]JNJ-54235012
binding, several experiments were initiated to evaluate the capacity of
such radioligand to monitor ex-vivo the level of activation or blockade
of M1 mAChR after in vivo administration of acetylcholinesterase inhibi-
tors or muscarinic antagonists, respectively. Dose-dependent activation of
M1 mAChR could be visualized after donepezil whereas scopolamine,
clozapine and olanzapine were blocking the ability of acetylcholine to in-
crease [3H]JNJ-54235012 binding.
Conclusion:Modulation of [3H]JNJ-54235012 binding by various drugs
represents a new way for studying central cholinergic system.
Policy of full disclosure: All authors are employee of Janssen Research
& Development.
P-50-003 In utero environment and function of fronto-limbic
regions in adolescence: A study in a longitudinal sample
of monozygotic twins
M. Levesque1, E. Ismaylova2, K. Marble3, M.-P. Verner2, K. Casey2,
M. Brendgen4, G. Dionne5, F. Vitaro2, M. Boivin5, R. Tremblay2,
L. Booij2. 1University of Montreal, Longueuil, Canada; 2University of
Montreal, Montreal, Canada; 3Queens University, Kingston, Canada;
4UQAM, Montreal, Canada; 5University of Laval, Laval, Canada
Objective: Much work demonstrates an association between early ad-
versity and brain development, with fronto-limbic regions being of par-
ticular interest given their involvement in emotion regulation. To
disentangle the effects of the environment from genetic influences, we
can address this question in monozygotic twins and thereby isolate the
effects of early adversity on brain development and later functioning.
We make use of birth weight as an index of the in utero environment
and test the hypothesis that greater discordance in birth weight may be
associated with greater discordance in brain activation in response to
emotional stimuli in fronto-limbic regions including the amygdala, hippo-
campus, anterior cingulate cortex and prefrontal cortex.
Methods: Fifty-two healthy pairs of monozygotic twins from the
Quebec Study of Newborn Twins, followed regularly since birth, were
scanned in a 3 T Siemens Scanner at age 15. During the scan, they viewed
happy, fearful, sad, angry and neutral faces from the Pictures of Facial
Affect series (Ekman 1976), allowing us to determine brain activation in
response to each of these emotions.
Results: Preliminary analyses demonstrated that greater BW
discordance is associated with greater discordance in response to anger
and sadness relative to neutral stimuli in frontal regions, but only in
girls (Anger: pFDR-Corr=0.008, X=−22, Y=38, Z=8; Sadness:
pFDR-Corr=0.043, X=−30, Y=50, Z=16). We will also present results ac-
counting for the postnatal environment including income and parenting
behaviors.
Conclusion: These findings support the idea that the in utero environ-
ment is associated with brain development in adolescence, and suggest
that it is necessary to account for gender when studying brain function
and emotion processing.
Policy of full disclosure: None.
P-50-004 Gender identity related regional brain activation assessed
using 7 Tesla functional magnetic resonance imaging
M. Spies1, G. Kranz2, S. Ganger2, R. Sladky3, M. Küblböck3,
A. Komorowski2, R. Seiger2, A. Hahn2, C. Windischberger3, S. Kasper2,
R. Lanzenberger2. 1Medical University of Vienna, Vienna, Austria;
2Department of Psychiatry and Psychotherapy, Medical University of Vienna,
Vienna, Austria; 3Center for Medical Physics and Biomedical Engineering,
Medical University of Vienna, Vienna, Austria
Objective: Studies aimed at defining brain regions associated with gender
identity, or a person’s subjectively experienced gender, have linked this
phenomenon to the superior frontal cortex and reward regions. Due to
their limitation to cissexual individuals, these studies may define sex,
rather than gender identity specific phenomena. We aim to identify
regions specifically linked to gender identity through inclusion of
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transsexual subject groups using functional magnetic resonance imaging
(fMRI).
Methods: 20 female-to-male (FtM, mean age±SD=26.50±7.58years)
and 19 male-to-female (MtF, 30.47±8.55years) transsexuals naive to cross-
sex hormone therapy, as well as 25 male (MC, 26.52±6.54years) and 26
female (FC, 25.61±6.31years) controls underwent an fMRI scan during
which a paradigm invoking identification with one’s perceived gender
was performed. Functional data was acquired using a Siemens
Magnetom 7 T scanner (EPI-sequence, TE/TR=0.023/1.4 s, 128×128 voxels,
32 slices). Standard preprocessing and statistics were carried out using
SPM8. Statistics implemented 2-sample T-test (FtM and MC vs MtF and
FC) to elucidate functional differences specific to male vs. female gender
identity.
Results: In comparison to the FtM and MC group, MtF and FC
showed greater activation in superior temporal (t =3.67), middle temporal
(t=4.09), inferior temporal (t=4.04), middle frontal (t =3.83) and superior
frontal regions (t =3.62) as well as the angular gyrus (t =3.46) and cuneus
(t=4.73). However, no regions showed greater activation in the FtM and
MC subject group. All T-values are p<0.001 uncorrected.
Conclusion: Our results allow not only for the isolation of brain activity
related to reflection upon one’s gender identity independent of biological
sex, but also for differentiation of activity that may be distinctive to
identification with a specific gender. However, further analysis must in-
corporate the consideration that gender identity may reflect a spectrum
rather than two extremes. Further, analysis in larger subject groups is
warranted.
Policy of full disclosure: This study is financed by a grant awarded
to R. Lanzenberger by the FWF Austrian Science Fund (P 23021,
2010–2014) Without any relevance to this work, S. Kasper declares that
he has received grant/research support from Eli Lilly, Lundbeck A/S,
Bristol-Myers Squibb, Servier, Sepracor, GlaxoSmithKline, Organon,
Dr. Willmar Schwabe GmbH & Co. KG and has served as a consultant
or on advisory boards for AstraZeneca, Austrian Sick Found,
Bristol-Myers Squibb, German Research Foundation (DFG),
GlaxoSmithKline, Eli Lily, Lundbeck A/S, Pfizer, Organon, Sepracor,
Janssen, and Novartis, and has served on speakers’ bureaus for
AstraZeneca, Eli Lilly, Lundbeck A/S, Servier, Sepracor and
Janssen. R. Lanzenberger received travel grants and conference speaker
honoraria from AstraZeneca, Lundbeck A/S and Roche Austria
GmbH. M. Spies, and G.S. Kranz received travel grants from Roche and
AOP Orphan Pharmaceuticals. S. Ganger, R. Sladky, M. Küblböck,
A. Komorowski, R. Seiger, A. Hahn, C. Windischberger report no conflict
of interest related to this study.
P-50-005 The norepinephrine transporter in adult attention deficit
hyperactivity disorder quantified with (S,S)-[ 18F]
FMeNER-D2 and PET
T. Vanicek1, M. Spies2, C. Rami-Mark3, M. Savli2, G. Kranz2,
A. Kutzelnigg2, M. Mitterhauser3, W. Wadsak3, N. D. Volkow4,
S. Kasper2, R. Lanzenberger2. 1Medical University of Vienna, Vienna,
Austria; 2Medical University of Vienna, Department for Psychiatry and
Psychotherapie, Vienna, Austria; 3Medical University of Vienna, Department
of Biomedical Imaging, Division of Nuclear Medicine, Vienna, Austria;
4Medical University of Vienna, National Institutes of Health, Devision
NIAAA, National Institutes of Health, Vienna, Austria
Objective: The norepinephrine transporter (NET) is a central target for
often prescribed medications in ADHD. Thus, the NET is suggested to
be highly involved in the underlying neurobiological mechanisms in
ADHD. The aim of this study was to quantify NET binding using positron
emission tomography and the highly selective radioligand (S,S)-[18F]
FMeNER-D2 in adult ADHD.
Methods: 22 medication-free ADHD patients (age: 32.16±10.86, mean±
SD, 12males) without psychiatric comorbidities, and 22 age and sex
matched healthy controls (HC, age: 32.00±10.56, 12males) underwent
PET scanning once. The NET binding potential was compared between
groups by means of a linear mixed model analysis including the
hippocampus, putamen, pallidum, thalamus, midbrain with pons (includ-
ing the locus coeruleus (LC)), and cerebellum (atlas-based ROIs).
Additionally, we included thalamic sub-nuclei (13 atlas-based ROIs) and
LC and thalamus (manually delineated ROIs) to the analysis. The 2-tailed
significance level was set at 0.05.
Results: The results of this investigation revealed no main effect of sub-
ject groups (F1,41<0.01, p=0.96, Fig. 1) or sex (F1,41<0.01,p =0.98) and no
interaction effects (all p>0.1). Further, we reveal no significant association
between ADHD symptoms severity and regional NET availability.
However, we found a significant negative correlation of NET BPND
with age in the thalamus (r=−.54) and midbrain (r=−.42, p<0.05 cor-
rected), but these correlations did not differ between HC and ADHD
patients.
Conclusion: Our findings show no significant differences in the NET
binding of (S,S)-[18F]FMeNER-D2 between ADHD patients and HC.
Thus, results imply that NET BPND is not a major player in the pathogen-
esis of ADHD. However, different molecules of noradrenergic trans-
mission might be altered, or the noradrenergic transmitter system might
be affected on different levels, such as cortical regions, which cannot be
reliably quantified with this radio-ligand.
Policy of full disclosure: Without any relevance to this work,
S. Kasper declares that he has received grant/research support from Eli
Lilly, Lundbeck A/S, Bristol-Myers Squibb, Servier, Sepracor,
GlaxoSmithKline, Organon, Dr. Willmar Schwabe GmbH & Co. KG and
has served as a consultant or on advisory boards for AstraZeneca,
Austrian Sick Found, Bristol-Myers Squibb, German Research
Foundation (DFG), GlaxoSmithKline, Eli Lily, Lundbeck A/S, Pfizer,
Organon, Sepracor, Janssen, and Novartis, and has served on speakers’
bureaus for AstraZeneca, Eli Lilly, Lundbeck A/S, Servier, Sepracor and
Janssen. R. Lanzenberger has received travel grants and conference
speaker honoraria from AstraZeneca, Lundbeck A/S and Roche
Austria GmbH. T. Vanicek has received a travel grant from
Sanova. M. Spies and G.S. Kranz received trave grants from Roche and
AOP Orphan. W. Wadsak has received research support from Rotem
GmbH, ABX, Iason, Advion and Raytest Austria and has served as a
consultant/trainer for Bayer and THP. A. Kutzelnigg has received
travel grants from Eli Lilly and Company, Affiris AG, Novartis
Pharmaceuticals Corporation, and AstraZeneca, payment for lectures in-
cluding service on speakers’ bureaus from Eli Lilly and Company,
Novartis Pharmaceuticals Corporation, AstraZeneca and Affiris AG and
has served as a consultant and on advisory boards for the Austrian
Federal Ministry of Health, Eli Lilly and Company, Biogen-Idec and
Medice Arzneimittel GmbH. The authors N.D.Volkow, M. Mitterhauser,
C. Rami-Mark and M. Savli report no financial relationships with com-
mercial interests.
Images display (S,S)-[18F]FMeNER-D2 distribution in ADHD
patients. NET BPND is found to be high in the thalamus and
midbrain, and low in the basal ganglia. The colour table represent
binding potential at each voxel, blue indicates lowest and red
highest N:
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P-50-006 In vivo pet imaging of neuropeptide y2 receptors in
diet-induced obesity in minipig
M. Winterdahl1, D. F. Smith2, H. Audrain3, A. Møller3, S. Jakobsen3,
A. K. O. Alstrup3, J. Scheel-Krüger3, D. Bender3, M. L. Kringelbach4,
A. M. Landau3. 1Aarhus, Denmark; 2Psychiatric Hospital Risskov, Aarhus
University, Aarhus, Denmark; 3Aarhus University Hospital, Aarhus,
Denmark; 4University of Oxford, Oxford, United Kingdom
Objective: Neuropeptide Y (NPY) is a potent orexigenic agent expressed
in both the central and peripheral nervous system. In the brain, NPY
increases food intake and body weight leading to metabolic changes pro-
moting energy storage. The activation of NPY Y2 receptors, the most
prominent NPY receptor in the CNS, has been linked to the induction
of satiety, and polymorphisms in this gene have been implicated in
human obesity. We have recently developed a novel positron-emitting
radioligand based on the NPY Y2 receptor antagonist, JNJ-31020028,
and have used the radiotracer for positron emission tomography (PET)
brain imaging in pigs. Here we examine changes in the binding potential
(BPND) of NPY Y2 receptors in response to diet-induced obesity.
Methods: Four average weight (25 kg) adult female Gottingen minipigs
were anesthetized and scanned at baseline with N-[11C]methyl-JNJ-
31020028 in a Siemens PET/CT scanner. Minipigs were then fed an unlimi-
ted, high-fat, palatable diet for 10–12 weeks which resulted in doubling of
their body weight (51 kg), prior to rescanning with N-[11C]methyl-JNJ-
31020028. PET data were registered to an average minipig MRI atlas
and processed using MINC tools. The BPND was obtained using the
Logan graphical analysis, with corpus callosum as a region of non-
displaceable binding.
Results: On average in the four pigs, JNJ-31020028 BPND was signifi-
cantly reduced in the striatum, thalamus and amygdala after weeks
with the high-fat diet.
Conclusion: Data demonstrate the use of this novel tracer in longitud-
inally examining physiological processes and reinforce the idea of NPY Y2
antagonism as a potential beneficial treatment of obesity.
Policy of full disclosure: None.
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P-51-001 Anxious and suicidal behaviors among relatives are
associated with suicide attempts and hospitalizations in
mood disorder subjects
N. Lebaron1, X. Zhang1, R. Herrell2, E. Yung1, A. Iskric1, S. Cho1, N. Low1.
1McGill University, Montreal, Canada; 2Walter Reed Army Institute for
Research, Maryland, USA
Objective: - To examine the association between suicidal behavior in sub-
jects with mood disorders and suicidal behavior in their relatives with
psychiatric disorders - To examine the association between number of
relatives with specific psychiatric disorders and clinical severity indicators
in subjects with mood disorders - To begin to consider possible interven-
tions for prevention of familial risk factors.
Methods: Participants were recruited from the Mood Disorders
Program of the McGill University Health Center in Montreal, Quebec.
Data was gathered using structured diagnostic interviews (SCID), family
history of psychiatric illness questionnaire and patient clinical records.
Ordinal and binary logistic regression analyses were to examine the as-
sociation between type of diagnoses among relatives and suicide attempts
and hospitalizations in the proband. Models were adjusted for age and
gender.
Results: The greater number of relatives with suicidal behavior
(attempts and completions), the greater the number of suicide attempts
(OR=1.1, p=0.016) among mood disorder subjects. In addition, the greater
number of relatives with anxiety (panic, worry), the less likely the mood
disorder subject was hospitalized (adjusted OR=0.3, p=0.032).
Conclusion: These results indicate that individuals with family mem-
bers who have a history of suicide attempts may be at risk for an increase
in suicide attempts. Individuals with family members with an anxiety dis-
order are less likely to be hospitalized. To elucidate the mechanisms be-
hind this association, future research should investigate the ways
relatives with psychiatric illnesses may interact in families with mood
disorders. The coping skills and the cognitive styles of mood disorder sub-
jects and their family members may be targets for intervention to reduce
clinical severity.
Policy of full disclosure: None.
P-51-002 The association between contacts with relatives with
psychiatric illness and cognitive distortions in mood
disorder subjects
N. Lebaron1, A. Iskric1, E. Yung1, G. Kraus1, N. Low1. 1McGill University,
Montreal, Canada
Objective: - To become better acquainted with the Types of Thinking
questionnaire, a measure of cognitive distortions - To understand the ef-
fect of contact with sick relatives on cognitive distortions among mood
disorder subjects - To understand the implications of specific cognitive
distortions on mood disorder subjects.
Methods: 102 outpatients from the Mood Disorders Program of the
McGill University Health Center in Montreal, Quebec completed
the Types of Thinking Questionnaire as well as a Family History
Questionnaire as part of a family study of mood disorders. Linear regres-
sions were conducted, controlling for age and gender, to examine the
associations between frequency of contact with sick relatives and cogni-
tive distortions.
Results: The greater the contact with relatives with psychiatric illnesses
was, the higher the levels of (1) Catastrophizing (unstandardized B=0.130,
p=0.040), (2) All-Or-Nothing thinking (unstandardized B=0.157, p=0.012)
and (3) Should Statements (unstandardized B=0.153, p=0.024) were
reported. In addition, total level of negative cognitive style (unstandar-
dized B=1.159, p=0.022) was higher as sick relative contact increased.
Conclusion: The mechanism by which contact with sick relatives ren-
ders its effect on the cognitive patterns of mood disorder subjects should
be explored.
Policy of full disclosure: None.
P-51-003 Factors influencing efficacy of specialized psychiatric help
under conditions of primary care unit
V. Lebedeva. Mental Health Research Institute, Tomsk, Russia
Objective: Using clinical diagnostic criteria of course and outcome of
mental disorders co-morbid with somatic pathology to distinguish basic
treatment programs and to assess their efficacy.
Methods: Clinical-diagnostic, clinical-follow-up “scale of efficacy of
therapy of patients with borderline states”, SF-36, correlation and factor
analyses. Material: 680 patients with mental disorders co-morbid with so-
matic pathology needing systematic therapy and dynamic observation by
a psychiatrist.
Results: We have developed six rehabilitative programs with their
gradual realization for patients with neurotic and somatoform disorders,
organic mental disorders, personality disorders, affective mood disorders,
alcohol dependence, for elderly. Basic therapeutic stages: initial, basic
therapy and maintenance therapy. Basic and important method of therapy
at all stages of treatment was medication. Most effective and used pre-
parations were tranquilizers (sonval, radedorm, nozepam, phenazepam,
grandaxin, sibazon, relanium); neuroleptics (sonapax, chlorprotixen, halo-
peridol, eglonil); antidepressants (amitriptiline, fluoxetin, azafen, pirazi-
dol, anafranil). Conducted by us investigations during 25 years allowed
distinguishing basic and obligatory principles of therapy providing its
quality and efficacy, gradual character, complexity (treatment of somatic
and mental pathology), sufficiency (necessary volume of therapy with
minimum side-effects), individual-differentiated approach (along with
other factors, account for financial possibilities), accessibility (not only ter-
ritorial but also psychological), continuity (collaboration of psychiatrist
and physicians at all stages of therapy), cooperativeness (possibility of
concomitant curing by doctors of various specialties). According to data
of follow-up and assessment of efficacy of treatment programs, recovery
has been achieved in 46,2% of cases, stable clinical improvement -
44,1%,. Temporary disability decreased in patients with somatoform dis-
orders as many as 1,8 times and number of not grounded seeking for
help and examinations per 1 patient during the year as many as 2,3 times.
Conclusion: Integrative approach to medical help rendering as well as
all-sided differentiated and grounded medication were enough effective
according not only to clinical but also economic indices.
Policy of full disclosure: None.
P-51-004 The functional role of the brain finger protein, Znf179,
in learning and memory
Y.-C. Lee1, P.-C. Pao1, J.-H. Tsou1, Y.-C. Yang2, W.-C. Chang1. 1Taipei
Medical University, Taipei, Taiwan; 2National Ilan University, Ilan, Taiwan
Objective: The objective of this study was to reveal the physiological func-
tions of Znf179 in the adult brain.
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Methods: We generated Znf179 knockout mice to address Znf179 func-
tions in vivo.
Results: Our data showed that most of the Znf179-/- embryos exhibited
blood vascular defects and died in utero. Upon further investigation, we
found that the survival rate of homozygous Znf179-knockout mice in
129/sv and C57BL/6 mixed genetic background was increased, providing
opportunity to study the physiological function of Znf179 in the adult
brain. The survived newborns of Znf179-/- mice manifested growth retar-
dation as indicated by smaller size and a reduced weight. Although the
overall organization of the brain did not appear to be severely affected
in Znf179-/- mice, our data showed that the brain size and the thickness
of cerebral cortex from the Znf179-/- mice were reduced. Moreover the
Znf179-/- mice displayed impairment of brain functions including motor
balance, and spatial learning and memory.
Conclusion: Our results revealed that deletion of both Znf179 alleles
resulted in embryonic lethality associated with defects in embryonic vas-
culature. Moreover, the homozygous Znf179 knockout mice in 129/sv and
C57BL/6 mixed genetic background can survive to adult, suggesting that
the presence of modifier genes in different mouse strains could support
survival of Znf179-/- mice. We also found that Znf179 deletion resulted
in impairment of brain functions. Taken together, our results provide evi-
dence for the important functions of Znf179 in embryo development and
in adult brain.
Policy of full disclosure: None.
P-51-005 Transcriptional activation of non-LTR retroelements
with age and in response to stresses
S. Mukherjee1, D. Sharma2, K. C. Upadhyaya2. 1JNU, Delhi, India; 2SLS,
JNU, Delhi, India
Objective: Basic objectives were to analyze the transcriptional regulation
of L1Rn elements in response to stresses.
Methods: Real time PCR analysis using RNA isolated from various
brain regions and various tissues from old and young wistar rats was car-
ried out to determine the change in L1 transcripts.
Results: There was no significant change in the expression of L1Rn in
various brain regions of 2 month old and 18 month old rats except cerebral
cortex. The heavy metals nickel, cadmium, lead, mercury and aluminum
upregulates the expression of L1 in tissue specific and age dependent
manner.
Conclusion: The results of this investigation conclusively prove that
LINE1 retroelements are transcriptionally activated in response to stress.
Policy of full disclosure: None.
P-51-006 Intranasal erythropoietin with low sialic acid shows safety
and tolerability: A phase I clinical trial
O. Santos Morales1, A. Díaz2, C. González3, L. Barrero3, E. Alfonso3,
Y. Pomares1, T. Festary4, P. Piedra1, C. Viada1, A. Martínez3, Y. Cruz4.
1Center of Molecular Immunology, Havana, Cuba; 2Center of Molecular
Immunology, National Center of Toxicology, Havana, Cuba; 3National Center
of Toxicology, Havana, Cuba; 4Cidem, Havana, Cuba
Objective: The objective of this study was to evaluate safety and tolerabil-
ity of NeuroEPO a neuroprotective candidate that has shown to be safe
and beneficial in preclinical models of acute and neurodegenerative
brain diseases.
Methods: We completed a randomized, open, two doses and parallel
Phase I clinical trial. Thirty healthy volunteers with ages ranging from
18 to 40 years were included. All participants gave their written informed
consent. Subjects from Group A and Group B received (1mg or 0.5 mg
NeuroEPO) respectively intranasal every 8 hours during 4 days.
Participants were randomly allocated to each treatment group. Primary
outcome of the study was adverse event. Vital signs, hematopoietic ac-
tivity, blood biochemistry and local tolerance were evaluated.
Results: 25 subjects were analysed, 12 in group A and 13 in group B. No
serious adverse event (AE) was reported. 95% of the AEs were mild,
2 (5%) were moderate. Most frequent AEs were headache (5; 11.3%),
ALAT increase (5; 11.3%) and nasopharyngeal stinging (4; 9.1%).
Hematopoietic activity and vital signs remain normal. No clinically sign-
ificant laboratory abnormality was identified. Transient discreet redness
of the nasal turbinate and slight congestion of the nasal mucosa was
seen in only 1 patient each one. No significant difference was found be-
tween doses.
Conclusion: Intranasal administration of NeuroEPO is safe and well tol-
erated in healthy volunteers. This study warrant further trials in clinical
conditions. Trial registration: RPCEC00000157
Policy of full disclosure: None.
P-51-007 Psychotropic drug utilization in geriatric psychiatry
inpatients of a university hospital
A. Shenoy1, S. Hadigal1, P. Kamath1, A. Kamath1. 1Kasturba Medical
College, Mangalore, Karnataka, India
Objective: Psychotropic drug polypharmacy is common in elderly
patients. A gender based difference in the prescription of potentially inap-
propriate psychotropic medication has been described with more use in
elderly females. The objective of our study is to describe the psychotropic
drug utilization pattern in elderly psychiatry inpatients of a university
hospital in India and determine the presence of any gender difference.
Methods: Hospital records of all psychiatry inpatients more than or
equal to 65 years of age admitted over a period of two years were studied.
Drugs prescribed before hospitalization, during hospital stay and on
discharge were recorded. The drug classes were delineated as follows -
antidepressants, antipsychotics, mood stabilizers and anxiolytics/
hypnotics.
Results: Of the 51 patients admitted, 58.8% were males. The mean age
was 73.67±5.8 years in males and 68.57±4.7 years in females (p<0.05).
Unspecified dementia was the commonest psychiatric illness followed
by bipolar affective disorder. 23.53% of the patients did not receive any
psychotropic drugs. 41.2% were prescribed antidepressants, 29.4% anti-
psychotics, 7.8% mood stabilizers and 47.1% anxiolytics. Lorazepam
was the most commonly prescribed drug followed by escitalopram
(27.5% and 13.7% respectively). No gender difference was seen in the
use of psychotropic medications. 45.1% of the patients were prescribed
more than one psychotropic drug on discharge.
Conclusion: A larger percentage of the patients were males and were
of significantly older age as compared to females. This is contrary to
some of the data reported by other similar studies. Anxiolytics and anti-
depressants were the most commonly prescribed psychotropic drugs.
No significant difference in the drug use was seen on admission and dis-
charge. No gender difference was seen. Polypharmacy seen in our study is
less than those reported by other studies although the appropriateness of
the prescribed medications needs to be determined.
Policy of full disclosure: None.
P-51-008 The dopamine stabilizer (-)-OSU6162 reduces aggressive
behaviour in mice at a dose affecting neither social
interaction nor locomotion
E. Studer1, J. Näslund1, A. Carlsson1, E. Eriksson1. 1Neuroscience and
Physiology, Gothenburg, Sweden
Objective: (-)-OSU6162 is a substance belonging to a new class of com-
pounds named “dopaminergic stabilizers” and has been shown to be ef-
fective in several preclinical tests of schizophrenia as well as models of
alcohol dependence. While its exact mechanism of action is still uncertain,
it is assumed to maintain dopamine homeostasis mainly by exerting an
atypical interaction with extrasynaptic and/or synaptic D2 receptors.
Interestingly, it reduces stimulant-induced hyperlocomotion without in-
ducing catalepsy even at high doses.
Methods: The effect of (-)-OSU6162 on aggressive behaviour and other
social behaviours in the resident intruder test was evaluated in male mice
of the outbred CD-1 strain. In addition, possible effects on spontaneous
locomotion were evaluated in a separate experiment.
Results: (-)-OSU6162 dose-dependently reduced aggressive behaviour
while not affecting other social behaviours and importantly, not by reduc-
ing spontaneous locomotion.
Conclusion: This study is the first to suggest that (-)-OSU6162 has
potential as an anti-aggressive agent. Given the well-established influence
of dopamine on aggression, we suggest the effect to be exerted by the
dopamine-stabilizing properties previously attributed this compound.
Policy of full disclosure: None.
P-51-009 Types of suicidal self-harm in the individuals under
investigation
E. Valzdorf. BNUEL, Irkutsk, Russia
Objective: To study and analyze the types of suicidal behavior in the
individuals held criminally liable.
Methods: The clinical psycho-pathological and statistical.
Results: The research revealed that most of the 90 individuals who com-
mitted suicides and underwent the forensic psychiatric assessment.
Among the suicidal individuals that were under the recognizance not to
leave and proper behavior 1 and 2 self-harm acts were committed by 5;
3–3; 4–1 and 7 self-destructive acts-1 person under investigation.
Among the persons whose measure of restraint was custody 1 self-harm
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act in their life was committed by 19; 2–22; 3–11;5–7; and 4–5; 7,8,9 and 12
acts-2; and 6,19 and 11 self-injuries were committed by 1. 15 - under inves-
tigation that were under recognizance not to leave and proper behavior
committed the following kinds of attempted suicide: self-hanging and
self-cutting on the left forearm – 7; self-cutting on the right forearm – 5;
abdominal self-cutting – 2; self-cutting on the neck and chest – 1; self-
burning, poisoning with food, deliberate drug overdose – 1. 75 – under
investigation whose measure of restraint was custody committed such
attempted suicides as self-cutting on the right forearm – 29; poisoning
with psychotropic medications - 16; poisoning with other medications –
13; abdominal self-cutting – 8; self-cutting on the neck – 5; self-shooting
from firearms – 4; self-cutting in the groin area, deliberate road traffic ac-
cident – 3; self-cutting on the chest, jumps from the window, jumps from a
height – 2; deliberate drug overdose, self-burning – 1.
Conclusion: The most popular type of self-harm among the suspects,
who had the measure of restraint in the form of recognizance not to
leave and proper behavior was self-hanging and self-cutting on the left
and right forearms, and among those in custody - self-cutting on the
left and right forearms, poisoning with psychotropic substances and
other medications.
Policy of full disclosure: None.
P-51-010 Causes and objects for committing attempted suicides
E. Valzdorf. BNUEL, Irkutsk, Russia
Objective: To investigate a diversity of causes of deliberate self-
destructive acts and objects for committing them in the individuals who
have committed crimes and have undergone the primary inpatient com-
prehensive forensic psychological and psychiatric assessment.
Methods: The statistical, method of comparative analysis and clinical
psychopathological.
Results: The research revealed the following causes of deliberate self-
destructive acts in the suicidal individuals: conflict with their woman
(parting, divorce, quarrel, unshared love) – in 21, conflicts (with mother,
with administration of the pretrial detention center) – 17, sense of frus-
tration – 15, protest against unfair sentence – 10, loss of life purpose, un-
willingness to live – 8, conflict with a sister-3, rape – 3, psychological
pressure from cell mates in the pretrial detention center – 2, fraternization
with a friend – 2 individuals, a wish to be alone in the pretrial detention
cell – 1, loss of a near relative – 1, conflicts with family – 1, effect of alcohol
withdrawal hallucinations – 1, matricide – 1, for the sake of an experiment
– 1, conflict with their aunt –1, an attempt to avoid quarantine in the
pretrial detention center – 1, to be sent to the health center of the pretrial
detention facility to have a less stricter custodial control – 1. The
self-destructive acts were committed by the following objects: razor
blade – 33, kitchen knife -11, washing line -10, medication – 4, glass – 3,
psychotropic medication – 3, penknife – 3, belt – 3, firearm – 3, sheet –
2, undershirt – 2, telephone cord – 2, electrical wire – 2, laces – 1, petrol
– 1, arch support from a boot – 1, syringe with a narcotic drug – 1, vinegar
– 1, jumping rope – 1, sharpened coin – 1, mirror – 1, and a parachute
line – 1.
Conclusion: The most frequent causes of the deliberate self-destructive
acts were: Conflicts with woman, protest against unfair sentence, conflicts
with relatives and administration of the pretrial detention center as well as
the feelings of frustration and hopelessness. The most widely used objects
included razor blade, washing line and medications including the psycho-
tropic ones.
Policy of full disclosure: None.
P-51-011 Assessment of psychological and sexologic status of an
individual with sadistic exhibitionism
E. Valzdorf. BNUEL, Irkutsk, Russia
Objective: To characterize and analyze the psychological and sexologic
status of an inpatient of the forensic assessment department.
Methods: The clinical psychopathologic and pathopsychological
methods.
Results: The sexologic and psychiatric research revealed the following:
the individual notes that in the early childhood he expressed an interest in
his own genitals and the genitals of other children. When in the first form
of school, he found a magazine with pornographic photos. This was the
first time he had felt arousal in the area of genitals. In the fourth form
he started to manipulate his genital organ while looking through the por-
nographic magazine, he felt excitement. He made his first deliberate sex-
ual intercourse at the age of 14 under alcohol intoxication. Until current
arrest he has been going to the park to masturbate for two years. In
terms of mental status the individual has clear consciousness. He is
correctly oriented in all spheres. He is neat in appearance. His manner
of walking is slow, during conversation he sits in one position and
grows red when excited. During most of the conversation, he does not
look at the conversation partner. Mimical responses are lively and corre-
spond to the theme of conversation. He expresses an interest in the dis-
cussion and talks eagerly and sincerely. He is emotionally cold. The
way of thinking is slow, of an average productivity. Intellect corresponds
to the level of the received education.
Conclusion: All things considered the commission has arrived at the
conclusion that the individual under consideration shows the signs of a
mixed personal disorder (schizoid, emotionally-unstable) and a psycho-
sexual disorder in the form of a true perversion, i.e. sadistic exhibitionism
(according to ICD-10). This was revealed through the permanent incli-
nation of the person to sudden exposure of his genital organs to strangers
in a public place, without a proposal to have an intimate contact, which
was accompanied by masturbation when a victim showed fear.
Policy of full disclosure: None.
P-51-012 The therapeutic principle in a structural biological
organization
E. Venga. Clinica Neuro Psichiatrica, Naples, Italy
Objective: The execution of a Function is supported by a biochemical
complement which has to be functional to the Function we represent.
Methods: We know that if a Function is physiologically modified,
according to our syntomatologic diagnostic criteria, we name it
Dysfunction. As any molecule expressing its own atomic organization
can alter the atomic-molecular organization of a Function, we do not
know if the transformation or alteration of the Function-Dysfunction is
compatible with the other Functions-Disfunctions.
Results: And if we succeed in altering - transforming the Function, can
we really have the scientific certainty of having cleared up the Disfunction
of the Function?
Conclusion: Is it only a representative symptomatic remission that
satisfies a therapeutic illusion?
Policy of full disclosure: None.
P-51-013 Water and ice: Using natural disasters to study prenatal
maternal stress
S. King1, D. P. Laplante2, M.W. O´Hara3, S. Kildea4. 1Department of
Psychiatry, McGill University, Douglas Mental Health University Institute,
Verdun, Quebec, Canada; 2Douglas Hospital Research Centre, Montreal,
Canada; 3Iowa City, USA; 4Brisbane, Australia
Objective: Little is known about effects of prenatal maternal stress in
humans, however, because it would be unethical to randomly assign preg-
nant women to stress conditions. Our objectives are to determine: (1) to
what extent do objective hardship and subjective distress during preg-
nancy influence the cognitive, behavioural, physical and motor develop-
ment of the unborn child? (2) Are these effects moderated by the timing
in pregnancy and the child’s sex? (3) What are the mechanisms of these
effects? And (4) will more intensive prenatal care buffer these effects?
Methods: We are running three studies of pregnant women exposed to
natural disasters. In each, we assessed objective exposure and subjective
distress within weeks of the disaster (PTSD symptoms). We then evalu-
ated pregnancy outcomes, and the cognitive, behavioural, motor and
physical development of the children. We began Project Ice Storm in
Quebec in 1998; The Iowa Flood Study in 2008, which added pre-disaster
data from an on-going study of pregnant women; and The QF2011
Queensland Flood Study in Australia last year which included pre-trauma
data on pregnant women, a pre-existing randomized controlled trial of
two prenatal care programs, plus birth biological specimens that will re-
veal the mechanisms of action of prenatal stress in humans. We will
give the background rationale for the research program, the methods of
the three studies, and a sampling of results.
Results: We demonstrate strong and long-lasting effects of prenatal
stress on children’s cognitive outcomes (IQ, language, memory); behav-
iour (anxiety, depression, aggression, autistic-like traits); motor develop-
ment (coordination, visual-motor integration); and physical
development (brain, sexual dimorphisms, body composition, immune
function, insulin secretion, obesity).
Conclusion: Using a natural disaster as a platform for studying prenatal
maternal stress is a powerful approach for capturing the unique effects of
objective and subjective aspects of stress exposure, as well as precise tim-
ing in utero effects.
Policy of full disclosure: None.
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P-51-014 Iatrogenic aluminum and Moroccan children’s memory
F.-Z. Azzaoui1, H. Hami2, S. Boulbaroud2, M. El Hioui2, A. Ahami2.
1Kenitra, Morocco; 2Faculty of Science, Kenitra, Morocco
Objective: The evaluation of the memory faculties among Moroccan
schooled children (aged 6–8 years) living in the Gharb Plain
(North-West of Morocco) and the study of the possible relationship be-
tween this faculty and the consumption of iatrogenic aluminum.
Methods: A cross-sectional study is conducted among 129 school-aged
children living in the urban, periurban and rural region of the Gharb Plain
(N-W of Morocco). The children suffering from cranial traumatism or
neurologic disease are excluded. The memory faculties are measured by
Memory Sub-test of WISC III (Wechsler Intelligence Scale for Children).
The consumption of iatrogenic aluminum and the quality of children#s
life are evaluated by the questionnaire. Statistical analyses are realized
by ANOVA 1, LSD and Pearson correlation coefficient.
Results: The obtained results show that the high rate of working mem-
ory impairments (66.67%) is registered among rural children. Significant
correlations between performance of working memory (p<0.05) and con-
sumption of iatrogenic aluminum are also found.
Conclusion: The children’s memory appears in connection with iatro-
genic aluminum consumption. However, several factors (environmental,
psychological, socio-economical, and nutritional factors) could influence
this performance. So, deeper investigations are needed for studying all
these factors.
Policy of full disclosure: None.
P-51-015 Atypical antipsychotics in the treatment of delirium
W.-M. Bahk1, H. R. Wang2, Y. S. Woo2, B.-H. Yoon3, S.-Y. Lee4. 1Yeouido
St. Mary´s Hospital, Seoul, Republic of Korea; 2Seoul, Republic of Korea;
3Naju, Republic of Korea; 4Iksan, Republic of Korea
Objective: This study aims to review the efficacy and safety of atypical
antipsychotics, comparing within class, placebo, or compared to another
active treatment for delirium.
Methods: We conducted a literature search using PubMed, EMBASE,
and the Cochrane database (January 1st in 1990-November 5th in 2012).
Selection criteria for review were prospective, controlled studies (compari-
son studies), using validated delirium rating scales as outcome measures.
Results: A total of six prospective, randomized controlled studies were
included in the review. The review showed that atypical antipsychotics
are effective and safe in treating delirium, even though there seemed to
be no difference between each agent. In particular, comparison studies
with haloperidol showed that the efficacy of atypical antipsychotics was
similar to that of low dose haloperidol.
Conclusion: This review found that atypical antipsychotics appear to be
effective and tolerable in the management of delirium, even though the
evidence is limited.
Policy of full disclosure: None.
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Satellite Symposia
Monday 23 June 2014
SA-01. New horizons in schizophrenia:
Navigating the evidence at the frontier of
patient care
supported by an educational grant from
F. Hoffmann-La Roche Ltd.
SA-01-001 Charting advances in schizophrenia: Unmet needs
and new targets
W. Honer. University of British Columbia, Institute of Mental Health,
Department of Psychiatry, Vancouver, BC, Canada
Policy of full disclosure: None.
SA-01-002 Exploring the evidence: New treatment approaches
in schizophrenia
W.W. Fleischhacker. Medical University Innsbruck, Innsbruck, Austria
Policy of full disclosure: None.
SA-01-003 Anchoring emerging evidence to real world
clinical practice
C. Correll. Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ, School
of Medicine, New York, USA
Policy of full disclosure: None.
SA-02. Predictive pharmacology - reductionism
and wishful thinking in antidepressant
development
supported by an educational grant from Lundbeck
SA-02-001 Introduction
R. Lam. University of British Columbia, Deptartment of Psychiatry, Vancouver,
Canada
Major Depressive Disorder (MDD) is a disabling neuropsychiatric disease
linked to significant morbidity and premature mortality. The associated
costs to patients, providers, and the public health are formidable, and
underline the importance of successful long-term outcomes. Yet most
patients do not achieve functional recovery, owing in part to the relative
paucity of treatment options and to our limited understanding of disease
mechanisms underlying this complex, heterogeneous disorder. Despite
great progress, traditional preclinical and clinical studies have proved
necessary, but not sufficient, to advance mechanism-based drug discovery
programmes. Rather, a comprehensive approach, from first principles to
patients, is essential for tailoring drug discovery to rigorously charac-
terised biological correlates of depressive symptoms. Recent advances in
the cognitive neurosciences are proving particularly important. An
increasingly robust evidence base has demonstrated the functionally
impairing effects of cognitive deficits in depressed patients. This patient
population frequently experiences a range of cognitive symptoms includ-
ing an impaired ability to think, concentrate, or make decisions that can
adversely affect work, school, and relationships. Further, well-designed
studies have documented cognitive impairment across the course of ill-
ness and its adverse impact on functional recovery. As interdisciplinary
research programs continue to identify neural pathways underlying de-
pressive symptomatology and novel targets for therapeutic intervention,
new therapies will emerge from the clinic, providing physicians with ad-
ditional options for individualized patient care. This symposium, chaired
by Dr Raymond Lam, will address these and other important issues.
Policy of full disclosure: None.
SA-02-002 Antidepressant effects on cognitive function - From
animal models to clinical trials
R. McIntyre. University of Toronto, UHN – Toronto Western Hospital, Toronto,
Canada
The brain, operating hierarchically from gene to network, is not immedi-
ately tractable to experimental research. Reductionist preclinical models
have therefore proved to be at once necessary, and limiting. While animal
models have proved indispensable, no one model can fully elucidate
complex, multidimensional neuropsychiatric disorders, particularly
depression. The growing interest in endophenotypes—as with the
Research Domain Criteria (RDoC)—lends well to deconstructing select
facets of the depressed state. Using an array of animal models—genetic,
pharmacological, environmental, and behavioural—can capture an
agent’s effects on well-specified clinical features, while improving success
rates across all phases of early drug discovery. Dr Roger McIntyre will
discuss the effects of antidepressants on cognitive dysfunction in MDD
patients, which will in turn shape a discussion of the recently completed
FOCUS study, a global, eight-week, randomised, double-blind,
parallel-group, placebo-controlled, fixed-dose trial that evaluated the
efficacy of vortioxetine on cognitive function in MDD patients.
Consistent with preclinical studies that show important inter-relationships
between brain areas critical for mood and cognition, results from the
FOCUS study demonstrate that vortioxetine can significantly reduce de-
pressive symptoms and independently improve executive function, atten-
tion, speed of processing, and memory.
Policy of full disclosure: None.
SA-02-003 The neurocircuitry behind depression
G.M. Goodwin. Warneford Hospital, University Department of Psychiatry,
Oxford, United Kingdom
Non-invasive neuroimaging tools have provided important insights into
the neurobiological abnormalities underlying cognitive as well as mood
and sleep-related disturbances in MDD patients. Patterns of neural
activity present an increasingly coherent picture of networks that govern
cognition. Networks distributed across prefrontal and subcortical regions,
in particular, have been implicated in the onset, progression, and clinical
symptomatology of MDD. These networks and their neuropharmacologi-
cal correlates are well-conserved, facilitating cross-species translational
efforts. Critically, functional magnetic resonance imaging (fMRI) analysis
in animal models can accelerate lead compound discovery and clarify the
effects of an investigational antidepressant on neural networks in healthy,
depressed, and remitted patients. Well-controlled studies before, during,
and after cognitive tasks and sleep, and in other areas of interest can es-
tablish important mechanistic relationships across all levels of brain func-
tion, with important implications for drug development, pivotal study
design, and patient care. Other modalities—including positron emission
tomography (PET), single-photon emission computed tomography
(SPECT), and electroencephalography (EEG)—are available to character-
ise an agent’s in vivo receptor occupancy and fine-grained electrophysio-
logical features. In Dr Guy Goodwin’s presentation, case studies with
agomelatine and vortioxetine will illustrate the benefits of human exper-
imental studies in early drug development, leading to robust translation
towards enriched patient populations, improved clinical endpoints, and
other features of well-designed clinical trials.
Policy of full disclosure: None.
SA-02-004 Translating preclinical studies to improved clinical
outcomes in depression
T. Robbins. University of Cambridge, Department of Psychology, Cambridge,
United Kingdom
Clinical depression entails cognitive deficits often across a range of
domains, including impairments of not only memory but also executive
functioning, such as decision-making, sustained attention (‘concentration’)
and working memory, although these deficits are frequently age-
dependent and correlated with discrete brain pathology. I will review evi-
dence of heterogeneous patterns of cognitive deficit across a number of
studies focusing especially on decision-making and attention, measured
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in a variety of ways. Depression is also associated with distinctive cogni-
tive or affective biases evident in so-called ‘hot’ cognition settings, in
which there is an emotional or motivational component. Examples include
the tendency to say “no” in tests of memory recognition, to over-react to
negative feedback when making decisions and also to respond more
quickly to sad rather than happy words arising theoretically from more
rapid access to, and retrieval from, semantic memory networks. These
phenomena indicate the importance in depression of a motivational inter-
face with respect to cognitive function that leads to the important distinc-
tion between ‘hot’ and cold’ cognition. I will also consider how both ‘cold’
and ‘hot’ cognition can be modelled in experimental animals in preclinical
studies, drawing upon the set of rich translational tests we already have
available for assessing ‘cold’ cognition in experimental animals and
their neural correlates, as well as ‘hot’ cognition, such as decision-making
following negative feedback. Issues of validation, including sensitivity to
‘cognitive-enhancing’ effects of drugs will be addressed.
Policy of full disclosure: None.
Tuesday 24 June 2014
SA-03. Impact of maintenance treatment on the
natural illness progression in
schizophrenia
supported by an educational grant from Lundbeck/
Otsuka
SA-03-001 The nature of relapse in schizophrenia
A. Malla. McGill University Douglas MHUI, Psychiatry, Montréal, Canada
Patients with schizophrenia have a high rate of response to treatment
after a first psychotic episode. During the course of schizophrenia, how-
ever - despite the prioritisation of relapse prevention as a treatment goal
- most patients experience relapses of psychosis. Such relapses result in
a negative trajectory of outcome in more than two thirds of patients.
Relapse is also associated with considerable psychosocial consequences
including physical harm, emotional distress, and strained relationships
-social and professional. The fluctuating course of relapses and incomplete
remissions in schizophrenia is associated with poor functional recovery.
Treatment refractoriness may emerge, and time to treatment response
may increase with successive psychotic episodes. Furthermore, longitudi-
nal MRI studies have revealed that structural brain alterations in schizo-
phrenia are, at least partially, related to the total length of relapses.
These observations suggest that relapse carries a biological risk, and
that active psychosis promotes disease progression. The risk of relapse fol-
lowing treatment for first-episode psychosis is significantly increased by
non-adherence to antipsychotic medication, substance abuse, interperso-
nal stress, and poor pre-morbid adjustment. Patients can relapse very
soon after treatment discontinuation, and the transition from remission
to relapse may occur with or without warning signs. Many of the risk fac-
tors for relapse are malleable to intervention, and attention to these can
help to prevent or attenuate relapses and the associated harm. Given
the high frequency of remission of psychotic symptoms following the
first episode of schizophrenia, and the high risk of relapse in the first
few critical years, effective treatment to sustain remission during this
phase of the disease is crucial for improving long-term outcome.
Policy of full disclosure: None.
SA-03-002 Comparative efficacy of LAIs versus oral antipsychotics
in schizophrenia
C. Correll. Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ, School
of Medicine, New York, USA
Non-adherence is a major barrier to maximising the acute and long-term
effectiveness of pharmacotherapy for schizophrenia. Long-acting inject-
able (LAI) antipsychotics, which release active ingredient gradually
(over a period of weeks) from a deep-tissue injection, were developed to
improve treatment adherence in schizophrenia, and thereby improve the
long-term outcome for patients. Measuring such benefits can be challeng-
ing, however, since randomised controlled trials generally increase adher-
ence compared with clinical practice, leading to an underestimation of any
potential difference in effectiveness between treatments. Consequently, in-
dividual randomised controlled trials and meta-analyses have shown
mixed results regarding the benefits of LAIs compared to oral antipsycho-
tics, underscoring the relevance of appropriately considering design,
population and treatment factors when interpreting these diverging
results. Mirror image studies provide a better reflection of the real-world
impact of schizophrenia treatment. In a mirror image study, each patient
acts as his/her own control: historical treatment with an oral antipsychotic
is compared with prospective treatment with an LAI. Such studies
strongly and consistently favour the use of LAIs over oral antipsychotics,
revealing significantly reduced rates of treatment discontinuation, relapse,
and hospitalisation with LAIs. Important emerging data suggest that con-
tinuous antipsychotic treatment may exert the biggest preventive effect on
treatment discontinuation, relapse and rehospitalisation when provided
early in the illness course, at a time when each single relapse is associated
with the greatest loss in social, educational, vocational and, possibly, bio-
logical reserve and functioning. Taken together, these real-world data in-
dicate that appropriate use of LAIs early in the disease course is a valuable
treatment option for patients with schizophrenia.
Policy of full disclosure: None.
SA-03-003 Differences among long-acting antipsychotics in the
maintenance treatment of schizophrenia
J. Kane. The Zucker Hillside Hospital, Glen Oaks, USA
A number of different typical and atypical long-acting injectable (LAI)
antipsychotics are currently available. Of the four atypical LAI antipsy-
chotics (aripiprazole, olanzapine, paliperidone, and risperidone), aripipra-
zole once-monthly is the most recently approved (Canada, US, and EU).
Aripiprazole once-monthly is an injectable, extended-release suspension
which provides a new option for the maintenance treatment of schizo-
phrenia in adults. Two large-scale, randomised, controlled clinical studies
of aripiprazole once-monthly have been completed, both of which inves-
tigated prevention of relapse as the primary outcome. In a 52-week study,
maintenance treatment with aripiprazole once-monthly statistically sign-
ificantly delayed the time to relapse, reduced the proportion of patients
experiencing relapse, and improved the symptoms of schizophrenia ver-
sus placebo. In a 38-week study, maintenance treatment with aripiprazole
once-monthly was non-inferior to oral aripiprazole, and statistically sign-
ificantly superior to a low reference dose of LAI aripiprazole, in terms of
the proportion of patients experiencing relapse. Other studies, completed
and ongoing - including a mirror image study - complement these
findings. The safety profile of aripiprazole once-monthly is favourable
and similar to that of oral aripiprazole. It is important to place in perspec-
tive the various characteristics of available LAI medications, so that clin-
icians, patients and families have the information necessary to make
informed decisions. Having a new option that is effective and safe will
be valuable in the maintenance treatment of schizophrenia.
Policy of full disclosure: None.
SA-04. Challenges in the management of bipolar
disorder: Focus on unmet needs
supported by an educational grant from Sunovion
This symposium reviews important challenges in the diagnosis and treat-
ment of bipolar disorder and highlights current unmet needs. Bipolar dis-
order is one of the most challenging psychiatric disorders to treat, with
multiple diagnostic complexities, frequent medical and psychiatric comor-
bidities, and high use of healthcare resources. The presentation of bipolar
disorder is dominated by the depressive phase, as patients spend
two-thirds of symptomatic time depressed. Cognitive impairment is com-
mon during both mood episodes and euthymia and strongly predicts the
functional impairments that reduce quality of life. While many treatment
options exist for the debilitating effects of mania and hypomania, the de-
velopment of medications for bipolar depression has been fraught with
difficulty, leading to a number of failed and negative trials. High placebo
rates have contributed the challenge of conducting successful clinical trials
in bipolar depression. However, the several agents that have been success-
ful in the treatment of bipolar depression may share an important mech-
anism of action. Commonalities in the select agents that have proven
efficacious in clinical trials of bipolar depression in addition to preclinical
data highlighting its role in mood regulation and cognition suggest that
the serotonin receptor 5-HT7 may provide a new research target in bipolar
depression. This symposium also considers Level 1 evidence for available
treatments for bipolar depression, including mood stabilizers, traditional
antidepressants, and atypical antipsychotics, as well as treatment guide-
lines. Both approved treatments and those more recently investigated
for bipolar depression are reviewed. In addition, the issue of the effect
of various agents on metabolic parameters in this population is examined
as an important limitation of current therapies. The program also dis-
cusses several nonpharmacologic approaches, such as psychoeducation
and cognitive behavioral therapy, that can contribute to improved
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outcomes in patients with bipolar disorder. The symposium concludes
with a presentation of both short- and longer-term clinical trial data of
Latuda® (lurasidone HCl), which demonstrated efficacy both as mono-
therapy and as adjunctive therapy with lithium or valproate in patients
with major depressive episodes associated with bipolar I disorder (bipolar
depression).
Policy of full disclosure: None.
SA-04-001 Challenges in the management of bipolar disorder
L. Yatham. Vancouver Coastal Health and Providence Healthcare, Department
of Psychiatry, Vancouver, Canada
Policy of full disclosure: None.
SA-04-002 Management of bipolar depression: Current practice
E. Vieta. University of Barcelona, Hospital Clinic, IDIBAPS, CIBE, Department
of Psychiatry, Barcelona, Spain
Policy of full disclosure: None.
SA-04-003 New data regarding the efficacy of Lurasidone in
bipolar depression
J. Calabrese. USA
Policy of full disclosure: None.
Wednesday, 25 June 2014
SA-05. Stepping up to the challenge of cognitive
dysfunction in major depressive disorder
A Medscape Education program supported by
an educational grant from Lundbeck
This independent Medscape Education program is an interactive live
symposium for an audience of non-US psychiatrists, neurologists and
primary care physicians. It has four learning objectives: 1) to discuss the
impact of cognitive dysfunction in patients with major depressive dis-
order (MDD); 2) to identify potential methods for measuring cognitive
dysfunction in clinical practice; 3) to describe the mode of action of anti-
depressants with respect to cognition and MDD; and 4) to discuss treat-
ment strategies for MDD patients with cognitive dysfunction. The
program is supported by an unrestricted educational grant from
Lundbeck. MDD has a significant deleterious effect on patients’ work,
social interactions, and quality of life. Many MDD patients report slowed
thoughts, poor concentration, distractibility, and reduced capacity to pro-
cess information. Both the Diagnostic and Statistical Manual of Mental
Disorders, 5th edition, and the International Classification of Diseases,
10th edition, include reduced concentration as a criterion for an MDD di-
agnosis. Some questionnaires are being developed for potential use in
clinical practice, such as the Perceived Deficits Questionnaire -
Depression. Even after treatment with conventional antidepressants,
patients frequently report cognitive problems, such as poor concentration
and memory. Some trials that primarily aim to improve measures of cog-
nitive function are underway with some conventional and newer antide-
pressants. Vortioxetine has been approved in the US and Europe for the
treatment of adults with MDD. In a randomized, double-blind, placebo-
controlled phase 3 study in MDD patients aged 18-65 years, and with cog-
nition as the primary endpoint, vortioxetine 10 and 20mg/day was sug-
gested to have a direct effect on cognition compared to placebo. The
live symposium will discuss the above in detail and will include a ques-
tion and answer session. The program will subsequently be available
online on Medscape Education. Note: Vortioxetine is not currently ap-
proved for use in Canada.
Policy of full disclosure: None.
SA-05-001 Recognizing cognitive impairment and its impact on
functional outcome in patients with major depressive
disorder
G.M. Goodwin. Warneford Hospital, University Department of Psychiatry,
Oxford, United Kingdom
Policy of full disclosure: None.
SA-05-002 Targeting cognition and depression in major depressive
disorder
R. McIntyre. University of Toronto, UHN – Toronto Western Hospital, Toronto,
Canada
Policy of full disclosure: None.
SA-05-003 Therapeutic options to address cognitive impairment
in patients with major depressive disorder
D. Nutt. Imperial College, London, United Kingdom
Policy of full disclosure: None.
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Scientific Symposium
Monday 23 June 2014
SC-01. Stem cells and related epigenetic factors in
alcoholism
supported by an unrestricted educational grant
of Suntory
SC-01-001 Altered retinoic acid homeostasis and microglial
activation: Implications for neuropsychiatric disorders
and therapeutic approaches
J. Hellmann-Regen. Germany
Microglial (MG) activation represents a hallmark of many neuropsychia-
tric disorders, including alcohol abuse-related pathologies. MG activation
results in a variety of microenvironmental changes that eventually lead to
altered stem cell differentiation, neuronal proliferation and survival. The
underlying mechanisms appear to be of complex nature and remain sub-
ject to discussion. Here, we suggest a potential role for retinoic acid (RA)
in mediating MG activation-associated effects on the microenvironment.
RA acts as a potent morphogen, endogenous neuroprotectant and inhibi-
tor of MG activation in the adult CNS. Altered RA homeostasis has pre-
viously been implicated in alcohol-related pathologies. Using primary
mouse microglia, we demonstrate strongly increased protein expression of
RA-degrading cytochromes CYP26A1, CYP26B1, CYP3A4 and CYP2C
in lipopolysaccharide (LPS) activated vs. resting MG. Correspondingly,
activated MG showed increased RA catabolism as determined by reversed
phase-high performance liquid chromatography (HPLC). As expected,
RA-administration attenuated LPS-induced MG activation. Furthermore,
the inhibitory actions of RA on MG activation were found to be mimicked
by the administration of liarozole, an inhibitor of RA-metabolism. In sum-
mary, our findings indicate that activation of microglia results in increased
breakdown of RA, which is an endogenous inhibitor of MG activation.
Increased turnover of RA may constitute a ‘vicious cycle’ of MG activation
and contribute to MG activation-associated microenvironmental changes.
Finally, our results on the RA-metabolism blocking agent liarozole sug-
gest RA homeostasis as a potential therapeutic target in neuropsychiatric
disorders.
Policy of full disclosure: None..
SC-01-002 Our liver regeneration therapies using autologous bone
marrow derived cells for liver cirrhosis
T. Takami1, S. Terai, I. Sakaida. 1Department of Gastroenterology and
Hepathology, Yamaguchi University, Yamaguchi, Japan
In our murine model, we have confirmed that GFP-positive bone marrow
cells (BMCs) infused via a tail vein efficiently repopulated cirrhotic liver
induced by repeated carbon tetrachloride treatment. Repopulated
GFP-positive BMCs were also seen to produce collegenases including
matrix metalloproteinase 9. As a result, reduced liver fibrosis, elevation
in serum albumin levels, and then a significant increase in survival rate
were confirmed. On these evidences, we have started “Autologous bone
marrow cell infusion (ABMi) therapy”, which was a method of liver re-
generation using non-cultured autologous whole BMCs for patients in-
cluding alcoholic liver cirrhosis, and reported the efficacy and safety of
this approach. Moreover, we recently confirmed that frequent BMCs
infusion contributed to suppressed tumor initiation during stages of hepa-
tocarcinogenesis through the stabilization of redox homeostasis in hepato-
carcinogenic mice with liver cirrhosis. On the other hand, our ABMi
therapy involves bone marrow (BM) aspiration under general anesthesia,
and is not indicated for patients for whom general anesthesia is difficult.
We therefore developed a less-invasive liver regeneration therapy in
which cells having curative effects on liver cirrhosis are isolated and
cultured from a small amount of autologous BM aspirated under local
anesthesia and infused back into the same patient. We revealed that
the infusion of cultured human BM derived mesenchymal stem cells
(BMSCs) under normal culture condition could reduce hepatic fibrosis
in the immunodeficient NOD-SCID cirrhotic mice, consistent with the
lower levels of reactive oxygen species from hepatocytes co-cultured
with BMSCs in vitro. For the clinical trial using cultured BMSCs, we are
now preparing safety evaluation guidelines and a system conforming to
Standard Operating Procedure at the cell processing facility in our univer-
sity hospital. Here, we present the current status and prospects for our
liver regeneration therapy using autologous BMCs.
Policy of full disclosure: None.
SC-01-003 The role of neurogenesis in alcohol dependence and
metabolic disease
D.-J. Kim. Department of Psychiatry, Seoul St. Mary’s Hospital, Catholic
University, Seoul, Republic of Korea
Alcohol has deleterious influences on glucose metabolism which may con-
tribute to the development of type 2 diabetes mellitus (T2DM). Insulin-like
growth factor I (IGF-I) and growth hormone (GH), which interact with in-
sulin to modulate metabolic control, have been shown to be related to
impaired glucose tolerance. Furthermore Brain-Derived Neurotropic
Factor (BDNF), a potent regulator of neuronal activity and neurogenesis,
is also an important regulator of glucose metabolism, so it may be asso-
ciated with an increased risk for T2DM in alcoholism. This study was con-
ducted to assess the possibility that altered circulating IGF-I, GH and
BDNF levels related to T2DM by alcohol use in type 2 diabetic Otsuka
Long-Evans Tokushima Fatty (OLETF) rats and non-diabetic
Long-Evans Tokushima Otsuka (LETO) rats. To investigate effect of
chronic alcohol consumption, rats were fed a liquid diet containing etha-
nol as 36% of calories or pair-fed a control diet. An Intraperitoneal
Glucose Tolerance Test (IP-GTT) was performed and IGF-I, GH and
BDNF levels were evaluated. Prior to an IP-GTT, OLETF-Ethanol (O-E)
group had significantly a decrease in the mean glucose levels compared
to OLETF-Control (O-C) group. At 120min post IP-GTT, the O-E group
had significantly an increase in the mean glucose levels compared to
O-C group. The serum IGF-I and BDNF levels were significantly lower
and the serum GH levels were significantly higher in the O-E group
than in L-C group. These results suggest that IGF-I, GH and BDNF are
prominent in defining the risk and development of T2DM, and may be ad-
versely affected by heavy alcohol use, possibly mediating its diabetogenic
effects. Thus, the overall glucose intolerance in the setting of alcoholism
may be attributable to inappropriate alteration of IGF-I, GH and BDNF
levels.
Policy of full disclosure: None.
SC-01-004 Stem cell therapy as a candidate treatment approach for
neural plasticity change in alcohol-induced brain
damage and depression
W. Ukai1, Y. Kigawa, E. Hashimoto, T. Ishii, K. Fuluse, H. Tsujino,
T. Saito. 1School of Medicine, Sapporo Medical University, Japan
In alcoholism and fetal alcohol spectrum disorder (FASD) research,
alcohol disruption of neuron development and alcohol-induced neuro-
degeneration is central to the pathology and clinical expression of these
disorders. The active role of neurogenesis in neurodegeneration and re-
generation processes has emerged at the front topic of adult central ner-
vous system (CNS) disorders and therapy. A number of in vitro and
in vivo studies demonstrate the impact of neurogenesis impairment as
the common mechanism in pathophysiology of alcoholism and other psy-
chiatric disorders such as depression. Many researchers has suggested
that antidepressant increased neurogenesis which was required for the
behavioral effects and alcohol treatment decreased this function. Stem
cell-based regenerative therapy promises great benefits for patients with
incurable brain diseases. We studied the involvement of corticolimbic
GABAergic interneuron disruption in cognitive and social impairment
in FASD and the effect of stem cell treatment. We used an animal
model of FASD created in fetal rats by the binge-like administration of
ethanol during the peak of GABAergic cell generation of dams
(E11-E14). We show that aspects of cognitive and social dysfunction are
reversed by intravenous administration of fetal rat brain-derived neural
stem cells (NSCs) at 45 days, a time point when neural developments
are already completed. We also show that alterations of PV-containing
GABAergic interneurons and synaptic density protein levels are essential
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for the therapeutic efficacy of intravenous NSC treatment in this animal
model. Moreover, in our recent study, we created new rat model of
refractory depression by combination of fetal (alcohol) and adolescent
(corticosterone) period stress exposures. We have indicated that depress-
ive behavior described in this model could be recovered by combined
treatment of antidepressant with stem cells but not by antidepressant
treatment alone. Our results suggest that alterations of neurogenesis func-
tion, especially GABA neuron production underlie the pathogenetic mech-
anism of alcohol-induced brain damage and depression and possible
therapeutic mechanism of stem cell treatment combined with drug for
these disorders.
Policy of full disclosure: None.
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